<SEC-DOCUMENT>0001493152-23-008960.txt : 20230327
<SEC-HEADER>0001493152-23-008960.hdr.sgml : 20230327
<ACCEPTANCE-DATETIME>20230324185538
ACCESSION NUMBER:		0001493152-23-008960
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230327
DATE AS OF CHANGE:		20230324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				911835664
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		23761130

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:BRTX="http://biorestorative.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_BRTX_biorestorative.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GrantIncome" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0258" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0260" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlement" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlement" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlement" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlement" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0325" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0334" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0361" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0410" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:SharesIssuedInSettlementOfLitigation" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:NoncashAccruedExpenseExchangedForConveritbleNotes" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:AccruedDipExpensesExchangedForConvertibleNotes" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:WarrantsIssuedAsConsiderationForIntangibleAssets" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" id="xdx2ixbrl0599" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember" id="xdx2ixbrl0765" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31_custom_PatentsAndTrademarkMember" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarkMember" id="xdx2ixbrl0789" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:AccruedResearchAndDevelopmentExpenses" contextRef="AsOf2022-12-31" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0835" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" id="xdx2ixbrl0927" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" id="xdx2ixbrl0929" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375" id="xdx2ixbrl0949" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1112" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1114" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1116" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1118" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl1126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109" id="xdx2ixbrl1164" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-12-31" id="xdx2ixbrl1239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2021-12-31" id="xdx2ixbrl1248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1298" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1303" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1304" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="brtx-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ComputerSoftwareAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ComputerSoftwareAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ManufacturingEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ManufacturingEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember27579265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-142022-09-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-14</xbrli:startDate>
        <xbrli:endDate>2022-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-212021-10-21_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-21</xbrli:startDate>
        <xbrli:endDate>2021-10-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember27580812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:TwoEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-18</xbrli:startDate>
        <xbrli:endDate>2021-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04_custom_PatrickFWilliamsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:PatrickFWilliamsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04_custom_MrAlstodtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:MrAlstodtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04_custom_MrSilvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:MrSilvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04_custom_DrNickolayKukekovMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:DrNickolayKukekovMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-022021-11-04_custom_ScientificAdvisoryBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:TwoEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-18</xbrli:startDate>
        <xbrli:endDate>2021-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:TwoEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-172022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-17</xbrli:startDate>
        <xbrli:endDate>2022-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember27581328">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember27581359">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember27581375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember27582265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember27582265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SharesIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SharesIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SectionThreeHundredAndEightyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SectionThreeHundredAndEightyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SectionThreeHundredAndEightyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:OfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_BoardAndScientificAdvisoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:BoardAndScientificAdvisoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20220101__20221231_zwBLYJqoVeg6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentAnnualReport_c20220101__20221231_zzMRISXRwZp6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE FISCAL YEAR ENDED <span id="xdx_907_edei--DocumentPeriodEndDate_c20220101__20221231_z4B2Or2380li"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_90E_edei--CurrentFiscalYearEndDate_c20220101__20221231_zP0Y6zoTmdKd" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">DECEMBER 31</ix:nonNumeric></span>, <span id="xdx_904_edei--DocumentFiscalYearFocus_c20220101__20221231_ziQW67mcF0Dk" title="Document Fiscal Year Focus"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentTransitionReport_c20220101__20221231_zIByVLi4OeU8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE TRANSITION PERIOD FROM__________ TO__________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityFileNumber_c20220101__20221231_z9HSj84qqVGe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-37603</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90C_edei--EntityRegistrantName_c20220101__20221231_zxhJKn3VUfTj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zUeBa4dNauIh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20220101__20221231_zkK2AQkrKpQc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">30-1341024</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220101__20221231_zsEb7YYoUjrg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">40
    Marcus Drive</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20220101__20221231_zYxOdDdXUYLg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite 1</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20220101__20221231_zFj8VoXEm8zf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20220101__20221231_zCPbfA44xKF8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20220101__20221231_zcCMmO7hKmec"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_908_edei--CityAreaCode_c20220101__20221231_zqKI1RRjzET1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_90A_edei--LocalPhoneNumber_c20220101__20221231_zfcQnY9Sn0a9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--Security12bTitle_c20220101__20221231_zp53uPrXLi56"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
                                            Stock</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$0.0001
    par value</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--TradingSymbol_c20220101__20221231_z99yKtuyefMe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">BRTX</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--SecurityExchangeName_c20220101__20221231_zhDY1ywKUkj6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zWAg9N0mDDM2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes &#9744;
<span id="xdx_906_edei--EntityVoluntaryFilers_c20220101__20221231_zpgMFFlACZLf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_908_edei--EntityCurrentReportingStatus_c20220101__20221231_zetGCs5c0Jy1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_900_edei--EntityInteractiveDataCurrent_c20220101__20221231_zNAXDsuIYqC"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityFilerCategory_c20220101__20221231_zKPccAXAiY9b"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90C_edei--EntitySmallBusiness_c20220101__20221231_zRVCRKKsccU8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20220101__20221231_zKaKMCwpZ7G"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_908_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zSnpxAF5nyLd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based
compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to
&#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_90A_edei--EntityShellCompany_c20220101__20221231_zlbjNzXjHbmc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was $<span id="xdx_901_edei--EntityPublicFloat_iI_c20220630_zFQaglVLvw07" title="Entity Public Float"><span id="xdx_908_edei--EntityPublicFloat_iI_c20220630_zSegH2nhTudb"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,495,444</ix:nonFraction></ix:nonFraction></span></span>
based on the closing sale price as reported on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICABLE
ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. <span id="xdx_90E_edei--EntityBankruptcyProceedingsReportingCurrent_c20220101__20221231_z6qjptzmQTVi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityBankruptcyProceedingsReportingCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 22, 2023, there were <span id="xdx_90F_edei--EntityCommonStockSharesOutstanding_iI_c20230322_zfuPP8mFnVa9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-22" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,767,615</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentsIncorporatedByReferenceTextBlock_c20220101__20221231_zeynQNzuHVT6" title="Documents Incorporated by Reference [Text Block]"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -5.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><p style="text-align: center; font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></p>
                                                                                <p style="text-align: center; font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Forward-Looking
    Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART
    I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk
    Factors.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">27</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_001">Unresolved Staff Comments.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_002">Properties.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_003">Legal Proceedings.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_004">Mine Safety Disclosures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ayt_024">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_005">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">52</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_006">[Reserved].</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_007">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_008">Quantitative and Qualitative Disclosures About Market Risk.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_009">Financial Statements and Supplementary Data.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_010">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_011">Controls and Procedures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_012">Other Information.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_013">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ayt_014">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_015">Directors, Executive Officers and Corporate Governance.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_016">Executive Compensation.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_017">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_018">Certain Relationships and Related Transactions, and Director Independence.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_019">Principal Accountant Fees and Services.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ayt_020">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_021">Exhibits and Financial Statement Schedules.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ayt_022">Form 10-K Summary.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ayt_023">Signatures</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">73</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_001"></span><b><span style="text-decoration: underline">PART
I</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="a_004"></span><span style="font-size: 10pt"><b><span style="text-decoration: underline">Forward-Looking
Statements</span></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking
statements contained in this Annual Report may not occur. Generally, these statements relate to business plans or strategies, projected
or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made
by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221;
&#8220;intend,&#8221; &#8220;estimate,&#8221; and &#8220;continue,&#8221; and their opposites and similar expressions are intended to
identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are
subject to a number of uncertainties, risks and other influences, many of which are beyond our control, that may influence the accuracy
of the statements and the projections upon which the statements are based. Factors which may affect our results include, but are not
limited to, the risks and uncertainties discussed in Item 1A of this Annual Report (&#8220;Risk Factors&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking
statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from
those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking
statements, whether from new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Intellectual
Property</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report includes references to our federally registered trademarks, <i>BioRestorative Therapies</i> and <i>Dragonfly</i> design,
<i>BRTX-100</i>, <i>ThermoStem</i> and <i>BRTX</i>. The <i>Dragonfly </i>logo is also registered with the U.S. Copyright Office. This
Annual Report also includes references to trademarks, trade names and service marks that are the property of other organizations. Solely
for convenience, trademarks and trade names referred to in this Annual Report appear without the &#174;, SM or &#8482; symbols, and copyrighted
content appears without the use of the symbol &#169;, but the absence of use of these symbols does not reflect upon the validity or enforceability
of the intellectual property owned by us or third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_002"></span><b><span style="text-decoration: underline">ITEM
    1.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">BUSINESS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
<span style="text-decoration: underline">Business Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Annual Report on Form 10-K, or the Annual Report, references to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;,
or &#8220;our&#8221; refer to BioRestorative Therapies, Inc. and its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from &#8220;Stem Cell Assurance, Inc.&#8221; to
&#8220;BioRestorative Therapies, Inc.&#8221; Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we
reincorporated in Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adult
<span style="background-color: white">stem cells. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent issued in our <i>Disc/Spine Program</i>. We submitted an IND application to the U.S. Food and Drug
Administration, or the FDA, to obtain authorization to commence a Phase 2 clinical trial investigating the use of <i>BRTX-100</i> in
the treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization from the FDA and
have commenced such clinical trial. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have obtained an exclusive license to use technology for investigational adult stem cell treatment of disc and spine conditions, including
protruding and bulging lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back
pain, buttock and leg pain, and numbness and tingling in the leg and foot. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Patents related to the <i>ThermoStem Program</i> have been issued in the United States and other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Events During 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, Robert Paccasassi was elected our Vice President of Quality Assurance/Regulatory Compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, we announced that we had initiated the site selection process for our active Phase 2 clinical trial targeting chronic
lumbar disc disease. To date, we have identified 17 sites in various cities in the United States and clinical trial agreements with 11
of such sites are in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, an Israeli patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, a United States patent related to <i>BRTX-100</i>, our lead cell therapy candidate, was issued. We have been granted exclusive
license rights with regard to the patent. See &#8220;Business &#8211; Disc/Spine Program <i>&#8211; Exclusive License</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we announced that we had completed the testing and certification of our clinical grade cell therapy manufacturing facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9;</i>In
June 2022, we announced that the first patient had been enrolled in our Phase 2 clinical trial evaluating the safety and efficacy of
<i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;In
December 2022, we entered into an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to us for intellectual
property developed to address chronic lumber disc disease have been made exclusive. See &#8220;Business &#8211; Disc/Spine Program &#8211;
<i>Exclusive License</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, we announced that we were awarded a Small Business Innovation Research (SBIR) Phase 1 grant from Eunice Kennedy Shriver
National Institute of Child Health &amp; Human Development of the National Institutes of Health to enable the development and evaluation
of our <i>ThermoStem Program</i> for the treatment of polycystic ovary syndrome (PCOS). The work is to be done in collaboration with
Dr. Sheng Wu, Associate Professor, Center for Metabolic Disease Research at Temple University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Materials
Events During 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, a notice of allowance was issued by the European Patent Office for a patent application related to our <i>ThermoStem Program.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, a notice of allowance was issued by the United States Patent Office for a patent application related to our <i>ThermoStem
Program.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
<span style="text-decoration: underline">Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described
below, relate to the treatment of disc/spine disease and metabolic disorders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disc/Spine
    Program (brtxDisc). </i></b>Our lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s
    own) cultured mesenchymal stem cells, or MSCs, collected from the patient&#8217;s bone marrow. We intend that the product will be
    used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure.
    The <i>BRTX-100</i> production process utilizes proprietary technology and involves collecting a patient&#8217;s bone marrow, isolating
    and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, <i>BRTX-100 </i>is to be
    injected by a physician into the patient&#8217;s damaged disc. The treatment is intended for patients whose pain has not been alleviated
    by non-surgical procedures and who potentially face the prospect of surgery. We have received authorization from the FDA to commence
    a Phase 2 clinical trial using <i>BRTX-100</i> to treat chronic lower back pain arising from degenerative disc disease. We have commenced
    such clinical trial through the execution of a CRO agreement with PRC Clinical, the execution of clinical trial site agreements,
    patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the expansion of our laboratory
    to include capabilities for clinical production. In March 2022, a United States patent related to our <i>Disc/Spine Program </i>was
    issued. We have been granted exclusive license rights with regard to the patent. See &#8220;Disc/Spine Program&#8221; below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Metabolic
    Program (ThermoStem)</i></b>. We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown
    adipose (fat) derived stem cells, or BADSC, to generate brown adipose tissue, or BAT. We refer to this as our <i>ThermoStem Program</i>.
    BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical
    research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced
    glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity
    and diabetes. Patents related to the <i>ThermoStem Program</i> have been issued in the United States and other jurisdictions. See
    &#8220;Metabolic Brown Adipose (Fat) Program&#8221; below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to
the spine and discs (and other parts of the body). We anticipate that FDA approval or clearance will be necessary for this device prior
to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.
See &#8220;Curved Needle Device&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents and patent applications for the <i>Disc/Spine Program</i>, the <i>ThermoStem Program</i> and the curved needle device are listed
below under &#8220;Technology; Research and Development.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
human being has stem cells in his or her body. These cells exist from the early stages of human development until the end of a person&#8217;s
life. Throughout our lives, our body continues to produce stem cells that regenerate to produce differentiated cells that make up various
aspects of the body such as skin, blood, muscle and nerves. These are generally referred to as adult (non-embryonic) stem cells. These
cells are important for the purpose of medical therapies aiming to replace lost or damaged cells or tissues or to otherwise treat disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
cell therapy relies on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones or repairing damaged or diseased
tissue. A great range of cells can serve in cell therapy, including cells found in peripheral and umbilical cord blood, bone marrow and
adipose (fat) tissue. Physicians have been using adult stem cells from bone marrow to treat various blood cancers for more than 65 years
(the first successful bone marrow transplant was performed in 1956). Recently, physicians have begun to use stem cells to treat various
other diseases. We intend to develop cell and tissue products and regenerative therapy protocols, primarily involving adult stem cells,
to allow patients to undergo cellular-based treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are concentrating initially on therapeutic areas in which risk to the patient is low, recovery is relatively easy, results can be demonstrated
through sufficient clinical data, and patients and physicians will be comfortable with the procedure. We believe that there will be readily
identifiable groups of patients who will benefit from these procedures. We also believe that these procedures will be significantly less
expensive than the most common surgical procedure alternatives and will compare favorably, over the long-term, to conservative treatment
costs which may persist for years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we have focused our initial developmental efforts on cellular-based therapeutic products and clinical development programs in selective
areas of medicine for which the treatment protocol is minimally invasive. Such areas include the treatment of the disc and spine and
metabolic-related disorders. Upon regulatory approval, we will seek to obtain third party reimbursement for our products and procedures;
however; if we are not successful, patients may be required to pay for our products and procedures out of pocket in full and without
the ability to be reimbursed by any governmental and other third party payers, which would adversely impact our prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have undertaken research and development efforts in connection with the development of investigational therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. See &#8220;Disc/Spine Program,&#8221; &#8220;Metabolic
Brown Adipose (Fat) Program&#8221; and &#8220;Curved Needle Device&#8221; below. As a result of these programs, we have five United States
patents, twelve foreign patents, three United States patent applications, and five foreign patent applications related to research regarding
our <i>ThermoStem Program</i>, we have obtained licenses for ten United States patent applications related to our <i>Disc/Spine Program,
</i>one United States patent related to our <i>Disc/Spine Program,</i> and we have obtained a license for one United States patent related
to a curved needle device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a research laboratory facility with Good Manufacturing Practice, or cGMP, capabilities to produce clinical grade products
and will seek to further develop cellular-based treatments, products and protocols, stem cell-related intellectual property, or IP, and
translational research applications. See &#8220;Laboratory&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any significant revenues to date. In November 2021, we completed a $23,000,000 public offering of our securities.
Such funds are sufficient for us to complete our Phase 2 clinical trial investigating the use of <i>BRTX</i>-<i>100</i> in the treatment
of chronic lower back pain arising from degenerative disc disease, as further described in this section, as well as to continue our pre-clinical
research and development efforts with respect to our <i>ThermoStem Program</i> and to satisfy our current working capital needs; however,
the implementation of our business plan, as discussed below, will require the receipt of additional financing to fund our research and
development efforts, including our contemplated Phase 3 clinical trial with regard to <i>BRTX-100</i> and our contemplated clinical trials
relating to our <i>ThermoStem Program</i>, and otherwise fund our operations. We intend to seek to raise capital through investment bankers
and from biotech funds, strategic partners and other financial institutions. We will require significant additional financing to complete
our contemplated Phase 3 clinical trial investigating the use of <i>BRTX-100.</i> We will also require a substantial amount of additional
funding to implement our other programs described in this section, and fund general operations. No assurance can be given that the amount
of funding that we anticipate may be required for such purposes is correct or that we will be able to accomplish our goals within the
timeframes projected. In addition, no assurance can be given that we will be able to obtain any required financing on commercially reasonable
terms or otherwise. If we are unable to obtain adequate funding, we may be required to significantly curtail or discontinue our proposed
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disc/Spine
Program</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the initiatives that we are currently pursuing is our <i>Disc/Spine Program</i>, with our initial product candidate being called <i>BRTX-100</i>.
We have obtained an exclusive license (see &#8220;<i>Exclusive License</i>&#8221; below) that permits us to use technology for adult
stem cell treatment of disc and spine conditions. The technology is an advanced stem cell culture and injection procedure into the intervertebral
disc, or IVD, that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
back pain is the most common, most disabling, and most costly musculoskeletal ailment faced worldwide. According to a 2016 market report
from Trinity Partners, a global life sciences consulting firm, of the 250 million American adults, nearly 25 million have chronic lower
back pain of which approximately 12 million have been diagnosed with and treated for disc degeneration and approximately 5.6 million
have pain caused by a protruding or injured disc. We believe that between 500,000 and one million invasive surgical procedures are performed
each year to try to alleviate the pain associated with these lower back conditions and that such procedures cost approximately $40 billion.
Clinical studies have documented that the source of the pain is most frequently damage to the IVD. This can occur when forces, whether
a single load or repetitive microtrauma, exceed the IVD&#8217;s inherent capacity to resist those loads. Aging, obesity, smoking, lifestyle,
and certain genetic factors may predispose one to an IVD injury. Current surgical approaches to back pain are extremely invasive (often
altering the spine&#8217;s biomechanics unfavorably and predisposing it to further disc degeneration) and are associated with unacceptably
low success rates (with a second operation occurring 10% to 20% of the time). In addition, current surgical approaches are costly with
spinal fusion surgery costing approximately $110,000, discectomy costing approximately $20,000 to $50,000 and disc replacement surgery
costing approximately $80,000 to $150,000. Even conservative treatments can be costly, with oral medications costing between $1,000 and
$2,000 per year, injection treatments costing approximately $8,000 per year and physical therapy costing approximately $20,000 annually.
We anticipate that the cost of a single treatment using BRTX-100 will compare favorably to conservative treatments which may continue
for years and will be less expensive than the most common surgical procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
once thought to be benign, the natural history of lower back pain is often one of chronic recurrent episodes of pain leading to progressive
disability. This is believed to be a direct result of the IVD&#8217;s poor healing capacity after injury. The IVD is the largest avascular
(having few or no blood vessels) structure in the body and is low in cellularity. Therefore, its inherent capacity to heal after injury
is poor. The clinical rationale of <i>BRTX-100</i> is to deliver a high concentration of the patient&#8217;s own cultured MSCs into the
site of pathology to promote healing and relieve pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed a mesenchymal stem cell product candidate, <i>BRTX-100, </i>derived from autologous (or a person&#8217;s own) human bone
marrow, cultured and formulated, in a proprietary method, specifically for introduction into a painful lumbar disc. The product candidate
was developed utilizing in part the exclusive license described below under &#8220;<i>Exclusive License</i>.&#8221; As described below
under &#8220;<i>BRTX-100</i>&#8221; and &#8220;<i>Production and Delivery</i>,&#8221; <i>BRTX-100</i> is a hypoxic (low oxygen) stem
cell product developed through a culturing process. In order to enhance the survivability of our bone marrow-derived MSCs in the avascular
environment of the damaged disc, <i>BRTX-100 </i>is designed to expand under hypoxic conditions. This process is intended to result in
a large cell count population with enhanced viability and therapeutic potential following injection into the injured disc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted an IND application to the FDA to obtain authorization to commence a Phase 2 clinical trial investigating the use of <i>BRTX-100</i>,
our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease. We received such
authorization from the FDA in February 2017. We have commenced our Phase 2 clinical trial through the execution of a CRO agreement with
PRC Clinical, the execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase
of manufacturing equipment and the expansion of our laboratory to include capabilities for clinical production. We believe that, based
upon our periodic reports to the FDA as to the commencement of the clinical trial, the existing IND remains effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to developing <i>BRTX-100</i>, we may also seek to sublicense the technology to a strategic third party, who may assist in gaining
FDA approval for a lumbar disc indication, or third parties for use in connection with cellular-based developmental programs with regard
to disc and spine related conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a laboratory, which includes a clean room facility, to perform the production of cell products (including <i>BRTX-100</i>)
for use in our clinical trials, for third party cell products or for general research purposes. We may also use this laboratory to develop
our pipeline of future products and expand our stem cell-related IP. See &#8220;Laboratory&#8221; and &#8220;Technology; Research and
Development&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, a United States patent related to <i>BRTX-100</i>, was issued. We have been granted exclusive license rights with respect
to the patent. See &#8220;<i>Exclusive License</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate<i>, BRTX-100,</i> is an autologous hypoxic (low oxygen) cultured mesenchymal stem cell product derived from a
patient&#8217;s own bone marrow and formulated with a proprietary biomaterial carrier (platelet lysate) to increase potency, viability
and survivability. We have designed the cryopreserved sterile cellular product candidate to be provided in vials for injection into painful
lumbar discs. We anticipate the product candidate will be delivered using a standard 20 gauge 3.5 inch introducer needle and a 25 gauge
6 inch needle that will extend into the disc center upon delivery. Upon regulatory approval, we plan to provide training to medical practitioners
with regard to the approved injection procedure. It is anticipated that the delivery of the product candidate will be a 30 minute procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mesenchymal
stem cells used in <i>BRTX-100 </i>are similar to other MSCs under development by others; however, in order to enhance the survivability
of our bone marrow-derived MSCs in the avascular environment of the damaged disc, <i>BRTX-100 </i>is designed to expand under hypoxic
conditions for a period of approximately three weeks. This process is intended to result in an approximate 40 million cell count population
with enhanced viability and therapeutic potential following injection locally into injured spinal discs. Publications and scientific
literature have indicated that MSCs preconditioned in hypoxic environment show enhanced skeletal muscle regeneration properties and improved
impacts upon circulation and vascular formation compared to MSCs cultured under normoxic (normal oxygen) conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the <i>Journal of Translational Medicine</i> published the results of our study evaluating the benefits of long-term hypoxic
culturing of human bone marrow-derived MSCs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2021, we were awarded a National Institutes of Health Small Business Technology Transfer (STTR) Phase 1 grant for $256,000
to evaluate the therapeutic effects on our hypoxic cultured bone marrow derived mesenchymal stem cells (<i>BRTX-100</i>) after encapsulation
with a PEG-peptide hydrogel. The work is being done in collaboration with Washington University of St. Louis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 2022, we have entered into clinical trial agreements with 11 sites to conduct our Phase 2 clinical trial targeting chronic lumbar
disc disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Production
and Delivery</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production of our product candidate, <i>BRTX-100, </i>begins with the physician collecting bone marrow from the patient under local anesthesia.
Peripheral blood is also collected from the patient. The physician will then send the patient&#8217;s bone marrow and blood samples to
our laboratory (or a contract laboratory) for culturing and formulation. The hypoxic culturing process is intended to result in the selection
of a cell population that is suitable for an improved possibility of survival in the internal disc environment. We anticipate that the
cell culturing process and product formulation will take approximately three weeks, with an additional two weeks required for quality
control testing required to meet product release criteria. We will then send the therapeutic cryopreserved stem cells (<i>BRTX-100</i>)
in a sterile vial back to the physician&#8217;s offices where it will undergo a controlled thaw prior to the procedure. The price structure
for the procedure and our services has not been determined and no assurances can be given as to the effect that such price structure
will have on the marketability of such procedure and services. The following illustrates the process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exclusive
License </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our license agreement with Regenerative Sciences, LLC, or Regenerative, that became effective in April 2012, or the Regenerative License
Agreement, we have obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from
Regenerative to utilize or sublicense a certain method for culturing cells for use in our developmental program involving disc and spine
conditions, including protruding or painful discs and the treatment of avascular zones. The investigational technology that has been
licensed is an advanced stem cell culture and injection procedure that may offer relief from lower back pain, buttock and leg pain, and
numbness and tingling in the leg and foot. Pursuant to the Regenerative License Agreement, we have also obtained a worldwide, exclusive,
royalty-bearing license from Regenerative to utilize or sublicense a certain investigational curved needle device for the administration
of specific cells and/or cell products to the disc and/or spine (and other parts of the body). It will be necessary to advance the design
of this investigational device to facilitate the delivery of substances, including living cells, to specific locations within the body
and minimize the potential for damage to nearby structures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents that are the subject of the Regenerative License Agreement have been assigned to Regenexx, LLC which we have been advised by
Regenerative is an affiliate of Regenerative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Animal
Study</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
efficacy and safety of our product candidate, <i>BRTX-100,</i> has been tested in a degenerative intervertebral rabbit disc model. In
this study, 80 rabbits underwent surgery to create a puncture in the discs. Four weeks post-surgery, each rabbit had either contrast,
a biomaterial carrier or <i>BRTX-100</i> injected into the discs. In order to study the biodistribution and efficacy of <i>BRTX-100</i>,
the rabbits were evaluated at day 56 and day 120.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key safety findings of the animal study are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    was no evidence or observation of gross toxicity related to the administration of <i>BRTX-100</i> at either time point. The clinical
    pathology across both groups and time points were within expected normal historical ranges and under the conditions of the test.
    No abnormalities (including fractures or overt signs of lumbar disc disease) were identified after review of the radiographic images
    taken at both endpoints for both groups. No toxicity or adverse finding was evident in the systemic tissues or the discs of animals
    receiving <i>BRTX-100</i>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    was no detectable presence of human cells (<i>BRTX-100</i>) observed at the day 56 interim time point. This is consistent with the
    proposed mechanism of action that <i>BRTX-100</i> acts through a paracrine effect of secreted growth and immunomodulation factors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key efficacy findings of the animal study are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
    </i>showed a statistically significant DHI (disc height increase) over the control group at day 120.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
    </i>showed a statistically significant improvement in disc histology over the control group at day 120 as graded by a validated histology
    scale. <i>BRTX-100</i> showed a significant improvement in the cellularity and matrix of the disc when compared to the control at
    day 120.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted an IND application to the FDA to obtain authorization to commence a Phase 2 clinical trial investigating the use of <i>BRTX-100</i>,
our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease. We have received
such authorization from the FDA. We have commenced our Phase 2 clinical trial through the execution of a CRO agreement with PRC Clinical,
the execution of clinical trial agreements with 11 sites, patient enrollment, the commencement of patient procedures, the purchase of
manufacturing equipment and the expansion of our laboratory to include capabilities for clinical production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following describes the Phase 2 clinical trial authorized by the FDA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 2 Prospective, Double-Blinded, Placebo Controlled, Randomized Study</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General </span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99
    patients; randomized 2:1, <i>BRTX-100</i> to control, 40 million cells/dose</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20
    clinical trial sites (we intend to utilize 15 clinical trial sites)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    efficacy endpoint at 12 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
    safety and efficacy follow up at 24 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have only one symptomatic diseased disc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have current diagnosis of chronic lumbar disc disease typical pain with degeneration of a single disc confirmed by
    history, exam, radiography, or other acceptable means</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have exhausted previous conservative non-operative therapies</span></td></tr>
</table>

<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Primary Efficacy Endpoint</span></td></tr>
</table>




<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responder
    endpoint - percentage of patients that meet the improvement in function and reduction in pain threshold</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in function defined as at least a 30% increase in function based on the Oswestry questionnaires (ODI)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    of pain defined as at least a 30% decrease in pain as measured using the Visual Analogue Scale (VAS)</span></td></tr>
</table>

<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Additional or Secondary Endpoints</span></td></tr>
</table>




<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    response at 12 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in pain as assessed with the VAS score and ODI at weeks 2, 12, 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in function as assessed with the ODI at weeks 2, 12, 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in function as assessed by Roland Morris Disability Questionnaire (RMDQ) at weeks 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline function as assessed by Functional Rating Index (FRI) at weeks 12, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline Quality of Life assessment (SF-12 questionnaire) scores at weeks 2, 12, 26, 52 and 104</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we entered into a Master Service Agreement with Professional Research Consulting Inc. d/b/a PRC Clinical, a contract research
organization, or CRO, specializing in clinical trial management, to conduct our Phase 2 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA approval process can be lengthy, expensive and uncertain and there is no guarantee that the clinical trial(s) will be completed or
that the product will ultimately receive approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an alternative to undertaking any necessary clinical trials ourselves, we may explore the licensing of our rights with respect to our
product candidate, <i>BRTX-100,</i> to a strategic partner. Such an arrangement could possibly eliminate or significantly reduce the
need to raise the substantial capital needed to commence and complete the clinical trials and undertake the commercialization of <i>BRTX-100
</i>and would provide licensing-related revenue to us in lieu of product sales revenue. No assurance can be given that any licensing
agreement will be entered into, whether upon commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Defined
Health Report</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we engaged Defined Health, a business development and strategy consulting firm, to conduct an independent review of <i>BRTX-100</i>.
Defined Health has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
review was intended to collect informed, independent opinions regarding <i>BRTX-100</i> among key opinion leaders, or KOLs (i.e., orthopedic
surgeons specializing in back and spine surgery with experience in stem cell therapy), who, upon studying applicable clinical material,
could offer opinions regarding the future therapeutic potential of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in the Defined Health report, the KOLs indicated that stem cell therapies have great potential to treat chronic lumbar disc disease
and other therapeutic areas. The KOLs reacted positively to the value proposition of our product candidate, <i>BRTX-100, </i>and were
optimistic that the clinical data presented to date is likely to be mirrored in future clinical investigations. Given the opportunity,
the KOLs indicated that they would likely participate in a clinical trial should it be offered at their center and that they would recommend
the study to appropriately eligible patients. The report indicated that, if <i>BRTX-100</i> were to be granted FDA approval, the KOLs
anticipate that it would be integrated into the standard of care for eligible chronic lumbar disc disease patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Similar
Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
data from studies of therapies comparative to <i>BRTX-100</i> have shown reduced pain, increased function, and an absence of significant
safety issues with a durable response, as shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
on Public Health</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States is the world&#8217;s leading consumer of hydrocodone (99%) and oxycodone (83%) and leads the world in per capital consumption
of such drugs (twice as much as second ranked Canada). In 2020, 91,000 persons in the United States died from overdoses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
annual healthcare and lost productivity costs in the United States related to pain, including headache, back pain and neck pain, are
estimated to be $600 billion, which is twice the annual costs related to heart disease and greater than the combined annual costs related
to cancer and diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metabolic
Brown Adipose (Fat) Program</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 2011, we have been engaging in pre-clinical research efforts with respect to an investigational platform technology utilizing brown
adipose (fat) derived stem cells, or BADSCs, for therapeutic purposes. We have labeled this initiative our <i>ThermoStem Program</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown
fat is a specialized adipose (fat) tissue found in the human body that plays a key role in the evolutionarily conserved mechanisms underlying
thermogenesis (generation of non-shivering body heat) and energy homeostasis in mammals - long known to be present at high levels in
hibernating mammals and human newborns. Recent studies have demonstrated that brown fat is present in the adult human body and may be
correlated with the maintenance and regulation of healthy metabolism, thus potentially being involved in caloric regulation. The pre-clinical
<i>ThermoStem Program</i> involves the use of a cell-based (brown adipose tissue construct) treatment for metabolic disease, such as
type 2 diabetes, obesity, hypertension and other metabolic disorders, as well as cardiac deficiencies. The diseases, disorders and syndromes
that may be targeted by our <i>ThermoStem Program</i> are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-k_003.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had initial success in transplanting the brown adipose tissue construct in animals, and we are currently exploring ways to deliver
into humans. Even though present, BAT mass is very low in healthy adults and even lower in obese populations. Therefore, it may not be
sufficient to either naturally impact whole body metabolism, or to be targeted by drugs intended to increase its activity in the majority
of the population. Increasing BAT mass is crucial in order to benefit from its metabolic activity and this is what our <i>ThermoStem
Program</i> seeks to accomplish. We may also identify other naturally occurring biologics and chemically engineered molecules that may
enhance brown adipose tissue performance and activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obesity,
the abnormal accumulation of white fat tissue, leads to a number of metabolic disorders and is the driving force behind the rise of type
2 diabetes and cardiovascular diseases worldwide. Pharmacological efforts to alter metabolic homeostasis through modulating central control
of appetite and satiety have had limited market penetration due to significant psychological and physiological safety concerns directly
attributed to modulating these brain centers. Adipose tissue is one of the largest organs in the human body and plays a key role in central
energy balance and lipid homeostasis. White and brown adipose tissues are found in mammals. White adipose tissue&#8217;s function is
to store energy, whereas BAT specializes in energy expenditure. As discussed in a 2020 article published in the <i>International Journal
of Molecular Sciences</i>, recent advancements in unraveling the mechanisms that control the induction, differentiation, proliferation,
and thermogenic activity of BAT, along with the application of imaging technologies for human BAT visualization, have generated optimism
that these advances may provide novel strategies for targeting BAT activation/thermogenesis, leading to efficacious and safe obesity
targeted therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a cell-based product candidate to target obesity and metabolic disorders using BADSCs. Our goal is to develop a bioengineered
implantable brown adipose tissue construct intended to mimic ones naturally occurring in the human body. We have isolated and characterized
a human multipotent stem cell population that resides within BAT depots. We have expanded these stem cells to clinically relevant numbers
and successfully differentiated them into functional brown adipocytes. We intend to use adult stem cells that may be differentiated into
progenitor or fully differentiated brown adipocytes, or a related cell type, which can be used therapeutically in patients. We are focusing
on the development of treatment protocols that utilize allogeneic cells (i.e., stem cells from a genetically similar but not identical
donor).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to deliver these differentiated cells into target locations <i>in vivo</i>, we seeded BADSCs onto 3-dimensional biological scaffolds.
Pre-clinical animal models of diet-induced obesity, that were transplanted with differentiated BADSCs supported by a biological scaffold,
presented significant reductions in weight and blood glucose levels compared to scaffold only controls. We are identifying technology
for <i>in vivo</i> delivery in small animal models. Having completed our proof of concept using our BAT in small animals, we are currently
developing our next generation BAT. It is anticipated that this next version will contain a higher purity of BADSC and a greater percent
of functional brown adipocytes, which is expected to increase the therapeutic effect compared to our first generation product. In addition,
we are exploring the delivery of the therapeutic using encapsulation technology, which will only allow for reciprocal exchange of small
molecules between the host circulation and the BAT implant. We expect that encapsulation may present several advantages over our current
biological scaffolds, including prevention of any immune response or implant rejection that might occur in an immunocompetent host and
an increase in safety by preventing the implanted cells from invading the host tissues. We have developed promising data on the loading
of human stem cell-derived tissue engineered brown fat into an encapsulation device to be used as a cell delivery system for our metabolic
platform program for the treatment of type 2 diabetes, obesity, hyperlipidemia and hypertension. This advancement may lead to successful
transplantation of brown fat in humans. We are evaluating the next generation of BAT constructs that will first be tested in small animal
models. No assurance can be given that this delivery system will be effective <i>in vivo</i> in animals or humans. Our allogeneic brown
adipose derived stem cell platform potentially provides a therapeutic and commercial model for the cell-based treatment of obesity and
related metabolic disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2012, we entered into an Assignment Agreement with the University of Utah Research Foundation, or the Foundation, and a Research
Agreement with the University of Utah, or the Utah Research Agreement. Pursuant to the Assignment Agreement, which provides for royalty
payments, we acquired the rights to two provisional patent applications that relate to human brown fat cell lines. No royalty amounts
are payable to date. The applications have been converted to a utility application in the United States and several foreign jurisdictions.
Pursuant to the Utah Research Agreement, the University of Utah provided research services relating to the identification of brown fat
tissue and the development and characterization of brown fat cell lines. The Utah Research Agreement provides that all inventions, discoveries,
patent rights, information, data, methods and techniques, including all cell lines, cell culture media and derivatives thereof, are owned
by us. In February 2019, we entered into a Services Agreement with the University of Utah pursuant to which the university has been retained
to provide research services with regard to the <i>ThermoStem Program</i>. Pursuant to this agreement, we will initiate preclinical models
to study the efficacy of our generation 2 encapsulated brown adipose tissue construct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2014, our research with regard to the identification of a population of brown adipose derived stem cells was published in <i>Stem
Cells</i>, a respected stem cell journal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2014, we entered into a Research Agreement with Pfizer Inc., a global pharmaceutical company. Pursuant to the Research Agreement
with Pfizer, we were engaged to provide research and development services with regard to a joint study of the development and validation
of a human brown adipose cell model. The Research Agreement with Pfizer provided for an initial payment to us of $250,000 and the payment
of up to an additional $525,000 during the two-year term of the Agreement, all of which has been received. The Research Agreement expired
upon completion of the services provided for therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, we entered into a one year research collaboration agreement with the University of Pennsylvania with regard to the understanding
of brown adipose biology and its role in metabolic disorders. In September 2018, we entered into a one year research collaboration agreement
with the University of Pennsylvania pursuant to which the university was provided access to our proprietary brown adipose tissue cells
for research purposes. No amounts were payable by or to us pursuant to either agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2015, a United States patent related to the <i>ThermoStem Program </i>was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2017, an Australian patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017, a Japanese patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, a United States patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, an Australian patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, an Israeli patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, our collaboration with the University of Pennsylvania resulted in a publication in <i>Cell Reports</i>, a respected peer
reviewed journal, with regard to our <i>ThermoStem Program</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, a European patent related to our <i>ThermoStem Program</i> was issued to us. This European patent was validated in Belgium,
France, Germany, Italy, Poland, Spain, Sweden, Switzerland, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, an Israeli patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, a European patent related to our <i>ThermoStem Program</i> was issued to us. This European patent was validated in France,
Germany, Italy, Spain, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2021, an Australian patent related to our <i>ThermoStem Program </i>was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, a Japanese patent related to our <i>ThermoStem Program</i> was issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, an Israeli patent related to our <i>ThermoStem Program</i> was issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, we announced that we were awarded a Small Business Innovation Research (SBIR) Phase 1 grant from Eunice Kennedy Shriver
National Institute of Child Health &amp; Human Development of the National Institutes of Health to enable the development and the evaluation
of our <i>ThermoStem Program</i> for the treatment of polycystic ovary syndrome (PCOS). The work is to be done in collaboration with
Dr. Sheng Wu, Associate Professor, Center for Metabolic Disease Research at Temple University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, a notice of allowance was issued by the European Patent Office for a patent application related to our <i>ThermoStem Program.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, a notice of allowance was issued by the United States Patent Office for a patent application related to our <i>ThermoStem
Program</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed proof of concept preclinical animal studies using our first generation brown adipose derived stem cells. We intend to
undertake additional preclinical animal studies in order to optimize delivery and explore the feasibility of targeting additional indications.
Such studies are planned to begin in 2023. Following the completion of such studies, if successful, we intend to file an IND with the
FDA and initiate a clinical trial. The FDA approval process can be lengthy, expensive and uncertain and there is no guarantee of ultimate
approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that much of our development work in this area will take place at our laboratory facility, outside core facilities at academic,
research or medical institutions, or contractors. See &#8220;Laboratory&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Curved
Needle Device</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Regenerative License Agreement discussed under &#8220;Disc/Spine Program-<i>Exclusive License</i>&#8221; above, we have licensed
and further developed an investigational curved needle device, or CND, that is a needle system with a curved inner cannula to allow access
to difficult-to-locate regions for the delivery or removal of fluids and other substances. The investigational CND is intended to deliver
stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or potentially
other areas of the body. The device is designed to rely on the use of pre-curved nested cannulae that allow the cells or material to
be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures such
as vertebra, spinal cord and spinal nerves. We anticipate that the use of the investigational CND will facilitate the delivery of substances,
including living cells, to specific locations within the body and minimize the potential for damage to nearby structures. The investigational
device may also have more general use applications. In August 2015, a United States patent for the CND was issued to the licensor, Regenerative.
We anticipate that FDA approval or clearance will be necessary for the investigational CND prior to commercialization. We do not intend
to utilize the CND in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>. The FDA review and approval process
can be lengthy, expensive and uncertain and there is no guarantee of ultimate approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Laboratory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a laboratory in Melville, New York for research purposes and have built a cleanroom within the laboratory for the production
of cell-based product candidates, such as <i>BRTX-100</i>, for use in a clinical trial, for third party cell products or general research
purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021 and 2022, we expanded our laboratory to include capabilities for the clinical production of our pipeline of clinical and investigational
cell therapy candidates. Our expanded cGMP facility includes process development space, ISO 7 cleanrooms and state-of-the-art equipment.
We have expanded our research and development operations to include clinical manufacturing, a necessary step for our Phase 2 clinical
trial for <i>BRTX-100</i>. The new facility has been designed to provide cGMP manufacturing according to FDA and European Medicines Agency
regulations and guidelines to support clinical grade cell production. As we develop our business and our stem cell product candidates
and we obtain regulatory approval, we will seek to establish ourselves as a key provider of adult stem cells for therapies and expand
to provide cells in other market areas for stem cell therapy. We may also use outside laboratories specializing in cell therapy services
and manufacturing of cell products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology;
Research and Development </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to utilize our laboratory or a third party laboratory in connection with cellular research activities. We also intend to obtain
cellular-based therapeutic technology licenses and increase our IP portfolio. We intend to seek to develop potential stem cell delivery
systems or devices. The goal of these specialized delivery systems or devices is to deliver cells into specific areas of the body, control
the rate, amount and types of cells used in a treatment, and populate these areas of the body with sufficient stem cells so that there
is a successful therapeutic result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to perform research to develop certain stem cell optimization compounds, media designed to enhance cellular growth and regeneration
for the purpose of improving pre-treatment and post-treatment outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our <i>Disc/Spine Program</i>, twelve patent applications have been filed with regard to technology that is the subject of the Regenerative
License Agreement (see &#8220;Disc/Spine Program-<i>Exclusive License</i>&#8221; above). Regenerative has been issued a patent from one
of these applications with regard to its curved needle therapeutic delivery device. This patent expires in March 2031. In addition, in
March 2022, a United States patent related to <i>BRTX-</i>100 was issued. This patent expires in December 2029. The other ten applications
remain pending. The patents that are the subject of the Regenerative License Agreement have been assigned to Regenexx, LLC which we have
been advised is an affiliate of Regenerative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our <i>ThermoStem Program</i>, we have three pending United States patent applications and five United States patents within three patent
families. Three of the patents expire in June 2032 and two of the patents expire in April 2034. With regard to the first patent family
in the <i>ThermoStem Program, </i>patent applications have been filed in five foreign jurisdictions (of which four applications have
been granted as foreign patents and one application has lapsed). The patents expire in June 2032. With regard to the second patent family
in the <i>ThermoStem Program,</i> patent applications have been filed in four foreign jurisdictions (of which four applications have
been granted as foreign patents). The patents expire in April 2034. With regard to the third patent family in the <i>ThermoStem Program</i>,
patent applications have been filed in four foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent applications and those of Regenexx, LLC are currently in prosecution (i.e., we and Regenexx, LLC are seeking issued patents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2014, we entered into a Research and Development Agreement with Rohto Pharmaceutical Co., Ltd., a Japanese pharmaceutical company,
or Rohto. Pursuant to the Research and Development Agreement with Rohto, we were engaged to provide research and development services
with regard to stem cells. The agreement with Rohto expired upon the completion of the services provided for therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured registrations in the U.S. Patent and Trademark Office for the following trademarks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="A picture containing text&#10;&#10;Description automatically generated" style="height: 50px; width: 122px" /></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRTX-100</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERMOSTEM</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRTX</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<i>Dragonfly Logo</i> is also registered with the U.S. Copyright Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have federal common law rights in the trademark <i>BioRestorative Therapies</i> and other trademarks and trade names used in the
conduct of our business that are not registered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on our ability to develop and protect our proprietary technology. We intend to rely on a combination
of patent, trade secret and know-how, copyright and trademark laws, as well as confidentiality agreements, licensing agreements, non-compete
agreements and other agreements, to establish and protect our proprietary rights. Our success will also depend upon our ability to avoid
infringing upon the proprietary rights of others, for if we are judicially determined to have infringed such rights, we may be required
to pay damages, alter our services, products or processes, obtain licenses or cease certain activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and 2021, we incurred $3,513,352 and $729,058, respectively, in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a Scientific Advisory Board whose purpose is to provide advice and guidance in connection with scientific matters relating
to our business. The Scientific Advisory Board has established a Disc Advisory Committee which focuses on matters relating to our <i>Disc/Spine
Program</i>. Our Scientific Advisory Board members are Dr. Wayne Marasco (Chairman), Dr. Wayne Olan, Dr. Joy Cavagnaro, Dr. Jason Lipetz,
Dr. Harvinder Sandhu and Dr. Christopher Plastaras. The Disc Advisory Committee members are Dr. Lipetz (Chairman), Dr. Olan, Dr. Sandhu
and Dr. Plastaras. See Item 10 of this Annual Report (&#8220;Directors, Executive Officers and Corporate Governance &#8211; Scientific
Advisory Board&#8221;) for a listing of the principal positions for Drs. Marasco, Olan, Cavagnaro, Lipetz, Sandhu and Plastaras.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete with many pharmaceutical, biotechnology and medical device companies, as well as other private and public stem cell companies
involved in the development and commercialization of cell-based medical technologies and therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
medicine is rapidly progressing, in large part through the development of cell-based therapies or devices designed to isolate cells from
human tissues. Most efforts involve cell sources, such as bone marrow, adipose tissue, embryonic and fetal tissue, umbilical cord and
peripheral blood and skeletal muscle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
working in the area of regenerative medicine with regard to the disc and spine include, among others, Mesoblast, SpinalCyte, DiscGenics
and Isto Biologics. Companies that are developing products and therapies to combat obesity and diabetes, including through the use of
brown fat, include, among others, Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer and Regeneron.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors and potential competitors have substantially greater financial, technological, research and development, marketing
and personnel resources than we do. We cannot, with any accuracy, forecast when or if these companies are likely to bring their products
and therapies to market in competition with those that we are pursuing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act, or the BPCIA, sets forth an abbreviated pathway for the approval of biosimilar and interchangeable
biological products that could be used by future competitors, if any, of our product candidates that are approved by the FDA as a biologic.
For the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product
and the proposed biosimilar product. Interchangeability requires that a product is biosimilar to the reference product, and the product
must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered
multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing
safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Under the BPCIA, an application for
a biosimilar product cannot be submitted to the FDA until four years following approval of the reference product, and it may not be approved
by the FDA until 12 years after the original branded product is approved under a biologics license application, or BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, if any of our product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period
of exclusivity. However, there is a risk that the FDA could permit biosimilar applicants to reference approved biologics other than our
therapeutic candidates, thus circumventing our exclusivity and potentially creating the opportunity for competition sooner than anticipated.
Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional
BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any
one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear,
and will depend on a number of marketplace and regulatory factors that are still developing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also face increased competition from stem cell therapies performed by treatment centers that do not require FDA premarket approval.
In August 2022, a federal District Court in the case of <i>United States v. California Stem Cell Treatment Center, Inc.</i> held that
certain autologous adipose stem cell treatments were not &#8220;biological products&#8221; and therefore did not require FDA approval.
The FDA has appealed the decision but, should it be upheld, we could face competition from stem cell clinics that would not be required
to undergo the costly and time-consuming FDA approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a comparison of <i>BRTX-100</i> to Mesoblast&#8217;s adult stem cell biologic:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-k_005.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that <i>BRTX-100</i> has competitive advantages to Mesoblast&#8217;s product for the following reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of autologous cells results in low to no risk of rejection, greater safety profile (introduction of viral/genetic) and streamlined
    regulatory path</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypoxic
    culturing creates increased cell proliferation, greater plasticity, increased paracrine effect and increased cell survival after
    application</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autologous
    platelet lysate provides growth factors that interact with the cells, allowing for better cell survival</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
    to no risk of safety concerns related to immunological and zoonotic (animal to human) transmission</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
regulatory approval, our cell product candidates are intended to be marketed to physicians, other health care professionals, hospitals,
research institutions, pharmaceutical companies and the military. It is anticipated that physicians who are trained and skilled in performing
spinal injections will be the physicians most likely to treat discs with injections of <i>BRTX-100</i> upon regulatory approval. These
physicians would include interventional physiatrists (physical medicine physicians), pain management anesthesiologists, interventional
radiologists and neurosurgeons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governmental
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is highly regulated in the United States. The federal government, through various departments and agencies, state
and local governments, and private third-party accreditation organizations, regulate and monitor the health care industry, associated
products, and operations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose
substantial requirements upon the clinical development, approval, manufacture, distribution and marketing of medical products, including
drugs, biologics, and medical devices. These agencies and other federal, state and local entities regulate research and development activities
and the testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval,
post-approval monitoring, advertising, promotion, sampling and import and export of medical products. The following is a general overview
of the laws and regulations pertaining to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Regulation of Stem Cell Treatment and Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates the manufacture of human stem cell treatments and associated products under the authority of the Public Health Service
Act, or PHSA, and the Federal Food, Drug, and Cosmetic Act, or FDCA. Stem cells can be regulated under the FDA&#8217;s Human Cells, Tissues,
and Cellular and Tissue-Based Products Regulations, or HCT/Ps, or may also be subject to the FDA&#8217;s drug, biologic, or medical device
regulations, each as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Human
Cells, Tissues, and Cellular and Tissue-Based Products Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 361 of the PHSA, the FDA issued specific regulations governing the use of HCT/Ps in humans. Pursuant to Part 1271 of Title 21
of the Code of Federal Regulations, or CFR, or the HCT/P Regulations, the FDA established a unified registration and listing system for
establishments that manufacture and process HCT/Ps. The regulations also include provisions pertaining to donor eligibility determinations;
current good tissue practices covering all stages of production, including harvesting, processing, manufacture, storage, labeling, packaging,
and distribution; and other procedures to prevent the introduction, transmission, and spread of communicable diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HCT/P Regulations define HCT/Ps as articles &#8220;containing or consisting of human cells or tissues that are intended for implantation,
transplantation, infusion or transfer into a human recipient.&#8221; The HCT/P Regulations strictly constrain the types of products that
may be regulated solely as HCT/P. Factors considered include the degree of manipulation, whether the product is intended for a homologous
function, whether the product has been combined with noncellular or non-tissue components, and the product&#8217;s effect or dependence
on the body&#8217;s metabolic function. In those instances where cells, tissues, and cellular and tissue-based products have been only
minimally manipulated, are intended strictly for homologous use, have not been combined with noncellular or nontissue substances, and
do not depend on or have any effect on the body&#8217;s metabolism, the manufacturer is only required to register with the FDA, submit
a list of manufactured products, and adopt and implement procedures for the control of communicable diseases. If one or more of the above
factors has been exceeded, the product would be regulated as a drug, biological product, or medical device rather than an HCT/P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are an enterprise in the early stages of operations and have not generated significant revenues from operations, it is difficult to
anticipate the likely regulatory status of the array of products and services that we may offer. We believe that some of the adult autologous
(self-derived) stem cells that will be used in our cellular therapy products and services, including the brown adipose (fat) tissue that
we intend to use in our <i>ThermoStem Program</i>, may be regulated by the FDA as HCT/Ps under the HCT/P Regulations. However, the FDA
may disagree with this position or conclude that some or all of our stem cell therapy products or services do not meet the applicable
definitions and exemptions to the regulation. In July 2020, the FDA issued an updated guidance document entitled &#8220;Regulatory Considerations
for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use&#8221; that provides additional
guidance on how FDA interprets the HCT/P Regulations, particularly the definition of the terms &#8220;minimally manipulated&#8221; and
&#8220;homologous use.&#8221; In the guidance, FDA stated it will exercise enforcement discretion until May 31, 2021 for products that
do not comply with the HCT/P Regulations. As of that date, manufacturers of products marketed as HCT/Ps that do not comply with the HCT/P
Regulations are subject to immediate FDA enforcement action. If we are not regulated solely under the HCT/P Regulations, we would need
to expend significant resources to comply with the FDA&#8217;s broad regulatory authority under the FDCA. Historically, the U.S. federal
courts have upheld the FDA&#8217;s authority to regulate stem cell products under the FDCA that do not comply with FDA&#8217;s interpretations
of the HCT/P Regulations. However, in August 2022, a federal District Court in the case of <i>United States v. California Stem Cell Treatment
Center, Inc.</i> held that certain autologous adipose stem cell treatments that FDA alleged were biological products were instead within
the HCT/P definition and therefore did not require FDA approval. The FDA has appealed the decision but, should it be upheld, it could
expand the types of stem cell products that are regulated solely under the HCT/P Regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulated solely under the FDA&#8217;s HCT/P statutory and regulatory provisions, once our laboratory in the United States becomes operational,
it will need to satisfy the following requirements, among others, to process and store stem cells:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">registration
    and listing of HCT/Ps with the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">donor
    eligibility determinations, including donor screening and donor testing requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">current
    good tissue practices, specifically including requirements for the facilities, environmental controls, equipment, supplies and reagents,
    recovery of HCT/Ps from the patient, processing, storage, labeling and document controls, and distribution and shipment of the HCT/Ps
    to the laboratory, storage, or other facility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tracking
    and traceability of HCT/Ps and equipment, supplies, and reagents used in the manufacture of HCT/Ps;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    event reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    inspection; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abiding
    by any FDA order of retention, recall, destruction, and cessation of manufacturing of HCT/Ps.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-reproductive
HCT/Ps and non-peripheral blood stem/progenitor cells that are offered for import into the United States and regulated solely under Section
361 of the PHSA must also satisfy the requirements under 21 C.F.R. &#167; 1271.420. Section 1271.420 requires that the importer of record
of HCT/Ps notify the FDA prior to, or at the time of, importation and provide sufficient information for the FDA to make an admissibility
decision. In addition, the importer must hold the HCT/P intact and under conditions necessary to prevent transmission of communicable
disease until an admissibility decision is made by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
including public warning letters, fines, consent decrees, orders of retention, recall or destruction of product, orders to cease manufacturing,
and criminal prosecution. If any of these events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that our cellular therapy activities are limited to developing products and services outside the United States, as described
in detail below, the products and services would not be subject to FDA regulation, but will be subject to the applicable requirements
of the foreign jurisdiction. We intend to comply with all applicable foreign governmental requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Drug
and Biological Product Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
HCT/P product that does not meet the criteria for being solely regulated under Section 361 of the PHSA will be regulated as a drug, device
or biological product under the FDCA and/or Section 351 of the PHSA, and applicable FDA regulations. The FDA has broad regulatory authority
over drugs and biologics marketed for sale in the United States. The FDA regulates the research, clinical testing, manufacturing, safety,
effectiveness, labeling, storage, recordkeeping, promotion, distribution, and production of drugs and biological products. The FDA also
regulates the export of drugs and biological products manufactured in the United States to international markets in certain situations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practice,
or GLP, or other applicable regulations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
submission of an IND, which allows clinical trials to begin unless the FDA objects within 30 days;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug or biologic
for its intended use or uses conducted in accordance with FDA regulations and Good Clinical Practices, or GCP, which are international
ethical and scientific quality standards meant to ensure that the rights, safety and well-being of trial participants are protected and
that the integrity of the data is maintained;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
registration of clinical trials of FDA-regulated products and certain clinical trial information;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
preparation and submission to the FDA of a new drug application, or NDA, in the case of a drug or BLA in the case of a biologic;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
review of the product by an FDA advisory committee, where appropriate or if applicable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
satisfactory completion of pre-approval inspection of manufacturing facilities and clinical trial sites at which the product, or components
thereof, are produced to assess compliance with cGMP requirements and of selected clinical trial sites to assess compliance with GCP
requirements; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
FDA approval of an NDA or BLA which must occur before a drug or biologic can be marketed or sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of an NDA requires a showing that the drug is safe and effective for its intended use and that the methods, facilities, and controls
used for the manufacturing, processing, and packaging of the drug are adequate to preserve its identity, strength, quality, and purity.
To obtain a BLA, a manufacturer must show that the proposed product is safe, pure, and potent and that the facility in which the product
is manufactured, processed, packed, or held meets established quality control standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of an NDA or BLA approval by the FDA, human clinical trials are typically conducted in the following phases (which may overlap):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 1: The investigational product is initially given to healthy human subjects or patients and tested for safety, dosage tolerance,
absorption, metabolism, distribution and excretion. These trials may also provide early evidence on effectiveness. During Phase 1 clinical
trials, sufficient information about the investigational product&#8217;s pharmacokinetics and pharmacologic effects may be obtained to
permit the design of well-controlled and scientifically valid Phase 2 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 2: These clinical trials are conducted in a limited number of human subjects in the target population to identify possible adverse
effects and safety risks, to determine the efficacy of the investigational product for specific targeted diseases and to determine dosage
tolerance and dosage levels. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
larger and more costly Phase 3 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 3: Phase 3 clinical trials are undertaken after Phase 2 clinical trials demonstrate that a dosage range of the investigational
product appears effective and has a tolerable safety profile. The Phase 2 clinical trials must also provide sufficient information for
the design of Phase 3 clinical trials. Phase 3 clinical trials are conducted to provide statistically significant evidence of clinical
efficacy and to further test for safety risks in an expanded human subject population at multiple clinical trial sites. These clinical
trials are intended to further evaluate dosage, effectiveness and safety, to establish the overall benefit-risk profile of the investigational
product and to provide an adequate basis for product labeling and approval by the FDA. In most cases, the FDA requires two adequate and
well-controlled Phase 3 clinical trials to demonstrate the efficacy of an investigational drug or biologic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted in accordance with FDA regulations, GCP requirements and their protocols in order for the data to be
considered reliable for regulatory purposes. Progress reports detailing the results of the clinical trials must be submitted at least
annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, or at all. These government regulations may delay or prevent approval of product candidates
for a considerable period of time and impose costly procedures upon our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may require, or companies may pursue, additional clinical trials, referred to as Phase 4 clinical trials, after a product is approved.
Such trials may be made a condition to be satisfied for continuing drug approval. The results of Phase 4 clinical trials can confirm
the effectiveness of a product candidate and can provide important safety information. In addition, the FDA has authority to require
sponsors to conduct post-marketing trials to specifically address safety issues identified by the agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act, or PREA, certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess
the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration
for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric
data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that
a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage
form, new dosing regimen, or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase
2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial
PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design,
age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request
for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with
supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon
initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early
phase clinical trials, and/or other clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, manufacturing processes
or facilities, require submission and FDA approval of a new NDA or BLA, or an NDA or BLA supplement, before the change can be implemented.
An NDA or BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA
uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
and biological products must also comply with applicable requirements, including monitoring and recordkeeping activities, manufacturing
requirements, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities
with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising
requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or
in patient populations that are not described in the drug&#8217;s approved labeling, or off-label use, limitations on industry-sponsored
scientific and educational activities and requirements for promotional activities involving the internet. Although physicians may, in
their independent professional medical judgment, prescribe legally available drugs for off-label uses, manufacturers typically may not
market or promote such off-label uses. Modifications or enhancements to the product or its labeling, or changes of the site of manufacture,
are often subject to the approval of the FDA and other regulators, who may or may not grant approval or may include a lengthy review
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined that, under the FDA&#8217;s current interpretation of the applicable law, our <i>BRTX-100</i> product candidate will
be regulated as a biological product under the PHSA. Therefore, we will need to expend significant resources to ensure regulatory compliance.
There is no assurance as to whether or when we will receive FDA approval of the <i>BRTX-100 </i>product candidate. The process of designing,
conducting, compiling and submitting the non-clinical and clinical studies required for BLA approval is time-consuming, expensive and
unpredictable. The process can take many years, depending on the product and the FDA&#8217;s requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations
and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form
of onerous risk management plans, restrictions on distribution or use, or post-marketing trial requirements. Further, even after regulatory
approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product, including
safety labeling or imposition of a Risk Evaluation and Mitigation Strategy, or REMS, the requirement to conduct post-market studies or
clinical trials or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval
for our products, or obtaining approval but for significantly limited use, would harm our business. Further, we cannot predict what adverse
governmental regulations may arise from future United States or foreign governmental action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals,
seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these
events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Expedited Review Programs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to expedite the review of NDAs and BLAs in several ways. Under the Fast Track program, the sponsor of a drug or biologic
product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after
the filing of the IND. Drug and biologic products are eligible for Fast Track designation if they are intended to treat a serious or
life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies
to the combination of the product candidate and the specific indication for which it is being studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of
a Fast Track NDA or BLA before the application is complete, a process known as rolling review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product submitted to the FDA for marketing, including under a Fast Track program, may also be eligible for the following other types
of FDA programs intended to expedite development and review:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence must indicate that such product candidates may demonstrate
substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor
of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement
of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review, and rolling review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a
significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition compared to marketed
products. The FDA aims to complete its review of priority review applications within six months as opposed to ten months for standard
review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Accelerated approval. Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses
and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means
that a product candidate may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate
has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical
endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity
and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require
that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled post-marketing
clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.
As a result of the FDA&#8217;s controversial use of the accelerated approval pathway for an Alzheimer&#8217;s drug (aducanumab), Congress
revised the accelerated approval process as a part of the Food and Drug Omnibus Reform Act of 2022 to provide the FDA with additional
authorities to enforce the post-approval study requirements and to withdraw approvals when those requirements are not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval
but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
with the passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review
and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative
medicine advanced therapy, or RMAT (which may include a cell therapy), that is intended to treat, modify, reverse or cure a serious or
life-threatening disease or condition, and preliminary clinical evidence indicates that the drug has the potential to address unmet medical
needs for such disease or condition. The benefits of a RMAT designation include early interactions with the FDA to expedite development
and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on
surrogate or intermediate endpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical
Device Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also has broad authority over the regulation of medical devices marketed for sale in the United States. The FDA regulates the research,
clinical testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, promotion, distribution,
and production of medical devices. The FDA also regulates the export of medical devices manufactured in the United States to international
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes, Class I, Class II, or Class III, depending upon the degree of risk
associated with the medical device and the extent of control needed to ensure safety and effectiveness. Class I devices are subject to
the lowest degree of regulatory scrutiny because they are considered low risk devices and need only comply with the FDA&#8217;s General
Controls. The General Controls include compliance with the registration, listing, adverse event reporting requirements, and applicable
portions of the Quality System Regulation as well as the general misbranding and adulteration prohibitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are subject to the General Controls as well as certain Special Controls such as 510(k) premarket notification. Class III devices
are subject to the highest degree of regulatory scrutiny and typically include life supporting and life sustaining devices and implants.
They are subject to the General Controls and Special Controls that include a premarket approval application, or PMA. &#8220;New&#8221;
devices are automatically regulated as Class III devices unless they are shown to be low risk, in which case they may be subject to de
novo review to be moved to Class I or Class II. Clinical research of an investigational device is subject to the FDA&#8217;s Investigational
Device Exemption, or IDE, regulations. Nonsignificant risk devices are subject to abbreviated requirements that do not require a submission
to the FDA but must have Institutional Review Board (IRB) approval and comply with other requirements pertaining to informed consent,
labeling, recordkeeping, reporting, and monitoring. Significant risk devices require the submission of an IDE application to the FDA
and the FDA&#8217;s approval of the IDE application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA premarket clearance and approval process can be lengthy, expensive and uncertain. It generally takes three to twelve months from
submission to obtain 510(k) premarket clearance, although it may take longer. Approval of a PMA could take one to four years, or more,
from the time the application is submitted and there is no guarantee of ultimate clearance or approval. Securing FDA clearances and approvals
may require the submission of extensive clinical data and supporting information to the FDA. Additionally, the FDA actively enforces
regulations prohibiting marketing and promotion of devices for indications or uses that have not been cleared or approved by the FDA.
In addition, modifications or enhancements of products that could affect the safety or effectiveness or effect a major change in the
intended use of a device that was either cleared through the 510(k) process or approved through the PMA process may require further FDA
review through new 510(k) or PMA submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we develop processes, products or services which qualify as medical devices subject to FDA regulation, we intend to comply
with such regulations. If the FDA determines that our products are regulated as medical devices and we have failed to comply with applicable
regulatory requirements, it can impose a variety of enforcement actions from public warning letters, application integrity proceedings,
fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure of our products, total
or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these events were to occur, it could
materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Good Manufacturing Practices and other FDA Regulations of Cellular Therapy Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
that fall outside of the HCT/P regulations and are regulated as drugs, biological products, or devices must comply with applicable cGMP
regulations. These cGMPs and related quality standards are designed to ensure the products that are processed at a facility meet the
FDA&#8217;s applicable requirements for identity, strength, quality, sterility, purity, and safety. In the event that our domestic United
States operations are subject to the FDA&#8217;s drug, biological product, or device regulations, we intend to comply with the applicable
cGMPs and quality regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals,
seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these
events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promotion
of Foreign-Based Cellular Therapy Treatment&#8212; &#8220;Medical Tourism&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may establish, or license technology to third parties in connection with their establishment of, adult stem cell therapy facilities outside
the United States. We also intend to work with hospitals and physicians to make the stem cell-based therapies available for patients
who travel outside the United States for treatment. &#8220;Medical tourism&#8221; is defined as the practice of traveling across international
borders to obtain health care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Trade Commission, or the FTC, has the authority to regulate and police advertising of medical treatments, procedures, and regimens
in the United States under the Federal Trade Commission Act, or the FTCA. The FTC has regulatory authority to prevent unfair and deceptive
practices and false advertising. Specifically, the FTC requires advertisers and promoters to have a reasonable basis to substantiate
and support claims. The FTC has many enforcement powers, one of which is the power to order disgorgement by promoters deemed in violation
of the FTCA of any profits made from the promoted business and can order injunctions from further violative promotion. Advertising that
we may utilize in connection with our medical tourism operations will be subject to FTC regulatory authority, and we intend to comply
with such regulatory r&#233;gime. Similar laws and requirements are likely to exist in other countries and we intend to comply with
such requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Regulation of Clinical Laboratories</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Congress
passed the Clinical Laboratory Improvement Amendments, or CLIA, in 1988, which provided the Centers for Medicare and Medicaid Services,
or CMS, authority over all laboratory testing, except research, that is performed on humans in the United States. The Division of Laboratory
Services, within the Survey and Certification Group, under the Center for Medicaid and State Operations, or CMSO, has the responsibility
for implementing the CLIA program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CLIA program is designed to establish quality laboratory testing by ensuring the accuracy, reliability, and timeliness of patient test
results. Under CLIA, a laboratory is a facility that does laboratory testing on specimens derived from humans and used to provide information
for the diagnosis, prevention, treatment of disease, or impairment of, or assessment of health. Laboratories that handle stem cells and
other biologic matter are, therefore, included under the CLIA program. Under the CLIA program, laboratories must be certified by the
government, satisfy governmental quality and personnel standards, undergo proficiency testing, be subject to inspections, and pay fees.
To the extent that our business activities require CLIA certification, we intend to obtain and maintain such certification. If we are
subject to CLIA, the failure to comply with CLIA standards could result in suspension, revocation, or limitation of a laboratory&#8217;s
CLIA certificate. In addition, fines or criminal penalties could also be levied. If any of these events were to occur, it could impact
our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Insurance Portability and Accountability Act&#8212;Protection of Patient Health Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
The Health Insurance Portability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
Act, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, imposes
specified requirements relating to the privacy, security and transmission of individually identifiable health information on certain
types of individuals and organizations. In addition, certain state laws govern the privacy and security of health information in certain
circumstances, many of which differ from each other and from HIPAA in significant ways and may not have the same effect, thus complicating
compliance efforts. Further, we may need to also comply with additional federal or state privacy laws and regulations that may apply
to certain diagnoses, such as HIV/AIDS, to the extent that they apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services, or HHS, through its Office for Civil Rights, investigates breach reports and determines whether
administrative or technical modifications are required and whether civil or criminal sanctions should be imposed. Companies failing to
comply with HIPAA and the implementing regulations may also be subject to civil money penalties or in the case of knowing violations,
potential criminal penalties, including monetary fines, imprisonment, or both. In some cases, the State Attorneys General may seek enforcement
and appropriate sanctions in federal court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Applicable U.S. Laws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above-described regulation by United States federal and state government, the following are other federal and state laws
and regulations that could directly or indirectly affect our ability to operate the business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local licensure, registration, and regulation of the development of pharmaceuticals and biologics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local licensure of medical professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    statutes and regulations related to the corporate practice of medicine;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws
    and regulations administered by U.S. Customs and Border Protection related to the importation of biological material into the United
    States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    laws and regulations administered by the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    laws and regulations administered by HHS;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local laws and regulations governing human subject research and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal physician self-referral prohibition, also known as Stark Law, and any state equivalents to Stark Law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal False Claims Act, or FCA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, or AKS, and any state equivalent statutes and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    and state coverage and reimbursement laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local laws and regulations for the disposal and handling of medical waste and biohazardous material;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupational
    Safety and Health Administration, or OSHA, regulations and requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Intermediate Sanctions rules of the IRS providing for potential financial sanctions with respect to &#8220;excess benefit transactions&#8221;
    with tax-exempt organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Physician Payments Sunshine Act (in the event that our products are classified as drugs, biologics, devices or medical supplies and
    are reimbursed by Medicare, Medicaid or the Children&#8217;s Health Insurance Program);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and other federal laws addressing the privacy of health information; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
    or services reimbursed by any third-party payer, including commercial insurers, state laws that require pharmaceutical companies
    to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
    by the federal government or otherwise restrict payments that may be made to healthcare professionals and other potential referral
    sources, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
    and other healthcare professionals or marketing expenditures, and state laws governing the privacy and security of health information
    in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
    compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation
of any of the laws described above or any other governmental laws and regulations may result in penalties, including civil and criminal
penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare
programs and imprisonment. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare
laws and regulations can be costly for manufacturers of branded prescription products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, we will need to comply with the government regulations of each individual country in which our therapy centers are located and
products are to be distributed and sold. These regulations vary in complexity and can be as stringent, and on occasion even more stringent,
than FDA regulations in the United States. Due to the fact that there are new and emerging cell therapy regulations that have recently
been drafted and/or implemented in various countries around the world, the application and subsequent implementation of these new and
emerging regulations have little to no precedence. Therefore, the level of complexity and stringency is not always precisely understood
for each country, creating greater uncertainty for the international regulatory process. Furthermore, government regulations can change
with little to no notice and may result in up-regulation of our product(s), thereby creating a greater regulatory burden for our cell
processing technology products. We have not yet thoroughly explored the applicable laws and regulations that we will need to comply with
in foreign jurisdictions. It is possible that we may not be permitted to expand our business into one or more foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any definitive plans or arrangements with respect to the establishment by us of stem cell therapy clinics in any country.
We intend to explore any such opportunities as they arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 40 Marcus Drive, Suite One, Melville, New York, and our telephone number is (631) 760-8100.
Our website is www.biorestorative.com. Our internet website and the information contained therein or connected thereto are not intended
to be incorporated by reference into this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have 10 employees, all of whom are full-time employees. We believe that our employee relations are good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_003"></span>ITEM
    1A</span></b>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">RISK
    FACTORS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors listed in this section provide examples of risks, uncertainties and events that may cause our actual results to differ materially
from the expectations we describe in our forward-looking statements. Readers should be aware that the occurrence of any of the events
described in these risk factors could have a material adverse effect on our business, results of operations and financial condition.
We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future
events, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preceding
the full risk factors is a list of certain of the risk factors that follow. Reference is made to the complete risk factors for a full
description of the risks involved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Business Generally</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history; we have incurred substantial losses since inception; we
                                            expect to continue to incur losses for the near term.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to obtain a significant amount of financing to complete our clinical trials and
                                            implement our business plan.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to enter into agreements in order to implement our business strategy.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            depend on our executive officers and on our ability to attract and retain additional qualified
                                            personnel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Cell Therapy Product Development Efforts</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            future success is significantly dependent on the timely and successful development and commercialization
                                            of BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease;
                                            if we encounter delays or difficulties in the development of this product candidate, as well
                                            as any other product candidates, our business prospects would be significantly harmed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may experience delays and other difficulties in enrolling a sufficient number of patients
                                            in our clinical trials which could delay or prevent the receipt of necessary regulatory approvals.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            development of our cell therapy product candidates is subject to uncertainty because autologous
                                            cell therapy is inherently variable.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            disruption to our access to the media (including cell culture media) and reagents we are
                                            using in the clinical development of our cell therapy product candidates could adversely
                                            affect our ability to perform clinical trials and seek future regulatory submissions.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            clinical trials may fail to demonstrate adequately the safety and efficacy of our product
                                            candidates, which would prevent or delay regulatory approval and commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain
                                            regulatory approval to commercialize a product candidate, and the approval may be for a narrower
                                            indication than we seek.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may never obtain FDA approval for any of our product candidates in the United States and,
                                            even if we do, we may never obtain approval for or commercialize any of our product candidates
                                            in any foreign jurisdiction, which would limit our ability to realize our full market potential.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            presently lack manufacturing capabilities to produce our product candidates in connection
                                            with our Phase 3 clinical trial and at commercial scale quantities and do not have an alternate
                                            manufacturing supply, which could negatively impact our ability to meet any future demand
                                            for the products.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            commercial potential and profitability of our products are unknown and subject to significant
                                            risk and uncertainty.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may have difficulties in sourcing brown adipose (fat) tissue.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            safety problems are encountered by us or others developing new stem cell-based therapies,
                                            our stem cell initiatives could be materially and adversely affected.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are vulnerable to competition and technological change, and also to physicians&#8217; inertia.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have limited experience in the development and marketing of cell therapies and may be unsuccessful
                                            in our efforts to establish a profitable business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            cell therapy business is based on novel technologies that are inherently expensive, risky
                                            and may not be understood by or accepted in the marketplace, which could adversely affect
                                            our future value.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            cell therapy product candidates for which we intend to seek approval as biologic products
                                            may face competition sooner than anticipated.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to significant product liability claims and litigation, including potential
                                            exposure from the use of our product candidates in human subjects, and our insurance may
                                            be inadequate to cover claims that may arise.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            internal computer systems, or those that are expected to be used by our clinical investigators,
                                            clinical research organizations or other contractors or consultants, may fail or suffer security
                                            breaches, which could result in a material disruption of development programs for our product
                                            candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            inability to obtain reimbursement for our products and services from private and governmental
                                            insurers could negatively impact demand for our products and services.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Intellectual Property</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to protect our proprietary rights.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            to United States patent law may have a material adverse effect on our intellectual property
                                            rights.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            certain countries, patent holders may be required to grant compulsory licenses, which would
                                            likely have a significant and detrimental effect on any future revenues in such country.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Government Regulation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we obtain regulatory approval for a product candidate, our products will remain subject
                                            to regulatory oversight.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws,
                                            false claims laws and health information privacy and security laws. If we are unable to comply,
                                            or have not fully complied, with such laws, we could face substantial penalties.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            failure to receive regulatory approvals for our cell therapy product candidates would likely
                                            have a material and adverse effect on our business and prospects.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we are unable to conduct clinical studies in accordance with regulations and accepted standards,
                                            we may be delayed in receiving, or may never receive, regulatory approvals of our product
                                            candidates from the FDA and other regulatory authorities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
                                            care companies have been the subjects of federal and state investigations, and we could become
                                            subject to investigations in the future.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is uncertain to what extent the government, private health insurers and third-party payors
                                            will approve coverage or provide reimbursement for the therapies and products to which our
                                            services relate. Availability for such reimbursement may be further limited by reductions
                                            in Medicare, Medicaid and other federal healthcare program funding in the United States.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitor
                                            companies or hospitals in the EU may be able to take advantage of EU rules permitting sales
                                            of unlicensed medicines for individual patients to sell competing products without a marketing
                                            authorization.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            pay no dividends.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
                                            who hold unregistered shares of our common stock are subject to resale restrictions pursuant
                                            to Rule 144 due to our former status as a &#8220;shell company.&#8221;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
                                            weaknesses in our internal control over financial reporting may cause us to fail to timely
                                            and accurately report our financial results or result in a material misstatement of our consolidated
                                            financial statements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            may be significant future issuances or resales of our common stock which may materially and
                                            adversely dilute stockholders&#8217; ownership interest and affect the market price of our
                                            securities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-takeover
                                            provisions and the regulations to which we may be subject may make it more difficult for
                                            a third party to acquire control of us, even if the change in control would be beneficial
                                            to our securityholders.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            common stock is classified as a &#8220;penny stock;&#8221; the restrictions of the penny
                                            stock regulations of the Securities and Exchange Commission may result in less liquidity
                                            for our common stock.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Associated with Our Nasdaq Listing</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            cannot assure you that we will be able to continue to comply with the minimum bid price requirement
                                            of Nasdaq.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            market price of our common stock may not attract new investors, including institutional investors,
                                            and may not satisfy the investing requirements of those investors. Consequently, the trading
                                            liquidity of our common stock may not improve.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Business Generally</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history; we have incurred substantial losses since inception; we expect to continue to incur losses for the
near term.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history. Since our inception, we have incurred net losses. As of December 31, 2022, our accumulated deficit
was $152,640,897.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to obtain a significant amount of financing to complete our clinical trials and implement our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have not generated revenues from our operations and have funded our operations through the sale of our equity securities
and debt securities. The implementation of our business plan, as discussed in this Annual Report under Item 1 (&#8220;Business&#8221;),
will require the receipt of sufficient equity and/or debt financing to purchase necessary equipment, technology and materials, fund our
clinical trials and other research and development efforts and otherwise fund our operations. We will require significant additional
funding to complete our clinical trials using <i>BRTX-100</i>. We will also require a substantial amount of additional funding to implement
our other programs described in this Annual Report under Item 1 (&#8220;Business&#8221;), including our metabolic <i>ThermoStem Program,
</i>and fund general operations. No assurance can be given that the amount of funding that we anticipate may be required for such purposes
is correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no assurance can be given that
we will be able to obtain any required financing on commercially reasonable terms or otherwise. In the event we do not obtain the financing
required for the above purposes, we may have to curtail our development, marketing and promotional activities, which would have a material
adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations
and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business strategy is high risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focusing our resources and efforts primarily on the development of cellular-based products and services which will require extensive
cash for research, development and commercialization activities. This is a high-risk strategy because there is no assurance that our
products and services, including our <i>Disc/Spine Program</i> and our <i>ThermoStem</i> metabolic brown fat research initiative, will
ever become commercially viable (commercial risk), that we will prevent other companies from depriving us of market share and profit
margins by offering services and products based on our inventions and developments (legal risk), that we will successfully manage a company
in a new area of business, regenerative medicine, and on a different scale than we have operated in the past (operational risk), that
we will be able to achieve the desired therapeutic results using stem and regenerative cells (scientific risk), or that our cash resources
will be adequate to develop our products and services until we become profitable, if ever (financial risk). We are using our cash in
one of the riskiest industries in the economy (strategic risk). This may make our securities an unsuitable investment for many investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to enter into agreements in order to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for a certain license agreement with Regenerative Sciences, LLC and agreements relating to the conduct of our Phase 2 clinical trial,
we do not have any material agreements or understandings in place with respect to the implementation of our business strategy. No assurances
can be given that we will be able to enter into any necessary agreements with respect to the development of our business. Our inability
to enter into any such agreements would have a material adverse effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our executive officers and on our ability to attract and retain additional qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
performance is substantially dependent on the performance of Lance Alstodt, our Chief Executive Officer. We rely upon him for strategic
business decisions and guidance. We are also dependent on the performance of Francisco Silva, our Vice President of Research and Development.
Each of Messrs. Alstodt and Silva is subject to an employment agreement with us. We do not have any key-man insurance policies on the
lives of either of our executive officers. We believe that our future success in developing marketable products and services and achieving
a competitive position will depend in large part upon whether we can attract and retain additional qualified management and scientific
personnel. Competition for such personnel is intense, and there can be no assurance that we will be able to attract and retain such personnel.
The loss of the services of Mr. Alstodt and/or Mr. Silva or the inability to attract and retain additional personnel and develop expertise
as needed would have a substantial negative effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
impact of COVID-19 and related risks could materially affect our results of operations and prospects</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in March 2020, the global pandemic related to the novel coronavirus COVID-19 began to impact the global economy. Because of the size
and breadth of this pandemic, all of the direct and indirect consequences of COVID-19 are not yet known and may not emerge for some time.
Risks presented by the ongoing effects of COVID-19 include, among others, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials. </i>We anticipate that the COVID-19 pandemic may negatively impact our clinical trials. Due to the worldwide efforts being taken
to combat COVID-19 and the increased clinical work being done in this respect, we believe that it may be difficult for certain needed
laboratory supplies, equipment and other materials to be obtained in order to conduct our clinical trials. We also anticipate that, due
to a fear of COVID-19 transmission, there may be a hesitancy on the part of certain individuals to become clinical trial participants.
We believe that these possible negative effects have lessened as more of the population has become vaccinated; however, the impact that
the vaccinations will have is uncertain at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adverse
Legislative and/or Regulatory Action.</i> Federal, state and local government actions to address and contain the impact of COVID-19 may
adversely affect us. For example, we may be subject to legislative and/or regulatory action that negatively impacts the manner in which
the clinical trials may be conducted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operational
Disruptions and Heightened Cybersecurity Risks.</i> Our operations could be disrupted if key members of our senior management or a significant
percentage of our workforce are unable to continue to work because of illness, government directives or otherwise. In addition, in connection
with increased remote working arrangements, we face a heightened risk of cybersecurity attacks or data security incidents and are more
dependent on internet and telecommunications access and capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Cell Therapy Product Development Efforts</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success is significantly dependent on the timely and successful development and commercialization of BRTX-100, our lead product
candidate for the treatment of chronic lumbar disc disease; if we encounter delays or difficulties in the development of this product
candidate, as well as any other product candidates, our business prospects would be significantly harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent upon the successful development, approval and commercialization of our product candidates. Before we are able to seek regulatory
approval of our product candidates, we must conduct and complete extensive clinical trials to demonstrate their safety and efficacy in
humans. Our lead product candidate, <i>BRTX-100</i>, is in early stages of development and we have just recently commenced a Phase 2
clinical trial using <i>BRTX-100</i> to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging
discs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, difficult to design and implement, and can take many years to complete. Importantly, a failure of one or more of
these or any other clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result
of, clinical trials that could delay or prevent our ability to complete our clinical studies, receive regulatory approval or commercialize
our cell therapy product candidates, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspensions,
    delays or changes in the design, initiation, enrollment, implementation or completion of required clinical trials; adverse changes
    in our financial position or significant and unexpected increases in the cost of our clinical development program; changes or uncertainties
    in, or additions to, the regulatory approval process that require us to alter our current development strategy; clinical trial results
    that are negative, inconclusive or less than desired as to safety and/or efficacy, which could result in the need for additional
    clinical studies or the termination of the product&#8217;s development; delays in our ability to manufacture the product in quantities
    or in a form that is suitable for any required clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
    property constraints that prevent us from making, using, or commercializing any of our cell therapy product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our product candidates or other materials necessary to conduct clinical trials of these product candidates may
    be insufficient or inadequate; the inability to generate sufficient pre-clinical, toxicology, or other in vivo or in vitro data,
    to support the initiation of clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective clinical study sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different clinical study sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application
    or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical
    trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials
    conducted by competitors or approved products post-market for related technology that raise FDA concerns about risk to patients of
    the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    collaborating with patient groups and investigators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CRO, other third parties, or us to adhere to clinical study requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s current Good Clinical Practices, or GCP, requirements, or applicable regulatory guidelines
    in other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients qualify for or complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    dropping out of a study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer
    of manufacturing processes from any academic collaborators to larger-scale facilities operated by either a contract manufacturing
    organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in our clinical trials caused by the COVID-19 pandemic or other health emergencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for
    use in clinical studies or the inability to do any of the foregoing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not accept clinical data from trials that are conducted at clinical sites in countries where the standard of care is potentially
    different from the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to raise sufficient funds to complete our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete pre-clinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required, or we
may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also
shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before
we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to successfully complete our clinical development program for our product candidates, and ultimately receive regulatory
approval to market one or more of the products, we may, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval for indications that are not as broad as the indications we sought;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    the product removed from the market after obtaining marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">encounter
    issues with respect to the manufacturing of commercial supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to additional post-marketing testing requirements; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to restrictions on how the product is distributed or used.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will not be able to commercialize our <i>BRTX-100</i> product candidate for at least five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience delays and other difficulties in enrolling a sufficient number of patients in our clinical trials which could delay or
prevent the receipt of necessary regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or complete as planned any clinical trials if we are unable to identify and enroll a sufficient number of
eligible patients to participate in the clinical trials required by the FDA or other regulatory authorities. We also may be unable to
engage a sufficient number of clinical trial sites to conduct our trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face challenges in enrolling patients to participate in our clinical trials due to the novelty of our cell-based therapies, the size
of the patient populations and the eligibility criteria for enrollment in the trial, and potential subjects&#8217; concern over the COVID-19
pandemic. In addition, some patients may have concerns regarding cell therapy that may negatively affect their perception of therapies
under development and their decision to enroll in the trials. Furthermore, patients suffering from diseases within target indications
may enroll in competing clinical trials, which could negatively affect our ability to complete enrollment of our trials. Enrollment challenges
in clinical trials often result in increased development costs for a product candidate, significant delays and potentially the abandonment
of the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have other delays in completing our clinical trials and we may not complete them at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have just recently commenced the clinical trials necessary to obtain FDA approval to market our product candidate, <i>BRTX-100</i>. Since
we lack significant experience in completing clinical trials and bringing a drug through commercialization, we have hired outside consultants
with such experience. Clinical trials for <i>BRTX-100 </i>and other product candidates in development may be delayed or terminated as
a result of many factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    failing to complete clinical trials due to dissatisfaction with the treatment, side effects, concerns over COVID-19, or other reasons;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by regulators to authorize us to commence a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or termination by regulators of clinical research for many reasons, including concerns about patient safety, the failure of study
    sites and/or investigators in our clinical research program to comply with GCP requirements, or our failure, or the failure of our
    contract manufacturers, to comply with current cGMP requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure to obtain clinical supply for our products necessary to conduct clinical trials from contract manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment
    candidates demonstrating a lack of efficacy during clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment
    candidates demonstrating significant safety signals; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to continue to fund clinical trials or to find a partner to fund the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure to complete clinical trials and obtain FDA approval for our product candidates could have a material adverse effect
on our cost to develop and commercialize, and our ability to generate revenue from, a particular product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
development of our cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
manufacturing an autologous cell therapy, the number and composition of the cell population varies from patient to patient. Such variability
in the number and composition of these cells could adversely affect our ability to manufacture autologous cell therapies in a cost-effective
or profitable manner and meet acceptable product release specifications for use in a clinical trial or, if approved, for commercial sale.
As a consequence, the development and regulatory approval process for autologous cell therapy products could be delayed or may never
be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
disruption to our access to the media (including cell culture media) and reagents we are using in the clinical development of our cell
therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
media (including cell culture media) and reagents, as well as devices, materials and systems, that we intend to use in our clinical trials,
and that we may need or use in commercial production, are provided by unaffiliated third parties. Any lack of continued availability
of these media, reagents, devices, materials and systems for any reason would have a material adverse effect on our ability to complete
these studies and could adversely impact our ability to achieve commercial manufacture of our planned therapeutic products. Although
other available sources for these media, reagents, devices, materials and systems may exist in the marketplace, we have not evaluated
their cost, effectiveness, or intellectual property foundation and therefore cannot guarantee the suitability or availability of such
other potential sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Products
that appear promising in research and development may be delayed or may fail to reach later stages of clinical development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of cellular based products is highly uncertain. Product candidates that appear promising in preclinical and early
research and development may be delayed or fail to reach later stages of development. Decisions regarding the further development of
product candidates must be made with limited and incomplete data, which makes it difficult to ensure or even accurately predict whether
the allocation of limited resources and the expenditure of additional capital on specific product candidates will result in desired outcomes.
Pre-clinical and clinical data can be interpreted in different ways, and negative or inconclusive results or adverse events during a
clinical trial could delay, limit or prevent the development of a product candidate. Positive preclinical data may not continue or occur
for future subjects in our clinical studies and may not be repeated or observed in ongoing or future studies involving our product candidates.
Furthermore, our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development despite
having successfully advanced through initial clinical studies. In addition, regulatory delays or rejections may be encountered as a result
of many factors, including changes in regulatory policy during the period of product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory
approval and commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trials of our product candidates are, and the manufacturing and marketing of our products will be, subject to extensive and
rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test
and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we
must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both
safe and effective for use in each target indication. In particular, because some of our product candidates are subject to regulation
as biological drug products, we will need to demonstrate that those products are safe, pure, and potent for use in their target indications.
Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended
use. The risk/benefit profile required for product licensure will vary depending on these factors and may include decrease or elimination
of pain, adequate duration of response, a delay in the progression of the disease, an improvement in function and/or decrease in disability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if such trials are successfully completed, we cannot guarantee that the FDA will interpret the results as we do, and more
trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory
to the FDA for support of a marketing application, we may be required to expend significant resources, which may not be available to
us, to conduct additional trials in support of potential approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product
candidate, and the approval may be for a narrower indication than we seek.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete
their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA
Advisory Committee or other regulatory authority recommends non-approval or restrictions or conditions on approval. In addition, we may
experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes
in regulatory authority policy during the period of product development, clinical trials and the review process. Regulatory authorities
also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form
of narrow indications, contraindications or a Risk Evaluation and Mitigation Strategy, or REMS. These regulatory authorities may require
warnings or precautions with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing
clinical trials. In addition, regulatory authorities may not approve the labeling claims or allow the promotional claims that are necessary
or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the
commercial prospects for our product candidates and materially and adversely affect our business, financial condition, results of operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may never obtain FDA approval for any of our product candidates in the United States and, even if we do, we may never obtain approval
for or commercialize any of our product candidates in any foreign jurisdiction, which would limit our ability to realize our full market
potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to eventually market any of our product candidates in any particular foreign jurisdiction, we must establish and comply with numerous
and varying regulatory requirements regarding safety and efficacy on a jurisdiction-by-jurisdiction basis. Approval by the FDA in the
United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, preclinical
studies and clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical
trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of our product candidates in those countries. The foreign regulatory approval process involves similar risks to those
associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets,
nor have we attempted to obtain such approval. If we fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and
our ability to realize the full market potential of our products may be unrealized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
presently lack manufacturing capabilities to produce our product candidates in connection with our Phase 3 clinical trial and at commercial
scale quantities and do not have an alternate manufacturing supply, which could negatively impact our ability to meet any future demand
for the products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have utilized our laboratory to provide the cell processing services necessary for clinical production of <i>BRTX-100 </i>for our Phase
2 disc clinical trial. We believe that we have sufficient laboratory capacity to provide such services with regard to the balance of
the Phase 2 trial; however, we would need to significantly expand our manufacturing capabilities to provide such cell processing services
in connection with a Phase 3 clinical trial and to meet potential commercial demand for <i>BRTX-100</i> and any other of our product
candidates, if approved, as well as any of our other product candidates that might attain regulatory approval. Such expansion would require
additional regulatory approvals. Even if we increase our manufacturing capabilities, it is possible that we may still lack sufficient
capacity to meet demand. Ultimately, if we are unable to supply our products to meet commercial demand, whether because of processing
constraints or other disruptions, delays or difficulties that we experience, sales of the products and their long-term commercial prospects
could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to utilize a third-party manufacturer for <i>BRTX-100</i> or any of our other product candidates; however, we do not have any
arrangements in place with a third-party manufacturer. If our facilities at which these product candidates would be manufactured or our
equipment were significantly damaged or destroyed, or if there were other disruptions, delays or difficulties affecting manufacturing
capacity, our planned and future clinical studies and commercial production for these product candidates would likely be significantly
disrupted and delayed. It would be both time consuming and expensive to replace this capacity with third parties, particularly since
any new facility would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our cell therapy product candidates to meet commercial demand (assuming commercial approval is obtained),
whether because of processing constraints or other disruptions, delays or difficulties that we experience, our production costs could
dramatically increase and sales of the product and its long-term commercial prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
commercial potential and profitability of our products are unknown and subject to significant risk and uncertainty.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully develop and obtain regulatory approval for our cell therapy product candidates, the market may not understand or accept
the products, which could adversely affect both the timing and level of future sales. Ultimately, the degree of market acceptance of
our product candidates (or any of our future product candidates) will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical effectiveness, safety and convenience of the product particularly in relation to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to distinguish our products (which involve adult cells) from any ethical and political controversies associated with stem
    cell products derived from human embryonic or fetal tissue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of the product, the reimbursement policies of government and third-party payors and our ability to obtain sufficient third-party
    coverage or reimbursement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are successful in achieving sales of our product candidates, it is not clear to what extent, if any, the products will be profitable.
The costs of goods associated with production of cell therapy products are significant. In addition, some changes in manufacturing processes
or procedures generally require FDA or foreign regulatory authority review and approval prior to implementation. We may need to conduct
additional pre-clinical studies and clinical trials to support approval of any such changes. Furthermore, this review process could be
costly and time-consuming and could delay or prevent the commercialization of product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have difficulties in sourcing brown adipose (fat) tissue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use brown adipose (fat) tissue to identify and characterize brown adipose derived stem cells for use in our pre-clinical <i>ThermoStem
Program. </i>There is no certainty that we will be able to continue to collect brown adipose samples through any relationships that we
have, have had or may establish with potential sources of brown adipose tissue. The inability to procure brown fat tissue would have
a material adverse effect upon our ability to advance our <i>ThermoStem Program.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
safety problems are encountered by us or others developing new stem cell-based therapies, our stem cell initiatives could be materially
and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of stem cells for therapeutic indications is still in the very early stages of development. If an adverse event occurs during clinical
trials related to one of our proposed products and/or services or those of others, the FDA and other regulatory authorities may halt
clinical trials or require additional studies. The occurrence of any of these events would delay, and increase the cost of, our development
efforts and may render the commercialization of our proposed products and/or services impractical or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are vulnerable to competition and technological change, and also to physicians&#8217; inertia.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete with many domestic and foreign companies in developing our technology and products, including biotechnology, medical device
and pharmaceutical companies. Many current and potential competitors have substantially greater financial, technological, research and
development, marketing, and personnel resources. There is no assurance that our competitors will not succeed in developing alternative
products and/or services that are more effective, easier to use, or more economical than those which we may develop, or that would render
our products and/or services obsolete and non-competitive. In general, we may not be able to prevent others from developing and marketing
competitive products and/or services similar to ours or which perform similar functions or which are marketed before ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may have greater experience in developing products, therapies or devices, conducting clinical trials, obtaining regulatory clearances
or approvals, manufacturing and commercialization. It is possible that competitors may obtain patent protection, approval or clearance
from the FDA or achieve commercialization earlier than we can, any of which could have a substantial negative effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete against cell-based therapies derived from alternate sources, such as bone marrow, adipose tissue, umbilical cord blood and
potentially embryos. Doctors historically are slow to adopt new technologies like ours, whatever the merits, when older technologies
continue to be supported by established providers. Overcoming such inertia often requires very significant marketing expenditures or
definitive product performance and/or pricing superiority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that physicians&#8217; inertia and skepticism will also be a significant barrier as we attempt to gain market penetration with
our future products and services. We may need to finance lengthy time-consuming clinical studies (so as to provide convincing evidence
of the medical benefit) in order to overcome this inertia and skepticism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not
realize the benefits of such alliances or licensing arrangements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates
and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges,
increase our near and long-term expenditures, issue securities that dilute the shares of our existing stockholders, or disrupt our management
and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming
and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements
for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third
parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. To date, such efforts
have not been successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
collaborations involving our product candidates, such as our collaborations with third-party research institutions, are subject to numerous
risks, which may include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization
    programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability
    of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate,
    repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing
    and distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information
    in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary
    information or expose us to potential liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of
    our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we
    would not have the exclusive right to commercialize such intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, if we enter into collaboration agreements and strategic partnerships or license our products or businesses, we may not be able
to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company
culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic
transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into
new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization
of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition,
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a profitable
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan has been focused historically on capturing a piece of the burgeoning field of cell therapy. We have limited experience
in the areas of cell therapy product development and marketing, and in the related regulatory issues and processes. Although we have
recruited a team that has experience with designing and conducting clinical trials and have hired FDA consultants, as a company, we have
limited experience in conducting clinical trials and no experience in conducting clinical trials through to regulatory approval of any
product candidate. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed
on time, if at all. We cannot assure that we will successfully achieve our clinical development goals or fulfill our plans to capture
a piece of the cell therapy market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in
the marketplace, which could adversely affect our future value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, commercialization and marketing of cell and tissue-based therapies are at an early-stage, substantially research-oriented,
and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize a cell therapy
product. In general, cell-based or tissue-based products may be susceptible to various risks, including undesirable and unintended side
effects, unintended immune system responses, inadequate therapeutic efficacy, or other characteristics that may prevent or limit their
approval or commercial use. In addition, <i>BRTX-100</i> is a cell-based candidate that is produced by using a patient&#8217;s own stem
cells derived from bone marrow. Regulatory approval of novel product candidates such as <i>BRTX-100</i>, which is manufactured using
novel manufacturing processes, can be more complex and expensive and take longer than other, more well-known or extensively studied pharmaceutical
or biopharmaceutical products, due to the FDA&#8217;s lack of experience with them. To our knowledge, the FDA has not yet approved a
disc related stem cell therapy product. This lack of experience may lengthen the regulatory review process, require us to conduct additional
studies or clinical trials, which would increase our development costs, lead to changes in regulatory positions and interpretations,
delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions.
Furthermore, the number of people who may use cell or tissue-based therapies is difficult to forecast with accuracy. Our future success
is dependent on the establishment of a large global market for cell- and tissue-based therapies and our ability to capture a share of
this market with our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell therapy product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated regulatory pathway for the
approval of products demonstrated to be biosimilar, or &#8220;highly similar,&#8221; to or &#8220;interchangeable&#8221; with an FDA-approved
innovator (original) biologic product. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve
biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to
an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years
after the original branded product is approved under a biologics license application, or BLA. The FDA has developed considerable experience
with the biosimilar and interchangeable biosimilar processes since the enactment of the BPCIA in 2009. Should any of our product candidates
be approved via the BLA pathway, we expect that biosimilar applicants will seek approval of biosimilar, and/or interchangeable, versions
of our product that could result in lower prices for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, if any of our product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period
of exclusivity. However, there is a risk that the FDA could approve biosimilar applicants for other reference products that no longer
have such exclusivity, thus potentially creating the opportunity for greater competition sooner than anticipated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA&#8217;s regulation of regenerative medicine products remains unpredictable and we are not certain what impact this will have on the
potential approval of our products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s regulation of therapies derived from stem cell products and technologies is evolving and may continue to evolve. In December
2016, the 21st Century Cures Act, or the Cures Act, was signed into law in the United States to advance access to medical innovations.
Among other things, the Cures Act established a new FDA regenerative medicine advanced therapy, or RMAT, designation. This designation
offers a variety of benefits to product candidates, including enhanced FDA support during clinical development, priority review on application
filing, accelerated approval based on potential surrogate endpoints, and the potential use of patient registry data and other forms of
real world evidence for post-approval confirmatory studies. There is no certainty that any of our product candidates will receive RMAT
designation or any other type of expedited review program designation from the FDA. In any event, the receipt of an FDA RMAT designation
or other expedited review program designation may not result in a faster development process, review or approval compared to products
considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates
in human subjects, and our insurance may be inadequate to cover claims that may arise.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential product liability risks inherent in the testing, processing and marketing of cell therapy products.
Such liability claims may be expensive to defend and result in large judgments against us. We face an inherent risk of product liability
exposure related to the testing of our current and any future product candidates in human clinical trials and will face an even greater
risk with respect to any commercial sales of our products should they be approved. No product candidate has been widely used over an
extended period of time, and therefore safety data is limited. Cell therapy companies derive the raw materials for manufacturing of product
candidates from human cell sources, and therefore the manufacturing process and handling requirements are extensive, which increases
the risk of quality failures and subsequent product liability claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to maintain insurance coverage adequate to cover our clinical trials and increase that coverage before commercializing product
candidates, if ever. At any time during our clinical trials or after commercialization, if that occurs, we may not be able to obtain
or maintain product liability insurance on acceptable terms with adequate coverage or at all, or if claims against us substantially exceed
our coverage, then our financial position could be significantly impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we are ultimately successful in any product liability litigation that may arise, such litigation could consume substantial amounts
of our financial and managerial resources, result in decreased demand for our products and injure our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to maintain errors and omissions, directors and officers, workers&#8217; compensation and other insurance at levels we believe to
be appropriate to our business activities. If, however, we were subject to a claim in excess of this coverage or to a claim not covered
by our insurance and the claim succeeded, we would be required to pay the claim from our own limited resources, which could have a material
adverse effect on our financial condition, results of operations and business. Additionally, liability or alleged liability could harm
our business by diverting the attention and resources of our management and damaging our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those that are expected to be used by our clinical investigators, clinical research organizations or other
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs
for our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology systems to keep financial records, maintain laboratory and corporate records, communicate with staff and
external parties and operate other critical functions. Any significant degradation or failure of these computer systems could cause us
to inaccurately calculate or lose data. Despite the implementation of security measures, these internal computer systems and those used
by our clinical investigators, clinical research organizations, and other contractors and consultants are vulnerable to damage from computer
viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. The techniques that could
be used by criminal elements or foreign governments to attack these computer systems are sophisticated, change frequently and may originate
from less regulated and remote areas of the world. While we have not experienced any such system failure, theft of information, accident
or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our clinical development activities. For example, the loss of clinical trial data from historical or future clinical trials could
result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. To the extent that
any disruption, theft of information, or security breach were to result in a loss of or damage to data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the clinical development and the future development
of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
operate and sell in international markets carries great risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to market our products and services both domestically and in foreign markets. A number of risks are inherent in international
transactions. In order for us to market our products and services in non-U.S. jurisdictions, we need to obtain and maintain required
regulatory approvals or clearances in these countries and must comply with the country specific regulations regarding safety, manufacturing
processes and quality. These regulations, including the requirements for approvals or clearances to market, may differ from the FDA regulatory
scheme. International operations and sales also may be limited or disrupted by political instability, price controls, trade restrictions
and changes in tariffs. Additionally, fluctuations in currency exchange rates may adversely affect demand for our services and products
by increasing the price of our products and services in the currency of the countries in which the products and services are offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will obtain regulatory approvals or clearances in all of the countries where we intend to market our products
and services, that we will not incur significant costs in obtaining or maintaining foreign regulatory approvals or clearances, or that
we will be able to successfully commercialize our products and services in various foreign markets. Delays in receipt of approvals or
clearances to market our products and services in foreign countries, failure to receive such approvals or clearances or the future loss
of previously received approvals or clearances could have a substantial negative effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
inability to obtain reimbursement for our products and services from private and governmental insurers could negatively impact demand
for our products and services.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance and sales of our product candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions
about formulary coverage as well as levels at which government authorities and third-party payors, such as private health insurers and
health maintenance organizations, reimburse patients for the price they pay for our product candidates, as well as levels at which these
payors pay directly for our product candidates, where applicable, could affect whether we are able to successfully commercialize these
products. We cannot guarantee that reimbursement will be available for any of our product candidates. We also cannot guarantee that coverage
or reimbursement amounts will not reduce the demand for, or the price of, our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize
our products. The Patient Protection and Affordable Care Act, or PPACA, as well as the Inflation Reduction Act, passed on August 16,
2022, and other health reforms include measures that would limit or prohibit payments for certain medical treatments or subject the pricing
of drugs and biologics to government control. In addition, in many foreign countries, particularly the countries of the European Union,
or the EU, the pricing of drugs and biologics is subject to government control. If our products are or become subject to government regulation
that limits or prohibits payment for our products, or that subjects the price of our products to government control, we may not be able
to generate revenue, attain profitability or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, third-party payors are increasingly limiting both coverage and the level of reimbursement of new drugs and biologics. They
may also impose strict prior authorization requirements and/or refuse to provide any coverage of uses of approved products for medical
indications other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether
and how much third-party payors will reimburse patients for their use of newly-approved drugs and biologics. If we are unable to obtain
adequate levels of reimbursement for our product candidates, our ability to successfully market and sell our product candidates will
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Intellectual Property</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our proprietary rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in large part upon our ability to protect our proprietary rights. There is no assurance, for example,
that any additional patents will be issued based on our or our licensor&#8217;s pending applications or, if issued, that such patents
will not become the subject of a re-examination, will provide us with competitive advantages, will not be challenged by any third parties,
or that the patents of others will not prevent the commercialization of products and services incorporating our technology. Furthermore,
there can be no guarantee that others will not independently develop similar products and services, duplicate any of our products and
services, or design around any patents we obtain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will also depend upon our ability to avoid infringing patents issued to others. If we were judicially determined to
be infringing on any third-party patent, we could be required to pay damages, alter our products, services or processes, obtain licenses,
or cease certain activities. If we are required in the future to obtain any licenses from third parties for some of our products and/or
services, there can be no guarantee that we would be able to do so on commercially favorable terms, if at all. United States and foreign
patent applications are not immediately made public, so we might be surprised by the grant to someone else of a patent on a technology
we are actively using. Although we conducted a freedom to operate, or FTO, search years ago on the licensed technology associated with
our <i>Disc/Spine Program</i>, modifications made, and/or further developments that may be made, to that technology may not be covered
by the initial FTO. No FTO has been undertaken with respect to our <i>ThermoStem </i>brown fat initiative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation,
which would result in substantial costs to us and the diversion of effort on our part, may be necessary to enforce or confirm the ownership
of any patents issued or licensed to us, or to determine the scope and validity of third-party proprietary rights. If our competitors
claim technology also claimed by us and prepare and file patent applications in the United States, we may have to participate in interference
proceedings declared by the U.S. Patent and Trademark Office, or the Patent Office, or a foreign patent office to determine priority
of invention, which could result in substantial costs and diversion of effort, even if the eventual outcome is favorable to us. Any such
litigation or interference proceeding, regardless of outcome, could be expensive and time-consuming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
challenges to our patents through oppositions, re-examination proceedings or interference proceedings could result in a loss of patent
rights in the relevant jurisdiction. If we are unsuccessful in actions we bring against the patents of other parties, and it is determined
that we infringe upon the patents of third parties, we may be subject to litigation, or otherwise prevented from commercializing potential
products and/or services in the relevant jurisdiction, or may be required to obtain licenses to those patents or develop or obtain alternative
technologies, any of which could harm our business. Furthermore, if such challenges to our patent rights are not resolved in our favor,
we could be delayed or prevented from entering into new collaborations or from commercializing certain products and/or services, which
could adversely affect our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course
of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on unpatented trade secrets and proprietary technological expertise. Some of our intended future cell-related
therapeutic products and/or services may fit into this category. We also rely, in part, on confidentiality agreements with our partners,
employees, advisors, vendors, and consultants to protect our trade secrets and proprietary technological expertise. There can be no guarantee
that these agreements will not be breached, or that we will have adequate remedies for any breach, or that our unpatented trade secrets
and proprietary technological expertise will not otherwise become known or be independently discovered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to obtain or maintain patent protection, failure to protect trade secrets, third-party claims against our patents, trade secrets, or
proprietary rights or our involvement in disputes over our patents, trade secrets, or proprietary rights, including involvement in litigation,
could divert our efforts and attention from other aspects of our business and have a substantial negative effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property in countries outside of the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
property law outside the United States is uncertain and, in many countries, is currently undergoing review and revisions. The laws of
some countries do not protect our patent and other intellectual property rights to the same extent as United States laws. Third parties
may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings
against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that are issued or pending
in the United States. It may be necessary or useful for us to participate in proceedings to determine the validity of our patents or
our competitors&#8217; patents that have been issued in countries other than the United States. This could result in substantial costs,
divert our efforts and attention from other aspects of our business, and could have a material adverse effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to United States patent law may have a material adverse effect on our intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Leahy-Smith America Invents Act, or AIA, which was signed into law in 2011, significantly changes United States patent law. It may take
some time to establish what the law means, since it is just being interpreted by the lower courts, Federal Circuit Courts of Appeal,
and the Supreme Court. The effects of these decisions are still not known. The first major change is that AIA switches the United States
patent system from a &#8220;first to invent&#8221; system to a &#8220;first to file&#8221; system. Now that the first to file system
is in effect, there is a risk that another company may independently develop identical or similar patents at approximately the same time,
and be awarded the patents instead of us. Further, for the second major change, AIA abolished interference proceedings, and establishes
derivation proceedings to replace interference proceedings in all cases in which the time period for instituting an interference proceeding
has not lapsed where an inventor named in an earlier application derived the claimed invention from a named inventor. Now that the derivation
proceedings are in effect, there is a risk that the inventorship of any pending patent application can be challenged for reasons of derivation.
The third major change is that AIA established post-grant opposition proceedings that will apply only to patent applications filed after
&#8220;first to file&#8221; became effective. Post-grant opposition will enable a person who is not the patent owner to initiate proceedings
in the Patent Office within nine months after the grant of a patent that can result in cancellation of a patent as invalid. In addition
to AIA, recent court decisions have created uncertainty with regard to our ability to obtain and maintain patents. Therefore there is
a risk that any of our patents once granted may be subject to post-grant opposition, which will increase uncertainty on the validity
of any newly granted patent or may ultimately result in cancellation of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Supreme Court has recently taken more limiting positions as to what constitutes patentable subject matter. As a result,
many patents covering what were previously patentable inventions are now determined to cover inventions which are deemed non-statutory
subject matter and are now invalid. As a result of this and subsequent opinions by the Court of Appeals for the Federal Circuit, the
Patent Office is now applying more stringent limitations to claims in patent applications and is refusing to grant patents in areas of
technology where patents were previously deemed available. Therefore there is a risk that we will be unable to acquire patents to cover
our products and if such patents are granted they may subsequently be found to be invalid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental
effect on any future revenues in such country.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries, including some countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to third parties. In addition, most countries limit the enforceability of patents against government agencies or government contractors.
In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement, which could materially
diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly common in developing countries,
either through direct legislation or international initiatives. Such compulsory licenses could be extended to our product candidates,
which may limit our potential revenue opportunities, including with respect to any future revenues that may result from our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Government Regulation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates for which we obtain regulatory approval will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information. Any regulatory
approvals that we receive for our product candidates also may be subject to a REMS or the specific obligations imposed as a condition
for marketing authorization by equivalent authorities in a foreign jurisdiction, limitations on the approved indicated uses for which
the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,
including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, in the United
States, the holder of an approved new drug application, or NDA, or BLA is obligated to monitor and report adverse events and any failure
of a product to meet the specifications in the NDA or BLA. The holder of an approved NDA or BLA also must submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising
and promotional materials must comply with the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations and are subject
to FDA oversight and post-marketing reporting obligations, in addition to other potentially applicable federal and state laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities may be subject to payment of application and program fees and are subject to continual
review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments
made in the NDA, BLA or foreign marketing application. If we or a regulatory authority discover previously unknown problems with a product,
such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or if
a regulatory authority disagrees with the promotion, marketing or labeling of our product, a regulatory authority may impose restrictions
relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements for any product candidate following approval, a regulatory authority may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    a warning or untitled letter asserting that we are in violation of the law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic
    partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the product or otherwise demand or require the withdrawal or recall of the product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">request
    and publicize a voluntary recall of the product; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government enforcement action or investigation of alleged violations of law could require us to expend significant time and resources
in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to
commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the research, manufacturing, distribution, sale, and promotion of drugs and biologic products are subject to regulation
by various federal, state, and local authorities, including the FDA, the Centers for Medicare and Medicaid Services, or CMS, other divisions
the Department of Health and Human Services, or HHS (e.g., the Office of Inspector General), the United States Department of Justice
offices of the United States Attorney, the Federal Trade Commission and state and local governments. Our operations are directly, or
indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations,
including the federal Anti-Kickback Statute, or AKS, the federal civil and criminal False Claims Act, or FCA, the Physician Payments
Sunshine Act and regulations and equivalent provisions in other countries. In addition, we may be subject to patient privacy laws by
both the federal government and the states in which we conduct our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and
the United States Congress continues to strengthen the arsenal of enforcement tools. For example, the Bipartisan Budget Act of 2018 increased
the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the AKS. Enforcement agencies
also continue to pursue novel theories of liability under these laws. Government agencies have recently increased regulatory scrutiny
and enforcement activity with respect to programs supported or sponsored by pharmaceutical companies, including reimbursement and co-pay
support, funding of independent charitable foundations and other programs that offer benefits for patients. Several investigations into
these programs have resulted in significant civil and criminal settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any
of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and
criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment
and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our
results of operations. Even if we are not determined to have violated these laws, government investigations into these issues typically
require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert
the attention of our management from operating our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in the event we determine to operate in foreign jurisdictions, including conducting clinical trials, we will need to comply with the
United States Foreign Corrupt Practices Act of 1977, or the FCPA. The FCPA prohibits a corporation, including its subsidiaries, third-party
contractors, distributors, consultants and employees, from corruptly making or offering to make payments to foreign officials for the
purpose of obtaining or enhancing business. Under the law, &#8220;foreign officials&#8221; include employees of health systems operated
by government entities. The FCPA also establishes specific record-keeping and internal accounting controls. Violations of the FCPA can
result in the imposition of civil penalties or criminal prosecution. Failure to comply with the FCPA will adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the FCPA, we will also need to comply with the foreign government laws and regulations of each individual country in which
any therapy centers that we may establish are located and products are to be distributed and sold. These regulations vary in complexity
and can be as stringent, and on occasion even more stringent, than FDA regulations in the United States. Due to the fact that there are
new and emerging stem cell and cell therapy regulations that have recently been drafted and/or implemented in various countries around
the world, the application and subsequent implementation of these new and emerging regulations have little to no precedence. Therefore,
the level of complexity and stringency is not always precisely understood today for each country, creating greater uncertainty for the
international regulatory process. Furthermore, there can be no guarantee that laws and regulations will not be implemented, amended and/or
reinterpreted in a way that will negatively affect our business. Likewise, there can be no assurance that we will be able, or will have
the resources, to maintain compliance with all such healthcare laws and regulations. Failure to comply with such healthcare laws and
regulations, as well as the costs associated with such compliance or with enforcement of such healthcare laws and regulations, may have
a material adverse effect on our operations or may require restructuring of our operations or impair our ability to operate profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future employees, consultants and advisors and our future principal investigators, medical institutions and commercial partners
may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of fraud or other misconduct by our current and future employees, consultants, advisors, principal investigators,
medical institutions and commercial partners, including contract laboratories, and CROs. Misconduct by these parties could include intentional
failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA
and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report
financial information or data accurately or disclose unauthorized activities to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not and in the future may not independently conduct all aspects of our product candidate research and preclinical and clinical
testing and product candidate manufacturing. If we rely on third parties, including CROs, medical institutions, and contract laboratories
to monitor and manage data for our ongoing preclinical and clinical programs, we will still maintain responsibility for ensuring their
activities are conducted in accordance with the applicable study protocol, legal, regulatory and scientific standards. We and our third-party
vendors will be required to comply with current cGMP, GCP, and Good Laboratory Practice, or GLP, requirements, which are a collection
of laws and regulations enforced by the FDA, the EU and comparable foreign authorities for all of our product candidates in clinical
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended
to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the
FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
precautions we take to detect and prevent employee and third-party misconduct may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects,
including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on our
business and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not received regulatory approval to market any of our product candidates in any jurisdiction. If we seek approval of any
of our cell therapy product candidates, we will be required to submit to the FDA and potentially other regulatory authorities extensive
pre-clinical and clinical data supporting its safety and efficacy, as well as information about the manufacturing process and to undergo
inspection of our manufacturing facility or other contract manufacturing facilities, if utilized, among other things. The process of
obtaining FDA and other regulatory approvals is expensive, generally takes many years and is subject to numerous risks and uncertainties,
particularly with complex and/or novel product candidates such as our cell-based product candidates. Changes in regulatory approval requirements,
policies, or court decisions may cause delays in the approval or rejection of an application, make it easier for our competitors to gain
regulatory approval to enter the marketplace, or allow competitors to enter the market without having to obtain FDA approval. Ultimately,
the FDA and other regulatory agencies have substantial discretion in the approval process and may refuse to accept any application or
may decide that our product candidate data are insufficient for approval without the submission of additional preclinical, clinical or
other studies. In addition, varying agency interpretations of the data obtained from preclinical and clinical testing could delay, limit
or prevent regulatory approval of a product candidate. Any difficulties or failures that we encounter in securing regulatory approval
for our product candidates would likely have a substantial adverse impact on our ability to generate product sales, and could make any
search for a collaborative partner more difficult. Similarly, any regulatory approval we ultimately obtain may be limited or subject
to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to conduct clinical studies in accordance with regulations and accepted standards, we may be delayed in receiving, or may
never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain marketing approvals for our product candidates in the United States and abroad, we must, among other requirements, complete adequate
and well-controlled clinical trials sufficient to demonstrate to the FDA and other regulatory bodies that the product candidate is safe
and effective for each indication for which approval is sought. If the FDA finds that patients enrolled in the trial are or would be
exposed to an unreasonable and significant risk of illness or injury, due to, among other things, occurrence of a serious adverse event
in an ongoing clinical trial, the FDA can place one or more of our clinical trials on hold. If safety concerns develop, we may, or the
FDA or an institutional review board may require us to, stop the affected trials before completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of our clinical trials also may be delayed or terminated for a number of other reasons, including if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators do not perform the clinical trials on the anticipated schedule or consistent with the clinical trial protocol,
    good clinical practices required by the FDA and other regulatory requirements, or other third parties do not perform data collection
    and analysis in a timely or accurate manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
    of clinical trial sites by the FDA or other regulatory authorities reveal violations that require us to undertake corrective action,
    suspend or terminate one or more sites, or prohibit use of some or all of the data in support of marketing applications; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or one or more institutional review boards suspends or terminates the trial at an investigational site, or precludes enrollment
    of additional subjects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development costs will increase if there are material delays in our clinical trials, or if we are required to modify, suspend, terminate
or repeat a clinical trial. If we are unable to conduct our clinical trials properly, we may never receive regulatory approval to market
our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
care companies have been the subjects of federal and state investigations, and we could become subject to investigations in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
federal and state government agencies have heightened civil and criminal enforcement efforts. There are numerous ongoing investigations
of health care companies, as well as their executives and managers. In addition, amendments to the federal FCA, including under healthcare
reform legislation, have made it easier for private parties to bring &#8220;<i>qui tam</i>&#8221; (or whistleblower) lawsuits against
companies under which the whistleblower may be entitled to receive a percentage of any money paid to the government. The FCA provides,
in part, that an action can be brought against any person or entity that has knowingly presented, or caused to be presented, a false
or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim
approved. The government has taken the position that claims presented in violation of the federal AKS, Stark Law or other healthcare-related
laws, including laws enforced by the FDA, may be considered a violation of the FCA. Penalties include substantial fines for each false
claim, plus three times the amount of damages that the federal government sustained because of the act of that person or entity and/or
exclusion from the Medicare and Medicaid programs. In addition, a majority of states have adopted similar state whistleblower and false
claims provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any government investigations involving any of our facilities or management. While we believe that we are in compliance
with applicable governmental healthcare laws and regulations, any future investigations of our business or executives could cause us
to incur substantial costs, and result in significant liabilities or penalties, as well as damage to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is uncertain to what extent the government, private health insurers and third-party payors will approve coverage or provide reimbursement
for the therapies and products to which our services relate. Availability for such reimbursement may be further limited by reductions
in Medicare, Medicaid and other federal healthcare program funding in the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that health care providers cannot obtain coverage or reimbursement for our products and therapies, they may elect not to provide
such products and therapies to their patients and, thus, may not need our services. Further, as cost containment pressures are increasing
in the health care industry, government and private payors may adopt strategies designed to limit the amount of reimbursement paid to
health care providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
the trend toward managed health care and bundled pricing for health care services in the United States, could significantly influence
the purchase of healthcare products and services, resulting in lower prices and reduced demand for our therapeutic products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may directly or indirectly receive revenues from federal health care programs, such as Medicare. Federal health care programs are subject
to changes in coverage and reimbursement rules and procedures, including retroactive rate adjustments. These contingencies could materially
decrease the range of services covered by such programs or the reimbursement rates paid directly or indirectly for our products and services.
To the extent that any health care reform favors the reimbursement of other therapies over our therapeutic products under development,
such reform could affect our ability to sell our services, which may have a material adverse effect on our revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation on reimbursement available from private and government payors may reduce the demand for, or the price of, our products and
services, which could have a material adverse effect on our revenues. Additional legislation or regulation relating to the health care
industry or third-party coverage and reimbursement may be enacted in the future which could adversely affect the revenues generated from
the sale of our products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there has been a trend in recent years towards reductions in overall funding for Medicare, Medicaid and other federal health care programs.
The reduced funding of governmental programs could have a negative impact on the demand for our services to the extent it relates to
products and services which are reimbursed by government and private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unintended
consequences of healthcare reform in the United States may adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is undergoing fundamental changes resulting from political, economic and regulatory influences. In the United States,
the PPACA was signed into law in 2010 under the Obama administration. By implementing comprehensive reforms, the law seeks to, among
other things, increase access to healthcare for the uninsured and control the escalation of healthcare expenditures within the economy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare
payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, following passage of the Bipartisan Budget
Act of 2018, will remain in effect through 2030 unless additional Congressional action is taken. In January 2013, President Obama signed
into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Congress
has since considered additional reductions in Medicare reimbursement for drugs and devices as part of legislation to reduce the budget
deficit. Similar legislation could be enacted in the future. The Medicare regulations and interpretive determinations that determine
how drugs, devices and services are covered and reimbursed also are subject to change. These laws, regulations, and interpretive determinations
may result in additional reductions in Medicare and other health care funding, which could impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
recently, on August 16, 2022, President Biden signed the Inflation Reduction Act, or the IRA, which provides for (i) the government to
set or negotiate prices for select high-cost Medicare Part D (beginning in 2026) and Medicare Part B drugs (beginning in 2028) that are
more than nine years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval, (ii) manufacturers to
pay a rebate for Medicare Part B and Part D drugs when prices increase faster than inflation beginning in 2022 for Medicare Part D and
2023 for Medicare Part B drugs, and (iii) Medicare Part D redesign which replaces the current coverage gap provisions and establishes
a $2,000 cap for out-of-pocket limits costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for 10%
of costs up to the $2,000 cap and 20% after that cap is reached. Implementation of the IRA is expected to be carried out through upcoming
actions by regulatory authorities, the outcome of which is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and decreased reimbursement. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates. It is difficult to predict how enforcement initiatives under the PPACA, the IRA, and/or additional
legislation or regulation enacted in the future may impact our business. If the PPACA, the IRA, and/or additional legislation or regulation
enacted in the future cause such unintended consequences or indirect impact, they could have a material adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitor
companies or hospitals in the EU may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients
to sell competing products without a marketing authorization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill
special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications
of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may, in certain countries,
also apply to products manufactured in a country outside the EU and imported to treat specific patients or small groups of patients.
In addition, advanced therapy medicinal products do not need a marketing authorization if they are prepared on a non-routine basis and
are used within the same EU member state in a hospital in accordance with a medical prescription for an individual patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
exemptions could allow our competitors to make sales in the EU without having obtained a marketing authorization and without undergoing
the expense of clinical trials, especially if those competitors have cell processing facilities in the relevant EU member state. Similarly,
certain hospitals may be able to compete with us on the basis of these rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
pay no dividends.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends in the past, and currently do not intend to pay any cash dividends in the foreseeable future. We intend
to retain earnings, if any, to finance the development and expansion of our business. Our future dividend policy will be subject to the
discretion of our Board of Directors and will be contingent upon future earnings, if any, our financial condition, capital requirements,
general business conditions, and other factors. Therefore, we can give no assurance that any dividends of any kind will ever be paid
to holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no assurance that an active trading market for our common stock will be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. However, no assurance can be given that an active market for our common stock will be sustained. In
addition, although there have been market makers in our common stock, we cannot assure that these market makers will continue to make
a market in our securities or that other factors outside of our control will not cause them to stop market making in our securities.
Making a market in securities involves maintaining bid and ask quotations and being able to effect transactions in reasonable quantities
at those quoted prices, subject to various securities laws and other regulatory requirements. Furthermore, the development and maintenance
of a public trading market depends upon the existence of willing buyers and sellers, the presence of which is not within our control
or that of any market maker. Market makers are not required to maintain a continuous two-sided market, are required to honor firm quotations
for only a limited number of securities, and are free to withdraw firm quotations at any time. Even with a market maker, factors such
as our past losses from operations and the small size of our company mean that there can be no assurance of an active and liquid market
for our securities developing in the foreseeable future. Even if there is a market for our securities, we cannot assure that securityholders
will be able to resell their securities at any price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders
who hold unregistered shares of our common stock are subject to resale restrictions pursuant to Rule 144 due to our former status as
a &#8220;shell company.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously were a &#8220;shell company&#8221; pursuant to Rule 144, promulgated under the Securities Act, or Rule 144, and, as such,
sales of our securities pursuant to Rule 144 cannot be made unless, among other things, we continue to remain subject to Section 13 or
15(d) of the Exchange Act, and we file all of our required periodic reports with the SEC under the Exchange Act. Because our unregistered
securities cannot be sold pursuant to Rule 144 unless we continue to meet such requirements, any unregistered securities we sell in the
future or issue to consultants or employees, in consideration for services rendered or for any other purpose, will have no liquidity
unless we continue to comply with such requirements. As a result, it may be more difficult for us to obtain financing to fund our operations
and pay our consultants and employees with our securities instead of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred, and will continue to incur, increased costs as a result of being an SEC reporting company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as a variety of related rules implemented by the SEC, have required changes
in corporate governance practices and generally increased the disclosure requirements of public companies. As a reporting company, we
incur significant legal, accounting and other expenses in connection with our public disclosure and other obligations. Based upon SEC
regulations currently in effect, we are required to establish, evaluate and report on our internal control over financial reporting.
We believe that compliance with the myriad of rules and regulations applicable to reporting companies and related compliance issues will
continue to require a significant amount of time and attention from our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
weaknesses in our internal control over financial reporting may cause us to fail to timely and accurately report our financial results
or result in a material misstatement of our consolidated financial statements.<sup></sup></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We identified control deficiencies in the design and operation of our internal control over financial reporting that constituted
a material weakness, as further described in Item 9A of this Annual Report (&#8220;Controls and Procedures&#8221;). A material weakness
is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility
that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. Our material
weakness related to the following control deficiencies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of risk assessment procedures on internal controls to detect financial reporting risks on a timely manner; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of sufficient formal management testing over documented formal procedures and controls, and time to evaluate continuous effectiveness of controls to achieve complete and accurate financial
    reporting and disclosures, including documented controls over the preparation and review of journal entries and account
    reconciliations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deficiencies described above, if not remedied, could result in a misstatement of one or more account balances or disclosures in our annual
or interim consolidated financial statements that would not be prevented or detected, and, accordingly, we determined that these control
deficiencies constitute a material weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address our material weakness, we have added accounting and finance personnel and implemented new financial accounting processes. We
intend to continue to take steps to remediate the material weakness described above through implementing enhancements and controls within
our accounting systems, hiring additional qualified accounting and finance resources and further evolving our accounting and quarterly
and annual close processes. We will not be able to remediate these control deficiencies until these steps have been completed and have
been operating effectively for a sufficient period of time and Management has concluded, through testing, that the controls are operating
effectively. The redesign and implementation of improvements to our accounting and proprietary systems and controls may be costly and
time consuming and the cost to remediate may impair our results of operations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to remediate our material weakness, identify future material weaknesses in our internal control over financial reporting or fail
to meet the demands that have been placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be
unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations.
Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the
SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate
any such material weakness, our reputation, results of operations and financial condition could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may fluctuate significantly and be highly volatile and this may make it difficult for a securityholder to resell our securities
at the volume, prices and times the securityholder finds attractive.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may be subject to significant fluctuations and be highly volatile, which may make it difficult for a
securityholder to resell our securities at the volume, prices and times the securityholder finds attractive. There are many factors that
will impact our stock price and trading volume, including, but not limited to, the factors listed above under &#8220;Risks Related to
Our Business Generally,&#8221; &#8220;Risks Related to Our Cell Therapy Product Development Efforts,&#8221; &#8220;Risks Related to Our
Intellectual Property,&#8221; &#8220;Risks Related to Government Regulation,&#8221; &#8220;Risks Related to Our Common Stock&#8221; and
&#8220;Risks Associated with Our Nasdaq Listing.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
markets, in general, experience significant price and volume volatility, and the market price of our securities may continue to be subject
to such market fluctuations that may be unrelated to our operating performance and prospects. Increased market volatility and fluctuations
could result in a substantial decline in the market price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may be significant future issuances or resales of our common stock which may materially and adversely dilute stockholders&#8217; ownership
interest and affect the market price of our securities</i></b>&#160;<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have authorization to issue up to 75,000,000 shares of common stock of which, as of March 22, 2023, 3,767,615 shares were issued
and outstanding. We are not restricted from issuing additional shares of our common stock in the future, including securities convertible
into, or exchangeable or exercisable for, shares of our common stock. In addition, there are 1,518,158 shares of Series B preferred stock
issued and outstanding. Such shares are convertible under certain circumstances into an equal number of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our November 2021 public offering of securities, we issued warrants for the purchase of an aggregate of 2,645,000 shares of common
stock as well as underwriter warrants for the purchase of 235,970 shares of common stock. We have an effective registration statement
on Form S-1 under the Securities Act registering the issuance of such shares. The shares issuable pursuant to the registration statement
on Form S-1 will be freely tradable in the public market, except for shares held by affiliates. In addition, in connection with the public
offering and pursuant to exchange agreements entered into with holders of convertible notes and warrants, we issued an aggregate of 313,789
shares of common stock and warrants for the purchase of an aggregate of 1,856,938 shares of common stock. The shares of common stock
issued to such holders are eligible for resale in the open market (subject to Rule 144 volume limitations applicable to affiliates),
potentially causing sales in the market to increase and our stock price to decline. We have registered the resale of the shares of common
stock issuable upon exercise of such warrants. The issuance of shares of common stock upon exercise of the above warrants would dilute
the ownership of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have an effective registration statement on Form S-8 under the Securities Act registering 1,175,000 shares of our common stock issuable
under our 2021 Stock Incentive Plan, or the 2021 Plan, and intend to file a registration statement on Form S-8 under the Securities Act
with respect to the registration of an additional 1,325,000 shares of our common stock under the 2021 Plan. As of March 22, 2023, options
to purchase 1,493,656 shares of our common stock were outstanding under the 2021 Plan. In addition, as of such date,97,826  RSUs were outstanding
under the 2021 Plan. The shares issuable pursuant to the registration statements on Form S-8 will be freely tradable in the public market,
except for shares held by affiliates. We may include a resale prospectus in our registration statement on Form S-8 with regard to the
2021 Plan covering the resale of the shares issuable to Messrs. Alstodt and Silva (and other affiliates) upon their exercise of options
held by them and the vesting of the above described RSUs. The resale of such shares will be currently subject to the volume limitations
imposed by Rule 144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we have an effective shelf registration statement on Form S-3 under the Securities Act registering $75,000,000 of our equity and debt
securities. Pursuant to the requirements of Form S-3, we currently may sell pursuant to such Form S-3, during any 12 month period, securities
having an aggregate market value of no more than one-third of the aggregate market value of the shares of our common stock held by non-affiliates.
As of March 22, 2023, the aggregate market value of shares of common stock held by non-affiliates was $9,286,812.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of a substantial number of shares of our common stock or securities convertible into, or exchangeable or exercisable for, shares
of our common stock, whether directly by us in future offerings or by our existing stockholders in the secondary market, the perception
that such issuances or resales could occur or the availability for future issuances or resale of shares of our common stock or securities
convertible into, or exchangeable or exercisable for, shares of our common stock could materially and adversely affect the market price
of our securities and our ability to raise capital through future offerings of equity or equity-related securities on attractive terms
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Board of Directors is authorized to designate and issue 18,456,842 shares of preferred stock without further stockholder
approval, containing such rights and preferences as our Board of Directors shall determine. We may also issue other equity and equity-related
securities that are senior to our common stock in the future for a number of reasons, including, without limitation, to support operations
and growth, and to comply with any future changes in regulatory standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions and the regulations to which we may be subject may make it more difficult for a third party to acquire control of us, even
if the change in control would be beneficial to our securityholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Nevada. Anti-takeover provisions in Nevada law and our articles of incorporation and bylaws could make it more difficult
for a third party to acquire control of us and may prevent stockholders from receiving a premium for their securities. Our certificate
of incorporation provides that our Board of Directors may issue up to 20,000,000 shares of preferred stock, in one or more series, without
stockholder approval and with such terms, preferences, rights and privileges as the Board of Directors may deem appropriate. Of such
20,000,000 authorized shares, 1,518,158 shares of Series B preferred stock are issued and outstanding. These provisions and other factors
may hinder or prevent a change in control, even if the change in control would be perceived as beneficial to, or sought by, our other
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock is classified as a &#8220;penny stock;&#8221; the restrictions of the penny stock regulations of the Securities and Exchange
Commission, or SEC, may result in less liquidity for our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted regulations which define a &#8220;penny stock&#8221; to be any equity security that has a market price (as therein defined)
of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Unless exempt, the rules
require the delivery, prior to any transaction involving a penny stock by a retail customer, of a disclosure schedule prepared by the
SEC relating to the penny stock market. Disclosure is also required to be made about commissions payable to both the broker/dealer and
the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing
recent price information for the penny stock held in the account and information on the limited market in penny stocks. The market price
for shares of our common stock is currently below $5.00 and we do not satisfy any of the exceptions to the SEC&#8217;s definition of
penny stock. Accordingly, our common stock is currently classified as a penny stock. As a result of the penny stock restrictions, brokers
or potential investors may be reluctant to trade in our securities, which may result in less liquidity for our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Associated with Our Nasdaq Listing</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot assure you that we will be able to continue to comply with the minimum bid price requirement of Nasdaq</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the market price of our common stock satisfied the initial listing minimum bid price requirement for Nasdaq, there can be no assurance
that the market price of our common stock will remain at the $1.00 per share level required for continuing compliance with that requirement.
There are many factors, such as negative financial or operational results, that could adversely affect the market price of our common
stock and jeopardize our ability to maintain Nasdaq&#8217;s minimum bid price requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing
requirements of those investors. Consequently, the trading liquidity of our common stock may not improve</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that our Nasdaq listing has helped generate greater and broader investor interest, including institutional investors, there
can be no assurances in that regard. In addition, there can be no assurance that the market price of our common stock will satisfy the
investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_001"></span>ITEM
    1B</span></b>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">UNRESOLVED
    STAFF COMMENTS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_002"></span>ITEM
    2.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">PROPERTIES</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices and laboratory are located at 40 Marcus Drive, Suite One, Melville, New York. We occupy 6,800 square feet
of space at the premises pursuant to a lease that expires in December 2024. The lease provides for an annual base rental during the five
year period ending in December 2024 ranging between $153,748 and $173,060. Our premises are suitable and adequate for our current operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_003"></span>ITEM
    3.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">LEGAL
    PROCEEDINGS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ayt_004"></span><span style="text-decoration: underline">ITEM
    4.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MINE
    SAFETY DISCLOSURES.</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_024"></span>PART
II</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_005"></span>ITEM
    5. </span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MARKET
    FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in our common stock are currently reported under the symbol &#8220;BRTX&#8221; on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 22, 2023, there were 352 record holders of our shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2022, we issued the following securities in a transaction not involving any public offering. For
the following transaction, we relied upon Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not
involving any public offering. For such transaction, we did not use general solicitation or advertising to market the securities, the
securities were offered to a single entity, the investor had access to information regarding us (including information contained in our
Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q for the periods ended March 31, 2022,
June 30, 2022 and September 30, 2022 and Current Reports on Form 8-K filed with the Securities and Exchange Commission and press releases
made by us), and we were available to answer questions by the prospective investor. We reasonably believe that the investor is an accredited
investor. No proceeds were received from the issuance.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date Issued</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Purchaser(s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consideration<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: right">11/21/2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">51,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(2</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">117,030</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    warrants were issued pursuant to an amendment to a license agreement. The value of the warrants was $117,030 as of November 21, 2022,
    the date of issuance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accredited
    investor.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information with respect to purchases of common stock made by affiliated purchasers during the quarter
ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares Purchased(1)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Number of <br />
Shares Purchased <br />
as Part of Publicly<br />
 Announced Plans <br />
or Programs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maximum<br />
 Number of Shares<br />
 that May Be<br />
 Purchased Under <br />
the Plans or<br />
 Programs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/1/22 &#8211; 10/31/22</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,531</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3.55</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/1/22 &#8211; 11/30/22</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/1/22 &#8211; 12/31/22</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,574</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.06</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
    were made by affiliated purchasers in open market transactions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_006"></span>ITEM
    6</span></b>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">[RESERVED]</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ayt_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ITEM
    7</span>.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis of the consolidated results of operations and financial condition of BioRestorative Therapies, Inc.
and its subsidiary as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021 should be read in conjunction
with our financial statements and the notes to those financial statements that are included elsewhere in this Annual Report following
Item 16 (&#8220;Form 10-K Summary&#8221;). References in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; to &#8220;us,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and similar terms refer to BioRestorative
Therapies, Inc.. This Annual Report contains forward-looking statements as that term is defined in the federal securities laws. The events
described in forward-looking statements contained in this Annual Report may not occur. Generally, these statements relate to business
plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits
from acquisitions that may be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results.
The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; and &#8220;continue,&#8221; and their opposites and similar expressions,
are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or
events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence
the accuracy of the statements and the projections upon which the statements are based. Reference is made to Item 1A of this Annual Report
(&#8220;Risk Factors&#8221;) for a discussion of some of the uncertainties, risks and assumptions associated with these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent issued in our <i>Disc/Spine Program</i>. We submitted an IND application to the FDA to obtain authorization
to commence a Phase 2 clinical trial investigating the use of <i>BRTX-100</i> in the treatment of chronic lower back pain arising from
degenerative disc disease. We have received such authorization from the FDA and have commenced such clinical trial through the execution
of a CRO agreement with PRC Clinical, the execution of clinical trial site agreements, patient enrollment, the commencement of patient
procedures, the purchase of manufacturing equipment and the expansion of our laboratory to include capabilities for clinical production.
We have obtained an exclusive license to use technology for investigational adult stem cell treatment of disc and spine conditions, including
protruding and bulging lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back
pain, buttock and leg pain, and numbness and tingling in the leg and foot.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
United States patents related to the <i>ThermoStem Program</i> were issued in September 2015, January 2019, March 2020, March 2021, and
July 2021; a notice of allowance for a United States patent application related to our <i>ThermoStem Program</i> was issued in February
2023; Australian patents related to the <i>ThermoStem Program</i> were issued in April 2017, October 2019 and August 2021; Japanese patents
related to the <i>ThermoStem Program</i> were issued in December 2017, June 2021 and February 2022; Israeli patents related to our <i>ThermoStem
Program</i> were issued in October 2019, May 2020 and March 2022; European patents related to the <i>ThermoStem Program </i>were issued
in April 2020 and January 2021; and a notice of allowance for a European patent application related to our <i>ThermoStem Program </i>was
issued in February 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or
materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this device
prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the
further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational
research applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, our accumulated deficit was $152,640,897. We have historically only generated a modest amount of revenue, and our
losses have principally been operating expenses incurred in research and development, marketing and promotional activities in order to
commercialize our products and services, plus costs associated with meeting the requirements of being a public company. We expect to
continue to incur substantial costs for these activities over at least the next year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, we completed a $23,000,000 underwritten public offering of units of securities pursuant to which an aggregate of 2,300,000
shares of our common stock and warrants for the purchase of an aggregate of 2,645,000 shares of our common stock were issued. We are
using the net proceeds from the offering as follows: (i) undertaking of clinical trials with respect to <i>BRTX-100</i> and its related
collection and delivery procedure; (ii) pre-clinical research and development with respect to our <i>ThermoStem Program</i>; and (iii)
for general corporate and working capital purposes. In connection with the public offering, our common stock was listed on the Nasdaq
Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, concurrently with the consummation of the public offering, we issued an aggregate of 313,789 shares of our common stock,
1,543,158 shares of our Series A preferred stock and warrants for the purchase of an aggregate of 1,856,938 shares of our common stock
in exchange for convertible promissory notes in the aggregate principal amount of $10,046,897, together with accrued interest thereon,
and warrants for the purchase of an aggregate of 3,677,997 shares of our common stock. Such indebtedness and warrants were exchanged
at a price of $10.00 per unit of securities, consistent with the public offering price of our units of common stock and warrants. The
newly issued warrants are exercisable for a period of five years at an exercise price of $10.00 per share. In September 2022, the 1,543,158
shares of Series A preferred stock were exchanged for an equal number of shares of Series B preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds received from our November 2021 public offering are sufficient for us to complete our Phase 2 clinical trial with regard
to <i>BRTX-100;</i> however, we will require significant additional funding to complete our contemplated Phase 3 <i>BRTX-100</i> clinical
trial (assuming the receipt of no revenues). We will also require a substantial amount of additional funding to implement our other programs
as discussed in this Annual Report under the caption Item 1 (&#8220;Business&#8221;), including our metabolic <i>ThermoStem Program</i>,
and fund general operations. No assurance can be given that the amount of funding that we anticipate may be required for such purposes
is correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no assurance can be given that
we will be able to obtain any required financing on commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2022 Compared with Year Ended December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected items in our consolidated statements of operations for the years ended December 31, 2022 and 2021,
respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For The Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">119,800</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">46,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,513,352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">729,058</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,580,473</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,624,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Operating Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,093,825</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,353,873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss From Operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,974,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,307,873</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Expense (Income):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest (income) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,815,366</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on extinguishment of notes payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,180,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on PPP Loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(250,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(110,518</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Other Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(479,256</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,995,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,494,769</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(44,303,295</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, we generated $119,800 and $46,000, respectively, of royalty revenue in connection with our
sublicense agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the year ended December 31, 2022, research and development expenses increased by $2.8
million, or 382%, compared to the year ended December 31, 2021, as we recommenced research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will continue to increase with the continuation of the aforementioned initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and administrative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes, severance costs and stock-based compensation to employees
(excluding any cash or non-cash compensation of our Vice President of Research and Development and our laboratory staff), as well as
corporate expenses such as legal and professional fees, investor relations and occupancy related expenses. For the year ended December
31, 2022, general and administrative expenses decreased by $10.0 million, or 39%, compared to the year ended December 31, 2021. The decrease
is primarily due to a decrease of $10.4 million in stock-based compensation during the year ended December 31, 2022 compared to the year
ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses related to operations will increase as we expand our staff, develop our infrastructure
and incur additional costs to support the growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, interest expense decreased $1.8 million, or 101%, as compared to the year ended December 31, 2021.
The decrease was due to the exchange of our outstanding convertible debt for common stock, preferred stock and warrants in connection
with our public offering in November 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Loss
on extinguishment of notes payable, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, we recorded a loss on extinguishment of notes payable, net of $16.2 million related to the conversion
of convertible debt principal pursuant to exchange agreements with noteholders in connection with our public offering. The Company did
not convert or extinguish any debt during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Gain
on PPP loan forgiveness</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, our outstanding PPP loan balance was forgiven in full, which was recorded as a gain in the consolidated
statement of operations. There were no gains recorded for PPP loan forgiveness for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
grant income of $110,518 for the year ended December 31, 2022 consists of funding received under a $256,000 National Institutes of Health
Small Business Technology Transfer (&#8220;STTR&#8221;) Phase 1 grant, which was awarded in September 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, Other income, net primarily relates to gains from settlements of certain accrued expenses and unrealized
gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure our liquidity in a number of ways, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-bottom: 2.5pt">Cash, Cash Equivalents and Investments</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">14,749,408</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">21,026,727</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Working Capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,688,188</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,104,086</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Notes Payable (Gross)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Availability
of Additional Funds</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon our accumulated deficit of $152.6 million as of December 31, 2022, along with our forecast for continued operating losses and our
need for financing to fund our contemplated clinical trials, as of such date, we required additional equity and/or debt financing to
continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2021, we completed a public offering of units, each consisting of one share of common stock and a warrant for the purchase
of one share of common stock. Pursuant to the public offering, we issued and sold 2,300,000 units at a public offering price of $10.00
per unit (resulting in gross proceeds of $23,000,000) and, pursuant to the exercise of an option granted to the underwriters, warrants
for the purchase of 345,000 shares of common stock at a public offering price of $0.01 per warrant, less underwriting discounts and commissions.
The net proceeds of the public offering are sufficient for us to complete our Phase 2 clinical trial investigating the use of <i>BRTX-100</i>.
Management believes that we have sufficient cash to fund operations for the twelve months from the issuance of the financial statements
included in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital
and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and services, competing technological and market developments, and the need to
enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service
offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require
us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further
indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds
on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing
agreements on unattractive terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2022 and 2021, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
experienced negative cash flows from operating activities for the years ended December 31, 2022 and 2021 in the amounts of $5.9 million
and $3.3 million, respectively. The net cash used in operating activities for the year ended December 31, 2022 was primarily due to cash
used to fund a net loss of $18.5 million, adjusted for non-cash expenses in the aggregate amount of $12.9 million. The net cash used
in operating activities for the year ended December 31, 2021 was primarily due to cash used to fund a net loss of $44.3 million, adjusted
for non-cash expenses in the aggregate amount of $40.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the year ended December 31, 2022
was $13.5 million compared to $31,000 for the year ended December 31, 2021. The net change was primarily the result of investments
in marketable securities of $13.0 million in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no financing activities during the year ended December 31, 2022. Net cash provided by financing activities during the year ended
December 31, 2021 was $21.3 million, primarily as a result of $21.1 million of net proceeds from an equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the
asset and its eventual disposition are less than its carrying amount. While our near-term liquidity is tight, historically we have been
successful in raising capital as needed (although there can be no assurance that we will continue to be successful in raising capital
as needed). We continue to progress our scientific agenda. We have not identified any impairment losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our consolidated financial statements for the years ended December 31, 2022 and 2021 included elsewhere in this Annual Report
following Item 16 (&#8220;Form 10-K Summary&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that
is material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_008"></span>ITEM
    7A</span>.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-align: justify; text-indent: -71.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ayt_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ITEM
    8.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">FINANCIAL
    STATEMENTS AND SUPPLEMENTARY DATA</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this Item 8 of this Annual Report are included in this Annual Report following Item 16 (&#8220;Form
10-K Summary&#8221;). As a smaller reporting company, we are not required to provide supplementary financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ayt_010"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ITEM
    9.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ayt_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ITEM
    9A.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">CONTROLS
    AND PROCEDURES</span></b>. &#160;&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended, or the Exchange Act), that are designed to ensure that information required to be disclosed in our reports under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms,
and that such information is accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures,
our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls
and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
of achieving the desired control objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the
Exchange Act, as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has completed such evaluation and has concluded that our disclosure controls and procedures were not effective to provide reasonable
assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is appropriate to allow
timely decisions regarding required disclosures. As a result of the material weakness in internal controls over financial reporting described
below, we concluded that our disclosure controls and procedures as of December 31, 2022 were not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial
reporting is a process designed under the supervision of our principal executive and principal financial officer and effected by our
Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of our consolidated financial statements for external reporting purposes in accordance with GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Weaknesses in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the framework established
in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this assessment, management has determined that our internal control over financial reporting as of December 31, 2022 was not
effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness, as defined in the standards established by the Sarbanes-Oxley is a deficiency, or a combination of deficiencies, in
internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim
consolidated financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of sufficient formal management testing over documented formal procedures and controls, and time to evaluate continuous
    effectiveness of controls to achieve complete and accurate financial reporting and disclosures, including documented controls over
    the preparation and review of journal entries and account reconciliations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Plan to Remediate the Material Weakness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness
are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    management personnel, including our Chief Financial Officer, who is overseeing the financial reporting process and implementation
    of enhanced controls and governance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
    of external financial consulting firm to continue to enhance financial reporting, financial operations and internal controls; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documentation
    of key procedures and controls using a risk-based approach.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies
contributing to the material weakness are remediated as soon as possible. We have documented key procedures and controls using a risk-based approach and have, therefore, made progress toward remediation. We continue to implement our remediation plan, which includes continued
engagement of an external financial consulting firm to enhance financial reporting and operations as well as design and implementation
of controls. We will consider the material weakness remediated after the applicable controls operate for a sufficient period of time,
and Management has concluded, through testing, that the controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing
basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm
pursuant to rules of the Securities and Exchange Commission that exempt smaller reporting companies from this requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than described above, there have been no changes in our internal control over financial reporting that occurred during our fourth quarter
of 2022 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_012"></span>ITEM
    9B.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">OTHER
    INFORMATION</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span id="ayt_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ITEM
    9C.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">DISCLOSURE
    REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_014"></span>PART
III</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_015"></span>ITEM
    10.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding our directors and executive officers is set forth below. Each of our officers devotes his full business time in providing services
on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 61%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Positions
    Held</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development, Secretary and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Paccasassi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Quality Assurance/Regulatory Compliance</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Compensation Committee Chair</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Audit Committee Chair</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Nominating Committee Chair</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lance
Alstodt</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Alstodt has served as our Chief Executive Officer, President and Chairman of the Board since November 2020. He served as our Executive
Vice President and Chief Strategy Officer from October 2018 to February 2020. Since 2013, Mr. Alstodt has served as Chief Executive Officer
of MedVest Consulting Corporation, an advisory and capital firm that focuses exclusively on the healthcare industry. Prior to MedVest,
he was an investment banker with over 23 years of experience with respect to healthcare investment banking, including mergers and acquisitions.
From 2011 to 2013, Mr. Alstodt was a Managing Director at Leerink Partners where he helped lead its medical technology sector. From 2009
to 2011, he was a Managing Director and Head of Medical Technology at Oppenheimer &amp; Co. From 2000 to 2009, Mr. Alstodt was a Managing
Director in the Healthcare Group and Global Mergers and Acquisitions Group at Bank of America Merrill Lynch. He previously spent seven
years as a Vice President in the Global Mergers and Acquisitions Group at J.P. Morgan Chase, where he worked extensively on acquisitions,
leveraged buyouts, private and public financings, exclusive sales and general advisory assignments. Mr. Alstodt received a degree in
Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing. We believe that Mr.
Alstodt&#8217;s executive-level management experience with us and other healthcare businesses and his extensive experience in the investment
banking field relating to the healthcare sector give him the qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Francisco
Silva</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
Silva has served as our Vice President of Research and Development since March 2013, having also previously served in such position from
April 2011 until March 2012. Mr. Silva was elected our Secretary and a director in November 2020. He served as our Research Scientist
from March 2012 to June 2012 and as our Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive
Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based
biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development
for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist
with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell
platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He
has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr.
Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship
and MBRS Fellowship from California State Polytechnic University. We believe that Mr. Silva&#8217;s executive-level management experience
with us since April 2011 and his extensive knowledge of the science related to our business give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
E. Kristal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
E. Kristal has served as our Chief Financial Officer since November 2021. Mr. Kristal is an experienced Wall Street and Bay Street professional
who has served in various management roles within multiple business lines of investment banks. From 2016 to 2020, he was Head of Equity
Research at H.C. Wainwright. Mr. Kristal provided investment banking and merchant banking services from 2013 to 2016 at H.C. Wainwright
and T.R. Winston. He is a Charted Financial Analyst. Mr. Kristal received a Bachelor of Arts degree in Economics from Wilfrid Laurier
University and a Bachelor of Commerce (Honors) degree in Finance from the University of Windsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
Paccasassi</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
Paccasassi has served as our Vice President of Quality Assurance/Regulatory Compliance since December 2021, having previously served
in such position from August 2016 to September 2020, and having previously served as our Director of Quality and Compliance from September
2015 to August 2016. Mr. Paccasassi has over 20 years of experience in highly regulated product operations, with specific expertise in
GMP (large and small molecule) clinical and commercial quality assurance and regulatory compliance leadership roles. He was the Director
of Quality Systems (GMP) at Merck KGaA (Dermstadt, Germany) from 2011 to 2014. In this role, Mr. Paccasassi was responsible for leading
the ongoing development and implementation of the Corporate Quality Unit&#8217;s global GMP policies, processes and directives. He held
key quality and compliance management roles at EMD Serono, Biogen Idec, Millennium Pharmaceuticals and Regeneron Pharmaceuticals. Mr.
Paccasassi was a Chief Technologist/Site Head overseeing all day to day technical and quality operations of two cGMP biologic production
laboratories for Curative Health Services. He was also a Medical Technologist working in the field of immunohematology at Brigham &amp;
Women&#8217;s Hospital, Boston, Massachusetts. Mr. Paccasassi received a Masters in Business Administration (MBA) degree from Johnson
&amp; Wales University and a Bachelor of Science degree in Medical Technology/Biology from the University of Rhode Island.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nickolay
Kukekov, Ph.D.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
Kukekov, Ph.D. has served as one of our directors since March 2021 and Chair of our Board&#8217;s Compensation Committee since November
2021. For more than the past fifteen years, Dr. Kukekov has held a number of healthcare investment banking positions. He has served as
Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline
Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr.
Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodmen &amp; Renshaw from 2006 to 2007. He serves
as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of
Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from
Columbia University College of Physicians and Surgeons. We believe that Dr. Kukekov&#8217;s extensive experience in the investment banking
field relating to the healthcare sector and his strong background in regenerative medicine give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patrick
F. Williams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
F. Williams has served as one of our directors and Chair of our Board&#8217;s Audit Committee since November 2021. Mr. Williams has more
than 20 years of experience across medical device, consumer product goods and technology sectors. Appointed as Chief Financial Officer
of STAAR Surgical Company, or STAAR, in July 2020, Mr. Williams is responsible for optimizing the financial performance of STAAR and
ensuring the scalability of various functions to support high growth expansion. From 2016 to 2019, he served as the Chief Financial Officer
of Sientra, Inc. before transitioning to General Manager for its miraDry&#174; business unit. From 2012 to 2016, Mr. Williams served as
Chief Financial Officer of ZELTIQ Aesthetics, Inc., a publicly-traded medical device company that was acquired by Allergan. Previously,
he served as Vice President in finance, strategy and investor relations roles from 2007 to 2012 at NuVasive, Inc., a San-Diego based
medical device company servicing the spine sector. He has also held finance roles with Callaway Golf and Kyocera Wireless. Mr. Williams
received an MBA in Finance and Management from San Diego State University and a Bachelor of Arts in Economics from the University of
California, San Diego. We believe that Mr. Williams&#8217; executive-level management experience with healthcare-related businesses,
including his financial management expertise, give him the qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
Rosa</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Rosa has served as one of our directors and Chair of our Board&#8217;s Nominating Committee since November 2021. Mr. Rosa has served
as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since
July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly-owned subsidiary, from October
2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and
President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly-held early-stage medical device company. From
2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals.
From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical,
Inc. He serves as a director on the board of directors of Biotricity Inc. <span style="background-color: white">(Nasdaq:BTCY) and Healthcare
Triangle, Inc. (Nasdaq:HCTI). Mr. Rosa is Chairman of Neuro Event Labs, a privately-held company in Finland, and an Advisory Board member
of SYNAPS Dx, a privately-held company in Bethesda, Maryland. </span> We believe that Mr. Rosa&#8217;s senior leadership experience in
the medical device industry and his strong technical, strategic, and operational expertise give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following persons are the members of our Scientific Advisory Board:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Positions</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
    Marasco, M.D., Ph.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor,
    Department of Cancer Immunology &amp; AIDS, Dana-Farber Cancer Institute;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor
    of Medicine, Harvard Medical School;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Faculty Member, Harvard Stem Cell Institute</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason
    Lipetz, M.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Disc Advisory Committee</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder,
    Long Island Spine Rehabilitation Medicine;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    of Spine Medicine, Northwell Health Spine Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Assistant Professor, Department of Physical Medicine and Rehabilitation, Zucker School of Medicine at Hofstra/Northwell</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
    J. Olan, M.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    Director, Tissue Bank</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Interventional and Endovascular Neurosurgery;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associate
    Professor, Neurosurgery and Radiology, George Washington University Medical Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Physician, Department of Radiology, National Institutes of Health</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joy
    Cavagnaro, Ph.D.,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DABT,
    RAC</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Founder, Access BIO, L.C.; Fellow, Academy of Toxicological Sciences and the Regulatory Professional Society;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Senior Pharmacologist and Director of Quality Assurance, Food and Drug Administration&#8217;s Center for Biologics Evaluation and
    Research</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvinder
    Sandhu, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthopedic
    Spine Surgeon, Hospital for Special Surgery;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Chief of Spinal Surgery Service, UCLA Medical Center</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Plastaras, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Director of Musculoskeletal Spine and Sports Rehabilitation Medicine and Physiatrist, MossRehab;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Director of The Penn Spine and Rehabilitation Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Director of Spine, Sports and Musculoskeletal Medicine Fellowship, University of Pennsylvania</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers, directors and Scientific Advisory Board members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
of Office</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a classified Board of Directors. The directors will hold office until the respective annual meetings of stockholders indicated below
and until their respective successors are elected and qualified or until their earlier resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Expires</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
executive officer will hold office until the initial meeting of the Board of Directors following the next annual meeting of stockholders
and until his successor is elected and qualified or until his or her earlier resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors is responsible for overseeing our accounting and financial reporting processes and the audits
of our financial statements. The members of the Audit Committee are Mr. Williams (Chair), Dr. Kukekov and Mr. Rosa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Financial Expert</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has determined that Mr. Williams qualifies as an &#8220;audit committee financial expert,&#8221; as that term is defined in Item
407(d)(5) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) Beneficial Ownership Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16 of the Exchange Act requires that reports of beneficial ownership of common stock and changes in such ownership be filed with the
Securities and Exchange Commission by Section 16 &#8220;reporting persons,&#8221; including directors, certain officers, holders of more
than 10% of the outstanding common stock and certain trusts of which reporting persons are trustees. We are required to disclose in this
Annual Report each reporting person whom we know to have failed to file any required reports under Section 16 on a timely basis during
the fiscal year ended December 31, 2022. To our knowledge, based solely on a review of copies of Forms 3, 4 and 5 filed with the Securities
and Exchange Commission, during the fiscal year ended December 31, 2022, our officers, directors and 10% stockholders complied with all
Section 16(a) filing requirements applicable to them, except that Mr. Silva filed one Form 4 late (reporting multiple transactions on
two trading days) and Dale Broadrick, a 10% stockholder, filed four Forms 4 late (reporting multiple late transactions on eleven trading
days).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics for Senior Financial Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has adopted a Code of Ethics for our principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions. A copy of the Code of Ethics is posted on our website, www.biorestorative.com.
We intend to satisfy the disclosure requirement under Item 5.05(c) of Form 8-K regarding an amendment to, or a waiver from, our Code
of Ethics by posting such information on our website, www.biorestorative.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_016"></span>ITEM
    11.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">EXECUTIVE
    COMPENSATION</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following Summary Compensation Table sets forth all compensation earned in all capacities during the fiscal years ended December 31,
2022 and 2021 by (i) our principal executive officer, and (ii) our two most highly compensated executive officers, other than our principal
executive officer, who were serving as an executive officer as of December 31, 2022 and whose total compensation for the 2022 fiscal
year, as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively
referred to as the Named Executive Officers):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
and Principal Position</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Stock Awards<sup>(1)</sup></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Option Awards<sup>(1)</sup></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">All Other Compensation</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); width: 37%; text-align: left">Lance Alstodt</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">2022</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">$</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">400,000</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">$</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">$</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">52,364</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">$</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">$</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 2%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">$</td><td style="background-color: rgb(204,238,255); width: 5%; text-align: right">452,364</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer <sup>(2)</sup></span></td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">2021</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">275,000</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">6,984,812</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">14,081,677</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">21,341,489</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-align: left">Francisco Silva</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">2022</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">375,000</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">52,364</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">427,364</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-align: left">VP, Research and Development</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">2021</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">259,375</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">6,984,812</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">14,081,677</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">$</td><td style="background-color: rgb(204,238,255); text-align: right">21,325,864</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left"></td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White">&#160;</td>
    <td style="background-color: White; text-align: left">&#160;</td><td style="background-color: White; text-align: right">&#160;</td><td style="background-color: White; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert
    Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">$</td><td style="text-align: right">-</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">$</td><td style="text-align: right">175,000</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief
    Financial Officer<sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">82,383</td><td style="text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reflect the aggregate grant date fair value of grants made in the fiscal year computed in accordance with stock-based accounting
    rules (FASB ASC Topic 718-Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 7  to our
    consolidated financial statements included in this Annual Report.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Kristal has been serving as our Chief Financial Officer since November 4, 2021.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information on outstanding equity awards as of December 31, 2022 to the Named Executive Officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td colspan="16" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Option Awards</b></td><td style="padding-bottom: 1.5pt; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Stock Awards</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Name</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br />
 Securities<br />
 Underlying<br />
 Unexercised<br />
 Options<br />
 exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br />
 Securities<br />
 Underlying<br />
 Unexercised<br />
 Options<br />
 unexercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Equity<br />
 Incentive<br />
 Plan<br />
 awards:<br />
 Number of<br />
 Securities<br />
 Underlying<br />
 Exercised<br />
 Unearned<br />
 options</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Option<br />
 Exercise<br />
 price</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Option<br />
 Expiration<br />
 date</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br />
 of shares<br />
 or units of <br />
stock that<br />
 have not<br />
 vested</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Market<br />
 value of<br />
 shares of <br />
units that<br />
 have not<br />
 vested</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Equity<br />
 Incentive<br />
 Plan<br />
 awards:<br />
 Number<br />
 of<br />
 Unearned<br />
 shares,<br />
 unites or<br />
 other<br />
 rights<br />
 that have<br />
 not<br />
 vested</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Equity<br />
 Incentive<br />
 Plan<br />
 awards:<br />
 Market<br />
 or<br />
 Payout<br />
 value of<br />
 unearned<br />
 shares,<br />
 units or<br />
 other<br />
 rights<br />
 that have<br />
 not<br />
 vested</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Lance Alstodt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">275,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,342</span></td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">5.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/18/2031</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,400</span></td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/4/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,935</span></td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">277,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,342</span></td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/18/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,400</span></td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/4/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,935</span></td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">277,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/4/2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/12/2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/23/2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2025</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/10/2026</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/12/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/29/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Option
    becomes exercisable on March 18, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    becomes exercisable in seven nearly equal quarterly installments beginning on February 4, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock vests to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023
    and 48,913 shares on March 18, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lance
Alstodt</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 16, 2020, Mr. Alstodt was elected our Chief Executive Officer, President and Chairman of the Board. On March 18, 2021, we entered
into an employment agreement with Mr. Alstodt which provides for a term ending on March 18, 2026. Pursuant to the employment agreement,
Mr. Alstodt currently is entitled to receive an annual salary of $400,000 (giving effect to a $150,000 performance salary increase received
in November 2021). Concurrently with the execution of the employment agreement, we granted to Mr. Alstodt pursuant to the 2021 Plan (i)
a ten year option for the purchase of 293,479 shares of our common stock at an exercise price of $47.60 per share (which exercise price
was subsequently reduced to $13.50 per share and further reduced, subject to stockholder approval, to $5.08 per share) and (ii) 146,740
restricted stock units, or RSUs. The option vests to the extent of 50% thereof on the date of grant, 12.5% on November 4, 2021 and the
balance in six equal quarterly installments commencing on December 18, 2021. The RSUs vest in three equal annual installments on the
first, second and third anniversaries of the date of grant. In the event that Mr. Alstodt&#8217;s employment is terminated by us without
&#8220;cause&#8221;, or Mr. Alstodt terminates his employment for &#8220;good reason&#8221; (each as defined in the employment agreement),
Mr. Alstodt will be entitled to receive severance in an amount up to one time his then annual base salary. If Mr. Alstodt&#8217;s employment
with us is terminated without cause, the option granted to Mr. Alstodt will vest and become exercisable and such option will remain exercisable
until its expiration date notwithstanding such termination of employment with us. In addition, the RSUs granted to Mr. Alstodt will vest
in the event of the termination of his employment without cause or in the event of a change in control (as defined in the 2021 Plan).
In March 2022, we and Mr. Alstodt agreed that, in lieu of a $50,000 increase in his annual salary (as provided for in his employment
agreement), we issued to Mr. Alstodt 12,438 RSUs (having a value of $50,000), which RSUs will vest in twelve equal monthly installments.
Such grant was in consideration of Mr. Alstodt deferring his right to receive the $50,000 increase in his salary for one year. Effective
in March 2023, pursuant to his employment agreement, Mr. Alstodt will be entitled to his annual increase of $50,000 in his salary (plus,
in March 2023, the $50,000 salary increase deferral discussed above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Francisco
Silva</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, we and Mr. Silva entered into an employment agreement which provides for a term ending on March 18, 2026. Pursuant to
the employment agreement, Mr. Silva is currently entitled to receive an annual salary of $375,000 (giving effect to a $150,000 performance
salary increase received in November 2021). Concurrently with the execution of the employment agreement, we granted to Mr. Silva pursuant
to the 2021 Plan (i) a ten year option for the purchase of 293,479 shares of our common stock at an exercise price of $47.60 per share
(which exercise price was subsequently reduced to $13.50 per share and further reduced, subject to stockholder approval, to $5.08 per
share) and (ii) 146,740 RSUs. The option vests to the extent of 50% thereof on the date of grant, 12.5% on November 4, 2021 and the balance
in six equal quarterly installments commencing on December 18, 2021. The RSUs vest in three equal annual installments on the first, second
and third anniversaries of the date of grant. In the event that Mr. Silva&#8217;s employment is terminated by us without &#8220;cause&#8221;,
or Mr. Silva terminates his employment for &#8220;good reason&#8221; (each as defined in the employment agreement), Mr. Silva will be
entitled to receive severance in an amount up to one time his then annual base salary. If Mr. Silva&#8217;s employment with us is terminated
without cause, the option granted to Mr. Silva will vest and become exercisable and such option will remain exercisable until its expiration
date notwithstanding such termination of employment with us. In addition, the RSUs granted to Mr. Silva will vest in the event of the
termination of his employment without cause or in the event of a change in control (as defined in the 2021 Plan). In March 2022, we and
Mr. Silva agreed that, in lieu of a $50,000 increase in his annual salary (as provided for in his employment agreement), we issued to
Mr. Silva 12,438 RSUs (having a value of $50,000), which RSUs will vest in twelve equal monthly installments. Such grant was in consideration
of Mr. Silva deferring his right to receive the $50,000 increase in his salary for one year. Effective in March 2023, pursuant to his
employment agreement, Mr. Silva will be entitled to his annual increase of $50,000 in his salary (plus, in March 2023, the $50,000 salary
increase deferral discussed above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning the compensation of our non-employee directors for the fiscal year ended December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fees<br />
 Earned<br />
 or Paid<br />
 in Cash</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Stock<br />
 Awards</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br />
Awards</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><sup>&#160;</sup></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Non-Equity<br />
 Incentive Plan<br />
 Compensation</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Nonqualified<br />
 Deferred<br />
 Compensation<br />
 Earnings</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">All Other<br />
 Compensation</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%; text-align: left">Nickolay Kukekov</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#8239;&#8239;&#8239;&#8239;-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patrick F. Williams</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Rosa</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2022, Dr. Kukekov held options for the purchase of 25,236 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2022, Mr. Williams held options for the purchase of 10,490 shares of common stock. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2022, Mr. Rosa held options for the purchase of 10,490 shares of common stock. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kukekov and Messrs. Williams and Rosa, our non-employee directors, as compensation for their services as a director, are entitled to
receive per annum $30,000 in cash and $90,000 in option grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_017"></span>ITEM
    12.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -1.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -1.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -1.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock, as of March 22, 2023, known by
us, through transfer agent records and reports filed with the SEC, to be held by: (i) each person who beneficially owns 5% or more of
the shares of common stock then outstanding; (ii) each of our directors; (iii) each of our Named Executive Officers (as defined above);
and (iv) all of our directors and executive officers as a group. The following table also sets forth certain information regarding the
beneficial ownership of our Series B preferred stock as of March 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this table reflects &#8220;beneficial ownership&#8221; as defined in Rule 13d-3 of the Exchange Act. To our knowledge,
and unless otherwise indicated, each stockholder has sole voting power and investment power over the shares listed as beneficially owned
by such stockholder, subject to community property laws where applicable. Percentage ownership is based on 3,767,615 shares of common
stock and 1,518,158 shares of Series B preferred stock outstanding as of March 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times ew Roman, Times, Serif; font-size: 10pt"><b>Name and Address of Beneficial</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of <br />
Shares of<br />
 Common Stock<br />
 Beneficially<br />
</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b>&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate<br />

    Percent of <br />
Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of <br />
Shares of Series<br />
 B Preferred<br />
 Stock<br />
 Beneficially<br />
 Owned</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate<br />

    Percent of Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Executive Officers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt<sup>(1) </sup>&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">453,701</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva<sup>(1) </sup>&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">444,642</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,862</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,350</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,868</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,868</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and executive officers as a group (7 persons)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">953,499</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0">21.4</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain
    Beneficial Owners</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale
    Broadrick<sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">623,404</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auctus
    Fund, LLC<sup>(9)</sup></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auctus
    Fund Management LLC<sup>(9)</sup></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred
    Sollami<sup>(9)</sup></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis
    Posner<sup>(9)</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">376,004</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(10)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.99</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,518,158</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(11)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is c/o BioRestorative Therapies, Inc., 40 Marcus Drive, Suite One, Melville, New York 11747.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    322,395 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    322,475 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days and 12,136
    shares of common stock held by Mr. Silva in a retirement account. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    7,868 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    692,032 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is 3003 Brick Church Pike, Nashville, Tennessee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Amendment No. 8 to Schedule 13D and Form 4 filed with the SEC. Includes 1,359 shares common stock issuable upon the exercise
    of currently exercisable warrants and 316,972 shares of common stock held by&#160;&#160;Fleetco Inc. of which Mr. Broadrick is a
    93% stockholder.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is 545 Boylston Street, 2<sup>nd</sup> Floor, Boston, Massachusetts 02116.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Amendment No. 1 to Schedule 13G filed with the SEC, Auctus Fund, LLC, or Auctus, holds a warrant for the purchase of up to
    1,676,580 shares of our common stock. In addition, Auctus&#8217; shares of Series B preferred stock are convertible into an
    aggregate of 1,518,158 shares of our common stock. However, such warrant is not exercisable to the extent Auctus would beneficially
    own, after such exercise, more than 9.99% of our outstanding shares of common stock.&#160;&#160;In addition, such Series B preferred
    stock is not convertible into shares of our common stock to the extent Auctus would own, after such conversion, more than 9.99% of
    our outstanding shares of common stock. Since Auctus has indicated in its Amendment No.1 to Schedule 13G filed with the SEC, as of
    December 31, 2022, that it owned 285,828 shares of common stock, which represented 7.8% of the then 3,673,629 outstanding shares of
    common stock, and that such warrant is exercisable for the purchase of 90,176 shares of our common stock (increasing Auctus&#8217;
    beneficial ownership of our common stock to 9.99%), such Series B preferred stock is not currently convertible into shares of our
    common stock.&#160;&#160;The number of shares of common stock beneficially owned by Auctus includes such 90,176 shares of common
    stock issuable upon exercise of the warrant. Based upon the increase in the number of shares of common stock that are outstanding from 3,673,629 to 3,767,615,
additional shares are issuable pursuant to an exercise of the warrant to maintain such 9.99% beneficial ownership interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to the Certificate of Designations of Preferred Stock with regard to the Series B preferred stock, Auctus, as the sole holder of
    the 1,518,158 outstanding shares of Series B preferred stock, is entitled to vote such shares based on the number of shares of common
    stock into which such shares are convertible (currently 1,518,158); however, pursuant to such Certificate of Designations of Preferred
    Stock, as indicated in footnote (10), such Series B preferred stock is not convertible into shares of our common stock to the extent
    Auctus would beneficially own, after such conversion, more than 9.99% of our then outstanding shares of common stock.&#160;&#160;Since
    Auctus has indicated in its Amendment No.1 to Schedule 13G filed with the SEC, as of December 31, 2022, that it owned 285,828 shares
    of common stock, which represented 7.8% of the outstanding shares of common stock, and that its warrant for the purchase of common
    stock is exercisable for the purchase of 90,176 shares of our common stock (increasing Auctus&#8217; beneficial ownership of our
    common stock to 9.99%), its Series B preferred stock is not currently convertible into shares of our common stock.&#160;&#160;Accordingly,
    as of March 22, &#160;2023, Auctus, as the sole holder of the Series B preferred stock, is not entitled to vote any such shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of December 31, 2022 with respect to compensation plans (including individual compensation
arrangements) under which our common stock are authorized for issuance, aggregated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    compensation plans previously approved by security holders; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    compensation plans not previously approved by security holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
COMPENSATION PLAN INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">securities to be</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued upon</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise of</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options (a)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price of</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding options</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">securities</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available for future</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance under</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plans (excluding</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">securities reflected</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in column (a))</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    compensation plans approved by security holders</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">864,639</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5.08</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,318,094</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">864,639</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5.08</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,318,094</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    options to purchase up to 1,089 shares of common stock under the Company&#8217;s 2010 Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    201,870 unvested restricted stock units outstanding at December 31, 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_018"></span>ITEM
    13.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is comprised of Lance Alstodt (Chair), Francisco Silva, Nickolay Kukekov, Patrick F. Williams and David Rosa. Each
of Dr. Kukekov, Mr. Williams and Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing
Rule 5605(a)(2) of The Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Williams (Chair), Dr. Kukekov and Mr. Rosa are the members of our Board&#8217;s Audit Committee. Each of Mr. Williams, Dr. Kukekov and
Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq Stock
Market and Rule 10A-3(b)(1) under the Exchange Act. Our Board of Directors has determined that Mr. Williams qualifies as an &#8220;audit
committee financial expert,&#8221; as that term is defined in Item 407(d)(5) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rosa (Chair), Dr. Kukekov and Mr. Williams are the members of our Board&#8217;s Nominating Committee. Each of Mr. Rosa, Dr. Kukekov and
Mr. Williams is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq
Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kukekov (Chair), Mr. Williams and Mr. Rosa are the members of our Board&#8217;s Compensation Committee. Each of Dr. Kukekov, Mr. Williams
and Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq
Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_019"></span>ITEM
    14.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">PRINCIPAL
    ACCOUNTANT FEES AND SERVICES</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
LLP served as our independent registered public accountants for the year ended December 31, 2022. Friedman LLP served as our independent
registered public accountants for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the fees billed or expected to be billed to us by Marcum LLP, our independent registered public accountants,
for professional services rendered with respect to the fiscal year ended December 31, 2022 and by Friedman LLP, our former independent
registered public accountants, for professional services rendered with respect to the fiscal years ended December 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marcum LLP</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Friedman
                                            LLP</b></p>

</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Audit fees (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">65,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-related fees (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax fees (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees (4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">135,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Fees consist of fees billed and expected to be billed for services rendered for the audit of our consolidated financial statements
    for the fiscal years ended December 31, 2022 and 2021, and the review of our condensed consolidated financial statements included
    in our Quarterly Reports on Form 10-Q.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related
    Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit of our
    financial statements and in connection with the filing of Forms S-1 and S-8 registration statements and are not reported under &#8220;Audit
    Fees.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Fees consist of fees billed for professional services related to preparation of our U.S. federal and state income tax returns and
    tax advice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Fees consist of fees billed for products and services provided by our independent registered public accountants, other than
    those disclosed above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for the appointment, compensation and oversight of the work of the independent registered public accountants,
and approves in advance any services to be performed by the independent registered public accountants, whether audit-related or not.
The Audit Committee reviews each proposed engagement to determine whether the provision of services is compatible with maintaining the
independence of the independent registered public accountants. The fees shown above were pre-approved either by our Board or our Audit
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_020"></span>PART
IV</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_021"></span>ITEM
    15.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">EXHIBITS
    AND FINANCIAL STATEMENT SCHEDULES</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exhibit No.</span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Incorporation, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.3</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations of Series B Preferred Stock, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.4</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.5</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex10-44.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated as of January 27, 2012, between Regenerative Sciences, LLC and BioRestorative Therapies, Inc. (&#8220;License Agreement&#8221;), incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.44</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex10-45.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to License Agreement, dated March 21, 2012, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.45</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420416091575/v434828_ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to License Agreement, dated November 30, 2015, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015, wherein such document is identified as Exhibit 10.20</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-4.htm">Letter agreement, dated November 21, 2022, by and among BioRestorative Therapies, Inc., Regenerative Sciences, LLC and Regenexx, LLC with regard to License Agreement*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177114000054/ex99_1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease, dated as of August 25, 2014, between BioRestorative Therapies, Inc. and 50 Republic Road, LLC, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated August 25, 2014, wherein such document is identified as Exhibit 99.1</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315221006285/ex10-37.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Amendment, dated as of June 4, 2019, between 50 Republic Road, LLC and BioRestorative Therapies, Inc., incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, wherein such document is identified as Exhibit 10.37</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-7.htm">BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of March 18, 2021, by and between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.2</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of March 18, 2021, by and between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.3</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.4</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.5</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Unit Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.6</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Unit Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.7</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/ex99_1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 4, 2021, wherein such document is identified as Exhibit 99.2</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/ex99_2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 4, wherein such document is identified as Exhibit 99.3</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.15</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.16</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.17</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-18.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.18</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-19.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.19</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant, dated November 9, 2021, issued by BioRestorative Therapies, Inc. pursuant to public offering, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.20</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant, dated November 9, 2021, issued by BioRestorative Therapies, Inc. to Auctus Fund, LLC, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.21</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-22.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.22</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-23.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.23</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-24.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.24</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-25.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.25</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-26.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.26</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-28.htm">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Lance Alstodt*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-29.htm">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Francisco Silva*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-30.htm">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Robert Kristal*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-31.htm">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Robert Paccasassi*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-32.htm">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Nickolay Kukekov*</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-33.htm">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Patrick F. Williams*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-34.htm">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and David Rosa*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 14</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315219004292/ex21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, wherein such document is identified as Exhibit 21</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Independent Registered Public Accounting Firm&#8217;s Consent*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Independent Registered Public Accounting Firm&#8217;s Consent*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Principal Executive Officer Certification*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Principal Financial Officer Certification*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex-32.htm">Section 1350 Certification**</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document *</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Schema Document *</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Calculation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Definition Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Label Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Presentation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_022"></span>ITEM
    16.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">FORM
    10-K SUMMARY</span></b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ayt_023"></span>SIGNATURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
    THERAPIES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 24, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 54%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capacity</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, Chairman of the Board and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2023</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
Francisco Silva</i></span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
President, Research and Development and Director</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2023</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<i>s/
Robert E. Kristal</i></span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Chief
Financial Officer</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2023</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Nickolay Kukekov</i></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Patrick F. Williams</i></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Rosa</i></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 AND 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">TABLE
OF CONTENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports of Independent Registered Public Accounting Firms (Marcum LLP, PCAOB ID 688; Friedman LLP, PCAOB ID <span id="xdx_902_edei--AuditorFirmId_c20220101__20221231_zzjhCYcqIY3j"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">711</ix:nonNumeric></span>)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    FINANCIAL STATEMENTS:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sa_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sa_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sa_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity as of December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sa_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sa_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 74; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="sa_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and<br />
Shareholders of BioRestorative Therapies, Inc. &amp; Subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of BioRestorative Therapies, Inc. &amp; Subsidiary (the &#8220;Company&#8221;)
as of December 31, 2021, the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash
flows for the year ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2021, and the results of its operations and its cash flows for the year ended December 31, 2021, in conformity with accounting principles
generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audit provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Friedman <span style="font-variant: small-caps">llp</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
served as the Company&#8217;s auditor from 2020-2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlton,
New Jersey</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
30, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet<b>s</b> of BioRestorative Therapies, Inc. and Subsidiary (the &#8220;Company&#8221;)
as of December 31, 2022, the related consolidated statements of operations, stockholders&#8217; equity and cash flows and the related
notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash
flow for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide<b>s
</b>a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90D_edei--AuditorName_c20220101__20221231_zIepH9tJ7cNe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Marcum LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<span style="font-variant: small-caps">LLP</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2020 (such date takes into account the acquisition of certain assets of Friedman LLP
by Marcum LLP effective September 1, 2022.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--AuditorLocation_c20220101__20221231_zATETgPluqwi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Marlton,
New Jersey</ix:nonNumeric> </span><b><br />
</b>March 24, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sa_002"></span><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zLvFPV7CqhX3" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zd3UUhXFU4Y3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zmIpA5UAU9dl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zc78IppliFo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zxTmherJW6Za" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzsph_zMFuwbSKFi0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,676,577</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,026,727</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzsph_zxFzWlLAeNe4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Investments held in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,072,831</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0064">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzsph_zsU7SdHtnAKh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzsph_zEvptAl5fY7e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,082</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtACzsph_maAzhZI_zBKf0ZrdXjSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,128,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,467,908</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzhZI_zGUJsocEZ5l5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzhZI_z7aWicVb5976" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzhZI_ztuiA1bFECkc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Intangible assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">803,438</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">589,740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Assets_i01TI_mtAzhZI_zSPL7i6nVGvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,434,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,453,446</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zLOpP2fPg0K4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_z38f0kntl5e9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maLCzrOD_zOTolHNC8UQ5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzrOD_zGMUPx79QILd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzrOD_zN37bTL4op5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Lease liability, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LoansPayableCurrent_i02I_maLCzrOD_zni5tGnfrMt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">PPP loan payable, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,970</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzrOD_maLzD8l_zJLB0oXeyev5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">440,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzD8l_zvJmPJWIieo3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermLoansPayable_i01I_maLzD8l_zjzEPV39dHPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">PPP loan payable, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtLzD8l_maLASEzXVv_zpxNaHwXExja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">856,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_i01B_zFjrri2dCeBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_maSEz26Y_zWBg7cZZnCYj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zccis8m9Z2Oi" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zo8EaWVIOeMc" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; Authorized, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_z6BssGytziCe" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zfaaGnrEqVXi" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_maSEz26Y_zN7CsKSpp8me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Series A Convertible Preferred stock, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2nMKf12sOuf" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWAyf8BoiEU5" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYGmV2oeDT2j" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLHW2RQTwVcb" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> designated shares, <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3FYUMspULH6" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2U46uyq0BR8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zJARZnS56Hjg" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zEsjSmU6LHsa" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding at December 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0131">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,432</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEz26Y_zPVTJgaoGKK8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Series B Convertible Preferred stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zqkamss81oeb" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zJhkc5AFccXb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zW3w5AoGEVok" title="Preferred stock, shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zsyEnQCPDNg5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> designated shares, <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zM0ru7dcwaOf" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFYCskPVoIAk" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zC0u9NFplvQ6" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zt5diGx4qdm6" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding at December 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_maSEz26Y_zxdp1d7Ta3Pc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Preferred
    stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maSEz26Y_zeqpt9cIc312" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Common stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zhNL8wmbYLm4" title="Common stock, par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_z8uBrxrszGRd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; Authorized, <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zMTKyvfL4g6l" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zEFR8ecwVXAl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221231_zrj8bfT1RDsk" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_znSldGQnEuhe" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,775</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20211231_z5drCRBot5uf" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zCsRJelH2BL7" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,520,391</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding at December 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEz26Y_zYAZyn6JGKwg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,457,418</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,727,292</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz26Y_zG8jMRZCiYGc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,640,897</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">134,146,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_mtSEz26Y_maLASEzXVv_zThxu3UM4Bua" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,832,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,596,949</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzXVv_z8phjZiVgQ0d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,434,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,453,446</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="sa_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zT5zmQrgnoCl" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_zIIjQ6KReTu3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231_zhrYaWYSqq3e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzNfg_zB2yQwdJ20o3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zSjEfSY0zuc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzQwd_zSnvIczo0RYi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,513,352</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">729,058</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzQwd_zw8riLAELm7a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,580,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,624,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtCzQwd_msCzNfg_zh2yDoSllAKi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,093,825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,353,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtCzNfg_maCzAjY_ziaK8E9bOAm4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,974,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,307,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zhFSX1VPZCUh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (income) expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestIncomeExpenseNet_i01N_di_maCziQG_maNIEzzFP_zKYPUBH9Uy6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest (income) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,650</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,815,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_maNIEzzFP_zGg7i0e7NcQi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on extinguishment of notes payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,180,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainOnPppLoanForgiveness_i01N_di_maCziQG_maNIEzzFP_zaMjTJewRSd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on PPP loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--GrantIncome_i01N_di_maCziQG_maNIEzzFP_z6csPfKVWLsf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:GrantIncome" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,518</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_i01N_di_maCziQG_maNIEzzFP_zX2XjDPDfvy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NonoperatingIncomeExpense_i01NT_di_maCzAjY_mtNIEzzFP_zvOrrSzkgjUi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total other (income) expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">479,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,995,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_iT_mtCzAjY_zwxS8tMeqyse" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,494,769</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,303,295</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_zNF7omBjHqRa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss Per Share - Basic and Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">37.30</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zyOuOBIFgUK9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted Average Number of Common Shares Outstanding - Basic and Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,617,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,187,741</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="sa_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_zOb5EQeaXQLc" summary="xdx: Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zcCMffF5FHm" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zB9fsFrB9PAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zbNd3JwpNRZ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z7fKh0M47plk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zbuBiEt3Roja" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_zH4eOr9u5fAg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series A Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_438_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zwzO1zDVpAv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">Balance at January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zDvYBA7dh3H8" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zKN6nQZUVXv9" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0SzILNXh1f8" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">715,544</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,511,269</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">89,842,833</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,331,492</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zjlTi970IgL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares and warrants issued for cash related to public offering, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbjzCCNarT3" title="Shares and warrants issued for cash related to public offering, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,072,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,072,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_zZQS9cG7aMfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zCzH0yHr9Mpg" title="Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants, shares" style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9FUuTR4gsk4" title="Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants, shares" style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,611,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,627,445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zOpvuslC9bna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in exchange of notes payable and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIOy7r9FiFV1" title="Shares issued in exchange for notes payable and accrued interest, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,377</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuedInCashlessExerciseOfWarrants_zypMXVDWk6P6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in cashless exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharesIssuedInCashlessExerciseOfWarrantsShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDtudWIz8xMd" title="Shares issued in cashless exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrantsShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">82,146</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:SharesIssuedInCashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">82,128</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedInLitigationSettlement_zwWycdhZ9jSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in litigation settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedInLitigationSettlementShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCiyevF3Xlvi" title="Shares issued in litigation settlement, shares" style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlementShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlement" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInLitigationSettlement" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_z7DvDNuBAYZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fair market value of beneficial conversion feature and warrants issued with convertible notes payable instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,404</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_z5SnO5oB5n5b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;- restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKzWDgMkm5Re" title="restricted stock units, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,671,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,671,503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zyCIUqrYZOod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;- options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ztBrMF7rxVgc" title="options, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,411,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,411,976</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zuAyPLxiMWHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;- common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp6D41D4Sll5" title="common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zDkZOGUkngFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,303,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,303,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zuSI3k0scUA6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOEPQb9vbvTl" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,432</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zSKaVGYNoewh" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXxFxu4z7Y6i" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,520,391</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,727,292</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">134,146,128</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,596,949</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConversionOfStockAmountIssued1_zDlV7CxjYwuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zNo1r0Zapfp" title="Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock, Shares" style="text-align: right">(<ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,543,158</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,432</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ConversionOfStockSharesIssued1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z4TH0tP474B6" title="Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zMIZJV6JsAA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants issued in connection with license exclusivity agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zmMczkdBthV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued in exchange for Series B&#160;&#160;Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zYCxZd3Imst8" title="Common stock issued in exchange for Series B Preferred Stock, Shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWaqCv2bAqq7" title="Common stock issued in exchange for Series B Preferred Stock, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zRuOTTIF0jSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;- restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7emXJZBqKsk" title="restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,735,097</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,735,108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zKme5XlP1ai9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;- options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsEuLvyfRAyd" title="options, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,741,864</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,741,864</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zKiMIEHS2kmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;- common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqnoySNye6Sf" title="common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,890</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zYy3iBDw7af3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,494,769</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,494,769</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zikLyZg7IOB7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxmxGHw1I5uc" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z75ll240wzyg" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,775</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,457,418</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,640,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,832,072</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="sa_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_zKsge6dVTS56" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: red; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zxXI9o0CL6Vk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231_zVDmSdFC6Ov2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: red; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zOVXbpcHDzk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td style="color: red; font-weight: bold">&#160;</td>
    <td style="color: red; font-weight: bold; text-align: left">&#160;</td><td style="color: red; font-weight: bold; text-align: right">&#160;</td><td style="color: red; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_maCzA25_maNCPBUzMkp_zIR5AgtKP4Q4" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,494,769</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,303,295</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zXjyqjorRDbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maCzA25_maNCPBUzMkp_zJ6xrwjEIsq2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,133,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzA25_maNCPBUzMkp_zAEKjE1eJoqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_di_msNCPBUzMkp_zLWZe96Ee8O8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,665</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_maCzA25_maNCPBUzMkp_z9CGmei117Gj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compenation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,612,862</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,108,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedInSettlementOfLitigation_i02_maNCPBUzMkp_zGU2LWbHDQm1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares issued in settlement of litigation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:SharesIssuedInSettlementOfLitigation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzA25_msNCPBUzMkp_zvrt7HJirR2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on extinguishment of note payables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,180,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GainOnPppLoanForgiveness_i02N_di_msNCPBUzMkp_zORyvrtwNWgd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on PPP loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--NoncashLeaseExpense_i02_maNCPBUzMkp_zUQgSFdHcmg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,044</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zmxtOMktZ2tl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzMkp_znKf0oFHsEvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzMkp_z63tZaoFRjY2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid assets and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">330,774</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzMkp_zGyzpXRYurW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,024</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maNCPBUzMkp_zttHpWNnR5de" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,898</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,673</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzMkp_zVX3LMm86Qv5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzjE7_mtNCPBUzMkp_zG2CLcNoazA" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,870,761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,329,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_i01B_z50xa6JI5zSe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msNCPBUzai2_z7beu1JYPcmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,039,166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzai2_zzLlJU1IqBw5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchase of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzai2_z77q35JfL0wh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Purchases of equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,658</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzai2_maCCERCzjE7_z360xit3vz83" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,479,389</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,658</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zFvXt1s8NHic" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maCzOx0_maNCPBUzJ18_zy7SD5OFGEX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of units in public offering, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,072,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromNotesPayable_i01_maCzOx0_maNCPBUzJ18_zzelL2bJ5Nll" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromRepaymentsOfDebt_i01_maNCPBUznBn_maNCPBUzJ18_zBQdXEE2Nsx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from PPP Loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzjE7_mtNCPBUzJ18_zIn6Vm0lFdpl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,322,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzjE7_zGSZas00Y4Rd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (decrease) increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,350,150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,962,117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_znqUP99oGvB8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Cash and cash equivalents - beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,026,727</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,064,610</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z9DrHpKVv9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents&#160;&#160;- end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,676,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,026,727</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td style="color: red; text-align: right">&#160;</td><td style="color: red; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zhcK3ttbcUff" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationRelatedText_i01B_zEx8X6sQYAjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zrDcKodsM5Ca" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssued1_i01_pp0p0_zkgb1YHVm6Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares issued in exchange for notes payable and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">317,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NoncashAccruedExpenseExchangedForConveritbleNotes_i01_pp0p0_zKh0xBb7MKTb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expense exchanged for converitble notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashAccruedExpenseExchangedForConveritbleNotes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">715,303</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount_i01_pp0p0_ze5ITomSu1Gb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">166,404</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering_i01_pp0p0_z8RVRbAJsngk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible debt and accrued interest exchanged for common and preferred shares and warrants in public offering</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,046,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedDipExpensesExchangedForConvertibleNotes_i01_pp0p0_zUUKsKI3equf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued DIP expenses exchanged for convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:AccruedDipExpensesExchangedForConvertibleNotes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">698,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantsIssuedAsConsiderationForIntangibleAssets_i01_pp0p0_zpkmmBfmC9A9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrants issued as consideration for intangible assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:WarrantsIssuedAsConsiderationForIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sa_006"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmh4v9pRAki3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
1 &#8211; <span id="xdx_82E_zNdxt28mA2ej">ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2022,
the Company had a net loss of $<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_z7dHJepdnrO4" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">18.5</ix:nonFraction></span> million (of which, $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_z72ZAMTq8tT7" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.6</ix:nonFraction></span> million was attributable to non-cash stock-based compensation) and negative
cash flows from operations of $<span id="xdx_90F_ecustom--NetCashProvidedByUsedInOperatingActivitie_iN_pn5n6_di_c20220101__20221231_z32SPqAZaD23" title="Cash flows from operations"><ix:nonFraction name="BRTX:NetCashProvidedByUsedInOperatingActivitie" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.8</ix:nonFraction></span> million. The Company&#8217;s operating activities consume the majority of its cash resources. The
Company anticipates that it will continue to incur net losses as it executes its development plans for 2023 and beyond, as well as other
potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash flows from
operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses primarily through
current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on cash on hand as of December 31, 2022, the Company believes it has sufficient cash to fund operations for the twelve months subsequent
to the filing date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development,
marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial condition
and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#8220;GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization of
assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in
the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead
cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem
cells collected from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral
disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a
platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders
and has labeled this initiative its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system
designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zfyVbJSW5lIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_82E_zun87tFlhRL9">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEDfld8mOouk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zJwbUNT5TSeg">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies
presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated financial
statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_za26SAORRPIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zXaInqJau9m5">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and
transactions have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zLpnaATMcbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zZxQ3ENSrgQ8">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities
at the date of the consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known
or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined
with precision, actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zHghKMZsiQA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zulwUOXTerH9">Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zEJzcWBODCNb" title="FDIC insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. As of December
31, 2022, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
royalties related to the Company&#8217;s sublicense comprised all of the Company&#8217;s revenue during the years ended December 31,
2022 and 2021. See &#8220;Revenue&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpK1uUThmvyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zV9gomiXUZE9">Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for revenue in accordance with ASC Topic 606, <i>Revenue from Contracts with Customers</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (&#8220;SCTC&#8221;)
entered into in January 2012. In November 2022, the Company&#8217;s license rights under the agreement became exclusive. Pursuant to
the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things,
stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the
right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration
of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or
as, the performance obligation is satisfied. The Company&#8217;s contracts have a single performance obligation which is not separately
identifiable from other promises in the contracts and is, therefore, not distinct. The Company&#8217;s performance obligation is satisfied
upon the transfer of risk of loss to the customer. The timing of the Company&#8217;s revenue recognition may differ from the timing of
receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company
has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services,
the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2022 and 2021,
the Company recognized $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231_zALvZxSxFKFg" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,800</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231_zrzksD8NW2fl" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,000</ix:nonFraction></span>, respectively, of revenue related to the Company&#8217;s sublicenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC Topic 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing
    component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or
    service to the customer and when the customer pays for that good or service will be one year or less.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
    Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has
    elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount
    of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the
    customer of the Company&#8217;s performance completed to date; the Company may recognize revenue in the amount to which the entity
    has a right to invoice.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contract
Modifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed above with the SCTC, there were no contract modifications during the years ended December 31, 2022 and 2021. Contract modifications
are not routine in the performance of the Company&#8217;s contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVsDmeHVVfZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zq4KqnDVezF3">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
There were <span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zHB8Va7Wnu2" title="Cash equivalents"><span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20211231_zRKSrT7ZgOHe" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents as of December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyMaNd4MXaX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3JRIkFhsIUe">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are reported at their outstanding unpaid principal balances net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#8217;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance
is determined to be uncollectible. The Company did <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20221231_zvR76JAlrBBh" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20211231_z2jVUWCd7Ema" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t record an allowance for doubtful accounts as of December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z7QZaQuURbXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zotAixuudUc4">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zNHQ171jQ7Ia" title="Property plant and equipment estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0599">three</span></span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zebr2EFsAs84" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">fifteen years</ix:nonNumeric></span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z7HjQQkl5kLh" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> - <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_z31K7O6DC0w" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8WDc8yTknEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zTNHl5hU2Px4">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2022 and 2021, we determined that there
was <span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zPNnRZF7p6Zf" title="Impairment of long-lived assets"><span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zmJCQbdpB0M2" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2022-01-01to2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment charge for our long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5EL4j7TmQy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z20P2ecqmv9l">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 350, <i>Intangibles
- Goodwill and Other</i>. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method,
which is determined by identifying the period over which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLSUAeNLbqR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYStEt1yL9Se">Fair
Value Measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; fair value is the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The
Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally
    developed methodologies that result in management&#8217;s best estimate of fair value.</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zbOmuIk07cZ7">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Marketable securities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" title="Assets fair value disclosure" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,072,831</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" title="Assets fair value disclosure" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,072,831</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" title="Assets fair value disclosure" style="width: 10%; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" title="Assets fair value disclosure" style="width: 10%; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" title="Assets fair value disclosure" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" title="Assets fair value disclosure" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" title="Assets fair value disclosure" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" title="Assets fair value disclosure" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zAW0a1XPysYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company recognized unrealized gain of $<span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_z5YqJUMYWX3i" title="Unrealized gain on marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,665</ix:nonFraction></span> on its marketable securities within Other income,
net in its Consolidated Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Options: NewSection; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjeWPr8GkESi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zPQhKbgFT0Je">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, accounts receivable, accounts payable and other current liabilities approximate their fair values based on the
short-term maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zRcPkx81fhZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zjdhsINXbPCc">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#8217;s
computation of diluted net loss per common share for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than the
average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" title="Total" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">864,639</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" title="Total" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839,639</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" title="Total potentially dilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" title="Total potentially dilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,739,871</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" title="Unvested" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">201,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" title="Unvested" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,479</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" title="Convertible notes" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" title="Convertible notes" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,400,749</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,416,147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zdYeSTzR4o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw18GIRvhrKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z81MWRbXrIMf">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 718, <i>Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;), which requires the measurement
and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASU 2018-07 Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company
accounts for stock options issued to non-employees for their services in accordance ASC 718. The Company uses valuation methods and assumptions
to value the stock options that are in line with the process for valuing employee stock options noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpwuyVzvE9yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zI4CnFG2mOF8">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DerivativesReportingOfDerivativeActivity"><p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_z873L7gC4EF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zeHOmHE66wKi">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
ASC. The accounting treatment of derivative financial instruments requires that the Company records embedded conversion options (&#8220;ECOs&#8221;)
and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each
subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period
at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of
debt discount on the consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification
of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the
contract is reclassified as of the date of the event that caused the reclassification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="BRTX:SequencingPolicyPolicyTextBlock"><p id="xdx_845_ecustom--SequencingPolicyPolicyTextBlock_zBplxoEP5Bp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zH8NqFKly3Rf">Sequencing
Policy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40-35 (&#8220;ASC 815&#8221;), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts
from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient
authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the
basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
Pursuant to ASC 815, issuances of securities to the Company&#8217;s employees and directors, or to compensate grantees in a share-based
payment arrangement, are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_z2Scqidx85he" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z0u8F9ujfxjf">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease is defined as a contract that conveys the right to control the use of identified property, plant or equipment for a period of time
in exchange for consideration. On January 1, 2019, the Company adopted ASC 842 and it primarily affected the accounting treatment for
operating lease agreements in which the Company is the lessee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, <i>Leases</i>, the Company recognized a right-of-use (&#8220;ROU&#8221;) asset and corresponding lease
liability on its balance sheets for its office space lease agreement. See Note 9 - Leases for further discussion, including the
impact on the Company&#8217;s financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets include any prepaid lease payments and exclude any lease incentives and initial direct costs incurred. Lease expense for minimum
lease payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate
the lease if it is reasonably certain that the Company will exercise that option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
in which the Company is the lessee are comprised of office rental. All of the leases are classified as operating leases. The Company
has a lease agreement for office space with a remaining term of <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGOsxiAyKBI5" title="Lease remaining term"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_LeaseAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">two years</ix:nonNumeric></span> as of December 31, 2022.</span></p>

</ix:nonNumeric><p id="xdx_852_zeRmYv8VxZP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zVOJolEbPnZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
3 - <span><span><span id="xdx_82B_zTzT8AcYBy93">PROPERTY AND EQUIPMENT</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9eSZ8RWGq1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z5JT7tfsKlai" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z2kRu6y6eaH5" title="Property and equipment, gross" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">352,133</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z0wFKAizArJ" title="Property and equipment, gross" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">352,133</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZcGmgWOQUe8" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zctkOhHbqS53" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zDtravMzYG7c" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputerSoftwareAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zScIeRjOfiQh" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ComputerSoftwareAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">107,648</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zh8ttA0aZZA2" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zM6w3vsvjP43" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zb7fb9TkScBf" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ManufacturingEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">242,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_z2qOeh6fJaeg" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ManufacturingEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,712</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBPSSXkCeUe" title="Property and equipment, gross" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">342,048</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMejPzHRvGMb" title="Property and equipment, gross" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">304,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zX9GcimW1xS" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,196,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231_zMvwN7Us6tk2" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">931,620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zGb37UmSTx42" title="Less: accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">935,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_znZA0V2zNsWb" title="Less: accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">893,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z5TUNyIac6N8" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">261,003</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zKtxoO5UqTy6" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,993</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



</ix:nonNumeric><p id="xdx_8A4_zpxajxEiP0Ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
depreciation expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zru09hoORm7c" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,212</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zZ9fU3RJqtg" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,633</ix:nonFraction></span>, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statement of operations.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zYgGbzQbWPm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
 4 - <span id="xdx_82A_zr9mXwBgb7p">INTANGIBLE ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with the SCTC (as amended) (the &#8220;SCTC Agreement&#8221;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain
medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the
body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for
culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones)
had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology. The Company did
not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights
became non-exclusive. However, the Company entered into an amended agreement under which it paid $<span id="xdx_906_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220101__20221231_zV13vYSIrYTa" title="Payment to acquire intangible assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span> and issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXIEjRHPARrk" title="Stock issued new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27579265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></span> warrants,
with a fair value of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zUB4hj19Yxd" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,030</ix:nonFraction></span>, in exchange for renewed exclusivity. The consideration transferred to the SCTC in exchange for exclusivity
was capitalized to intangible assets on the Company&#8217;s consolidated balance sheet as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office has issued a notice of allowance
for a patent application relating to the Company&#8217;s BRTX-100 clinical program. This patent was issued in March 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zz5ob2QNHGYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z3HT9mUl0tEk">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of January 1, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zR5sXscArwYb" title="Finite Lived Intangible Assets, Gross, beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_PatentsAndTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zjX0FEK6zSw6" title="Finite Lived Intangible Assets, gross, beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,301,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2BCF6Ub6bDd" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">640,908</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20210101__20211231_zhZY2LMNgImk" title="Finite Lived Intangible Assets, Net, beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">664,268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zW21m9E1loYl" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231_zS0EF0PJShna" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z16LeSwQBqZk" title="Finite Lived Intangible Assets, Gross, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_custom_PatentsAndTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zrcVS6ZFIxNh" title="Finite Lived Intangible Assets, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,301,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zzdO0qsShm9d" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">715,436</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20220101__20221231_ziF74mUAzUhi" title="Finite Lived Intangible Assets, Net, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">589,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Consideration transferred for license exclusivity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIIuyilwgzIj" title="Consideration transferred for license exclusivity" style="text-align: right"><ix:nonFraction name="BRTX:ConsiderationTransferredForLicenses" contextRef="From2022-01-012022-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231_zZwwWg9QA178" title="Consideration transferred for license exclusivity" style="text-align: right"><ix:nonFraction name="BRTX:ConsiderationTransferredForLicenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zOk3jTfDcRWd" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231_zbnV5QIafEd9" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zLFLfwghXz31" title="Finite Lived Intangible Assets, Gross, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIjyOrsWJZ6h" title="Finite Lived Intangible Assets, gross, beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z9R8BK6jiYFf" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">793,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20220101__20221231_z0axz7mgX6Nk" title="Finite Lived Intangible Assets, Net, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">803,438</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhwNz2iVMyog" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3XvcIExYQE9" title="Finite Lived Intangible Assets, weighted average amortization period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_LicensesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">11.25</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zLprpsGjpIx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zuYakqSqMWC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_ze6dKh9GVy4f">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_z111QHGgf6ib" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_PatentsAndTrademarkMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zOcIjRIprHI7" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,232</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zSvPCXNe1O81" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">640,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zQsLGcm9Clsd" title="Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkI3R4uA8ncj" title="Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zeqlmrAk0Oc7" title="Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zYNdRMNLXXL3" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_custom_PatentsAndTrademarkMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdvH1UPoFa6k" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zLw7u3xiVMfj" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjqAZlC0iQM3" title="Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zemPn2tTSNNg" title="Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z0AgdgMgVXsh" title="Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCmYU0PaxmNj" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z7iLe7KaisVi" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,092</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zNXhaLnNN7Gl" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">793,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zrwhArUOB7t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3lONGEusWI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B9_z24iYDJQ20G5">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221231_zM1WUu8puxm" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zmJ8qFYSBEY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,131</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zXveE2K88kFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zeVSPq4NT1ja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zrYqmkW3iogg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zCfWHjd4m9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zglxyIb6jcUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80B_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zUeefxf9Klsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
 5 - <span id="xdx_829_zEtL27GGXHU1">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zwBSApfXDN93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zxPwPamjgYe5">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zaGGhfBp9Wff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zGZwRLKduE1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zcEgT8XwVLph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedResearchAndDevelopmentExpenses_iI_maALAOLzJ5Y_zdABJUl0Lbh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:AccruedResearchAndDevelopmentExpenses" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zmQ2gGIHIkX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,822</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,928</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zECYx3mc4q96" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,072</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,970</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



</ix:nonNumeric><p id="xdx_8A2_zNrM8joHQONj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zMXpCpsZpsul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
6 - <span id="xdx_82D_zRyYbdY9Poij">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_z6vD8WR7Ruyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the notes payable activity during the year ended December 31, 2022 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z0U2tHHDdg9l">SCHEDULE OF NOTES PAYABLE ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Outstanding, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--LoansPayable_iS_c20220101__20221231_zpdYlJWz25Md" title="Loans payable outstanding beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ProceedsFromIssuanceOfDebt_c20220101__20221231_z2TTt3e07Ar2" title="Issuances" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DebtInstrumentDecreaseForgiveness_iN_di_c20220101__20221231_zhV0UK3vXrdc" title="Forgiveness" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LoansPayable_iE_c20220101__20221231_zTOQ2ieZBEbk" title="Loans payable outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



</ix:nonNumeric><p id="xdx_8AB_zlm55UBSezHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwfDdLnBi61j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
 7 - <span id="xdx_823_znRDN6LBjqkg">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCQLCzatzywj" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJ7CxJ2xwUik" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbnxa33JYyfa" title="Preferred stock, liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. On September 8,
2022, the Company issued <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zK1YF30WN4kd" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_za83UBjE2nz8" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8O12SUCwACd" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockVotingRights">The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as
provided for the Series A.</ix:nonNumeric></span> The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption
by the Company or any Series B holder. The exchange of Series A for Series B had no impact on the Company&#8217;s financial statements
as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zp2gCvH4Ifz5" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRN6RY2xn2Dj" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the outstanding
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion &#8211; From time to time, in the event of that an event occurs, including adjustment due to merger, consolidation, etc.,
subdivision or combination of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the
effect of reducing a Series B holder&#8217;s beneficial ownership of shares of common stock to less than <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_z7ZAufGB3rBd" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction></span>% of the then publicly disclosed
outstanding shares of Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such
effect, which notice shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable
detail with regard thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such
notice shall have the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase
the Series B holder&#8217;s beneficial ownership of Common Stock to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zHv08AtDpcea" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, Auctus converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zGjKmg3CbUKc" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Series B into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zVMjgNpuwll4" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion is <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztKRsSduCct8" title="Conversion of stock shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Stock Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company&#8217;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#8220;2021
Plan&#8221;). Pursuant to the 2021 Plan, a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zrEv2Q3DlXQ" title="Number of shares of common stock authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,175,000</ix:nonFraction></span> shares of common stock were initially authorized to be issued pursuant
to the grant of stock options, restricted stock units, restricted stock, stock appreciation rights and other incentive awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendments
to 2021 Stock Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, subject to stockholder approval, the Company&#8217;s Board of Directors approved amendments to the 2021 Plan to increase
the number of shares of Common Stock authorized to be issued from <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20211209_z9B5JA6OdXFd"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,175,000</ix:nonFraction></span> to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20211210_z7OufqxFPjx9" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-10" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> and to clarify certain provisions of the 2021
Plan as to the authority of the Board of Directors and the Compensation Committee to make adjustments to, among other things, the exercise
price of granted options. Concurrently, subject to stockholder approval of the amendments to the 2021 Plan, the Company&#8217;s Compensation
Committee reduced the exercise price of the outstanding options under the 2021 Plan for the purchase of an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20220914__20220915_zlqMsOTeQQ38" title="Aggregate purchase of common stock, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2022-09-142022-09-15" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">838,549</ix:nonFraction></span> shares
of the Company&#8217;s common stock from $<span id="xdx_902_eus-gaap--SharePrice_iI_c20220915__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zBL7Gy4hukF6"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.50</ix:nonFraction></span> per share to $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20220915__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zPwRypVJwXnh" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></span> per share (the closing price of the Company&#8217;s common stock on
the day immediately preceding the Compensation Committee determination), including the options held by the Company&#8217;s officers and
directors as follows: <span id="xdx_902_ecustom--DescriptionOfStockOptionsHeldByOfficerAndDirector_c20220914__20220915_zuj5dbNjPp9b" title="Description of stock options held by officer and director"><ix:nonNumeric contextRef="From2022-09-142022-09-15" name="BRTX:DescriptionOfStockOptionsHeldByOfficerAndDirector">(i) Lance Alstodt, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board: 335,538 shares,
(ii) Francisco Silva, the Company&#8217;s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal,
the Company&#8217;s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company&#8217;s Vice President of Quality Assurance
and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company&#8217;s directors: 25,236 shares; (vi) Patrick F. Williams,
one of the Company&#8217;s directors: 10,490 shares; and (vii) David Rosa, one of the Company&#8217;s directors: 10,490 shares.</ix:nonNumeric></span> On November
3, 2022, the Company&#8217;s stockholders approved the amendments to the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact resulting from the amendments was immaterial to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Common Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20221231_zCh4MPooH7O3" title="Vested common stock, shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,898</ix:nonFraction></span> shares of immediately vested common stock with an aggregate value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231_zQJAAeFM3Oal" title="Aggregate common stock services rendered"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,888</ix:nonFraction></span>
to third parties for services rendered. During the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20211231_z94YrjyDE7m2" title="Vested common stock, shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of immediately vested
common stock with a value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231_zTqsyzXQOoa1" title="Aggregate common stock services rendered"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,476</ix:nonFraction></span> to a consultant for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
and Option Valuation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Activity Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211021__20211021__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJegf3obTGPe" title="Stock issued new issues, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-212021-10-21_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,917</ix:nonFraction></span> shares of common stock to a warrant holder, as a result of the cashless exercise of <span id="xdx_901_ecustom--CashlessExerciseOfWarrants_pid_c20211021__20211021__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDN9XeCQZFD7" title="Cashless exercise of warrants"><ix:nonFraction name="BRTX:CashlessExerciseOfWarrants" contextRef="From2021-10-212021-10-21_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span>
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp8srCIQ1WT3" title="Stock issued new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27580812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,832</ix:nonFraction></span>, shares of the Company&#8217;s common stock, as a result
of the cashless exercise of <span id="xdx_906_ecustom--CashlessExerciseOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt75Z7o6y6Ad" title="Cashless exercise of warrants"><ix:nonFraction name="BRTX:CashlessExerciseOfWarrants" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27580812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,473</ix:nonFraction></span> warrants by Auctus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTC1mfXHV4ti" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></span> warrants to the SCTC as part of consideration transferred in exchange for
exclusivity under a license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zOuyIV8iOJ3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zOrdaxljWDCc">SCHEDULE OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd4Nh0CXnlZ9" title="Number of Options Outstanding Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,598</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcGhj2zdgtO1" title="Weighted average exercise price, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.40</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7cO4Hu6jSf2" title="Number of Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">4,862,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zml1yDOPGRJb" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqFbv9xYroYh" title="Number of Options Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">195,473</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjVY6mgGiCoi" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged or forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUaAKCNwtbTl" title="Number of Options Exchanged or Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,964</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLaXAA6YDk82" title="Weighted Average Exercise Price Exchanged or Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzvZwqmKzFj" title="Number of Options Outstanding Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,739,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjiXMu5AsRkk" title="Weighted average exercise price, beginning balance" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwfSIIZbWJjh" title="Number of Options Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt-sec:duryear" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z24SoF8wjjpe" title="Number of Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">51,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPhUEuXy7tN8" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPgSRJUwm52" title="Number of warrants outstanding, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWsr4fiefsc" title="Weighted average exercise price, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfY4QM3cBG52" title="Number of warrants outstanding, expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSHJyBdkhlrl" title="Weighted average exercise price, expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoMAOWeVHVme" title="Number of Options Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,082</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziSBknt3oy6f" title="Weighted average exercise price, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.71</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKYqAUIvaRD4" title="Number of Options Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt-sec:duryear" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYtHfLYUvVM" title="Aggregate Intrinsic Value Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqTYLnWIBd99" title="Number of Options Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,082</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr2RVNGYT0H9" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.71</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcsOo2SCbzzg" title="Weighted Average Remaining Life in Years Outstanding Ending"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt-sec:duryear" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">3.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIX5sRtDtpg" title="Aggregate Intrinsic Value Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zhunbhb3vFfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="BRTX:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zLtW3xeSNUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to warrants granted during 2022 and 2021, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zM3Q788gyCgd">SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMvGAiHM9Wn4" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.40</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUa4wX5jcDa2" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.98</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZJFlIgfgLjd" title="Expected term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zL200eFHX2Y7" title="Expected term (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.10</ix:nonNumeric></span> - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvAHbtmjB3Hj" title="Expected term (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWC2XP7huk3" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">313.55</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdg9AcduYQB5" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">314.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy8d1XEONiE8" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8PP1FFITYci" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zg0HfL5MNyt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated fair value of the warrants granted during the years ended December 31, 2022 and 2021 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj3vksd6p0jf" title="Weighted average estimated fair value of warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27579265" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.28</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPZXpVjGcsoe" title="Weighted average estimated fair value of warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27580812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.77</ix:nonFraction></span>
per warrant, respectively. The Company did not issue any shares during the years ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zIZTEBuLKvUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zGdgp7ZC63y3">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 44%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOzaVg05GL59" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.92</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zNxNAcuZCaRd" title="Warrants outstanding, number of warrants" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zd8n75XgKkxg" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.9</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zWfrVEaUQnq5" title="Warrants exercisable, exercisable number of warrants" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7T8okIt08S5" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zeSebgIHfwyj" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,501,937</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdfGCAbbhVO6"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zXyMmLaFCSM7" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,501,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zF2L9mZmEkB9" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zQEmQMZXNhwg" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0QfHjmmqF4i" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zxQ9nH8wOKx" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKjFPftSTCpl" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zdq4Lp8Lyt3k" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB47YjJpwQr3" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zwO4pm9kjpB1" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcSr6m5jve3e" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">800.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zLJWuMGrxPAd" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTxdcUeiF1h6" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zQETJV7D8QTi" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zqk8O4ghtpm8" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,240.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_ziQ80gOPY3C" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVBCh8CXCg5" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.1</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_zLGN8Q6oGbQ2" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXIcZViHwRKb" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,800.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zaMvUapSecPd" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zwQ6TYROPLN1" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.2</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zb74Zi8xFHzl" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z03zfrSg1YE3" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,400.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zLbJnkFHuO0a" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zz1hJ74P7Sp7" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.2</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_fKDEp_zCmcDJ1Utpt5" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zyoxbJsqUkce" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zIuI5nKGc5v7" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zdpKW9qo3Eoh" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.1</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_fKDEp_zAhj1JOl85N" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z9lOrmIjzVv6" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8,000.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zLmOj98tGluj" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zM16slMZ1dB8" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_fKDEp_zy0VUpS5vwAc" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zoGyNOwnZjHh" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,000.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6JVx3FuMZji" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zALlBxKyG9e4" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_fKDEp_zGwpRz4mjks9" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zpkb1VJZ5uLb" title="Warrants outstanding, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16,000.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_za7cJzBqbM4j" title="Warrants outstanding, number of warrants" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhoaDtHgclQ5" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.3</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_fKDEp_zy1uBTNrqDEa" title="Warrants exercisable, exercisable number of warrants" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_fKDEp_zqZr7OXjinei" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_fKDEp_zm7MSkwMUmn4" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zkeDTqoRG2a8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company, pursuant to two employment agreements, granted to its Chief Executive Officer, President and Chairman of
the Board and its Vice President, Research and Development options to purchase an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_z4FRdRX7Y1Ab" title="Number of option issued to purchase shares of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">586,959</ix:nonFraction></span> shares of the Company&#8217;s
common stock. The options initially <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_z5C87Iyd2g3j" title="Description of share based payment award vesting rights"><ix:nonNumeric contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">vested to the extent of 50% on the date of grant, 25% on the one-year anniversary of the grant date
and 25% on the two-year anniversary of the grant date.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, the Company granted options to purchase an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104_zd5Yqw9027l9" title="Number of option issued to purchase shares of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-11-022021-11-04" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,824</ix:nonFraction></span> shares of its common stock (including options to purchase
<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211102__20211104__srt--TitleOfIndividualAxis__custom--PatrickFWilliamsMember_zl6iVzdMxHah"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-11-022021-11-04_custom_PatrickFWilliamsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,490</ix:nonFraction></span> shares each granted to Robert Kristal, its Chief Financial Officer, Patrick Williams, a director of the Company, and David Rosa,
a director of the Company) to its officers and directors. Also included within the <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--MrAlstodtMember_zcmIShFi0SR8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-11-022021-11-04_custom_MrAlstodtMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,824</ix:nonFraction></span> share option grants were grants to each of
Mr. Alstodt and Mr. Silva for the purchase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--MrSilvaMember_zNm1u4ExYvxg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-11-022021-11-04_custom_MrSilvaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,059</ix:nonFraction></span> shares of common stock and to Dr. Nickolay Kukekov, a director of the Company, for
the purchase of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--DrNickolayKukekovMember_zoWlm7jVfoz3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-11-022021-11-04_custom_DrNickolayKukekovMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,236</ix:nonFraction></span> shares of common stock. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20211102__20211104_zdtxUDjpWwke" title="Share-based compensation arrangement by share-based payment award, description"><ix:nonNumeric contextRef="From2021-11-022021-11-04" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">Such options are exercisable to the extent of 50% on the date of grant and 50% quarterly
over a period of two years commencing one year from the date of grant.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, the Company granted options to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211102__20211104__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember_zxVvdUEjbDce" title="Options to purchase shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-11-022021-11-04_custom_ScientificAdvisoryBoardMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,767</ix:nonFraction></span> shares of the Company&#8217;s common stock to members
of its Scientific Advisory Board and various employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company reduced the exercise price of all options from $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211209_zkSChF7aIvC4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-09" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.50</ix:nonFraction></span> per share to $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211210_z9jQMTFEeT1l"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-10" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></span> per share, subject to stockholder
approval. On November 3, 2022, stockholder approval was obtained. Per ASC 718 - <i>Compensation - Stock Compensation</i>, the Company
accounted for these changes as a modification and the net effect was immaterial to the financial statements as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted an option for the purchase of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zKrTqjcyOEz" title="Number of Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z41Grh7waTHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z41jvRlK6xNb">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z0htSgZLMxVg" title="Number of Options Outstanding Beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,215</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zLACIEDVEGk9" title="Weighted average outstanding beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zEyBsIf7KJJ4" title="Number of Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">838,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zyOJAFxHqe5" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zTv1o9IGqWma" title="Number of Options Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zPc6CVcdfbEg" title="Weighted Average Exercise Price Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zRZlzYdhgFS7" title="Number of Options Outstanding Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">839,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zSKSNTbfRMV1" title="Weighted Average Exercise Price Outstanding Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zpFx7wwKDXK8" title="Number of Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zVvPl0gtty4b" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zHyticBxYibb" title="Number of Options Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z9Ud3scCE3Uj" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zQ5CR0592oOa" title="Number of Options Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJ0toreo1sfc" title="Weighted Average Exercise Price Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zTJHQs9T6N4i" title="Number of Options Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">864,639</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zhDeR1Z7o6zb" title="Weighted Average Exercise Price Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zDvB6ocfrrU7" title="Weighted Average Remaining Life in Years Outstanding Ending"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.8</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20221231_zmNhYFjpKHa9" title="Aggregate Intrinsic Value Outstanding Ending" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfiKun1fYpfb" title="Number of Options Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">578,628</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20221231_zuBRlNKlJ92i" title="Weighted Average Exercise Price Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_ziKPFOAgWDah" title="Weighted Average Remaining Life in Years Exercisable Ending"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.8</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zq62wMxghiQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2022 and 2021, was approximately
$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zGM4kOditGA3" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.88</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zUJRZB6yM4n2" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.05</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaC8Zw0s9uu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zsZZFqtNG8Ch">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUi1pRRyTzpg" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.42</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBRy8732sBn4" title="Expected term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.50</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxLxiNUDh7lb" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">285.91</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGZxG1lmhMo2" title="Expected dividends" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zY6vKc7S2tP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 92; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#8220;RSUs&#8221;) to employees, consultants or non-employee directors
(&#8220;Eligible Individuals&#8221;). The number, terms and conditions of the RSUs that are granted to Eligible Individuals are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Individual one
unrestricted, fully transferable share of the Company&#8217;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company, pursuant to two employment agreements, granted an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlH2Ii2WxBw1" title="Number of option issued to purchase shares of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,479</ix:nonFraction></span> RSUs to its Chief Executive Officer,
President, and Chairman of the Board and its Vice President, Research and Development with a fair value of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYpNrMyVfQfj" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">47.60</ix:nonFraction></span> per share. The RSUs
vest to the extent of one-third on the one-year anniversary of the grant date, one-third on the two-year anniversary of the grant date,
and one-third on the three-year anniversary of the grant date. The RSUs had a grant date fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCLRfgXNTUf3" title="Fair value of restricted stock units"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,969,624</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 18, 2022, the Company granted an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220317__20220318__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi7CblvCxpw" title="Number of option issued to purchase shares of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-03-172022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,876</ix:nonFraction></span> RSUs to its Chief Executive Officer, President and Chairman of the Board and
its Vice President, Research and Development with a fair value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220318__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1kVS5keRNYe" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.21</ix:nonFraction></span> per share. The RSUs vest in twelve equal monthly installments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ziQWhFgrM8i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zK4OnVu5gNvf">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Outstanding, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7ruj8I7X9ec" title="Number of shares outstanding beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWU9gwnsBuh" title="Number of shares granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ4xFg3IJbnh" title="Number of shares forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1164">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMlTpl4Y0MB8" title="Number of shares vested" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZsFIt7oprpa" title="Number of shares outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">201,870</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AC_zG2reU58Xtpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zWgn53WFH2L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zveUfSxAoorc">SCHEDULE OF STOCK OPTION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4wVPE52dCH3" title="Stock-based compensation expense" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyYDc2BYMYSi" title="Stock-based compensation expense" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,479</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMN4tnm8lsEf" title="Unrecognized expense" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">803,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQTaVcLFo6cc" title="Stock-based compensation expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,612,862</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1FGqhTV6UV" title="Stock-based compensation expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,027,476</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwMmnQ8r2x4" title="Unrecognized expense" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,294,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5GNJoPn2LYj" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.73</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVoNThiixP6" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember27582265" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,612,862</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKwTrTrlpY2" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember27582265" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,108,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVxSbf1kuTR4" title="Unrecognized expense" style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,097,941</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A9_zhwUaOwYGaZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zw2wPr6d8628" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zue5Pm5NOC5k">SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqlHr7YFhi72" title="Stock-based compensation award" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">7,741,864</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAveqV0rIEV8" title="Stock-based compensation award" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">19411976</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOjzSNxdXdmg" title="Stock-based compensation award" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">4,735,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlaZMA2CX3rf" title="Stock-based compensation award" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">3,671,503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zV05i5E9eKAh" title="Stock-based compensation award" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-12-31_custom_SharesIssuedForServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">135,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zfvCuOM9Lwz7" title="Stock-based compensation award" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-12-31_custom_SharesIssuedForServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">25,476</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231_zA0jHrxnRZ28" title="Stock-based compensation award" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">12,612,862</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231_zEUWDLTO0cmk" title="Stock-based compensation award" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">23,108,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_za82eLcv4vy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_z3yWSsXG4dCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
 8 - <span id="xdx_82F_zqBzO3kIdQFi">INCOME TAXES</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company identified its federal and New York tax returns as its &#8220;major&#8221; tax jurisdictions. The period its income tax returns
are subject to examination for these jurisdictions is 2018 through 2022. The Company believes its income tax filing positions and deductions
will be sustained on audit, and it does not anticipate any adjustments that would result in a material change to its financial position.
Therefore, no liabilities for uncertain tax positions have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company had approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zI8E9dnTNaog" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,900,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zngKeIsfWlfb" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,300,000</ix:nonFraction></span>, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;),
certain future carryforwards do not expire. At December 31, 2022, approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20221231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zJWSzufo7wk1" title="Operating loss carry-forwards subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2022-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction></span> of federal net operating losses will expire
from 2030 to 2038 and approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20221231_zSlYn71GQd5l" title="Operating loss carry-forwards not subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,900,000</ix:nonFraction></span> have no expiration. <span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zhYy1K72NN04" title="Income tax examination, description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SectionThreeHundredAndEightyTwoMember" name="us-gaap:IncomeTaxExaminationDescription">In accordance with Section 382 of the Internal Revenue Code, the
usage of the Company&#8217;s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership
changes.</ix:nonNumeric></span> The Section 382 limitations resulted in approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zpgA0JRKLN6b" title="Federal net operating loss carry-forwards"><span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zLtjnWIMHMib" title="Federal net operating loss carry-forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_SectionThreeHundredAndEightyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_custom_SectionThreeHundredAndEightyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,200,000</ix:nonFraction></ix:nonFraction></span></span> of federal NOLs not being realizable
as of December 31, 2022 and 2021 and the cumulative reversal of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_z6LAWjTUsZIi" title="Deferred tax assets, operating loss carryforwards"><span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zHYW3ZPE7Ibf" title="Deferred tax assets, operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_SectionThreeHundredAndEightyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31_custom_SectionThreeHundredAndEightyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,600,000</ix:nonFraction></ix:nonFraction></span></span> of net operating loss deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not performed a formal analysis for the year ended December 31, 2022, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxo7kMnJ4Sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2022 and 2021 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zPGPgpCirK5c" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zqHIKS6yQzkf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_z2EWfdn8UMa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzjDN_maDTAGzPKX_zxlbm7o863Ff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,200,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,100,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzjDN_maDTAGzPKX_z2Gls5i1bd66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,810,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzPKX_zCCTw5dB54j9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzPKX_zn0eqBdup87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research &amp; development tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">330,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_msDTLzhRs_mtDTAGzPKX_maDTALNzfjZ_zzd8bY60V9yi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,995,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,958,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDITLzXDW_zNWZR3fb6rRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzXDW_zbv4sTRD5sTd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzXDW_msDTALNzfjZ_z1QbuJoyIf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_mtDTALNzfjZ_zRN5sFEShJ3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,776,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,954,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zzyjh1Tam3I" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,776,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,954,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_zuHkoff91Z31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Deferred tax asset, net of valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220101__20221231_zs4dWkbGqYhb" title="Change in valuation allowance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,822,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_zCIkkTE1tHC" title="Change in valuation allowance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,856,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zle5qQRyI6Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zooHXSN2G1Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2022 and 2021 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zyIra2pymnne" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zN8pM83pF9qi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z6EBCU4nJhh6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzexe_zS7DdAdTDUo3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzexe_zGsxdo8LXBv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State and local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzexe_zCd8JG3v8gO2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maITEBzexe_zf3zFvNhRK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzexe_zEJVx9DPPFQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income tax provision (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z2MBeT4l28tc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z09LfIwM8dJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2022 and 2021 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zyAWAvu0AbLk" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_z8XWsoAm2Nvi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231_zXShsA2E1oF7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zlTzCt1GcsUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal statutory blended income tax rates</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zv6tIPY7ZJU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State statutory income tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_zF6pRXWkT6sh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">8.9</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_zfzoLKyDsKsh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKYmliGY8TB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">31.5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z8WFOqbT2OAj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zQzWekPwGa1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, the Company has not filed its 2022 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80D_eus-gaap--LesseeOperatingLeasesTextBlock_zuT4sYm0XFC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
 9 - <span id="xdx_825_zm5KZCfk8Lla">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zO6nTSqYMSDi" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-12-31_custom_MelvilleLeaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,800</ix:nonFraction></span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. <span id="xdx_904_eus-gaap--LessorOperatingLeaseDescription_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zeIMVMZzoTO1" title="Lease description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MelvilleLeaseMember" name="us-gaap:LessorOperatingLeaseDescription">The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zymVzYrgGdWj" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,600</ix:nonFraction></span> and
$<span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zC9vr08INZXc" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,260</ix:nonFraction></span>.</ix:nonNumeric></span> In June 2019, <span id="xdx_905_eus-gaap--LessorOperatingLeaseDescription_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zMIl0TDXRJ93" title="Lease description"><ix:nonNumeric contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember" name="us-gaap:LessorOperatingLeaseDescription">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced</ix:nonNumeric></span> on January 1, 2020 with annual base rent ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_z3xIdAIkh15j" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,748</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zTRPi0wFpaF7" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zzLpn2qirZg3" title="Weighted average incremental borrowing rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zZenbPICcdaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z23EYUeuXTXh" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_z8EB2RiBVbZd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zgyuob3ipOu9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zFYBuNNB2086" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,132</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,372</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_znlqh1MFVxKb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,372</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbx0OMThpQJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,132</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,372</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingLeaseLiabilityReduction_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z8ky0aEnYTt8" title="Non-current leases - right of use assets" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231_zsfaJWUEKYLa" title="Non-current leases - right of use assets" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">357,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231_ze6MkL5jtsy" title="Current liabilities - operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20211231_zNu915d4DJL2" title="Current liabilities - operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Non-current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zI09nGPRE2vf" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20211231_zeiKHOQrzgg7" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zMLqWXM3TG44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbvtZWaRmtt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zjfFnIaXkhll" style="display: none">SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zZgZ6LXCbUd1" title="2022" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20221231_zbRnoUHM1Ay1" title="2023" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20221231_zgdgnlCBig38" title="Total future minimum lease payments" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">341,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20221231_zDnG1J0WZRO2" title="Amount representing interest" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zlC73twgH2T2" title="Present value of net future minimum lease payments" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,645</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zeVIxaaJ8HRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zHgXiG0hcpi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 - <span id="xdx_82C_zOqGqGzXpr53">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 17, 2023, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_ziSYKTWik0f7" title="Shares options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,357</ix:nonFraction></span>
stock options to its officers and a certain employee, of which <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_zg66umQ0gRYf" title="Vested and exercisable percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
were vested and exercisable upon grant. The remaining <span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_zce9B7pi2Vt2" title="Remaining percentage of options vested"><ix:nonFraction name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the options issued to the Company&#8217;s officers and employee will vest quarterly in eight nearly equal installments
commencing one year from the date of grant. The Company issued an additional <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardAndScientificAdvisoryMember_z0K6wBZ41Zx8" title="Shares options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_BoardAndScientificAdvisoryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228,660</ix:nonFraction></span>
stock options to its board members and scientific advisory board members, which will vest monthly over one year. The granted stock
options had an estimated fair value of approximately $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6C0UnW4C7w" title="Estimated fair value of granted"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,745,000</ix:nonFraction></span>
as of the grant date, of which approximately <span id="xdx_908_ecustom--RecognizedStockbasedCompensationExpensePercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7ddGtnk9WFa" title="Recognized stock-based compensation expense percentage">$<ix:nonFraction name="BRTX:RecognizedStockbasedCompensationExpensePercentage" contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">562,500</ix:nonFraction></span>
was immediately recognized as stock-based compensation expense, which will be reflected in the Company&#8217;s consolidated results
of operations for the first quarter of 2023. </span></p>

</ix:nonNumeric><p id="xdx_81C_zijat0pLneAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>ex10-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40
Marcus Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
New York 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
21, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
Sciences, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenexx,
LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">403
Summit Blvd., Suite 201</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broomfield,
Colorado 80021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re: <U>License
Agreement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the License Agreement, dated as of January 27, 2012, between BioRestorative Therapies, Inc. (&ldquo;<U>BRT</U>&rdquo;) and
Regenerative Sciences, LLC (&ldquo;<U>RSI</U>&rdquo;), as amended (the &ldquo;<U>Agreement</U>&rdquo;). All capitalized terms used but
not defined herein shall have the respective meanings ascribed thereto in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties acknowledge and agree that the Patent Rights have been assigned by RSI to Regenexx, LLC (&ldquo;<U>Regenexx</U>&rdquo;) and that,
pursuant to a letter agreement, dated as of September 24, 2019, among BRT, RSI and Regenexx, the rights and obligations of RSI under
the Agreement have been assigned to and assumed by Regenexx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Section 5.1 of the Agreement is hereby terminated and of no further force or effect. Accordingly, the grant to BRT of the perpetual,
exclusive, irrevocable, royalty-bearing, sublicensable and transferable Licenses pursuant to Section 2.1(a) of the Agreement is
unconditional and not subject to any limitation in any respect; provided, however, that the foregoing shall not be deemed to limit
the sublicenses granted to Licensor pursuant to Section 2.1(c) of the Agreement. For the sake of clarity, the Parties acknowledge
and agree that the exclusive nature of the Licenses granted to BRT pursuant to the Agreement has remained in effect for a continuous
uninterrupted period since the Effective Date and, notwithstanding anything in the Agreement to the contrary, shall continue in
effect in perpetuity subject to the obligation of BRT to pay royalties as set forth in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Each of RSI and Regenexx represents and warrants that, to date, except for the rights granted to BRT pursuant to the Agreement and
except as contemplated by Section 2.1(d) of the Agreement, it has not granted to any Person any license or other right with respect
to the Intellectual Property Rights that have been licensed to BRT pursuant to the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
In consideration of the foregoing, (a) within thirty (30) days of the date hereof, BRT shall pay to Regenexx one hundred
seventy-five thousand dollars ($175,000) by wire transfer to an account designated in writing by Regenexx, and (b) concurrently with
the execution hereof, BRT shall deliver to Regenexx a warrant for the purchase of up to fifty-one thousand three hundred seventy
(51,370) shares of common stock of BRT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Regenexx represents and warrants that (a) all reports provided pursuant to Section 4.6(b) of the Agreement have been true and
complete in all material respects, giving effect to the additional $71,100 royalty payment made by Regenexx in August 2022 following
the completion of its internal audit of the procedures completed and (b) for the Calendar Quarter ended June 30, 2022, $31,700 is
payable by Regenexx to BRT pursuant to Section 4.4 of the Agreement. Regenexx shall pay BRT the $31,700 by wire transfer within five
(5) days of receipt of an invoice from BRT with regard thereto. Based upon the foregoing, BRT hereby agrees that it will not assert
any claims for additional royalties payable by Regenexx to BRT pursuant to Section 4.4 of the Agreement with regard to procedures
performed through June 30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Regenexx understands and agrees that the Company is relying and may rely upon the following representations, warranties,
acknowledgements, consents, confirmations and covenants made by Regenexx in entering into this letter agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Regenexx recognizes that the acquisition of the Warrant involves a high degree of risk and is suitable only for persons of adequate
financial means who have no need for liquidity in this investment in that (i) Regenexx may not be able to liquidate its investment
in the event of emergency; (ii) transferability is extremely limited; and (iii) Regenexx could sustain a complete loss of its
investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Regenexx represents that it (i) is competent to understand and does understand the nature of this investment; and (ii) is able to
bear the economic risk of this investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Regenexx represents and warrants that it is an &ldquo;accredited investor,&rdquo; as such term is defined in Rule 501 of Regulation
D promulgated under the Securities Act of 1933, as amended (the &ldquo;<U>Act</U>&rdquo;). Regenexx meets the requirements of at
least one of the suitability standards for an &ldquo;accredited investor&rdquo; as set forth on the Accredited Investor
Certification attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Regenexx represents and warrants that it has significant prior investment experience, including investment in restricted securities,
and that it has read this letter agreement in order to evaluate the merits and risks of the investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Regenexx represents and warrants that it has reviewed the Warrant and all reports, statements and other documents regarding the
Company that have been filed with the Securities and Exchange Commission (collectively, the &ldquo;<U>SEC Reports</U>&rdquo;),
including the risk factors set forth in the Company&rsquo;s latest Annual Report on Form 10-K and other filings, as applicable.
Regenexx also represents and warrants that it has been furnished by the Company with all information regarding the Company which it
had requested or desired to know; that all documents which could be reasonably provided have been made available for its inspection
and review; that it has been afforded the opportunity to ask questions of and receive answers from duly authorized representatives
of the Company concerning the Company, and any additional information which it had requested for the purpose of verifying the
information set forth in the SEC Reports; and that it has had the opportunity to consult with its own tax or financial advisor
concerning an investment in the Company. Regenexx confirms that no oral representations have been made or oral information furnished
to Regenexx or its advisers in connection with this letter agreement that are inconsistent in any respect with the SEC Reports, this
letter agreement or the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> </TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Regenexx acknowledges that this offering has not been reviewed by the SEC because it is intended to be a non-public offering
pursuant to Section 4(a)(2) of the Act and/or Rule 506 of Regulation D promulgated thereunder. Regenexx represents and warrants that
the Warrant is being and will be acquired for its own account, for investment and not for distribution to others. Regenexx agrees
that it will not sell, transfer or otherwise dispose of the Warrant or any portion thereof, unless it is registered under the Act or
unless an exemption from such registration is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Regenexx consents that the Company shall, if it desires, permit the transfer of the Warrant by Regenexx out of its name only when
its request for transfer is accompanied by an opinion of counsel satisfactory to the Company that neither the sale nor the proposed
transfer results in a violation of the Act or any applicable state &ldquo;blue sky&rdquo; laws (collectively, &ldquo;Securities
Laws&rdquo;). Regenexx agrees to be bound by any requirements of such Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Regenexx acknowledges and agrees that the Company is relying on Regenexx&rsquo;s representations contained in this letter agreement
in determining whether to enter into this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Regenexx consents to the placement of a legend on the Warrant stating that it has not been registered under the Act and setting
forth or referring to the restrictions on transferability and sale thereof. Regenexx is aware that the Company will make a notation
in its appropriate records with respect to the restrictions on the transferability of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Regenexx represents and warrants that the address to send notices to Regenexx set forth on the cover page hereof is Regenexx&rsquo;s
true and correct address.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Regenexx represents and warrants that it is unaware of, is in no way relying on, and did not become aware of, this offering through,
or as a result of, any form of general solicitation or advertising, including, without limitation, articles, notices, advertisements
or other communications published in any newspaper, magazine or other similar media or broadcast over television or radio or any
seminar or meeting where the attendees have been invited by any such means of general solicitation or advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
Regenexx represents and warrants to the Company that any information which Regenexx has heretofore furnished or furnishes herewith
to the Company is complete and accurate and may be relied upon by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
Regenexx represents and warrants that it was not formed for the specific purpose of acquiring the Warrant, it is duly organized,
validly existing and in good standing under the laws of the state of its organization, the consummation of the transactions
contemplated hereby is authorized by, and will not result in a violation of, its charter or other organizational documents, it has
full power and authority to execute and deliver this letter agreement and all other related agreements or certificates and to carry
out the provisions hereof and thereof and to acquire and hold the Warrant, the execution and delivery of this letter agreement has
been duly authorized by all necessary action, this letter agreement has been duly executed and delivered on behalf of Regenexx and
is a legal, valid and binding obligation of Regenexx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> </TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
Regenexx represents and warrants that the execution and delivery of this letter agreement will not violate or be in conflict with
any order, judgment, injunction, agreement or other document to which Regenexx is a party or by which it is bound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
THE WARRANT OFFERED HEREBY HAS NOT BEEN REGISTERED UNDER THE ACT OR THE SECURITIES LAWS OF ANY STATE AND IS BEING OFFERED AND SOLD IN
RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH LAWS. THE WARRANT IS SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND SUCH LAWS PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM. THE WARRANT HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR
ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE
ACCURACY OR ADEQUACY OF THE SEC REPORTS. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
Regenexx represents and warrants that neither its managers nor its members have adopted any resolutions relative to the distribution
of the Warrant, or any portion thereof, to its members and have no present intention to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Each of RSI and Regenexx, on behalf of themselves and their respective Affiliates and the respective officers, directors, employees,
agents and representative of RSI and Regenexx and their Affiliates (the &ldquo;<U>Covenanting Parties</U>&rdquo;), agrees that it
will not in any way disparage BRT or its officers or directors, or make or solicit any comments, statements or the like, that may be
considered to be derogatory or detrimental to the good name or business reputation of BRT or its officers or directors. Each of RSI
and Regenexx, on behalf of themselves and their respective Covenanting Parties, similarly agrees not to otherwise take or condone
any action which is intended, or would reasonably be expected, to harm BRT, to impair BRT&rsquo;s reputation, or to lead to unwanted
or unfavorable publicity to BRT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
The invalidity or unenforceability of any provision of this letter agreement shall not affect the validity or enforceability of any
other provision of this letter agreement, and each provision of this letter agreement shall be severable and enforceable to the
extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
BRT, RSI and Regenexx agree that this letter agreement shall constitute an amendment to, and shall be incorporated in, the
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> </TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
amended hereby, the Agreement shall continue in full force and effect in accordance with its terms. Except as provided for herein, nothing
in this letter agreement shall be deemed to waive any rights that any Party has under or pursuant to the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>AGREED:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGENERATIVE
SCIENCES, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGENEXX, LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> </TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Accredited
Investor Certification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Initial
the appropriate box(es))</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenexx
represents and warrants that it, he or she is an &ldquo;accredited investor&rdquo; based upon the satisfaction of one or more of the
following criteria:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
                                            he or she is a natural person who has a net worth or joint net worth with his or her spouse
                                            in excess of $1,000,000 at the date hereof<SUP>1</SUP>; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
                                            he or she is a natural person who had an individual income in excess of $200,000 in each
                                            of the two most recent years or a joint income with his or her spouse in excess of $300,000
                                            in each of those years and has a reasonable expectation of reaching the same income level
                                            in the current year; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
                                            he or she is a director or executive officer of the Company; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
                                            it is either (a) a bank as defined in Section 3(a)(2) of the Securities Act of 1933, as amended
                                            (the &ldquo;Securities Act&rdquo;), or a savings and loan association or other institution
                                            as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in its individual
                                            or fiduciary capacity, (b) a broker or dealer registered pursuant to Section 15 of the Securities
                                            Exchange Act of 1934, (c) an insurance company as defined in Section 2(13) of the Securities
                                            Act, (d) an investment company registered under the Investment Company Act of 1940 or a business
                                            development company as defined in Section 2(a)(48) of such act, (e) a small business investment
                                            company licensed by the United States Small Business Administration under Section 301(c)
                                            or (d) of the Small Business Investment Act of 1958, (f) a plan established and maintained
                                            by a state or its political subdivisions, or any agency or instrumentality of a state or
                                            its political subdivisions, for the benefit of its employees, if such plan has total assets
                                            in excess of $5,000,000 or (g) an employee benefit plan within the meaning of Title I of
                                            the Employee Retirement Income Security Act of 1974, if the investment decision is made by
                                            a plan fiduciary, as defined in Section 3(21) of such act, which plan fiduciary is a bank,
                                            savings and loan association, an insurance company or a registered investment advisor, or
                                            if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed
                                            plan, with investment decisions made solely by persons who otherwise meet these suitability
                                            standards; or</FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>For purposes of calculating net worth: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The undersigned&rsquo;s primary residence shall not be included as an asset; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Indebtedness that is secured by the undersigned&rsquo;s primary residence, up to the estimated fair market value of the primary
residence at the date hereof, shall not be included as a liability (except that if the amount of such indebtedness outstanding at
the date hereof exceeds the amount outstanding 60 days before the date hereof, other than as a result of the acquisition of the
primary residence, the amount of such excess shall be included as a liability); and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Indebtedness that is secured by the undersigned&rsquo;s primary residence in excess of the estimated fair market value of the
primary residence at the date hereof shall be included as a liability.</FONT></P>


<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
                                            it is a private business development company as defined in Section 202(a)(22) of the Investment
                                            Advisers Act of 1940; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
                                            it is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986,
                                            as amended, a corporation, a Massachusetts or similar business trust or a partnership not
                                            formed for the specific purpose of acquiring the Warrants offered hereby, with total assets
                                            in excess of $5,000,000; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
                                            it is a trust, with total assets in excess of $5,000,000, not formed for the specific purpose
                                            of acquiring the Warrants, whose purchase is directed by a sophisticated person who has such
                                            knowledge and experience in financial and business matters that he or she is capable of evaluating
                                            the merits and risks of the prospective investment; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
                                            it is a corporation, partnership or other entity, and each and every equity owner of such
                                            entity initials a separate Accredited Investor Certification pursuant to which it, he or
                                            she certifies that it, he or she meets the qualifications set forth in either (1), (2), (3),
                                            (4), (5), (6) or (7) above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGENEXX,
    LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    21 , 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>ex10-7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>November
3, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021
STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
1<BR>
<BR>
PURPOSE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) is to promote the success and
enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and its Subsidiaries
(as defined below) by linking the individual interests of Employees, Consultants and members of the Board to those of the Company&rsquo;s
stockholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to the Company&rsquo;s
stockholders. The Plan is further intended to provide flexibility to the Company and its Subsidiaries in their ability to motivate, attract,
and retain the services of those individuals upon whose judgment, interest, and special effort the successful conduct of the Company&rsquo;s
operation is largely dependent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
2<BR>
<BR>
DEFINITIONS AND CONSTRUCTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise.
The singular pronoun shall include the plural where the context so indicates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
&ldquo;<U>Administrator</U>&rdquo; shall mean the entity that conducts the general administration of the Plan as provided in Article
10 hereof. With reference to the duties of the Administrator under the Plan which have been delegated to one or more persons pursuant
to Section 10.6 hereof, or which the Board has assumed, the term &ldquo;Administrator&rdquo; shall refer to such person(s) unless the
Committee or the Board has revoked such delegation or the Board has terminated the assumption of such duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
&ldquo;<U>Applicable Accounting Standards</U>&rdquo; shall mean Generally Accepted Accounting Principles in the United States, International
Financial Reporting Standards or such other accounting principles or standards as may apply to the Company&rsquo;s financial statements
under United States federal securities and other applicable laws from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
&ldquo;<U>Applicable Law</U>&rdquo; shall mean any applicable law, including without limitation, (a) provisions of the Code, the Securities
Act, the Exchange Act and any rules or regulations thereunder; (b) corporate, securities, tax or other laws, statutes, rules, requirements
or regulations, whether federal, state, local or foreign; and (c) rules of any securities exchange or automated quotation system on which
the Shares are listed, quoted or traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
&ldquo;<U>Award</U>&rdquo; shall mean an Option, a Restricted Stock award, a Dividend Equivalent award, a Stock Payment award, a Restricted
Stock Unit award, a Performance Share award, an Other Incentive Award, or a Stock Appreciation Right, which may be awarded or granted
under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
&ldquo;<U>Award Agreement</U>&rdquo; shall mean any written notice, agreement, contract or other instrument or document evidencing an
Award, including through electronic medium, which shall contain such terms and conditions with respect to an Award as the Administrator
shall determine, consistent with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
&ldquo;<U>Board</U>&rdquo; shall mean the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
&ldquo;<U>Cause</U>&rdquo; shall mean (a) the Administrator&rsquo;s determination that the Participant failed to substantially perform
the Participant&rsquo;s duties (other than any such failure resulting from the Participant&rsquo;s Disability); (b) the Administrator&rsquo;s
determination that the Participant failed to carry out, or comply with, any lawful and reasonable directive of the Board or the Participant&rsquo;s
immediate supervisor; (c) the Participant&rsquo;s commission of any act which, if the Participant were convicted would constitute, or
the Participant&rsquo;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for, any (i)
felony, (ii) indictable offense or (iii) crime involving moral turpitude; (d) the Participant&rsquo;s unlawful use (including being under
the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&rsquo;s
duties and responsibilities; or (e) the Participant&rsquo;s commission of an act of fraud, embezzlement, misappropriation, willful or
gross misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries. Notwithstanding the foregoing, if the Participant
is a party to a written employment, consulting, or other agreement with the Company or any of its Subsidiaries in which the term &ldquo;cause&rdquo;
is defined, then &ldquo;Cause&rdquo; shall be as such term is defined in the applicable written employment or consulting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8
&ldquo;<U>Change in Control</U>&rdquo; shall mean the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A &ldquo;change in ownership,&rdquo; as described in Section 1.409A-3(i)(5)(v) of the Treasury Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
A &ldquo;change in effective control,&rdquo; as described in Section 1.409A-3(i)(5)(vi) of the Treasury Regulations (but substituting
&ldquo;50 percent&rdquo; for &ldquo;30 percent&rdquo; in the first sentence of Section 1.409A-3(i)(5)(vi)(A)(1)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
A &ldquo;change in ownership of a substantial portion of the assets,&rdquo; as described in Section 1.409A-3(i)(5)(vii) of the Treasury
Regulations (but substituting &ldquo;50 percent&rdquo; for &ldquo;40 percent&rdquo; in the first sentence thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9
&ldquo;<U>Code</U>&rdquo; shall mean the Internal Revenue Code of 1986, as amended from time to time, together with the regulations and
official guidance promulgated thereunder, whether issued prior or subsequent to the grant of any Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10
&ldquo;<U>Committee</U>&rdquo; shall mean the committee appointed by the Board to administer the Plan or the Board if no committee is
appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11
&ldquo;<U>Common Stock</U>&rdquo; shall mean the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12
&ldquo;<U>Company</U>&rdquo; shall mean BioRestorative Therapies, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13
&ldquo;<U>Consultant</U>&rdquo; shall mean any consultant or advisor to the Company or any Subsidiary who provides consulting or advisory
services, other than as an Employee or Director, and such consultant or advisor (a) is a natural person (or an entity wholly-owned, directly
or indirectly, by a natural person), (b) has provided and/or will provide bona fide services to the Company, and (c) such services are
not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or
maintain a market for the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14
&ldquo;<U>Director</U>&rdquo; shall mean a member of the Board, as constituted from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15
&ldquo;<U>Disability</U>,&rdquo; unless otherwise specified in an Award Agreement or under the terms of a Program, shall mean total and
permanent disability as defined in Section 22(e)(3) of the Code. For purposes of the Plan, a Participant shall be deemed to have incurred
a Disability if the Participant is determined to be totally disabled by the Social Security Administration or in accordance with the
applicable disability insurance program of the Company. Notwithstanding the foregoing, if the Participant is a party to a written employment,
consulting, or other agreement with the Company or any of its Subsidiaries in which the term &ldquo;disability&rdquo; is defined, then
&ldquo;Disability&rdquo; shall be as such term is defined in the applicable written employment or consulting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16
&ldquo;<U>Dividend Equivalent</U>&rdquo; shall mean a right to receive the equivalent value (in cash or Shares) of dividends paid on
Shares, awarded under Section 8.1 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17
&ldquo;<U>Effective Date</U>&rdquo; shall mean the date the Plan is approved by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18
&ldquo;<U>Eligible Individual</U>&rdquo; shall mean any person who is an Employee, a Consultant or a Non-Employee Director, as determined
by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19
&ldquo;<U>Employee</U>&rdquo; shall mean any officer or other employee (within the meaning of Section 3401(c) of the Code) of the Company
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20
&ldquo;<U>Equity Restructuring</U>&rdquo; shall mean a nonreciprocal transaction between the Company and its stockholders, such as a
stock dividend, stock split, reverse stock split, spin-off, rights offering or recapitalization through a large, nonrecurring cash dividend,
that affects the number or kind of Shares (or other securities of the Company) or the share price of Common Stock (or other securities)
and causes a change in the per share value of the Common Stock underlying outstanding stock-based Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.21
&ldquo;<U>Exchange Act</U>&rdquo; shall mean the Securities Exchange Act of 1934, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.22
&ldquo;<U>Expiration Date</U>&rdquo; shall have the meaning given to such term in Section 11.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23
&ldquo;<U>Fair Market Value</U>&rdquo; shall mean, as of any given date, the value of a Share, determined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
if the Common Stock is listed on any established stock exchange or a national market system, including, without limitation, Nasdaq, its
Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange
or system on the day immediately preceding the day of determination (or, if the determination is made after the close of business for
trading, then on the day of determination) (or, if no closing sales price or closing bid was reported on that date, as applicable, on
the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source
as the Administrator deems reliable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
if the Common Stock is regularly quoted on an automated quotation system (including the OTCQB market) or by a recognized securities dealer,
its Fair Market Value shall be the closing sales price for such stock (or the mean between the high bid and low asked prices for the
Common Stock, if selling prices are not reported), as quoted on such system or by such securities dealer on the day immediately preceding
the day of determination (or, if the determination is made after the close of business for trading, then on the day of determination)
(or, if no such prices were reported on that date, as applicable, on the last date such prices were reported), as reported in The Wall
Street Journal or such other source as the Administrator deems reliable; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
in the absence of an established market for the Common Stock, the Fair Market Value shall be determined by the Administrator in good
faith, using such criteria as it shall determine, in its sole discretion, to be appropriate for valuation, provided that the determination
shall be consistent with the requirements of Sections 422 and 409A of the Code, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24
&ldquo;<U>Greater Than 10% Stockholder</U>&rdquo; shall mean an individual then-owning (within the meaning of Section 424(d) of the Code)
more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any &ldquo;parent corporation&rdquo;
or &ldquo;subsidiary corporation&rdquo; (as defined in Sections 424(e) and 424(f) of the Code, respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25
&ldquo;<U>Incentive Stock Option</U>&rdquo; shall mean an Option that is intended to qualify as an incentive stock option and conforms
to the applicable provisions of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26
&ldquo;<U>Non-Employee Director</U>&rdquo; shall mean a Director of the Company who is not an Employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27
&ldquo;<U>Non-Qualified Stock Option</U>&rdquo; shall mean an Option that is not an Incentive Stock Option or which is designated as
an Incentive Stock Option but does not meet the applicable requirements of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28
&ldquo;<U>Option</U>&rdquo; shall mean a right to purchase Shares at a specified exercise price, granted under Article 5 hereof. An Option
shall be either a Non-Qualified Stock Option or an Incentive Stock Option; <U>provided</U>, <U>however</U>, that Options granted to Non-Employee
Directors and Consultants shall only be Non-Qualified Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29
&ldquo;<U>Organizational Documents</U>&rdquo; shall mean, collectively, (a) the Company&rsquo;s articles of incorporation, certificate
of incorporation, bylaws or other similar organizational documents relating to the creation and governance of the Company, and (b) the
Committee&rsquo;s charter or other similar organizational documentation relating to the creation and governance of the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30
&ldquo;<U>Other Incentive Award</U>&rdquo; shall mean an Award denominated in, linked to or derived from Shares or value metrics related
to Shares, granted pursuant to Section 8.5 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31
&ldquo;<U>Participant</U>&rdquo; shall mean a person who has been granted an Award pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32
&ldquo;<U>Performance Share</U>&rdquo; shall mean a contractual right awarded under Section 8.4 hereof to receive a number of Shares
or the Fair Market Value of such number of Shares in cash based on the attainment of specified performance goals or other criteria determined
by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33
&ldquo;<U>Plan</U>&rdquo; shall mean this BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as it may be amended, supplemented,
and restated from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.34
&ldquo;<U>Program</U>&rdquo; shall mean any program adopted by the Administrator pursuant to the Plan containing the terms and conditions
intended to govern a specified type of Award granted under the Plan and pursuant to which such type of Award may be granted under the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35
&ldquo;<U>Restricted Stock</U>&rdquo; shall mean an award of Shares made under Article 7 hereof that is subject to certain restrictions
and may be subject to risk of forfeiture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36
&ldquo;<U>Restricted Stock Unit</U>&rdquo; shall mean a contractual right awarded under Section 8.3 hereof to receive in the future a
Share or the Fair Market Value of a Share in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37
&ldquo;<U>Securities Act</U>&rdquo; shall mean the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.38
&ldquo;<U>Share Limit</U>&rdquo; shall have the meaning provided in Section 3.1(a) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.39
&ldquo;<U>Shares</U>&rdquo; shall mean shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40
&ldquo;<U>Stock Appreciation Right</U>&rdquo; shall mean an Award entitling the Participant (or other person entitled to exercise pursuant
to the Plan) to exercise all or a specified portion thereof (to the extent then exercisable pursuant to its terms) and to receive from
the Company an amount determined by multiplying the difference obtained by subtracting the exercise price per share of such Award from
the Fair Market Value on the date of exercise of such Award by the number of Shares with respect to which such Award shall have been
exercised, subject to any limitations the Administrator may impose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41
&ldquo;<U>Stock Payment</U>&rdquo; shall mean a payment in the form of Shares awarded under Section 8.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.42
&ldquo;<U>Subsidiary</U>&rdquo; shall mean (a) a corporation, association or other business entity of which fifty percent (50%) or more
of the total combined voting power of all classes of capital stock is owned, directly or indirectly, by the Company and/or by one or
more Subsidiaries, (b) any partnership or limited liability company of which fifty percent (50%) or more of the equity interests are
owned, directly or indirectly, by the Company and/or by one or more Subsidiaries, and (c) any other entity not described in clauses (a)
or (b) above of which fifty percent (50%) or more of the ownership or the power (whether voting interests or otherwise), pursuant to
a written contract or agreement, to direct the policies and management or the financial and the other affairs thereof, are owned or controlled
by the Company and/or by one or more Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.43
&ldquo;<U>Substitute Award</U>&rdquo; shall mean an Award granted under the Plan in connection with a corporate transaction, such as
a merger, combination, consolidation or acquisition of property or stock, in any case, upon the assumption of, or in substitution for,
an outstanding equity award previously granted by a company or other entity that is a party to such transaction; <U>provided</U>, <U>however</U>,
that in no event shall the term &ldquo;Substitute Award&rdquo; be construed to refer to an award made in connection with the cancellation
and repricing of an Option or Stock Appreciation Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44
&ldquo;<U>Termination of Service</U>&rdquo; shall mean, unless otherwise determined by the Administrator:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
As to a Consultant, the time when the engagement of a Participant as a Consultant to the Company and its Subsidiaries is terminated for
any reason, with or without cause, including, without limitation, by resignation, discharge, death, Disability or retirement, but excluding
terminations where the Consultant simultaneously commences or remains in employment and/or service as an Employee and/or Director of
the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As to a Non-Employee Director, the time when a Participant who is a Non-Employee Director ceases to be a Director for any reason, including,
without limitation, a termination by resignation, failure to be elected, removal, death, Disability or retirement, but excluding terminations
where the Participant simultaneously commences or remains in employment and/or service as an Employee of and/or Consultant to the Company
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
As to an Employee, the time when the employee-employer relationship between a Participant and the Company and its Subsidiaries is terminated
for any reason, including, without limitation, a termination by resignation, discharge, death, Disability or retirement, but excluding
terminations where the Participant simultaneously commences or remains in service as a Consultant to and/or Director of the Company or
any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator, in its sole discretion, shall determine the effect of all matters and questions relating to any Termination of Service,
including, without limitation, whether a Termination of Service has occurred, whether any Termination of Service resulted from a discharge
for Cause and whether any particular leave of absence constitutes a Termination of Service; <U>provided</U>, <U>however</U>, that, with
respect to Incentive Stock Options, unless the Administrator otherwise provides in the terms of any Program, Award Agreement or otherwise,
or as otherwise required by Applicable Law, a leave of absence, change in status from an employee to an independent contractor or other
change in the employee-employer relationship shall constitute a Termination of Service only if, and to the extent that, such leave of
absence, change in status or other change interrupts employment for the purposes of Section 422(a)(2) of the Code. For purposes of the
Plan, a Participant&rsquo;s employee-employer relationship or consultancy relationship shall be deemed to be terminated in the event
that the Subsidiary employing or contracting with such Participant ceases to remain a Subsidiary following any merger, sale of stock
or other corporate transaction or event (including, without limitation, a spin-off).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
3<BR>
<BR>
SHARES SUBJECT TO THE PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Number of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to Sections 3.1(b) and 11.2 hereof, the aggregate number of Shares which may be issued or transferred pursuant to Awards under
the Plan is Two Million Five Hundred Thousand (2,500,000) Shares (the &ldquo;<U>Share Limit</U>&rdquo;). No more than Two Million Five
Hundred Thousand (2,500,000) Shares may be issued upon the exercise of Incentive Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If any Shares subject to an Award are forfeited or expire or such Award is settled for cash (in whole or in part), the Shares subject
to such Award shall, to the extent of such forfeiture, expiration or cash settlement, again be available for future grants of Awards
under the Plan and shall be added back to the Share Limit in the same number of Shares as were debited from the Share Limit in respect
of the grant of such Award (as may be adjusted in accordance with Section 11.2 hereof). In addition, the following Shares shall be added
back to the Share Limit and will be available for future grants of Awards: (i) Shares tendered by a Participant or withheld by the Company
in payment of the exercise price of an Option or Stock Appreciation Right; (ii) Shares tendered by the Participant or withheld by the
Company to satisfy any tax withholding obligation with respect to an Award; and (iii) Shares subject to a Stock Appreciation Right that
are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof. Any Shares forfeited by the
Participant or repurchased by the Company under Section 7.4 hereof at the same price paid by the Participant so that such Shares are
returned to the Company will again be available for Awards. The payment of Dividend Equivalents in cash in conjunction with any outstanding
Awards shall not be counted against the Shares available for issuance under the Plan. Notwithstanding the provisions of this Section
3.1(b), no Shares may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as
an incentive stock option under Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Substitute Awards shall not reduce the Shares authorized for grant under the Plan, except to the extent required by reason of Section
422 of the Code. Additionally, in the event that a company acquired by the Company or any Subsidiary, or with which the Company or any
Subsidiary combines, has shares available under a pre-existing plan approved by its stockholders and not adopted in contemplation of
such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the
extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination
to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be
used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan to the extent that grants of Awards
using such available shares are (i) permitted without stockholder approval under the rules of the principal securities exchange on which
the Common Stock is then listed, if applicable, and (ii) made only to individuals who were not employed by or providing services to the
Company or its Subsidiaries immediately prior to such acquisition or combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
4<BR>
<BR>
GRANTING OF AWARDs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Participation.</U> The Administrator may, from time to time, select from among all Eligible Individuals, those to whom one or more
Awards shall be granted and shall determine the nature and amount of each Award, which shall not be inconsistent with the requirements
of the Plan. No Eligible Individual or other Person shall have any right to be granted an Award pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Award Agreement</U>. Each Award shall be evidenced by an Award Agreement stating the terms and conditions applicable to such Award,
consistent with the requirements of the Plan and any applicable Program. Award Agreements evidencing Incentive Stock Options shall contain
such terms and conditions as may be necessary to meet the applicable provisions of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>At-Will Service</U>. Nothing in the Plan or in any Program or Award Agreement hereunder shall confer upon any Participant any right
to continue as an Employee, Director or Consultant of the Company or any Subsidiary, or shall interfere with or restrict in any way the
rights of the Company or any Subsidiary, which rights are hereby expressly reserved, to discharge any Participant at any time for any
reason whatsoever, with or without Cause, and with or without notice, or to terminate or change all other terms and conditions of any
Participant&rsquo;s employment or engagement, except to the extent expressly provided otherwise in a written agreement between the Participant
and the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Stand-Alone and Tandem Awards</U>. Awards granted pursuant to the Plan may, in the sole discretion of the Administrator, be granted
either alone, in addition to, or in tandem with, any other Award granted pursuant to the Plan. Awards granted in addition to or in tandem
with other Awards may be granted either at the same time as or at a different time from the grant of such other Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
5<BR>
<BR>
granting OF OPTIONS and stock appreciation rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Granting of Options and Stock Appreciation Rights to Eligible Individuals</U>. The Administrator is authorized to grant Options and
Stock Appreciation Rights to Eligible Individuals from time to time, in its sole discretion, on such terms and conditions as it may determine
which shall not be inconsistent with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Qualification of Incentive Stock Options</U>. No Incentive Stock Option shall be granted to any person who is not an Employee of the
Company or any &ldquo;parent corporation&rdquo; or &ldquo;subsidiary corporation&rdquo; of the Company (as defined in Sections 424(e)
and 424(f) of the Code, respectively). No person who qualifies as a Greater Than 10% Stockholder may be granted an Incentive Stock Option
unless such Incentive Stock Option conforms to the applicable provisions of Section 422 of the Code. Any Incentive Stock Option granted
under the Plan may be modified by the Administrator, with the consent of the Participant, to disqualify such Option from treatment as
an &ldquo;incentive stock option&rdquo; under Section 422 of the Code. To the extent that the aggregate fair market value of stock with
respect to which &ldquo;incentive stock options&rdquo; (within the meaning of Section 422 of the Code, but without regard to Section
422(d) of the Code) are exercisable for the first time by a Participant during any calendar year under the Plan and all other plans of
the Company or any &ldquo;parent corporation&rdquo; or &ldquo;subsidiary corporation&rdquo; of the Company (as defined in Section 424(e)
and 424(f) of the Code, respectively) exceeds one hundred thousand dollars ($100,000), the Options shall be treated as Non-Qualified
Stock Options to the extent required by Section 422 of the Code. The rule set forth in the preceding sentence shall be applied by taking
Options and other &ldquo;incentive stock options&rdquo; into account in the order in which they were granted and the fair market value
of stock shall be determined as of the time the respective options were granted. In addition, to the extent that any Options otherwise
fail to qualify as Incentive Stock Options, such Options shall be treated as Nonqualified Stock Options. Any interpretations and rules
under the Plan with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Option and Stock Appreciation Right Exercise Price</U>. The exercise price per Share subject to each Option and Stock Appreciation
Right shall be set by the Administrator, but shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on
the date the Option or Stock Appreciation Right, as applicable, is granted (or, as to Incentive Stock Options, on the date the Option
is modified, extended or renewed for purposes of Section 424(h) of the Code). In addition, in the case of Incentive Stock Options granted
to a Greater Than 10% Stockholder, such price shall not be less than one hundred ten percent (110%) of the Fair Market Value of a Share
on the date the Option is granted (or the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code).
Notwithstanding the foregoing, in the case of an Option or Stock Appreciation Right that is a Substitute Award, the exercise price per
share of the Shares subject to such Option or Stock Appreciation Right, as applicable, may be less than the Fair Market Value per share
on the date of grant; <U>provided</U> that the exercise price of any Substitute Award shall be determined in accordance with the applicable
requirements of Sections 424 and 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Option and SAR Term</U>. The term of each Option and the term of each Stock Appreciation Right shall be set by the Administrator in
its sole discretion; <U>provided</U>, <U>however</U>, that the term shall not be more than ten (10) years from the date the Option or
Stock Appreciation Right, as applicable, is granted, or five (5) years from the date an Incentive Stock Option is granted to a Greater
Than 10% Stockholder. Except as limited by the requirements of Section 409A or Section 422 of the Code, and subject to the limitations
set forth in the previous sentence, the Administrator may extend the term of any outstanding Option or Stock Appreciation Right, and
may extend the time period during which vested Options or Stock Appreciation Rights may be exercised, in connection with any Termination
of Service of the Participant or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Termination of Services</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Unless otherwise provided in an Award Agreement, if a Participant has a Termination of Service for any reason other than for Cause or
due to death or Disability, the Participant may exercise any vested outstanding Option or Stock Appreciation Right, to the extent exercisable
on the date of Termination of Service, at any time within three months after the date of such Termination of Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Unless otherwise provided in an Award Agreement, if a Participant has a Termination of Service due to death or Disability, the Participant
(or in the case of death, the Participant&rsquo;s estate or the beneficiary who acquired the right to exercise the Option or Stock Appreciation
Right by bequest or inheritance or otherwise by reason of the death of the Participant) may exercise any vested outstanding Option or
Stock Appreciation Right, to the extent exercisable on the date of Termination of Service, at any time within twelve months after the
date of such Termination of Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Unless otherwise provided in an Award Agreement, if a Participant has a Termination of Service for Cause, any Option or Stock Appreciation
Right held by the Participant under the Plan, to the extent not exercised prior to the Termination of Service, and whether or not vested,
will terminate immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notwithstanding the foregoing, nothing in this Section 5.5 will extend the exercise period for any Option or Stock Appreciation Right
beyond the stated term of the Option or Stock Appreciation Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Option and SAR Vesting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The terms and conditions pursuant to which an Option or Stock Appreciation Right vests in the Participant and becomes exercisable shall
be determined by the Administrator and set forth in the applicable Award Agreement. Such vesting may be based on service with the Company
or any Subsidiary, specified performance goals, or any other criteria selected by the Administrator. At any time after the grant of an
Option or Stock Appreciation Right, the Administrator may, in its sole discretion and subject to whatever terms and conditions it selects,
accelerate the vesting of the Option or Stock Appreciation Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Unless otherwise permitted by the Plan, no portion of an Option or Stock Appreciation Right which is unexercisable at a Participant&rsquo;s
Termination of Service shall thereafter become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Substitution of Stock Appreciation Rights</U>. The Administrator may, in its sole discretion, substitute an Award of Stock Appreciation
Rights for an outstanding Option at any time prior to or upon exercise of such Option; <U>provided</U><I>,</I> <U>however</U>, that such
Stock Appreciation Rights shall be exercisable with respect to the same number of Shares for which such substituted Option would have
been exercisable, and shall also have the same exercise price and remaining term as the substituted Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
6<BR>
<BR>
EXERCISE OF OPTIONS and stock appreciation rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Exercise and Payment</U>. An exercisable Option or Stock Appreciation Right may be exercised in whole or in part. However, an Option
or Stock Appreciation Right shall not be exercisable with respect to fractional shares and the Administrator may require that, by the
terms of the Option or Stock Appreciation Right, a partial exercise must be with respect to a minimum number of Shares. Payment of the
amounts payable with respect to Stock Appreciation Rights pursuant to this Article 6 shall be in cash, Shares (based on its Fair Market
Value as of the date the Stock Appreciation Right is exercised), or a combination of both, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Manner of Exercise</U>. All or a portion of an exercisable Option or Stock Appreciation Right shall be deemed exercised upon delivery
of all of the following to the Secretary of the Company, the Administrator or such other person or entity designated by the Administrator,
or his, her or its office, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A written or electronic notice complying with the applicable rules established by the Administrator stating that the Option or Stock
Appreciation Right, or a portion thereof, is exercised. The notice shall be signed by the Participant or other person then entitled to
exercise the Option or Stock Appreciation Right or such portion thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Such representations and documents as the Administrator, in its sole discretion, deems necessary or advisable to effect compliance with
Applicable Law. The Administrator may, in its sole discretion, also take such additional actions as it deems appropriate to effect such
compliance including, without limitation, placing legends on share certificates and issuing stop-transfer notices to agents and registrars;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In the event that the Option or Stock Appreciation Right shall be exercised pursuant to Section 9.3 hereof by any person or persons other
than the Participant, appropriate proof of the right of such person or persons to exercise the Option or Stock Appreciation Right, as
determined in the sole discretion of the Administrator; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Full payment of the exercise price and applicable withholding taxes for the Shares with respect to which the Option or Stock Appreciation
Right, or portion thereof, is exercised, in a manner permitted by the Administrator in accordance with Sections 9.1 and 9.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Notification Regarding Disposition</U>. The Participant shall give the Company prompt written or electronic notice of any disposition
of Shares acquired by exercise of an Incentive Stock Option which occurs within (a) two (2) years after the date of granting (including
the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code) of such Option to such Participant,
or (b) one (1) year after the date of transfer of such Shares to such Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
7<BR>
<BR>
RESTRICTED STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Award of Restricted Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Administrator is authorized to grant Restricted Stock to Eligible Individuals, and shall determine the terms and conditions, including
the restrictions applicable to each award of Restricted Stock, which terms and conditions shall not be inconsistent with the Plan or
any applicable Program, and may impose such conditions on the issuance of such Restricted Stock as it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Administrator shall establish the purchase price, if any, and form of payment for Restricted Stock; <U>provided</U>, <U>however</U>,
that if a purchase price is charged, such purchase price shall be no less than the par value of the Shares to be purchased, unless otherwise
permitted by Applicable Law. In all cases, legal consideration shall be required for each issuance of Restricted Stock to the extent
required by Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Rights as Stockholders</U>. Subject to Section 7.4 hereof, upon issuance of Restricted Stock, the Participant shall have, unless otherwise
provided by the Administrator, all the rights of a stockholder with respect to the Shares, subject to the restrictions in the Plan, an
applicable Program or in the applicable Award Agreement, including the right to receive all dividends and other distributions paid or
made with respect to the Shares; <U>provided</U>, <U>however</U>, that, in the sole discretion of the Administrator, any extraordinary
distributions with respect to the Shares may be subject to the restrictions set forth in Section 7.3 hereof. In addition, with respect
to Restricted Stock that is subject to performance-based vesting (including the continuation of services for a specified period of time),
dividends which are paid prior to vesting shall only be paid out to the Participant to the extent that the performance-based vesting
conditions are subsequently satisfied and the share of Restricted Stock vests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Restrictions</U>. All shares of Restricted Stock (including any shares received by Participants thereof with respect to shares of
Restricted Stock as a result of stock dividends, stock splits or any other form of recapitalization) shall be subject to such restrictions
and vesting requirements as the Administrator shall provide in the applicable Program or Award Agreement. By action taken after the Restricted
Stock is issued, the Administrator may, on such terms and conditions as it may determine to be appropriate, accelerate the vesting of
such Restricted Stock by removing any or all of the restrictions imposed by the terms of any Program or by the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Repurchase or Forfeiture of Restricted Stock</U>. Except as otherwise determined by the Administrator, if no purchase price was paid
by the Participant for the Restricted Stock, upon a Termination of Service, the Participant&rsquo;s rights in unvested Restricted Stock
then subject to restrictions shall lapse and be forfeited, and such Restricted Stock shall be surrendered to the Company and cancelled
without consideration on the date of such Termination of Service. If a purchase price was paid by the Participant for the Restricted
Stock, upon a Termination of Service the Company shall have the right to repurchase from the Participant the unvested Restricted Stock
then-subject to restrictions at a cash price per share equal to the price paid by the Participant for such Restricted Stock or such other
amount as may be specified in an applicable Program or the applicable Award Agreement. The Administrator in its sole discretion may provide
that, upon certain events, including without limitation a Change in Control, the Participant&rsquo;s death, retirement or Disability,
any other specified Termination of Service or any other event, the Participant&rsquo;s rights in unvested Restricted Stock shall not
terminate, such Restricted Stock shall vest and cease to be forfeitable and, if applicable, the Company shall cease to have a right of
repurchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<U>Certificates/Book Entries for Restricted Stock</U>. Restricted Stock granted pursuant to the Plan may be evidenced in such manner
as the Administrator shall determine. Certificates or book entries evidencing shares of Restricted Stock must include an appropriate
legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock, and the Company may, in its sole discretion,
retain physical possession of any stock certificate until such time as all applicable restrictions lapse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
<U>Section 83(b) Election</U>. If a Participant makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted
Stock as of the date of transfer of the Restricted Stock rather than as of the date or dates upon which the Participant would otherwise
be taxable under Section 83(a) of the Code, the Participant shall be required to deliver a copy of such election to the Company promptly
after filing such election with the Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
8<BR>
<BR>
DIVIDEND EQUIVALENTS; STOCK PAYMENTS; RESTRICTED STOCK UNITS; PERFORMANCE SHARES; OTHER INCENTIVE AWARDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
<U>Dividend Equivalents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to Section 8.1(b) hereof, Dividend Equivalents may be granted by the Administrator, either alone or in tandem with another Award,
based on dividends declared on Common Stock, to be credited as of dividend payment dates during the period between the date the Dividend
Equivalents are granted to a Participant and the date such Dividend Equivalents terminate or expire, as determined by the Administrator.
Such Dividend Equivalents shall be converted to cash or additional Shares by such formula and at such time and subject to such limitations
as may be determined by the Administrator. In addition, Dividend Equivalents with respect to an Award that is subject to performance-based
vesting that are based on dividends paid prior to the vesting of such Award shall only be paid out to the Participant to the extent that
the performance-based vesting conditions are subsequently satisfied and the Award vests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding the foregoing, no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
<U>Stock Payments</U>. The Administrator is authorized to make one or more Stock Payments to any Eligible Individual. The number or value
of Shares of any Stock Payment shall be determined by the Administrator and may be based upon one or more specific performance criteria
or any other specific criteria, including service to the Company or any Subsidiary, determined by the Administrator. Stock Payments may,
but are not required to, be made in lieu of base salary, bonus, fees or other cash compensation otherwise payable to such Eligible Individual.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
<U>Restricted Stock Units</U>. The Administrator is authorized to grant Restricted Stock Units to any Eligible Individual. The number
and terms and conditions of Restricted Stock Units shall be determined by the Administrator. The Administrator shall specify the date
or dates on which the Restricted Stock Units shall become fully vested and nonforfeitable, and may specify such conditions to vesting
as it deems appropriate, including conditions based on one or more specific performance criteria or other specific criteria, including
service to the Company or any Subsidiary, in each case, on a specified date or dates or over any period or periods, as determined by
the Administrator. The Administrator shall specify, or may permit the Participant to elect, the conditions and dates upon which the Shares
underlying the Restricted Stock Units shall be issued, which dates shall not be earlier than the date as of which the Restricted Stock
Units vest and become nonforfeitable and which conditions and dates shall be consistent with the applicable provisions of Section 409A
of the Code or an exemption therefrom. On the distribution dates, the Company shall issue to the Participant one unrestricted, fully
transferable Share (or the Fair Market Value of one such Share in cash) for each vested and nonforfeitable Restricted Stock Unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
<U>Performance Share Awards</U>. Any Eligible Individual selected by the Administrator may be granted one or more Performance Share awards
which shall be denominated in a number or range of Shares and the vesting of which may be linked to any specific performance criteria
(in each case on a specified date or dates or over any period or periods determined by the Administrator) and/or time-vesting or other
criteria, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
<U>Other Incentive Awards</U>. The Administrator is authorized to grant Other Incentive Awards to any Eligible Individual, which Awards
may cover Shares or the right to purchase Shares or have a value derived from the value of, or an exercise or conversion privilege at
a price related to, or that are otherwise payable in or based on, Shares, stockholder value or stockholder return, in each case, on a
specified date or dates or over any period or periods determined by the Administrator. Other Incentive Awards may be linked to such specific
performance criteria as determined appropriate by the Administrator. Other Incentive Awards may be paid in cash, Shares, or a combination
of cash and Shares, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6
<U>Other Terms and Conditions</U>. All applicable terms and conditions of each Award described in this Article 8, including without limitation,
as applicable, the term, vesting conditions and exercise/purchase price applicable to the Award, shall be set by the Administrator in
its sole discretion, <U>provided</U>, <U>however</U>, that the value of the consideration paid by a Participant for an Award, if any,
shall not be less than the par value of a Share, unless otherwise permitted by Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7
<U>Exercise upon Termination of Service</U>. Awards described in this Article 8 are exercisable or distributable, as applicable, only
while the Participant is an Employee, Director or Consultant, as applicable. Except as otherwise provided in the Plan, the Administrator,
however, in its sole discretion may provide that such Award may be exercised or distributed subsequent to a Termination of Service as
provided under an applicable Program, Award Agreement, payment deferral election and/or in certain events, including without limitation,
a Change in Control, the Participant&rsquo;s death, retirement or Disability or any other specified Termination of Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
9<BR>
<BR>
Additional terms of awards</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
<U>Payment</U>. The Administrator shall determine the method or methods by which payments by any Participant with respect to any Awards
granted under the Plan shall be made, including, without limitation: (a) cash or check, (b) Shares (including, in the case of payment
of the exercise price of an Award, Shares issuable pursuant to the exercise of the Award) held for such minimum period of time as may
be established by the Administrator, in each case, having a Fair Market Value on the date of delivery equal to the aggregate payments
required, (c) other form of legal consideration acceptable to the Administrator, or (d) any combination of the foregoing. The Administrator
shall also determine the methods by which Shares shall be delivered or deemed to be delivered to Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
<U>Tax Withholding and Tax Bonuses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company and its Subsidiaries shall have the authority and the right to deduct or withhold, or require a Participant to remit to the
Company or a Subsidiary, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Participant&rsquo;s social
security, Medicare and any other employment tax obligation) required by law to be withheld with respect to any taxable event concerning
a Participant arising in connection with any Award. The Administrator may in its sole discretion and in satisfaction of the foregoing
requirement allow a Participant to satisfy such obligations by any payment means described in Section 9.1 hereof, including without limitation,
by allowing such Participant to elect to have the Company or a Subsidiary withhold Shares otherwise issuable under an Award (or allow
the surrender of Shares). Notwithstanding anything in this Section 9.2 to the contrary, the Company shall not allow a Participant to
make any such election if the election would cause a violation of Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Committee, in its discretion, shall have the authority, at the time of grant of any Award under the Plan or at any time thereafter,
to approve cash bonuses to designated Participants to be paid upon their exercise or receipt of (or the lapse of restrictions relating
to) Awards in order to provide funds to pay all or a portion of federal and state taxes due as a result of such exercise or receipt (or
the lapse of such restrictions). The Committee shall have full authority in its discretion to determine the amount of any such tax bonus.
Notwithstanding the foregoing, tax bonuses shall not be granted with respect to Awards that are Stock Appreciation Rights or Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3
<U>Transferability of Awards</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
No Award under the Plan may be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution,
unless and until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions applicable
to such Shares have lapsed. No Award or interest or right therein shall be liable for or otherwise subject to the debts, contracts or
engagements of the Participant or the Participant&rsquo;s successors in interest or shall be subject to disposition by transfer, alienation,
anticipation, pledge, hypothecation, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary
or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy)
unless and until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions applicable
to such Shares have lapsed, and any attempted disposition of an Award prior to the satisfaction of these conditions shall be null and
void and of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
During the lifetime of the Participant, only the Participant may exercise any exercisable portion of an Award granted to him under the
Plan. Notwithstanding the foregoing, a Non-Qualified Stock Option granted under the Plan may be transferred, in whole or in part, during
a Participant&rsquo;s lifetime, upon the approval of the Administrator, to a Participant&rsquo;s &ldquo;family members&rdquo; (as such
term is defined in Rule 701(c)(3) of the Securities Act and General Instructions A(1)(a)(5) to Form S-8) through a gift or domestic relations
order. The transferred portion of a Non-Qualified Stock Option may only be exercised by the person or entity who acquires a proprietary
interest in such Option pursuant to the transfer. The terms applicable to the transferred portion shall be the same as those in effect
for the Option immediately prior to such transfer and shall be set forth in such documents issued to the transferee as the Administrator
may deem appropriate. After the death of the Participant, any exercisable portion of an Award may, prior to the time when such portion
becomes unexercisable under the Plan or the applicable Program or Award Agreement, be exercised by the Participant&rsquo;s personal representative
or by any person empowered to do so under the deceased Participant&rsquo;s will or under the then-applicable laws of descent and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding Section 9.3(a) hereof, a Participant may, in the manner determined by the Administrator, designate a beneficiary to exercise
the rights of the Participant and to receive any distribution with respect to any Award upon the Participant&rsquo;s death. A beneficiary,
legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions
of the Plan and any Program or Award Agreement applicable to the Participant, and to any additional restrictions deemed necessary or
appropriate by the Administrator. If the Participant is married or a domestic partner in a domestic partnership qualified under Applicable
Law and resides in a &ldquo;community property&rdquo; state, a designation of a person other than the Participant&rsquo;s spouse or domestic
partner, as applicable, as his or her beneficiary with respect to more than fifty percent (50%) of the Participant&rsquo;s interest in
the Award shall not be effective without the prior written or electronic consent of the Participant&rsquo;s spouse or domestic partner.
If no beneficiary has been designated or survives the Participant, payment shall be made to the person entitled thereto pursuant to the
Participant&rsquo;s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed
or revoked by a Participant at any time provided the change or revocation is delivered to the Administrator in writing prior to the Participant&rsquo;s
death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4
<U>Conditions to Issuance of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Administrator shall determine the methods by which Shares shall be delivered or deemed to be delivered to Participants. Notwithstanding
anything herein to the contrary, neither the Company nor its Subsidiaries shall be required to issue or deliver any certificates or make
any book entries evidencing Shares pursuant to the exercise of any Award, unless and until the Administrator has determined, with advice
of counsel, that the issuance of such Shares is in compliance with Applicable Law, and the Shares are covered by an effective registration
statement or applicable exemption from registration. In addition to the terms and conditions provided herein, the Administrator may require
that a Participant make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems advisable
in order to comply with any such Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
All Share certificates delivered pursuant to the Plan and all Shares issued pursuant to book entry procedures are subject to any stop-transfer
orders and other restrictions as the Administrator deems necessary or advisable to comply with Applicable Law. The Administrator may
place legends on any Share certificate or book entry to reference restrictions applicable to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Administrator shall have the right to require any Participant to comply with any timing or other restrictions with respect to the
settlement, distribution or exercise of any Award, including a window-period limitation, as may be imposed in the sole discretion of
the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
No fractional Shares shall be issued and the Administrator shall determine, in its sole discretion, whether cash shall be given in lieu
of fractional Shares or whether such fractional Shares shall be eliminated by rounding down.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company, in its sole discretion, may (i) retain physical possession of any stock certificate evidencing Shares until any restrictions
thereon shall have lapsed and/or (ii) require that the stock certificates evidencing such Shares be held in custody by a designated escrow
agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock
power, endorsed in blank, relating to such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by Applicable Law, the
Company and/or its Subsidiaries may, in lieu of delivering to any Participant certificates evidencing Shares issued in connection with
any Award, record the issuance of Shares in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
<U>Market Stand-Off</U>. In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective
registration statement filed under the Securities Act, including the Company&rsquo;s initial public offering, the Participant will not
directly or indirectly sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any Option or other contract for
the purchase of, any Option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the
foregoing transactions with respect to, any Shares acquired under this Plan or any Award issued under this Plan without the prior written
consent of the Company or its underwriters. Such restriction (the &ldquo;<B>Market Stand-Off</B>&rdquo;) will be in effect for such period
of time following the date of the final prospectus for the offering as may be requested by the Company or such underwriters. In no event,
however, will such period exceed a) 180 days or b) such other period as may be requested by the Company or the underwriters to accommodate
regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions
or amendments thereto). In the event of the declaration of a stock dividend, a spin-off, a stock split, an adjustment in conversion ratio,
a recapitalization or a similar transaction affecting the Company&rsquo;s outstanding securities without receipt of consideration, any
new, substituted or additional securities which are by reason of such transaction distributed with respect to any Stock shall be subject
to the Market Stand-Off. The Company may impose stop-transfer instructions with respect to any and all Stock or Options previously referred
to in this Section until the end of the applicable stand-off period. The Company&rsquo;s underwriters will be beneficiaries of the agreement
set forth in this Section. A Participant will be subject to this Section only if the directors and officers of the Company are subject
to similar arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6
<U>Forfeiture and Claw-Back Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Unless otherwise provided in an Award Agreement: (i) any proceeds, gains or other economic benefit actually or constructively received
by the Participant upon any receipt or exercise of the Award, or upon the receipt or resale of any Shares underlying the Award, must
be paid to the Company, and (ii) the Award shall terminate and any unexercised portion of the Award (whether or not vested) shall be
forfeited, if (x) a Termination of Service occurs within six months following receipt or exercise of the Award, (y) the Participant at
any time engages in any activity in competition with the Company, or which is inimical, contrary or harmful to the interests of the Company,
as further defined by the Administrator or (z) the Participant incurs a Termination of Service for Cause; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
All Awards (including any proceeds, gains or other economic benefit actually or constructively received by a Participant upon any receipt
or exercise of any Award or upon the receipt or resale of any Shares underlying the Award) shall be subject to the applicable provisions
of any claw-back policy implemented by the Company, whether implemented prior to or after the grant of such Award, including without
limitation, any claw-back policy adopted to comply with the requirements of Applicable Law, to the extent set forth in such claw-back
policy and/or in the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7
<U>Leave of Absence</U>. Unless the Administrator provides otherwise, vesting of Awards granted hereunder shall not be suspended during
any unpaid leave of absence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
10<BR>
<BR>
ADMINISTRATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
<U>Administrator</U>. The Committee (or another committee or a subcommittee of the Board assuming the functions of the Committee under
the Plan) shall administer the Plan (except as otherwise permitted herein) unless otherwise determined by the Board. Except as may otherwise
be provided in the Organizational Documents, appointment of Committee members shall be effective upon acceptance of appointment, Committee
members may resign at any time by delivering written or electronic notice to the Board, and vacancies in the Committee may only be filled
by the Board. Notwithstanding the foregoing, (a) the full Board, acting by a majority of its members in office, shall conduct the general
administration of the Plan with respect to Awards granted to Non-Employee Directors of the Company and (b) the Board or Committee may
delegate its authority hereunder to the extent permitted by Section 10.6 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
<U>Duties and Powers of Administrator</U>. It shall be the duty of the Administrator to conduct the general administration of the Plan
in accordance with its provisions. The Administrator shall have the power to interpret the Plan and all Programs and Award Agreements,
and to adopt such rules for the administration, interpretation and application of the Plan and any Program as are not inconsistent with
the Plan, to interpret, amend or revoke any such rules and to amend any Program or Award Agreement provided that the rights or obligations
of the holder of the Award that is the subject of any such Program or Award Agreement are not materially adversely affected by such amendment,
unless the consent of the Participant is obtained or such amendment is otherwise permitted under Section 9.5, Section 11.2, Section 11.7,
or Section 11.10 hereof. Without limiting the generality of the foregoing, the Administrator shall have the power to reduce the exercise
price of an Option granted pursuant to the Plan (either directly or pursuant to the cancellation of the Option and the regrant of an
Option) to an exercise price equal to the Fair Market Value of a Share at the time of the exercise price reduction or Option regrant.
Any such interpretations and rules with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of
the Code. In its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee
in its capacity as the Administrator under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3
<U>Action by the Committee</U>. Unless otherwise established by the Board or in the Organizational Documents or as required by Applicable
Law, a majority of the Administrator shall constitute a quorum and the acts of a majority of the members present at any meeting at which
a quorum is present, and acts approved in writing by a majority of the members of the Administrator in lieu of a meeting, shall be deemed
the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other information
furnished to that member by any officer or other employee of the Company or any Subsidiary, the Company&rsquo;s independent certified
public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration
of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
<U>Authority of Administrator</U>. Subject to any specific designation in the Plan and Applicable Law, the Administrator has the exclusive
power, authority and sole discretion to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designate Eligible Individuals to receive Awards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Determine the type or types of Awards to be granted to each Eligible Individual;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Determine the number of Awards to be granted and the number of Shares to which an Award will relate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the exercise price, grant
price, or purchase price, any specific performance criteria, any restrictions or limitations on the Award, any schedule for vesting,
lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, and any provisions
related to non-competition and recapture of gain on an Award, based in each case on such considerations as the Administrator in its sole
discretion determines;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Determine whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an Award may be
paid in cash, Shares, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Prescribe the form of each Award Agreement, which need not be identical for each Participant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Decide all other matters that must be determined in connection with an Award;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Establish, adopt, or revise any Programs, rules and regulations as it may deem necessary or advisable to administer the Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Interpret the terms of, and any matter arising pursuant to, the Plan, any Program or any Award Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Make all other decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or advisable
to administer the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5
<U>Decisions Binding</U>. The Administrator&rsquo;s interpretation of the Plan, any Awards granted pursuant to the Plan, any Program,
any Award Agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive
on all parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6
<U>Delegation of Authority</U>. To the extent permitted by Applicable Law, the Board or Committee may from time to time delegate to a
committee of one or more members of the Board or one or more officers of the Company the authority to grant or amend Awards or to take
other administrative actions pursuant to this Article 10; <U>provided</U>, <U>however</U>, that in no event shall an officer of the Company
be delegated the authority to grant Awards to, or amend Awards held by, officers of the Company (or Directors) to whom authority to grant
or amend Awards has been delegated hereunder; <U>provided</U>, <U>further</U>, that any delegation of administrative authority shall
only be permitted to the extent it is permissible under the Organizational Documents, and other Applicable Law. Any delegation hereunder
shall be subject to the restrictions and limits that the Board or Committee specifies at the time of such delegation or that are otherwise
included in the applicable Organizational Documents, and the Board or Committee, as applicable, may at any time rescind the authority
so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 10.6 shall serve in such capacity at
the pleasure of the Board or the Committee, as applicable, and the Board or the Committee may abolish any committee at any time and re-vest
in itself any previously delegated authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
11<BR>
<BR>
MISCELLANEOUS PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1
<U>Amendment, Suspension or Termination of the Plan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as otherwise provided in this Section 11.1, the Plan may be wholly or partially amended or otherwise modified, suspended or terminated
at any time or from time to time by the Board; provided that, except as provided in Section 9.5, Section 11.2, Section 11.7, or Section
11.10 hereof, no amendment, suspension or termination of the Plan shall, without the consent of the Participant, impair any rights or
obligations under any Award theretofore granted or awarded, unless the Award itself otherwise expressly so provides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No Awards may be granted or awarded during any period of suspension or after termination of the Plan, and notwithstanding anything herein
to the contrary, in no event may any Award be granted under the Plan after the tenth (10<SUP>th</SUP>) anniversary of the date on which
the Plan was adopted by the Board (the &ldquo;<U>Expiration Date</U>&rdquo;). Any Awards that are outstanding on the Expiration Date
shall remain in force according to the terms of the Plan, the applicable Program and the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
A Participant shall not have the right to a change in the exercise price of an Option, an increase in the exercise period for exercise
of an Option, or a change to the number of securities received on exercise of an Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2
<U>Changes in Common Stock or Assets of the Company, Acquisition or Liquidation of the Company and Other Corporate Events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other
than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Company&rsquo;s stock
or the share price of the Company&rsquo;s stock other than an Equity Restructuring, the Administrator may make equitable adjustments,
if any, to reflect such change with respect to (i) the aggregate number and kind of shares that may be issued under the Plan; (ii) the
number and kind of Shares (or other securities or property) subject to outstanding Awards; (iii) the terms and conditions of any outstanding
Awards (including, without limitation, any applicable performance targets or criteria with respect thereto); and/or (iv) the grant or
exercise price per share for any outstanding Awards under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event of any transaction or event described in Section 11.2(a) hereof or any unusual or nonrecurring transactions or events affecting
the Company, any Subsidiary, or the financial statements of the Company or any Subsidiary, or of changes in Applicable Law or Applicable
Accounting Standards, the Administrator, in its sole discretion, and on such terms and conditions as it deems appropriate, either by
the terms of the Award or by action taken prior to the occurrence of such transaction or event, is hereby authorized to take any one
or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent dilution or
enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Award under the
Plan, to facilitate such transactions or events or to give effect to such changes in Applicable Law or Applicable Accounting Standards:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To provide for the termination of any such Award in exchange for an amount of cash and/or other property, if any, equal to the amount
that would have been attained upon the exercise of such Award or realization of the Participant&rsquo;s rights (and, for the avoidance
of doubt, if as of the date of the occurrence of the transaction or event described in this Section 11.2, the Administrator determines
in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&rsquo;s rights,
then such Award may be terminated by the Company without payment);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted
for by similar options, rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof,
with appropriate adjustments as to the number and kind of shares and applicable exercise or purchase price;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To make adjustments in the number and type of securities subject to outstanding Awards and Awards which may be granted in the future
and/or in the terms, conditions and criteria included in such Awards (including the grant or exercise price, as applicable);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
To provide that such Award shall be exercisable or payable or fully vested with respect to all securities covered thereby, notwithstanding
anything to the contrary in the Plan or an applicable Program or Award Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
To replace such Award with other rights or property selected by the Administrator in its sole discretion; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
To provide that the Award cannot vest, be exercised or become payable after such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the contrary in Sections 11.2(a) and 11.2(b)
hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The number and type of securities subject to each outstanding Award and the exercise price or grant price thereof, if applicable, shall
be equitably adjusted; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Administrator shall make such equitable adjustments, if any, as the Administrator in its discretion may deem appropriate to reflect
such Equity Restructuring with respect to the aggregate number and kind of shares that may be issued under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adjustments provided under this Section 11.2(c) shall be nondiscretionary and shall be final and binding on the affected Participant
and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except as may otherwise be provided in any applicable Award Agreement or other written agreement entered into between the Company (or
a Subsidiary) and a Participant, if a Change in Control occurs and a Participant&rsquo;s outstanding Awards are not continued, converted,
assumed, or replaced by the surviving or successor entity in such Change in Control, then, immediately prior to the Change in Control,
such outstanding Awards, to the extent not continued, converted, assumed, or replaced, shall become fully vested and, as applicable,
exercisable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse. Upon, or in anticipation of, a Change
in Control, the Administrator may cause any and all Awards outstanding hereunder to terminate at a specific time in the future, including
but not limited to the date of such Change in Control, and shall give each Participant the right to exercise such Awards during a period
of time as the Administrator, in its sole and absolute discretion, shall determine. For the avoidance of doubt, if the value of an Award
that is terminated in connection with this Section 11.2(d) is zero or negative at the time of such Change in Control, such Award shall
be terminated upon the Change in Control without payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Administrator may, in its sole discretion, include such further provisions and limitations in any Award, agreement or certificate,
as it may deem equitable and in the best interests of the Company that are not inconsistent with the provisions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Unless otherwise determined by the Administrator, no adjustment or action described in this Section 11.2 or in any other provision of
the Plan shall be authorized to the extent it would (i) cause the Plan to violate Section 422(b)(1) of the Code or (ii) cause an Award
to fail to be exempt from or fail to comply with Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The existence of the Plan, any Program, any Award Agreement and/or any Award granted hereunder shall not affect or restrict in any way
the right or power of the Company or the stockholders of the Company or any Subsidiary to make or authorize any adjustment, recapitalization,
reorganization or other change in the Company&rsquo;s or such Subsidiary&rsquo;s capital structure or its business, any merger or consolidation
of the Company or any Subsidiary, any issue of stock or of options, warrants or rights to purchase stock or of bonds, debentures, preferred
or prior preference stocks whose rights are superior to or affect the Common Stock, the securities of any Subsidiary, or the rights thereof
or which are convertible into or exchangeable for Common Stock or securities of any Subsidiary, or any sale or transfer of all or any
part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution
(other than normal cash dividends) of Company assets to stockholders, or any other change affecting the Shares or the share price of
the Common Stock including any Equity Restructuring, for reasons of administrative convenience, the Company in its sole discretion may
refuse to permit the exercise of any Award during a period of thirty (30) days prior to the consummation of any such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3
<U>Approval of Plan by Stockholders</U>. The Plan shall be submitted for the approval of the Company&rsquo;s stockholders within twelve
(12) months after the date of the Board&rsquo;s initial adoption of the Plan. Awards may be granted or awarded prior to such stockholder
approval; and, <U>provided</U> that if such approval has not been obtained at the end of said 12-month period, no Options previously
granted or awarded under the Plan shall qualify as Incentive Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4
<U>No Stockholders Rights</U>. Except as otherwise provided herein or in an applicable Program or Award Agreement, a Participant shall
have none of the rights of a stockholder with respect to Shares covered by any Award until the Participant becomes the record owner of
such Shares, including the right to participate in any new issues of stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5
<U>Paperless Administration</U>. In the event that the Company establishes, for itself or using the services of a third party, an automated
system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response,
then the paperless documentation, granting or exercise of Awards by a Participant may be permitted through the use of such an automated
system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6
<U>Effect of Plan upon Other Compensation Plans</U>. The adoption of the Plan shall not affect any other compensation or incentive plans
in effect for the Company or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company or any Subsidiary:
(a) to establish any other forms of incentives or compensation for Employees, Directors or Consultants of the Company or any Subsidiary
or (b) to grant or assume options or other rights or awards otherwise than under the Plan in connection with any proper corporate purpose
including without limitation, the grant or assumption of options in connection with the acquisition by purchase, lease, merger, consolidation
or otherwise, of the business, stock or assets of any corporation, partnership, limited liability company, firm or association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7
<U>Compliance with Laws</U>. The Plan, the granting and vesting of Awards under the Plan, the issuance and delivery of Shares and the
payment of money under the Plan or under Awards granted or awarded hereunder are subject to compliance with all Applicable Law and to
such approvals by any listing, regulatory or governmental authority as may, in the opinion of counsel for the Company, be necessary or
advisable in connection therewith. Any securities delivered under the Plan shall be subject to such restrictions, and the person acquiring
such securities shall, if requested by the Company, provide such assurances and representations to the Company as the Company may deem
necessary or desirable to assure compliance with all Applicable Law. The Administrator, in its sole discretion, may take whatever actions
it deems necessary or appropriate to effect compliance with Applicable Law, including, without limitation, placing legends on share certificates
and issuing stop-transfer notices to agents and registrars. Notwithstanding anything to the contrary herein, the Administrator may not
take any actions hereunder, and no Awards shall be granted, that would violate Applicable Law. To the extent permitted by Applicable
Law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8
<U>Titles and Headings, References to Sections of the Code or Exchange Act</U>. The titles and headings of the sections in the Plan are
for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall
control. References to sections of the Code or the Exchange Act shall include any amendment or successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9
<U>Governing Law</U>. The Plan and any Programs or Award Agreements hereunder shall be administered, interpreted and enforced under the
internal laws of the State of Delaware without regard to conflicts of laws thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10
<U>Section 409A</U>. To the extent that the Administrator determines that any Award granted under the Plan is subject to Section 409A
of the Code, the Plan, any applicable Program and the Award Agreement covering such Award shall be interpreted in accordance with Section
409A of the Code. Notwithstanding any provision of the Plan to the contrary, in the event that, following the Effective Date, the Administrator
determines that any Award may be subject to Section 409A of the Code, the Administrator may adopt such amendments to the Plan, any applicable
Program and the Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive
effect), or take any other actions, that the Administrator determines are necessary or appropriate to avoid the imposition of taxes on
the Award under Section 409A of the Code, either through compliance with the requirements of Section 409A of the Code or with an available
exemption therefrom. The Company makes no representations or warranties as to the tax treatment of any Award under Section 409A of the
Code or otherwise. The Company shall have no obligation under this Section 11.10 or otherwise to take any action (whether or not described
herein) to avoid the imposition of taxes, penalties or interest under Section 409A of the Code with respect to any Award and shall have
no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute
non-compliant, &ldquo;nonqualified deferred compensation&rdquo; subject to the imposition of taxes, penalties and/or interest under Section
409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11
<U>No Rights to Awards</U>. No Eligible Individual or other person shall have any claim to be granted any Award pursuant to the Plan,
and neither the Company nor the Administrator is obligated to treat Eligible Individuals, Participants or any other persons uniformly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12
<U>Unfunded Status of Awards</U>. The Plan is intended to be an &ldquo;unfunded&rdquo; plan for incentive compensation. With respect
to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Program or Award Agreement shall
give the Participant any rights that are greater than those of a general creditor of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13
<U>Indemnification</U>. To the extent allowable pursuant to Applicable Law and the Organizational Documents, each member of the Board
and any officer or other employee to whom authority to administer any component of the Plan is delegated shall be indemnified and held
harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in
connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may
be involved by reason of any action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her
in satisfaction of judgment in such action, suit, or proceeding against him or her; <U>provided</U>, <U>however</U>, that he or she gives
the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on
his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which
such persons may be entitled pursuant to the Organizational Documents, as a matter of law, or otherwise, or any power that the Company
may have to indemnify them or hold them harmless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.14
<U>Relationship to other Benefits</U>. No payment pursuant to the Plan shall be taken into account in determining any benefits under
any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except
to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.15
<U>Expenses</U>. The expenses of administering the Plan shall be borne by the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>4
<FILENAME>ex10-28.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.28</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Lance Alstodt (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>: </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,762</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <B>Grant
of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. <B>Grant;
Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the number
of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be an Incentive Stock Option within the meaning of Section 422 of the Code, although the Company makes no representation or
guarantee that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. <B>Consideration;
Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant to the
Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with the
remainder vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment
vesting on the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Participant&rsquo;s involuntary Termination of Service by the Company without Cause, 100% of the Shares subject to the
Option shall become immediately vested and exercisable. Upon the Participant&rsquo;s Termination of Service for any other reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <B>Expiration</B>.
The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan. The Expiration
Date shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder, not
more than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this
paragraph shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
The Option shall not be subject to Section 9.6(a) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than
Cause, death or Disability, the Participant may exercise the vested portion of the Option at any time until the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <B>Termination
for Cause</B>. If the Participant has a Termination of Service for Cause, the Participant may exercise the vested portion of the
Option, but only within such period of time ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s
Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the
Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the
date 24 months following the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion
of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the
time period ending on the earlier of: (a) the date 24 months following the Participant&rsquo;s Termination of Service, or (b) the
Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or
incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an
executed stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise
Agreement</B>&rdquo;), which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may
be required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on
the date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of
attestation whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation
equal to the Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of
Shares thereby purchased and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock
Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the
aggregate Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company
to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy
any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as
a result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the
maximum amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company
shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or
the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the
appropriate legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other
appropriate means as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the
Participant any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the
Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or
service with the Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect
to any Shares of Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the
Company to the holder of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized
transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the
limited conditions set forth in Section 9.3(b) of the Plan.. No assignment or transfer of the Option, or the rights represented
thereby, whether voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will
or the laws of descent or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any
interest or right herein whatsoever, but immediately upon such assignment or transfer the Option will terminate and become of no
further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control
prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with
respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and
exercisability shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in
Control with respect to the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash-Out</B>.
In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance notice to
the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common Stock
received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of a
Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social
insurance, payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all
Tax-Related Items is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings
regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent
sale of any Shares acquired on exercise; and (b) does not commit to structure the Option to reduce or eliminate the
Participant&rsquo;s liability for Tax-Related Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Qualification as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock
option as defined in Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands
that in order to obtain the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which
incentive stock option treatment is desired within one (1) year following the date of exercise of the Option or within two (2) years
from the Grant Date. The Participant understands and agrees that the Company shall not be liable or responsible for any additional
tax liability the Participant incurs in the event that the Internal Revenue Service for any reason determines that this Option does
not qualify as an incentive stock option within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Disqualifying Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2)
years from the Grant Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of
the Option (a &ldquo;<B>Disqualifying Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty
(30) days after such disposition of the date and terms of such disposition. The Participant also agrees to provide the Company with
any information concerning any such dispositions as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to
compliance by the Company and the Participant with all applicable requirements of federal and state securities laws and with all
applicable requirements of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common
Stock shall be issued pursuant to this Option unless and until any then applicable requirements of state or federal laws and
regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands
that the Company is under no obligation to register the Shares with the Securities and Exchange Commission, any state securities
commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the
Secretary of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant
under this Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records
of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without
regard to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company
to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and
provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a
conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of
the Plan will govern and prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the
Plan is not approved by the Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this
Agreement will be deemed to be outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this
Agreement will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the
person(s) to whom this Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or
enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be
severable and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time,
in its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any
Options or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment,
modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the
Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or
retroactively; provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement
without the Participant&rsquo;s consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected
compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile
transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the
original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document
bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and
understands the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this
Agreement. The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the
underlying Shares and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 5.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>5
<FILENAME>ex10-29.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.29</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Francisco Silva (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>: </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,762</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <B>Grant
of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the
number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be an Incentive Stock Option within the meaning of Section 422 of the Code, although the Company makes no representation or guarantee
that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. <B>Consideration;
Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant to the
Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with the
remainder vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment
vesting on the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Participant&rsquo;s involuntary Termination of Service by the Company without Cause, 100% of the Shares subject to the
Option shall become immediately vested and exercisable. Upon the Participant&rsquo;s Termination of Service for any other reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <B>Expiration</B>.
The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan. The Expiration
Date shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder, not
more than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this
paragraph shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
The Option shall not be subject to Section 9.6(a) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than
Cause, death or Disability, the Participant may exercise the vested portion of the Option at any time until the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <B>Termination
for Cause</B>. If the Participant has a Termination of Service for Cause, the Participant may exercise the vested portion of the
Option, but only within such period of time ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s
Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the
Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the
date 24 months following the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion
of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the
time period ending on the earlier of: (a) the date 24 months following the Participant&rsquo;s Termination of Service, or (b) the
Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or
incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an
executed stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise
Agreement</B>&rdquo;), which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may
be required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on
the date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of
attestation whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation
equal to the Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of
Shares thereby purchased and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock
Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the
aggregate Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company
to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy
any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as
a result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the
maximum amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company
shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or
the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the
appropriate legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other
appropriate means as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the
Participant any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the
Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or
service with the Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect
to any Shares of Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the
Company to the holder of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized
transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the
limited conditions set forth in Section 9.3(b) of the Plan.. No assignment or transfer of the Option, or the rights represented
thereby, whether voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will
or the laws of descent or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any
interest or right herein whatsoever, but immediately upon such assignment or transfer the Option will terminate and become of no
further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control
prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with
respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and
exercisability shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in
Control with respect to the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash-Out</B>.
In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance notice to
the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common Stock
received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of a
Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social
insurance, payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all
Tax-Related Items is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings
regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent
sale of any Shares acquired on exercise; and (b) does not commit to structure the Option to reduce or eliminate the
Participant&rsquo;s liability for Tax-Related Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Qualification as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock
option as defined in Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands
that in order to obtain the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which
incentive stock option treatment is desired within one (1) year following the date of exercise of the Option or within two (2) years
from the Grant Date. The Participant understands and agrees that the Company shall not be liable or responsible for any additional
tax liability the Participant incurs in the event that the Internal Revenue Service for any reason determines that this Option does
not qualify as an incentive stock option within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Disqualifying Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2)
years from the Grant Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of
the Option (a &ldquo;<B>Disqualifying Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty
(30) days after such disposition of the date and terms of such disposition. The Participant also agrees to provide the Company with
any information concerning any such dispositions as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to
compliance by the Company and the Participant with all applicable requirements of federal and state securities laws and with all
applicable requirements of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common
Stock shall be issued pursuant to this Option unless and until any then applicable requirements of state or federal laws and
regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands
that the Company is under no obligation to register the Shares with the Securities and Exchange Commission, any state securities
commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the
Secretary of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant
under this Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records
of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without
regard to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company
to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and
provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a
conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of
the Plan will govern and prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the
Plan is not approved by the Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this
Agreement will be deemed to be outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this
Agreement will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the
person(s) to whom this Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or
enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be
severable and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time,
in its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any
Options or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment,
modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the
Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or
retroactively; provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement
without the Participant&rsquo;s consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected
compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile
transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the
original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document
bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and
understands the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this
Agreement. The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the
underlying Shares and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco Silva</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: NewSection Last; Value: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>6
<FILENAME>ex10-30.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.30</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Robert Kristal (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>: </FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88,968</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the
number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be an Incentive Stock Option within the meaning of Section 422 of the Code, although the Company makes no representation or guarantee
that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant
to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<B>Vesting Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with
the remainder vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment
vesting on the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Participant&rsquo;s Termination of Service for any reason, the unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.
The Expiration Date shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder,
not more than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this
paragraph shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<B>Termination for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other
than Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time ending
on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<B>Termination due to Disability</B>. If the Participant has a Termination of Service as</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
result of the Participant&rsquo;s Disability, the Participant may exercise the vested portion of the Option, but only within such period
of time ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<B>Termination due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested
portion of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time
period ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<B>Election to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death
or incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;),
which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be
required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<B>Payment of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the
date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the </FONT>Participant must make arrangements satisfactory to the
Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may
satisfy any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a
result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum
amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<B>Issuance of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the
Company shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee,
or the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate
legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means
as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this
Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the
Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of
Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder
of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned
by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited
conditions set forth in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether
voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent
or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever,
but immediately upon such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<B>Acceleration of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change
in Control prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable
with respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability
shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to
the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<B>Cash Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common
Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of
a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Qualification as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock option
as defined in Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in
order to obtain the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which incentive stock
option treatment is desired within one (1) year following the date of exercise of the Option or within two (2) years from the Grant Date.
The Participant understands and agrees that the Company shall not be liable or responsible for any additional tax liability the Participant
incurs in the event that the Internal Revenue Service for any reason determines that this Option does not qualify as an incentive stock
option within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Disqualifying Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2) years
from the Grant Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of the Option
(a &ldquo;<B>Disqualifying Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty (30) days after
such disposition of the date and terms of such disposition. The Participant also agrees to provide the Company with any information concerning
any such dispositions as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary
of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company.
Either party may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard
to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to
the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the Plan is not approved by the
Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this Agreement will be deemed to be
outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure
to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this
Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or
enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable
and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in
its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options
or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or
termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment
with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by
electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands
the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The
Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares
and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>7
<FILENAME>ex10-31.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.31</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Robert Paccasassi (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>: </FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88,968</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the
number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be an Incentive Stock Option within the meaning of Section 422 of the Code, although the Company makes no representation or guarantee
that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant
to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<B>Vesting Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with
the remainder vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment
vesting on the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Participant&rsquo;s Termination of Service for any reason, the unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.
The Expiration Date shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder,
not more than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this
paragraph shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<B>Termination for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other
than Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time ending
on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as </FONT>a result of the Participant&rsquo;s Disability, the
Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the
date 12 months following the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<B>Termination due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested
portion of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time
period ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<B>Election to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death
or incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;),
which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be
required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<B>Payment of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the
date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<B>Withholding</B>. Prior to the issuance of Shares upon the exercise of the Option, the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant
must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations
of the Company. The Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise of the Option
by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a
result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum
amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<B>Issuance of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the
Company shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee,
or the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate
legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means
as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this
Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the
Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of
Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder
of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned
by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited
conditions set forth in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether
voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent
or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever,
but immediately upon such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<B>Acceleration of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change
in Control prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable
with respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability
shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to
the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<B>Cash Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common
Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of
a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Qualification as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock option
as defined in Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in
order to obtain the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which incentive stock
option treatment is desired within one (1) year following the date of exercise of the Option or within two (2) years from the Grant Date.
The Participant understands and agrees that the Company shall not be liable or responsible for any additional tax liability the Participant
incurs in the event that the Internal Revenue Service for any reason determines that this Option does not qualify as an incentive stock
option within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Disqualifying Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2) years
from the Grant Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of the Option
(a &ldquo;<B>Disqualifying Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty (30) days after
such disposition of the date and terms of such disposition. The Participant also agrees to provide the Company with any information concerning
any such dispositions as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary
of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company.
Either party may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard
to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to
the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the Plan is not approved by the
Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this Agreement will be deemed to be
outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure
to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this
Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or
enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable
and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in
its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options
or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or
termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment
with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by
electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands
the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The
Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares
and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 0pt 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Paccasassi</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>8
<FILENAME>ex10-32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Non-Qualified Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by
and between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Nickolay Kukekov (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,028</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the
number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be a Non-Qualified Stock Option and <I>not </I>an Incentive Stock Option within the meaning of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant
to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<B>Vesting Schedule</B>. The Option will become vested and exercisable in twelve equal monthly installments (at a rate of 1/12 per month)
with the first installment vesting on the one-month anniversary of the Grant Date and continuing every month thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Participant&rsquo;s Termination of Service for any reason, the unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<B>Termination for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other
than Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time ending
on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<B>Termination due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability,
the Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the
date 12 months following the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<B>Termination due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested
portion of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time
period ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<B>Election to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death
or incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;),
which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be
required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<B>Payment of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the
date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<B>Withholding</B>. Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory
to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant
may satisfy any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a
result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum
amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<B>Issuance of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the
Company shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee,
or the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate
legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means
as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this
Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the
Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of
Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder
of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned
by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited
conditions set forth in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether
voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent
or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever,
but immediately upon such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<B>Acceleration of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change
in Control prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable
with respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability
shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to
the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<B>Cash Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common
Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of
a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B>Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B>Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B>Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary
of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company.
Either party may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B>Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard
to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B>Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company
to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B>Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and
provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict
between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the Plan is not approved
by the Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this Agreement will be deemed
to be outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<B>Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this
Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<B>Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity
or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable
and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<B>Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time,
in its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options
or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or
termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment
with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<B>Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<B>No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<B>Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by
electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<B>Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and
understands the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this
Agreement. The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the
underlying Shares and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Non-Qualified Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay Kukekov</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>9
<FILENAME>ex10-33.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 10.33</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Non-Qualified Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by
and between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Patrick Williams (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,028</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the
number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be a Non-Qualified Stock Option and <I>not </I>an Incentive Stock Option within the meaning of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant
to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<B>Vesting Schedule</B>. The Option will become vested and exercisable in twelve equal monthly installments (at a rate of 1/12 per month)
with the first installment vesting on the one-month anniversary of the Grant Date and continuing every month thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Participant&rsquo;s Termination of Service for any reason, the unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<B>Termination for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other
than Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time ending
on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<B>Termination due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability,
the Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the
date 12 months following the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<B>Termination due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested
portion of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time
period ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<B>Election to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death
or incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;),
which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be
required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<B>Payment of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the
date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<B>Withholding</B>. Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory
to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant
may satisfy any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a
result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum
amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<B>Issuance of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the
Company shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee,
or the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate
legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means
as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this
Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the
Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of
Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder
of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned
by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited
conditions set forth in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether
voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent
or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever,
but immediately upon such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<B>Acceleration of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change
in Control prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable
with respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability
shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to
the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<B>Cash Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common
Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of
a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B>Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B>Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B>Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary
of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company.
Either party may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B>Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard
to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B>Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company
to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B>Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and
provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict
between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the Plan is not approved
by the Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this Agreement will be deemed
to be outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<B>Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this
Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<B>Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity
or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable
and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<B>Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time,
in its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options
or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or
termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment
with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<B>Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<B>No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<B>Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by
electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<B>Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and
understands the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this
Agreement. The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the
underlying Shares and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Non-Qualified Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Williams</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>10
<FILENAME>ex10-34.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.34</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Non-Qualified Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 17, 2023 by
and between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and David Rosa (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    Price per Share</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Option Shares</B>: </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,028</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B>:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    17, 2033</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the
number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be a Non-Qualified Stock Option and <I>not </I>an Incentive Stock Option within the meaning of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of the services to be rendered by the Participant
to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not otherwise defined herein have the
meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Exercise Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<B>Vesting Schedule</B>. The Option will become vested and exercisable in twelve equal monthly installments (at a rate of 1/12 per month)
with the first installment vesting on the one-month anniversary of the Grant Date and continuing every month thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Participant&rsquo;s Termination of Service for any reason, the unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Termination of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<B>Termination for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other
than Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time ending
on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<B>Termination due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability,
the Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the
date 12 months following the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<B>Termination due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested
portion of the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time
period ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Manner of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<B>Election to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death
or incapacity, the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;),
which shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
any representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be
required by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<B>Payment of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent
permitted by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
in cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
by delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the
date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
through a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
by reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
by any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
in any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<B>Withholding</B>. Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory
to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant
may satisfy any federal, state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
tendering a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
authorizing the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a
result of the exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum
amount of tax required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
delivering to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<B>Issuance of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the
Company shall issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee,
or the Participant&rsquo;s legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate
legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means
as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>No Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this
Agreement shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the
Company at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of
Common Stock subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder
of such Shares, or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned
by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Transferability</B>. The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited
conditions set forth in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether
voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent
or distribution or pursuant to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever,
but immediately upon such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Change in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<B>Acceleration of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change
in Control prior to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable
with respect to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability
shall occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to
the Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<B>Cash Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common
Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of
a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B>Adjustments</B>. The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Tax Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B>Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B>Notices</B>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary
of the Company at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company.
Either party may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B>Governing Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard
to conflict of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B>Interpretation</B>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company
to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B>Options Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and
provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict
between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail. Notwithstanding the foregoing or anything in this Agreement or the Plan to the contrary, if the Plan is not approved
by the Company&rsquo;s stockholders within 12 months of the Board&rsquo;s initial adoption of the Plan, this Agreement will be deemed
to be outside the Plan and will otherwise remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<B>Successors and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this
Agreement may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<B>Severability</B>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity
or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable
and enforceable to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<B>Discretionary Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time,
in its discretion. The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options
or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or
termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment
with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<B>Amendment</B>. The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<B>No Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<B>Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by
electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<B>Acceptance</B>. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and
understands the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this
Agreement. The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the
underlying Shares and that the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Non-Qualified Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Rosa</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
consent to the incorporation by reference in the Registration Statements of BioRestorative Therapies, Inc. on Forms S-8
(Nos. 333-255681, 333-196299, 333-203310, 333-210555, 333-214621, 333-228434 and 333-233309) and S-3 (Nos. 333-269631 and 333-265052)
of our report dated March 30, 2022, with respect to our audit of the consolidated financial statements of BioRestorative Therapies, Inc.
and Subsidiary as of December 31, 2021 and for the year ended December 31, 2021, which report is included in this Annual Report on Form
10-K of BioRestorative Therapies, Inc. for the year ended December 31, 2022. We were dismissed as auditors on September
13, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements incorporated
by reference for the periods after the date of our dismissal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Friedman LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Friedman
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlton,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>12
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statement of BioRestorative Therapies, Inc. on Forms S-3
(Nos. <FONT STYLE="background-color: white">333-269631, and 333-265052</FONT>) and S-8 (Nos. 333-255681, <FONT STYLE="background-color: white">333-196299,
333-203310, 333-210555, 333-214621, 333-228434 and 333-233309</FONT>), of our report dated March 24, 2023, with respect to our audit
of the consolidated financial statements of BioRestorative Therapies, Inc. and Subsidiary as of December 31, 2022 and for the year ended
December 31, 2022, which report is included in this Annual Report on Form 10-K of BioRestorative Therapies, Inc. for the
year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlton,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
24, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>13
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
31.1</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Lance Alstodt, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of BioRestorative Therapies, Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify; width: 49%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 49%"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
  Alstodt</FONT></I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: justify">Date:
                                 March 24, 2023</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Principal Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>14
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
31.2</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert Kristal, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of BioRestorative Therapies, Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify; width: 49%">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 49%"><I>/s/ Robert Kristal</I></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: justify">Date:
March 24, 2023</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Robert
Kristal</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Principal
Financial Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>15
<FILENAME>ex-32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND PRINCIPAL FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF</B> <B>THE</B> <B>SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, the undersigned officers of BioRestorative Therapies, Inc. (the &ldquo;Company&rdquo;) hereby certify that
the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with the
requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="vertical-align: bottom; text-align: left; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 49%"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></I></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Date:
March 24, 2023</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Alstodt</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="vertical-align: bottom; text-align: left; width: 49%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 49%"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></I></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
Kristal</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished solely pursuant to 18 U.S.C. &sect; 1350 and is not being filed as part of the Report or as
a separate disclosure document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND PRINCIPAL FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF</B> <B>THE</B> <B>SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, the undersigned officers of BioRestorative Therapies, Inc. (the &ldquo;Company&rdquo;) hereby certify that
the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2022 (the &ldquo;Report&rdquo;) fully complies with the
requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="vertical-align: bottom; text-align: left; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 49%"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></I></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Date:
March 24, 2023</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Alstodt</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="vertical-align: bottom; text-align: left; width: 49%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 49%"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></I></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
Kristal</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished solely pursuant to 18 U.S.C. &sect; 1350 and is not being filed as part of the Report or as
a separate disclosure document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %( D # 2(  A$! Q$!_\0
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M  4Z^,W.8/#./^P:W_Q==+^W=_R3GP]_V%O_ &D]?%$$9FN(8A@-)(J9/;)
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MM_\ %U\XS> ;R/7?$>E":*:XT6&2=]@.)]K*NU.^27'!J36O!^E^'9IK&_\
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M_P"+H_X>=_&3_GAX9_\ !:W_ ,77R311_9N$_P"?0?6JW\Q];?\ #SOXR?\
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MX74UK96KPS-9::EG)IL!EP+:ZMT"%CC[T<B[@4/3((YJ]_PQU\<O^B5>)/\
MP&_^O1_PQU\<O^B5>)/_  &_^O3]KA_YE]Z$HUE]DYH>+O#VAS:I?Z!9:A#J
M.HH\+1W<D9ALXY'#2>65&9"0-HSC -3ZMXZT6/6/$6KZ-97RZIK F3_B8/'Y
M5JDO^LVA!\S$?*"> #FM[_ACKXY?]$J\2?\ @-_]>E_X8[^.7_1*_$G_ ("_
M_7H]IAW]M?>AVK?RF#??$32TN-;UK3;.[@\1ZQ"D4XE=3:VS95G>,8RVYD!
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M4?YU]Z#V%7L>/X]Z,>]>P?\ #'7QQ_Z)5XD_\!?_ *]'_#'7QQ_Z)5XD_P#
M7_Z]'UJC_.OO0>PJ]CQ_'O1CWKV#_ACKXX_]$J\2?^ O_P!>C_ACKXX_]$J\
M2?\ @+_]>CZU1_G7WH/85>QX_CWHQ[U[!_PQW\<?^B5>)/\ P%_^O1_PQU\<
M?^B5>)/_  %_^O1]:H_SK[T'L*O8\?Q[T8]Z]@_X8Z^./_1*O$G_ ("__7H_
MX8[^./\ T2KQ)_X"_P#UZ/K5'^=?>@]A5['C^/>C'O7L'_#'7QQ_Z)5XD_\
M 7_Z]'_#'?QQ_P"B5>)/_ 7_ .O1]:H_SK[T'L*O8\?Q[T8]Z]@_X8Z^./\
MT2KQ)_X"_P#UZ/\ ACKXX_\ 1*O$G_@+_P#7H^M4?YU]Z#V%7L>/X]Z,>]>P
M?\,=_''_ *)5XD_\!?\ Z]'_  QU\<?^B5>)/_ 7_P"O1]:H_P Z^]!["KV/
M'\>]&/>O8/\ ACKXX_\ 1*O$G_@+_P#7H_X8[^./_1*O$G_@+_\ 7H^M4?YU
M]Z#V%7L>/X]Z,>]>P?\ #'7QQ_Z)5XD_\!?_ *]'_#'?QQ_Z)5XD_P# 7_Z]
M'UJC_.OO0>PJ]CQ_'O1CWKV#_ACOXX_]$J\2?^ O_P!>C_ACKXX_]$J\2?\
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M60,2 >1UI<T ,VMZ_K1M;U_6G>8O'.,\<TNX9Q0 S:WK^M&UO7]:<6 I=PH
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M/@SMPU,"W8V:VL2C'S5;I.>_-+0 4444 %%%% !1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !5+6O\ D$WG_7)OY5=JEK7_ "";S_KDW\J
M+M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 C52U348=+T^>[G;;#"I=C]*NMTKR_P"-FN-:Z5:Z7$Q5
MKM]TG&<(OK[9KSL?B%A</*KU6Q45=GEVMS:EXIN[S79+::2W9B#*JY6-1T ^
M@Z]JHOH]_'8K?-9S16C<I<$?)['-=9IE]:K::7?/>10V-EITMK=6IDP_F'</
ME3ODD'\*IZJR7'AO??K8K<)%#'9&RN"Y<#JKITZ?K7Y0X14OK,9^^_>^9OO[
MIV'PG\;><O\ 9UX1YH.WKW[$5V7BWQI#X>7R8AY]ZPRJ9X'N:^<6O+O2]U]I
M^TWT(+1AVP&/]TG^5=S\/-'UKXAZ7%J-[%):I(QWW%RI#28[JI[?6OH,5GV+
MQ6&C1P,.:K+>W0[L)AZ/,YUI>ZN@W4M4N=6N&GNYS,Y/ ;H/8"FVNG75XW^C
M6DTYQT6,_P Z]=T?P#I.EJC-#]KG'_+6;G\A71PPK'\J*JKCH!BO#P_ ^)Q$
MO;8ZM:3WMJSU)YU"FN7#PT1XE'X+UR10W]G2C/9B!_6DD\&ZW%RVG2$?[)!-
M>YJ@[4>6,Y[U[/\ J'@>6SJRO\O\CE_MO$?RH^>KJQNK$@7-M- 3_P ]$.*9
M;S/;7230N5DCY!';_P#77T'-;K)PRAE]&&0:Y?6OAYI.HJ6CB^R39XDAXY]Q
M7@8S@:OATZN!J\S71H[:6>*I[E>&AY8VL74EW%<EU\R(%8_D&U ?08JEJFJL
MS/<2CS+B0X55&/,8UM>+/#%SX0MY[R[D5M.A0R2WB](U R2P[8'/H:X/X7_$
M;PUXPUK[7J$\VGV\;E;<7,?[MES\K;AT)]#7A9;DV*Q&.>&Q[<(WYG?JUHDO
M(]*I43H.M@H\S\NGJ>L?#7P.^#J%^-TDAW'(_0>U>JQQA5PHP.PJGILD$EI$
MUM)&\)7Y3&P(Q[8JYN 7K7]!4X0ITU&"M%'P$I2E*\]R2BBBM1!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6O^
M03>?]<F_E5VJ6M?\@F\_ZY-_*@"[1110 4444 %%%% !1110 4444 %%%% !
M1368K^->5_$[XKZ[X#U:[BM=(LKZQ@TN;4Q(UPPE81LJE @'))88H ]6HKRF
MX_:&\.6(M1>+?VLEQ,]LT;6I9[>5#@K( ?E)Z@]/>J5U^TEX;:1)+&XEN;6)
MIQ<J+5VD_=G:%CQP2S8(SP5.10!['17F-G\>M"OKZWM(;;56EDNH[*X_T(_Z
M!-)(8HTGY^4EU/X8J37_ (X:'X=\27.@W2WTVJQ^6L<%I;>;YS.P0*A!P2"P
MR#C&>: /2J*\IL/CQ8Z]XA\.Z;HUE=7D.I7+6MS>2PF.*VD6)G,9/_/0;>5[
M?A4+?M!:?''=0S65S;WD+RQ&7RC);1L)9HXM[CD;V@?@#CB@#URBO)M+_:*\
M-:M)'9VLEU?:H^V.*"SMBWVF0XWB+/9"<$MCI5?1_P!H"+4+^2"YT:_M9VEF
MMK;35AWW5Q)'*ZDH,[<;8V8@GC:: /8:*\Y\,_&[0/%VK0V.G&\99LB.]EMR
MENT@A69HMQ_C6-LD8_A8=JRM2^/5O<7NBV.A:==W=QJ5_#;I+<0%(C;,[*UR
MG.64%"![D=J /6Z*** "BBB@!K?=]*^=/BMJW]J>-+Q-V^*V58%!Z9')_4U]
M$SL$A9F^ZHR?PKY3U:Y^VZK>W&<^=<229]B>*^)XHJN-"%)/=F]+<J?Q;NC<
M<CMBCY02QPO.20/U^GK1C<<>N>^*Z;X+Z$GCK5I=:D7?X>T^7RX&QC[;..'.
M/^>:' ]SFO@<#@IX^M&E TDU%'8?#SX6I+'#JFM0[CC=!:-TQU#/[^E>M0J$
MQM&!@=.GT%1JN.W(X-3*.E?LN#P5+!4U"F<TFY/4>HZ\8J11313UKN2LM"0Z
M4M%%,!O\5(WTIVWG/>DVTK 5;BW2ZADBEB66)QM:-QE64]00>M?/OQ4^!T6C
M0RZKX:MMEDI,EQIZ#/E]RZ#T]ORKZ,VBHW@5PP*Y5NM<.+P=/&4^2INMGU/1
MR_'U\NK>UHO?==&?'?@OXB:QX+N4DT^=IK0G,EK*V5;Z9Z?A7TOX"^)&F>/+
M$O:MY5Y&N9;5S\R^_N/>O$?C?\.5\)ZP=5L(MNEWCX:-1Q%*>2!_LGK^=>?:
M3JUWH.HP:A87!@N8FW)(I(4CNI]O:OD*.,K976="L^:)^E8C*\)G^$6+PRY:
MGZ]F?<&[Y<TZN&^&WQ$@\?:.)0!;W\/RW%OGHW]X?[-=MNQFON*56-:"G#5,
M_*J]&>&J2I55:2W'T4C<*>U>4>,_C>W@_P =3Z-+IOVFPM+6"ZNIH&9ITCD\
MW+A,8VIY63SD[N*V,3UBBO+9OCYH$"H9H]2MDD80Q/):'$EQA2+<<_ZW#K\O
M?.,\54T']H72;S3]0GU>&ZT6:QOWLY;>> ED&^18RWH2(R3Z=* /7:*\@U#X
M])8ZU);7.D7VD:=#%:W$NH:E%M01S2,N-JY(;"\=O6K+_M%^&X9D@GMM6AN&
M42R0FS.^"$[-LTG.%1@ZD'TSZ4 >K45YOXP^-&F^%&U"W^S7E_<6<2LTEM#F
M'S7C,D4+.3P[J!C_ 'E]:P-4^.VI:%#X0:\T6,OK%@E_=#<R"W#/&I3D'&/,
M!RY XH ]GHKP33?VBM8USP_=:CI^AV$YM[ZWM7/VMMB^?)Y:J?ESO7(9N,;3
MP:ZGPQ\9UUCQ)K^A7]M#I5UX>98=4N99P84FE8&W6,]7#I\W^SD*><T >I45
MY!J7QJU:VU;6-)@\.JVHV-Z\$:R78V2P)!Y[2$@<,5! 7U(S5WX9_&;_ (6-
MJ$ 73S9Z??V;7VG3>9N>6-9"C!UQ\K C(P<8H ]2HIJY(YIU !1110 4444
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ME=/-D8+M<B3&Y=_\8'!SZ8KT/P7X;?PGH-GI3ZA+J2VJB*&6:-498U4!5PH
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M*** "BBB@ HHHH *I:U_R";S_KDW\JNU2UK_ )!-Y_UR;^5 %VBBB@ HHHH
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MT44 %%%% !1110 4444 %%%% !5+6O\ D$WG_7)OY5=JEK7_ "";S_KDW\J
M+M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[!>V5Q+9WUM*LT%Q"</&X.0P/\_:H4DW<K,LL>.PL:-56DE^)^H-O-M5>W'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN([@%C\S C:&R<;<$8KZ2CQDXS@<<T 24444 %(:6DH \E^-;>9:O&,EF0@
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MU<6@(NY%;&!&"#&I3.T,?O#/2I[F^^+&G:<UK(MY?!=/@NVU*&VB$PFE0+)
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M]RH8;L'"YYX."?SIZR%NG/KQC% $E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45P<0M
M4M17',9% '$:Y#ND7']X']:[I#E0?:N4O[<LW_ Q_.NK3A1]* '4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\
MOVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M
M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110
M?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PD
MNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PD
MNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/
M5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_
M +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A
M110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A
M1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%%
M!_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG
M_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\
MSU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[
M]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[
M]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^
M%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_
MPDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\]7_[]M_A110 ?\)+
MI_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\]7_[]M_A1_PDNG_\
M]7_[]M_A110 ?\)+I_\ SU?_ +]M_A1_PDNG_P#/5_\ OVW^%%% !_PDNG_\
>]7_[]M_A5;4_$%E<:?<QI(Q9HR /+8=OI110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $J D # 2(  A$! Q$!_\0
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M-_A2?\,CZ^V,:UI/M^Z;_"CV&&_Y^![2K_*?0?\ PM3PA_T,NF_^!"_XT?\
M"U/"'_0RZ9_X$+_C7SZ/V1=?_P"@SI)_[9/_ (4?\,C:_P!?[9TG'_7)_P#"
MG[##?\_&'M*O\I]!?\+4\(?]#+IO_@0O^-'_  M3PA_T,NF_^!"_XU\^_P##
M(NOGIK.D_P#?I_\ "D_X9%\08S_;6DX_ZXO_ (4O88;_ )^,/:5?Y3Z#_P"%
MJ>$/^AETW_P(7_&C_A:GA#_H9=-_\"%_QKY]_P"&1=?'!UG2<_\ 7)_\*/\
MAD?7L9&LZ3C_ *Y-_A1[##?\_&'M*O\ *?07_"U/"'_0RZ;_ .!"_P"-'_"U
M/"'_ $,NF_\ @0O^-?/O_#(?B \C6=)Q_P!<7_PH_P"&0_$/_09TK_OR_P#A
M1[##?\_ ]I5_E/H$_%;P@#C_ (233B3V%P#2'XK>#UD\MO$NFK)_<:X /Y5X
M1IO[*?B;2[ZWO(=7TDS6[[E#Q/M;ZXKJKCX0^+((UE>Z\+)Y49WS36;,3@EB
M22/3UI.CAUM,I5*K^R>F_P#"U_!P56_X273=K$@-YXP<=:6+XJ>$+B1(XO$N
MFN[':J_:!DD]J^?/!/AMO'2WFF^'?$OA/5_LD[S20QVL@:)G/S8]LUUMQ\!?
M%5];BWGNO#JP$!6DALV#@ CD<=?E'YU#IT;?$:7J1=IQL>H^%#_Q6GBPC_GM
M"?\ R&*[*N,\(KM\8>*E_NR0#\HEKM*X[)/1FIA>,H]4D\-ZDNBE5U=H&%J7
M(&),'')XSGUXKR76-!^(^OF"P(D72MT<YN)[F-9U(5<!B@^^&#'(X(KU;X@2
M:E%X*UQ](61M46SE-JL8RQDVG;C\<5Y6VL?$SPGI45M/$-4\N./?>"T,\H9]
M[;6"E=VW"H2/[^>U #;/3/BL;6STY;F6&%55I=0FFADG"Y4,O3EN'8''?%4_
M$'AOXJ:II=_937LDT,ETX MWB0^4"#&P<Y.T@'<N <XQ5O5/B9XYL]6M[%M$
M\BXGN/W42VKS1R*(XV,0<'@@LP9B,# QFKECXW^(-^I2]TA-*>5;DH8[-YO+
MF5#Y<+'( &<GS.AQB@"]XZL?%_B#4?#6L>'+>XTVZ6&:)XYI$41,Q7;YZ,#O
M3Y3G;SR*RM/TOXJ22B2;46@2.0ND,K1,7DW*#O*KS#C<54<\<TEMXS^(ECI\
M+KX=DU.>>%Y?,EA:+:R1QLX89.T.2P5?[RFM:Z\4>/E\(Z5>6NDVUSJ;I<37
M<:0.!\J@QH!D%68GW^Y[T 16>C_$:X\%"WGU&2WUY]0#22HL(9+?'S!#R,%@
M3SS@X[5FR:7\6X9+&VBN4G1?-:6^DFCRV8UP"@4<J^=I'&.M9D?Q7\:ZCXB&
MA&TMVNA:Q2F&W@=))79@206^[M3E@1]#DUKZ?XN^(VH:G;PQ64<276R)7FT]
MA!%MD8/,#NSM(V  \CDT 2WVA_$RUV?9M6FNHWG5 V^)2B!$VNW'*[O,W <G
MC%7/"]I\4_[8N_[7OK!+)58P.RAP[ [%4JI!!*+YGH"^.U9]Q\0_&6O?#635
MM-TI[2]N[V6T3R[9II($5'7S-@.3OD48/0 C-5H_&_C^/4(_-T>^BTRS&V1#
M8>9-<'R'^7.[&/,52&'7>!0!4TOP_P#%:QNI+H7,MN][,TTYF>&9_,$6U0>B
MB+=T &>1FM9M!^*.GW!73[^WF6:,">ZN/+WB5(0=V !G?+\GLJ@U->>.?B%8
M^"=#U*V\+?;]7N&E2^LO*8.A4DA\9P RK@#^\1ZU6;XA>/H;B?/AJ94C6 X-
MJP<EGQ*D>"0S!2IR?0T )HGAOXBWWBCPK/KD\TVG64IN)@7B0*2L@(D"Y+L"
M5"X.,'GD5CVGPQ\=)<1VUW=W0TJWOKB_0VVH'[0_G^8KQY;@*@*%.V6/I6Y\
M0/%'CR'5M2M-+TVX@M+5XGBN+>S,S^7\I:3((#[B64QKR N:I-X\^)-FA,NB
M37D]U=0M#;)8LL<-N5P^7W9W9^;D<=* *>D^#?&VF63RSV$PU..Q$6EW=O<H
MWV+;NW"2$MM,DF1DJ2,M["MSQEH?B76HY5?3KJ2_F\.QJD5K=;5BN_.0R+YI
MP,^_<*?6JUSXV^).GV>8O#ZS0_)$#+$[/#@H&D<_Q\,W '\-7?#WB;QO>>*M
M3N=3TVXAL+/2Y!':VMLPC><-&5968@.S L0,<#(H O\ A71M>T?Q)XBFN-.G
MDT[4D5SY]RGVA92I#"-@?]5P,?Q!F]*SH_#_ (XM_AKX3MM-^U:?K>G3-Y]O
M)=*P9 CA1*22'3<48X.:C\+>,OB'?6&O7E]I+QW4>GQRZ=8-9%0TP+*QSGJ1
M@[.U2#QS\0M)M[B34M 2\42;$^PVLF>LJ@XW<@[8S[!Z (=2\,^,=<\#VJ7:
M7=QKMOJ0N;6.66+&T ;1<E2%9,ECA>0,=:EU#P_XODT#QM86MC<6=YJ5\)K6
MX^V*P*[4\PQY/R!MK@#MFLJ?QCX\T&SU6_O;:XEMX0EU#!<6Q B4N_F9=?O
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MV>/SER1G:,8.!D#%8,?A;XEMK%M>SN)&QB6!9T$#,)(CN=<?>**XR.A(KW?
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MDR%PQ0\,N01Q6WX+^.@\5ZK9Z1)X=D<7,4D,5XTD86YGCA$IC*8X4@C!/&:
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M[^2]5CL:2Z))B$I!^2,$\XR.!Q5&.U^(R:>+NUEUHK&TB-9WC 2R?(/.8'/
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M-$DB-,V#M/S-P <XK1TGXW3>(%\4K;Z9]F&CV?G*YF#3/(.&7R^X!'WJI?\
M"^+S:L[^'XX@+=7F1KC,JRA%D<;<?<V,"K=R<5T7B?QAX,^%NJ0ZCJ%B+&;6
M%R;Z*W!W@L-^X]@-P9O09)H Y3Q-\?M8L=+O%@T%;&[DW&SN)Y"8]H+@%QC[
MY*'"]#D<UHV/Q[N[JXT^WD\.3PQWFH#3EF:49AXYDE0#*#([^JT^P^/^DW$=
MTEYI-W'<+-(;2W2-2;B%#DR#)^4JO)S^'6N@U3XN^&-+56?SG\^UAO$\N(9F
MCE4LAP>2?EY]* ,KQY\9E\&^,KG1DTC[?+%9K/(\,N)]I5R&V[3E%V'<3TW
MUBWOQ\U&*QA>VT6WCN)5#)++,S0R 3B-V0@9";<L&8 5)J7QZ\/:=JD%PFD3
M022$PZO<7$8$MJJI(RQGDEB3&>!QCDUJM\=O#5K9RW-SINI6UK"D8EDDM0 K
MON*Q?[3-M/ X/&.M #-8^,6KZ7X@U*TC\.FZAB,9MXO-*3F/R7DD=L C&4 7
M'7<.E8VJ?M%7]MH=C+;:$DFH7D,LD<$DS%1M!*.2H/RD*<CJ#VK>7]H#PS-*
M1:P:A=#RDE5H+;<&WL%B7.>K$\'IUJ72?C-HNH:;KNH)I5U#8Z.D+,VU-TK2
M_P (4="&!!SQD4 94_QVU&VNI)&\+/<:;"Y'VFVN"SR ;5RB;>06;CG[M5YO
MCYK4FE?;+7PNID>V:56:YW+OVN4&%!./D.[H1GI6U%\?/#C,42UO]T,<@*B$
M962,$O#U^\%4MGI[TL/QKT^;3M1FMM'GD^S7\=K%#'(G^DH[1J9D/3 ,@R"<
M\4 5?%WQ>U.RL!!IEI;G49-'CU.*9G8QRR/P$B7;\X!!SG! (JG+\?+Q;Z'3
MX_#YDU61&#P^8VV.99"G+;<%"!D$>O2M6+XZ^&WNFA6PO5>.*64/+"JJ$4NH
M.XG"JS1N!T *C/45!'^T%H<D,MVFCZBUJ/*\F6.-6>;<K,WRYRH3:V2>#CB@
M#$_X:2N?-U 1^'&!M(X5*O<@$3.0"I&.$&>7[9&0*Z;Q-\8I?#E[9VK:4L<M
MW8QW,;3S_)$[.%99&4':B [BW3TS6'#\7/ UKK%SJ4>B72:M) [WC+9[I57<
M1MD]"Q3\<+FM1?C-::CI/BJ[L=!FD.BV"W/EW3(AFD)<&W(Y*[63'IS0!2A^
M/%[=:L]C:^'&NI?.\L&.9OE5=VXN-OREMI*#^($=*T_!?QJF\4:EI=M<:'+I
M\>H1SRPMYOF,?+&=I4#Y3C(.['(XS7*:Q^TK%:137-AH:SQQV\$KR-*21<,2
M)82JC),>W!;D9]JZSP?\7+'Q+=7%H-,&G7ZPSS)\Z&.18SSAQU.2"<=.#0!S
MX_:-NTM+:[E\)7FRZ\P1%)<[0BY'F #Y23E<=<U/<_M 75NNI,OA_P"UQVD$
M,CS6USNB8R%0'!(!\K+$;\<%35O2/C_X?_L;3[S4["?29[M@L\"H&,;.@D#8
MZLC @[L5-;?&C2U\(ZKXBU+3C8V5C>FS2/>IF="H*OCH<J<[1GB@#F]2_:&U
M6SUXI_8+);QPA9+3SOWGG%HMK,X&T1X?@@G-;'_"WM6U35M9M[;2X84L-&N+
MM;.=B[/,@C(#X'"$,0,$YP:V?$WQ$N]%UC[!I.BVNM+-I;:@BPSA95"[2OF)
MCA&!(7U*GBJ6L?%U='T/0]8@TV&^TK4H7,M[#(5CCE7@*=PW%<[LD] M &+'
M\<-;T>UN);S0%N[:38;*2UE*HI*(65R5X0%L!CSZBN@\3_%O5]#GTR*U\-&^
M-Y9PW,C/=;!$TA;$>0I!QL/.?2K'B3XPZ!X;A2&XMYKF%[2"X:2SA#0L96*Q
M(I.,DE3CCM5%?CYI'_"3+8R6=Q%8-"Q6\N$VL95?8RE2?EVD$$G'.,=: ,N/
MXY:G=6\DD>AW'V9VQY[G$D3M@J@3'( ZFK,/QTU&.XG-[X<-I8K&76Y>=F.X
MJQ3<@7@$H0<9QD5=N/COIDUG97=AI=U<VEY,\*74I2-(PL>\L><X&<8QGFG3
M?M >'UBD LM0F<#Y3% &\R,!M\BY/W5V/UYXH Y>V_: U%6N-7O].D@T"*W6
M9X/*(> '8I._'S8+'CT-;_C+XKZKI#7-C:Z?'8ZC:V-M>.DIWOF1ANCC3&'"
M@$$YR#ZU?\4_%;P]8:I+HNJ6$MW;NL4IVP;D2-L-ODSQM!*FF>)/C18Z/XLF
MTD6$MP+<2)/=LF?WBA288UZL2&'H,D4 9W_"Z-43)DT&X2"-ODDC?=).$_U@
M9<#9VQSZUG:U\?+V:2SL-.M()+RZMTG:YMB\\47))4Y49RO<=#]*[32?BIIF
MO0WIL;2X=K2P^V2R/M"(=I8(Q!X? YXXZ5AZ/\>=&U#0A*;.2RU7[-&S6KA0
MBR2;-BAQU7,@Z= >: &Z)\7K_5M'U9)],FAU#2+:VENIAR&DF93&%7'&5)/M
M6=>?M!ZEI8NKB\\,?9K&-=T=PUV0IR,J7^7CH0>N,CK5G2/CQX8>21QI%['?
M7D\<$\EO;[A-/L7< >IV C.>@K>\5?$K1+>[U#1M0L6N%M'03Q3H LJF-I R
M ]1\A&3@9&* .;3]H2[F4!/#I:=TP(3.P+MD@2+\O,)QP_7)'%,E_: U#1YI
MK74=#CFU".ZNH'M[)W+(D8;RV)9<?-M/3U%=?X,^*6B>,]6N+"QM+JVEMX1O
M>XMO+1/N'RLG^(;E^7ZXZ5WRVRAE?:A?'+;>: /*=#^,6J7=_K*7VBQV\>FZ
M:]T8(I6:6:9)&5U4E0I7"J<]?FZ5Q_\ PN+Q?JUFK:9!9I(9)YF8 O 8UC+1
MJC[>3NZD]:^A?L:;MVU<X(W8YY.3^9I5M42-455"J-H&, #Z4 >*:/\ &[5_
M)ALSX:FN;B!C#<2B8(S-'$9)3L R"=ORCH0>H/%2V_Q^U"33X+]_"LQLVB,L
MABN-[C=OV;5 Y^[\V<8S[5[+]C3YFVJK-@,5&"0/>DBLTA4(BHBCHJ+@#KT'
MXT >:^%?C"VM^)&TZXTY+>V2UCGDU""XWQ%G QL! ++GY<XX(.<5Z:JYY!(/
M(ZU&MA$J@>5&<#'W!R,_Y-3JI#9S_P#7H X[_A&/%7_0T)]?L2\?3TI1X9\6
M=_%2D8_Y\UZUV6*,4@.,_P"$9\5C)'BE,^ILD_G3E\-^*U_YFB/K_P ^2>V?
MI78XHQ3 XW_A&O%?'_%4ID#_ )\TZYI?^$:\5<'_ (2=-WO9J<5V.*,4 <=_
MPC?BOC_BJE/N;-.:3_A&?%9Y_P"$H7/_ %Z+Q]*[+%&* .-_X1GQ9T'BI1R?
M^7-.^/\ Z_YTO_"-^*MH!\3H1G/_ !YK^7TKL<48H XP>&/%2K\OBB,'^]]B
M3-._X1OQ9G/_  E*=<_\>:FNQQ1B@#CO^$;\5ALCQ3'C_KR3GZTO_"-^*MQS
MXH0K_=^QJ*[#%&* .._X1OQ9CGQ2G/'_ !YKTI5\.>*PN/\ A*(S[FR0FNPQ
M1B@#C_\ A&_%8P?^$I4GWLUQ2?\ "-^+.?\ BJESV_T).*['%&* .._X1OQ9
M_P!#4@_[<EH_X1OQ9_T-2_\ @$E=CBC% ''?\(WXL_Z&I?\ P"2C_A&_%G_0
MU+_X!+78XHQ0!S?A/PQ/H<]]<W=^;^[O'#R2;-HX&!@5TM)2T 5[ZP@U*TEM
M;F))[>52DD4BAE93P01Z5B0?#_0+5D:+2;-&2(P*?*Y"$Y(_$DY/4YKHZ* ,
M*3P5HLMG=VCZ;;-:WC[[B'RP%E88P3CN,4^3PAI,FGRV)L+;[)*59X5B 4LN
M-K$#N,+@^PK:HH PY/!>BR2P2G3+42P%6B=8@&C*YP01Z9/YUG-\+O#<U]JE
MY/I-K=7&IR"6Z:XC\S>0 !UZ=.U=;10!SDWP]\/W&\2:39E7?>P$0'/&3D=#
M\J_E5BX\':1=1E9M.M9,OYG,8^]D$'/7.0#6W10!S;_#W0GCT^,:?#'#8O))
M##&NV,%_OY7N#U.>]6KSP?I&H:=/87.FVD]G/N\V!X1M?<<MD>YYK:HH Y>Z
M^&OAR\C='TN!"\20&2,8<QJP95)],BM+5O"^F:]&D>I6%O?QQAE1+B(.%#+M
M8<^HX/KFM:B@#G[SP+H6I6_D7>E6<T6[<5,(ZYW9SUZ\U+>>#]'U&]M[N[TR
MTN;F",Q1RR1 LB'^$>U;=% '/W'@/0;JX6>72+*695= [P G# AN??)_,TO_
M  A&C&U%J=-M7M0R-Y3Q!AE/N'GNO8]LUOT4 <_'X$T**2-X]+M8_+C$*A(P
M!L#;@N!Q@-R/2J^J?#?P_JVF7]A-IL"6U\BQW*PKL\U5)90<=LD_G7444 <W
M_P *[\/;RW]D60S;_9.(0#Y7]S/I4\?@G18[.ZM$TVU2UNBC30I$ KE<;21Z
M@*.?:MVB@# N/ NAW6!-I=I)^Z: AHAAHV.64CN">>>])#X%T.V_U6DV48$8
MB&V$#"#.%_#)_.N@HH Y^3P/HTMTUPVFVOFL&5F$>-RD@E6Q]X9 //<5-'X/
MTB)[ATTVU5KA?+FVQ >:N=V&]?FYK:HH Q(?!NCV\PEBTRSCDW,^Y8%!W,=S
M'\3D_C3+7P3HMI-%-%IEI%+&C1HT<0&U6^\!Z9[^HK>HH YT^ =!:>WG?2+%
MYH%VQL8!\N!@8^@  IO_  KOP[_9?]FG1[-K#S?/-OY0">9_?QZ]L^E=)10!
MS]SX$T.\O)[N?3+9[J> 6TDVS#/&.B''8=AVJ63P;H\FGPV)TVU-E#&T45N8
MAL1&X90.V>_UK;HH Q;CPCI-W:_9YM/M9(MB1%&B!&Q?NK]!V]*IS?#GPY<+
M<"71K&8W&/-,D(/F8((S^(S7344 <]_P@/A_YC_8]D2TBS,?)'+JNU6QTSCB
MI(/!&AVTEQ)%I5FCW!+2E80"Y*[3D^X)'XUNT4 9%QX4TFZE,LVFVDDI01EF
MB!)4=%/J!Z5!-X*TBXU*74)=/M9+Z5562Z:$&1@IXR?:MZB@#!M/ VAZ?,DM
MKI=K;NL)M]T<>"8B22A]02><U7M_AOX:M%M%AT2PC6U+-"JP#$9;&XCZX'Y"
MNFHH X?1/@WX9T&^N;N"R,DDTPN LTC,(G&<%/[O7\>AK:U#P/H>K274E[I=
MK=O=J%G::/<9  < ^W)_.MZB@#"@\%Z/:3&6#3[:.1F1F(3JR8V'Z@ 8K<I:
M* "BBB@ HHHH **** "BF[J-U(!U%-W4;J+H!U%-S[T9HN@'44W-&: '44W=
M2@YI@+1110 4444 %%%% !1110 444G- "T4F:6E< HHHI@%%)2T %%%)S0
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M^$/A^^M!-J:"Y%O%<E_.4# =5)..!VH ZYK&W?.Z&-SW)4$TU=.MEZ6\(_X
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MPGB6><M*I\OR(P"92X&!D'(4G)Z8HU[A;R/8VT^U8'-O"V>N4'^%,72;+/\
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MLJR_Y]+?_OTO^%>-:A^UQ\.DM6ETWQ!%JMRUFM]':QJR$HV,*S$81L'.QN<
MUWG@+XK^'/B3)J$>@7[7_P!@D\N65872)SD@M&S "1001N7/(- '4_V59_\
M/I;_ /?I?\*J:CH-E?6<]N;>*(R(8_,CB7<A(X8''45JKTHVBA:.X'@'CZ)K
M[P/<>$?&<LUBT4T3PZS#$TBSI$X92"O(<]#]35N[U*Z^+EQIGA_P]97=GX5M
M?+?4-1N$,*RJI!\E%/+$X^E>XM;QR*5= ZG^%AD4+;QJ,! !V'I6OM&X\K,E
M"SN<CX5P/&GBO P!)"!_W[6NQ/0UQ_A4?\5IXL_Z[0_^BUKL/I61J<_XZ\.O
MXM\):KHR7'V5K^W> 2[<A<J0?YUYKH_P7T)+*WT2]U1?[<4B[D^Q*JL8L,@&
MP@Y7:Q&[^]D]:]1\7:3/K_AO4=.MKN2RGNX'BCN8QGRV((!]:\QTGX,ZGX?T
MGQ)<P:BEWKFHZ6UC 0758/F9A&CLV1&"W'.>M !K'P!T:%82NLWEGI\<GSQ2
MNKF. J5\F-B. 6<G<<G)'-=#X@^#>@>(KP7MRCBX5H.N'7;'&8PA!Z@JQR#]
M>M<A8_ OQ'$NEY\2I;):J6,$*R'RV8JQC5BV2@*]^>:ZCP;\/=7\&S75C%J?
MVG3[Z$^=/([F6&?9M#H&)^\?F/IB@#-3X0^%+S4U@&IO-+823E+-G1OLR2X=
MDP1GJ=P)Y7@#BG7WP1\(?VD8S/)'=.R7,<$KAT"Q+M?;&1@JV<M[\US^D_L^
MZWH_F2KXA47+SQSMM60AV41CS'RQWL=ARIX^:B3]GW7KK7GU2?Q' 9FN&D5X
MX9%,"DJ28P&P&.TY4Y')H Z?1/AOX>L[/7]-TO7[J%]3MULC)!<H);6,%B$C
M(&<CS2><D!A3]6^!6A:U:"TU.[NKBT^Q?V8(UV1?NLC(RH&2<#KTZCK69<?
MFXFO+*>?5$N4MKI;KRF5T5F"JI;(/#[5//N*9;_"7Q1?>!M(TR\UX1ZJM_\
M;;VZFW22%5;]TJ$'Y2$5 >Q)- &GK'PET5(;V^O-?U"S0B >>9D1;94B,( .
M,?,C%3GUK7\0?"[2/$6E6.G()-.M;1_,0V@4&4&,QLKY!SE"1GKP,5Q.N?L]
MZEJ$/V>#Q 1!+*)YX9C(R-*#DR#YOO\  P.GM5OQ=\*_$^I^/GU?3=72&WF0
MD22NX,3*B>7&5#8:,LK'@9^8\T 6Y?@CX/T5XY;J\FBB_P"/>U6XF4+"C<B-
M21\QSD@GYJU='^$/ANR\/WVE6Q:>QOKF.65_E9BT;APK-_$-R\Y]<5S+? W7
M[J^AN;KQ/'((X52+;&^=X+'=R>HW8!ZXXJWX?^#^J^'_ !?874>H#^QVNKB^
MOU1G5KACS "I/W@SR$GH0%!S0!-JGP8\)VMUI@FU&ZLU>Z18K59E6.>8 [!M
MZ[@"3GTJ.\^&W@F^2VAAU/[/).Z6D36SIND$<1C:,#'=-V[T//%3^'_@S>:?
MXPM=9U'5?[16SO9+J%6WE\L)!N;)P&Q)C"C&%%8M]^SO?7"[HO$(@FBDDD@9
M(V7R@^=Z@YZ,#AO:@#I]"^ 7A70=>FU2".YF:960VLTV854D$ #MM  7T''>
MJUO^SKX=CN(9I+B[NY(G(7[3M=?+PPV;<8.-Q(;KG'-=MX0TF[T'1X-.N)UF
M@MHTBA;>S/@#G>S=>>GM70JHQ0!YK=? SPU=3V4C"X"VKQ$(LNU66-2OEL .
M5;.6'<J#VJMIO[/F@:3-I,MO<74;Z=*DBM%M7S0CAT#\<[2H^;J17JFT>E)Y
M8QC% 'FMY\#?#]]K4^JO+?+=SN9F*S819"X;>!Z\;<_W211HOP3T_0IKJ:SU
M2^B>]$GV]?E,5X')/S1[=J@;F 5<#!KTO:*38IQQWS0!RFB^ ;31_"LGAV2Z
MN;_2WM_LVRZ<$B/&UE![#'Y5@3?!'2[ZTLH-1U'4-1-G%]G@DFD *1=%0X'(
M []^]>E[11M% 'F,/P)T6SUC^T;*[OK*[5W*R1.N KYW*H(^7.>H]*=I7P)T
M'1M)U.P2YOIEU")XII))OF(9@Q8?[60/KSZUZ7M&<]Z7:* /)YOV>] FVF2\
MU%BP8S@2*//D.<.P P"-QP!QP.*FF^ ^DW%NL$FHW[0AY"0"G*R "5.G1]H/
ML>F*]2VCTI-@[#% 'E5U^SQX7N[$VI%RBX&UU9=P8!\<XYP78\ULZ?\ "?2-
M/FOGB:3R[S3O[-EMXPL<3IS\Q4#E^3SVSQ7>[105!H \DTK]G/PQI+6S127<
MAMYO-4W3B4$; I!!XP2-V>N236WH?P<T/P[XCAUFT5ENHX/('F!6&<,-X)&0
M<.0<=:[_ &CTHVB@#RVW_9^\.P7"/'<7JP*5D6+S!@2 CY\XST &.E0R?L[^
M'9;>:!KJ^\J1 $_>#=&^$#2*W7)$8^F3CK7K.T>E)M&,4 >3:?\ L[^%[$*8
M&N1&+=[8^8P8[2<IM)Y4ID 8[#%7KKX'Z3>>'['2YM1OO]'GFG-P'59)&E_U
MBG P >.!7I>T4NT#H* /,/#OP/TO2O#^J:9>WD]^VHE!<2*1'M1)&=$0 < %
MCR>>:M^&/@KH7A7Q!%K$$EQ<75OO6#[0P*HC _*..<;C\QYYKT3:*-HSGO0!
MY_K'PO34=%\86(U6Z:3Q"WF"27!^R2; J/%@9&W:I'NM8TW[.OAU[2[MTFN;
M:.Z2-9/)(!&U55AN/.QM@.WIGFO6-@_IUI0H P!@4 ><WOP3T2[\%CPS'/>6
MM@;@W3F*0>9(QZ[CCG\:H:I^SSX<U)<+->6K[7CWQ.NYE<OO!!').]OFZ]/2
MO5=HHVB@#S[5O@UH&M:G)>W/GO+);K;%0_ 15V@CT..XYK/D^ ^D2:?!:#5-
M21[93';7$<BAX8SNR@^7!R'89//->H[12>6O3:,4 >32?LY^')+I9S<7C&)Q
M)!'(RND8W,SK@C#!B[9W9Z^U7;?X$Z!;Z;KMBT]Y)9ZK''$T;2 "%$<R($P.
M<,3R<^E>F;1Z4;1D'^M 'E5Y^S[X>OH+I?M%Y;FXM8[63[(PC0A3\Q" 8!<$
M!O7 J23]G_1'NHYHM1U.T*IC$,P'SA74/G&<@2-[<UZEM%&T4 >30?LZ^';>
MS2S%Q?>0B !=Z_ZP$D2=.Q/3I6OX;^#.B>&]6MM1ADN9K^*?[2\\K#,DGEM'
MR . 0Y.!Q7H6T4BJ%Z4 ?!7Q2^,/P\\._%3QYIE[\,S=ZPFMV]C-=?V@R+?P
MRF%KF[90>!$4ARO?CUK:_P"$R_9POIEU5-$U:99;Z731,T4ODR1W#NWF%F;'
MD[C(5R?E). ,UI>*_B=X<M?B_P",$UGPQX-CT;1[Z:&[L;Y&;Q!J#+;)-)=0
M(.&C)2,8( (C)+#&*R-/^.7PE\0>5HL?PF+QRW\=W?(K0R6UM=3-MA?>K8D#
M$KD)]W//2@"QK'Q'_9P\2V-_JS>&]3U5Y[.#0X[BTLY&DFL[96GBDB.X?*@A
M+;QS\@%+X@^)'P9C\*A]%\%ZIKVA7VKV%O-=6^]#<>0'"S0$-N=HR6!7"YW'
MK5#PO^T)X"A\)F\N?A!;6MT\L;7?V2X@^QI>7,4@\H2,<(#"LN<X )V_>(K.
MT[]H?P#HOB#5]17X9Z;_ &4[>;9?8X#'=RR!;=(-ZM\L7$Q!;V!'6@#3G\2?
MLU1:3906V@ZY<K!,;B&TL8IA*BS ;$(##]U(JX"G@A6%2ZAXZ_9PUS3=&NY_
M#VJ);6=V8+6UD22(Q&X9+E)&CW?<=Y$*MVSVJ?X9^-O 7B3XZ6>B^'O ZQ+X
MA"_;9=<8%[5[.U#6\-O;Y#)''YC?-T8LV*P/^$[LK#5_$%KXJ^%OA/6K_2;Z
M_P!*T\Z# RF/[# DLDLYD;)39Y>%49RE $/QB\>> H_!?P@U:\^&']K)-H]W
M):V::S+$MI9P2(7@8J?WJG:I^;CY<'BN@U?QE^S??:H]U<^&=2OKMII?L]G9
MPO)#?2S;EF,"A@K;&#KV QQGBEN_C9\-OB%XB\'^$4^'VDZB]K>6=I;S7*!K
M6&WN2HG$(7E&#$?(V<]Z^I;?X+^!H-6N=2C\)Z5'?7$R7$DRP+N\Q%*HP_NG
M!/3UH \-\!>//@E\0)-(\#Z/::AK2Z0#KUF^I^;*AN!"9&225R27$<@RK<8;
M'.*^?_#/CCX4?$%;#1(O -YX/75-*NCJMY9:EO;3OLTH>W50WRO)*G(;.0#@
M=*^^M#^$G@_PWJ37^E^&M/T^[:V^QF6WB"$P@!=G';  ^@JDWP)^'[6[6Y\'
M:/Y+)Y946R@%0NT#_OGB@#Y.M=<_9IU&/3KN'PKX@U1UBB60K#-,WG7$LL*"
M8E_FG=VE&>N.3VKI]3^-'[/\W@&[\,WEGK%AX>:^_M"-1#*DCW =G2:%U;<&
M+Q.%Y&2IKZ3TOX.>"M#A2.P\+Z;:JLD,^(X0/WD3%HV^JLQ(/J:BA^"7@2$7
M83PEI(%U>#4)O]'7YK@;L2?[PW-_WT: /F*TU3P7X)U;2?%7PTT@^(KWQI83
M^'M(@U2\73K&WL+(-)<.)VRQ,C,S;SRQ)/05B:GK'[/>BP-8:9X _P")S8VU
MK9W-E:3,+;=)B-XVN%)621$NBV[^(-P?3Z\UGX-^"/$/A.P\+:EX5TN[\.6!
M4V>G20#RH",XV#^'J>GK22?!?P/+?37C>%=+\^:*."0K H#)&04! X^7:N/]
MT4 ?'\*_!KXH6,NEVVB:QX5\4ZG#'>>9I:&8VZ-*4=;-V<!0V-\GE^I)STKK
M8]-^#_@7]H[0_A0GAN-[ZYM+>=]4:]"B.^B >W7RL_ZR18RY8<97IS7T4WP(
M^'[7T-Z/"&E_:855(I!" 4"MN&/3GGBM.Z^%?A&\U9]5G\-Z;-JKW<=\U\\"
MF;SXQM23?UW*.!0!\4:#XV^$G_"QO%NB:G\.$L=,TU+^REN[6_9S/]FF2/<T
M38!=V<!=K$@ YXKTGX>_M'? WX=?;+GP_#K>GV6I+]H>22":2UBD*M+]EB#,
M1&Y.\A%&"<\U]!:K\%O ^N6[07WA32[F(RS7&'@4XEE8-(_^\Q"DGN14</P+
M\ PZ>;)/!^E+:MDF+R!C)0H3]=I(^AH \ET+]N;P;<6LTFN6>HZ#)#<SQ2HT
M0D%K&C,(VG(/R-(8W 49P1S4L/[<7@[5&C@T^RU6&]DN(X4CU6T-NDF9(E<*
MV3EE6:-L?[8YKTZ#]G_X<VB62Q>"](5;)9(X%%N,*L@(?ZY!.<^M79O@QX(N
ML>=X4TN0@D@M"#R0@)_*-/\ OD>E 'F"_MO?#LO:1SG5[0W%Q<0DR61/EI"_
MER3_ "D[H@_R[AFNJ^"_[0EA\;M:\20:5I=W9:?I0M7M[J\PK7D<T>]9 @)*
MJ1G!/4>E:^E_ 'X>Z*M@MCX.TFT2PD:6T6*''E,QRV/8GJ.AK<\%_#7PM\/E
MO1X;T*RT;[;)YMS]CCV^:PZ$_3MZ4 5_"W_(Z>+?^NT/_HI:T_&'BJT\$^&]
M0US4?/;3["$W$_V:%II2@Z[$4$L>G K-\+?\CIXM_P"NT/\ Z+6NNV+SP* .
M6\4>-(O#?@/4_%!@DN;:ST]M0\A?D>1 F_:,_=/0<UYEX<_:S\':UHUK>:C'
M?:==3133M:QQ&Y'EQDKNR@Z,0P7('*GTKV+Q';Z9<:#?PZPMN=)>%ENUN3^[
M\LCY@WMBO+M)7X5^(96OK6QT^U,SSV@G51%Y^=RR %3DJ=C'F@"7Q%^TEX9T
MFUB-BLNJ7C31I]E7"G80C,RG.&(1PV!UZ9K5\&_';0O' A2TM-2ANY+>VN&M
M9[4AU6<XC.,\CC)(R%[G-8&GZ?\ !^/4TO;/3M((@LXR+]8_W21H^U$SG[P(
M'09P*U=/TGX7:'J%DUJVE6MXXCCM667YE"R;T523PN_)QTS0 ]?CQH\=_J5O
MJ*?8Q;Z@VGV^S=*\[(,NY4#A1[9J[)\;O#>+I(YI&GAEDB=2N%#)C(W=.0P/
MK@^U4XM?^'VO66HW:?938:/J.YKS:0@N74$LC#DY#<GI1=:+\,M#O;6PN8=)
MM)I"UY!;R/PV1S(1T!VYQGM0!5C^/VG7&DM.+*1+Q#(39S':75&8;T;HR_(Q
M)]JT=,^-VB7UU/;7"W-G*)5AA<Q$QW3,%(\H]3UZ=>M5VA^'.CW=W#]EL$GD
M8DHHWF5SORJ@$X/#Y[9:DL[7X?ZC9Z#XE06]C!'=QSVK!MJ"<Q[$#=MP5B..
MYH U=:^,7AWPYJ5[87CW37=FR^9#!;F1F#!CE0/38Q/<!:IVGQLT6\U+58XH
MYIM+TRQ^VR7\<9*R8D:-A&O5@"IY]16;JNO?"[0UUG7&.FW$\ER8;MH,O-).
M3M(QZ_.<]N:T;B/X?Z#>:I:_9[&SN+I%@U%5<)Y<;*7"N<C QDX'K0!!XI^/
M6@^';NWM(UDN;B1H6D+8"16[@EIMP)X4#D=>14MG\>O#%[<3AC=V]C#%'(^H
M3P,D0+.ZA.><DH3GH<CUK-TW_A4S3M<:?%HUQ<R0*S1Q89_+'R#Y2>G\P*HZ
M?_PK7QUX7AA:$65K>?Z%%',Q$LL4<@F\O )RN1GGH#[T ='XJ^-FA^%].O'"
M75[=P6?VQ88X2 S%#(D1/9V4%MOI6S9^/K.36-)T>[S!K>H6GVJ.!>5^Z&*%
MNQ&:YO7_ !#\,9KB36-2NM+N+@V+2NQR7,"@@G;WP-PYYY(J[J6I> ='U^+7
M-0>RT_46M(TAOYSL)BD7"@9/]WOCIQ0!3M_C)/)?VUI<:&]K"U_-82W[3AK9
M64J%"N!\S,6  XY4C-++\>=*:UM;VPMY]1TBYM;F>._C^52\) :/:>>IQGL5
M/I4%JOPKTS3[&VCNM+AM$1K^&$W!$8R3E]N?4$@'G(-6(;;X8W-U&L?]DF>S
M22,0+($$:R(/,&W./F&,_AGF@"SH'Q<EOIM2?5M*DT?3]-MI)+FZ9O,19(S^
M\0..#@8^I-1ZM\=M'T^.XCA@NY=1AB2>2RGA,;1JQ7"L>BMM8, >H-2P^+/A
MYH?A\Z,NJ:7%I#,UJ;5I R$D?,IZYX/7U-5+<_#*SBDD6?2RC6*/*6ER)+?*
ME"V>N/EQWQ0!-J_QOTW0H]$^TQRF74$AGGVC,=G%("0S-^! 7N:F;XZ>&K>)
MI+F>ZMF2,R/#/ 4=2&">60?XR67"CU%4VNOAOXC66_2"QU!=(\FQ:55^2)7&
M8QS@$ '@]LT0Z3\,KSP_+>1QZ;=Z1IY>%YLF1(68@L?7).#N]J -;4?C/X8T
M>WTB>]U"2UCU.-9;<S0,NY68*2<CY=I(SGH#26/QJ\.:AJD>GPW,QNY)HX1&
MT)&"Z[D)/0*0#UYSVK*N]:^&_B"SM+;5SI\JVJ7,%O%?8)$:?)(5]5(48/<#
M-0:G_P *YT.XT>[6PLYTUR_$T<\/W#*BES+(<X 7GCU- &YJ7QCT+2IKA97N
MV6"XDMVDCMR4+1X\X@_W8\C<W;-8FI?M :6MY;Q:9!/=H9)!/<7"&***- V9
M!W8$H5&.X-6=4C^&MUK$T=]+I,E]*[7<B-+@EQR[$=!D*=P_BQS4:ZY\-;N:
M["K8.(08YY&A*J@=3*0<CNI9N/6@"U/\?O"]M#%(PU)TEW"(K9L=X5BA/TW*
MP_"JVK?M#^&+*PU*6SDN=1N+2-WCAAA($[*A9@K'C"X.X]L5:.K_  X=8X%G
MTN01VK7"1Q99A#EBQ&.V2Q]>36;'8_#K4K'43)IMJFEF]$$LAP(&?R=V]3D#
M:4)!(Z]Z -S6OC)H7AEK.+5)9HKFZM%O$AAC,AP1D*,=3_/%1:?\9M*U;Q%:
M:99+.\$EO///>S1E([?RD#%&SU?GE>PK%UKQ!\,?[2T?5)8K'4M2O%$%K)
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MK1WF7<AC\PW \ @\>F*LWG@WQ)+?2M;>)Y+6P!C6"S$(;8BCY@7ZG/'-:?\
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M?^!1H ZNBN4_X07_ *CNL?\ @4:/^$%_ZCNL?^!1H ZNBN4_X07_ *CNL?\
M@4:/^$%_ZCNL?^!1H ZNBN4_X07_ *CNL?\ @4:/^$%_ZCNL?^!1H @\*_\
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MRL6R2N=VTKAAZ>]2:;X2^(&E:P9CJ$E\9+^VDE\R\/E-;JI5U*[>&'!^7[Q
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M7$AC1@/D9QC<P;)QC@$"O1V7=3=NV@!P[48]J6B@!*,#TI:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI.* %HIN5]13J "
MBDS2T %%%% !1110 4444 %%%% !1110 4444 )2U'('+?*5Q[BFXE]5_(T
M345#^]]5_(T?O?5?R- $U%0_O?5?R-'[WU7\C0!-14/[WU7\C1^]]5_(T 34
M5#^]]5_(T?O?5?R- $U%0_O?5?R-'[WU7\C0!-14/[WU7\C1^]]5_(T 345#
M^]]5_(T?O?5?R- $U%0_O?5?R-'[WU7\C0!-14/[WU7\C1^]]5_(T 345#^]
M]5_(T?O?5?R- $U%1*KDY)'X5+0 4444 %%%% !1110 4444 %%%% !1110
MW<!P3[T;E/ /-?+.K>*?&G@;5/%47AS3]3\07-UJBS0ZQ/;2.@;<W^AR1MP
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M;K[0+EX[X1B"U6WD/DOC#*"!R&Y;+8QTKW182/QZ]\]LGWIWEGUXSD#TH \
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MB^]O&6U\/_OA(\ ::*7[, "2&) RQ"CGH!G%>UM"6&&&X>F:3[.VUN<D]^E
M'B_AGXK>(_'B^*K6RM;32KW3;59+>%@7G:4'Y@5/!4X(!ZC/>LNW^(_CK4+Z
M"[BT^YL='N;=V:2:P^6UDF#-;E\_,5C"C=@$?O.>F*]TM='MK6\GNHK2WBN)
MSF66.,!W^I[U9:WW9[<8% 'C^G_$+5]0^%<]S:O<'Q+9K"M\TD >6%&<!YU0
M* PV;G5=H..HS7-P_$#QQ_::1P7%W<1Y/]G*^FA3J*>>5W2_)^[PF/0\9[U]
M!+:A69@JHS'G;CG'X>G%/6-@N,X Z4 >0:KXZUB3X76FHV=RZZ[:W,,>H0I;
M'S7);+Q(-I"LP/4C'N*Q[;XH^-=)TW-_HAN'EN&>WGEMY-Z1[I-L4BJOWSL4
M @8&>:]U6U2/[D:KD\[0!^-.:$LIW<]\=>: /)=&\=>+-2UB07^FPZ99S:7=
MW5M;I;R/-YT4FQ09",;L8.,<YXS6':?$SQSX?TK2K:_T634=4GTY;N<R1L6>
M1E).PHH553C<&PW/&:]V:-F(I#!O^^H.?\]: /(D^)'CF+5XH)?#MI):+.D4
MA@$NYAO5"5)&.=^02>BUD^//'_C#3=>U2+38YHK?^SXY)(##YOV"0NH9MZH>
M0N>F\'TXKW1864<MGU]Z9]G.3SCOE>#G'7_]= 'B/B[QWXDCL;-K":;1YFT-
M+_R+F(/+-(9=KI\J'$A0 J=N 6&5]-KP7XB\67EAK>H:K:7L5E+<216K3^6D
MEK"%R&9-N2<\9&[Z5ZDU@DDBR,B-*H(#LH)&?0U-Y;;2.A]: /FK3?BAXYDL
MG;45NH573I)(KL6PC5F#/B9\H,KPB#&TG=G;S7HWB3XHW6GZ/X<N])L'U>:^
MN$@G6.!V6,C:)1O PI&3R?0UZ/)9M<*\<BQM&Q^ZPW#'&,CZT^.S6%56)%C4
M'(55  ]\#\: /"];^*7CC[+:6Z:*NGW=S/ 1<6\$L@\LM&QB''#;7?+-@?*:
MV=>^('C73_$NK6.E:#%=V]O<[4GO!+@@@$;-JXP.?SKV QDMGWX]NU'ELV<]
M.@';ZT >!>(OC]KN@W7DC0D@RL"K+?QRQ1PRL"9%;)Y4 <,,8STJ76OC5XG\
M+V-[=2:"LUC$S1132"3<7."A. !MP<#!R:]MO](M]4C2*]MH+N*-MX2:,."?
M7!Z4^\TNWU"U:VNH8[BW8;6AD4%<?2@#R/Q!\7/$%KH_A_\ LK3(;V^U:PDF
M>6VA>6W@<*V&5\X(#  J1GWKU#PE?3:IX;TJ\NMGVJ:UCDEV1M&-[*"V%;D<
M]C5Z&Q2VC2.%%AC08"QJ  /0>@]JL*NV@#PO5OA[\';6;6I;^YLK"X:ZVW;-
M?F*6&1M[&('.Y0P=\J.""?2J,/@'X877Q?M-(M76]NI-/*OHMO+OM5$3*^Z<
M _-U0!3D<59G^ OAZW\;2:AJGB>6]U/6)IC!;WBH2Y,<W&#G<425MI[!!6U\
M/?@+9?#KQ/9:E!K=S=0V,$T%K:W$:*1YH3S-\@&Y\E 0#TH PO!NA_"'QAH8
M-N(I85O&EEL=0O2SJ\(8!'4M]Q%5F5>@&?>M2[7X:Z;HMCX,,JW>F7ER848W
M!9K)PGFJS2DAHP HVXZ5SGB7]F_2XTT33;/4MLMQ/#!+<3,L;^5'-+//L"CY
MGD21HSD_=-7]2_9GT?[5KFLW_B2\*72NYF*IB.,*^W)Z':KXSZ** -+_ (0G
MX2Z!]IMI+JPMO)LY(;R(WY+20EOF,P)RYW,<'KDX%3:AIOPEFU#[9*NDZIJ(
MBFO5ABN%D:1)HDCE95W8(:,+U[<UB>'?@'HFK6MYJMKXJ;5M:NIH+E=5^SQE
M$GB;S%(3NIW<KG!JS'^RUH$>DR6D>IW#>;.+B6<(F]CY#1-@CHAWLV!P#CTH
M U(OAS\,]8L1%YBWL/AX^7/B\=O* 8.(I2IPRJ54[3G!%6O$5S\.]4OH]5GG
ML=3U+4(X[E/LMP"TT>#;K*!G& )"O_UZMZ/\*7TGP+J_A6TU^XBLKLN;.XBA
MC6:V5G+E=PYDY)&3S@X]ZY'0_P!G'2/#MG=:#%XDE:WU&".:ZM_(CWR-%,KA
MXWQE%X"[<D#.>M %BQTGX8ZI<>,M"TM#=6EO;076K06-T6MG4,P$?!QDF([@
M.OKFMCPSX-^&VI74]EI+6LEQ$S7SZ?'=9-HTL91R%!^7*O@C. 35+P[\(M(\
M+S:SH#>(Y+F\U;1A8V]N88XI(;*)F"N=H&]@9L&1NO%:W@OX$Z7X'U2/4K&Y
MFFN8[>Y@PZ*@?SBA)8CGC8,9]: ,K1_#_P )K-;B>SO=/%I;WB!HXKYC;VLY
M1H@57.%+!F!/0DDUC>$=.^%UOJ'B#4?[4L[RV-U 1<M^Z@M/L@-O% #D%F0[
MP3CG/M6#HG[--IJV@_\ "/:KXN/]MV=I':WMKIT*"-+8EY%1A@%FRY82'GBM
MKQ)^SGX;M=/O-2U'Q&T%K:L;B.2XA7R8H_,,A60*1Y@^=NOJ": +_B3PW\$X
MY(FU*[TU'TW[-:@)>-F-6(2&-@"?E)*X^HKKY?#?@37_  SI^G&:VGT'1[M(
MX(5N#Y N%;Y%8YPQ#8Q[URZ_LWZ"T$4VGZH]EY<S74$D<$6Q=[1,JX(Y4>4
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M ^EO)+:QK*WEQ2.H5Y N?O$*!D]A7;1W$>U?G49!(Y'2G?:$.,'.>F#G/TH
MD7A1QBEI*6@ HHHH X_PM_R.GBW_ *[0_P#HM:ZSSE%<GX6_Y'3Q;_UVA_\
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MEXVN6@2]@N5=,(%\R1&(Y +< <LH) YJBO[2%M_9XN1HLIBQ.D31RY64QJK
M(,9P5<$D\#!'6@"O!XG^)>@VL=I-IOVPR3%H[N2U9WRQ)6!L'MD_O>P XJP_
MBKXEZ=']LN+197DM(Y4TVVL"55OM!61 V[[XCV\GCFKV@?&34/$GCBPTF#25
MLH&LIYYX9)@TKND:L@&.!&=QPV3G/M6<O[3=DUE=W4>@WD7V=E.VY?:9-QVJ
M$XZG9*,>L9]10!K^)_%WC*RU#6X['37CMH7A6W46)G_=, 6F!W?O&W?*8QC'
M6LJ\\9?%&UBDO[G1+6.UA0RR6@MF+84$DE]WL'P!VQ20?M#7>^>&7PVTMU"+
MB7$%P H1'VH.>=QX+#MN%=+XF^+3>&V@@O-)4S-IRWLJ-< +N9M@1./FVDY=
MN-J\X- '':?\3/B-=6.FW%KX>DO3<K(RRFR,*-'L!5MN<JRN2,'[P%6;[Q?\
M3%TS68+C3XTEC2...XM[)G==\>?-1,X;YN,9RO%%Y^T%?_V=<7-GX:#&)0%D
MDNLP&4 L>0N?+VHQ#>N..:T%^/DDD,TMOX9N)88[IXED\]1\BY\QL8R#QP#U
MR* (]4\1>/-$-J8X+B:V;2;7S4-EY[13EB+AVP<LX&SY/]JF:CXG\?Z?XHTN
M[72YWBN=)A>ZT^* R1QS?.9=CYPKH"#@_>^[3=0^-FIV/@WPMXA;3;5&O[N>
M&\LHKC&%178*KD<2':/E[DXS4R_M%6G]H75J=*F6&"9HS)&Y+,0A<(JXW%\J
M5/\ "/6@"BWQ"^)2Z,L__"/%KEK,2XDMB/);S2N^09Y)3!"+[UK>*-4\=VMY
MI5WIE@;N>32U,T488P+<#S#G:2#U*<'MCTJCI_QVO=<U[PGIUMI']G?VE<Q_
M:6N)@Y,;AB/* ^]T&2<;:ED_:"?[1>0V?AN>[,3R.=MS@B.,/O+C;\LF(SA.
MX(H N:!XP\>Q^*([/6](CCTF%9/,N([=BUUAF4.O)V<!#@\8)K8^(MWXMM]<
MTE?#,6Z*:)HYVDA\V*,EUP[#(Y"Y(%4O%GQH3PSXH?1;72WU*Z:WCE54D* ,
MW16)7 &._J,56U;XS7-K;Z+-9Z+)<RZI9>?':.XC"/N8$.^. -A[<Y% $6O>
M.O'E@- &G>')+R>XL&GU!3#^[278Q !SD'<J_+W#5R&G:U\3;A;&&6WU"9?M
M<ER<VAB:YB+-@%L_NE4;0$Y)SFNH/[01:SEN[?0)IX$9]\0G_P!)C5(C(Y>,
M+E<GY5'.>M1S?M"&+[!$VAO)<W-G+=&W%TOR[<E26^Z48*<,#VQ0!G1^+/B5
MI]G,TVG3W=PLKQ>9)9DJ/F8QQA%/<;5,G;.:Z&/7/B%>>'?$KSVB6&HBS^T:
M9]GM=[1R;W'ED%L2':%/;[U8NM?M'O'I.K3V&C2*T"-';W=U+Y4?F>6S;F4C
M<H./ER,-TS5GQI\:M1\.W>AV,-BIDEMH;J]DD'S,LD<C;8HP.<%!DYXR* &Z
M/K/Q,MYHX19+=6]Q+)<K<7EN4D2,;RL+\\%B% /\.:L^$?&/Q#U+6M"AU+1[
M6TL)PS7$WV=U(&6S&>?D9<+ST:L/1/CAKEC?:E=^)8+=-$C+"'[. -A+N$9C
MC/1,8[EA6Q=?M!/;W$@.DM"T9:-X)91M3/E['EDQA%P^3Z=QF@#+A^*'Q#O;
M>[N+#P^UW NH&"';9M& JRNC(23EAM53O ZD]JDM?%7Q+LYK96TUKLR70@FO
M+NW**/G?Y1&IX&W;\X]JW- ^. U1[LMX>O+:U@LI+J-E<&21HT5F4(!P"'&#
MWY-5;K]H46"VS/HOVHR6:73_ &*[\SA@2IC&T;HUQAW_ (2<8H KMXF^)<,T
M,\]O!;1^5/(D<=BS1NYB#QHY#9&U@PW#[QP*O>(O%GCHVNAQZ9I$T5Q?:?YD
MWF6VYTG(PRN0<1E5.\?WB,5@W7QF\6W.O6TT&GP6&AR0"9XO];/Q 9"5P,')
M( YK4U+X^-8Q&Y&E-.C-)$EK#*"RLLHC!F.!Y?7('I0!#J$/CNSTS0-,LK^Y
M=VT>!Y;EK7>QNQ.AD9VSQ\A;Y.]:WAWQ-\0=8O=5M-2TRWTI8=/9K>18F+/.
M4&QU).,;\_(?057_ .%UZA<:I90)X=6UCN;Z*W\^]O H\LL5=\ <,#C'KFGZ
MY\=Y=.UK4M+M= EOYK>=K>)5N KDH3N:0$?(#C*?WA0!C:/XP^*5Y;16_P#9
MT,3F"W4W-Q9,&)*KOFV9QRVY=F>,9KHM?USQTO\ 9;:7IBP3S6$;W+/$98XI
M?G+H(P1SE4 .>-U1>*OC)/8:AH%I86)5=0B@O)Y)''F>7(,[8TQ\Q ')R-OI
MS7/:7\;-?TV\2^\16T$>BR0RR(L'R[6R^P,<9Z)CZM0!?F\7>.Y+N#4)-+O(
M_LD\R7>GP6AV)"0NT@Y_?'&Y@5Q@\5C7_C3XISZHE^NA2P^3:;6LQ:L8EW%?
MWS?-\[ 9^3MS6]>_'Q;7<RZ9Y;QW#P&%I0(TRJ&.263'R(=^>G'?%:NC_&&?
M6;J=%T2:S@%C)<174TI;]ZD6\HR8'RX_B[T 9D>M^/;_ ,3:L9K&2&"VTBX\
MF&VA(@EGPAB=92?F+?,-N/EQ4EIKWQ&N] \2)+8BRO5L&FTMUM\NDBNRA&R<
M2,5 ;\:Y.'X_>++C2[7R=)MUU&*Q:.]C2WD/^FF2/:L0. 5\N3<,GJ1DUZ+\
M(?B)?>-+6Z35TMK6]C,:K%%E=S&,-)P>I#$@XZ4 <;;^)?B7H]A,T5D+\7=Q
MYD$]U;L&MHF8 %@/O \G'\(KW73VF:UA:<*)&12VT8&['.!Z9S4XBYR#@]:<
M%Q0!PI^)UNLS12Z-J\3KEFQ;$@*!][/H:=#\2(+NU-U#I.JR1#RS\\!3*LQ7
M.#S@8R>/2LV*_P#$,$;R#Q-H\T**V'E3:QP3G// 'I2V]YK5XLH;Q/ID@&R2
MRFC8#S3@A@XZ[<D<=\4 : ^)%DUQ%;P:?J4DMQ)Y5NWV4A';H<GJ%'7)JQJ7
MC(Z/):I?Z=)+.%)=K7,OE-G'!QSD'GZUBW%WXBM;.UD?Q;IYN8HB+I([?=O;
M.2R)UZ4MPVHS:+9/IOB6/399&:Y:34E&^=>XV'E5&* -&;XG6MO'%*VDZH;:
M523(ML??@CU/]:=<>/"[6\,&E7[2W<:^0TD15"[ %5<_P\'GZ5C76J>(8;=Y
M)/&&C1P+$J&3R,-YC'@XSQP16E9W.HVTEFFI>)=/GE0N\J*PC!C9<*1GJ0W/
MXT 6K_QI#H]U_IVGS-<&!6\RTC,@9BQ!C! !.".]%W\1[2RFEA?3M0)2-79A
M <*I&3D]L5AZ;;^.9H9(;+6[.Z6!O*-U/;%/,.<Y'J ._0FN@70/$)TNY\W4
MX9=5E"D3*FV(8XVE.F",YH CF^)EDC6GEV-_/)=;3#Y=NS##@%2Q[#) /H0:
MLW?C(Z)8Q2:I:L+HEA)'9DS"-AR < =<CM5./P_XM33T1=;M#=^8^]Q"5C1#
M]T*OJ*M6>@Z_;P3?:=4CN[O9Y<<J)Y848&21W)Q^% %74/B-#I5Q%%-I.JLL
MRJPECM]PR0#@^A&1^55=6^($,-T;2XT*_GD29?)5;<.K'(PY_NX)!_#-6'TG
MQK;6K1V^KVDVT,P\V++D_P!PGICWJ5='\9LZNNMVB"15\R*2#/E$$$[2.N1D
M<T 27?Q BT2:SM+NPNI;N:'S)!9H98XF!P5+>N:BE^*=JEO<2)I6I22VQ GM
MQ#B2,%202,]#CM3KCP[XFN-0N5;78UTV<D>5'"%=5(P0K?P\\YZ\TR;P]XF7
M4$DL-5M[2V5%62.=#,T@"X )^N>?>@"R/B1:W$%W):6%[-]GB$IWQ% ^>=JD
M]6QSCWJ*S^(S:I-'#;:/>PN6'F/=IY<:+U8[NY /3O5==)\;-(D$FKV2I)&Z
MO-;P8,+8^1@#][%-72?'2R2O)J^G2+@)'#Y!VGW/O_C0!;D^),=O?75E)I&H
M/=P*[A8(BZNJG@ANF3Z5)I?Q*LM6>WCCL-0667.4:W8; .I/MG(^HJI'H/BZ
M\T^(7>LP6]_%<%]]NA\MTV\ CZU%:^'/&-TS1ZIKMLUI*VZ1+6,QOM_NJW;Z
MT 6+'XC2:K(T$&C7UK<;CAKN/9'@'#9;MQ[5VL;;D5@<@C.14,$)^SA9!U7!
M7J/_ *]3C@8H 6BBB@#C_"O_ ".GBW_KM#_Z+6NPKCO"I_XK;Q;_ -=H?_1:
MUV- $<T*S+M<!EZ%6&0:KC2[?@M#$QXY\L=L[?RS5RB@#,F\/6-Q-;RR6\3/
M;RF>)M@!20C&\8[X)&?>K7V&/<3@ D8/R@_CS[59HH IG2;;RA$(8Q$.0NP8
M!!R#^!I9--AD<LR1EBNPDQ@DKZ'U'M5NB@"E_9-OP#%&0"#_ *M>HY!Z=CTJ
M7[#$>"BD8Q]P?A5BB@"K)I\<B[2%P>OR@^W]3^=)'ID$.-D4:;0%78@4J!V!
M'0>U6Z* **Z3"DF]$C1QG:RH 0"<D?3OCUJ2338)BI>-&*D,OR#AO4>]6J*
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M/>KM% %./2K:%E*0Q(5SM*QJ"N>N".F:<NG0(TA$<8,G+D(!N.,9/J<5:HH
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MVYKU2B@#B8?$FO0(JIX-G"J-H'VQ.!V'3I4O_"6>(L8_X0Z?_P #$_PKL:*
M.-'BSQ%_T)]P?^WQ/\*/^$L\1'_F3Y__  ,3_"NRHH XUO%?B%NO@^X_\#$_
MPH_X2SQ%_P!"?/\ ^!B?X5V5% '&_P#"6>(O^A/N/_ Q/\*/^$L\1?\ 0GS^
MW^F)_A7944 <;_PEGB'_ *$Z?_P,3_"E_P"$L\1?]"?<?^!B?X5V-% '&?\
M"5>(<D_\(=/_ .!B?X4X>+/$0_YD^X_\#$_PKL:* .._X2[Q%_T)\_\ X&)_
MA1_PEWB+_H3Y_P#P,3_"NQHH X[_ (2[Q%_T)\__ (&)_A1_PEWB+_H3Y_\
MP,3_  KL:* ./\%V.I?VOKFIW]C_ &>;Z53'"T@<@*H7M]*["F+]RGT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %J D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***2@!:*3--9@5X(/?\* %D^[4?UKE/''Q0\(?#>S:X\4>)
M-,T*/[P%]<JKD$XR$SD_@*\1U;_@H=\"=)NQ"/%;W_.#)8V<LB#ZG%;T\-7K
M:TXMKR1C*M3IOWI6/II3AN>!4E>&^#?VR/@SX\N([;3/'^DI<R<+;WLAMW_\
M? 'ZU[3:SPW$<=Q#+'+#(N4D1PRL.Q!'!%9RIU*6E2+7JBXSA/6+N6J*3</6
MBH+%HHHH **** "BBB@ HHHH **** "BBB@ HI,T9% "T4W<OJ/SHWK_ 'A^
M= #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2B@!:**
M2@!:*3(HS0 M%)N'K1D4 +129HS0 M%)FC</6@!:*;O4=Q1YBYQD9ZT .HII
M=1U(HW+ZT .HI-P/0TM !1110 4444 %%%% !1110 444F: !NAIG:G,1M/-
M1LRX + 9J6M;H.MALTD<<+L[A44$EB0,8[\U^>?[67_!1>32]0OO"'PGN(Y+
MJVD,%[XG*"2)'[I;*>&8<Y<\#MFNN_X*0_M*7'P]\*V_P\\.736^MZ]&9-0N
M86P]K9GC /8R$8^@/K7Y>1J(8U5,#8NW;Z =O?\ GZU]=D^5PK)5L1MV/G,Q
MS#V2=.CN7O$.N:EXLU2?4]=U*[UG4YF+27FH3M+*Q]R?Z<>U9IW(N!@"K-C8
MWNJWB0V%I/?79Y2&WC+N?3@5[M\/?@#H=QX9UZZ\::H-'UFVB9X;(7D8DME"
ME@\JDY))XVU]W%1@N6$;(^/J5&O?J:G@#1"3[R*Q[A@"/QS7M/P'_:R^(/[/
MNH1OH^J2:IX?# SZ#J4K26[KQG8QR8CCICCVKQF9OFQN##M@8S_M8]Z%EPN,
MX'TK.I1I8B+C5CS>78VI5JE%IP9^Y_[//[1'A3]HKPF-<\.3217$"K'?Z;<X
M6>SE(SM<=#[,."*]7# ].:_"+]GWXWZK^S]\2M.\5:=(TEB&6+5;$OQ=6Q(#
M*>VX#D'VQ7[C>&-?L?%.A6.LZ=.+G3[ZWCN8)@?OHX# _7!K\TS7+OJ-5<KO
M&1]W@<8L5"SW-E:=3%-/KQD>D%%%%, HHHH **3<,XSS1N'K0 M%)N'K1N'K
M2N@%HI-P]:-P]:+H!C $YI R;CZBHF8\<?Q5A^,M4ETGPQJMW:S1P3PP2.DD
MJY12!D9%.,>:7*9U*D81E*7V3$\5?%S0O".J/8ZB\D4ZK&_W#AD8X!7'4@UJ
M^#_&NE^-M,^UZ9<B49 D1AAD)Z CJ,^]?//B7QE8:EXYMO$7B%X8]"T'3EO=
M1DF7]W&HCW,<>I8@ >IKY_\ AS\<?C%^UI\:I(?AI>6?P_\ !VFW,=U>+&B;
MWM]^ 9LKND=U!^4<+FO>GE\(T8M?$HWD^GIZGS6%S"OB*[?,O9N5DK:_>?IE
M13?,7CYAS[TNX>M>"?4BT5#]L@\X0^='YI&X1[ANQTSCTI#?6ZLBF>,%SM4%
MQ\Q]!ZT 3T5"EY!('*3QL$;:Q5P=I]#Z&D6^MV9P)XB4(#C>,J3T!],T 3T5
M']HB+*OFIN;H-PR:8]];1J[-<1*J':Q9P I]#Z&@">BH_M$6,^8F/7<*//CR
M!YBY/09ZT"NB2BH8[R"92T<T;JIP2K @'TIJZA;2*&6XB93T97!!H&6**@^W
M6Q9%%Q$6?E1O&6^GK2M>6Z1^8T\:Q]-Y88].M,5T345"MY;O))&L\;/']]0X
M)7ZCM4JL&Y!R/:D,/NTWSD_O#.<4[/%<3\4O%U[X'\ :YK^F64.HZA90AX+*
M:3RUGD+*H0MVSG H2YM!-VW.S\P#O090!DL,>M>$V'[1-SJ'B+4+6'2(&TBU
MCLG2]BNPYEDD$@NH\>L31E?<C%9.N?M(:GHO@AM9FL--^WM-:RQ6$<LDK0VD
MX8I)*0,%B%/W<@'KTK98>L]D<_MZ?<^BTF2095P1C/YT>:O]\>M>&3?M'6T/
MCA/#YLK4SMHCWLBB\7S4O!#YXM<8YS$"V_Z5SUC^U5=_V'JNH3>'K2WEAFG%
ME$UZ/]+@AM#,TJGU1QY;+VR#WI_5ZSZ#^L4NY]*>8.<,..M&X*,D\5X]X=^+
MVJ74W@F+5=.M;&T\06Y>2_;S(HA,P^2VC##<9".<M@$ XJ3XN?%K5O .M6MG
MINC6FIQKI-SK%VMS=_9V,<$D2&.,D8W?O2>?2H]E._*D:.JDKL]<\Y/[XI?,
M7^][U\Z:M^TCJ5I8^*]2MM'L_L>G7UK86/GF7S)VE5'W.%!P<.!Y:Y8'K@4V
M^_:4U>QOM=M)?#45L^GZ4U^;:2X<2PR;5)20@8(+-C"G<.XK7ZM6M>QBL32>
MB9]&-,BYRP&.M!D7IN&<XKQ*'XO>(+.31([O1(9Y=0T>2_@6W9XFO[P([&TM
MM_1@$R=_4'(Z&L[_ (:$O)M)C\G2K.[U6:RC=HA<&.*&Z>X$7V>0L,H4#9;.
M,D8'6L_8U>QI[5'OOGIQ\Z]<=:7*R8VG/>OG/6OVDM4T%9HKSP[9R2V\$QNY
M1> 0"XCG2)0&[QLI)![,NVOH+2YFFLX923F2-7(8Y(R,U-2G*G:ZT9<9J6Q-
M,OR]^>,CK]*^2_VI/VPM5\"^+X?AK\,]+@UWX@7$7F7$LY'V?38R,Y8?Q/CG
M!P!W]*^K]1NOLMG/,>?+B=^.O"D_TK\H_P!G;[5XN\7?$?XA:HL<VH:IJTT,
M4QRTJ .=P'HN,#\*]G)\''%59.HKJ/0\+.L<\!A^:)/>>"_CQXX:34?$OQ6O
M--OG)=+.VNWV(X/ 81X0#TVUJ^'_ (U?M$_LY[M2U'54^(WA.W8?:K>\8R2%
M#U(;&^/'][D=.*]6P%P/ESZ+3D(7?NV")1^^\TX0+@YW9]B?S-?<5,'AYQ]F
MZ:1^84<^QL*RN[W9]8? CXV>'OCY\.-.\7>'9C]FN 4FMI,"6VE'WHW Z$?J
M,&O14;<N1S7YA_\ !/GXCZ;X;_:@\:>#= ED_P"$0\0I)=6$'\*30\L<=@06
M&?85^G,,B^6.@K\ZQ^%^IXATOF?L.#Q'UBDJA+13?,7UHWKZUP';=#J*;O7U
MHWKZT!=#J*;O7UHWKZT!=#J*;O7UHWKZT!=#J92-,@4$M@'N>*:TR*I);% -
MI*XK;<''-0SE!&68A HR2>WK7/ZKXVTVUD:VMFDU.]Z?9K-?,;\3T7\361J\
M?B?6-&O99GCT.U2"1UBB_>W# *3@L>%_ 5HHM-7TN<<L1%IJ.K[+_,_(#XY7
M'B+]H#]H3QSKFEV4NH6J7[VJ7 XMXX8OD7,C$*HXSUKF&\-^#/!OS>(=:?Q'
MJ*<?V7X>?]RK>DERPQ]=@)K%\7_$/Q#XHFGL]3O673TEDV:?: 0VR'><GREX
M+$]2V:Y7G;MSA?[HZ5^O8:G&G1C"/1'Y_B)RG4<I'=ZC\6]2:S?3]!M;/PGI
MK@AHM*!664?]-)CEW_05Q$C>8S.[EW;[[,22_P!3G^=1  4I-=5K'+<5N><@
M_3C'M3***8A\:Y;.<<8_.OUH_P""9/Q"G\8_L[G1;N226X\-WTEBCR')\EOG
MC7/L"17Y+Q_Q>F*_1C_@DC-+_9GQ&A^;R/M-LX7/&[80:^9X@IQEA'4>\3WL
MHJ..(4>Y^B"^WI3Z8A'XUF:]XDL_#XA-VMP1)D*8('EZ8Z[0<=:_-UJKGW1J
MT9%<K_PL32.?W6H'_MPF_P#B:/\ A8FD?\\=0_\  &7_ .)JN4#JLBC(KE?^
M%C:/_P \M0_\ )O_ (FD_P"%D:-\W[O4!MZYL9>__ :.7R%S+N=,S$2GTQ3#
M-UR5'UKE;KXF:#:@23S75JA95\R>TE1%R0!EB,#D@?C5":\O_'%^]MITKV>A
MPN5GU",[9)B#@QQ'LN>K_@/6J4>IA.M&F^1:R9W2R!AD,"*7</6N07X;6Y4;
M=5U@+V OFX]J7_A6L'_06UG_ ,#FIVI]9?@9<^(_Y]_B==N'K1D>M<E_PK>#
M_H*ZQ_X&M1_PK>W_ .@KK'_@:U/EI_S?@+FK_P#/O\3J_,!;@@KCFO,OCOJ-
MU_PA?]FZ9;RW=YJDHM@L*EFQC)/TP*[70?#:Z!'+&DUW=><VYFNIS(1CI@GI
M7C'[;'@OQGXV_9_U^V\$W]S8ZS;,MTT5DYCFNH$.98%<?,N1Z=< 5IA^55XL
MC$TY8C#2@].9=#XL_;2^-&EV?A1/ASI%TMUX@O'@D\136,P>&W6%3Y5ON'WF
M+'>P]0!7S?\  _XP:O\  CXE:-XNTB=PMM*%O;8,=MS;' DC*^XY![$#TK@(
M55@P&Y3N(;(^Z<\AN^[ZTR1OE(;H1WK]1I8.G&C*G+WN;N?#1E*G.*I_9/Z$
M/#^MVOB?1M/U:S<365] EU ^.6C=0RD^_-;#*-K]^*\&_8AU"XU+]EWP#)<[
MC)'8^2&8Y)578+^E>\R#<C =QZU^3UE[.K.G_*?HE.;J4XR/$;WP;XGTS7O'
M=]8Z/9ZEKVI(3H^N7,R*L,1C1!;.,[XU0AC\O#;L]<UY]I_[/_CFVL?".G7)
ML6@\,W<T\$EM<LZ7%N[HZQ(TA\Q),[R7/K@'%=[<?#7QA>?$*XNI;J3_ (1J
M?Q!+<26JR[2;=M-$1DW YP9<_)V/-<KI/P)\::I:>&(=4U&ZB>'49Y;J]DF)
MFBMHR4M%55;&\1@#?Z'+ FNZD^6SYU]QS5(M_8?WD&B_"#Q= ^LJ-*AL/,D3
MS2-11O[0E_M))Q(55OEVQ ]?F;&WIBK.C_!WQ%,U[9ZA:1Z=.-.OH;_64U!7
M;6+AYUD@FVYS&05)W/\ <+;1Q6-??!?QOKO@F]T:*QN++4&U^XN9+B>4()(_
M*D\MPZOER25 8XV'!P<5H>._@WXGOKKQ7JFG:+<;K_2M%"Q?:_,EEECGD:\0
MJ7"EB@BW= ^!3<]?C7W$*#M\#^\=_P *U^*6N:MX6\2O9Z597UC/_;%Q92Z@
M\C">8A)XX77Y640@ ;^,L:MV_P *?$&DWS-+X?76_"]IK4ER--N+V/[7?"1"
M/-F8';+Y3GY$<@[3SRM6]0^%WBYOB):ZK9V]\NC7M_;-=0_;?+-G''9.@FB0
M-@-N8*4Y&0#VK-M?AAXZF\)WMH+*\"1:=)9VRR7?D7%W&MY')F7:Q"3R1!P6
M!QSVS2DV_M((Q5](LT/$GPY\::E>ZQ;6VFJ]EY]Y?V=Q_:"J)5FM]B6X7)VL
MK'[Q^7 ^E2:]X/\ B3XH\8>&_$5EI=GIMEH=FML--OKXBXF$J%+@CR\Q\#;M
M+]UXZU@:A\)_&SV]UJ>B:1J&G16T>HS:+H,VIX$/FQQ1F"4AB,.PDD7D[" ,
MU])>%M/GT_0]-@G1DEBM(HG5FW$,% ()[\]_KZUG*7)9JS-H1Y[\QX5\+_@W
MXM\%_#WQGHEY$MQ>:II*I;2QS*J^>89%:(@'@AF'[WJ^>?NUDZ-\$/%4BZ5$
M^BMX?T@3CS].M=00R1C[ 89)E9255Y),<#CNPR:^H]M&".U8JM+70T]C'N?-
MO@[X<^-?#_C'2-9NO#L+K:^'C8P16[P 6\RO(5!R?D9E*;BF03FL;2/@A\0M
M-\&ZA8:I:6-_J":K;^(+!-/O&>U>\;FY2X28@M%O^?:#QN.WE0*^J^?2DY]*
M/;2[ J4;[GBGPS\/:OX#UKQ%+K6AS27VM:TTB7-FD<D;(Z@Y\P'>(E.0/, (
M]*]JMU*JV1@[C2LAR".WM2QKM7&*SE-S=VC6,>56$\Q.F>O3WKG/&4=C<^$]
M4-_9+J-I#;O<O:2#Y9#$/,4$]N4&*?XR\20^#?"FJ:W=+)+:V-N\[QQ@;F Z
M*,]*\1\9?M 7GA_05LM:\&PM+>'RKFP:]$D#6LD!<?,JG)9<H4( !YSMYJH0
M<M8DSJ1C\1G^#?B/I6H:?H6H?\(#I^C6-[J443ZQY;"RB+XF!4E =QDF= Y&
MSS-PSR,V_"/B;0&:W,7@VSAAO=?NM/@C4.I1;;S07._@C*M@(2H#'OQ5WQ-\
M0-+_ .$7U6-O"=K);>$K6WO]-T:^O3"UU"JJPDC55*/$IVJIR1N3G& :Y?5O
MB%X6AOO%?AC4_!MN]MIKKJ=Y&NHNZI.ZK*SH& \M6:8#*XRQ.0!S7;:^T?Q.
M2_\ ?_ UM/\ 'N@OJEL)O ^F1^'S=6UO)?1NKW*3SPDJP&,NN%V8!)QCCM63
MJ_CC1X/##W,WPYT+>FEW.N:/;O<!U^SR,(;A)"%_=N\>W/8_=ZBNGM;[PZ_Q
M*:#0_ ]E)XKMK_[';S7%QY4*+#:QN\_ .TA9!& H)..PYJCHNH>'K36/%6C2
M?#[1K6&ZU6+P^YM;@NEY(\3W.&!4!(P5/ ZLQ.*7NW^'\1]/B_ T+C6-&CM[
M31;S0EBDTW[-8QR0738@>Y@9V:+=R&0#"GJ.H[BN4U3XM>']:L_">H>*O \5
MU'9Z/>3WHNKD2S6$D2JZVQ!^^9 @?YNP!K<OO'7A?7M2T/64\(6+W]_]FL8[
MJ^G*1PL\;%HY-BM\\2 J#C(W]JZG7IO#'A7QH=,'A.PC5M.N-2CNK@;/MLBV
M[1-# ,8D<1(%8,1A6&,\U-H1U</Q&[VW.(U[XEVW@6/4]6U#P9IZ:X^H65S=
M1Q7+3P.TL3-'.NU3ME4+L+8QWSCFN[\33Z1K_B;2]"@\+V%[?ZQ9MJM\]X^$
MC@95CDPR_?D(  [84&N;L;WPEIMYHNBV'@G38+.]T >)IHIYCYQ'EE!$@"D,
MP5BOS,% .!66WQ?T?5+KX:PW'A"WNKG4+87>GC2[US<6D?FB/9&0JL^.KKPN
MU#R:5ENH_B%Y/3F_ SKSXS6&@^$_#GB0>%[61YKN?3;%))YM\%M'&QW!BI^?
M!V>8OR@-@L*M:WXRT32?#7Q"GC\&:?-I^AZ@NAK'()#+=,7B<M(^#N.YP<*6
M<%:Z7Q#>>!/"?CJT\#?\(U:WD<UE=WJQR3J\<$K0N3 D3'Y5EBCG/RC:"!G&
M17!V/Q/\(:QX+?5;OP/NTSQ!;3ZC?^3J4C6CR00121.K' W,2L9?:#N3'(K5
M*Z^#\2'&SW+6J?$CPUIMO+8OX"TV32H-%2X,9<D;6GCD9=^-K+YA#==VX9(Q
M7TWX3TN'2=+\N&2:597:Y8SR;V#2$N1GT&>!Z5X-)XK\(R:+XR:^\&Z2EAX=
MBA6*Q:7][/(Z1[$*LH15+LJ9W=LD<5ZY\'=4TWQ!X!T_6-(GN)K74PUXRW5S
MY[QR.Q+H&S@*K94!>!CBL,1RNUHV^9M2NGN===0K<1E#_JW5D;UP1VK\B[K6
MF_9+^.GCWP7XFCN3X=N[LW^GFU3<$#MN60 ]5P=IQW%?KQY;[0,5\:?\%.OA
M+IGB+X*+XV$"Q:]X;GC\J[3 =X';:Z-Z@9##W%>AD^*^K5]=I'!FF#CC,/:1
MY3??%3PU#X-U?Q'8ZG#K%CIL"S3);.0VYON(PQ\NX\5\E?%CX_:_\3FA@2/^
MQ-(C!(L+64C>Q[R-_$1Z>U>=P:G<PV-S:I/)#;W6WSH48[90IRNX=\'D>YJ
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MK]8R[%1Q&%C.^VC]3\\Q^'EAZTDUH%&*7;MZTC,/6O4/.$HHZT](6D.%&30
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MR&.G\7TIJ/-K>QC4J\GNI79@_$?6[[Q+X4O;VU4Q:'%);A6D'-ZQGC4C:?\
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MGVKVNHI(S(P]!T]<U=.I*E-3CNAS@JD7%]3\8X_^"?\ \<]O'A*/_P #(_\
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M%:/% ^_\.]);_=U&0?\ LE2?\/:O$G?X;Z:1_P!A23_XW7P5O-)N-2\EP?\
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M,L.V>U?*G[#O[847Q^\.W&@^(S':^.M(A#SH@VK?0@X\Y!ZYQN'8G/2OJQ9
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MDTU59K/5).#,1_RR/J3V;VKS+Q=\3M>\7:F]S)>W%E K_N+6VD*"-?\ :/\
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M(7C&W\$^'[G5+K&R-=J1]Y'/0"LXPE5?LX;L5:M&A3E5F[**NSE/VC_&&I^
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MP"LLQV%AQR57<V/:OH;;7YV_\%9_&/EV/@#PE'+GS9Y]5FB]-B^5&3_W\?\
M[YKT,NH>VQ<*=]/\CBQCC1H2G9?<?G?'?74$*(MU<*@& /.?M^-/^W7?_/\
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MECC"@CMV]J?MHVT_D/7J1NN[H<<8K@+7X,^'+7Q)>:T]H;BZN'W[9CO1&[D
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MO#IOA+QM_P (1.^LV\FHP_:&U=#:NC>5T0+G<,=SBO.?^"C&CZ/=?&+P]?\
MC/4KO1=0FT;RH8=)MOM,;(DKG)9B.?FZ5Z-_P24PW@CX@\#)U6'_ -%"N$_X
M*S6:P_$+X>70'S2Z==1Y[85T/_LQKXBG+_A9M_6Q]1.#_L[GYF?)::+\./\
MH:->/_<,3_XNG-HOPWVG_BJ->';_ )!:?_%UP>[D]OI2C)[U]OR[I'R]W>[D
MS].?^";^I167P[\6Z5X,N3K5K#JPN)I-60V\B.\2 *%7/R_)G/J37UY]L\9'
MG^S-)SW_ -*?_P")KX3_ ."25T3<?$VWW9S]@D(_[_"OT71 W7UK\LS9^RQD
MX\JZ?B?=Y=3<\.I<[/,/B'>>(6\(WJZI9Z?:V?F6^^:"=W8'SX]HQM[G _&N
MD6^\8L,_V9I/_@4__P 347Q@C \!7Q!(*RVS*0<8/VB.NQ6)1M Z5Y<I+E^$
M]"-"7/\ &]NYR7VWQG_T#-)_\"G_ /B:/MGC/_H&:3_X%/\ _$UV*Q+BE\I:
M.==@5!V^-_><@+[QG_T"]*_\"G_^)J>PO/$LMY&E[IVFQVYSO:&X=F'T!6NH
M\L4BPJN<#&>3S4N2[&L:3C]MC(\C'&*J-J0^T-"&C\U1DQ[ANQZXZX]ZX;X\
M?%6V^"WPI\3>,KM@\.F6KR0PMC]Y-TC3\6Q^M?GE\+OV6_C%\6OA_=_&^R\?
M:EIGC_5))-2TVSCG=1<QY/&[.%!&51<8X&:Z:&%6(@YSGR).WS(J5G3?+&-S
M]10&:,%\[2,':>37XC_M:^+-)\8?M+?$#5]#"?V:^H"!)(<!96CC6-W7'!#.
MK'=[UN^*/VV_CKJ6@WWA#6/$TEF%W65XPLDAOP1PR,XY4CUXS7@1^6/##"KZ
MG_/UK[7*,LJ8*;JSE>^FG8^7S+'0Q$52BMCZ#_8+OK[3OVL/!_V&1U^T^?#,
MJ<[HBF6!_3\J_:)F^4\9'IC-?G%_P2[^!=V+[5?BEJMJT4#1FPTGS!PX)S+*
M/4<  CWK]'BH:,_2OFL\K1K8M^SZ;GM953E3PZYSP[X_6?AB:_T>+5?$#>']
M2O;2YLVF%K]IBFLW*><LJD85=WEX?.58#L37+V/AWP1#K]GK%EK6M7&KQ:K_
M &%'++;R3)<-'!Y/V9HL['55&6? SS7JWQ$^$>G?$;6]'O[NX>WNM*BD-D5&
M?)F+QL)0,X.WR\;6!!W<BN7T?]GFQL[N=;^\2]LQXA?Q!!&J-&Q9LDI(P;YL
M$@@CKC%>=!KE5Y:G9*,G*Z1C^&_#7@NR\(>&[&#Q;<SI]GU>TM[H1[$9G3%Q
MM3&(Q%C(4<#&*Q]%\(^"FDT?3/"'B^YT;4YQ'<Z9':VH9S!<6X65E4C!BD$+
M.S?P.OT%=/:_ 75]/T465KXN*26-Y<3Z5<_8E8P17&?.AD'20$-PW4$"M31_
M@3%X?\1Z!K.GZY=176BVT6F62RQJ^-/5 )[=NY,C@.6ZAD0=!1SI)^\#BV_A
M.#TW3_ _A'QIXJ@T[Q)]GDATE=)FMKW2!.5-NG+)*P'F8$N6C P22>U07'A/
MP3HVA P^,M9BTRSGM="U8P0+(-6F23S(K=3@[64G9A>B$+[UWFJ? %]<U;4Y
M;SQ).VGW%S/>6EDL*C[-<RHJ&0MU;:H. >!NJAXP_9P;Q8WB6==<2U?5+FTG
MBM/LH-JIMSG=,@(WR.>K\'  [4_:1:7O$\C_ )2AJG@7X<QZA<^';Z_^R:F+
MD^-=02>V&Z6W69VV3$@@HK$_*3N  -9.B_#7P%-=^&+6TU/6VU"XA2YT%8XY
M(UM[-9&<@Q@A3'()64[@258=*[R;X"V]QXP7Q2=:O/[8$QDDB+![.2+R/)\D
MPGC;MVGGG(S5+0/@#-X>U;PAJ::U%=2:*;@21SVI9"LK!ML&&S$%(P!R,4W-
M):2&J;;LXE>^_9DL[S3=4L4\07*Q3:=#I>G^;:12_9;:*994C;_GL%*A5W8P
MO')YJ_J_[.NDZUJTFKS:C?0ZRVP+<0$I##&(6B:)(-WEJ&#L>1GYNM>R)"O3
M'4<T[[.G<9_K7.ZU3HS=48=CEOAKX9N_!OA6TT6[U1M8^Q*(8KAH1$1&!A4(
M!.<#'/>NK7J:18PO2G8Q65V]6:I**LA:***!A2-]T]Z6D;.TXZX[T <3XZ^)
MEE\/9O#T>H133#6=073XI($W+$S*Q5Y/1/EP6Z D5SLGQ_TV*:/.F:B+5!$;
MZ[\M/+L?,D:.,O\ -EMQ4GY<\<\5UOBCP+I/C.XTR?5(I)OL+2ND6XA6$D1C
M96'<;6. :Y"Q_9W\*V,.EP0OJ'V.QM8;-K;[:WEW*PDF,3C^/83Q^N:W7L^6
MTMS&7M+^[L6?!?QXTKQMJEKI\%I?:?=3I>,T=[$$,7V:41/NY_B+*RD9!!ZT
M:C\?=$TF3QE'-!>R-X5$1NMD(S<!B%+1<_,%8[6Z8(-6-.^!_A;2?$UMX@2V
MFGU&+33I9%U,9$EA\WS5WJ>&96QAL9XZUD2?LU^"+DW[BQGM[J^MYK:[O([D
M^;<>9()27)SEE< @]*/<"U0TM:^.&G:3=ZN1;SS:9H\"O?ZA&%*13,JLEN!G
M+R$,O Q]X<U5A^/VEV\R1:S:7>@SFY-JT&H"-"A^SF=&+!B/F52!@_>&,9JA
MXX\"^&/!/A?7M=UJ?5;[3Y;..WU6V#*PU C$:2R(%&)1E<.FW[H/.*Q[?2O
M/AW7DTNX&LZCJJ3R79U#4':9F=K"3 =C@8$"N%&!R >IS5*,.QDY36[.BB_:
M&TB=K25-,U!M,E2U-QJ"QJ8[1KD9A1UW;B3QD@'&15F\^/VBZ<L+2V6H_O\
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M[>)[L?\ ;HI_]FI/^&,--X_XJN[XZ9M$X_6ONW)7/BY8S#6UJ:GR[+Y8)VY
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M02,XZ4_:2ON/V<%T/)4_9Z\/?9M,M#<WG]GZ5876GV,.Y?W:7"LK_/C<P"G
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MGK0.E+7WCW/S%WZ,]B_9G_Y&351DX^RYQG_:%?1J_=/X5\Y?LT*?^$DU0_\
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MG3&2DKH?13,FCGUI7+'T4SFBC7L(?13<TF:>H#Z*9FC-(!]%-&:44 +1113
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MFO?%G2=#GL(7^TW#7D4,_P"YC),,<KJB.P/0%F'7I@U5M?C1X?G\4:1H:SW
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M_.O6AGS5+DY=?4^:EPA+G?+.T6[[?\$YOX*^!W\$>%1%=;6U&Z?S[C8/E4D
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M[E3(F4C<WW1UZGL.]&O8+KN:-%9EUX@TVSMY)[C4K."".3RGEEG155_[I).
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M&OZ2->M_[2MKW4VMY86*W:VC2-*URC9 ?+-C !(->S_L^Z'I/A_X9:?!H1U
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MYCN9F_B9FRS-U)-?8OPY^&ME\,O"9L(+B34+^8M<ZEJ]W@W.H7+#YYI&]3T
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M8+2-8DQZ 8KY+/J\7&%%/7<_0N$<+/GJ8E[)6^\^5?C8A7XFZN2,$B,X_P"
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MC=[5@_\ ";Z!_P!!K3O_  +3_&E_X3;0/^@UI_\ X%I_C3Y9_P K^YA[2/\
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M 'Z;_P"*H_X9+^$/_0@Z/_WZ;_XJO7**/;U?YW][#V%+^1?<CR0?LF_"$?\
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M444 %%%% !1110 4444 -9=U<5\4?@SX/^,_A\:+XPT:'6;!9/.C63*M%(.
MZ,.5..XKMZ*:;B[H32:LSP[1?V)O@IX?U&QOK3P!IGVJS97ADE4R?,O1F#'#
M$>]>T?85#9#L/0=A[?2K-%5.<JEN9WL*,8Q5HJQ ;4-CYVR!_DT_R1QS@"I*
H*@=K";:3;[TZB@8W;[TM+10 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !S 1@# 2(  A$! Q$!_\0
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M P: /@S]FR'^P_V\==M&^_--,>?3%7?V_O!+_"7XV:#\0-.C,,<]QOF>,8
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MOVA/V>=,^/.BV]IJ;-A.@'UKL/A+\-[;X7>![30+3F"+\ZU=#\26&O06T@N
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%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '& D # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^T247*6Z$K)%'&<?ORPX7N 2*(TIRT2!SBMV?7P8-R*8WW3WKPGX@?MA>#O
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M*K^RZ?\ .'U^?\I]A_\ "T/"O_0?LO\ OZ*/^%H>%?\ H/V7_?T5\@>6.NP
M?2FIY<C.J,CNAVLJD$J<9P1V.*/[+I_S!]?G_*?8/_"T/"O_ $'[+_OZ*/\
MA:'A7_H/V7_?T5\?1^7,N^-DD7)7*D$9'4?6G>6/[H_*C^RH?S!]?GV/K_\
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MW?6MK=?9B+IYXF5([AWCB<J#N.6C8$=@0:/JL.XGCZW\I]@?\)MHG_04M_\
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M18$F28L_GJ>6382..YK*NOCQ)9Z7]H?3].FN)+>*]BCM;IGB,;*S/$SX 65
MN<'L13E^,>KZ<L,4VE0:K>S7MVL<5HY4I#$ZA(SGCSBK9&>"!0W!K<JTNB*T
MOAGQU=:))IUS%<^8\9BD43QBR-H8N(0@'$P?G/\ 2I+UO&&CQV]SJUW?6FFQ
MRJNLNU[$BS*9/E^Q$_ZL!, @]0<=:WO 'CZ_\9^,;E7:TBTUM&CO8+.VFWO
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M+_\ 06U/_P %DE+V.9+>,_Q'[;+?YH?@=6?V*_@I_P!"#IW_ 'U)_P#%4?\
M#%?P4_Z$'3O^^I/_ (JN4_X>(?!;_H+:G_X+)*/^'B'P7_Z"VI_^"R2E[+,>
MTOQ%[;+.\/P.L_X8K^"G_0@:=_WU)_\ %4H_8K^"O_0@:=_WU)_\57)_\/$O
M@O\ ]!74_P#P624G_#Q3X,#IJNI_^"V2G[',EO&?XC]MEO\ -#\#K_\ ABWX
M*_\ 0@:=^<G_ ,55K1?V1OA'X=UJRU73?!-C:W]E,MQ;SHS[HY%.58?-U!KA
MO^'BOP8_Z"NI_P#@MDK1\,?MY?"7Q=XBTO0]-U+4'O\ 4[A+6W62PD53(QP
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M?&X7<K$DDCY5ZGL/2O6?^$BTO_GZ3\C1_P )%I?_ #])^1H^L/\ D']3I_\
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M_ S1;;QIK'A74&UG5O$&CZ?=:A>V6E-&C#:ZB"!&8$,Y0[V;[H) 7.*RM/\
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M%_\ !B/_ (FOU7V>]&SWH_UDQ_=?<'^K>![/[S\J/^'>/QE_Y\M%_P#!B/\
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M?#V"IR4XIW7F,XY]<5\2:G_R%M0_Z^9?_0C7VZWW37Q+JO\ R%K_ /Z^9/\
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M'IVI:3</6C</6@04J_>%)N'K1N'K2ZJX^IZS\(?^0'=_]?!_D*[VO/\ X/\
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M3P 6Z_2E\L'V^IH^HRZ5&/ZU#^4^@/\ A#_"O_0-T[_OI?\ &E_X0[PM_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3O]*^(]27=K%_T
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M$_NE&>N,UN>'_",'A_5-9U%+N>YN=4E$LJN%CCCP21M1 !GGEL9.!DFO9?\
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M=04K//=I<"&1"!P3L*O@?WL]*8?BAKFDMJEI=ZKHPGMKG4766^@=%_<O^ZM
MJGF1E.0>X[&O75.A;X5]QY[J5K_$?33?&'Q!W6S'_;"D'QAUX]K/_OQ7S):?
M$C4M)AU,[K72WGN;R_ UDR-N=1&5LH]O1SN/] :6?XU:LDT$HLK$/*UVCZ'(
MDGV^V$,(=7DYP0>3@+T'&:/9X?\ D0O:5OYCZ:/Q@U_/2T_[\BE/Q@U_!Q]C
M_P"_%?.4?QEN;&]FCO[G2;S3(X+ADUNSWBVGF6V$T<*G)R^25(R<XXYXK?\
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M*[VN8\"ZA!J6GS26[EU68@DC'.!VKIZ\J;;DVSWJ,5"FHQ=T%%%%0;!1110
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MNJ?]<&KYYUB[O;'1=0N=-M?MNI1P.UK;;@OF2A?D&3P.<=:]7!_!(^<S/^)
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MLX0XBB,3')GW_P 1&<\YQ24I#]G$];COK>:\N;-)E:[ME1YX<_-$K@E"1_M
M58\ML$[6P.I["O!=!\-^,?#WBJ77++2/$+Z:SP)<65]J,<UU<_Z'(C$DMC8L
M[*P!/'4#'%+=>"?&'B+P=JVF^(HM?N]4GT6**QFL]4$5LL@B!ECF"N"93(&^
M8Y!R,$"CF:'[%=SW@QLJY*L!ZD<4E><?#O2_$.E^+M8^VVVK'1)+:/[/)K%S
MNDMF4*!;J@=@X #'S.&Y(.>*](/<FJ3;U,)1Y1**7USQBDIZD!11^!_*CT]^
MGO3U **7MF@_*<'BEJ-(2BCMFE'WA33U*T/5O@__ ,@6[/?[0?\ T$5W]<%\
M(?\ D!W?_7P?Y"N]KY^M_$9]EA/X$0HHHK$ZPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** &2?TK\Z_C?K6N:';12>'I%349
MM?2'RV4$3QY=GA]MX0CZXK]$Y.]?$&M0PRZQ=F5(YC'>22)N&=CACAA[CUKV
M<MBY2DCR\<^7E9XS!\9)[WQ)J&J6MS ?#4]A&-(MIU9?.N?.$<DA*@MDDE !
MQ\A/%6M'^-]UJ]C;:A#H,2:;BS%TTERPF1KB5XMJ+C!PRY.3T/K7HUQH6E7=
MN8)]-LYH2NSRW@0KMW;L8QC&[YOKS3X='TRWA\J+3[2*'Y?W:0JJ_*<KP!_"
M>1Z5[G+4Z2/*=2+Z'E_B[XG7^N>$X(-%-O9ZA>VUG<2M'<G= LMYY#Q@KRC8
M&-QYZU;'QKVZY/H]K8VEP^Z.&PO#<NL+$S&$F5V' !5OF7J1CJ<UZ##H&D6S
M3-#IEE$TSB20I @+L&W!B<<G=S]>::WAO1'6\#:18$7@(N0;=#YP)R0W'///
MUYI\L_YB>>/8XZP^(>K6OC"?2]932$M7OXK**6TN6'E!K8S%F+<,I*D U5A^
M*EWKVE7=Y%8):6,,>GR&>"Z*RNUS( %7CA0.I[YXKNIO#.B7$;1RZ38R1LJ(
M5>W0@JAR@Z=!V]*LII>GQQM&EE;+&P4,BQ*%.W[F1T^7MZ=J?++JPYX]CSRX
M^,-[9QQR7>C6L<=]Y@T]DNB 66Z%N6F)&$7)#9';@]:Z[P%XFG\66NHO>6UK
M;SV.ISZ;*+.<S0OY9 WJQ['/Z5=U30;/4M.EM1'#;AXVB$BPQL45FW,H5@5P
MQZCH:@\)>%;#P7I)T^P9G1IGN)9I-H:25_O,0H ';  P,"CEE??0'.-M$>9:
M5X\\5Z?I^I^(72\U;2X);BW>'43'%!).;P0P"V9?FP%+;MWH*Z+5_BM<>'[R
M_%YIEK)8Z?>G3KE;:Y;[6\XB,A>.(CF+MD\]3VKO39V9M6MC;PFW9BQA*@H2
M6W9QTSGG/K4;:3IS:H-2>QM7U'88_M;1*9=I&"N[&<8I\KZ,7-'JCS[4_B]J
MNDW&DVAT*UU*[O;4:@_]F71FC6W+*NU7/!D&[GMQ[T7'Q@N[2QNY[C2K:T:T
MOQ;7T<L[G[! 02DTNT?/N X,>5&><5VZ^%=!2.%$T;3U2&0S1J+=,)(3RXXX
M/^ I?^$7T/RPG]CV&T3?:,>0F#)_?/')HM/^8.:'1&JK;E5AR& (/UI:;N'K
M^M&]?7]:T6QGIT'44W>OK^M&]?7]:8KCJ*;N'K^M&X<\T#NCUC]G#_D=-1_Z
M\O\ V<5](+V^E?-_[.!'_"9:@?\ IR_]G%?1ZL.*^3Q_\=GT."_@I#Z***\X
M[PHHHH PO&G_ "*NJ?\ 7!J^</%6J3:#X3US4;=4:XL;">ZB$@RNY(RPR/3(
MKZ.\:'_BE=3_ .N+"O!&C69'215>-T*.C %64C!!!Z@@D?C7JX/X)(^<S.WM
M(GGFK?%*X\.PZ7>7UB][:W/AV#59H;&/=)YLDD:$@GA8AO)+'H*BU#X_^'-)
MU22TN+:\>.WC1[J\M-L\5NSQ&54RI.X;1]\?*"1ZUOV/PK\*:38WMG9Z6UK!
M>*L<OE74P;RU.5C5M^40?W%('/2IH/AGX4MIA)#HT,*_919-#&SK"\(4H%>/
M.UL*2 2"<'K7;:1YB<.J*?@3Q=JGB;QAXFL-0TRXT>*QAL)(+&[*-(GG1ERV
MY3@@C!QU%8=G\;K.&&W2YT_4KZ)%MC>:J(XHHX!<3O%$60'GYE .WG!!KLO"
MO@G0_!)NSHMB;1[ORQ/(TSRO)L&$!9R3\HX'M42_#WPVMM-;KI$(AF$ D7<V
M&$,AEB'7^%R6_&BTB5R)O30YOQC\3KCP3\6-.T;4DMH?"<NDO<7E^W^LM[C>
MRQ9)XV-L9?\ >(]:YWPW^T%+#X=DU+Q3I?V2636YK*.WM&426MMO186DC8[G
M;$B[B/?IBO3M?\%Z'XJDN'U?2[?4&N($MIO/!(>-)/-52/9_FSUS69JWPG\(
M:Y>275]HD,UQ+,\\KB1U\QF=7;< P##>BM@\ BIY9%*4+:Q,:3XW:=#-&+K1
M=4MH;B1HK2=_+(NMMT+9R &RH5F!Y'(JOJ_Q2N_^$\L[.UMIHM#L5U-M2G:6
M%/.EMF1 A+GY4)<>G4>]=7?_  ^\-:I9BUNM*BF@$4L*KN8;5ED$CX(/!+@-
MGJ"!BJR_"WPDNER:<=$B>SDCFC>.21V+"9E>4EBV<LR*V<YRH-.T@O3_ )3(
M\-?&BT\8LMOH>@ZCJ&HH)WN;)9(D-HD3["S.3A@6. %SQ4'A7XTQ:UX;6^U+
M1+G2[E8+&>2V65)5*W<[0Q%6!YY4DUOV/PM\+::]K)::5]FFMKA[E)H[B42&
M1R"Y=MV7#$ E6R,CI4"_"'P;%-:R+HB*UJX>(":3:")?-0$;L$*_S*#PN>,4
M)2!RI_RF-=?&:UATN'79--U*WTP07TJ6OEQ-+>+;NL9=3GY/F. ._>II?C3
MLFH6B^&M6EUG3OM4E[I:M%YD$,$:2/*7)VL"LB8 .2372W'@'P]=:;#I\VEP
MO9PQS1)%EL*DK[Y!U_B8 USOQ!^$-EXRBG^Q_8=,NKUY'O+V:&225_,C6-BF
MUU&2BJ-K97('%.TA)POM8V/%WBZ32_A;JWBG2T19HM(.I6RW*%E&8PZ[U'7
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M-O'JJ3PW$-M-::/#?L?.6-69994S^\RSEP3U/-='?_#;1-2L[&!Q>01V=H;
M&VNFC:6V)R89"/O(3SZ^].+J/L#Y"M-\6_#5O8"\>ZE\GRY)#^Z.5VRB(*?0
MLS +GKFLO5OC-8R:&]UH4%W>7,;Q+,3;$Q6A>81;9B#@$_-C&1CFMZX^&OAV
MZ_MO-BT9UAH7N6BD*D-$!Y;1_P!P@@'CN,U5O/A7H-]Y8G;4FPL2S8O&477E
MOOC,P'WRK<C\NE5^\Z@G [210DC*. #@4WUI68LQ8]2<TE::V,^IZM^S?_R.
MFH_]>7_LPKZ07M]*^;_V</\ D=-1_P"O+_V<5](+V^E?*9A_O#/?P7\%#J**
M*\X[PI*6B@#!\:_\BKJG_7%J^:_&VOR>$_!>OZY##'<2Z;9272PS$A'*C(#$
M=!GJ:^E?&G_(K:G_ -<6KYXUK1K7Q#HM]I5\ADLKZ%H)T5MI*,,$ ]J]3!_!
M(^=S)VJ0/*-/^.FH?;-/%]IT.I:>9;E);OP_#)-#=+':I/NA#D$!"S*_)!(X
M-=5J/QL\+Z7<Q)<S70BN-/.IV]PD&Y)X1&)#M .[<$8'! [^E=-J7A?3M6DL
M'N(FW6-O-:P>6Y0+'+'Y<@P/5?RKEM/^!?A32M2CU"R&HV=W%&T<+PWK#RMT
M0B9UR.&**!GGZ5W<LSS+P>X^\^-GA?3=0TFQO)KBWN]0CAE$7EAS LKE(FD*
ML0 [#@KGU-3_ !*\<7G@2316@MK.ZAO;N.UDBN!*K/N=5RLBCRX]H).7(SC'
M4TS2?@SX7T&ZTZXTZ"ZLYK*/R\QW1Q<KYC2@3 CY\.S$=.I[5L^)_!.G>,)H
M3JDU]):)M\S3X;IH[6YVN'7SHQP^& /X52YNI/N7M$FUSQ5:Z+K-MI2VM[J6
MH3Q27"V]E!YGEPH=IEDY&U Q /<^E<3X8^,BS:'IT^J1S7^I7JVT<5EI-FSR
M>?+%)*1DG!!6,D'@#IWKM-<\(V/B+5[35)IKZUU*VC:%;FPNF@:2%CDQ28^\
MF><52TKX::!H=U8SVEK)')9/%)!F9B%,<3Q)]0%D;\<'M2]X2<;:F39_&+1]
M0E#6?VC5%O/(&G:?96;?:Y"\32,""0#@*Q.2 N,9JKXJ^,5IIMQ>:7I\4L6N
MVSVKF&\B&QX7N$BD(PQY&\=<?CBM*+X.^&K6UMXK.._L)K9XY+>\M;QXYX&1
M67Y'[;E=@WJ#5>'X&^$[>_GO!;WCS3,7(DNV95)F69L#WD0,<Y].E+WBER%C
MQ5\5K#PCXLU'2+_2=4>VM+.WNS?6\(E5WFF,*1*H.2Q8=>GTJ&^^+6E>&X-4
MNM:\Z.VL]2-C*(;?:UK\J%A*"WS$;Q\R9^G%;6O^ M(\2Z]'K-Z+DWJQQQ,L
M5PR1RK'+YL8=!P=K\CZFLCQ)\%_"WBZ[NKK4;>\\Z[GFN+@P73()&E";P?\
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M^?B/\C1_:=7L'U&GW/F7_A77B7_H#S?]]+_C1_PKKQ+_ - >;_OI?\:^FO\
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M** #S/:CS/:BB@ \SVH\SVHHH /,]J/,]J** #S/:CS/:BB@ \SVH\SVHHH
M/,]J/,]J** #S/:CS/:BB@ \SVH\SVHHH /,]J/,]J** #S/:CS/:BB@ \SV
9H\SVHHH /,]J/,]J** #S/:CS/:BB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>brtx-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOBGbP9z5Z8qekhvWB5benqvyUhAgC3HSdbW5XG0R4K -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:BRTX="http://biorestorative.com/20221231" elementFormDefault="qualified" targetNamespace="http://biorestorative.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://biorestorative.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" id="OrganizationLiquidityAndBusinessOperations">
	  <link:definition>00000007 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000009 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000010 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
	  <link:definition>00000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000012 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
	  <link:definition>00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000014 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/Leases" id="Leases">
	  <link:definition>00000015 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000020 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
	  <link:definition>00000021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/NotesPayableTables" id="NotesPayableTables">
	  <link:definition>00000022 - Disclosure - NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
	  <link:definition>00000023 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000024 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000025 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" id="OrganizationLiquidityAndBusinessOperationsDetailsNarrative">
	  <link:definition>00000026 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" id="ScheduleOfFairValueRecurringBasisDetails">
	  <link:definition>00000027 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" id="ScheduleOfWeightedAverageDilutiveCommonSharesDetails">
	  <link:definition>00000028 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
	  <link:definition>00000030 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" id="ScheduleOfFiniteLivedIntangibleAssetsDetails">
	  <link:definition>00000032 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" id="ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails">
	  <link:definition>00000033 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" id="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails">
	  <link:definition>00000034 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000035 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
	  <link:definition>00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" id="ScheduleOfNotesPayableActivityDetails">
	  <link:definition>00000037 - Disclosure - SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
	  <link:definition>00000038 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" id="ScheduleOfWarrantsGrantedAssumptionsDetails">
	  <link:definition>00000039 - Disclosure - SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" id="ScheduleOfStockWarrantsDetails">
	  <link:definition>00000040 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000041 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" id="ScheduleOfStockOptionGrantedAssumptionsDetails">
	  <link:definition>00000042 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" id="ScheduleOfUnvestedRestrictedStockUnitsDetails">
	  <link:definition>00000043 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" id="ScheduleOfStockOptionExpenseDetails">
	  <link:definition>00000044 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" id="ScheduleOfStockCompensationByAwardTypeDetails">
	  <link:definition>00000045 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
	  <link:definition>00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" id="ScheduleOfIncomeTaxProvisionBenefitDetails">
	  <link:definition>00000048 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" id="ScheduleOfStatutoryFederalIncomeTaxRateDetails">
	  <link:definition>00000049 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000050 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" id="ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails">
	  <link:definition>00000051 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" id="ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails">
	  <link:definition>00000052 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="brtx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="brtx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="brtx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="brtx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="BRTX_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ComputerSoftwareAndEquipmentMember" name="ComputerSoftwareAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccumulatedAmortizationMember" name="AccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarkMember" name="PatentsAndTrademarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BeneficialOwnershipMember" name="BeneficialOwnershipMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AuctusFundLLCMember" name="AuctusFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" name="TwoThousandTwentyOneStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoEmploymentAgreementsMember" name="TwoEmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" name="ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatrickFWilliamsMember" name="PatrickFWilliamsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MrAlstodtMember" name="MrAlstodtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MrSilvaMember" name="MrSilvaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DrNickolayKukekovMember" name="DrNickolayKukekovMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ScientificAdvisoryBoardMember" name="ScientificAdvisoryBoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedForServicesMember" name="SharesIssuedForServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" name="ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SectionThreeHundredAndEightyTwoMember" name="SectionThreeHundredAndEightyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MelvilleLeaseMember" name="MelvilleLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_OfficersMember" name="OfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BoardAndScientificAdvisoryMember" name="BoardAndScientificAdvisoryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GainOnPppLoanForgiveness" name="GainOnPppLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GrantIncome" name="GrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" name="SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" name="SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInCashlessExerciseOfWarrants" name="SharesIssuedInCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" name="SharesIssuedInCashlessExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInLitigationSettlement" name="SharesIssuedInLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInLitigationSettlementShares" name="SharesIssuedInLitigationSettlementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedInSettlementOfLitigation" name="SharesIssuedInSettlementOfLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes" name="NoncashAccruedExpenseExchangedForConveritbleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" name="BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" name="ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccruedDipExpensesExchangedForConvertibleNotes" name="AccruedDipExpensesExchangedForConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets" name="WarrantsIssuedAsConsiderationForIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SequencingPolicyPolicyTextBlock" name="SequencingPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" name="ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NetCashProvidedByUsedInOperatingActivitie" name="NetCashProvidedByUsedInOperatingActivitie" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ConsiderationTransferredForLicenses" name="ConsiderationTransferredForLicenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccruedGeneralAndAdministrativeExpenses" name="AccruedGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" name="DescriptionOfStockOptionsHeldByOfficerAndDirector" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" name="EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_OperatingLeaseLiabilityReduction" name="OperatingLeaseLiabilityReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RecognizedStockbasedCompensationExpensePercentage" name="RecognizedStockbasedCompensationExpensePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>brtx-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="brtx-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" xlink:href="brtx-20221231.xsd#OrganizationLiquidityAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipment" xlink:href="brtx-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20221231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NotesPayable" xlink:href="brtx-20221231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficit" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxes" xlink:href="brtx-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:href="brtx-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20221231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NotesPayableTables" xlink:href="brtx-20221231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficitTables" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesTables" xlink:href="brtx-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:href="brtx-20221231.xsd#OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="brtx-20221231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="brtx-20221231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:href="brtx-20221231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNotesPayableActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockCompensationByAwardTypeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:href="brtx-20221231.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:href="brtx-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInSettlementOfLitigation" xlink:label="loc_BRTXSharesIssuedInSettlementOfLitigation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXSharesIssuedInSettlementOfLitigation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" xlink:title="00000007 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NotesPayable" xlink:title="00000012 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="00000015 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficitTables" xlink:title="00000023 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="00000025 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:title="00000026 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_BRTXAccruedResearchAndDevelopmentExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_BRTXAccruedResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="00000053 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>brtx-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="brtx-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" xlink:href="brtx-20221231.xsd#OrganizationLiquidityAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipment" xlink:href="brtx-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20221231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NotesPayable" xlink:href="brtx-20221231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficit" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxes" xlink:href="brtx-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:href="brtx-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20221231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NotesPayableTables" xlink:href="brtx-20221231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficitTables" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesTables" xlink:href="brtx-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:href="brtx-20221231.xsd#OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="brtx-20221231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="brtx-20221231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:href="brtx-20221231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNotesPayableActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockCompensationByAwardTypeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:href="brtx-20221231.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:href="brtx-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesAConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesAConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLoansPayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLongTermLoansPayable_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesAConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesAConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" xlink:label="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" xlink:label="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInCashlessExerciseOfWarrants" xlink:label="loc_BRTXSharesIssuedInCashlessExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInCashlessExerciseOfWarrants_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" xlink:label="loc_BRTXSharesIssuedInCashlessExerciseOfWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInCashlessExerciseOfWarrantsShares_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInLitigationSettlement" xlink:label="loc_BRTXSharesIssuedInLitigationSettlement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInLitigationSettlement_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInLitigationSettlementShares" xlink:label="loc_BRTXSharesIssuedInLitigationSettlementShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInLitigationSettlementShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" xlink:title="00000007 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NotesPayable" xlink:title="00000012 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="00000015 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficitTables" xlink:title="00000023 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="00000025 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:title="00000026 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_LeaseAgreementMember" xlink:label="loc_BRTXLeaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXLeaseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="loc_BRTXComputerSoftwareAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXComputerSoftwareAndEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_LicensesMember" xlink:label="loc_BRTXLicensesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXLicensesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ConsiderationTransferredForLicenses" xlink:label="loc_BRTXConsiderationTransferredForLicenses_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_BRTXConsiderationTransferredForLicenses_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_190" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_160" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceOneMember" xlink:label="loc_BRTXExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTwoMember" xlink:label="loc_BRTXExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceThreeMember" xlink:label="loc_BRTXExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceFourMember" xlink:label="loc_BRTXExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceFiveMember" xlink:label="loc_BRTXExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceSixMember" xlink:label="loc_BRTXExercisePriceSixMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceSixMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceSevenMember" xlink:label="loc_BRTXExercisePriceSevenMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceSevenMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceEightMember" xlink:label="loc_BRTXExercisePriceEightMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceEightMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceNineMember" xlink:label="loc_BRTXExercisePriceNineMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceNineMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTenMember" xlink:label="loc_BRTXExercisePriceTenMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTenMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceElevenMember" xlink:label="loc_BRTXExercisePriceElevenMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceElevenMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTwelveMember" xlink:label="loc_BRTXExercisePriceTwelveMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwelveMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedForServicesMember" xlink:label="loc_BRTXSharesIssuedForServicesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_BRTXSharesIssuedForServicesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_TwoEmploymentAgreementsMember" xlink:label="loc_BRTXTwoEmploymentAgreementsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXTwoEmploymentAgreementsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" xlink:label="loc_BRTXChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatrickFWilliamsMember" xlink:label="loc_BRTXPatrickFWilliamsMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXPatrickFWilliamsMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MrAlstodtMember" xlink:label="loc_BRTXMrAlstodtMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXMrAlstodtMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MrSilvaMember" xlink:label="loc_BRTXMrSilvaMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXMrSilvaMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DrNickolayKukekovMember" xlink:label="loc_BRTXDrNickolayKukekovMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXDrNickolayKukekovMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScientificAdvisoryBoardMember" xlink:label="loc_BRTXScientificAdvisoryBoardMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXScientificAdvisoryBoardMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_270" xlink:type="arc" order="273" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" xlink:label="loc_BRTXDescriptionOfStockOptionsHeldByOfficerAndDirector_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXDescriptionOfStockOptionsHeldByOfficerAndDirector_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_CashlessExerciseOfWarrants" xlink:label="loc_BRTXCashlessExerciseOfWarrants_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXCashlessExerciseOfWarrants_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_320" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_320" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_320" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_320" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_320" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_320" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="loc_BRTXSectionThreeHundredAndEightyTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXSectionThreeHundredAndEightyTwoMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="00000053 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="loc_us-gaapLessorOperatingLeaseDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseDescription_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_OfficersMember" xlink:label="loc_BRTXOfficersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXOfficersMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BoardAndScientificAdvisoryMember" xlink:label="loc_BRTXBoardAndScientificAdvisoryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXBoardAndScientificAdvisoryMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_RecognizedStockbasedCompensationExpensePercentage" xlink:label="loc_BRTXRecognizedStockbasedCompensationExpensePercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXRecognizedStockbasedCompensationExpensePercentage_40" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>brtx-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="BRTX_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesAConvertiblePreferredStockMember" xlink:to="BRTX_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesBConvertiblePreferredStockMember" xlink:to="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_LeaseAgreementMember" xlink:label="BRTX_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LeaseAgreementMember" xlink:to="BRTX_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MedicalEquipmentMember" xlink:label="BRTX_MedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MedicalEquipmentMember" xlink:to="BRTX_MedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MedicalEquipmentMember_lbl" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ComputerSoftwareAndEquipmentMember" xlink:to="BRTX_ComputerSoftwareAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember_lbl" xml:lang="en-US">Computer Software and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="BRTX_ManufacturingEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ManufacturingEquipmentMember" xlink:to="BRTX_ManufacturingEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ManufacturingEquipmentMember_lbl" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="BRTX_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_LicensesMember" xlink:label="BRTX_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LicensesMember" xlink:to="BRTX_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_LicensesMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="BRTX_AccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccumulatedAmortizationMember_lbl" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="BRTX_PatentsAndTrademarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarkMember_lbl" xml:lang="en-US">Patents and Trademark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BeneficialOwnershipMember" xlink:label="BRTX_BeneficialOwnershipMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BeneficialOwnershipMember_lbl" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AuctusFundLLCMember" xlink:label="BRTX_AuctusFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AuctusFundLLCMember_lbl" xml:lang="en-US">Auctus Fund LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_lbl" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_TwoEmploymentAgreementsMember" xlink:label="BRTX_TwoEmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoEmploymentAgreementsMember" xlink:to="BRTX_TwoEmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoEmploymentAgreementsMember_lbl" xml:lang="en-US">Two Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" xlink:label="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" xlink:to="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_lbl" xml:lang="en-US">Chief Executive Officer and Chairman of the Board and its Vice President [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatrickFWilliamsMember" xlink:label="BRTX_PatrickFWilliamsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatrickFWilliamsMember" xlink:to="BRTX_PatrickFWilliamsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatrickFWilliamsMember_lbl" xml:lang="en-US">Patrick F Williams [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MrAlstodtMember" xlink:label="BRTX_MrAlstodtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MrAlstodtMember" xlink:to="BRTX_MrAlstodtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MrAlstodtMember_lbl" xml:lang="en-US">Mr. Alstodt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MrSilvaMember" xlink:label="BRTX_MrSilvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MrSilvaMember" xlink:to="BRTX_MrSilvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MrSilvaMember_lbl" xml:lang="en-US">Mr. Silva [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DrNickolayKukekovMember" xlink:label="BRTX_DrNickolayKukekovMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DrNickolayKukekovMember" xlink:to="BRTX_DrNickolayKukekovMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DrNickolayKukekovMember_lbl" xml:lang="en-US">Dr Nickolay Kukekov [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScientificAdvisoryBoardMember" xlink:label="BRTX_ScientificAdvisoryBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScientificAdvisoryBoardMember" xlink:to="BRTX_ScientificAdvisoryBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ScientificAdvisoryBoardMember_lbl" xml:lang="en-US">Scientific Advisory Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceOneMember" xlink:label="BRTX_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceOneMember" xlink:to="BRTX_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTwoMember" xlink:label="BRTX_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwoMember" xlink:to="BRTX_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceThreeMember" xlink:label="BRTX_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceThreeMember" xlink:to="BRTX_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceFourMember" xlink:label="BRTX_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFourMember" xlink:to="BRTX_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceFiveMember" xlink:label="BRTX_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFiveMember" xlink:to="BRTX_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceSixMember" xlink:label="BRTX_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceSixMember" xlink:to="BRTX_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceSevenMember" xlink:label="BRTX_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceSevenMember" xlink:to="BRTX_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceEightMember" xlink:label="BRTX_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceEightMember" xlink:to="BRTX_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceNineMember" xlink:label="BRTX_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceNineMember" xlink:to="BRTX_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTenMember" xlink:label="BRTX_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTenMember" xlink:to="BRTX_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceElevenMember" xlink:label="BRTX_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceElevenMember" xlink:to="BRTX_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTwelveMember" xlink:label="BRTX_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwelveMember" xlink:to="BRTX_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedForServicesMember" xlink:label="BRTX_SharesIssuedForServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedForServicesMember" xlink:to="BRTX_SharesIssuedForServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedForServicesMember_lbl" xml:lang="en-US">Shares Issued for Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:to="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_lbl" xml:lang="en-US">Expire from 2030 to 2038 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SectionThreeHundredAndEightyTwoMember" xlink:to="BRTX_SectionThreeHundredAndEightyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember_lbl" xml:lang="en-US">Section 382 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MelvilleLeaseMember" xlink:label="BRTX_MelvilleLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MelvilleLeaseMember_lbl" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_OfficersMember" xlink:label="BRTX_OfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OfficersMember" xlink:to="BRTX_OfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_OfficersMember_lbl" xml:lang="en-US">Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BoardAndScientificAdvisoryMember" xlink:label="BRTX_BoardAndScientificAdvisoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BoardAndScientificAdvisoryMember" xlink:to="BRTX_BoardAndScientificAdvisoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BoardAndScientificAdvisoryMember_lbl" xml:lang="en-US">Board And Scientific Advisory [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Investments held in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">PPP loan payable, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">PPP loan payable, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,677,775 and 3,520,391 issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (income) expense:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest (income) expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of notes payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="BRTX_GainOnPppLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnPppLoanForgiveness" xlink:to="BRTX_GainOnPppLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_GainOnPppLoanForgiveness_lbl" xml:lang="en-US">Gain on PPP loan forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GrantIncome" xlink:label="BRTX_GrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (income) expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding - Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares and warrants issued for cash related to public offering, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares and warrants issued for cash related to public offering, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" xlink:label="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" xlink:to="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_lbl" xml:lang="en-US">Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" xlink:label="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" xlink:to="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_lbl" xml:lang="en-US">Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Shares issued in exchange of notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Shares issued in exchange for notes payable and accrued interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInCashlessExerciseOfWarrants" xlink:label="BRTX_SharesIssuedInCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInCashlessExerciseOfWarrants" xlink:to="BRTX_SharesIssuedInCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued in cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" xlink:label="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" xlink:to="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares_lbl" xml:lang="en-US">Shares issued in cashless exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInLitigationSettlement" xlink:label="BRTX_SharesIssuedInLitigationSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInLitigationSettlement" xlink:to="BRTX_SharesIssuedInLitigationSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInLitigationSettlement_lbl" xml:lang="en-US">Shares issued in litigation settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInLitigationSettlementShares" xlink:label="BRTX_SharesIssuedInLitigationSettlementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInLitigationSettlementShares" xlink:to="BRTX_SharesIssuedInLitigationSettlementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInLitigationSettlementShares_lbl" xml:lang="en-US">Shares issued in litigation settlement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Fair market value of beneficial conversion feature and warrants issued with convertible notes payable instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;- restricted share units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;- options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;- common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued in connection with license exclusivity agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Common stock issued in exchange for Series B&#160;&#160;Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Common stock issued in exchange for Series B Preferred Stock, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compenation</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInSettlementOfLitigation" xlink:label="BRTX_SharesIssuedInSettlementOfLitigation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInSettlementOfLitigation" xlink:to="BRTX_SharesIssuedInSettlementOfLitigation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedInSettlementOfLitigation_lbl" xml:lang="en-US">Shares issued in settlement of litigation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of note payables, net</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NoncashLeaseExpense" xlink:label="BRTX_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid assets and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from sale of units in public offering, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US">Proceeds from PPP Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents - beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents&#160;&#160;- end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Shares issued in exchange for notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes" xlink:label="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes" xlink:to="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes_lbl" xml:lang="en-US">Accrued expense exchanged for converitble notes</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" xlink:label="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" xlink:to="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount_lbl" xml:lang="en-US">Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" xlink:label="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" xlink:to="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering_lbl" xml:lang="en-US">Convertible debt and accrued interest exchanged for common and preferred shares and warrants in public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedDipExpensesExchangedForConvertibleNotes" xlink:label="BRTX_AccruedDipExpensesExchangedForConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedDipExpensesExchangedForConvertibleNotes" xlink:to="BRTX_AccruedDipExpensesExchangedForConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccruedDipExpensesExchangedForConvertibleNotes_lbl" xml:lang="en-US">Accrued DIP expenses exchanged for convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets" xlink:label="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets" xlink:to="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets_lbl" xml:lang="en-US">Warrants issued as consideration for intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="BRTX_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SequencingPolicyPolicyTextBlock" xlink:label="BRTX_SequencingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SequencingPolicyPolicyTextBlock" xlink:to="BRTX_SequencingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SequencingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Sequencing Policy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NOTES PAYABLE ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX PROVISION (BENEFIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NetCashProvidedByUsedInOperatingActivitie" xlink:label="BRTX_NetCashProvidedByUsedInOperatingActivitie" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NetCashProvidedByUsedInOperatingActivitie" xlink:to="BRTX_NetCashProvidedByUsedInOperatingActivitie_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_NetCashProvidedByUsedInOperatingActivitie_lbl" xml:lang="en-US">Cash flows from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets fair value disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC insured limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite Lived Intangible Assets, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated amortization, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Net, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ConsiderationTransferredForLicenses" xlink:label="BRTX_ConsiderationTransferredForLicenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ConsiderationTransferredForLicenses" xlink:to="BRTX_ConsiderationTransferredForLicenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ConsiderationTransferredForLicenses_lbl" xml:lang="en-US">Consideration transferred for license exclusivity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, gross, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated amortization, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Net, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite Lived Intangible Assets, weighted average amortization period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payment to acquire intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedResearchAndDevelopmentExpenses" xlink:label="BRTX_AccruedResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedResearchAndDevelopmentExpenses" xlink:to="BRTX_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Accrued research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Accrued general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans payable outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_LoansPayable_2_lbl" xml:lang="en-US">Loans payable outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of Options Exchanged or Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exchanged or Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Number of Options Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Number of warrants outstanding, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of warrants outstanding, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of Options Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants outstanding, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants exercisable, weighted average remaining life in years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercisable, exercisable number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average remaining amortization period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Stock-based compensation award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock voting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion, converted instrument, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of stock shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2_lbl" xml:lang="en-US">Number of shares of common stock authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Aggregate purchase of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" xlink:label="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" xlink:to="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector_lbl" xml:lang="en-US">Description of stock options held by officer and director</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Aggregate common stock services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_CashlessExerciseOfWarrants" xlink:label="BRTX_CashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_CashlessExerciseOfWarrants" xlink:to="BRTX_CashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average estimated fair value of warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Number of option issued to purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Description of share based payment award vesting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research &amp; development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory blended income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State statutory income tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_lbl" xml:lang="en-US">Tax return to provision adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Federal net operating loss carry-forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carry-forwards subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carry-forwards not subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax examination, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Deferred tax assets, operating loss carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Net Lease Cost And Other Supplemental Lease Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost (cost resulting from lease payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Net lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease - operating cash flows (fixed payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="BRTX_OperatingLeaseLiabilityReduction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_OperatingLeaseLiabilityReduction_lbl" xml:lang="en-US">Operating lease - operating cash flows (liability reduction)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Non-current leases - right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current liabilities - operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current liabilities - operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="BRTX_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Minimum Payments Under Non-cancelable Leases For Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Amount representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of net future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="us-gaap_LessorOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl" xml:lang="en-US">Lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Shares options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vested and exercisable percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_lbl" xml:lang="en-US">Remaining percentage of options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xml:lang="en-US">Estimated fair value of granted</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_RecognizedStockbasedCompensationExpensePercentage" xlink:label="BRTX_RecognizedStockbasedCompensationExpensePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RecognizedStockbasedCompensationExpensePercentage" xlink:to="BRTX_RecognizedStockbasedCompensationExpensePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RecognizedStockbasedCompensationExpensePercentage_lbl" xml:lang="en-US">Recognized stock-based compensation expense percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesAConvertiblePreferredStockMember" xlink:to="BRTX_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesBConvertiblePreferredStockMember" xlink:to="BRTX_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnPppLoanForgiveness" xlink:to="BRTX_GainOnPppLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GainOnPppLoanForgiveness_doc" xml:lang="en-US">Gain on PPP loan forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GrantIncome_doc" xml:lang="en-US">Grant Income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatentsAndTrademarksMember_doc" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LicensesMember" xlink:to="BRTX_LicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_LicensesMember_doc" xml:lang="en-US">License [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccumulatedAmortizationMember_doc" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" xlink:to="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants_doc" xml:lang="en-US">Shares issued in connection with public offering in exchange for notes payable accrued interest and outstanding warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInCashlessExerciseOfWarrants" xlink:to="BRTX_SharesIssuedInCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInCashlessExerciseOfWarrants_doc" xml:lang="en-US">Shares issued in cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInLitigationSettlement" xlink:to="BRTX_SharesIssuedInLitigationSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInLitigationSettlement_doc" xml:lang="en-US">Shares issued In litigation settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ConsiderationTransferredForLicenses" xlink:to="BRTX_ConsiderationTransferredForLicenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ConsiderationTransferredForLicenses_doc" xml:lang="en-US">Consideration transferred for licenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" xlink:to="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares_doc" xml:lang="en-US">SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedResearchAndDevelopmentExpenses" xlink:to="BRTX_AccruedResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccruedResearchAndDevelopmentExpenses_doc" xml:lang="en-US">Accrued research and development expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xml:lang="en-US">Accrued general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AuctusFundLLCMember_doc" xml:lang="en-US">Auctus Fund LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_doc" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInLitigationSettlementShares" xlink:to="BRTX_SharesIssuedInLitigationSettlementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInLitigationSettlementShares_doc" xml:lang="en-US">Shares issued in litigation settlement shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_CashlessExerciseOfWarrants" xlink:to="BRTX_CashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_CashlessExerciseOfWarrants_doc" xml:lang="en-US">Cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" xlink:to="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector_doc" xml:lang="en-US">Description of stock options held by officer and director</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInSettlementOfLitigation" xlink:to="BRTX_SharesIssuedInSettlementOfLitigation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInSettlementOfLitigation_doc" xml:lang="en-US">Shares issued in settlement of litigation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash Lease Expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes" xlink:to="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes_doc" xml:lang="en-US">Non cash accrued expense exchanged for converitble notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" xlink:to="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount_doc" xml:lang="en-US">Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" xlink:to="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering_doc" xml:lang="en-US">Converitble debt and accrued interest exchanged for common and preferred shares and warrants in public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedDipExpensesExchangedForConvertibleNotes" xlink:to="BRTX_AccruedDipExpensesExchangedForConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccruedDipExpensesExchangedForConvertibleNotes_doc" xml:lang="en-US">Accrued dip expenses exchanged for convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options forfeitures in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets" xlink:to="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets_doc" xml:lang="en-US">Warrants issued as consideration for intangible assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_doc" xml:lang="en-US">Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceOneMember" xlink:to="BRTX_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwoMember" xlink:to="BRTX_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise PriceTwo [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceThreeMember" xlink:to="BRTX_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFourMember" xlink:to="BRTX_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFiveMember" xlink:to="BRTX_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceSixMember" xlink:to="BRTX_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceSevenMember" xlink:to="BRTX_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceEightMember" xlink:to="BRTX_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceNineMember" xlink:to="BRTX_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTenMember" xlink:to="BRTX_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceElevenMember" xlink:to="BRTX_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwelveMember" xlink:to="BRTX_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SequencingPolicyPolicyTextBlock" xlink:to="BRTX_SequencingPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SequencingPolicyPolicyTextBlock_doc" xml:lang="en-US">Sequencing policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoEmploymentAgreementsMember" xlink:to="BRTX_TwoEmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_TwoEmploymentAgreementsMember_doc" xml:lang="en-US">Two Employment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" xlink:to="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_doc" xml:lang="en-US">Chief Executive Officer and Chairman of the Board and its Vice President [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatrickFWilliamsMember" xlink:to="BRTX_PatrickFWilliamsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatrickFWilliamsMember_doc" xml:lang="en-US">Patrick F Williams [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MrSilvaMember" xlink:to="BRTX_MrSilvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MrSilvaMember_doc" xml:lang="en-US">Mr Silva [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DrNickolayKukekovMember" xlink:to="BRTX_DrNickolayKukekovMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DrNickolayKukekovMember_doc" xml:lang="en-US">Dr Nickolay Kukekov [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LeaseAgreementMember" xlink:to="BRTX_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MedicalEquipmentMember" xlink:to="BRTX_MedicalEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MedicalEquipmentMember_doc" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ComputerSoftwareAndEquipmentMember" xlink:to="BRTX_ComputerSoftwareAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember_doc" xml:lang="en-US">Computer Software and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ManufacturingEquipmentMember" xlink:to="BRTX_ManufacturingEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ManufacturingEquipmentMember_doc" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" xlink:to="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares_doc" xml:lang="en-US">Shares issued in cashless exercise of warrants shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:to="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_doc" xml:lang="en-US">Expire from 2030 to 2038 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SectionThreeHundredAndEightyTwoMember" xlink:to="BRTX_SectionThreeHundredAndEightyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember_doc" xml:lang="en-US">Section 382 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MelvilleLeaseMember_doc" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_OperatingLeaseLiabilityReduction_doc" xml:lang="en-US">Operating lease liability reduction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OfficersMember" xlink:to="BRTX_OfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_OfficersMember_doc" xml:lang="en-US">Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_doc" xml:lang="en-US">Effective income tax rate reconciliation tax return to provision adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Schedule of share based payment award warrants valuation assumptions [Table text block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatentsAndTrademarkMember_doc" xml:lang="en-US">Patents and Trademark [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_BeneficialOwnershipMember_doc" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MrAlstodtMember" xlink:to="BRTX_MrAlstodtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MrAlstodtMember_doc" xml:lang="en-US">Mr. Alstodt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScientificAdvisoryBoardMember" xlink:to="BRTX_ScientificAdvisoryBoardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ScientificAdvisoryBoardMember_doc" xml:lang="en-US">Scientific Advisory Board [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RecognizedStockbasedCompensationExpensePercentage" xlink:to="BRTX_RecognizedStockbasedCompensationExpensePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RecognizedStockbasedCompensationExpensePercentage_doc" xml:lang="en-US">Recognized stock-based compensation expense percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_doc" xml:lang="en-US">Remaining percentage of options vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedForServicesMember" xlink:to="BRTX_SharesIssuedForServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedForServicesMember_doc" xml:lang="en-US">Shares Issued for Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_2_lbl" xml:lang="en-US">License [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnPppLoanForgiveness" xlink:to="BRTX_GainOnPppLoanForgiveness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GainOnPppLoanForgiveness_3_lbl" xml:lang="en-US">GainOnPppLoanForgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GrantIncome_3_lbl" xml:lang="en-US">GrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NetCashProvidedByUsedInOperatingActivitie" xlink:to="BRTX_NetCashProvidedByUsedInOperatingActivitie_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NetCashProvidedByUsedInOperatingActivitie_2_lbl" xml:lang="en-US">NetCashProvidedByUsedInOperatingActivitie</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_3_lbl" xml:lang="en-US">Loans Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_2_lbl" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>brtx-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="brtx-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" xlink:href="brtx-20221231.xsd#OrganizationLiquidityAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipment" xlink:href="brtx-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20221231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NotesPayable" xlink:href="brtx-20221231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficit" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxes" xlink:href="brtx-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:href="brtx-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20221231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20221231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NotesPayableTables" xlink:href="brtx-20221231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficitTables" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesTables" xlink:href="brtx-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:href="brtx-20221231.xsd#OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="brtx-20221231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="brtx-20221231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:href="brtx-20221231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNotesPayableActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20221231.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockOptionExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStockCompensationByAwardTypeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="brtx-20221231.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:href="brtx-20221231.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:href="brtx-20221231.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:href="brtx-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20221231.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:href="brtx-20221231.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_BRTXSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" xlink:label="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" xlink:label="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInCashlessExerciseOfWarrants" xlink:label="loc_BRTXSharesIssuedInCashlessExerciseOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares" xlink:label="loc_BRTXSharesIssuedInCashlessExerciseOfWarrantsShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInCashlessExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInLitigationSettlement" xlink:label="loc_BRTXSharesIssuedInLitigationSettlement" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInLitigationSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInLitigationSettlementShares" xlink:label="loc_BRTXSharesIssuedInLitigationSettlementShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesIssuedInLitigationSettlementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedInSettlementOfLitigation" xlink:label="loc_BRTXSharesIssuedInSettlementOfLitigation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXSharesIssuedInSettlementOfLitigation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfDebt" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes" xlink:label="loc_BRTXNoncashAccruedExpenseExchangedForConveritbleNotes" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXNoncashAccruedExpenseExchangedForConveritbleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" xlink:label="loc_BRTXBifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXBifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" xlink:label="loc_BRTXConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedDipExpensesExchangedForConvertibleNotes" xlink:label="loc_BRTXAccruedDipExpensesExchangedForConvertibleNotes" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXAccruedDipExpensesExchangedForConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets" xlink:label="loc_BRTXWarrantsIssuedAsConsiderationForIntangibleAssets" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXWarrantsIssuedAsConsiderationForIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations" xlink:title="00000007 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NotesPayable" xlink:title="00000012 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="00000015 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SequencingPolicyPolicyTextBlock" xlink:label="loc_BRTXSequencingPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXSequencingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficitTables" xlink:title="00000023 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_BRTXScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_BRTXScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:label="loc_BRTXScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_BRTXScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="00000025 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative" xlink:title="00000026 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_NetCashProvidedByUsedInOperatingActivitie" xlink:label="loc_BRTXNetCashProvidedByUsedInOperatingActivitie" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_BRTXNetCashProvidedByUsedInOperatingActivitie" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_LeaseAgreementMember" xlink:label="loc_BRTXLeaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="loc_BRTXComputerSoftwareAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXComputerSoftwareAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_LicensesMember" xlink:label="loc_BRTXLicensesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ConsiderationTransferredForLicenses" xlink:label="loc_BRTXConsiderationTransferredForLicenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_BRTXConsiderationTransferredForLicenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_BRTXAccruedResearchAndDevelopmentExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_BRTXAccruedResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLoansPayable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceOneMember" xlink:label="loc_BRTXExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTwoMember" xlink:label="loc_BRTXExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceThreeMember" xlink:label="loc_BRTXExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceFourMember" xlink:label="loc_BRTXExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceFiveMember" xlink:label="loc_BRTXExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceSixMember" xlink:label="loc_BRTXExercisePriceSixMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceSevenMember" xlink:label="loc_BRTXExercisePriceSevenMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceEightMember" xlink:label="loc_BRTXExercisePriceEightMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceNineMember" xlink:label="loc_BRTXExercisePriceNineMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTenMember" xlink:label="loc_BRTXExercisePriceTenMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceElevenMember" xlink:label="loc_BRTXExercisePriceElevenMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExercisePriceTwelveMember" xlink:label="loc_BRTXExercisePriceTwelveMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharesIssuedForServicesMember" xlink:label="loc_BRTXSharesIssuedForServicesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_BRTXSharesIssuedForServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_TwoEmploymentAgreementsMember" xlink:label="loc_BRTXTwoEmploymentAgreementsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXTwoEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" xlink:label="loc_BRTXChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_PatrickFWilliamsMember" xlink:label="loc_BRTXPatrickFWilliamsMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXPatrickFWilliamsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MrAlstodtMember" xlink:label="loc_BRTXMrAlstodtMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXMrAlstodtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MrSilvaMember" xlink:label="loc_BRTXMrSilvaMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXMrSilvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DrNickolayKukekovMember" xlink:label="loc_BRTXDrNickolayKukekovMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXDrNickolayKukekovMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ScientificAdvisoryBoardMember" xlink:label="loc_BRTXScientificAdvisoryBoardMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXScientificAdvisoryBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector" xlink:label="loc_BRTXDescriptionOfStockOptionsHeldByOfficerAndDirector" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXDescriptionOfStockOptionsHeldByOfficerAndDirector" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_CashlessExerciseOfWarrants" xlink:label="loc_BRTXCashlessExerciseOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="loc_BRTXSectionThreeHundredAndEightyTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXSectionThreeHundredAndEightyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="loc_BRTXOperatingLeaseLiabilityReduction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_BRTXOperatingLeaseLiabilityReduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="00000053 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="loc_us-gaapLessorOperatingLeaseDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_OfficersMember" xlink:label="loc_BRTXOfficersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_BoardAndScientificAdvisoryMember" xlink:label="loc_BRTXBoardAndScientificAdvisoryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXBoardAndScientificAdvisoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20221231.xsd#BRTX_RecognizedStockbasedCompensationExpensePercentage" xlink:label="loc_BRTXRecognizedStockbasedCompensationExpensePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXRecognizedStockbasedCompensationExpensePercentage" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742507920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
    Marcus Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
                                            Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,495,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityBankruptcyProceedingsReportingCurrent', window );">Entity Bankruptcy Proceedings, Reporting Current</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,767,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Marlton,
New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityBankruptcyProceedingsReportingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12, 13, 15d<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityBankruptcyProceedingsReportingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402743150400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,676,577<span></span>
</td>
<td class="nump">$ 21,026,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments held in marketable securities</a></td>
<td class="nump">13,072,831<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">363,082<span></span>
</td>
<td class="nump">436,181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">15,128,490<span></span>
</td>
<td class="nump">21,467,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">261,003<span></span>
</td>
<td class="nump">37,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">241,760<span></span>
</td>
<td class="nump">357,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">803,438<span></span>
</td>
<td class="nump">589,740<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">16,434,691<span></span>
</td>
<td class="nump">22,453,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">170,902<span></span>
</td>
<td class="nump">50,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">130,072<span></span>
</td>
<td class="nump">134,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">139,328<span></span>
</td>
<td class="nump">119,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">PPP loan payable, current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">440,302<span></span>
</td>
<td class="nump">363,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">162,317<span></span>
</td>
<td class="nump">301,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">PPP loan payable, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191,030<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">602,619<span></span>
</td>
<td class="nump">856,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,677,775 and 3,520,391 issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">168,457,418<span></span>
</td>
<td class="nump">155,727,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(152,640,897)<span></span>
</td>
<td class="num">(134,146,128)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">15,832,072<span></span>
</td>
<td class="nump">21,596,949<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">16,434,691<span></span>
</td>
<td class="nump">22,453,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742406432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,677,775<span></span>
</td>
<td class="nump">3,520,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,677,775<span></span>
</td>
<td class="nump">3,520,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742461728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 119,800<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,513,352<span></span>
</td>
<td class="nump">729,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,580,473<span></span>
</td>
<td class="nump">25,624,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,093,825<span></span>
</td>
<td class="nump">26,353,873<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,974,025)<span></span>
</td>
<td class="num">(26,307,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense</a></td>
<td class="num">(11,650)<span></span>
</td>
<td class="nump">1,815,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of notes payable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,180,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnPppLoanForgiveness', window );">Gain on PPP loan forgiveness</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GrantIncome', window );">Grant income</a></td>
<td class="num">(110,518)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(107,088)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense</a></td>
<td class="num">(479,256)<span></span>
</td>
<td class="nump">17,995,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,494,769)<span></span>
</td>
<td class="num">$ (44,303,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic and Diluted</a></td>
<td class="num">$ (5.11)<span></span>
</td>
<td class="num">$ (37.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Common Shares Outstanding - Basic and Diluted</a></td>
<td class="nump">3,617,858<span></span>
</td>
<td class="nump">1,187,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnPppLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnPppLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739245008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series B Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 88,511,269<span></span>
</td>
<td class="num">$ (89,842,833)<span></span>
</td>
<td class="num">$ (1,331,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">715,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares and warrants issued for cash related to public offering, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">21,072,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,072,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares and warrants issued for cash related to public offering, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants', window );">Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants</a></td>
<td class="nump">$ 15,432<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">22,611,982<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,627,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares', window );">Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants, shares</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued in exchange of notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">317,376<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">317,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued in exchange for notes payable and accrued interest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInCashlessExerciseOfWarrants', window );">Shares issued in cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(82,146)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(82,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares', window );">Shares issued in cashless exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInLitigationSettlement', window );">Shares issued in litigation settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInLitigationSettlementShares', window );">Shares issued in litigation settlement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Fair market value of beneficial conversion feature and warrants issued with convertible notes payable instruments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166,404<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">166,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">&#160;&#160;&#160;&#160;&#160;- restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,671,503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,671,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">restricted stock units, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">&#160;&#160;&#160;&#160;&#160;- options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,411,976<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,411,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">options, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">&#160;&#160;&#160;&#160;&#160;- common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">25,475<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,303,295)<span></span>
</td>
<td class="num">(44,303,295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 15,432<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">155,727,292<span></span>
</td>
<td class="num">(134,146,128)<span></span>
</td>
<td class="nump">21,596,949<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,520,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">&#160;&#160;&#160;&#160;&#160;- restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">4,735,097<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,735,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">&#160;&#160;&#160;&#160;&#160;- options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,741,864<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,741,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">&#160;&#160;&#160;&#160;&#160;- common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">135,888<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,494,769)<span></span>
</td>
<td class="num">(18,494,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock</a></td>
<td class="num">$ (15,432)<span></span>
</td>
<td class="nump">$ 15,432<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock, Shares</a></td>
<td class="num">(1,543,158)<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with license exclusivity agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117,030<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued in exchange for Series B&#160;&#160;Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (250)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common stock issued in exchange for Series B Preferred Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 168,457,418<span></span>
</td>
<td class="num">$ (152,640,897)<span></span>
</td>
<td class="nump">$ 15,832,072<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in cashless exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with public offering in exchange for notes payable accrued interest and outstanding warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued In litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInLitigationSettlementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in litigation settlement shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInLitigationSettlementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=128088960&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126965701&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402738795680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (18,494,769)<span></span>
</td>
<td class="num">$ (44,303,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,133,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">120,545<span></span>
</td>
<td class="nump">89,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="num">(33,665)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compenation</a></td>
<td class="nump">12,612,862<span></span>
</td>
<td class="nump">23,108,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesIssuedInSettlementOfLitigation', window );">Shares issued in settlement of litigation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of note payables, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,180,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnPppLoanForgiveness', window );">Gain on PPP loan forgiveness</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">160,122<span></span>
</td>
<td class="nump">116,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid assets and other current assets</a></td>
<td class="nump">73,099<span></span>
</td>
<td class="num">(330,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">120,075<span></span>
</td>
<td class="num">(68,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(4,898)<span></span>
</td>
<td class="nump">812,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(163,132)<span></span>
</td>
<td class="num">(101,190)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,870,761)<span></span>
</td>
<td class="num">(3,329,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(13,039,166)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(265,223)<span></span>
</td>
<td class="num">(30,658)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(13,479,389)<span></span>
</td>
<td class="num">(30,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of units in public offering, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,072,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Proceeds from PPP Loan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,322,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(19,350,150)<span></span>
</td>
<td class="nump">17,962,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents - beginning of year</a></td>
<td class="nump">21,026,727<span></span>
</td>
<td class="nump">3,064,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#160;&#160;- end of year</a></td>
<td class="nump">1,676,577<span></span>
</td>
<td class="nump">21,026,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued in exchange for notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">317,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes', window );">Accrued expense exchanged for converitble notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">715,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount', window );">Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">166,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering', window );">Convertible debt and accrued interest exchanged for common and preferred shares and warrants in public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,046,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_AccruedDipExpensesExchangedForConvertibleNotes', window );">Accrued DIP expenses exchanged for convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">698,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets', window );">Warrants issued as consideration for intangible assets</a></td>
<td class="nump">$ 117,030<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_AccruedDipExpensesExchangedForConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued dip expenses exchanged for convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_AccruedDipExpensesExchangedForConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Converitble debt and accrued interest exchanged for common and preferred shares and warrants in public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnPppLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnPppLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash accrued expense exchanged for converitble notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesIssuedInSettlementOfLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesIssuedInSettlementOfLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued as consideration for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746296512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmh4v9pRAki3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
1 &#8211; <span id="xdx_82E_zNdxt28mA2ej">ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2022,
the Company had a net loss of $<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_z7dHJepdnrO4" title="Net loss">18.5</span> million (of which, $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_z72ZAMTq8tT7" title="Share based compensation">12.6</span> million was attributable to non-cash stock-based compensation) and negative
cash flows from operations of $<span id="xdx_90F_ecustom--NetCashProvidedByUsedInOperatingActivitie_iN_pn5n6_di_c20220101__20221231_z32SPqAZaD23" title="Cash flows from operations">5.8</span> million. The Company&#8217;s operating activities consume the majority of its cash resources. The
Company anticipates that it will continue to incur net losses as it executes its development plans for 2023 and beyond, as well as other
potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash flows from
operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses primarily through
current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on cash on hand as of December 31, 2022, the Company believes it has sufficient cash to fund operations for the twelve months subsequent
to the filing date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development,
marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial condition
and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#8220;GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization of
assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in
the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead
cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem
cells collected from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral
disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a
platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders
and has labeled this initiative its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system
designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402747289312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zfyVbJSW5lIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_82E_zun87tFlhRL9">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEDfld8mOouk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zJwbUNT5TSeg">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies
presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated financial
statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_za26SAORRPIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zXaInqJau9m5">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and
transactions have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zLpnaATMcbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zZxQ3ENSrgQ8">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities
at the date of the consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known
or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined
with precision, actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zHghKMZsiQA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zulwUOXTerH9">Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zEJzcWBODCNb" title="FDIC insured limit">250,000</span>. As of December
31, 2022, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
royalties related to the Company&#8217;s sublicense comprised all of the Company&#8217;s revenue during the years ended December 31,
2022 and 2021. See &#8220;Revenue&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpK1uUThmvyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zV9gomiXUZE9">Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for revenue in accordance with ASC Topic 606, <i>Revenue from Contracts with Customers</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (&#8220;SCTC&#8221;)
entered into in January 2012. In November 2022, the Company&#8217;s license rights under the agreement became exclusive. Pursuant to
the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things,
stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the
right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration
of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or
as, the performance obligation is satisfied. The Company&#8217;s contracts have a single performance obligation which is not separately
identifiable from other promises in the contracts and is, therefore, not distinct. The Company&#8217;s performance obligation is satisfied
upon the transfer of risk of loss to the customer. The timing of the Company&#8217;s revenue recognition may differ from the timing of
receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company
has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services,
the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2022 and 2021,
the Company recognized $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231_zALvZxSxFKFg" title="Revenue">119,800</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231_zrzksD8NW2fl" title="Revenue">46,000</span>, respectively, of revenue related to the Company&#8217;s sublicenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC Topic 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing
    component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or
    service to the customer and when the customer pays for that good or service will be one year or less.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
    Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has
    elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount
    of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the
    customer of the Company&#8217;s performance completed to date; the Company may recognize revenue in the amount to which the entity
    has a right to invoice.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contract
Modifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed above with the SCTC, there were no contract modifications during the years ended December 31, 2022 and 2021. Contract modifications
are not routine in the performance of the Company&#8217;s contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVsDmeHVVfZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zq4KqnDVezF3">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
There were <span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zHB8Va7Wnu2" title="Cash equivalents"><span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20211231_zRKSrT7ZgOHe" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyMaNd4MXaX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3JRIkFhsIUe">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are reported at their outstanding unpaid principal balances net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#8217;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance
is determined to be uncollectible. The Company did <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20221231_zvR76JAlrBBh" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20211231_z2jVUWCd7Ema" title="Allowance for doubtful accounts">no</span></span>t record an allowance for doubtful accounts as of December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z7QZaQuURbXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zotAixuudUc4">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zNHQ171jQ7Ia" title="Property plant and equipment estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0599">three</span></span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zebr2EFsAs84" title="Property plant and equipment estimated useful lives">fifteen years</span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z7HjQQkl5kLh" title="Property plant and equipment estimated useful lives">3</span> - <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_z31K7O6DC0w" title="Property plant and equipment estimated useful lives">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8WDc8yTknEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zTNHl5hU2Px4">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2022 and 2021, we determined that there
was <span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zPNnRZF7p6Zf" title="Impairment of long-lived assets"><span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zmJCQbdpB0M2" title="Impairment of long-lived assets">no</span></span> impairment charge for our long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span>&#160;</p>

<p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5EL4j7TmQy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z20P2ecqmv9l">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 350, <i>Intangibles
- Goodwill and Other</i>. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method,
which is determined by identifying the period over which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLSUAeNLbqR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYStEt1yL9Se">Fair
Value Measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; fair value is the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The
Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally
    developed methodologies that result in management&#8217;s best estimate of fair value.</span></td></tr>
  </table>
<p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zbOmuIk07cZ7">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Marketable securities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" style="width: 10%; text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" style="width: 14%; text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" style="width: 10%; text-align: right" title="Assets fair value disclosure">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" style="width: 10%; text-align: right" title="Assets fair value disclosure">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zAW0a1XPysYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company recognized unrealized gain of $<span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_z5YqJUMYWX3i" title="Unrealized gain on marketable securities">33,665</span> on its marketable securities within Other income,
net in its Consolidated Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjeWPr8GkESi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zPQhKbgFT0Je">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, accounts receivable, accounts payable and other current liabilities approximate their fair values based on the
short-term maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zRcPkx81fhZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zjdhsINXbPCc">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#8217;s
computation of diluted net loss per common share for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than the
average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" style="width: 14%; text-align: right" title="Total">864,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" style="width: 14%; text-align: right" title="Total">839,639</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" style="text-align: right" title="Total potentially dilutive shares">4,791,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" style="text-align: right" title="Total potentially dilutive shares">4,739,871</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" style="text-align: right" title="Unvested">201,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" style="text-align: right" title="Unvested">293,479</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,543,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,543,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" style="text-align: right" title="Total">7,400,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" style="text-align: right" title="Total">7,416,147</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zdYeSTzR4o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw18GIRvhrKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z81MWRbXrIMf">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 718, <i>Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;), which requires the measurement
and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASU 2018-07 Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company
accounts for stock options issued to non-employees for their services in accordance ASC 718. The Company uses valuation methods and assumptions
to value the stock options that are in line with the process for valuing employee stock options noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpwuyVzvE9yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zI4CnFG2mOF8">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_z873L7gC4EF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zeHOmHE66wKi">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
ASC. The accounting treatment of derivative financial instruments requires that the Company records embedded conversion options (&#8220;ECOs&#8221;)
and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each
subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period
at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of
debt discount on the consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification
of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the
contract is reclassified as of the date of the event that caused the reclassification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--SequencingPolicyPolicyTextBlock_zBplxoEP5Bp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zH8NqFKly3Rf">Sequencing
Policy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40-35 (&#8220;ASC 815&#8221;), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts
from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient
authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the
basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
Pursuant to ASC 815, issuances of securities to the Company&#8217;s employees and directors, or to compensate grantees in a share-based
payment arrangement, are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_z2Scqidx85he" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z0u8F9ujfxjf">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease is defined as a contract that conveys the right to control the use of identified property, plant or equipment for a period of time
in exchange for consideration. On January 1, 2019, the Company adopted ASC 842 and it primarily affected the accounting treatment for
operating lease agreements in which the Company is the lessee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, <i>Leases</i>, the Company recognized a right-of-use (&#8220;ROU&#8221;) asset and corresponding lease
liability on its balance sheets for its office space lease agreement. See Note 9 - Leases for further discussion, including the
impact on the Company&#8217;s financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets include any prepaid lease payments and exclude any lease incentives and initial direct costs incurred. Lease expense for minimum
lease payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate
the lease if it is reasonably certain that the Company will exercise that option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
in which the Company is the lessee are comprised of office rental. All of the leases are classified as operating leases. The Company
has a lease agreement for office space with a remaining term of <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGOsxiAyKBI5" title="Lease remaining term">two years</span> as of December 31, 2022.</span></p>

<p id="xdx_852_zeRmYv8VxZP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746528768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zVOJolEbPnZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
3 - <span><span><span id="xdx_82B_zTzT8AcYBy93">PROPERTY AND EQUIPMENT</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9eSZ8RWGq1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z5JT7tfsKlai" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z2kRu6y6eaH5" style="width: 15%; text-align: right" title="Property and equipment, gross">352,133</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z0wFKAizArJ" style="width: 15%; text-align: right" title="Property and equipment, gross">352,133</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZcGmgWOQUe8" style="text-align: right" title="Property and equipment, gross">123,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zctkOhHbqS53" style="text-align: right" title="Property and equipment, gross">123,487</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zDtravMzYG7c" style="text-align: right" title="Property and equipment, gross">117,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zScIeRjOfiQh" style="text-align: right" title="Property and equipment, gross">107,648</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zh8ttA0aZZA2" style="text-align: right" title="Property and equipment, gross">18,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zM6w3vsvjP43" style="text-align: right" title="Property and equipment, gross">12,979</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zb7fb9TkScBf" style="text-align: right" title="Property and equipment, gross">242,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_z2qOeh6fJaeg" style="text-align: right" title="Property and equipment, gross">30,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBPSSXkCeUe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">342,048</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMejPzHRvGMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">304,661</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zX9GcimW1xS" style="text-align: right" title="Property and equipment, gross">1,196,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231_zMvwN7Us6tk2" style="text-align: right" title="Property and equipment, gross">931,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zGb37UmSTx42" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(935,839</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_znZA0V2zNsWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(893,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z5TUNyIac6N8" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">261,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zKtxoO5UqTy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">37,993</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>



<p id="xdx_8A4_zpxajxEiP0Ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
depreciation expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zru09hoORm7c" title="Depreciation">42,212</span> and $<span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zZ9fU3RJqtg" title="Depreciation">14,633</span>, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746285952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zYgGbzQbWPm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
 4 - <span id="xdx_82A_zr9mXwBgb7p">INTANGIBLE ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with the SCTC (as amended) (the &#8220;SCTC Agreement&#8221;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain
medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the
body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for
culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones)
had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology. The Company did
not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights
became non-exclusive. However, the Company entered into an amended agreement under which it paid $<span id="xdx_906_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220101__20221231_zV13vYSIrYTa" title="Payment to acquire intangible assets">175,000</span> and issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXIEjRHPARrk" title="Stock issued new issues">51,370</span> warrants,
with a fair value of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zUB4hj19Yxd" title="Fair value of warrants">117,030</span>, in exchange for renewed exclusivity. The consideration transferred to the SCTC in exchange for exclusivity
was capitalized to intangible assets on the Company&#8217;s consolidated balance sheet as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office has issued a notice of allowance
for a patent application relating to the Company&#8217;s BRTX-100 clinical program. This patent was issued in March 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zz5ob2QNHGYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z3HT9mUl0tEk">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of January 1, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zR5sXscArwYb" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zjX0FEK6zSw6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,301,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2BCF6Ub6bDd" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(640,908</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20210101__20211231_zhZY2LMNgImk" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">664,268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zW21m9E1loYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(74,528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231_zS0EF0PJShna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(74,528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z16LeSwQBqZk" style="text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zrcVS6ZFIxNh" style="text-align: right" title="Finite Lived Intangible Assets, beginning balance">1,301,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zzdO0qsShm9d" style="text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(715,436</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20220101__20221231_ziF74mUAzUhi" style="text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">589,740</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Consideration transferred for license exclusivity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIIuyilwgzIj" style="text-align: right" title="Consideration transferred for license exclusivity">292,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231_zZwwWg9QA178" style="text-align: right" title="Consideration transferred for license exclusivity">292,030</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zOk3jTfDcRWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(78,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231_zbnV5QIafEd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(78,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zLFLfwghXz31" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIjyOrsWJZ6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z9R8BK6jiYFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance">(793,768</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20220101__20221231_z0axz7mgX6Nk" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance">803,438</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhwNz2iVMyog" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3XvcIExYQE9" title="Finite Lived Intangible Assets, weighted average amortization period">11.25</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zLprpsGjpIx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zuYakqSqMWC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_ze6dKh9GVy4f">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_z111QHGgf6ib" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zOcIjRIprHI7" style="width: 14%; text-align: right" title="Beginning Balance">637,232</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zSvPCXNe1O81" style="width: 14%; text-align: right" title="Beginning Balance">640,908</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zQsLGcm9Clsd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkI3R4uA8ncj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">74,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zeqlmrAk0Oc7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">74,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zYNdRMNLXXL3" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdvH1UPoFa6k" style="text-align: right" title="Beginning Balance">711,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zLw7u3xiVMfj" style="text-align: right" title="Beginning Balance">715,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjqAZlC0iQM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zemPn2tTSNNg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">78,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z0AgdgMgVXsh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">78,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCmYU0PaxmNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z7iLe7KaisVi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">790,092</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zNXhaLnNN7Gl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">793,768</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zrwhArUOB7t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3lONGEusWI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B9_z24iYDJQ20G5">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221231_zM1WUu8puxm" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zmJ8qFYSBEY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">89,131</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zXveE2K88kFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zeVSPq4NT1ja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zrYqmkW3iogg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zCfWHjd4m9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zglxyIb6jcUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402830303680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zUeefxf9Klsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
 5 - <span id="xdx_829_zEtL27GGXHU1">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zwBSApfXDN93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zxPwPamjgYe5">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zaGGhfBp9Wff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zGZwRLKduE1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zcEgT8XwVLph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">28,370</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedResearchAndDevelopmentExpenses_iI_maALAOLzJ5Y_zdABJUl0Lbh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,672</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zmQ2gGIHIkX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,822</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,928</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zECYx3mc4q96" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,072</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">134,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p id="xdx_8A2_zNrM8joHQONj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746620992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zMXpCpsZpsul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
6 - <span id="xdx_82D_zRyYbdY9Poij">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_z6vD8WR7Ruyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the notes payable activity during the year ended December 31, 2022 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z0U2tHHDdg9l">SCHEDULE OF NOTES PAYABLE ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Outstanding, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--LoansPayable_iS_c20220101__20221231_zpdYlJWz25Md" style="width: 14%; text-align: right" title="Loans payable outstanding beginning">250,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ProceedsFromIssuanceOfDebt_c20220101__20221231_z2TTt3e07Ar2" style="text-align: right" title="Issuances"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DebtInstrumentDecreaseForgiveness_iN_di_c20220101__20221231_zhV0UK3vXrdc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness">(250,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LoansPayable_iE_c20220101__20221231_zTOQ2ieZBEbk" style="border-bottom: Black 2.5pt double; text-align: right" title="Loans payable outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>



<p id="xdx_8AB_zlm55UBSezHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746609760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwfDdLnBi61j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
 7 - <span id="xdx_823_znRDN6LBjqkg">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCQLCzatzywj" title="Preferred stock, shares issued">1,543,158</span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJ7CxJ2xwUik" title="Preferred stock, par value">.01</span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbnxa33JYyfa" title="Preferred stock, liquidation preference">0.001</span> per share. On September 8,
2022, the Company issued <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zK1YF30WN4kd" title="Preferred stock, shares issued">1,543,158</span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_za83UBjE2nz8" title="Preferred stock, shares issued">1,543,158</span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8O12SUCwACd" title="Preferred stock voting rights">The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as
provided for the Series A.</span> The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption
by the Company or any Series B holder. The exchange of Series A for Series B had no impact on the Company&#8217;s financial statements
as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zp2gCvH4Ifz5" title="Preferred stock voting percentage">9.99</span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRN6RY2xn2Dj" title="Preferred stock voting percentage">9.99</span>% of the outstanding
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion &#8211; From time to time, in the event of that an event occurs, including adjustment due to merger, consolidation, etc.,
subdivision or combination of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the
effect of reducing a Series B holder&#8217;s beneficial ownership of shares of common stock to less than <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_z7ZAufGB3rBd" title="Ownership percentage">9.5</span>% of the then publicly disclosed
outstanding shares of Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such
effect, which notice shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable
detail with regard thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such
notice shall have the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase
the Series B holder&#8217;s beneficial ownership of Common Stock to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zHv08AtDpcea" title="Preferred stock voting percentage">9.99</span>% of the then publicly disclosed outstanding shares of Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, Auctus converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zGjKmg3CbUKc" title="Debt conversion, converted instrument, shares issued">25,000</span> shares of Series B into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zVMjgNpuwll4" title="Debt conversion, converted instrument, shares issued">25,000</span> shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion is <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztKRsSduCct8" title="Conversion of stock shares">1,518,158</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Stock Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company&#8217;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#8220;2021
Plan&#8221;). Pursuant to the 2021 Plan, a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zrEv2Q3DlXQ" title="Number of shares of common stock authorized">1,175,000</span> shares of common stock were initially authorized to be issued pursuant
to the grant of stock options, restricted stock units, restricted stock, stock appreciation rights and other incentive awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendments
to 2021 Stock Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, subject to stockholder approval, the Company&#8217;s Board of Directors approved amendments to the 2021 Plan to increase
the number of shares of Common Stock authorized to be issued from <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20211209_z9B5JA6OdXFd">1,175,000</span> to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20211210_z7OufqxFPjx9" title="Common stock, shares authorized">2,500,000</span> and to clarify certain provisions of the 2021
Plan as to the authority of the Board of Directors and the Compensation Committee to make adjustments to, among other things, the exercise
price of granted options. Concurrently, subject to stockholder approval of the amendments to the 2021 Plan, the Company&#8217;s Compensation
Committee reduced the exercise price of the outstanding options under the 2021 Plan for the purchase of an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20220914__20220915_zlqMsOTeQQ38" title="Aggregate purchase of common stock, shares">838,549</span> shares
of the Company&#8217;s common stock from $<span id="xdx_902_eus-gaap--SharePrice_iI_c20220915__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zBL7Gy4hukF6">13.50</span> per share to $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20220915__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zPwRypVJwXnh" title="Share price">5.08</span> per share (the closing price of the Company&#8217;s common stock on
the day immediately preceding the Compensation Committee determination), including the options held by the Company&#8217;s officers and
directors as follows: <span id="xdx_902_ecustom--DescriptionOfStockOptionsHeldByOfficerAndDirector_c20220914__20220915_zuj5dbNjPp9b" title="Description of stock options held by officer and director">(i) Lance Alstodt, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board: 335,538 shares,
(ii) Francisco Silva, the Company&#8217;s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal,
the Company&#8217;s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company&#8217;s Vice President of Quality Assurance
and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company&#8217;s directors: 25,236 shares; (vi) Patrick F. Williams,
one of the Company&#8217;s directors: 10,490 shares; and (vii) David Rosa, one of the Company&#8217;s directors: 10,490 shares.</span> On November
3, 2022, the Company&#8217;s stockholders approved the amendments to the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact resulting from the amendments was immaterial to the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Common Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20221231_zCh4MPooH7O3" title="Vested common stock, shares">15,898</span> shares of immediately vested common stock with an aggregate value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231_zQJAAeFM3Oal" title="Aggregate common stock services rendered">135,888</span>
to third parties for services rendered. During the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20211231_z94YrjyDE7m2" title="Vested common stock, shares">5,000</span> shares of immediately vested
common stock with a value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231_zTqsyzXQOoa1" title="Aggregate common stock services rendered">25,476</span> to a consultant for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
and Option Valuation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Activity Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211021__20211021__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJegf3obTGPe" title="Stock issued new issues, shares">22,917</span> shares of common stock to a warrant holder, as a result of the cashless exercise of <span id="xdx_901_ecustom--CashlessExerciseOfWarrants_pid_c20211021__20211021__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDN9XeCQZFD7" title="Cashless exercise of warrants">25,000</span>
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp8srCIQ1WT3" title="Stock issued new issues">147,832</span>, shares of the Company&#8217;s common stock, as a result
of the cashless exercise of <span id="xdx_906_ecustom--CashlessExerciseOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt75Z7o6y6Ad" title="Cashless exercise of warrants">170,473</span> warrants by Auctus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTC1mfXHV4ti" title="Warrants issued">51,370</span> warrants to the SCTC as part of consideration transferred in exchange for
exclusivity under a license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zOuyIV8iOJ3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zOrdaxljWDCc">SCHEDULE OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd4Nh0CXnlZ9" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning">3,750,598</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcGhj2zdgtO1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance">4.40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7cO4Hu6jSf2" style="text-align: right" title="Number of Options Granted">4,862,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zml1yDOPGRJb" style="text-align: right" title="Weighted Average Exercise Price Granted">9.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqFbv9xYroYh" style="text-align: right" title="Number of Options Exercised">(195,473</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjVY6mgGiCoi" style="text-align: right" title="Weighted average exercise price, exercised">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged or forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUaAKCNwtbTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Exchanged or Forfeited">(3,677,964</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLaXAA6YDk82" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Exchanged or Forfeited">3.39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzvZwqmKzFj" style="text-align: right" title="Number of Options Outstanding Beginning">4,739,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjiXMu5AsRkk" style="text-align: right" title="Weighted average exercise price, beginning balance">11.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwfSIIZbWJjh" title="Number of Options Outstanding">4.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z24SoF8wjjpe" style="text-align: right" title="Number of Options Granted">51,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPhUEuXy7tN8" style="text-align: right" title="Weighted average exercise price, granted">2.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPgSRJUwm52" style="text-align: right" title="Number of warrants outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWsr4fiefsc" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfY4QM3cBG52" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding, expired">(159</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSHJyBdkhlrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">16,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoMAOWeVHVme" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending">4,791,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziSBknt3oy6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">10.71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKYqAUIvaRD4" title="Number of Options Outstanding">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYtHfLYUvVM" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqTYLnWIBd99" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">4,791,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr2RVNGYT0H9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">10.71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcsOo2SCbzzg" title="Weighted Average Remaining Life in Years Outstanding Ending">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIX5sRtDtpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable Ending"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zhunbhb3vFfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zLtW3xeSNUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to warrants granted during 2022 and 2021, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zM3Q788gyCgd">SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMvGAiHM9Wn4" title="Risk free interest rate">4.40</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUa4wX5jcDa2" title="Risk free interest rate">0.98</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZJFlIgfgLjd" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zL200eFHX2Y7" title="Expected term (years)">4.10</span> - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvAHbtmjB3Hj" title="Expected term (years)">5.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWC2XP7huk3" title="Expected volatility">313.55</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdg9AcduYQB5" title="Expected volatility">314.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy8d1XEONiE8" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8PP1FFITYci" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AA_zg0HfL5MNyt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated fair value of the warrants granted during the years ended December 31, 2022 and 2021 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj3vksd6p0jf" title="Weighted average estimated fair value of warrants granted">2.28</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPZXpVjGcsoe" title="Weighted average estimated fair value of warrants granted">11.77</span>
per warrant, respectively. The Company did not issue any shares during the years ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zIZTEBuLKvUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zGdgp7ZC63y3">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 44%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOzaVg05GL59" title="Warrants outstanding, exercise price">2.92</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zNxNAcuZCaRd" style="width: 14%; text-align: right" title="Warrants outstanding, number of warrants">51,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zd8n75XgKkxg" title="Warrants exercisable, weighted average remaining life in years">4.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zWfrVEaUQnq5" style="width: 14%; text-align: right" title="Warrants exercisable, exercisable number of warrants">51,370</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7T8okIt08S5" title="Warrants outstanding, exercise price">10.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zeSebgIHfwyj" style="text-align: right">4,501,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdfGCAbbhVO6">3.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zXyMmLaFCSM7" style="text-align: right">4,501,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zF2L9mZmEkB9" title="Warrants outstanding, exercise price">12.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zQEmQMZXNhwg" style="text-align: right" title="Warrants outstanding, number of warrants">235,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0QfHjmmqF4i" title="Warrants exercisable, weighted average remaining life in years">3.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zxQ9nH8wOKx" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">235,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKjFPftSTCpl" title="Warrants outstanding, exercise price">60.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zdq4Lp8Lyt3k" style="text-align: right" title="Warrants outstanding, number of warrants">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB47YjJpwQr3" title="Warrants exercisable, weighted average remaining life in years">2.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zwO4pm9kjpB1" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcSr6m5jve3e" title="Warrants outstanding, exercise price">800.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zLJWuMGrxPAd" style="text-align: right" title="Warrants outstanding, number of warrants">869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTxdcUeiF1h6" title="Warrants exercisable, weighted average remaining life in years">1.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zQETJV7D8QTi" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zqk8O4ghtpm8" title="Warrants outstanding, exercise price">2,240.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_ziQ80gOPY3C" style="text-align: right" title="Warrants outstanding, number of warrants">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVBCh8CXCg5" title="Warrants exercisable, weighted average remaining life in years">1.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_zLGN8Q6oGbQ2" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXIcZViHwRKb" title="Warrants outstanding, exercise price">2,800.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zaMvUapSecPd" style="text-align: right" title="Warrants outstanding, number of warrants">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zwQ6TYROPLN1" title="Warrants exercisable, weighted average remaining life in years">1.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zb74Zi8xFHzl" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z03zfrSg1YE3" title="Warrants outstanding, exercise price">3,400.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zLbJnkFHuO0a" style="text-align: right" title="Warrants outstanding, number of warrants">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zz1hJ74P7Sp7" title="Warrants exercisable, weighted average remaining life in years">1.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_fKDEp_zCmcDJ1Utpt5" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zyoxbJsqUkce" title="Warrants outstanding, exercise price">4,000.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zIuI5nKGc5v7" style="text-align: right" title="Warrants outstanding, number of warrants">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zdpKW9qo3Eoh" title="Warrants exercisable, weighted average remaining life in years">1.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_fKDEp_zAhj1JOl85N" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z9lOrmIjzVv6" title="Warrants outstanding, exercise price">8,000.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zLmOj98tGluj" style="text-align: right" title="Warrants outstanding, number of warrants">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zM16slMZ1dB8" title="Warrants exercisable, weighted average remaining life in years">0.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_fKDEp_zy0VUpS5vwAc" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zoGyNOwnZjHh" title="Warrants outstanding, exercise price">14,000.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6JVx3FuMZji" style="text-align: right" title="Warrants outstanding, number of warrants">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zALlBxKyG9e4" title="Warrants exercisable, weighted average remaining life in years">0.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_fKDEp_zGwpRz4mjks9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zpkb1VJZ5uLb" title="Warrants outstanding, exercise price">16,000.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_za7cJzBqbM4j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, number of warrants">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhoaDtHgclQ5" title="Warrants exercisable, weighted average remaining life in years">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_fKDEp_zy1uBTNrqDEa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_fKDEp_zqZr7OXjinei" style="text-align: right">4,791,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_fKDEp_zm7MSkwMUmn4" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">4,791,082</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zkeDTqoRG2a8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company, pursuant to two employment agreements, granted to its Chief Executive Officer, President and Chairman of
the Board and its Vice President, Research and Development options to purchase an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_z4FRdRX7Y1Ab" title="Number of option issued to purchase shares of common stock">586,959</span> shares of the Company&#8217;s
common stock. The options initially <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_z5C87Iyd2g3j" title="Description of share based payment award vesting rights">vested to the extent of 50% on the date of grant, 25% on the one-year anniversary of the grant date
and 25% on the two-year anniversary of the grant date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, the Company granted options to purchase an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104_zd5Yqw9027l9" title="Number of option issued to purchase shares of common stock">140,824</span> shares of its common stock (including options to purchase
<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211102__20211104__srt--TitleOfIndividualAxis__custom--PatrickFWilliamsMember_zl6iVzdMxHah">10,490</span> shares each granted to Robert Kristal, its Chief Financial Officer, Patrick Williams, a director of the Company, and David Rosa,
a director of the Company) to its officers and directors. Also included within the <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--MrAlstodtMember_zcmIShFi0SR8">140,824</span> share option grants were grants to each of
Mr. Alstodt and Mr. Silva for the purchase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--MrSilvaMember_zNm1u4ExYvxg">42,059</span> shares of common stock and to Dr. Nickolay Kukekov, a director of the Company, for
the purchase of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--DrNickolayKukekovMember_zoWlm7jVfoz3">25,236</span> shares of common stock. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20211102__20211104_zdtxUDjpWwke" title="Share-based compensation arrangement by share-based payment award, description">Such options are exercisable to the extent of 50% on the date of grant and 50% quarterly
over a period of two years commencing one year from the date of grant.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2021, the Company granted options to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211102__20211104__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember_zxVvdUEjbDce" title="Options to purchase shares granted">110,767</span> shares of the Company&#8217;s common stock to members
of its Scientific Advisory Board and various employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company reduced the exercise price of all options from $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211209_zkSChF7aIvC4">13.50</span> per share to $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211210_z9jQMTFEeT1l">5.08</span> per share, subject to stockholder
approval. On November 3, 2022, stockholder approval was obtained. Per ASC 718 - <i>Compensation - Stock Compensation</i>, the Company
accounted for these changes as a modification and the net effect was immaterial to the financial statements as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted an option for the purchase of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zKrTqjcyOEz" title="Number of Options Granted">25,000</span> shares of common stock during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z41Grh7waTHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z41jvRlK6xNb">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z0htSgZLMxVg" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning">1,215</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zLACIEDVEGk9" style="width: 11%; text-align: right" title="Weighted average outstanding beginning balance">5.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zEyBsIf7KJJ4" style="text-align: right" title="Number of Options Granted">838,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zyOJAFxHqe5" style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zTv1o9IGqWma" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired">(126</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zPc6CVcdfbEg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired">5.08</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zRZlzYdhgFS7" style="text-align: right" title="Number of Options Outstanding Beginning">839,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zSKSNTbfRMV1" style="text-align: right" title="Weighted Average Exercise Price Outstanding Beginning">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zpFx7wwKDXK8" style="text-align: right" title="Number of Options Granted">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zVvPl0gtty4b" style="text-align: right" title="Weighted Average Exercise Price Granted">4.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zHyticBxYibb" style="text-align: right" title="Number of Options Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z9Ud3scCE3Uj" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zQ5CR0592oOa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJ0toreo1sfc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zTJHQs9T6N4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending">864,639</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zhDeR1Z7o6zb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding Ending">5.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zDvB6ocfrrU7" title="Weighted Average Remaining Life in Years Outstanding Ending">7.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20221231_zmNhYFjpKHa9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfiKun1fYpfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">578,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20221231_zuBRlNKlJ92i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending">5.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_ziKPFOAgWDah" title="Weighted Average Remaining Life in Years Exercisable Ending">7.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zq62wMxghiQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2022 and 2021, was approximately
$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zGM4kOditGA3" title="Weighted average grant date fair value of stock options granted">4.88</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zUJRZB6yM4n2" title="Weighted average grant date fair value of stock options granted">5.05</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaC8Zw0s9uu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zsZZFqtNG8Ch">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUi1pRRyTzpg" title="Risk free interest rate">2.42</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBRy8732sBn4" title="Expected term (years)">3.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxLxiNUDh7lb" title="Expected volatility">285.91</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGZxG1lmhMo2" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A5_zY6vKc7S2tP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#8220;RSUs&#8221;) to employees, consultants or non-employee directors
(&#8220;Eligible Individuals&#8221;). The number, terms and conditions of the RSUs that are granted to Eligible Individuals are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Individual one
unrestricted, fully transferable share of the Company&#8217;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company, pursuant to two employment agreements, granted an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlH2Ii2WxBw1" title="Number of option issued to purchase shares of common stock">293,479</span> RSUs to its Chief Executive Officer,
President, and Chairman of the Board and its Vice President, Research and Development with a fair value of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYpNrMyVfQfj" title="Exercise price">47.60</span> per share. The RSUs
vest to the extent of one-third on the one-year anniversary of the grant date, one-third on the two-year anniversary of the grant date,
and one-third on the three-year anniversary of the grant date. The RSUs had a grant date fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCLRfgXNTUf3" title="Fair value of restricted stock units">13,969,624</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 18, 2022, the Company granted an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220317__20220318__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi7CblvCxpw" title="Number of option issued to purchase shares of common stock">24,876</span> RSUs to its Chief Executive Officer, President and Chairman of the Board and
its Vice President, Research and Development with a fair value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220318__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1kVS5keRNYe" title="Exercise price">4.21</span> per share. The RSUs vest in twelve equal monthly installments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ziQWhFgrM8i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zK4OnVu5gNvf">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Outstanding, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7ruj8I7X9ec" style="width: 14%; text-align: right" title="Number of shares outstanding beginning">293,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWU9gwnsBuh" style="text-align: right" title="Number of shares granted">24,876</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ4xFg3IJbnh" style="text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1164">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMlTpl4Y0MB8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares vested">(116,486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZsFIt7oprpa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending">201,870</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_8AC_zG2reU58Xtpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zWgn53WFH2L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zveUfSxAoorc">SCHEDULE OF STOCK OPTION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4wVPE52dCH3" style="width: 11%; text-align: right" title="Stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyYDc2BYMYSi" style="width: 11%; text-align: right" title="Stock-based compensation expense">81,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMN4tnm8lsEf" style="width: 11%; text-align: right" title="Unrecognized expense">803,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQTaVcLFo6cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense">12,612,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1FGqhTV6UV" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense">23,027,476</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwMmnQ8r2x4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrecognized expense">1,294,684</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5GNJoPn2LYj" title="Weighted average remaining amortization period (years)">0.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVoNThiixP6" style="text-align: right" title="Stock-based compensation expense">12,612,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKwTrTrlpY2" style="text-align: right" title="Stock-based compensation expense">23,108,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVxSbf1kuTR4" style="text-align: right" title="Unrecognized expense">2,097,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_8A9_zhwUaOwYGaZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zw2wPr6d8628" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zue5Pm5NOC5k">SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqlHr7YFhi72" style="width: 14%; text-align: right" title="Stock-based compensation award">7,741,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAveqV0rIEV8" style="width: 14%; text-align: right" title="Stock-based compensation award">19411976</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOjzSNxdXdmg" style="text-align: right" title="Stock-based compensation award">4,735,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlaZMA2CX3rf" style="text-align: right" title="Stock-based compensation award">3,671,503</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zV05i5E9eKAh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">135,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zfvCuOM9Lwz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">25,476</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231_zA0jHrxnRZ28" style="text-align: right" title="Stock-based compensation award">12,612,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231_zEUWDLTO0cmk" style="text-align: right" title="Stock-based compensation award">23,108,955</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_za82eLcv4vy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402830264096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_z3yWSsXG4dCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
 8 - <span id="xdx_82F_zqBzO3kIdQFi">INCOME TAXES</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company identified its federal and New York tax returns as its &#8220;major&#8221; tax jurisdictions. The period its income tax returns
are subject to examination for these jurisdictions is 2018 through 2022. The Company believes its income tax filing positions and deductions
will be sustained on audit, and it does not anticipate any adjustments that would result in a material change to its financial position.
Therefore, no liabilities for uncertain tax positions have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company had approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zI8E9dnTNaog" title="Operating loss carry forwards">59,900,000</span> and $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zngKeIsfWlfb" title="Operating loss carry forwards">10,300,000</span>, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;),
certain future carryforwards do not expire. At December 31, 2022, approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20221231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zJWSzufo7wk1" title="Operating loss carry-forwards subject to expiration">8,000,000</span> of federal net operating losses will expire
from 2030 to 2038 and approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20221231_zSlYn71GQd5l" title="Operating loss carry-forwards not subject to expiration">51,900,000</span> have no expiration. <span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zhYy1K72NN04" title="Income tax examination, description">In accordance with Section 382 of the Internal Revenue Code, the
usage of the Company&#8217;s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership
changes.</span> The Section 382 limitations resulted in approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zpgA0JRKLN6b" title="Federal net operating loss carry-forwards"><span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zLtjnWIMHMib" title="Federal net operating loss carry-forwards">28,200,000</span></span> of federal NOLs not being realizable
as of December 31, 2022 and 2021 and the cumulative reversal of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_z6LAWjTUsZIi" title="Deferred tax assets, operating loss carryforwards"><span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zHYW3ZPE7Ibf" title="Deferred tax assets, operating loss carryforwards">9,600,000</span></span> of net operating loss deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not performed a formal analysis for the year ended December 31, 2022, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxo7kMnJ4Sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2022 and 2021 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zPGPgpCirK5c" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zqHIKS6yQzkf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_z2EWfdn8UMa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzjDN_maDTAGzPKX_zxlbm7o863Ff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13,200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11,100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzjDN_maDTAGzPKX_z2Gls5i1bd66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,810,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzPKX_zCCTw5dB54j9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">655,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzPKX_zn0eqBdup87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research &amp; development tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">330,000</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_msDTLzhRs_mtDTAGzPKX_maDTALNzfjZ_zzd8bY60V9yi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,995,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,958,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDITLzXDW_zNWZR3fb6rRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzXDW_zbv4sTRD5sTd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzXDW_msDTALNzfjZ_z1QbuJoyIf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(219,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_mtDTALNzfjZ_zRN5sFEShJ3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,776,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,954,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zzyjh1Tam3I" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,776,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,954,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_zuHkoff91Z31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Deferred tax asset, net of valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220101__20221231_zs4dWkbGqYhb" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(5,822,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_zCIkkTE1tHC" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(7,856,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A8_zle5qQRyI6Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zooHXSN2G1Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2022 and 2021 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zyIra2pymnne" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zN8pM83pF9qi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z6EBCU4nJhh6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzexe_zS7DdAdTDUo3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzexe_zGsxdo8LXBv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State and local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzexe_zCd8JG3v8gO2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maITEBzexe_zf3zFvNhRK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzexe_zEJVx9DPPFQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income tax provision (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z2MBeT4l28tc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z09LfIwM8dJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2022 and 2021 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zyAWAvu0AbLk" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_z8XWsoAm2Nvi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231_zXShsA2E1oF7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zlTzCt1GcsUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal statutory blended income tax rates</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zv6tIPY7ZJU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State statutory income tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_zF6pRXWkT6sh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.9</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_zfzoLKyDsKsh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKYmliGY8TB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31.5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17.7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z8WFOqbT2OAj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_zQzWekPwGa1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, the Company has not filed its 2022 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739224160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--LesseeOperatingLeasesTextBlock_zuT4sYm0XFC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
 9 - <span id="xdx_825_zm5KZCfk8Lla">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zO6nTSqYMSDi" title="Area of land">6,800</span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. <span id="xdx_904_eus-gaap--LessorOperatingLeaseDescription_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zeIMVMZzoTO1" title="Lease description">The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zymVzYrgGdWj" title="Rent expense">132,600</span> and
$<span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zC9vr08INZXc" title="Rent expense">149,260</span>.</span> In June 2019, <span id="xdx_905_eus-gaap--LessorOperatingLeaseDescription_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zMIl0TDXRJ93" title="Lease description">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced</span> on January 1, 2020 with annual base rent ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_z3xIdAIkh15j" title="Rent expense">153,748</span> and $<span id="xdx_90A_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zTRPi0wFpaF7" title="Rent expense">173,060</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zzLpn2qirZg3" title="Weighted average incremental borrowing rate">12</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zZenbPICcdaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z23EYUeuXTXh" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_z8EB2RiBVbZd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zgyuob3ipOu9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zFYBuNNB2086" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">163,132</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">158,372</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_znlqh1MFVxKb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">163,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">158,372</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbx0OMThpQJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">163,132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">158,372</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingLeaseLiabilityReduction_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">119,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">101,190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z8ky0aEnYTt8" style="text-align: right" title="Non-current leases - right of use assets">241,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231_zsfaJWUEKYLa" style="text-align: right" title="Non-current leases - right of use assets">357,805</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231_ze6MkL5jtsy" style="text-align: right" title="Current liabilities - operating lease liabilities">139,328</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20211231_zNu915d4DJL2" style="text-align: right" title="Current liabilities - operating lease liabilities">119,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Non-current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zI09nGPRE2vf" style="text-align: right" title="Non-current liabilities - operating lease liabilities">162,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20211231_zeiKHOQrzgg7" style="text-align: right" title="Non-current liabilities - operating lease liabilities">301,645</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zMLqWXM3TG44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbvtZWaRmtt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zjfFnIaXkhll" style="display: none">SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zZgZ6LXCbUd1" style="width: 14%; text-align: right" title="2022">168,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20221231_zbRnoUHM1Ay1" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023">173,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20221231_zgdgnlCBig38" style="text-align: right" title="Total future minimum lease payments">341,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20221231_zDnG1J0WZRO2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amount representing interest">(39,443</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zlC73twgH2T2" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net future minimum lease payments">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zeVIxaaJ8HRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742473648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zHgXiG0hcpi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 - <span id="xdx_82C_zOqGqGzXpr53">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 17, 2023, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_ziSYKTWik0f7" title="Shares options, granted">400,357</span>
stock options to its officers and a certain employee, of which <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_zg66umQ0gRYf" title="Vested and exercisable percentage">50</span>%
were vested and exercisable upon grant. The remaining <span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_zce9B7pi2Vt2" title="Remaining percentage of options vested">50</span>%
of the options issued to the Company&#8217;s officers and employee will vest quarterly in eight nearly equal installments
commencing one year from the date of grant. The Company issued an additional <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardAndScientificAdvisoryMember_z0K6wBZ41Zx8" title="Shares options, granted">228,660</span>
stock options to its board members and scientific advisory board members, which will vest monthly over one year. The granted stock
options had an estimated fair value of approximately $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6C0UnW4C7w" title="Estimated fair value of granted">1,745,000</span>
as of the grant date, of which approximately <span id="xdx_908_ecustom--RecognizedStockbasedCompensationExpensePercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7ddGtnk9WFa" title="Recognized stock-based compensation expense percentage">$562,500</span>
was immediately recognized as stock-based compensation expense, which will be reflected in the Company&#8217;s consolidated results
of operations for the first quarter of 2023. </span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742488448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEDfld8mOouk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zJwbUNT5TSeg">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies
presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated financial
statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_za26SAORRPIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zXaInqJau9m5">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and
transactions have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zLpnaATMcbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zZxQ3ENSrgQ8">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities
at the date of the consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known
or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined
with precision, actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zHghKMZsiQA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zulwUOXTerH9">Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zEJzcWBODCNb" title="FDIC insured limit">250,000</span>. As of December
31, 2022, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
royalties related to the Company&#8217;s sublicense comprised all of the Company&#8217;s revenue during the years ended December 31,
2022 and 2021. See &#8220;Revenue&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpK1uUThmvyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zV9gomiXUZE9">Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for revenue in accordance with ASC Topic 606, <i>Revenue from Contracts with Customers</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (&#8220;SCTC&#8221;)
entered into in January 2012. In November 2022, the Company&#8217;s license rights under the agreement became exclusive. Pursuant to
the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things,
stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the
right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration
of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or
as, the performance obligation is satisfied. The Company&#8217;s contracts have a single performance obligation which is not separately
identifiable from other promises in the contracts and is, therefore, not distinct. The Company&#8217;s performance obligation is satisfied
upon the transfer of risk of loss to the customer. The timing of the Company&#8217;s revenue recognition may differ from the timing of
receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company
has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services,
the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2022 and 2021,
the Company recognized $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231_zALvZxSxFKFg" title="Revenue">119,800</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231_zrzksD8NW2fl" title="Revenue">46,000</span>, respectively, of revenue related to the Company&#8217;s sublicenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Practical
Expedients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of ASC Topic 606, the Company has adopted several practical expedients including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing
    component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or
    service to the customer and when the customer pays for that good or service will be one year or less.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfied
    Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has
    elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount
    of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the
    customer of the Company&#8217;s performance completed to date; the Company may recognize revenue in the amount to which the entity
    has a right to invoice.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contract
Modifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed above with the SCTC, there were no contract modifications during the years ended December 31, 2022 and 2021. Contract modifications
are not routine in the performance of the Company&#8217;s contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVsDmeHVVfZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zq4KqnDVezF3">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
There were <span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zHB8Va7Wnu2" title="Cash equivalents"><span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20211231_zRKSrT7ZgOHe" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyMaNd4MXaX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z3JRIkFhsIUe">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are reported at their outstanding unpaid principal balances net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#8217;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance
is determined to be uncollectible. The Company did <span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20221231_zvR76JAlrBBh" title="Allowance for doubtful accounts"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20211231_z2jVUWCd7Ema" title="Allowance for doubtful accounts">no</span></span>t record an allowance for doubtful accounts as of December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z7QZaQuURbXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zotAixuudUc4">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zNHQ171jQ7Ia" title="Property plant and equipment estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0599">three</span></span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zebr2EFsAs84" title="Property plant and equipment estimated useful lives">fifteen years</span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z7HjQQkl5kLh" title="Property plant and equipment estimated useful lives">3</span> - <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_z31K7O6DC0w" title="Property plant and equipment estimated useful lives">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8WDc8yTknEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zTNHl5hU2Px4">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2022 and 2021, we determined that there
was <span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zPNnRZF7p6Zf" title="Impairment of long-lived assets"><span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zmJCQbdpB0M2" title="Impairment of long-lived assets">no</span></span> impairment charge for our long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span>&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5EL4j7TmQy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z20P2ecqmv9l">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 350, <i>Intangibles
- Goodwill and Other</i>. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method,
which is determined by identifying the period over which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLSUAeNLbqR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYStEt1yL9Se">Fair
Value Measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; fair value is the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The
Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally
    developed methodologies that result in management&#8217;s best estimate of fair value.</span></td></tr>
  </table>
<p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zbOmuIk07cZ7">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Marketable securities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" style="width: 10%; text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" style="width: 14%; text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" style="width: 10%; text-align: right" title="Assets fair value disclosure">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" style="width: 10%; text-align: right" title="Assets fair value disclosure">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zAW0a1XPysYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company recognized unrealized gain of $<span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_z5YqJUMYWX3i" title="Unrealized gain on marketable securities">33,665</span> on its marketable securities within Other income,
net in its Consolidated Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjeWPr8GkESi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zPQhKbgFT0Je">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, accounts receivable, accounts payable and other current liabilities approximate their fair values based on the
short-term maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zRcPkx81fhZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zjdhsINXbPCc">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#8217;s
computation of diluted net loss per common share for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than the
average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" style="width: 14%; text-align: right" title="Total">864,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" style="width: 14%; text-align: right" title="Total">839,639</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" style="text-align: right" title="Total potentially dilutive shares">4,791,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" style="text-align: right" title="Total potentially dilutive shares">4,739,871</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" style="text-align: right" title="Unvested">201,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" style="text-align: right" title="Unvested">293,479</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,543,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,543,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" style="text-align: right" title="Total">7,400,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" style="text-align: right" title="Total">7,416,147</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zdYeSTzR4o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw18GIRvhrKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z81MWRbXrIMf">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 718, <i>Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;), which requires the measurement
and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASU 2018-07 Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company
accounts for stock options issued to non-employees for their services in accordance ASC 718. The Company uses valuation methods and assumptions
to value the stock options that are in line with the process for valuing employee stock options noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpwuyVzvE9yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zI4CnFG2mOF8">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_z873L7gC4EF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zeHOmHE66wKi">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
ASC. The accounting treatment of derivative financial instruments requires that the Company records embedded conversion options (&#8220;ECOs&#8221;)
and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each
subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period
at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of
debt discount on the consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification
of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the
contract is reclassified as of the date of the event that caused the reclassification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SequencingPolicyPolicyTextBlock', window );">Sequencing Policy</a></td>
<td class="text"><p id="xdx_845_ecustom--SequencingPolicyPolicyTextBlock_zBplxoEP5Bp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zH8NqFKly3Rf">Sequencing
Policy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40-35 (&#8220;ASC 815&#8221;), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts
from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient
authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the
basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
Pursuant to ASC 815, issuances of securities to the Company&#8217;s employees and directors, or to compensate grantees in a share-based
payment arrangement, are not subject to the sequencing policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_z2Scqidx85he" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z0u8F9ujfxjf">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease is defined as a contract that conveys the right to control the use of identified property, plant or equipment for a period of time
in exchange for consideration. On January 1, 2019, the Company adopted ASC 842 and it primarily affected the accounting treatment for
operating lease agreements in which the Company is the lessee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, <i>Leases</i>, the Company recognized a right-of-use (&#8220;ROU&#8221;) asset and corresponding lease
liability on its balance sheets for its office space lease agreement. See Note 9 - Leases for further discussion, including the
impact on the Company&#8217;s financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets include any prepaid lease payments and exclude any lease incentives and initial direct costs incurred. Lease expense for minimum
lease payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate
the lease if it is reasonably certain that the Company will exercise that option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
in which the Company is the lessee are comprised of office rental. All of the leases are classified as operating leases. The Company
has a lease agreement for office space with a remaining term of <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGOsxiAyKBI5" title="Lease remaining term">two years</span> as of December 31, 2022.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SequencingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sequencing policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SequencingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746305312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE RECURRING BASIS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zbOmuIk07cZ7">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">Marketable securities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" style="width: 10%; text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" style="width: 14%; text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" style="width: 10%; text-align: right" title="Assets fair value disclosure">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" style="width: 10%; text-align: right" title="Assets fair value disclosure">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise price could be less than the
average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" style="width: 14%; text-align: right" title="Total">864,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" style="width: 14%; text-align: right" title="Total">839,639</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" style="text-align: right" title="Total potentially dilutive shares">4,791,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" style="text-align: right" title="Total potentially dilutive shares">4,739,871</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" style="text-align: right" title="Unvested">201,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" style="text-align: right" title="Unvested">293,479</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,543,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,543,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" style="text-align: right" title="Total">7,400,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" style="text-align: right" title="Total">7,416,147</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402832455328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9eSZ8RWGq1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z5JT7tfsKlai" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z2kRu6y6eaH5" style="width: 15%; text-align: right" title="Property and equipment, gross">352,133</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z0wFKAizArJ" style="width: 15%; text-align: right" title="Property and equipment, gross">352,133</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZcGmgWOQUe8" style="text-align: right" title="Property and equipment, gross">123,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zctkOhHbqS53" style="text-align: right" title="Property and equipment, gross">123,487</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zDtravMzYG7c" style="text-align: right" title="Property and equipment, gross">117,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zScIeRjOfiQh" style="text-align: right" title="Property and equipment, gross">107,648</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zh8ttA0aZZA2" style="text-align: right" title="Property and equipment, gross">18,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zM6w3vsvjP43" style="text-align: right" title="Property and equipment, gross">12,979</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zb7fb9TkScBf" style="text-align: right" title="Property and equipment, gross">242,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_z2qOeh6fJaeg" style="text-align: right" title="Property and equipment, gross">30,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBPSSXkCeUe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">342,048</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMejPzHRvGMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">304,661</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zX9GcimW1xS" style="text-align: right" title="Property and equipment, gross">1,196,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231_zMvwN7Us6tk2" style="text-align: right" title="Property and equipment, gross">931,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zGb37UmSTx42" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(935,839</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_znZA0V2zNsWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(893,627</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z5TUNyIac6N8" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">261,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zKtxoO5UqTy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">37,993</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402747427616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zz5ob2QNHGYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z3HT9mUl0tEk">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of January 1, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zR5sXscArwYb" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zjX0FEK6zSw6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,301,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2BCF6Ub6bDd" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(640,908</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20210101__20211231_zhZY2LMNgImk" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">664,268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zW21m9E1loYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(74,528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231_zS0EF0PJShna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(74,528</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z16LeSwQBqZk" style="text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zrcVS6ZFIxNh" style="text-align: right" title="Finite Lived Intangible Assets, beginning balance">1,301,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zzdO0qsShm9d" style="text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(715,436</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20220101__20221231_ziF74mUAzUhi" style="text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">589,740</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Consideration transferred for license exclusivity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIIuyilwgzIj" style="text-align: right" title="Consideration transferred for license exclusivity">292,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231_zZwwWg9QA178" style="text-align: right" title="Consideration transferred for license exclusivity">292,030</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zOk3jTfDcRWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(78,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231_zbnV5QIafEd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(78,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zLFLfwghXz31" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIjyOrsWJZ6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z9R8BK6jiYFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance">(793,768</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20220101__20221231_z0axz7mgX6Nk" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance">803,438</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhwNz2iVMyog" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3XvcIExYQE9" title="Finite Lived Intangible Assets, weighted average amortization period">11.25</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zuYakqSqMWC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_ze6dKh9GVy4f">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_z111QHGgf6ib" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zOcIjRIprHI7" style="width: 14%; text-align: right" title="Beginning Balance">637,232</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zSvPCXNe1O81" style="width: 14%; text-align: right" title="Beginning Balance">640,908</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zQsLGcm9Clsd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkI3R4uA8ncj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">74,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zeqlmrAk0Oc7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">74,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zYNdRMNLXXL3" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdvH1UPoFa6k" style="text-align: right" title="Beginning Balance">711,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zLw7u3xiVMfj" style="text-align: right" title="Beginning Balance">715,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjqAZlC0iQM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zemPn2tTSNNg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">78,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z0AgdgMgVXsh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">78,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCmYU0PaxmNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z7iLe7KaisVi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">790,092</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zNXhaLnNN7Gl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">793,768</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3lONGEusWI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B9_z24iYDJQ20G5">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221231_zM1WUu8puxm" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zmJ8qFYSBEY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">89,131</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zXveE2K88kFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zeVSPq4NT1ja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zrYqmkW3iogg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zCfWHjd4m9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,131</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746614064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zwBSApfXDN93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zxPwPamjgYe5">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zaGGhfBp9Wff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zGZwRLKduE1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zcEgT8XwVLph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accrued payroll</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">26,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">28,370</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedResearchAndDevelopmentExpenses_iI_maALAOLzJ5Y_zdABJUl0Lbh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,672</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zmQ2gGIHIkX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,822</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,928</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zECYx3mc4q96" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,072</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">134,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402747368432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF NOTES PAYABLE ACTIVITY</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_z6vD8WR7Ruyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the notes payable activity during the year ended December 31, 2022 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z0U2tHHDdg9l">SCHEDULE OF NOTES PAYABLE ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Outstanding, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--LoansPayable_iS_c20220101__20221231_zpdYlJWz25Md" style="width: 14%; text-align: right" title="Loans payable outstanding beginning">250,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ProceedsFromIssuanceOfDebt_c20220101__20221231_z2TTt3e07Ar2" style="text-align: right" title="Issuances"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forgiveness</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DebtInstrumentDecreaseForgiveness_iN_di_c20220101__20221231_zhV0UK3vXrdc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness">(250,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LoansPayable_iE_c20220101__20221231_zTOQ2ieZBEbk" style="border-bottom: Black 2.5pt double; text-align: right" title="Loans payable outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742615728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zOuyIV8iOJ3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zOrdaxljWDCc">SCHEDULE OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd4Nh0CXnlZ9" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning">3,750,598</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcGhj2zdgtO1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance">4.40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7cO4Hu6jSf2" style="text-align: right" title="Number of Options Granted">4,862,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zml1yDOPGRJb" style="text-align: right" title="Weighted Average Exercise Price Granted">9.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqFbv9xYroYh" style="text-align: right" title="Number of Options Exercised">(195,473</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjVY6mgGiCoi" style="text-align: right" title="Weighted average exercise price, exercised">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged or forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUaAKCNwtbTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Exchanged or Forfeited">(3,677,964</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLaXAA6YDk82" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Exchanged or Forfeited">3.39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzvZwqmKzFj" style="text-align: right" title="Number of Options Outstanding Beginning">4,739,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjiXMu5AsRkk" style="text-align: right" title="Weighted average exercise price, beginning balance">11.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwfSIIZbWJjh" title="Number of Options Outstanding">4.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z24SoF8wjjpe" style="text-align: right" title="Number of Options Granted">51,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPhUEuXy7tN8" style="text-align: right" title="Weighted average exercise price, granted">2.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPgSRJUwm52" style="text-align: right" title="Number of warrants outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWsr4fiefsc" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfY4QM3cBG52" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding, expired">(159</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSHJyBdkhlrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired">16,083</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoMAOWeVHVme" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending">4,791,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziSBknt3oy6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">10.71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKYqAUIvaRD4" title="Number of Options Outstanding">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYtHfLYUvVM" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqTYLnWIBd99" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">4,791,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr2RVNGYT0H9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">10.71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcsOo2SCbzzg" title="Weighted Average Remaining Life in Years Outstanding Ending">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIX5sRtDtpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable Ending"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zLtW3xeSNUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to warrants granted during 2022 and 2021, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zM3Q788gyCgd">SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMvGAiHM9Wn4" title="Risk free interest rate">4.40</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUa4wX5jcDa2" title="Risk free interest rate">0.98</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZJFlIgfgLjd" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zL200eFHX2Y7" title="Expected term (years)">4.10</span> - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvAHbtmjB3Hj" title="Expected term (years)">5.00</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWC2XP7huk3" title="Expected volatility">313.55</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdg9AcduYQB5" title="Expected volatility">314.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy8d1XEONiE8" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8PP1FFITYci" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock', window );">SCHEDULE OF STOCK WARRANTS</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zIZTEBuLKvUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zGdgp7ZC63y3">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life In Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 44%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOzaVg05GL59" title="Warrants outstanding, exercise price">2.92</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zNxNAcuZCaRd" style="width: 14%; text-align: right" title="Warrants outstanding, number of warrants">51,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zd8n75XgKkxg" title="Warrants exercisable, weighted average remaining life in years">4.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zWfrVEaUQnq5" style="width: 14%; text-align: right" title="Warrants exercisable, exercisable number of warrants">51,370</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7T8okIt08S5" title="Warrants outstanding, exercise price">10.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zeSebgIHfwyj" style="text-align: right">4,501,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdfGCAbbhVO6">3.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zXyMmLaFCSM7" style="text-align: right">4,501,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zF2L9mZmEkB9" title="Warrants outstanding, exercise price">12.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zQEmQMZXNhwg" style="text-align: right" title="Warrants outstanding, number of warrants">235,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0QfHjmmqF4i" title="Warrants exercisable, weighted average remaining life in years">3.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zxQ9nH8wOKx" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">235,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKjFPftSTCpl" title="Warrants outstanding, exercise price">60.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zdq4Lp8Lyt3k" style="text-align: right" title="Warrants outstanding, number of warrants">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB47YjJpwQr3" title="Warrants exercisable, weighted average remaining life in years">2.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zwO4pm9kjpB1" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcSr6m5jve3e" title="Warrants outstanding, exercise price">800.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zLJWuMGrxPAd" style="text-align: right" title="Warrants outstanding, number of warrants">869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTxdcUeiF1h6" title="Warrants exercisable, weighted average remaining life in years">1.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zQETJV7D8QTi" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zqk8O4ghtpm8" title="Warrants outstanding, exercise price">2,240.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_ziQ80gOPY3C" style="text-align: right" title="Warrants outstanding, number of warrants">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVBCh8CXCg5" title="Warrants exercisable, weighted average remaining life in years">1.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_zLGN8Q6oGbQ2" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXIcZViHwRKb" title="Warrants outstanding, exercise price">2,800.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zaMvUapSecPd" style="text-align: right" title="Warrants outstanding, number of warrants">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zwQ6TYROPLN1" title="Warrants exercisable, weighted average remaining life in years">1.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zb74Zi8xFHzl" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z03zfrSg1YE3" title="Warrants outstanding, exercise price">3,400.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zLbJnkFHuO0a" style="text-align: right" title="Warrants outstanding, number of warrants">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zz1hJ74P7Sp7" title="Warrants exercisable, weighted average remaining life in years">1.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_fKDEp_zCmcDJ1Utpt5" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zyoxbJsqUkce" title="Warrants outstanding, exercise price">4,000.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zIuI5nKGc5v7" style="text-align: right" title="Warrants outstanding, number of warrants">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zdpKW9qo3Eoh" title="Warrants exercisable, weighted average remaining life in years">1.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_fKDEp_zAhj1JOl85N" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z9lOrmIjzVv6" title="Warrants outstanding, exercise price">8,000.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zLmOj98tGluj" style="text-align: right" title="Warrants outstanding, number of warrants">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zM16slMZ1dB8" title="Warrants exercisable, weighted average remaining life in years">0.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_fKDEp_zy0VUpS5vwAc" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zoGyNOwnZjHh" title="Warrants outstanding, exercise price">14,000.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6JVx3FuMZji" style="text-align: right" title="Warrants outstanding, number of warrants">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zALlBxKyG9e4" title="Warrants exercisable, weighted average remaining life in years">0.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_fKDEp_zGwpRz4mjks9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zpkb1VJZ5uLb" title="Warrants outstanding, exercise price">16,000.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_za7cJzBqbM4j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, number of warrants">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhoaDtHgclQ5" title="Warrants exercisable, weighted average remaining life in years">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_fKDEp_zy1uBTNrqDEa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_fKDEp_zqZr7OXjinei" style="text-align: right">4,791,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_fKDEp_zm7MSkwMUmn4" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">4,791,082</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z41Grh7waTHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z41jvRlK6xNb">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z0htSgZLMxVg" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning">1,215</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zLACIEDVEGk9" style="width: 11%; text-align: right" title="Weighted average outstanding beginning balance">5.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zEyBsIf7KJJ4" style="text-align: right" title="Number of Options Granted">838,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zyOJAFxHqe5" style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zTv1o9IGqWma" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired">(126</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zPc6CVcdfbEg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired">5.08</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zRZlzYdhgFS7" style="text-align: right" title="Number of Options Outstanding Beginning">839,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zSKSNTbfRMV1" style="text-align: right" title="Weighted Average Exercise Price Outstanding Beginning">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zpFx7wwKDXK8" style="text-align: right" title="Number of Options Granted">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zVvPl0gtty4b" style="text-align: right" title="Weighted Average Exercise Price Granted">4.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zHyticBxYibb" style="text-align: right" title="Number of Options Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z9Ud3scCE3Uj" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zQ5CR0592oOa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJ0toreo1sfc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zTJHQs9T6N4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending">864,639</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zhDeR1Z7o6zb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding Ending">5.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zDvB6ocfrrU7" title="Weighted Average Remaining Life in Years Outstanding Ending">7.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20221231_zmNhYFjpKHa9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfiKun1fYpfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">578,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20221231_zuBRlNKlJ92i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending">5.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_ziKPFOAgWDah" title="Weighted Average Remaining Life in Years Exercisable Ending">7.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaC8Zw0s9uu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zsZZFqtNG8Ch">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUi1pRRyTzpg" title="Risk free interest rate">2.42</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBRy8732sBn4" title="Expected term (years)">3.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxLxiNUDh7lb" title="Expected volatility">285.91</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGZxG1lmhMo2" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ziQWhFgrM8i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zK4OnVu5gNvf">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Outstanding, January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7ruj8I7X9ec" style="width: 14%; text-align: right" title="Number of shares outstanding beginning">293,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWU9gwnsBuh" style="text-align: right" title="Number of shares granted">24,876</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ4xFg3IJbnh" style="text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1164">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMlTpl4Y0MB8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares vested">(116,486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZsFIt7oprpa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending">201,870</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">SCHEDULE OF STOCK OPTION EXPENSE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zWgn53WFH2L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zveUfSxAoorc">SCHEDULE OF STOCK OPTION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Amortization Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4wVPE52dCH3" style="width: 11%; text-align: right" title="Stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyYDc2BYMYSi" style="width: 11%; text-align: right" title="Stock-based compensation expense">81,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMN4tnm8lsEf" style="width: 11%; text-align: right" title="Unrecognized expense">803,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQTaVcLFo6cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense">12,612,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1FGqhTV6UV" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense">23,027,476</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwMmnQ8r2x4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrecognized expense">1,294,684</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5GNJoPn2LYj" title="Weighted average remaining amortization period (years)">0.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVoNThiixP6" style="text-align: right" title="Stock-based compensation expense">12,612,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKwTrTrlpY2" style="text-align: right" title="Stock-based compensation expense">23,108,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVxSbf1kuTR4" style="text-align: right" title="Unrecognized expense">2,097,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE</a></td>
<td class="text"><p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zw2wPr6d8628" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p style="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zue5Pm5NOC5k">SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqlHr7YFhi72" style="width: 14%; text-align: right" title="Stock-based compensation award">7,741,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAveqV0rIEV8" style="width: 14%; text-align: right" title="Stock-based compensation award">19411976</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOjzSNxdXdmg" style="text-align: right" title="Stock-based compensation award">4,735,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlaZMA2CX3rf" style="text-align: right" title="Stock-based compensation award">3,671,503</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zV05i5E9eKAh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">135,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zfvCuOM9Lwz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">25,476</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231_zA0jHrxnRZ28" style="text-align: right" title="Stock-based compensation award">12,612,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231_zEUWDLTO0cmk" style="text-align: right" title="Stock-based compensation award">23,108,955</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based payment award warrants valuation assumptions [Table text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402743060912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxo7kMnJ4Sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2022 and 2021 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zPGPgpCirK5c" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zqHIKS6yQzkf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_z2EWfdn8UMa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzjDN_maDTAGzPKX_zxlbm7o863Ff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13,200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11,100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzjDN_maDTAGzPKX_z2Gls5i1bd66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,810,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzPKX_zCCTw5dB54j9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">655,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzPKX_zn0eqBdup87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research &amp; development tax credits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">330,000</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_msDTLzhRs_mtDTAGzPKX_maDTALNzfjZ_zzd8bY60V9yi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,995,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,958,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDITLzXDW_zNWZR3fb6rRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzXDW_zbv4sTRD5sTd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzXDW_msDTALNzfjZ_z1QbuJoyIf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(219,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_mtDTALNzfjZ_zRN5sFEShJ3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,776,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,954,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zzyjh1Tam3I" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,776,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,954,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_zuHkoff91Z31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Deferred tax asset, net of valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220101__20221231_zs4dWkbGqYhb" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(5,822,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_zCIkkTE1tHC" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(7,856,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX PROVISION (BENEFIT)</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zooHXSN2G1Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2022 and 2021 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zyIra2pymnne" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zN8pM83pF9qi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z6EBCU4nJhh6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzexe_zS7DdAdTDUo3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzexe_zGsxdo8LXBv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State and local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzexe_zCd8JG3v8gO2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maITEBzexe_zf3zFvNhRK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzexe_zEJVx9DPPFQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income tax provision (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1284">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z09LfIwM8dJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2022 and 2021 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zyAWAvu0AbLk" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_z8XWsoAm2Nvi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231_zXShsA2E1oF7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zlTzCt1GcsUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal statutory blended income tax rates</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zv6tIPY7ZJU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State statutory income tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_zF6pRXWkT6sh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.9</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_zfzoLKyDsKsh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKYmliGY8TB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31.5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17.7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z8WFOqbT2OAj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746396752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zZenbPICcdaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z23EYUeuXTXh" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_z8EB2RiBVbZd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zgyuob3ipOu9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zFYBuNNB2086" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">163,132</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">158,372</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_znlqh1MFVxKb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">163,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">158,372</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbx0OMThpQJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">163,132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">158,372</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingLeaseLiabilityReduction_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">119,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">101,190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z8ky0aEnYTt8" style="text-align: right" title="Non-current leases - right of use assets">241,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231_zsfaJWUEKYLa" style="text-align: right" title="Non-current leases - right of use assets">357,805</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231_ze6MkL5jtsy" style="text-align: right" title="Current liabilities - operating lease liabilities">139,328</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20211231_zNu915d4DJL2" style="text-align: right" title="Current liabilities - operating lease liabilities">119,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Non-current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zI09nGPRE2vf" style="text-align: right" title="Non-current liabilities - operating lease liabilities">162,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20211231_zeiKHOQrzgg7" style="text-align: right" title="Non-current liabilities - operating lease liabilities">301,645</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbvtZWaRmtt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zjfFnIaXkhll" style="display: none">SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zZgZ6LXCbUd1" style="width: 14%; text-align: right" title="2022">168,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20221231_zbRnoUHM1Ay1" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023">173,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20221231_zgdgnlCBig38" style="text-align: right" title="Total future minimum lease payments">341,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20221231_zDnG1J0WZRO2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amount representing interest">(39,443</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zlC73twgH2T2" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net future minimum lease payments">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742260432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 18,494,769<span></span>
</td>
<td class="nump">$ 44,303,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">12,612,862<span></span>
</td>
<td class="nump">$ 23,108,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NetCashProvidedByUsedInOperatingActivitie', window );">Cash flows from operations</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NetCashProvidedByUsedInOperatingActivitie">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NetCashProvidedByUsedInOperatingActivitie</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742521808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">$ 13,072,831<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">13,072,831<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739915888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,400,749<span></span>
</td>
<td class="nump">7,416,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">864,639<span></span>
</td>
<td class="nump">839,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,791,082<span></span>
</td>
<td class="nump">4,739,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">201,870<span></span>
</td>
<td class="nump">293,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739143968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">119,800<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">$ 33,665<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=BRTX_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease remaining term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=BRTX_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=BRTX_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402738761264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,196,842<span></span>
</td>
<td class="nump">$ 931,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(935,839)<span></span>
</td>
<td class="num">(893,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">261,003<span></span>
</td>
<td class="nump">37,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">352,133<span></span>
</td>
<td class="nump">352,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">123,486<span></span>
</td>
<td class="nump">123,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember', window );">Computer Software and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">117,544<span></span>
</td>
<td class="nump">107,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,779<span></span>
</td>
<td class="nump">12,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">242,852<span></span>
</td>
<td class="nump">30,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 342,048<span></span>
</td>
<td class="nump">$ 304,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402746311440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 42,212<span></span>
</td>
<td class="nump">$ 14,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739214352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite Lived Intangible Assets, Net, beginning balance</a></td>
<td class="nump">$ 589,740<span></span>
</td>
<td class="nump">$ 664,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(78,332)<span></span>
</td>
<td class="num">(74,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ConsiderationTransferredForLicenses', window );">Consideration transferred for license exclusivity</a></td>
<td class="nump">292,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite Lived Intangible Assets, Net, ending balance</a></td>
<td class="nump">803,438<span></span>
</td>
<td class="nump">589,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember', window );">Patents and Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, beginning balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, gross, beginning balance</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_LicensesMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, beginning balance</a></td>
<td class="nump">$ 1,301,500<span></span>
</td>
<td class="nump">1,301,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ConsiderationTransferredForLicenses', window );">Consideration transferred for license exclusivity</a></td>
<td class="nump">292,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, gross, beginning balance</a></td>
<td class="nump">$ 1,593,530<span></span>
</td>
<td class="nump">1,301,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text">11 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated amortization, beginning balance</a></td>
<td class="num">$ (715,436)<span></span>
</td>
<td class="num">(640,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(78,332)<span></span>
</td>
<td class="num">(74,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated amortization, ending balance</a></td>
<td class="num">$ (793,768)<span></span>
</td>
<td class="num">$ (715,436)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ConsiderationTransferredForLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration transferred for licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ConsiderationTransferredForLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402738815168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 78,332<span></span>
</td>
<td class="nump">$ 74,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember', window );">Patents and Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">711,760<span></span>
</td>
<td class="nump">637,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">78,332<span></span>
</td>
<td class="nump">74,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">790,092<span></span>
</td>
<td class="nump">711,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">715,436<span></span>
</td>
<td class="nump">640,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">78,332<span></span>
</td>
<td class="nump">74,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">$ 793,768<span></span>
</td>
<td class="nump">$ 715,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402747253264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 89,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">89,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">89,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">89,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">$ 89,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742237744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 21, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment to acquire intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issues</a></td>
<td class="nump">22,917<span></span>
</td>
<td class="nump">51,370<span></span>
</td>
<td class="nump">147,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402743105664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 26,250<span></span>
</td>
<td class="nump">$ 28,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">103,822<span></span>
</td>
<td class="nump">76,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">$ 130,072<span></span>
</td>
<td class="nump">$ 134,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742431840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable outstanding beginning</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Issuances</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Forgiveness</a></td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable outstanding ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402744402832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Options Outstanding Beginning</a></td>
<td class="nump">4,739,871<span></span>
</td>
<td class="nump">3,750,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 11.78<span></span>
</td>
<td class="nump">$ 4.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Options Granted</a></td>
<td class="nump">51,370<span></span>
</td>
<td class="nump">4,862,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="nump">$ 9.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Options Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(195,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Options Exchanged or Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,677,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exchanged or Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Number of Options Outstanding</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants outstanding, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">195,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of warrants outstanding, expired</a></td>
<td class="num">(159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 16,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Options Outstanding Ending</a></td>
<td class="nump">4,791,082<span></span>
</td>
<td class="nump">4,739,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="nump">$ 11.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable Ending</a></td>
<td class="nump">4,791,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years Outstanding Ending</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Exercisable Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options forfeitures in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402737747888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">313.55%<span></span>
</td>
<td class="nump">314.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742166400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF STOCK WARRANTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">4,791,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">4,791,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">4,501,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">4,501,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">235,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">235,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 60.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 800.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2,240.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2,800.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 3,400.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceNineMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 4,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTenMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 8,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceElevenMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 14,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwelveMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 16,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742574592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding Beginning</a></td>
<td class="nump">839,639<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding Beginning</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">838,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding Ending</a></td>
<td class="nump">864,639<span></span>
</td>
<td class="nump">839,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding Ending</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life in Years Outstanding Ending</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable Ending</a></td>
<td class="nump">578,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable Ending</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years Exercisable Ending</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402830387920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">285.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402743058112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding beginning</a></td>
<td class="nump">293,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="nump">24,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="num">(116,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding ending</a></td>
<td class="nump">201,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402737783072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION EXPENSE (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,612,862<span></span>
</td>
<td class="nump">$ 23,108,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">2,097,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">81,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">803,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">12,612,862<span></span>
</td>
<td class="nump">$ 23,027,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 1,294,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402743157520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation award</a></td>
<td class="nump">12,612,862<span></span>
</td>
<td class="nump">23,108,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation award</a></td>
<td class="nump">7,741,864<span></span>
</td>
<td class="nump">19,411,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation award</a></td>
<td class="nump">4,735,108<span></span>
</td>
<td class="nump">3,671,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=BRTX_SharesIssuedForServicesMember', window );">Shares Issued for Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation award</a></td>
<td class="nump">135,890<span></span>
</td>
<td class="nump">25,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=BRTX_SharesIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=BRTX_SharesIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402734097888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Mar. 18, 2022</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Oct. 21, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 08, 2022</div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,612,862<span></span>
</td>
<td class="nump">23,108,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Aggregate purchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector', window );">Description of stock options held by officer and director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) Lance Alstodt, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board: 335,538 shares,
(ii) Francisco Silva, the Company&#8217;s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal,
the Company&#8217;s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company&#8217;s Vice President of Quality Assurance
and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company&#8217;s directors: 25,236 shares; (vi) Patrick F. Williams,
one of the Company&#8217;s directors: 10,490 shares; and (vii) David Rosa, one of the Company&#8217;s directors: 10,490 shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,898<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Aggregate common stock services rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,888<span></span>
</td>
<td class="nump">$ 25,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,791,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">838,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Such options are exercisable to the extent of 50% on the date of grant and 50% quarterly
over a period of two years commencing one year from the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 5.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,735,108<span></span>
</td>
<td class="nump">3,671,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember', window );">Chief Executive Officer and Chairman of the Board and its Vice President [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_PatrickFWilliamsMember', window );">Patrick F Williams [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_MrAlstodtMember', window );">Mr. Alstodt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_MrSilvaMember', window );">Mr. Silva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_DrNickolayKukekovMember', window );">Dr Nickolay Kukekov [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=BRTX_ScientificAdvisoryBoardMember', window );">Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=BRTX_TwoEmploymentAgreementsMember', window );">Two Employment Agreements [Member] | Chief Executive Officer and Chairman of the Board and its Vice President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of share based payment award vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vested to the extent of 50% on the date of grant, 25% on the one-year anniversary of the grant date
and 25% on the two-year anniversary of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=BRTX_TwoEmploymentAgreementsMember', window );">Two Employment Agreements [Member] | Chief Executive Officer and Chairman of the Board and its Vice President [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of option issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,969,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,370<span></span>
</td>
<td class="nump">147,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 11.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as
provided for the Series A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Beneficial Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock shares</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Auctus Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock options held by officer and director</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_PatrickFWilliamsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_PatrickFWilliamsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_MrAlstodtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_MrAlstodtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_MrSilvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_MrSilvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_DrNickolayKukekovMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_DrNickolayKukekovMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_ScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_ScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=BRTX_TwoEmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=BRTX_TwoEmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402737775888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">13,810,000<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">655,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research &amp; development tax credits</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">27,995,000<span></span>
</td>
<td class="nump">21,958,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Depreciation</a></td>
<td class="num">(106,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(113,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(219,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">27,776,000<span></span>
</td>
<td class="nump">21,954,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(27,776,000)<span></span>
</td>
<td class="num">(21,954,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net of valuation allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">$ (5,822,000)<span></span>
</td>
<td class="num">$ (7,856,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739159024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402922892528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory blended income tax rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State statutory income tax rate, net of federal benefit</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment', window );">Tax return to provision adjustment</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.50%)<span></span>
</td>
<td class="num">(17.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax return to provision adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402739218784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carry-forwards</a></td>
<td class="nump">$ 59,900,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carry-forwards not subject to expiration</a></td>
<td class="nump">51,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, operating loss carryforwards</a></td>
<td class="nump">13,200,000<span></span>
</td>
<td class="nump">11,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember', window );">Expire from 2030 to 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carry-forwards subject to expiration</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember', window );">Section 382 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carry-forwards</a></td>
<td class="nump">$ 28,200,000<span></span>
</td>
<td class="nump">28,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination, description</a></td>
<td class="text">In accordance with Section 382 of the Internal Revenue Code, the
usage of the Company&#8217;s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership
changes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, operating loss carryforwards</a></td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742457280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost (cost resulting from lease payments)</a></td>
<td class="nump">$ 163,132<span></span>
</td>
<td class="nump">$ 158,372<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">163,132<span></span>
</td>
<td class="nump">158,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease - operating cash flows (fixed payments)</a></td>
<td class="nump">163,132<span></span>
</td>
<td class="nump">158,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_OperatingLeaseLiabilityReduction', window );">Operating lease - operating cash flows (liability reduction)</a></td>
<td class="nump">119,055<span></span>
</td>
<td class="nump">101,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Non-current leases - right of use assets</a></td>
<td class="nump">241,760<span></span>
</td>
<td class="nump">357,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current liabilities - operating lease liabilities</a></td>
<td class="nump">139,328<span></span>
</td>
<td class="nump">119,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current liabilities - operating lease liabilities</a></td>
<td class="nump">$ 162,317<span></span>
</td>
<td class="nump">$ 301,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_OperatingLeaseLiabilityReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_OperatingLeaseLiabilityReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742508592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 168,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">173,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">341,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amount representing interest</a></td>
<td class="num">(39,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net future minimum lease payments</a></td>
<td class="nump">$ 301,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402747951856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced<span></span>
</td>
<td class="text">The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $132,600 and
$149,260.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 153,748<span></span>
</td>
<td class="nump">$ 132,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 173,060<span></span>
</td>
<td class="nump">$ 149,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140402742548736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">838,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Estimated fair value of granted</a></td>
<td class="nump">$ 1,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_RecognizedStockbasedCompensationExpensePercentage', window );">Recognized stock-based compensation expense percentage</a></td>
<td class="nump">562500.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares options, granted</a></td>
<td class="nump">400,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vested and exercisable percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage', window );">Remaining percentage of options vested</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Board And Scientific Advisory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares options, granted</a></td>
<td class="nump">228,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_RecognizedStockbasedCompensationExpensePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized stock-based compensation expense percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_RecognizedStockbasedCompensationExpensePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining percentage of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_OfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_OfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_BoardAndScientificAdvisoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_BoardAndScientificAdvisoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BRTX="http://biorestorative.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brtx-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ComputerSoftwareAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ComputerSoftwareAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember27579265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-08</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="AsOf2021-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="AsOf2021-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="From2022-09-142022-09-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="From2021-10-212021-10-21_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-21</startDate>
            <endDate>2021-10-21</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember27580812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:TwoEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="From2021-11-022021-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="From2021-11-022021-11-04_custom_PatrickFWilliamsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:PatrickFWilliamsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="From2021-11-022021-11-04_custom_MrAlstodtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:MrAlstodtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="From2021-11-022021-11-04_custom_MrSilvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:MrSilvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="From2021-11-022021-11-04_custom_DrNickolayKukekovMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:DrNickolayKukekovMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="From2021-11-022021-11-04_custom_ScientificAdvisoryBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:TwoEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:TwoEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="From2022-03-172022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-18</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember27581328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember27581359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember27581375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember27582265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember27582265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SharesIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SharesIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SectionThreeHundredAndEightyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SectionThreeHundredAndEightyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SectionThreeHundredAndEightyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:OfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_BoardAndScientificAdvisoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:BoardAndScientificAdvisoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001505497</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0064"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GrantIncome
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0258"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0260"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInLitigationSettlement
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInLitigationSettlement
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInLitigationSettlement
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInLitigationSettlement
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0325"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0410"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:SharesIssuedInSettlementOfLitigation
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:NoncashAccruedExpenseExchangedForConveritbleNotes
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:AccruedDipExpensesExchangedForConvertibleNotes
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:WarrantsIssuedAsConsiderationForIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      id="xdx2ixbrl0599">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember"
      id="xdx2ixbrl0765"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl0789"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:AccruedResearchAndDevelopmentExpenses
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0835"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      id="xdx2ixbrl0927"
      unitRef="Shares"
      xsi:nil="true"/>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      id="xdx2ixbrl0929"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375"
      id="xdx2ixbrl0949"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1112"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1114"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1116"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1118"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109"
      id="xdx2ixbrl1164"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1284"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1298"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1303"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1304"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-37603</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">40     Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite 1</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">760-8100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common                                             Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">8495444</dei:EntityPublicFloat>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">8495444</dei:EntityPublicFloat>
    <dei:EntityBankruptcyProceedingsReportingCurrent contextRef="From2022-01-01to2022-12-31">true</dei:EntityBankruptcyProceedingsReportingCurrent>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-22" decimals="INF" unitRef="Shares">3767615</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2022-01-01to2022-12-31">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">711</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Marlton, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1676577</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21026727</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13072831</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">363082</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">436181</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15128490</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21467908</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">261003</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">37993</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">241760</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">357805</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">803438</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">589740</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16434691</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22453446</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">170902</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">50827</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">130072</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">134970</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">139328</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">119055</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">58970</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">440302</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">363822</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">301645</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">191030</us-gaap:LongTermLoansPayable>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">602619</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">856497</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15432</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15182</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3677775</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3677775</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3520391</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3520391</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">369</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">353</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">168457418</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">155727292</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-152640897</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-134146128</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15832072</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21596949</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16434691</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22453446</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">119800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">46000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3513352</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">729058</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">15580473</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">25624815</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">19093825</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">26353873</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18974025</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-26307873</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">11650</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1815366</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-16180056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">250000</BRTX:GainOnPppLoanForgiveness>
    <BRTX:GrantIncome
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">110518</BRTX:GrantIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">107088</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">479256</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-17995422</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18494769</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-44303295</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-5.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-37.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">3617858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">1187741</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">715544</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">72</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">88511269</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-89842833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-1331492</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">230</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">21072453</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">21072683</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants
      contextRef="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">15432</BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">313789</BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">31</BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">22611982</BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants>
    <BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">22627445</BRTX:SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8069</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">317376</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">317377</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrantsShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">177239</BRTX:SharesIssuedInCashlessExerciseOfWarrantsShares>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18</BRTX:SharesIssuedInCashlessExerciseOfWarrants>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-82146</BRTX:SharesIssuedInCashlessExerciseOfWarrants>
    <BRTX:SharesIssuedInCashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-82128</BRTX:SharesIssuedInCashlessExerciseOfWarrants>
    <BRTX:SharesIssuedInLitigationSettlementShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">750</BRTX:SharesIssuedInLitigationSettlementShares>
    <BRTX:SharesIssuedInLitigationSettlement
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">21000</BRTX:SharesIssuedInLitigationSettlement>
    <BRTX:SharesIssuedInLitigationSettlement
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">21000</BRTX:SharesIssuedInLitigationSettlement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">166404</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">166404</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3671503</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3671503</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19411976</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19411976</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">25475</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">25476</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-44303295</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-44303295</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">15432</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3520391</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">155727292</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-134146128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21596949</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">-1543158</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">-15432</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">15432</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">117030</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">117030</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">-25000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">-250</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">247</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">116486</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">11</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4735097</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4735108</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7741864</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7741864</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15898</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">135888</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">135890</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-18494769</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18494769</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">15182</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3677775</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">168457418</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-152640897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15832072</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-18494769</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-44303295</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1133539</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">120545</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">89108</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">33665</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12612862</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">23108955</us-gaap:ShareBasedCompensation>
    <BRTX:SharesIssuedInSettlementOfLitigation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">21000</BRTX:SharesIssuedInSettlementOfLitigation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-16180056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">250000</BRTX:GainOnPppLoanForgiveness>
    <BRTX:NoncashLeaseExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">160122</BRTX:NoncashLeaseExpense>
    <BRTX:NoncashLeaseExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">116044</BRTX:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">11000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-73099</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">330774</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">120075</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-68024</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-4898</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">812673</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-163132</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-101190</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5870761</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3329908</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">13039166</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">175000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">265223</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">30658</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-13479389</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-30658</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">21072683</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">21322683</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-19350150</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">17962117</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21026727</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3064610</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1676577</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21026727</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">317376</us-gaap:StockIssued1>
    <BRTX:NoncashAccruedExpenseExchangedForConveritbleNotes
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">715303</BRTX:NoncashAccruedExpenseExchangedForConveritbleNotes>
    <BRTX:BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">166404</BRTX:BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount>
    <BRTX:ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">10046897</BRTX:ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering>
    <BRTX:AccruedDipExpensesExchangedForConvertibleNotes
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">698901</BRTX:AccruedDipExpensesExchangedForConvertibleNotes>
    <BRTX:WarrantsIssuedAsConsiderationForIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">117030</BRTX:WarrantsIssuedAsConsiderationForIntangibleAssets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmh4v9pRAki3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82E_zNdxt28mA2ej"&gt;ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#x201c;Stem Pearls&#x201d;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#x201c;BRT&#x201d; or the &#x201c;Company&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2022,
the Company had a net loss of $&lt;span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20221231_z7dHJepdnrO4" title="Net loss"&gt;18.5&lt;/span&gt; million (of which, $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231_z72ZAMTq8tT7" title="Share based compensation"&gt;12.6&lt;/span&gt; million was attributable to non-cash stock-based compensation) and negative
cash flows from operations of $&lt;span id="xdx_90F_ecustom--NetCashProvidedByUsedInOperatingActivitie_iN_pn5n6_di_c20220101__20221231_z32SPqAZaD23" title="Cash flows from operations"&gt;5.8&lt;/span&gt; million. The Company&#x2019;s operating activities consume the majority of its cash resources. The
Company anticipates that it will continue to incur net losses as it executes its development plans for 2023 and beyond, as well as other
potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash flows from
operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses primarily through
current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on cash on hand as of December 31, 2022, the Company believes it has sufficient cash to fund operations for the twelve months subsequent
to the filing date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development,
marketing and promotional activities, which would have a material adverse effect on the Company&#x2019;s business, financial condition
and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#x201c;GAAP&#x201d;), which contemplate continuation of the Company as a going concern and the realization of
assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in
the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#x2019;s
website is at www.biorestorative.com. BRT is currently developing a Disc/Spine Program referred to as &#x201c;brtxDISC&#x201d;. Its lead
cell therapy candidate, &lt;i&gt;BRTX-100&lt;/i&gt;, is a product formulated from autologous (or a person&#x2019;s own) cultured mesenchymal stem
cells collected from the patient&#x2019;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral
disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a
platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders
and has labeled this initiative its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system
designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-18500000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">12600000</us-gaap:ShareBasedCompensation>
    <BRTX:NetCashProvidedByUsedInOperatingActivitie
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">-5800000</BRTX:NetCashProvidedByUsedInOperatingActivitie>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zfyVbJSW5lIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - &lt;span id="xdx_82E_zun87tFlhRL9"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEDfld8mOouk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zJwbUNT5TSeg"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies
presented below is designed to assist in understanding the Company&#x2019;s consolidated financial statements. Such consolidated financial
statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_za26SAORRPIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zXaInqJau9m5"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and
transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zLpnaATMcbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zZxQ3ENSrgQ8"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities
at the date of the consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known
or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined
with precision, actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zHghKMZsiQA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zulwUOXTerH9"&gt;Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zEJzcWBODCNb" title="FDIC insured limit"&gt;250,000&lt;/span&gt;. As of December
31, 2022, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
royalties related to the Company&#x2019;s sublicense comprised all of the Company&#x2019;s revenue during the years ended December 31,
2022 and 2021. See &#x201c;Revenue&#x201d; below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpK1uUThmvyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zV9gomiXUZE9"&gt;Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for revenue in accordance with ASC Topic 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (&#x201c;SCTC&#x201d;)
entered into in January 2012. In November 2022, the Company&#x2019;s license rights under the agreement became exclusive. Pursuant to
the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things,
stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the
right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration
of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or
as, the performance obligation is satisfied. The Company&#x2019;s contracts have a single performance obligation which is not separately
identifiable from other promises in the contracts and is, therefore, not distinct. The Company&#x2019;s performance obligation is satisfied
upon the transfer of risk of loss to the customer. The timing of the Company&#x2019;s revenue recognition may differ from the timing of
receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company
has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services,
the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2022 and 2021,
the Company recognized $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231_zALvZxSxFKFg" title="Revenue"&gt;119,800&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231_zrzksD8NW2fl" title="Revenue"&gt;46,000&lt;/span&gt;, respectively, of revenue related to the Company&#x2019;s sublicenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Practical
Expedients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of ASC Topic 606, the Company has adopted several practical expedients including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
    Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing
    component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or
    service to the customer and when the customer pays for that good or service will be one year or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unsatisfied
    Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has
    elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount
    of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting
    period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
    to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the
    customer of the Company&#x2019;s performance completed to date; the Company may recognize revenue in the amount to which the entity
    has a right to invoice.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Contract
Modifications&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
as disclosed above with the SCTC, there were no contract modifications during the years ended December 31, 2022 and 2021. Contract modifications
are not routine in the performance of the Company&#x2019;s contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVsDmeHVVfZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zq4KqnDVezF3"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
There were &lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zHB8Va7Wnu2" title="Cash equivalents"&gt;&lt;span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20211231_zRKSrT7ZgOHe" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyMaNd4MXaX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z3JRIkFhsIUe"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are reported at their outstanding unpaid principal balances net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#x2019;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance
is determined to be uncollectible. The Company did &lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20221231_zvR76JAlrBBh" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20211231_z2jVUWCd7Ema" title="Allowance for doubtful accounts"&gt;no&lt;/span&gt;&lt;/span&gt;t record an allowance for doubtful accounts as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z7QZaQuURbXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zotAixuudUc4"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zNHQ171jQ7Ia" title="Property plant and equipment estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zebr2EFsAs84" title="Property plant and equipment estimated useful lives"&gt;fifteen years&lt;/span&gt;. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z7HjQQkl5kLh" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_z31K7O6DC0w" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8WDc8yTknEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zTNHl5hU2Px4"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2022 and 2021, we determined that there
was &lt;span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zPNnRZF7p6Zf" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zmJCQbdpB0M2" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charge for our long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5EL4j7TmQy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_z20P2ecqmv9l"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records its intangible assets at cost in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 350, &lt;i&gt;Intangibles
- Goodwill and Other&lt;/i&gt;. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method,
which is determined by identifying the period over which the cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLSUAeNLbqR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zYStEt1yL9Se"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
defined in ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; fair value is the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The
Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally
    developed methodologies that result in management&#x2019;s best estimate of fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zbOmuIk07cZ7"&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;Marketable securities as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;13,072,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" style="width: 14%; text-align: right" title="Assets fair value disclosure"&gt;13,072,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zAW0a1XPysYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company recognized unrealized gain of $&lt;span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_z5YqJUMYWX3i" title="Unrealized gain on marketable securities"&gt;33,665&lt;/span&gt; on its marketable securities within Other income,
net in its Consolidated Statement of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjeWPr8GkESi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zPQhKbgFT0Je"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of cash, accounts receivable, accounts payable and other current liabilities approximate their fair values based on the
short-term maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zRcPkx81fhZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zjdhsINXbPCc"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#x2019;s
computation of diluted net loss per common share for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise price could be less than the
average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" style="width: 14%; text-align: right" title="Total"&gt;864,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" style="width: 14%; text-align: right" title="Total"&gt;839,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" style="text-align: right" title="Total potentially dilutive shares"&gt;4,739,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" style="text-align: right" title="Unvested"&gt;201,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" style="text-align: right" title="Unvested"&gt;293,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;1,543,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;1,543,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" style="text-align: right" title="Total"&gt;7,400,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" style="text-align: right" title="Total"&gt;7,416,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zdYeSTzR4o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw18GIRvhrKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_z81MWRbXrIMf"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;), which requires the measurement
and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASU 2018-07 Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company
accounts for stock options issued to non-employees for their services in accordance ASC 718. The Company uses valuation methods and assumptions
to value the stock options that are in line with the process for valuing employee stock options noted above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpwuyVzvE9yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zI4CnFG2mOF8"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d;
that a deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_z873L7gC4EF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zeHOmHE66wKi"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
ASC. The accounting treatment of derivative financial instruments requires that the Company records embedded conversion options (&#x201c;ECOs&#x201d;)
and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each
subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period
at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of
debt discount on the consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification
of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the
contract is reclassified as of the date of the event that caused the reclassification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--SequencingPolicyPolicyTextBlock_zBplxoEP5Bp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zH8NqFKly3Rf"&gt;Sequencing
Policy&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 815-40-35 (&#x201c;ASC 815&#x201d;), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts
from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#x2019;s inability to demonstrate it has sufficient
authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the
basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
Pursuant to ASC 815, issuances of securities to the Company&#x2019;s employees and directors, or to compensate grantees in a share-based
payment arrangement, are not subject to the sequencing policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_z2Scqidx85he" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_z0u8F9ujfxjf"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease is defined as a contract that conveys the right to control the use of identified property, plant or equipment for a period of time
in exchange for consideration. On January 1, 2019, the Company adopted ASC 842 and it primarily affected the accounting treatment for
operating lease agreements in which the Company is the lessee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;, the Company recognized a right-of-use (&#x201c;ROU&#x201d;) asset and corresponding lease
liability on its balance sheets for its office space lease agreement. See Note 9 - Leases for further discussion, including the
impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets include any prepaid lease payments and exclude any lease incentives and initial direct costs incurred. Lease expense for minimum
lease payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate
the lease if it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
in which the Company is the lessee are comprised of office rental. All of the leases are classified as operating leases. The Company
has a lease agreement for office space with a remaining term of &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGOsxiAyKBI5" title="Lease remaining term"&gt;two years&lt;/span&gt; as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_zeRmYv8VxZP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEDfld8mOouk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zJwbUNT5TSeg"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies
presented below is designed to assist in understanding the Company&#x2019;s consolidated financial statements. Such consolidated financial
statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_za26SAORRPIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zXaInqJau9m5"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and
transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zLpnaATMcbfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zZxQ3ENSrgQ8"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities
at the date of the consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known
or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined
with precision, actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zHghKMZsiQA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zulwUOXTerH9"&gt;Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Depository Insurance Coverage of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zEJzcWBODCNb" title="FDIC insured limit"&gt;250,000&lt;/span&gt;. As of December
31, 2022, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
royalties related to the Company&#x2019;s sublicense comprised all of the Company&#x2019;s revenue during the years ended December 31,
2022 and 2021. See &#x201c;Revenue&#x201d; below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpK1uUThmvyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zV9gomiXUZE9"&gt;Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for revenue in accordance with ASC Topic 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (&#x201c;SCTC&#x201d;)
entered into in January 2012. In November 2022, the Company&#x2019;s license rights under the agreement became exclusive. Pursuant to
the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things,
stem cell disc procedures and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the
right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration
of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or
as, the performance obligation is satisfied. The Company&#x2019;s contracts have a single performance obligation which is not separately
identifiable from other promises in the contracts and is, therefore, not distinct. The Company&#x2019;s performance obligation is satisfied
upon the transfer of risk of loss to the customer. The timing of the Company&#x2019;s revenue recognition may differ from the timing of
receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company
has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services,
the Company records deferred revenue until the performance obligations are satisfied. During the years ended December 31, 2022 and 2021,
the Company recognized $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231_zALvZxSxFKFg" title="Revenue"&gt;119,800&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231_zrzksD8NW2fl" title="Revenue"&gt;46,000&lt;/span&gt;, respectively, of revenue related to the Company&#x2019;s sublicenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Practical
Expedients&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of ASC Topic 606, the Company has adopted several practical expedients including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
    Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing
    component since the Company expects, at contract inception, that the period between when the Company transfers a promised good or
    service to the customer and when the customer pays for that good or service will be one year or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unsatisfied
    Performance Obligations - all performance obligations related to contracts with a duration for less than one year; the Company has
    elected to apply the optional exemption provided in ASC Topic 606 and, therefore, is not required to disclose the aggregate amount
    of transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting
    period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
    to Invoice - the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the
    customer of the Company&#x2019;s performance completed to date; the Company may recognize revenue in the amount to which the entity
    has a right to invoice.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Contract
Modifications&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
as disclosed above with the SCTC, there were no contract modifications during the years ended December 31, 2022 and 2021. Contract modifications
are not routine in the performance of the Company&#x2019;s contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">119800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">46000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVsDmeHVVfZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zq4KqnDVezF3"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
There were &lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_zHB8Va7Wnu2" title="Cash equivalents"&gt;&lt;span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20211231_zRKSrT7ZgOHe" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyMaNd4MXaX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z3JRIkFhsIUe"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are reported at their outstanding unpaid principal balances net of allowances for doubtful accounts. The Company periodically
assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for allowances
for doubtful receivables based on management&#x2019;s estimate of uncollectible amounts considering age, collection history, and any other
factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance
is determined to be uncollectible. The Company did &lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20221231_zvR76JAlrBBh" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20211231_z2jVUWCd7Ema" title="Allowance for doubtful accounts"&gt;no&lt;/span&gt;&lt;/span&gt;t record an allowance for doubtful accounts as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z7QZaQuURbXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zotAixuudUc4"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zNHQ171jQ7Ia" title="Property plant and equipment estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zebr2EFsAs84" title="Property plant and equipment estimated useful lives"&gt;fifteen years&lt;/span&gt;. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z7HjQQkl5kLh" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_z31K7O6DC0w" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_srt_MaximumMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8WDc8yTknEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zTNHl5hU2Px4"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2022 and 2021, we determined that there
was &lt;span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zPNnRZF7p6Zf" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zmJCQbdpB0M2" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charge for our long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5EL4j7TmQy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_z20P2ecqmv9l"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records its intangible assets at cost in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 350, &lt;i&gt;Intangibles
- Goodwill and Other&lt;/i&gt;. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method,
which is determined by identifying the period over which the cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLSUAeNLbqR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zYStEt1yL9Se"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
defined in ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; fair value is the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The
Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally
    developed methodologies that result in management&#x2019;s best estimate of fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zbOmuIk07cZ7"&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;Marketable securities as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;13,072,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" style="width: 14%; text-align: right" title="Assets fair value disclosure"&gt;13,072,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zAW0a1XPysYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company recognized unrealized gain of $&lt;span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20220101__20221231_z5YqJUMYWX3i" title="Unrealized gain on marketable securities"&gt;33,665&lt;/span&gt; on its marketable securities within Other income,
net in its Consolidated Statement of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zaI77mM5kGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zbOmuIk07cZ7"&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;Marketable securities as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6Xnuba84TVj" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;13,072,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4b3Y4FW1OUd" style="width: 14%; text-align: right" title="Assets fair value disclosure"&gt;13,072,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0LIZaRPnKXg" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znRqhGrRobLh" style="width: 10%; text-align: right" title="Assets fair value disclosure"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231_zVTksfIPhMx9" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqXBYD6tXsKh" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcZIjV6coi72" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYbrVmWhvIpj" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13072831</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">13072831</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">33665</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjeWPr8GkESi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zPQhKbgFT0Je"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of cash, accounts receivable, accounts payable and other current liabilities approximate their fair values based on the
short-term maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zRcPkx81fhZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zjdhsINXbPCc"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered common stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#x2019;s
computation of diluted net loss per common share for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise price could be less than the
average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" style="width: 14%; text-align: right" title="Total"&gt;864,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" style="width: 14%; text-align: right" title="Total"&gt;839,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" style="text-align: right" title="Total potentially dilutive shares"&gt;4,739,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" style="text-align: right" title="Unvested"&gt;201,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" style="text-align: right" title="Unvested"&gt;293,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;1,543,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;1,543,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" style="text-align: right" title="Total"&gt;7,400,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" style="text-align: right" title="Total"&gt;7,416,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zdYeSTzR4o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z6bXux6jf6v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise price could be less than the
average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zUJT8Ab3ciRl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zcgD9ZQUfSAi" style="width: 14%; text-align: right" title="Total"&gt;864,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zNwTi5Rwmz29" style="width: 14%; text-align: right" title="Total"&gt;839,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zCbRlfgL01x5" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_z0OYCUfKovt9" style="text-align: right" title="Total potentially dilutive shares"&gt;4,739,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zYdN30vrvH46" style="text-align: right" title="Unvested"&gt;201,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zocVscvj19w4" style="text-align: right" title="Unvested"&gt;293,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zQUDpkQXIdYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;1,543,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z1G0SsjPlETg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;1,543,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_fKDIp_zfde4O8wTy7k" style="text-align: right" title="Total"&gt;7,400,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_fKDIp_zZgLhmBUzD2b" style="text-align: right" title="Total"&gt;7,416,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">864639</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">839639</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4791082</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4739871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">201870</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">293479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">7400749</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">7416147</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zw18GIRvhrKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_z81MWRbXrIMf"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;), which requires the measurement
and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair
value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management
to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the
expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based
vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to
the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting
term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASU 2018-07 Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company
accounts for stock options issued to non-employees for their services in accordance ASC 718. The Company uses valuation methods and assumptions
to value the stock options that are in line with the process for valuing employee stock options noted above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpwuyVzvE9yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zI4CnFG2mOF8"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d;
that a deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_z873L7gC4EF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zeHOmHE66wKi"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
ASC. The accounting treatment of derivative financial instruments requires that the Company records embedded conversion options (&#x201c;ECOs&#x201d;)
and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each
subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period
at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of
debt discount on the consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification
of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the
contract is reclassified as of the date of the event that caused the reclassification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesReportingOfDerivativeActivity>
    <BRTX:SequencingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_ecustom--SequencingPolicyPolicyTextBlock_zBplxoEP5Bp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zH8NqFKly3Rf"&gt;Sequencing
Policy&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 815-40-35 (&#x201c;ASC 815&#x201d;), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts
from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#x2019;s inability to demonstrate it has sufficient
authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the
basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
Pursuant to ASC 815, issuances of securities to the Company&#x2019;s employees and directors, or to compensate grantees in a share-based
payment arrangement, are not subject to the sequencing policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</BRTX:SequencingPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_z2Scqidx85he" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_z0u8F9ujfxjf"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease is defined as a contract that conveys the right to control the use of identified property, plant or equipment for a period of time
in exchange for consideration. On January 1, 2019, the Company adopted ASC 842 and it primarily affected the accounting treatment for
operating lease agreements in which the Company is the lessee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;, the Company recognized a right-of-use (&#x201c;ROU&#x201d;) asset and corresponding lease
liability on its balance sheets for its office space lease agreement. See Note 9 - Leases for further discussion, including the
impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets include any prepaid lease payments and exclude any lease incentives and initial direct costs incurred. Lease expense for minimum
lease payments is recognized on a straight-line basis over the lease term. The lease terms may include options to extend or terminate
the lease if it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
in which the Company is the lessee are comprised of office rental. All of the leases are classified as operating leases. The Company
has a lease agreement for office space with a remaining term of &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGOsxiAyKBI5" title="Lease remaining term"&gt;two years&lt;/span&gt; as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2022-12-31_custom_LeaseAgreementMember">P2Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zVOJolEbPnZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
3 - &lt;span&gt;&lt;span&gt;&lt;span id="xdx_82B_zTzT8AcYBy93"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9eSZ8RWGq1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z5JT7tfsKlai" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z2kRu6y6eaH5" style="width: 15%; text-align: right" title="Property and equipment, gross"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z0wFKAizArJ" style="width: 15%; text-align: right" title="Property and equipment, gross"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZcGmgWOQUe8" style="text-align: right" title="Property and equipment, gross"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zctkOhHbqS53" style="text-align: right" title="Property and equipment, gross"&gt;123,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zDtravMzYG7c" style="text-align: right" title="Property and equipment, gross"&gt;117,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zScIeRjOfiQh" style="text-align: right" title="Property and equipment, gross"&gt;107,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zh8ttA0aZZA2" style="text-align: right" title="Property and equipment, gross"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zM6w3vsvjP43" style="text-align: right" title="Property and equipment, gross"&gt;12,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Manufacturing equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zb7fb9TkScBf" style="text-align: right" title="Property and equipment, gross"&gt;242,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_z2qOeh6fJaeg" style="text-align: right" title="Property and equipment, gross"&gt;30,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBPSSXkCeUe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMejPzHRvGMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;304,661&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zX9GcimW1xS" style="text-align: right" title="Property and equipment, gross"&gt;1,196,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231_zMvwN7Us6tk2" style="text-align: right" title="Property and equipment, gross"&gt;931,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zGb37UmSTx42" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation"&gt;(935,839&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_znZA0V2zNsWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation"&gt;(893,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z5TUNyIac6N8" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;261,003&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zKtxoO5UqTy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;37,993&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;



&lt;p id="xdx_8A4_zpxajxEiP0Ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
depreciation expense for the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zru09hoORm7c" title="Depreciation"&gt;42,212&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zZ9fU3RJqtg" title="Depreciation"&gt;14,633&lt;/span&gt;, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9eSZ8RWGq1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z5JT7tfsKlai" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z2kRu6y6eaH5" style="width: 15%; text-align: right" title="Property and equipment, gross"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_z0wFKAizArJ" style="width: 15%; text-align: right" title="Property and equipment, gross"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZcGmgWOQUe8" style="text-align: right" title="Property and equipment, gross"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zctkOhHbqS53" style="text-align: right" title="Property and equipment, gross"&gt;123,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zDtravMzYG7c" style="text-align: right" title="Property and equipment, gross"&gt;117,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zScIeRjOfiQh" style="text-align: right" title="Property and equipment, gross"&gt;107,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zh8ttA0aZZA2" style="text-align: right" title="Property and equipment, gross"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zM6w3vsvjP43" style="text-align: right" title="Property and equipment, gross"&gt;12,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Manufacturing equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zb7fb9TkScBf" style="text-align: right" title="Property and equipment, gross"&gt;242,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_z2qOeh6fJaeg" style="text-align: right" title="Property and equipment, gross"&gt;30,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBPSSXkCeUe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMejPzHRvGMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;304,661&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zX9GcimW1xS" style="text-align: right" title="Property and equipment, gross"&gt;1,196,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231_zMvwN7Us6tk2" style="text-align: right" title="Property and equipment, gross"&gt;931,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zGb37UmSTx42" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation"&gt;(935,839&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_znZA0V2zNsWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation"&gt;(893,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_z5TUNyIac6N8" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;261,003&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zKtxoO5UqTy6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;37,993&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;



</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      unitRef="USD">352133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      unitRef="USD">352133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">123486</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">123487</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputerSoftwareAndEquipmentMember"
      decimals="0"
      unitRef="USD">117544</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ComputerSoftwareAndEquipmentMember"
      decimals="0"
      unitRef="USD">107648</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">18779</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">12979</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ManufacturingEquipmentMember"
      decimals="0"
      unitRef="USD">242852</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ManufacturingEquipmentMember"
      decimals="0"
      unitRef="USD">30712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">342048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">304661</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1196842</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">931620</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">935839</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">893627</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">261003</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">37993</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">42212</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">14633</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zYgGbzQbWPm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
 4 - &lt;span id="xdx_82A_zr9mXwBgb7p"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a license agreement with the SCTC (as amended) (the &#x201c;SCTC Agreement&#x201d;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain
medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the
body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for
culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones)
had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology. The Company did
not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights
became non-exclusive. However, the Company entered into an amended agreement under which it paid $&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220101__20221231_zV13vYSIrYTa" title="Payment to acquire intangible assets"&gt;175,000&lt;/span&gt; and issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXIEjRHPARrk" title="Stock issued new issues"&gt;51,370&lt;/span&gt; warrants,
with a fair value of $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zUB4hj19Yxd" title="Fair value of warrants"&gt;117,030&lt;/span&gt;, in exchange for renewed exclusivity. The consideration transferred to the SCTC in exchange for exclusivity
was capitalized to intangible assets on the Company&#x2019;s consolidated balance sheet as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2017, the Company received authorization from the Food and Drug Administration (the &#x201c;FDA&#x201d;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office has issued a notice of allowance
for a patent application relating to the Company&#x2019;s BRTX-100 clinical program. This patent was issued in March 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zz5ob2QNHGYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_z3HT9mUl0tEk"&gt;SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of January 1, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zR5sXscArwYb" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zjX0FEK6zSw6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,301,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2BCF6Ub6bDd" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(640,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20210101__20211231_zhZY2LMNgImk" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;664,268&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zW21m9E1loYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231_zS0EF0PJShna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z16LeSwQBqZk" style="text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zrcVS6ZFIxNh" style="text-align: right" title="Finite Lived Intangible Assets, beginning balance"&gt;1,301,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zzdO0qsShm9d" style="text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(715,436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20220101__20221231_ziF74mUAzUhi" style="text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;589,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Consideration transferred for license exclusivity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIIuyilwgzIj" style="text-align: right" title="Consideration transferred for license exclusivity"&gt;292,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231_zZwwWg9QA178" style="text-align: right" title="Consideration transferred for license exclusivity"&gt;292,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zOk3jTfDcRWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231_zbnV5QIafEd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zLFLfwghXz31" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, ending balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIjyOrsWJZ6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,593,530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z9R8BK6jiYFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance"&gt;(793,768&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20220101__20221231_z0axz7mgX6Nk" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance"&gt;803,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average remaining amortization period as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhwNz2iVMyog" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0765"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3XvcIExYQE9" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;11.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zLprpsGjpIx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zuYakqSqMWC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_ze6dKh9GVy4f"&gt;SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance as of January 1, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_z111QHGgf6ib" style="width: 14%; text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zOcIjRIprHI7" style="width: 14%; text-align: right" title="Beginning Balance"&gt;637,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zSvPCXNe1O81" style="width: 14%; text-align: right" title="Beginning Balance"&gt;640,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zQsLGcm9Clsd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkI3R4uA8ncj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zeqlmrAk0Oc7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zYNdRMNLXXL3" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdvH1UPoFa6k" style="text-align: right" title="Beginning Balance"&gt;711,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zLw7u3xiVMfj" style="text-align: right" title="Beginning Balance"&gt;715,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjqAZlC0iQM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0789"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zemPn2tTSNNg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z0AgdgMgVXsh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCmYU0PaxmNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z7iLe7KaisVi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;790,092&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zNXhaLnNN7Gl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;793,768&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zrwhArUOB7t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3lONGEusWI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B9_z24iYDJQ20G5"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20221231_zM1WUu8puxm" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zmJ8qFYSBEY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: justify"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zXveE2K88kFl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zeVSPq4NT1ja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zrYqmkW3iogg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zCfWHjd4m9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zglxyIb6jcUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">175000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27579265"
      decimals="INF"
      unitRef="Shares">51370</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">117030</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zz5ob2QNHGYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_z3HT9mUl0tEk"&gt;SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance as of January 1, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zR5sXscArwYb" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zjX0FEK6zSw6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,301,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2BCF6Ub6bDd" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(640,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20210101__20211231_zhZY2LMNgImk" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;664,268&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zW21m9E1loYl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20210101__20211231_zS0EF0PJShna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z16LeSwQBqZk" style="text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zrcVS6ZFIxNh" style="text-align: right" title="Finite Lived Intangible Assets, beginning balance"&gt;1,301,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zzdO0qsShm9d" style="text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(715,436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20220101__20221231_ziF74mUAzUhi" style="text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;589,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Consideration transferred for license exclusivity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIIuyilwgzIj" style="text-align: right" title="Consideration transferred for license exclusivity"&gt;292,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ConsiderationTransferredForLicenses_c20220101__20221231_zZwwWg9QA178" style="text-align: right" title="Consideration transferred for license exclusivity"&gt;292,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zOk3jTfDcRWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20220101__20221231_zbnV5QIafEd9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zLFLfwghXz31" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, ending balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIjyOrsWJZ6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,593,530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z9R8BK6jiYFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance"&gt;(793,768&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20220101__20221231_z0axz7mgX6Nk" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance"&gt;803,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average remaining amortization period as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhwNz2iVMyog" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0765"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3XvcIExYQE9" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;11.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">1301500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">640908</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">664268</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">74528</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">74528</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">1301500</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">715436</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">589740</us-gaap:FiniteLivedIntangibleAssetsNet>
    <BRTX:ConsiderationTransferredForLicenses
      contextRef="From2022-01-012022-12-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">292030</BRTX:ConsiderationTransferredForLicenses>
    <BRTX:ConsiderationTransferredForLicenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">292030</BRTX:ConsiderationTransferredForLicenses>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">78332</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">78332</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">803438</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2022-01-012022-12-31_custom_LicensesMember">P11Y3M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zuYakqSqMWC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_ze6dKh9GVy4f"&gt;SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance as of January 1, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_z111QHGgf6ib" style="width: 14%; text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zOcIjRIprHI7" style="width: 14%; text-align: right" title="Beginning Balance"&gt;637,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zSvPCXNe1O81" style="width: 14%; text-align: right" title="Beginning Balance"&gt;640,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zQsLGcm9Clsd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zkI3R4uA8ncj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zeqlmrAk0Oc7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;74,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zYNdRMNLXXL3" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdvH1UPoFa6k" style="text-align: right" title="Beginning Balance"&gt;711,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zLw7u3xiVMfj" style="text-align: right" title="Beginning Balance"&gt;715,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjqAZlC0iQM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0789"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zemPn2tTSNNg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z0AgdgMgVXsh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"&gt;78,332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCmYU0PaxmNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z7iLe7KaisVi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;790,092&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zNXhaLnNN7Gl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;793,768&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">637232</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">640908</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">74528</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">74528</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">711760</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">715436</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">78332</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">78332</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">790092</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z3lONGEusWI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B9_z24iYDJQ20G5"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20221231_zM1WUu8puxm" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zmJ8qFYSBEY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: justify"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zXveE2K88kFl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zeVSPq4NT1ja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zrYqmkW3iogg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zCfWHjd4m9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89131</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89131</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89131</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89131</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89131</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zUeefxf9Klsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
 5 - &lt;span id="xdx_829_zEtL27GGXHU1"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zwBSApfXDN93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zxPwPamjgYe5"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zaGGhfBp9Wff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zGZwRLKduE1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zcEgT8XwVLph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued payroll&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;26,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;28,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedResearchAndDevelopmentExpenses_iI_maALAOLzJ5Y_zdABJUl0Lbh8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zmQ2gGIHIkX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103,822&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,928&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zECYx3mc4q96" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;130,072&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;134,970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p id="xdx_8A2_zNrM8joHQONj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zwBSApfXDN93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zxPwPamjgYe5"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zaGGhfBp9Wff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zGZwRLKduE1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zcEgT8XwVLph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accrued payroll&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;26,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;28,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedResearchAndDevelopmentExpenses_iI_maALAOLzJ5Y_zdABJUl0Lbh8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zmQ2gGIHIkX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103,822&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,928&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zECYx3mc4q96" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;130,072&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;134,970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">26250</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">28370</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <BRTX:AccruedResearchAndDevelopmentExpenses contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">29672</BRTX:AccruedResearchAndDevelopmentExpenses>
    <BRTX:AccruedGeneralAndAdministrativeExpenses contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">103822</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <BRTX:AccruedGeneralAndAdministrativeExpenses contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">76928</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">130072</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">134970</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zMXpCpsZpsul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
6 - &lt;span id="xdx_82D_zRyYbdY9Poij"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_z6vD8WR7Ruyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the notes payable activity during the year ended December 31, 2022 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_z0U2tHHDdg9l"&gt;SCHEDULE OF NOTES PAYABLE ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LoansPayable_iS_c20220101__20221231_zpdYlJWz25Md" style="width: 14%; text-align: right" title="Loans payable outstanding beginning"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ProceedsFromIssuanceOfDebt_c20220101__20221231_z2TTt3e07Ar2" style="text-align: right" title="Issuances"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forgiveness&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtInstrumentDecreaseForgiveness_iN_di_c20220101__20221231_zhV0UK3vXrdc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness"&gt;(250,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LoansPayable_iE_c20220101__20221231_zTOQ2ieZBEbk" style="border-bottom: Black 2.5pt double; text-align: right" title="Loans payable outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;



&lt;p id="xdx_8AB_zlm55UBSezHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_z6vD8WR7Ruyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the notes payable activity during the year ended December 31, 2022 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_z0U2tHHDdg9l"&gt;SCHEDULE OF NOTES PAYABLE ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LoansPayable_iS_c20220101__20221231_zpdYlJWz25Md" style="width: 14%; text-align: right" title="Loans payable outstanding beginning"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ProceedsFromIssuanceOfDebt_c20220101__20221231_z2TTt3e07Ar2" style="text-align: right" title="Issuances"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forgiveness&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtInstrumentDecreaseForgiveness_iN_di_c20220101__20221231_zhV0UK3vXrdc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness"&gt;(250,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LoansPayable_iE_c20220101__20221231_zTOQ2ieZBEbk" style="border-bottom: Black 2.5pt double; text-align: right" title="Loans payable outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;



</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LoansPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">250000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwfDdLnBi61j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
 7 - &lt;span id="xdx_823_znRDN6LBjqkg"&gt;STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 8, 2021, in connection with the Company&#x2019;s public offering, the Company&#x2019;s Board of Directors adopted a resolution
allowing for the designation and issuance of &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCQLCzatzywj" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of the Company&#x2019;s Preferred Stock, $&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJ7CxJ2xwUik" title="Preferred stock, par value"&gt;.01&lt;/span&gt; par value per share, designated
as Series A Preferred Stock (&#x201c;Series A&#x201d;). The Series A had a liquidation preference of $&lt;span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbnxa33JYyfa" title="Preferred stock, liquidation preference"&gt;0.001&lt;/span&gt; per share. On September 8,
2022, the Company issued &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zK1YF30WN4kd" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B Preferred Stock (&#x201c;Series B&#x201d;) to Auctus Fund, LLC (&#x201c;Auctus&#x201d;)
in exchange for an equal number of shares of the Company&#x2019;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#x2019;s Board
of Directors cancelled the Series A.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
B Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 8, 2022, the Company issued &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_za83UBjE2nz8" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B to Auctus in exchange for an equal number of shares of the Company&#x2019;s
outstanding Series A. &lt;span id="xdx_90D_eus-gaap--PreferredStockVotingRights_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8O12SUCwACd" title="Preferred stock voting rights"&gt;The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as
provided for the Series A.&lt;/span&gt; The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption
by the Company or any Series B holder. The exchange of Series A for Series B had no impact on the Company&#x2019;s financial statements
as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Dividends&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Voting
Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than &lt;span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zp2gCvH4Ifz5" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Conversion&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Optional
Conversion - Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than &lt;span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRN6RY2xn2Dj" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the outstanding
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automatic
Conversion &#x2013; From time to time, in the event of that an event occurs, including adjustment due to merger, consolidation, etc.,
subdivision or combination of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the
effect of reducing a Series B holder&#x2019;s beneficial ownership of shares of common stock to less than &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_z7ZAufGB3rBd" title="Ownership percentage"&gt;9.5&lt;/span&gt;% of the then publicly disclosed
outstanding shares of Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such
effect, which notice shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable
detail with regard thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such
notice shall have the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase
the Series B holder&#x2019;s beneficial ownership of Common Stock to &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zHv08AtDpcea" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then publicly disclosed outstanding shares of Common
Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 25, 2022, Auctus converted &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zGjKmg3CbUKc" title="Debt conversion, converted instrument, shares issued"&gt;25,000&lt;/span&gt; shares of Series B into &lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zVMjgNpuwll4" title="Debt conversion, converted instrument, shares issued"&gt;25,000&lt;/span&gt; shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion is &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_ztKRsSduCct8" title="Conversion of stock shares"&gt;1,518,158&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2021
Stock Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2021, the Company&#x2019;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#x201c;2021
Plan&#x201d;). Pursuant to the 2021 Plan, a total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zrEv2Q3DlXQ" title="Number of shares of common stock authorized"&gt;1,175,000&lt;/span&gt; shares of common stock were initially authorized to be issued pursuant
to the grant of stock options, restricted stock units, restricted stock, stock appreciation rights and other incentive awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amendments
to 2021 Stock Incentive Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2021, subject to stockholder approval, the Company&#x2019;s Board of Directors approved amendments to the 2021 Plan to increase
the number of shares of Common Stock authorized to be issued from &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20211209_z9B5JA6OdXFd"&gt;1,175,000&lt;/span&gt; to &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20211210_z7OufqxFPjx9" title="Common stock, shares authorized"&gt;2,500,000&lt;/span&gt; and to clarify certain provisions of the 2021
Plan as to the authority of the Board of Directors and the Compensation Committee to make adjustments to, among other things, the exercise
price of granted options. Concurrently, subject to stockholder approval of the amendments to the 2021 Plan, the Company&#x2019;s Compensation
Committee reduced the exercise price of the outstanding options under the 2021 Plan for the purchase of an aggregate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20220914__20220915_zlqMsOTeQQ38" title="Aggregate purchase of common stock, shares"&gt;838,549&lt;/span&gt; shares
of the Company&#x2019;s common stock from $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20220915__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zBL7Gy4hukF6"&gt;13.50&lt;/span&gt; per share to $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_c20220915__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zPwRypVJwXnh" title="Share price"&gt;5.08&lt;/span&gt; per share (the closing price of the Company&#x2019;s common stock on
the day immediately preceding the Compensation Committee determination), including the options held by the Company&#x2019;s officers and
directors as follows: &lt;span id="xdx_902_ecustom--DescriptionOfStockOptionsHeldByOfficerAndDirector_c20220914__20220915_zuj5dbNjPp9b" title="Description of stock options held by officer and director"&gt;(i) Lance Alstodt, the Company&#x2019;s President, Chief Executive Officer and Chairman of the Board: 335,538 shares,
(ii) Francisco Silva, the Company&#x2019;s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal,
the Company&#x2019;s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company&#x2019;s Vice President of Quality Assurance
and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company&#x2019;s directors: 25,236 shares; (vi) Patrick F. Williams,
one of the Company&#x2019;s directors: 10,490 shares; and (vii) David Rosa, one of the Company&#x2019;s directors: 10,490 shares.&lt;/span&gt; On November
3, 2022, the Company&#x2019;s stockholders approved the amendments to the 2021 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
impact resulting from the amendments was immaterial to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Compensatory
Common Stock Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20221231_zCh4MPooH7O3" title="Vested common stock, shares"&gt;15,898&lt;/span&gt; shares of immediately vested common stock with an aggregate value of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231_zQJAAeFM3Oal" title="Aggregate common stock services rendered"&gt;135,888&lt;/span&gt;
to third parties for services rendered. During the year ended December 31, 2021, the Company issued &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20211231_z94YrjyDE7m2" title="Vested common stock, shares"&gt;5,000&lt;/span&gt; shares of immediately vested
common stock with a value of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231_zTqsyzXQOoa1" title="Aggregate common stock services rendered"&gt;25,476&lt;/span&gt; to a consultant for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
and Option Valuation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d;
method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Activity Summary&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 21, 2021, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211021__20211021__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJegf3obTGPe" title="Stock issued new issues, shares"&gt;22,917&lt;/span&gt; shares of common stock to a warrant holder, as a result of the cashless exercise of &lt;span id="xdx_901_ecustom--CashlessExerciseOfWarrants_pid_c20211021__20211021__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDN9XeCQZFD7" title="Cashless exercise of warrants"&gt;25,000&lt;/span&gt;
warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued an aggregate of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp8srCIQ1WT3" title="Stock issued new issues"&gt;147,832&lt;/span&gt;, shares of the Company&#x2019;s common stock, as a result
of the cashless exercise of &lt;span id="xdx_906_ecustom--CashlessExerciseOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt75Z7o6y6Ad" title="Cashless exercise of warrants"&gt;170,473&lt;/span&gt; warrants by Auctus.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTC1mfXHV4ti" title="Warrants issued"&gt;51,370&lt;/span&gt; warrants to the SCTC as part of consideration transferred in exchange for
exclusivity under a license agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zOuyIV8iOJ3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the warrant activity during the years ended December 31, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zOrdaxljWDCc"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life In Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd4Nh0CXnlZ9" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning"&gt;3,750,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcGhj2zdgtO1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;4.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7cO4Hu6jSf2" style="text-align: right" title="Number of Options Granted"&gt;4,862,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zml1yDOPGRJb" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;9.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqFbv9xYroYh" style="text-align: right" title="Number of Options Exercised"&gt;(195,473&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjVY6mgGiCoi" style="text-align: right" title="Weighted average exercise price, exercised"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchanged or forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUaAKCNwtbTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Exchanged or Forfeited"&gt;(3,677,964&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLaXAA6YDk82" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Exchanged or Forfeited"&gt;3.39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"/&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzvZwqmKzFj" style="text-align: right" title="Number of Options Outstanding Beginning"&gt;4,739,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjiXMu5AsRkk" style="text-align: right" title="Weighted average exercise price, beginning balance"&gt;11.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwfSIIZbWJjh" title="Number of Options Outstanding"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z24SoF8wjjpe" style="text-align: right" title="Number of Options Granted"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPhUEuXy7tN8" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPgSRJUwm52" style="text-align: right" title="Number of warrants outstanding, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWsr4fiefsc" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfY4QM3cBG52" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding, expired"&gt;(159&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSHJyBdkhlrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;16,083&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoMAOWeVHVme" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending"&gt;4,791,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziSBknt3oy6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;10.71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKYqAUIvaRD4" title="Number of Options Outstanding"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYtHfLYUvVM" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqTYLnWIBd99" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending"&gt;4,791,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr2RVNGYT0H9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;10.71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcsOo2SCbzzg" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIX5sRtDtpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zhunbhb3vFfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zLtW3xeSNUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to warrants granted during 2022 and 2021, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zM3Q788gyCgd"&gt;SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMvGAiHM9Wn4" title="Risk free interest rate"&gt;4.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUa4wX5jcDa2" title="Risk free interest rate"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZJFlIgfgLjd" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zL200eFHX2Y7" title="Expected term (years)"&gt;4.10&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvAHbtmjB3Hj" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWC2XP7huk3" title="Expected volatility"&gt;313.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdg9AcduYQB5" title="Expected volatility"&gt;314.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy8d1XEONiE8" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8PP1FFITYci" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zg0HfL5MNyt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average estimated fair value of the warrants granted during the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj3vksd6p0jf" title="Weighted average estimated fair value of warrants granted"&gt;2.28&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPZXpVjGcsoe" title="Weighted average estimated fair value of warrants granted"&gt;11.77&lt;/span&gt;
per warrant, respectively. The Company did not issue any shares during the years ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zIZTEBuLKvUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock warrants at December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zGdgp7ZC63y3"&gt;SCHEDULE
OF STOCK WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life In Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 44%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOzaVg05GL59" title="Warrants outstanding, exercise price"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zNxNAcuZCaRd" style="width: 14%; text-align: right" title="Warrants outstanding, number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zd8n75XgKkxg" title="Warrants exercisable, weighted average remaining life in years"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zWfrVEaUQnq5" style="width: 14%; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7T8okIt08S5" title="Warrants outstanding, exercise price"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zeSebgIHfwyj" style="text-align: right"&gt;4,501,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdfGCAbbhVO6"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zXyMmLaFCSM7" style="text-align: right"&gt;4,501,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zF2L9mZmEkB9" title="Warrants outstanding, exercise price"&gt;12.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zQEmQMZXNhwg" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0QfHjmmqF4i" title="Warrants exercisable, weighted average remaining life in years"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zxQ9nH8wOKx" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKjFPftSTCpl" title="Warrants outstanding, exercise price"&gt;60.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zdq4Lp8Lyt3k" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB47YjJpwQr3" title="Warrants exercisable, weighted average remaining life in years"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zwO4pm9kjpB1" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcSr6m5jve3e" title="Warrants outstanding, exercise price"&gt;800.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zLJWuMGrxPAd" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTxdcUeiF1h6" title="Warrants exercisable, weighted average remaining life in years"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zQETJV7D8QTi" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zqk8O4ghtpm8" title="Warrants outstanding, exercise price"&gt;2,240.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_ziQ80gOPY3C" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVBCh8CXCg5" title="Warrants exercisable, weighted average remaining life in years"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_zLGN8Q6oGbQ2" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXIcZViHwRKb" title="Warrants outstanding, exercise price"&gt;2,800.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zaMvUapSecPd" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zwQ6TYROPLN1" title="Warrants exercisable, weighted average remaining life in years"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zb74Zi8xFHzl" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z03zfrSg1YE3" title="Warrants outstanding, exercise price"&gt;3,400.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zLbJnkFHuO0a" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zz1hJ74P7Sp7" title="Warrants exercisable, weighted average remaining life in years"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_fKDEp_zCmcDJ1Utpt5" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zyoxbJsqUkce" title="Warrants outstanding, exercise price"&gt;4,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zIuI5nKGc5v7" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zdpKW9qo3Eoh" title="Warrants exercisable, weighted average remaining life in years"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_fKDEp_zAhj1JOl85N" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z9lOrmIjzVv6" title="Warrants outstanding, exercise price"&gt;8,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zLmOj98tGluj" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zM16slMZ1dB8" title="Warrants exercisable, weighted average remaining life in years"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_fKDEp_zy0VUpS5vwAc" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zoGyNOwnZjHh" title="Warrants outstanding, exercise price"&gt;14,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6JVx3FuMZji" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zALlBxKyG9e4" title="Warrants exercisable, weighted average remaining life in years"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_fKDEp_zGwpRz4mjks9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zpkb1VJZ5uLb" title="Warrants outstanding, exercise price"&gt;16,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_za7cJzBqbM4j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, number of warrants"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhoaDtHgclQ5" title="Warrants exercisable, weighted average remaining life in years"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_fKDEp_zy1uBTNrqDEa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_fKDEp_zqZr7OXjinei" style="text-align: right"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_fKDEp_zm7MSkwMUmn4" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zkeDTqoRG2a8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2021, the Company, pursuant to two employment agreements, granted to its Chief Executive Officer, President and Chairman of
the Board and its Vice President, Research and Development options to purchase an aggregate of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_z4FRdRX7Y1Ab" title="Number of option issued to purchase shares of common stock"&gt;586,959&lt;/span&gt; shares of the Company&#x2019;s
common stock. The options initially &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_z5C87Iyd2g3j" title="Description of share based payment award vesting rights"&gt;vested to the extent of 50% on the date of grant, 25% on the one-year anniversary of the grant date
and 25% on the two-year anniversary of the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2021, the Company granted options to purchase an aggregate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104_zd5Yqw9027l9" title="Number of option issued to purchase shares of common stock"&gt;140,824&lt;/span&gt; shares of its common stock (including options to purchase
&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211102__20211104__srt--TitleOfIndividualAxis__custom--PatrickFWilliamsMember_zl6iVzdMxHah"&gt;10,490&lt;/span&gt; shares each granted to Robert Kristal, its Chief Financial Officer, Patrick Williams, a director of the Company, and David Rosa,
a director of the Company) to its officers and directors. Also included within the &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--MrAlstodtMember_zcmIShFi0SR8"&gt;140,824&lt;/span&gt; share option grants were grants to each of
Mr. Alstodt and Mr. Silva for the purchase of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--MrSilvaMember_zNm1u4ExYvxg"&gt;42,059&lt;/span&gt; shares of common stock and to Dr. Nickolay Kukekov, a director of the Company, for
the purchase of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20211102__20211104__srt--TitleOfIndividualAxis__custom--DrNickolayKukekovMember_zoWlm7jVfoz3"&gt;25,236&lt;/span&gt; shares of common stock. &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20211102__20211104_zdtxUDjpWwke" title="Share-based compensation arrangement by share-based payment award, description"&gt;Such options are exercisable to the extent of 50% on the date of grant and 50% quarterly
over a period of two years commencing one year from the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 4, 2021, the Company granted options to purchase an aggregate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211102__20211104__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember_zxVvdUEjbDce" title="Options to purchase shares granted"&gt;110,767&lt;/span&gt; shares of the Company&#x2019;s common stock to members
of its Scientific Advisory Board and various employees and consultants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2021, the Company reduced the exercise price of all options from $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211209_zkSChF7aIvC4"&gt;13.50&lt;/span&gt; per share to $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211210_z9jQMTFEeT1l"&gt;5.08&lt;/span&gt; per share, subject to stockholder
approval. On November 3, 2022, stockholder approval was obtained. Per ASC 718 - &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;, the Company
accounted for these changes as a modification and the net effect was immaterial to the financial statements as a whole.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company granted an option for the purchase of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zKrTqjcyOEz" title="Number of Options Granted"&gt;25,000&lt;/span&gt; shares of common stock during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z41Grh7waTHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the option activity during the years ended December 31, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z41jvRlK6xNb"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z0htSgZLMxVg" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning"&gt;1,215&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zLACIEDVEGk9" style="width: 11%; text-align: right" title="Weighted average outstanding beginning balance"&gt;5.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zEyBsIf7KJJ4" style="text-align: right" title="Number of Options Granted"&gt;838,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zyOJAFxHqe5" style="text-align: right"&gt;5.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zTv1o9IGqWma" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired"&gt;(126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zPc6CVcdfbEg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zRZlzYdhgFS7" style="text-align: right" title="Number of Options Outstanding Beginning"&gt;839,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zSKSNTbfRMV1" style="text-align: right" title="Weighted Average Exercise Price Outstanding Beginning"&gt;5.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zpFx7wwKDXK8" style="text-align: right" title="Number of Options Granted"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zVvPl0gtty4b" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;4.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zHyticBxYibb" style="text-align: right" title="Number of Options Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z9Ud3scCE3Uj" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zQ5CR0592oOa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJ0toreo1sfc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zTJHQs9T6N4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending"&gt;864,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zhDeR1Z7o6zb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding Ending"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zDvB6ocfrrU7" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20221231_zmNhYFjpKHa9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfiKun1fYpfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending"&gt;578,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20221231_zuBRlNKlJ92i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_ziKPFOAgWDah" title="Weighted Average Remaining Life in Years Exercisable Ending"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zq62wMxghiQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2022 and 2021, was approximately
$&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zGM4kOditGA3" title="Weighted average grant date fair value of stock options granted"&gt;4.88&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zUJRZB6yM4n2" title="Weighted average grant date fair value of stock options granted"&gt;5.05&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaC8Zw0s9uu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zsZZFqtNG8Ch"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUi1pRRyTzpg" title="Risk free interest rate"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBRy8732sBn4" title="Expected term (years)"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxLxiNUDh7lb" title="Expected volatility"&gt;285.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGZxG1lmhMo2" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zY6vKc7S2tP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#x201c;RSUs&#x201d;) to employees, consultants or non-employee directors
(&#x201c;Eligible Individuals&#x201d;). The number, terms and conditions of the RSUs that are granted to Eligible Individuals are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Individual one
unrestricted, fully transferable share of the Company&#x2019;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2021, the Company, pursuant to two employment agreements, granted an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlH2Ii2WxBw1" title="Number of option issued to purchase shares of common stock"&gt;293,479&lt;/span&gt; RSUs to its Chief Executive Officer,
President, and Chairman of the Board and its Vice President, Research and Development with a fair value of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYpNrMyVfQfj" title="Exercise price"&gt;47.60&lt;/span&gt; per share. The RSUs
vest to the extent of one-third on the one-year anniversary of the grant date, one-third on the two-year anniversary of the grant date,
and one-third on the three-year anniversary of the grant date. The RSUs had a grant date fair value of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20210318__20210318__us-gaap--TypeOfArrangementAxis__custom--TwoEmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCLRfgXNTUf3" title="Fair value of restricted stock units"&gt;13,969,624&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
March 18, 2022, the Company granted an aggregate of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220317__20220318__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi7CblvCxpw" title="Number of option issued to purchase shares of common stock"&gt;24,876&lt;/span&gt; RSUs to its Chief Executive Officer, President and Chairman of the Board and
its Vice President, Research and Development with a fair value of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220318__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1kVS5keRNYe" title="Exercise price"&gt;4.21&lt;/span&gt; per share. The RSUs vest in twelve equal monthly installments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ziQWhFgrM8i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the unvested RSUs as of December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zK4OnVu5gNvf"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7ruj8I7X9ec" style="width: 14%; text-align: right" title="Number of shares outstanding beginning"&gt;293,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWU9gwnsBuh" style="text-align: right" title="Number of shares granted"&gt;24,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ4xFg3IJbnh" style="text-align: right" title="Number of shares forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1164"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMlTpl4Y0MB8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares vested"&gt;(116,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZsFIt7oprpa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"&gt;201,870&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zG2reU58Xtpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zWgn53WFH2L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zveUfSxAoorc"&gt;SCHEDULE OF STOCK OPTION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrecognized at December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Amortization Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4wVPE52dCH3" style="width: 11%; text-align: right" title="Stock-based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyYDc2BYMYSi" style="width: 11%; text-align: right" title="Stock-based compensation expense"&gt;81,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMN4tnm8lsEf" style="width: 11%; text-align: right" title="Unrecognized expense"&gt;803,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQTaVcLFo6cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense"&gt;12,612,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1FGqhTV6UV" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense"&gt;23,027,476&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwMmnQ8r2x4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrecognized expense"&gt;1,294,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5GNJoPn2LYj" title="Weighted average remaining amortization period (years)"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVoNThiixP6" style="text-align: right" title="Stock-based compensation expense"&gt;12,612,862&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKwTrTrlpY2" style="text-align: right" title="Stock-based compensation expense"&gt;23,108,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVxSbf1kuTR4" style="text-align: right" title="Unrecognized expense"&gt;2,097,941&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_8A9_zhwUaOwYGaZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zw2wPr6d8628" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents stock compensation by award type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zue5Pm5NOC5k"&gt;SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqlHr7YFhi72" style="width: 14%; text-align: right" title="Stock-based compensation award"&gt;7,741,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAveqV0rIEV8" style="width: 14%; text-align: right" title="Stock-based compensation award"&gt;19411976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOjzSNxdXdmg" style="text-align: right" title="Stock-based compensation award"&gt;4,735,108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlaZMA2CX3rf" style="text-align: right" title="Stock-based compensation award"&gt;3,671,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares issued for services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zV05i5E9eKAh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;135,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zfvCuOM9Lwz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;25,476&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231_zA0jHrxnRZ28" style="text-align: right" title="Stock-based compensation award"&gt;12,612,862&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231_zEUWDLTO0cmk" style="text-align: right" title="Stock-based compensation award"&gt;23,108,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_za82eLcv4vy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember">The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as
provided for the Series A.</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      unitRef="Pure">0.095</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-09" decimals="INF" unitRef="Shares">1175000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-10" decimals="INF" unitRef="Shares">2500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2022-09-142022-09-15"
      decimals="INF"
      unitRef="Shares">838549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharePrice
      contextRef="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">13.50</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-09-15_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:SharePrice>
    <BRTX:DescriptionOfStockOptionsHeldByOfficerAndDirector contextRef="From2022-09-142022-09-15">(i) Lance Alstodt, the Company&#x2019;s President, Chief Executive Officer and Chairman of the Board: 335,538 shares,
(ii) Francisco Silva, the Company&#x2019;s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal,
the Company&#x2019;s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company&#x2019;s Vice President of Quality Assurance
and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company&#x2019;s directors: 25,236 shares; (vi) Patrick F. Williams,
one of the Company&#x2019;s directors: 10,490 shares; and (vii) David Rosa, one of the Company&#x2019;s directors: 10,490 shares.</BRTX:DescriptionOfStockOptionsHeldByOfficerAndDirector>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">15898</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">135888</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">25476</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-212021-10-21_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">22917</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <BRTX:CashlessExerciseOfWarrants
      contextRef="From2021-10-212021-10-21_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">25000</BRTX:CashlessExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27580812"
      decimals="INF"
      unitRef="Shares">147832</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <BRTX:CashlessExerciseOfWarrants
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27580812"
      decimals="INF"
      unitRef="Shares">170473</BRTX:CashlessExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zOuyIV8iOJ3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the warrant activity during the years ended December 31, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zOrdaxljWDCc"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life In Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd4Nh0CXnlZ9" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning"&gt;3,750,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcGhj2zdgtO1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;4.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7cO4Hu6jSf2" style="text-align: right" title="Number of Options Granted"&gt;4,862,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zml1yDOPGRJb" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;9.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqFbv9xYroYh" style="text-align: right" title="Number of Options Exercised"&gt;(195,473&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjVY6mgGiCoi" style="text-align: right" title="Weighted average exercise price, exercised"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchanged or forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUaAKCNwtbTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Exchanged or Forfeited"&gt;(3,677,964&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLaXAA6YDk82" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Exchanged or Forfeited"&gt;3.39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"/&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzvZwqmKzFj" style="text-align: right" title="Number of Options Outstanding Beginning"&gt;4,739,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjiXMu5AsRkk" style="text-align: right" title="Weighted average exercise price, beginning balance"&gt;11.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwfSIIZbWJjh" title="Number of Options Outstanding"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z24SoF8wjjpe" style="text-align: right" title="Number of Options Granted"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPhUEuXy7tN8" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPgSRJUwm52" style="text-align: right" title="Number of warrants outstanding, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWsr4fiefsc" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfY4QM3cBG52" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding, expired"&gt;(159&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSHJyBdkhlrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;16,083&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoMAOWeVHVme" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending"&gt;4,791,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziSBknt3oy6f" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;10.71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKYqAUIvaRD4" title="Number of Options Outstanding"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYtHfLYUvVM" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqTYLnWIBd99" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending"&gt;4,791,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr2RVNGYT0H9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;10.71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcsOo2SCbzzg" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIX5sRtDtpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3750598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">4.40</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="0"
      unitRef="Shares">4862710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="USDPShares">9.91</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="Shares">195473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="USDPShares">4.00</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="Shares">3677964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="USDPShares">3.39</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4739871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">11.78</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328">P4Y10M24D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="0"
      unitRef="Shares">51370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="INF"
      unitRef="USDPShares">2.92</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="INF"
      unitRef="Shares">159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="INF"
      unitRef="USDPShares">16083</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375"
      decimals="INF"
      unitRef="Shares">4791082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375"
      decimals="INF"
      unitRef="USDPShares">10.71</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359">P3Y10M24D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375"
      decimals="INF"
      unitRef="Shares">4791082</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember27581375"
      decimals="INF"
      unitRef="USDPShares">10.71</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359">P3Y10M24D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <BRTX:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zLtW3xeSNUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to warrants granted during 2022 and 2021, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zM3Q788gyCgd"&gt;SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMvGAiHM9Wn4" title="Risk free interest rate"&gt;4.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUa4wX5jcDa2" title="Risk free interest rate"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZJFlIgfgLjd" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zL200eFHX2Y7" title="Expected term (years)"&gt;4.10&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zvAHbtmjB3Hj" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWC2XP7huk3" title="Expected volatility"&gt;313.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdg9AcduYQB5" title="Expected volatility"&gt;314.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy8d1XEONiE8" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8PP1FFITYci" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BRTX:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="INF"
      unitRef="Pure">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="Pure">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="INF"
      unitRef="Pure">3.1355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="Pure">3.1400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27581359"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27581328"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember27579265"
      decimals="INF"
      unitRef="USDPShares">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember27580812"
      decimals="INF"
      unitRef="USDPShares">11.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zIZTEBuLKvUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock warrants at December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zGdgp7ZC63y3"&gt;SCHEDULE
OF STOCK WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life In Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 44%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOzaVg05GL59" title="Warrants outstanding, exercise price"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zNxNAcuZCaRd" style="width: 14%; text-align: right" title="Warrants outstanding, number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zd8n75XgKkxg" title="Warrants exercisable, weighted average remaining life in years"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_fKDEp_zWfrVEaUQnq5" style="width: 14%; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7T8okIt08S5" title="Warrants outstanding, exercise price"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zeSebgIHfwyj" style="text-align: right"&gt;4,501,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zdfGCAbbhVO6"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_fKDEp_zXyMmLaFCSM7" style="text-align: right"&gt;4,501,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zF2L9mZmEkB9" title="Warrants outstanding, exercise price"&gt;12.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zQEmQMZXNhwg" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0QfHjmmqF4i" title="Warrants exercisable, weighted average remaining life in years"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_fKDEp_zxQ9nH8wOKx" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zKjFPftSTCpl" title="Warrants outstanding, exercise price"&gt;60.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zdq4Lp8Lyt3k" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zB47YjJpwQr3" title="Warrants exercisable, weighted average remaining life in years"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_fKDEp_zwO4pm9kjpB1" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcSr6m5jve3e" title="Warrants outstanding, exercise price"&gt;800.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zLJWuMGrxPAd" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTxdcUeiF1h6" title="Warrants exercisable, weighted average remaining life in years"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_fKDEp_zQETJV7D8QTi" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zqk8O4ghtpm8" title="Warrants outstanding, exercise price"&gt;2,240.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_ziQ80gOPY3C" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJVBCh8CXCg5" title="Warrants exercisable, weighted average remaining life in years"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_fKDEp_zLGN8Q6oGbQ2" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXIcZViHwRKb" title="Warrants outstanding, exercise price"&gt;2,800.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zaMvUapSecPd" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zwQ6TYROPLN1" title="Warrants exercisable, weighted average remaining life in years"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_fKDEp_zb74Zi8xFHzl" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z03zfrSg1YE3" title="Warrants outstanding, exercise price"&gt;3,400.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zLbJnkFHuO0a" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zz1hJ74P7Sp7" title="Warrants exercisable, weighted average remaining life in years"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_fKDEp_zCmcDJ1Utpt5" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zyoxbJsqUkce" title="Warrants outstanding, exercise price"&gt;4,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zIuI5nKGc5v7" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zdpKW9qo3Eoh" title="Warrants exercisable, weighted average remaining life in years"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_fKDEp_zAhj1JOl85N" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z9lOrmIjzVv6" title="Warrants outstanding, exercise price"&gt;8,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zLmOj98tGluj" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zM16slMZ1dB8" title="Warrants exercisable, weighted average remaining life in years"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_fKDEp_zy0VUpS5vwAc" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zoGyNOwnZjHh" title="Warrants outstanding, exercise price"&gt;14,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6JVx3FuMZji" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zALlBxKyG9e4" title="Warrants exercisable, weighted average remaining life in years"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_fKDEp_zGwpRz4mjks9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zpkb1VJZ5uLb" title="Warrants outstanding, exercise price"&gt;16,000.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_za7cJzBqbM4j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding, number of warrants"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhoaDtHgclQ5" title="Warrants exercisable, weighted average remaining life in years"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_fKDEp_zy1uBTNrqDEa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_fKDEp_zqZr7OXjinei" style="text-align: right"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_fKDEp_zm7MSkwMUmn4" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;4,791,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">2.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">4501937</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember">P3Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">4501937</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">235970</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember">P3Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">235970</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">60.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">800.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">869</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember">P1Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="USDPShares">2240.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">50</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember">P1Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">50</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="USDPShares">2800.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">264</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember">P1Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">264</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="USDPShares">3400.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">264</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember">P1Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">264</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="USDPShares">4000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">55</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember">P1Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">55</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="USDPShares">8000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">19</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember">P0Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">19</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="USDPShares">14000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">18</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember">P0Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">18</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="USDPShares">16000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">16</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember">P0Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">16</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">4791082</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">4791082</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember"
      decimals="INF"
      unitRef="Shares">586959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember">vested to the extent of 50% on the date of grant, 25% on the one-year anniversary of the grant date
and 25% on the two-year anniversary of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-11-022021-11-04"
      decimals="INF"
      unitRef="Shares">140824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-11-022021-11-04_custom_PatrickFWilliamsMember"
      decimals="INF"
      unitRef="Shares">10490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-11-022021-11-04_custom_MrAlstodtMember"
      decimals="INF"
      unitRef="Shares">140824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-11-022021-11-04_custom_MrSilvaMember"
      decimals="INF"
      unitRef="Shares">42059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-11-022021-11-04_custom_DrNickolayKukekovMember"
      decimals="INF"
      unitRef="Shares">25236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-11-022021-11-04">Such options are exercisable to the extent of 50% on the date of grant and 50% quarterly
over a period of two years commencing one year from the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-11-022021-11-04_custom_ScientificAdvisoryBoardMember"
      decimals="INF"
      unitRef="Shares">110767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-09"
      decimals="INF"
      unitRef="USDPShares">13.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-10"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z41Grh7waTHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the option activity during the years ended December 31, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z41jvRlK6xNb"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z0htSgZLMxVg" style="width: 11%; text-align: right" title="Number of Options Outstanding Beginning"&gt;1,215&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zLACIEDVEGk9" style="width: 11%; text-align: right" title="Weighted average outstanding beginning balance"&gt;5.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zEyBsIf7KJJ4" style="text-align: right" title="Number of Options Granted"&gt;838,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zyOJAFxHqe5" style="text-align: right"&gt;5.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20211231_zTv1o9IGqWma" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired"&gt;(126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zPc6CVcdfbEg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zRZlzYdhgFS7" style="text-align: right" title="Number of Options Outstanding Beginning"&gt;839,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zSKSNTbfRMV1" style="text-align: right" title="Weighted Average Exercise Price Outstanding Beginning"&gt;5.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zpFx7wwKDXK8" style="text-align: right" title="Number of Options Granted"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zVvPl0gtty4b" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;4.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zHyticBxYibb" style="text-align: right" title="Number of Options Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_z9Ud3scCE3Uj" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220101__20221231_zQ5CR0592oOa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJ0toreo1sfc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zTJHQs9T6N4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending"&gt;864,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zhDeR1Z7o6zb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding Ending"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zDvB6ocfrrU7" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20221231_zmNhYFjpKHa9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zfiKun1fYpfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending"&gt;578,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20221231_zuBRlNKlJ92i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_ziKPFOAgWDah" title="Weighted Average Remaining Life in Years Exercisable Ending"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">1215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">838550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">839639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">4.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">864639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">578628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">4.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaC8Zw0s9uu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zsZZFqtNG8Ch"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUi1pRRyTzpg" title="Risk free interest rate"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBRy8732sBn4" title="Expected term (years)"&gt;3.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxLxiNUDh7lb" title="Expected volatility"&gt;285.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGZxG1lmhMo2" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">2.8591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">293479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">47.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2021-03-182021-03-18_custom_TwoEmploymentAgreementsMember_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">13969624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-03-172022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">24876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-18_custom_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ziQWhFgrM8i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the unvested RSUs as of December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zK4OnVu5gNvf"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7ruj8I7X9ec" style="width: 14%; text-align: right" title="Number of shares outstanding beginning"&gt;293,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAWU9gwnsBuh" style="text-align: right" title="Number of shares granted"&gt;24,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ4xFg3IJbnh" style="text-align: right" title="Number of shares forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1164"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMlTpl4Y0MB8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares vested"&gt;(116,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZsFIt7oprpa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"&gt;201,870&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">293480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109"
      decimals="INF"
      unitRef="Shares">24876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember27582109"
      decimals="INF"
      unitRef="Shares">116486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">201870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zWgn53WFH2L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zveUfSxAoorc"&gt;SCHEDULE OF STOCK OPTION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrecognized at December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Amortization Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4wVPE52dCH3" style="width: 11%; text-align: right" title="Stock-based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyYDc2BYMYSi" style="width: 11%; text-align: right" title="Stock-based compensation expense"&gt;81,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMN4tnm8lsEf" style="width: 11%; text-align: right" title="Unrecognized expense"&gt;803,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQTaVcLFo6cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense"&gt;12,612,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1FGqhTV6UV" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation expense"&gt;23,027,476&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwMmnQ8r2x4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrecognized expense"&gt;1,294,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5GNJoPn2LYj" title="Weighted average remaining amortization period (years)"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVoNThiixP6" style="text-align: right" title="Stock-based compensation expense"&gt;12,612,862&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKwTrTrlpY2" style="text-align: right" title="Stock-based compensation expense"&gt;23,108,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVxSbf1kuTR4" style="text-align: right" title="Unrecognized expense"&gt;2,097,941&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">81479</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">803257</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">12612862</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">23027476</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1294684</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">P0Y8M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember27582265"
      decimals="0"
      unitRef="USD">12612862</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember27582265"
      decimals="0"
      unitRef="USD">23108955</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">2097941</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zw2wPr6d8628" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents stock compensation by award type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zue5Pm5NOC5k"&gt;SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqlHr7YFhi72" style="width: 14%; text-align: right" title="Stock-based compensation award"&gt;7,741,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAveqV0rIEV8" style="width: 14%; text-align: right" title="Stock-based compensation award"&gt;19411976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOjzSNxdXdmg" style="text-align: right" title="Stock-based compensation award"&gt;4,735,108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlaZMA2CX3rf" style="text-align: right" title="Stock-based compensation award"&gt;3,671,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares issued for services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zV05i5E9eKAh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;135,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zfvCuOM9Lwz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;25,476&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20221231_zA0jHrxnRZ28" style="text-align: right" title="Stock-based compensation award"&gt;12,612,862&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0p0_c20211231_zEUWDLTO0cmk" style="text-align: right" title="Stock-based compensation award"&gt;23,108,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">7741864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">19411976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="Shares">4735108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="Shares">3671503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SharesIssuedForServicesMember"
      decimals="0"
      unitRef="Shares">135890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_custom_SharesIssuedForServicesMember"
      decimals="0"
      unitRef="Shares">25476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2022-12-31" decimals="0" unitRef="Shares">12612862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">23108955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_z3yWSsXG4dCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
 8 - &lt;span id="xdx_82F_zqBzO3kIdQFi"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company identified its federal and New York tax returns as its &#x201c;major&#x201d; tax jurisdictions. The period its income tax returns
are subject to examination for these jurisdictions is 2018 through 2022. The Company believes its income tax filing positions and deductions
will be sustained on audit, and it does not anticipate any adjustments that would result in a material change to its financial position.
Therefore, no liabilities for uncertain tax positions have been recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, the Company had approximately $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zI8E9dnTNaog" title="Operating loss carry forwards"&gt;59,900,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zngKeIsfWlfb" title="Operating loss carry forwards"&gt;10,300,000&lt;/span&gt;, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#x201c;Tax Act&#x201d;),
certain future carryforwards do not expire. At December 31, 2022, approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20221231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zJWSzufo7wk1" title="Operating loss carry-forwards subject to expiration"&gt;8,000,000&lt;/span&gt; of federal net operating losses will expire
from 2030 to 2038 and approximately $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20221231_zSlYn71GQd5l" title="Operating loss carry-forwards not subject to expiration"&gt;51,900,000&lt;/span&gt; have no expiration. &lt;span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zhYy1K72NN04" title="Income tax examination, description"&gt;In accordance with Section 382 of the Internal Revenue Code, the
usage of the Company&#x2019;s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership
changes.&lt;/span&gt; The Section 382 limitations resulted in approximately $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zpgA0JRKLN6b" title="Federal net operating loss carry-forwards"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zLtjnWIMHMib" title="Federal net operating loss carry-forwards"&gt;28,200,000&lt;/span&gt;&lt;/span&gt; of federal NOLs not being realizable
as of December 31, 2022 and 2021 and the cumulative reversal of approximately $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_z6LAWjTUsZIi" title="Deferred tax assets, operating loss carryforwards"&gt;&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zHYW3ZPE7Ibf" title="Deferred tax assets, operating loss carryforwards"&gt;9,600,000&lt;/span&gt;&lt;/span&gt; of net operating loss deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not performed a formal analysis for the year ended December 31, 2022, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxo7kMnJ4Sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2022 and 2021 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zPGPgpCirK5c" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zqHIKS6yQzkf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_z2EWfdn8UMa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzjDN_maDTAGzPKX_zxlbm7o863Ff" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;13,200,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11,100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzjDN_maDTAGzPKX_z2Gls5i1bd66" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,810,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzPKX_zCCTw5dB54j9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;655,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzPKX_zn0eqBdup87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Research &amp;amp; development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;330,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_msDTLzhRs_mtDTAGzPKX_maDTALNzfjZ_zzd8bY60V9yi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,995,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,958,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDITLzXDW_zNWZR3fb6rRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(106,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzXDW_zbv4sTRD5sTd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzXDW_msDTALNzfjZ_z1QbuJoyIf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_mtDTALNzfjZ_zRN5sFEShJ3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,954,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zzyjh1Tam3I" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,954,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_zuHkoff91Z31" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Deferred tax asset, net of valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1262"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220101__20221231_zs4dWkbGqYhb" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(5,822,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_zCIkkTE1tHC" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(7,856,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zle5qQRyI6Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zooHXSN2G1Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision (benefit) as of December 31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zyIra2pymnne" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zN8pM83pF9qi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_z6EBCU4nJhh6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Federal:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzexe_zS7DdAdTDUo3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1272"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzexe_zGsxdo8LXBv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State and local:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzexe_zCd8JG3v8gO2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maITEBzexe_zf3zFvNhRK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1280"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzexe_zEJVx9DPPFQ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1284"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z2MBeT4l28tc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z09LfIwM8dJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2022 and 2021 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zyAWAvu0AbLk" style="display: none"&gt;SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_z8XWsoAm2Nvi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210101__20211231_zXShsA2E1oF7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zlTzCt1GcsUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Federal statutory blended income tax rates&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zv6tIPY7ZJU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State statutory income tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_zF6pRXWkT6sh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_zfzoLKyDsKsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax return to provision adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKYmliGY8TB2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z8WFOqbT2OAj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zQzWekPwGa1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this filing, the Company has not filed its 2022 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">59900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2022-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember"
      decimals="0"
      unitRef="USD">8000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">51900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2022-01-012022-12-31_custom_SectionThreeHundredAndEightyTwoMember">In accordance with Section 382 of the Internal Revenue Code, the
usage of the Company&#x2019;s net operating loss carryforwards are subject to annual limitations due to several greater than 50% ownership
changes.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_SectionThreeHundredAndEightyTwoMember"
      decimals="0"
      unitRef="USD">28200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_custom_SectionThreeHundredAndEightyTwoMember"
      decimals="0"
      unitRef="USD">28200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_SectionThreeHundredAndEightyTwoMember"
      decimals="0"
      unitRef="USD">9600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-12-31_custom_SectionThreeHundredAndEightyTwoMember"
      decimals="0"
      unitRef="USD">9600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxo7kMnJ4Sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2022 and 2021 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zPGPgpCirK5c" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zqHIKS6yQzkf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_z2EWfdn8UMa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzjDN_maDTAGzPKX_zxlbm7o863Ff" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;13,200,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11,100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzjDN_maDTAGzPKX_z2Gls5i1bd66" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,810,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzPKX_zCCTw5dB54j9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;655,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzPKX_zn0eqBdup87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Research &amp;amp; development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;330,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_msDTLzhRs_mtDTAGzPKX_maDTALNzfjZ_zzd8bY60V9yi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,995,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,958,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesOther_iNI_di_maDITLzXDW_zNWZR3fb6rRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(106,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzXDW_zbv4sTRD5sTd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzXDW_msDTALNzfjZ_z1QbuJoyIf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(219,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_mtDTALNzfjZ_zRN5sFEShJ3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,954,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zzyjh1Tam3I" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,954,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_zuHkoff91Z31" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Deferred tax asset, net of valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1262"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20220101__20221231_zs4dWkbGqYhb" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(5,822,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_zCIkkTE1tHC" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(7,856,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13810000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">655000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">358000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">27995000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21958000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">106000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">113000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">219000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">27776000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21954000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">27776000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21954000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5822000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-7856000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zooHXSN2G1Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision (benefit) as of December 31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zyIra2pymnne" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zN8pM83pF9qi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_z6EBCU4nJhh6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Federal:&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzexe_zS7DdAdTDUo3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1272"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzexe_zGsxdo8LXBv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State and local:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzexe_zCd8JG3v8gO2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maITEBzexe_zf3zFvNhRK5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1280"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzexe_zEJVx9DPPFQ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1284"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z09LfIwM8dJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2022 and 2021 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zyAWAvu0AbLk" style="display: none"&gt;SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_z8XWsoAm2Nvi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210101__20211231_zXShsA2E1oF7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zlTzCt1GcsUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Federal statutory blended income tax rates&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zv6tIPY7ZJU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State statutory income tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_zF6pRXWkT6sh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_zfzoLKyDsKsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax return to provision adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKYmliGY8TB2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_z8WFOqbT2OAj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.089</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.067</BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.315</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.177</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--LesseeOperatingLeasesTextBlock_zuT4sYm0XFC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
 9 - &lt;span id="xdx_825_zm5KZCfk8Lla"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a lease for &lt;span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zO6nTSqYMSDi" title="Area of land"&gt;6,800&lt;/span&gt; square feet of space located in Melville, New York (the &#x201c;Melville Lease&#x201d;) with respect
to its corporate and laboratory operations. &lt;span id="xdx_904_eus-gaap--LessorOperatingLeaseDescription_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zeIMVMZzoTO1" title="Lease description"&gt;The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zymVzYrgGdWj" title="Rent expense"&gt;132,600&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zC9vr08INZXc" title="Rent expense"&gt;149,260&lt;/span&gt;.&lt;/span&gt; In June 2019, &lt;span id="xdx_905_eus-gaap--LessorOperatingLeaseDescription_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zMIl0TDXRJ93" title="Lease description"&gt;the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced&lt;/span&gt; on January 1, 2020 with annual base rent ranging between $&lt;span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_z3xIdAIkh15j" title="Rent expense"&gt;153,748&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zTRPi0wFpaF7" title="Rent expense"&gt;173,060&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was &lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zzLpn2qirZg3" title="Weighted average incremental borrowing rate"&gt;12&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zZenbPICcdaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z23EYUeuXTXh" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_z8EB2RiBVbZd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zgyuob3ipOu9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zFYBuNNB2086" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt"&gt;Operating lease cost (cost resulting from lease payments)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;163,132&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;158,372&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_znlqh1MFVxKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;163,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;158,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbx0OMThpQJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease - operating cash flows (fixed payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;163,132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;158,372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OperatingLeaseLiabilityReduction_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease - operating cash flows (liability reduction)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;119,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;101,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Non-current leases - right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z8ky0aEnYTt8" style="text-align: right" title="Non-current leases - right of use assets"&gt;241,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231_zsfaJWUEKYLa" style="text-align: right" title="Non-current leases - right of use assets"&gt;357,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231_ze6MkL5jtsy" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;139,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20211231_zNu915d4DJL2" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;119,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Non-current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zI09nGPRE2vf" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20211231_zeiKHOQrzgg7" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zMLqWXM3TG44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbvtZWaRmtt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December
31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zjfFnIaXkhll" style="display: none"&gt;SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zZgZ6LXCbUd1" style="width: 14%; text-align: right" title="2022"&gt;168,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20221231_zbRnoUHM1Ay1" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023"&gt;173,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20221231_zgdgnlCBig38" style="text-align: right" title="Total future minimum lease payments"&gt;341,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20221231_zDnG1J0WZRO2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amount representing interest"&gt;(39,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of net future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zlC73twgH2T2" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net future minimum lease payments"&gt;301,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zeVIxaaJ8HRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2022-12-31_custom_MelvilleLeaseMember"
      decimals="INF"
      unitRef="sqft">6800</us-gaap:AreaOfLand>
    <us-gaap:LessorOperatingLeaseDescription contextRef="From2022-01-012022-12-31_custom_MelvilleLeaseMember">The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $132,600 and
$149,260.</us-gaap:LessorOperatingLeaseDescription>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">132600</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">149260</us-gaap:PaymentsForRent>
    <us-gaap:LessorOperatingLeaseDescription contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced</us-gaap:LessorOperatingLeaseDescription>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">153748</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">173060</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zZenbPICcdaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z23EYUeuXTXh" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_z8EB2RiBVbZd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zgyuob3ipOu9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zFYBuNNB2086" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt"&gt;Operating lease cost (cost resulting from lease payments)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;163,132&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;158,372&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_znlqh1MFVxKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;163,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;158,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbx0OMThpQJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease - operating cash flows (fixed payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;163,132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;158,372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OperatingLeaseLiabilityReduction_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease - operating cash flows (liability reduction)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;119,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;101,190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Non-current leases - right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z8ky0aEnYTt8" style="text-align: right" title="Non-current leases - right of use assets"&gt;241,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231_zsfaJWUEKYLa" style="text-align: right" title="Non-current leases - right of use assets"&gt;357,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20221231_ze6MkL5jtsy" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;139,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20211231_zNu915d4DJL2" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;119,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Non-current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zI09nGPRE2vf" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20211231_zeiKHOQrzgg7" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">163132</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">158372</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">163132</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">158372</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">163132</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">158372</us-gaap:OperatingLeasePayments>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">119055</BRTX:OperatingLeaseLiabilityReduction>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">101190</BRTX:OperatingLeaseLiabilityReduction>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">241760</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">357805</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">139328</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">119055</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">301645</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbvtZWaRmtt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases following the year ended December
31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zjfFnIaXkhll" style="display: none"&gt;SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fiscal Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zZgZ6LXCbUd1" style="width: 14%; text-align: right" title="2022"&gt;168,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20221231_zbRnoUHM1Ay1" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023"&gt;173,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20221231_zgdgnlCBig38" style="text-align: right" title="Total future minimum lease payments"&gt;341,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20221231_zDnG1J0WZRO2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amount representing interest"&gt;(39,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of net future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zlC73twgH2T2" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of net future minimum lease payments"&gt;301,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">168028</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">173060</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">341088</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">39443</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">301645</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zHgXiG0hcpi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 - &lt;span id="xdx_82C_zOqGqGzXpr53"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 17, 2023, the Company granted &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_ziSYKTWik0f7" title="Shares options, granted"&gt;400,357&lt;/span&gt;
stock options to its officers and a certain employee, of which &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_zg66umQ0gRYf" title="Vested and exercisable percentage"&gt;50&lt;/span&gt;%
were vested and exercisable upon grant. The remaining &lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OfficersMember_zce9B7pi2Vt2" title="Remaining percentage of options vested"&gt;50&lt;/span&gt;%
of the options issued to the Company&#x2019;s officers and employee will vest quarterly in eight nearly equal installments
commencing one year from the date of grant. The Company issued an additional &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardAndScientificAdvisoryMember_z0K6wBZ41Zx8" title="Shares options, granted"&gt;228,660&lt;/span&gt;
stock options to its board members and scientific advisory board members, which will vest monthly over one year. The granted stock
options had an estimated fair value of approximately $&lt;span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6C0UnW4C7w" title="Estimated fair value of granted"&gt;1,745,000&lt;/span&gt;
as of the grant date, of which approximately &lt;span id="xdx_908_ecustom--RecognizedStockbasedCompensationExpensePercentage_pid_dp_uPure_c20230216__20230217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7ddGtnk9WFa" title="Recognized stock-based compensation expense percentage"&gt;$562,500&lt;/span&gt;
was immediately recognized as stock-based compensation expense, which will be reflected in the Company&#x2019;s consolidated results
of operations for the first quarter of 2023. &lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember"
      decimals="INF"
      unitRef="Shares">400357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage
      contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_OfficersMember"
      decimals="INF"
      unitRef="Pure">0.50</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_custom_BoardAndScientificAdvisoryMember"
      decimals="INF"
      unitRef="Shares">228660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1745000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <BRTX:RecognizedStockbasedCompensationExpensePercentage
      contextRef="From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Pure">5625</BRTX:RecognizedStockbasedCompensationExpensePercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /&6>%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #QEGA603TJ2N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O39U"J'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1!X5=V!0U)&D8()6(2%R&1KM- 1%?7QC#=ZP8?/V,TPHP$[=.@I05W6P.0T
M,9S&KH4K8((11I>^"V@6XES]$SMW@)V38[)+:AB&<FCF7-ZAAK>GQY=YW<+Z
M1,IKS+^2%70*N&:7R:_-PV:W99)7O"FJIN"W.\[%:B7J^_?)]8??5=CUQN[M
M/S:^",H6?MV%_ )02P,$%     @ \99X5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M?-<)HWY7-,9B5YV$(!HY"*'6#B"['=CWCC/WID'FO1"CH8LQ1"+H17[D1B/
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M=DEQ^(93NJ,XW,A:/PH=VV,WVR\%SQC+FQA(6IID.E2%,HIS?UB510:7UDQ
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M3!0044T6W:['3L.AOTW+5I*)AFF'Q(.FCE6Y2>KQ@"64JY*T+U&4X4F1C%,
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M>F?1P ;9B7 WT:)NA6\E-,EH.]S0?PNE,:#OF1!Z/S$!^C_A[ =02P,$%
M  @ \99X5A8GTS1_!@  7@\  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&ULI5=M3R,Y$O[>OZ*4':U :I)^R1LS@!0@[.0T PC"[NI.]\'I=A)KNMM9
MVSTA^^OOL;O3)#<$1G="(F6W755/U5-E^VPMU3>]Y-S0<YX5^KRU-&;UL=/1
MR9+G3+?EBA?X,I<J9P9#M>CHE>(L=9ORK!,%0;^3,U&T+L[<W+VZ.).ER43!
M[Q7I,L^9VESR3*[/6V%K._$@%DMC)SH79RNVX(_</*WN%4:=1DLJ<EYH(0M2
M?'[>&H4?+[MVO5OPN^!KO2.313*3\IL=3-+S5F =XAE/C-7 \/.=7_$LLXK@
MQE^USE9CTF[<E;?:;QQV8)DQS:]D]H=(S?*\-6Q1RN>LS,R#7'_F-9Z>U9?(
M3+O_M*[6]N(6):4V,J\WPX-<%-4O>Z[CL+-A&!S8$-4;(N=W9<AY><T,NSA3
M<DW*KH8V*SBH;C><$X5-RJ-1^"JPSUQ,;J>CV]\FEU_&-'I\'$\?SSH&:NW'
M3E*KN*Q41 =4A!%]E859:AH7*4_W%73@3^-4M'7J,GI3XS5/VA2'/D5!%+VA
M+VY QDY??$#?;U*F:Y%EQ(J4)H5AQ4+,,DXCK;G1="UTDDE=*D[_&LVT4:#*
MOU^+0V6E^[H56SX?]8HE_+R%^M!<?>>MBU]_"?O!IS<P=!L,W;>T_URBWE3Q
MNH.W=].QUZ43^L$ 39?<NY+YBA4;$IH8K9@R&S(28B825"8GME"<HT@->&N6
M9):<'J^F5W3$L 'S(,0Q'=GI7W\91E'PR7T=;7>YR?#3<9ON2Z5+!CU0WVAI
MUOF>G=LZ(V<&[8:G/DS(8D$2'Q5VB6*A,6<;08:$I]PG_IQDI4;A^Z3DAF5F
M<S+C3&%E V&N9/YB$N9+(S+Q-R=IF]>L04H)5]:NE_-4)"Q#\7_'-T3%6/QH
MD$X+2U&FPK+(M1TY)[WBB9B+! JR3%L2=K#6#FBE9%HFX&"-.@45MPOT"A@1
M2'"V FC#KZU"C+R93#?'CM [>.G(X4TMO)$6S'T?J07\$P4[_JEPO!\ RKE9
MRM0B]A)TO]+M=^!^S.,[1/$;I2NNW!E3(*2YR#A:7\$U'4D+?(/S1!-698*7
M-@2OKS[VEBRUEF><-.*OYX*G=IM4*0*X3=&61UAHSRUG7D!_$QU2MIGKRE7%
M%TRENQGJ5*DQ/%D6,I.+3=O62J,V%:E72$0 IU>VJ1W9N-W@*%15*410#F%>
M+T6RI()SE,\/<&8;NN$S5>(,=0T2Q3-*$B!$%K*-CY1A;P7 F_$$54B%+$X:
M<&WZ+-?\.U?^7C"0&JY<M&R!%]OJW4E<6=@@5KX)@ZR(E#Y0..CY01!0+_3C
M04!A./"#.$";]7:\Q.2>,<43#E>@O025E/B[*I:F%&_0L1UYKU4)*N^7U&X[
MN;D>;7N(#13J*4'4JL0QNE_BP/8B2M *7<D:)5C6AG/[(=QWCA6%+)$2A'[)
MC/OT5 B#\:-!K6NZKRK>^C=5+,4U27VCN_G<=@-81+/4I<6&N!L[AWRS#-<?
MFV?/DI!MFP9;K5 @%2S%,PBHI)IIM3L67CCXI.GR8?KG28A(-VB =J%8;MF'
M_ERK7+\X %I_90K9LAC;.R>?QZJ3+Y&X76E3$Q+U8;V$"Q]1FY_'UT\X"^YN
MZ&9R.YF.Z<OD]_'UC\>$5T5#[X=#TY>J\+4E9YF7P :/1KE49IOMJ30L\RY9
MYOC/7&O[!RM<5JK#/Z38[P_Z&,5!Z/> _:C?#?S38$C'U.]W_:@_]/9T\N>5
M:S<G^#L:=/U>9)<VTG]9PT6#YS.0.CYH;Q#V_&[<AY+>\-0?= ,<B0@:*J$R
M"%(6>LZ5+1V;VFV_VY:;P(EY0M%IY*JBD=[R>NC'<>2\KJ5WO(X:KWNGL=^+
MK=<0!GT+?1C$\'_H_>'NIY:5J'Q<MT$WV_LLW]BN*VA)PM;> 4LG*/!VU-M+
MI(>5XN56M<\M_7^1BT9?[QZFDW^.II.[6QK_>3^^?1S_[Y1[AVP?ZD!^H'X\
M\".$'E+%MT/YJHE5_?PDNP9AB.0$5%/KH.HJ^]7/NQ1X\7UP&OC!:>2DB@5[
M(=@:V!Z&!7_&Y<4>>AO<!+2[Z>DZ6_HE5][[N;IYFCX]C ^D#$[&A H*X]#*
MW1VYMR/W=^1!+=-KU^?.SILGY[CB7+G+58+.;:KG3S/;/!Y'U9OI97GU\D2/
M7(A"4\;GV!JT![U6=7YN!T:NW MJ)@W>8TY<X@',E5V [W,IS79@#31/ZHO_
M %!+ P04    " #QEGA63[&5C],"  !M!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6RM5=MNVS ,?<]7$%ZQ)[>^Y-HL"9"+AP9HTR"7;<"P!\5F
M8J&RY4E*T_[])-MQLR$-4& O-B7Q'![2%-T[</$D8T0%+PE+9=^*E<JZCB/#
M&!,B;WB&J3[9<I$0I9=BY\A,((ER4,(<WW5;3D)H:@UZ^=Y<#'I\KQA-<2Y
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MD3_5U[JMKFVKQ76:2PN^,"NVVSSWZ6ZU J=@7A\Z;=?F?CAP1TBN#]B#S66
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MFXRJ"Y,GC++O+=+CUJN^_.X O=!,6:U,"O/6;SU:OS,]-J\*-]/-"]=($G-
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M=Y'1GT+:LW]AR7Z6DJN8V[)3':.)%$QRX:1SEY&&/(\B):I<_$2E$BT(>Z9
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MOYW0 GKCC]P\V>AGC4>95M57_.5F]NO!$6)D"I,U""*%?Q[-E2D*A 1X_%>
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M/2&."=[Q'GB765:U99.7"^W.J?_G<FJ;&ACG?_M.S/!.^N&A-+VVZS0SOQZ
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M\)A;!G5;WZ:S:LT4>"2':>W D3,OX#AZA1.\5C_^X]79^:N?]7U(>2AQ(>&
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M<2-?13RGQ$^(6\1<>GU7&G0%/C(E'6T[GV,+(Q&$#IJQ=_U8%>V*7 0)X;V
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M$FU% ZI-7?'4NV13W7P7M0_PZ$6BUT7*(QIA"H2&NWSE:TY9+<6?[&&KR#U
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M>M4D3<NBC1<3+3+;.I="4R.VPXB^?% : UI?"=+0;F("'+ZE^O\!4$L#!!0
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M5IMKR*_<]S>\NL-N&<GB"E)<4:IS\9E<+ZM[H9IHD9=>#(0F9Y?#F*Y2E":
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M?;X<#R[.1W7!T<QYD!G1<ID\;%S]-(DFMV]'DT6.V0_RI:XC2W0]0DCSJ4A
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MZ^/^?%S.US3"LHW[SFB+<<7BV(<LC_0I3N:::&IMBT58E#Y]+9EF[0?.9V?
MD=AV\MAV?CNV\V 8/ 1WL[_@VA_[L^%-\79FP\ O"^]Q^*&#-2QXB%679FT6
M#847LM5"/L,RO<"BRYF?H(7ID;:X65Q%3K00STA/"JCYNA_+ X;?!N64<OJ'
M_KZ-<\%PI!][=L%PY&]D%L^M-^%+]LI"?U![)9Z7__X>]FZVZQWS./<46SUN
M<B5B2TP4BA5O"*_>,\S5JY\;JC-@5&\E-W=VR!@2_8L-F^7L3KW[(8]46VZ]
M;5#=+DJ?.#Z>9WO4W%K,N2_F*4N\1J'G2ZA<V<X6OV-BRW7:_N6K>?,\3'O&
M@WC:>=\2N6)<04R7J-JL=Y%#9-K-IA,M-K:#7 B-_:@=KO$/ )5& />70NC]
MQ!R0_Z48_ ]02P,$%     @ \99X5J5Q4H,*!   "PH  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&ULK59;;^HX$'[/KQAECU:ME#8W;NT"$J5A6PD"
MXK*K\VB" ]%)8H[ME/;?[]@)::DXJ+O:%[ ]MV_&\TW</3#^0^PHE?":I;GH
MF3LI]_>V+:(=S8BX97N:HR1F/",2MWQKBSVG9*.-LM3V'*=E9R3)S7Y7G\UX
MO\L*F28YG7$01981_O9 4W;HF:YY/)@GVYU4!W:_NR=;NJ!RM9]QW-FUETV2
MT5PD+ =.XYXY<.\?FDI?*_R5T(/XL :5R9JQ'VKSO.F9C@)$4QI)Y8'@WPL=
MTC15CA#&S\JG68=4AA_71^\CG3OFLB:"#EGZ=[*1NY[9,6%#8U*D<LX.3[3*
M1P.,6"KT+QPJ7<>$J!"2994Q(LB2O/PGKU4=OF+@50:>QET&TB@?B23]+F<'
MX$H;O:F%3E5;([@D5Y>RD!RE"=K)_C@8+((%7"W).J7BNFM+=*I$=E0Y>"@=
M>+]PX'HP8;G<"0CR#=V<.K 130W).T)Z\"YZ?*31+?BN!9[C>1?\^76*OO;G
M_RI%BK<FSF56VC7.VRDZW(L]B6C/Q'X7E+]0L__[;V[+^>,"JD:-JG')>W\Q
M? H>5^, IB,(@R7HBX#A=+&$0?@(T^53,(?%:C8;!Y,@7 [&E<9S.)K.)X/E
M\S0\E]+%H.=36NZH$;,4Z9GD6Y"J$4!+<RD@Q[F0J@)"Q(0$DF^ R1U5M-[O
M4XKTE"2M-)*\'!+(MGLXYF?\]_R,[Y3PLJT FX)F:XQ[; RX('2-<0W9F.XI
M1TR8VH<\KO0O)HGD5:*8LZR2[\F;RDI<PS=P6[[E^IY:-3N6W_:,\+0>YU0^
M![P!5I]$1.P@QE(+N(J35\1^.=Q7?:4)62=I(M\PITVA!YYVZ-Y93K.I5HYK
MN7>.$;+\)BHXQY"E2X$^N1I=P&(H, 01@N+%?P.OX5KMEH,KO]FV.D[3&!X-
MJVB)MF:?,'Z48F#_SO*]SCN84PC_QE/+LWRWK?!@,JU&$R[0L%G3L/EE&HY6
MR]4\@,ES^#Q936 V^*XZ<P&K\!%[-9R&-\-!. S&@P?4KP8G-BM,9\$<&S;\
MLSH\Q\N+*,[S<E3(@E,#AWZ2%5G=*%!@SW/(515)'M%4$[:Z2R3@YRJ6A\A9
M; WUE=8DISP3ZL+5<:U5CP \?%/LHB?L,H[4.R7W_U4U8Y2("&>)YO5[WY?3
MV\"X/G9 QW*\CMHTP&W[EM-RC"53$RC6Q8)CL4ZI##ZVLM/I&(.,%;GB?37?
M5( DQVI0-1.P4QL-'ZZ-62F%%Y(65)5)3<'+$2XWI?WA YU1OM7/$($C!-&4
MW^KZM'[I#,H/_+MZ^4R:$+Y-<H'Q8S1U;MO86;Q\>I0;R?;Z<[]F$A\/>KG#
MUQKE2@'E,6/RN%$!ZO=?_Q]02P,$%     @ \99X5GO'WY?K @  9P<  !D
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MS7O4U.,KOH067/^#31-K&2!9<4'+!BP5E)C43_C8]&$'8 =' $X#</8!WA&
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MGOA$>GR=WBB^3$Z )UPI'B27"Z0>BGB!?G_&N7JYB1UD/R+T?@)02P,$%
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MC&X!4]8235UDN<F\931!K);Q23#Y-)!^8O@T^C09/T\GX.$.S!\?YI/'K_^
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MN0WM0SLO:3<,PQX4FXF%RI(K*4G[]Z-DQTN[I-C#7BQ1XCD\I$7VMU+=ZP+
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M%9+E97NOF%3#HEQNU70&KB^H\S5C\E#HB=',>^\?4$L#!!0    ( /&6>%;
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M#0C\3Q!X@;\OH'KX$.,&- MXL <^?#G<K\FF61U T_*%!_A&Y$E_10H4U]_
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MV6F&/P.0Q@#/MT+HX\(X:'XOX6]02P,$%     @ \99X5K,W'BC*!   FA4
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M/T-[C]B5FIQ1N\BI7912&].4LBTKW1!+$5Y;KQ6!G8EMYV+;?WEK:U>9JHK
MSE+E>P^_5Z^:7:,<Y[6BGV%5SS8A\(&9OS T(28'62;XI)_PRTN!W#U;"N40
MK]9:$=JYX.!!</"7R^%(H*IT581VGJZ'OL@O[25>41"5-CC/L"K\*V<*W9/F
MFJ%8V3.'A 7?IBIK3_/9_%S3L]W\H_F^.>_8IOT!)CLLC8E8T51"@DL-Z=5:
MNA,0V?DC&RB^L2W\G"M](+"/:WUF0V$,]/LEY^I^8 +DI\#H-U!+ P04
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MS4]N%T!\8,I _C^+8_'VH ;(SG8Z_P%02P,$%     @ \99X5A-,"N*H @
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M-;KZE8ARC)4;Q0L[.I9<Z4%DEVL]^5$8 WV?<JX.&Q.@^B\)?P-02P,$%
M  @ \99X5CN O&G: @  4@<  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&ULG97);MLP$(9?9: "10HTT>)-36T!WH(8S6)8<7H(>J"EL2Q$(EV2MI.W
M+TG)JIO(!M*+Q&U^?C,<#KL[QI_%"E'"2YY1T;-64JXO;5M$*\R)N&!KI&IF
MR7A.I.KRQ!9KCB0V1GEF>X[3MG.24BOHFK$I#[IL([.4XI2#V.0YX:\#S-BN
M9[G6?F"6)BNI!^R@NR8)ABCGZRE7/;M2B=,<J4@9!8[+GM5W+P>^7F\6/*:X
M$P=MT)XL&'O6G4G<LQP-A!E&4BL0]=OB$+-,"RF,WZ6F56VI#0_;>_4KX[OR
M94$$#EGV,XWEJF?Y%L2X))M,SMCN&DM_6EHO8IDP7]B5:QT+HHV0+"^-%4&>
MTN)/7LHX'!AX[A$#KS3P#'>QD:$<$4F"+F<[X'JU4M,-XZJQ5G IU8<22JYF
M4V4G@W!X/1[-;\9P?P7SN\=Q^# >P4S]9I.A;H8/]\,?:F;R$,+9""5),_$%
MSF&&0O(TDAA#*%GT#'.:2@%GLW"NYI]N,5\@_]6UI6+4.]E1R3,H>+PC/*X'
MMXS*E8 QC3'^5\!6SE4>>GL/!]Y)Q1%&%]!POX+G>!Z(%>$H3L@VJL UC&SC
M6."TT/E )40,0Y:K2R*(R;,^YX0FJ!)7PN(5#M=-R:L9[N\(C^'I1DG"1&(N
M:@-5[-^LWU]?UDNQ)A'V+'4;!?(M6L'G3V[;^7["NV;E7?.4>G"WT><';%D&
M#-1]%I+0.*4)+#!)*56M.NI"MVUT=478!MZW1M-WNO:VAJ=5\;0^QI.H(,NW
M^5$0M-X3-/U.NQZ@70&T/P:@ZN$2TR,()[7JCPY.G%JG@NQ\#'*K;FD]8>==
MD,Y=M]WTCX3)KPC\_\\;-+\Z&O_]D3FNWWF;-/9!G<N1)Z::"XC8ALJBY%6C
MU8/1+^KDW^7%:W-+N$IB 1DNE:EST5%9PXL*7G0D6YNJN6!2U6#37*E'#[E>
MH.:7C,E]1V]0/:/!'U!+ P04    " #QEGA6/%LQU7X#  #V"P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6RM5MMNVS@0_15"6Q0IT$07RY*5V@;B
M2[?%-K$1-^T"BWV@I;$D1")5DK:3?GU)2E%L1Q;2PB\V27'.G#,S&DU_2]D]
M3P $>L@SP@=&(D1Q:9H\3"#'_((60.23%64Y%G++8I,7#'"DC?+,="S+,W.<
M$F/8UV=S-NS3M<A2 G.&^#K/,7L<04:W \,VG@YNTS@1ZL <]@L<PP+$73%G
M<F?6*%&: ^$I)8C!:F!<V9=C6QOH&]]2V/*=-5)2EI3>J\WG:&!8BA%D$ H%
M@>7?!L:090I)\OA1@1JU3V6XNWY"_ZC%2S%+S&%,L^]I))*!T3-0!"N\SL0M
MW7Z"2E!7X84TX_H7;:N[EH'"-1<TKXPE@SPEY3]^J *Q8V#[1PR<RL Y-'"/
M&'0J@XX66C+3LB98X&&?T2UBZK9$4PL=&VTMU:1$I7$AF'R:2CLQ7(P_32=W
M7Z9H]A$MOL[&_Z#9_.OGV0V:_CN?WBRFZ&P" J<9?X?.T2+!#,Y',FH1FN-'
MF4V!KAC#) :U?H]FA<[-?]>0+X']+TWN%A-T]N9=WQ22K')IAA6Q44G,.4+,
M=M U)2+A:$HBB/8!3*FRENH\21TYK8@3""]0QWZ/',MQ&@B-7V]NM]#IU)'O
M:#SW6.0%#>_/ESJ8(<WE>\FQCAX\J#4TA:Q$[&I$]8)N9)@\V^EY4L]F5\K+
MBT['MGI!MUM?W"/MUJ3=5M)WA$%(8Y+^E*Q;B)8HWJY_*_ #US[@V>I-M;!+
M7N 0!H;L41S8!HSAV[]LS_K0DH!NK:7;JN56(F(6)@B3"$U@(UM:H4MZ6NJJ
MR[A)8"OTZXF743@1V%X4O#H*WLG+L!6QF2]JTNV]J)*>[?I!<XGZM2#_)"7J
MOW1N=9RN?U"AK<[^,#>]6DJO5<K?0(#A3!?H522[?\H%P^J[]ZH:;07_W1H]
M$=A>'((Z#L'):S1XD=XCK3)H:)66X[N^UUR'MO7\:;5.4HD5S'Y;#UROYQY0
M;??WATFP=T8%NU7/=ST322UX(\LR!CG&J4$Q)3'".64B_5EFI0"6T@B=/<KV
MRIL__>V.>B@O/_U.!T7XD3?58SO$[\;"W)F@<F"Q'BRY++8U$>6$49_6P^N5
M'MD.SD=JJ-63V3-,.1%?8Q:GA*,,5A+2NO!EOEDY9)8;00L]IRVID%.?7B9R
M, >F+LCG*TK%TT8YJ$?]X2]02P,$%     @ \99X5AA1A7A1 P  ^0T  !D
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M:AZJ^:@6H%J(:A&JQ90F%Y,VWMI'XZU]--Z*:B:J6:AFHYJ#:BZJ>:CFHUJ
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M;(?JF.V7S84$+Y[D5<]]=!7I[YVLU/MG0_D0V$3;M%#-1C4'U5Q4\U#-1[4
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M0?7^=9:5C[_4#=QG^;?-8E_^"U!+ P04    " #QEGA6A/]+;?$#  #?#0
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M4ITS7F3WHB)99A+D@DF5;DTQ5@\BX'J ZE\R)K<5/4'YQ/+^ %!+ P04
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M;LF\N, +="9E(5-W58.B>29CPYB4A<P>+=3-V!PW%"N,25G([--"3A"T<SL
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /&6>%86!/M0V0<  '4T   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #QEGA67BN+KS &    '   &               @($=$   >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ \99X5KZQODQD P  (P\
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M965T-RYX;6Q02P$"% ,4    " #QEGA6*?5"?R8;  !+30  &
M    @($P-P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M\99X5NZQ*NM9 P  %0<  !@              ("!C%(  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /&6>%86)],T?P8  %X/   9
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M970Q-"YX;6Q02P$"% ,4    " #QEGA6U=Y73$0%  "Y"P  &0
M    @(%6>@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M /&6>%9U01<03@(  /L$   9              " @=%_  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ \99X5@!7("N*'   IE<  !D
M             ("!5H(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #QEGA6M8 G#E,$  !7"0  &0              @($7GP  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /&6>%9#,I-W+P,
M +(&   9              " @:&C  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ \99X5CI;2&L%!   , L  !D              ("!
M!Z<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #QEGA6
M6;1Z>M("  !*!@  &0              @(%#JP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /&6>%9Z25%5C0(  *@%   9
M      " @4RN  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ \99X5O0;L4DI!P  WA4  !D              ("!$+$  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #QEGA6)U[&W]\$  !>#
M&0              @(%PN   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( /&6>%:E<5*#"@0   L*   9              " @8:]  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ \99X5GO'WY?K
M @  9P<  !D              ("!Q\$  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #QEGA65N_IQ/P"   9#@  &0
M@('IQ   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /&6
M>%8#N&!"V ,  !P1   9              " @1S(  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ \99X5HES?ZR8!   4!@  !D
M         ("!*\P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " #QEGA6$/]JJD,$  #6%@  &0              @('ZT   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /&6>%;>5G+Q9P(  *8%
M   9              " @735  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ \99X5F74%IFH!   ,Q<  !D              ("!$M@
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #QEGA69 <L
M6?@#  #@$0  &0              @('QW   >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( /&6>%9$ZCP3:@(  /L%   9
M  " @2#A  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M\99X5L#/)P;8 @  M0@  !D              ("!P>,  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #QEGA6'?Q_#, "  !2!P  &0
M            @('0Y@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( /&6>%8!90(5@P(  &H&   9              " @<?I  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ \99X5K,W'BC*!
MFA4  !D              ("!@>P  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " #QEGA6?0,A5G8#   1#@  &0              @(&"
M\0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /&6>%8H
M#^"CE 8  (@V   9              " @2_U  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ \99X5K#^:R<#!   YQ$  !D
M     ("!^OL  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /&6>%;A5$3$"1@  !5T 0 9              "
M@6$- 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ \99X
M5H3_2VWQ P  WPT  !D              ("!H24! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " #QEGA6:A&@O[L"  !N"0  &0
M        @(')*0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( /&6>%9_-E.20P,  -L)   9              " @;LL 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ \99X5D2AR_*N P  =0P
M !D              ("!-3 ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " #QEGA6BA]A1ED#  !0"@  &0              @($:- $
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /&6>%;XQC9"
MG@(  $0&   9              " @:HW 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ \99X5MK>'<3K P  7PP  !D
M ("!?SH! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #Q
MEGA6":2_F"H$  "B%0  &0              @(&A/@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /&6>%:,7=!Y,P,  $X3   -
M          "  0)# 0!X;"]S='EL97,N>&UL4$L! A0#%     @ \99X5I>*
MNQS     $P(   L              ( !8$8! %]R96QS+RYR96QS4$L! A0#
M%     @ \99X5FXGSJ+"!   $"0   \              ( !24<! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( /&6>%8/E%1(V@$  %D@   :
M      "  3A, 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( /&6>%8A7:<FS0$  "0@   3              "  4I. 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     ^ #X Z1   $A0 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>168</ContextCount>
  <ElementCount>321</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations</Role>
      <ShortName>ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biorestorative.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityDeficit</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/PropertyAndEquipment</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IntangibleAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biorestorative.com/role/NotesPayableTables</Role>
      <ShortName>NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/NotesPayable</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative</Role>
      <ShortName>ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails</Role>
      <ShortName>SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockWarrantsDetails</Role>
      <ShortName>SCHEDULE OF STOCK WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails</Role>
      <ShortName>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails</Role>
      <ShortName>SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails</Role>
      <ShortName>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SubsequentEvents</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife -  form10-k.htm 122</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>brtx-20221231.xsd</File>
    <File>brtx-20221231_cal.xml</File>
    <File>brtx-20221231_def.xml</File>
    <File>brtx-20221231_lab.xml</File>
    <File>brtx-20221231_pre.xml</File>
    <File>ex-32.htm</File>
    <File>ex10-28.htm</File>
    <File>ex10-29.htm</File>
    <File>ex10-30.htm</File>
    <File>ex10-31.htm</File>
    <File>ex10-32.htm</File>
    <File>ex10-33.htm</File>
    <File>ex10-34.htm</File>
    <File>ex10-4.htm</File>
    <File>ex10-7.htm</File>
    <File>ex23-1.htm</File>
    <File>ex23-2.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="668">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 668,
    "http://xbrl.sec.gov/dei/2022": 40
   },
   "contextCount": 168,
   "dts": {
    "calculationLink": {
     "local": [
      "brtx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brtx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "brtx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 495,
   "entityCount": 1,
   "hidden": {
    "http://biorestorative.com/20221231": 21,
    "http://fasb.org/us-gaap/2022": 116,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 140
   },
   "keyCustom": 36,
   "keyStandard": 285,
   "memberCustom": 38,
   "memberStandard": 25,
   "nsprefix": "BRTX",
   "nsuri": "http://biorestorative.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biorestorative.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://biorestorative.com/role/IntangibleAssets",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - NOTES PAYABLE",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://biorestorative.com/role/NotesPayable",
     "shortName": "NOTES PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://biorestorative.com/role/StockholdersEquityDeficit",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://biorestorative.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://biorestorative.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://biorestorative.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://biorestorative.com/role/PropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://biorestorative.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://biorestorative.com/role/IntangibleAssetsTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NOTES PAYABLE (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://biorestorative.com/role/NotesPayableTables",
     "shortName": "NOTES PAYABLE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://biorestorative.com/role/StockholdersEquityDeficitTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://biorestorative.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://biorestorative.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative",
     "shortName": "ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "BRTX:NetCashProvidedByUsedInOperatingActivitie",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
     "shortName": "SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://biorestorative.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_PatentsAndTrademarkMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails",
     "shortName": "SCHEDULE OF NOTES PAYABLE ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember27581359",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
     "shortName": "SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember27581359",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://biorestorative.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
     "shortName": "SCHEDULE OF STOCK WARRANTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
     "shortName": "SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
     "shortName": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember27582265",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
     "shortName": "SCHEDULE OF STOCK OPTION EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember27582265",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
     "shortName": "SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-10",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails",
     "shortName": "SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails",
     "shortName": "SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - INCOME TAXES (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://biorestorative.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails",
     "shortName": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails",
     "shortName": "SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - LEASES (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://biorestorative.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://biorestorative.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2023-02-162023-02-17_us-gaap_SubsequentEventMember_us-gaap_StockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://biorestorative.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations",
     "shortName": "ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://biorestorative.com/role/PropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "BRTX_AccruedDipExpensesExchangedForConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued dip expenses exchanged for convertible notes.",
        "label": "Accrued DIP expenses exchanged for convertible notes"
       }
      }
     },
     "localname": "AccruedDipExpensesExchangedForConvertibleNotes",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_AccruedGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued general and administrative expenses.",
        "label": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_AccumulatedAmortizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Amortization [Member]",
        "label": "Accumulated Amortization [Member]"
       }
      }
     },
     "localname": "AccumulatedAmortizationMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_AuctusFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auctus Fund LLC [Member]",
        "label": "Auctus Fund LLC [Member]"
       }
      }
     },
     "localname": "AuctusFundLLCMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_BeneficialOwnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Ownership [Member]",
        "label": "Beneficial Ownership [Member]"
       }
      }
     },
     "localname": "BeneficialOwnershipMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount.",
        "label": "Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount"
       }
      }
     },
     "localname": "BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_BoardAndScientificAdvisoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board And Scientific Advisory [Member]"
       }
      }
     },
     "localname": "BoardAndScientificAdvisoryMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_CashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants.",
        "label": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "CashlessExerciseOfWarrants",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "BRTX_ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief Executive Officer and Chairman of the Board and its Vice President [Member]",
        "label": "Chief Executive Officer and Chairman of the Board and its Vice President [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerAndChairmanOfTheBoardAndVicePresidentMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ComputerSoftwareAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Software and Equipment [Member]",
        "label": "Computer Software and Equipment [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareAndEquipmentMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ConsiderationTransferredForLicenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration transferred for licenses.",
        "label": "Consideration transferred for license exclusivity"
       }
      }
     },
     "localname": "ConsiderationTransferredForLicenses",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Converitble debt and accrued interest exchanged for common and preferred shares and warrants in public offering.",
        "label": "Convertible debt and accrued interest exchanged for common and preferred shares and warrants in public offering"
       }
      }
     },
     "localname": "ConveritbleDebtAndAccruedInterestExchangedForCommonAndPreferredSharesAndWarrantsInPublicOffering",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_DescriptionOfStockOptionsHeldByOfficerAndDirector": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock options held by officer and director",
        "label": "Description of stock options held by officer and director"
       }
      }
     },
     "localname": "DescriptionOfStockOptionsHeldByOfficerAndDirector",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "BRTX_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "Schedule Of Future Minimum Payments Under Non-cancelable Leases For Operating Leases",
        "verboseLabel": "Schedule Of Net Lease Cost And Other Supplemental Lease Information"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://biorestorative.com/20221231",
     "xbrltype": "stringItemType"
    },
    "BRTX_DrNickolayKukekovMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr Nickolay Kukekov [Member]",
        "label": "Dr Nickolay Kukekov [Member]"
       }
      }
     },
     "localname": "DrNickolayKukekovMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation tax return to provision adjustment.",
        "label": "Tax return to provision adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "BRTX_ExercisePriceEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight [Member]",
        "label": "Exercise Price Eight [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eleven [Member]",
        "label": "Exercise Price Eleven [Member]"
       }
      }
     },
     "localname": "ExercisePriceElevenMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member]",
        "label": "Exercise Price Five [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member]",
        "label": "Exercise Price Four [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nine [Member]",
        "label": "Exercise Price Nine [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One [Member]",
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member]",
        "label": "Exercise Price Seven [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six [Member]",
        "label": "Exercise Price Six [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Ten [Member]",
        "label": "Exercise Price Ten [Member]"
       }
      }
     },
     "localname": "ExercisePriceTenMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member]",
        "label": "Exercise Price Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twelve [Member]",
        "label": "Exercise Price Twelve [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwelveMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise PriceTwo [Member]",
        "label": "Exercise Price Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expire from 2030 to 2038 [Member]",
        "label": "Expire from 2030 to 2038 [Member]"
       }
      }
     },
     "localname": "ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_GainOnPppLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on PPP loan forgiveness.",
        "label": "GainOnPppLoanForgiveness",
        "negatedLabel": "Gain on PPP loan forgiveness"
       }
      }
     },
     "localname": "GainOnPppLoanForgiveness",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Income.",
        "label": "GrantIncome",
        "negatedLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_LeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Agreement [Member]",
        "label": "Lease Agreement [Member]"
       }
      }
     },
     "localname": "LeaseAgreementMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_LicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License [Member]",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicensesMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment [Member]",
        "label": "Manufacturing Equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_MelvilleLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melville Lease [Member]",
        "label": "Melville Lease [Member]"
       }
      }
     },
     "localname": "MelvilleLeaseMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_MrAlstodtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr. Alstodt [Member]",
        "label": "Mr. Alstodt [Member]"
       }
      }
     },
     "localname": "MrAlstodtMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_MrSilvaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr Silva [Member]",
        "label": "Mr. Silva [Member]"
       }
      }
     },
     "localname": "MrSilvaMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_NetCashProvidedByUsedInOperatingActivitie": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NetCashProvidedByUsedInOperatingActivitie",
        "negatedLabel": "Cash flows from operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitie",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_NoncashAccruedExpenseExchangedForConveritbleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash accrued expense exchanged for converitble notes.",
        "label": "Accrued expense exchanged for converitble notes"
       }
      }
     },
     "localname": "NoncashAccruedExpenseExchangedForConveritbleNotes",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense.",
        "label": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_OfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers [Member]",
        "label": "Officers [Member]"
       }
      }
     },
     "localname": "OfficersMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_OperatingLeaseLiabilityReduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability reduction.",
        "label": "Operating lease - operating cash flows (liability reduction)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityReduction",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_PatentsAndTrademarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Trademark [Member]",
        "label": "Patents and Trademark [Member]"
       }
      }
     },
     "localname": "PatentsAndTrademarkMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Trademarks [Member]",
        "label": "Patents and Trademarks [Member]"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_PatrickFWilliamsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patrick F Williams [Member]",
        "label": "Patrick F Williams [Member]"
       }
      }
     },
     "localname": "PatrickFWilliamsMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_RecognizedStockbasedCompensationExpensePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized stock-based compensation expense percentage.",
        "label": "Recognized stock-based compensation expense percentage"
       }
      }
     },
     "localname": "RecognizedStockbasedCompensationExpensePercentage",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]",
        "label": "SCHEDULE OF STOCK WARRANTS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BRTX_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based payment award warrants valuation assumptions [Table text block].",
        "label": "SCHEDULE OF WARRANTS GRANTED ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BRTX_ScientificAdvisoryBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific Advisory Board [Member]",
        "label": "Scientific Advisory Board [Member]"
       }
      }
     },
     "localname": "ScientificAdvisoryBoardMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_SectionThreeHundredAndEightyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Section 382 [Member]",
        "label": "Section 382 [Member]"
       }
      }
     },
     "localname": "SectionThreeHundredAndEightyTwoMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_SequencingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sequencing policy [Policy Text Block]",
        "label": "Sequencing Policy"
       }
      }
     },
     "localname": "SequencingPolicyPolicyTextBlock",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "BRTX_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.",
        "label": "Weighted average exercise price, exercisable",
        "periodEndLabel": "Weighted average exercise price, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were exercised.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price, expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options forfeitures in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price Exchanged or Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining percentage of options vested.",
        "label": "Remaining percentage of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardRemainingOptionVestedPercentage",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.",
        "label": "Weighted Average Remaining Life in Years Outstanding Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.",
        "label": "Number of Options Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "BRTX_SharesIssuedForServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued for Services [Member]",
        "label": "Shares Issued for Services [Member]"
       }
      }
     },
     "localname": "SharesIssuedForServicesMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_SharesIssuedInCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in cashless exercise of warrants.",
        "label": "Shares issued in cashless exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedInCashlessExerciseOfWarrants",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_SharesIssuedInCashlessExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in cashless exercise of warrants shares.",
        "label": "Shares issued in cashless exercise of warrants, shares"
       }
      }
     },
     "localname": "SharesIssuedInCashlessExerciseOfWarrantsShares",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in connection with public offering in exchange for notes payable accrued interest and outstanding warrants.",
        "label": "Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrants",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares.",
        "label": "Shares issued in connection with the public offering in exchange for notes payable, accrued interest and outstanding warrants, shares"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithPublicOfferingInExchangeForNotesPayableAccruedInterestAndOutstandingWarrantsShares",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "BRTX_SharesIssuedInLitigationSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued In litigation settlement.",
        "label": "Shares issued in litigation settlement"
       }
      }
     },
     "localname": "SharesIssuedInLitigationSettlement",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_SharesIssuedInLitigationSettlementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in litigation settlement shares.",
        "label": "Shares issued in litigation settlement, shares"
       }
      }
     },
     "localname": "SharesIssuedInLitigationSettlementShares",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "BRTX_SharesIssuedInSettlementOfLitigation": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in settlement of litigation.",
        "label": "Shares issued in settlement of litigation"
       }
      }
     },
     "localname": "SharesIssuedInSettlementOfLitigation",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_TwoEmploymentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Employment Agreements [Member]",
        "label": "Two Employment Agreements [Member]"
       }
      }
     },
     "localname": "TwoEmploymentAgreementsMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_TwoThousandTwentyOneStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Stock Incentive Plan [Member]",
        "label": "2021 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneStockIncentivePlanMember",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_WarrantsIssuedAsConsiderationForIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued as consideration for intangible assets.",
        "label": "Warrants issued as consideration for intangible assets"
       }
      }
     },
     "localname": "WarrantsIssuedAsConsiderationForIntangibleAssets",
     "nsuri": "http://biorestorative.com/20221231",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r479",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r479",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r479",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r479",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r479",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r313",
      "r414",
      "r425",
      "r444",
      "r445",
      "r457",
      "r462",
      "r467",
      "r511",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r313",
      "r414",
      "r425",
      "r444",
      "r445",
      "r457",
      "r462",
      "r467",
      "r511",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r306",
      "r313",
      "r342",
      "r343",
      "r344",
      "r413",
      "r414",
      "r425",
      "r444",
      "r445",
      "r457",
      "r462",
      "r467",
      "r508",
      "r511",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r306",
      "r313",
      "r342",
      "r343",
      "r344",
      "r413",
      "r414",
      "r425",
      "r444",
      "r445",
      "r457",
      "r462",
      "r467",
      "r508",
      "r511",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r196",
      "r314",
      "r489",
      "r504"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r458",
      "r466",
      "r514"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r431",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r458",
      "r466",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r196",
      "r314",
      "r489",
      "r490",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r506",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r501",
      "r502",
      "r503",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r76",
      "r83",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Fair market value of beneficial conversion feature and warrants issued with convertible notes payable instruments"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r68",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Warrants issued in connection with license exclusivity agreement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r167",
      "r235",
      "r240",
      "r241",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r25",
      "r34",
      "r134",
      "r273"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r34",
      "r53",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization expense",
        "negatedLabel": "Finite Lived Intangible Assets, Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r135",
      "r145",
      "r163",
      "r180",
      "r218",
      "r221",
      "r225",
      "r238",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r378",
      "r380",
      "r387",
      "r465",
      "r509",
      "r510",
      "r560"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r157",
      "r168",
      "r180",
      "r238",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r378",
      "r380",
      "r387",
      "r465",
      "r509",
      "r510",
      "r560"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r159",
      "r447"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r30",
      "r36",
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents\u00a0\u00a0- end of year",
        "periodStartLabel": "Cash and cash equivalents - beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r133"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC insured limit"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r180",
      "r198",
      "r199",
      "r201",
      "r203",
      "r207",
      "r208",
      "r238",
      "r254",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r277",
      "r278",
      "r281",
      "r285",
      "r292",
      "r387",
      "r446",
      "r488",
      "r497",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants outstanding, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants exercisable, exercisable number of warrants",
        "verboseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding, number of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r501",
      "r502",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,677,775 and 3,520,391 issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r142",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Issuance of Series B Preferred Stock in exchange for Series A Preferred Stock, Shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r277",
      "r278",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r547",
      "r549"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r547",
      "r549"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r38",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt conversion, converted instrument, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r178",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "NOTES PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "negatedLabel": "Forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r2",
      "r3",
      "r136",
      "r143",
      "r360"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r120",
      "r546"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred tax asset, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r120",
      "r546"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards",
        "verboseLabel": "Deferred tax assets, operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Operating loss carry-forwards not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Operating loss carry-forwards subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r119",
      "r120",
      "r546"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research &amp; development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r120",
      "r546"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r120",
      "r546"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r120",
      "r546"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r34",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r34",
      "r216"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesReportingOfDerivativeActivity": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.",
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesReportingOfDerivativeActivity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r93",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r175",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r205",
      "r384",
      "r385",
      "r421",
      "r423",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net Loss Per Share - Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r181",
      "r356",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory blended income tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r544",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r544",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r544",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State statutory income tax rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r139",
      "r149"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining amortization period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r155",
      "r172",
      "r173",
      "r174",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195",
      "r206",
      "r239",
      "r294",
      "r348",
      "r349",
      "r350",
      "r368",
      "r369",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r406",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r34",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "SCHEDULE OF FAIR VALUE RECURRING BASIS"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r270",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r386",
      "r410",
      "r411",
      "r412",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r270",
      "r307",
      "r312",
      "r386",
      "r410",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r270",
      "r307",
      "r312",
      "r386",
      "r411",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r270",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r386",
      "r412",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r270",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r410",
      "r411",
      "r412",
      "r455",
      "r456",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r162",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedPeriodEndLabel": "Finite Lived Intangible Assets, Accumulated amortization, ending balance",
        "negatedPeriodStartLabel": "Finite Lived Intangible Assets, Accumulated amortization, beginning balance",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r57",
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "periodEndLabel": "Finite Lived Intangible Assets, gross, beginning balance",
        "periodStartLabel": "Finite Lived Intangible Assets, beginning balance"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r57",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite Lived Intangible Assets, Net, ending balance",
        "periodStartLabel": "Finite Lived Intangible Assets, Net, beginning balance"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Assets, weighted average amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r34",
      "r69",
      "r70"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of notes payable, net",
        "negatedTerseLabel": "Loss on extinguishment of note payables, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r34",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r357",
      "r358",
      "r365",
      "r370",
      "r373",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income tax examination, description"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r194",
      "r195",
      "r217",
      "r355",
      "r371",
      "r374",
      "r424"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r171",
      "r353",
      "r354",
      "r358",
      "r359",
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r496",
      "r556"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid assets and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r56",
      "r415",
      "r416",
      "r417",
      "r419",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r52",
      "r55"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedLabel": "Interest (income) expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r402",
      "r464"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease remaining term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseDescription": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessor's operating lease.",
        "label": "Lease description"
       }
      }
     },
     "localname": "LessorOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r180",
      "r238",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r379",
      "r380",
      "r381",
      "r387",
      "r453",
      "r509",
      "r560",
      "r561"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r138",
      "r147",
      "r465",
      "r499",
      "r507",
      "r554"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r158",
      "r180",
      "r238",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r379",
      "r380",
      "r381",
      "r387",
      "r465",
      "r509",
      "r560",
      "r561"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member] [Default Label]",
        "verboseLabel": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r1",
      "r137",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans Payable",
        "periodEndLabel": "Loans payable outstanding ending",
        "periodStartLabel": "Loans payable outstanding beginning"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "PPP loan payable, current portion"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "PPP loan payable, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Investments held in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Unrealized gain on marketable securities",
        "negatedLabel": "Unrealized gain on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r35",
      "r140",
      "r150",
      "r156",
      "r169",
      "r170",
      "r174",
      "r180",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r200",
      "r218",
      "r220",
      "r224",
      "r226",
      "r238",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r385",
      "r387",
      "r454",
      "r509"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (income) expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r18",
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r218",
      "r220",
      "r224",
      "r226",
      "r454"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r399",
      "r464"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost (cost resulting from lease payments)"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of net future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, current portion",
        "verboseLabel": "Current liabilities - operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, net of current portion",
        "verboseLabel": "Non-current liabilities - operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r397",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating lease - operating cash flows (fixed payments)"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset",
        "verboseLabel": "Non-current leases - right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r401",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Federal net operating loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "ORGANIZATION, LIQUIDITY AND BUSINESS OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payment to acquire intangible assets",
        "negatedLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred stock voting percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r4",
      "r77",
      "r78",
      "r497",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred stock, liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r4",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Preferred stock voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from sale of units in public offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Issuances"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNotesPayableActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from PPP Loan"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r63",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r148",
      "r422",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property plant and equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r115",
      "r151",
      "r568"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r83",
      "r146",
      "r429",
      "r430",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r155",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195",
      "r239",
      "r348",
      "r349",
      "r350",
      "r368",
      "r369",
      "r383",
      "r426",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r219",
      "r222",
      "r223",
      "r227",
      "r228",
      "r230",
      "r303",
      "r304",
      "r418"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "SCHEDULE OF STOCK OPTION EXPENSE"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "SCHEDULE OF INCOME TAX PROVISION (BENEFIT)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "SCHEDULE OF NOTES PAYABLE ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r54",
      "r56",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r96",
      "r105",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r164",
      "r165",
      "r166",
      "r207",
      "r277",
      "r278",
      "r279",
      "r281",
      "r285",
      "r290",
      "r292",
      "r457",
      "r488",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r84",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "SCHEDULE OF WARRANT ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r492",
      "r493",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r492",
      "r493",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compenation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Description of share based payment award vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r92",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based compensation arrangement by share-based payment award, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of shares forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average estimated fair value of warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares outstanding ending",
        "periodStartLabel": "Number of shares outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Fair value of restricted stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of warrants outstanding, exercised",
        "negatedLabel": "Number of Options Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "negatedLabel": "Number of warrants outstanding, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Number of Options Exchanged or Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Options Outstanding Ending",
        "periodStartLabel": "Number of Options Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Stock-based compensation award",
        "verboseLabel": "Number of shares of common stock authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of Options Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Options Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "options, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Shares options, granted",
        "verboseLabel": "Number of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate Intrinsic Value Outstanding Ending",
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options Outstanding Ending",
        "periodStartLabel": "Number of Options Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Aggregate purchase of common stock, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Number of option issued to purchase shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted Average Exercise Price Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r320",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Number of Options Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Vested and exercisable percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value Exercisable Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life in Years Exercisable Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Life in Years Outstanding Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Vested common stock, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r180",
      "r198",
      "r199",
      "r201",
      "r203",
      "r207",
      "r208",
      "r238",
      "r254",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r277",
      "r278",
      "r281",
      "r285",
      "r292",
      "r387",
      "r446",
      "r488",
      "r497",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r76",
      "r155",
      "r172",
      "r173",
      "r174",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195",
      "r206",
      "r239",
      "r294",
      "r348",
      "r349",
      "r350",
      "r368",
      "r369",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r406",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative",
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r206",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative",
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r91",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "- options"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Estimated fair value of granted"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Shares issued in exchange for notes payable and accrued interest"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r16",
      "r76",
      "r77",
      "r83",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Shares issued in exchange for notes payable and accrued interest, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r4",
      "r5",
      "r76",
      "r77",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Common stock issued in exchange for Series B Preferred Stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares and warrants issued for cash related to public offering, net, shares",
        "verboseLabel": "Stock issued new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Shares issued in exchange of notes payable and accrued interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r17",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Common stock issued in exchange for Series B\u00a0\u00a0Preferred Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Aggregate common stock services rendered"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares and warrants issued for cash related to public offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "- restricted share units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r83",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "- common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r49",
      "r465",
      "r499",
      "r507",
      "r554"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r179",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r294",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r394",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r394",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r394",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r394",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed.",
        "label": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedText",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r233",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r209",
      "r210",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
      "http://biorestorative.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants exercisable, weighted average remaining life in years"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r197",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Common Shares Outstanding - Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r469": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r471": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r472": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r473": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r474": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r475": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r477": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r478": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r479": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001493152-23-008960-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-008960-xbrl.zip
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MS0;#R(<'?WA/A\@-<2RD@1 "_0$FR>N!DG1Z#CB7EH#-VU;PD[8%+;/63+3
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M@PH6X"*C<1IA9SGS[#O/]Q(&RKD;.B6*>9@@\.\O]AUNBRYH6]G3^JF#/>N
MWE2'-'>#+/NYF]F6HJ>49(8@=^H4HE[JM![O+D:_IV"DVB,.%-V^K;W\\%[X
MM-ZX3Z_,)H&%N^2)T-3;ZCO"L$G>7;//:,,F([V6D,C#)OB!S?45A=B$)M<8
M)"(Q=CBVZCU%)U:S)50X?:1B$ZBMK)CQQ@0EMN?'<SO*VSC=^(/4\DEMUWE
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M6NXC^[1<M>6_V-LP_EG)'Z"\*1XQ[(QC\Q+Z&K(?V)'AEI2\*5$> HN0W3H
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M(NM<E(FW#)],*HU8=^%7E'5DLV3?$50(9.>D]:31<FDOD' :56[Q]B51P6J
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MT4%MI6.S1C)L#9HS($P9]C,&)):8X%G-%W <XW*4TR^UNC).%U<R>)WE5%O
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M\YLH^P,+],[8*:T0UNJT6%27B\J"V1%N530E?_&$$2N=_4(O/M)OH/HC#H(
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MTC$);C-,28A)0[!+@#@)<;;<;*2SO4[8%2G,@"MRJ"5!D,0(KT\6HO!NW=)
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M"SW5]"I.9TT+\)W)4R,/AFT6( 6?JU1!6:WCG5BW&=X%43A_W>$DQV2(9G%
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MU(T.G%;#$]]L7#>-.$1^63IM75[!\]@$B[3NFE+:*Z_4CII"%"Z?M"Z:E$M
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M1I!":&C]7B)-[D7S5# M2*\GWN"" KO-TN<HQ.'YVY><1L'6#WO,B.__S"Y
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M5^W BE#X;"-+]=YU)C?%W#N6;)("N7J13MMMTP<[?L?ZB._.<W@%F3K2^"^
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M8U+".TK/$ 6L#$_+@<]!]@LNZ,#?;"=^23(<Q-&O./P41(DJQM5.T['3KVO
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M-8G_C";:7+"?)+^?_PE74@D^9MW!,$!UV2-5\J3S[T ,7\\D/,[PX8GA3V1
M,-26)(W^D89?Z9= =>OQ537E3"SYS-<V$ZM--,_$DSW"X'\N/NR1%G\P0'7:
M(U7RI'/QJ3W2XMGPH7.QU9  >&+Q=*H)*.?I\8T\@72[_T+G;E\W]0Y+MVMQ
M\@8IL\B8F^&3/5;E%<E)9#68YK$JCS! 'OMYJ0)'6<1.8V;SF6OZ*WC+RMK&
MKS#)]) 3@SKH]*A1F9+O@%ICCZVF:0^H>A_Y^EQ(E8D^\C]#ZGL> C)!I8GV
M5*5'ZKU@=KY<]^FCG$+![/<'^,>'YY3VBN24%H4'YI3V" .6 ^[%]M&K08!C
MQG*SR7%1$"BSG/PAUV7I4<BZ['=:N.V>(14$PUT=NCZ[&EG$A<%DE>E;<6U(
M#*.1]\DA ;:.1]?@,JR8$%KPZ1I0XI/17I_X &3QA+/54U ](G"3)L\X)^/T
M<384AG__)!8P8ZMUDB7,T(]_5;?*1AJOWK+(Z6<Z&3G0P^E?)#-64_=J@/-6
MZG_^Z^CU\DIUT^F[WP8S$3LVV-C/'T_]QHJQ7NKH(V^=6X+@Z^C?RJIUT\6%
MS_\+]'*5S<:.OCF=N-S1E?,#<W2\]?/^Y[^.3BZO5#<]O/OMKR;,?IS=QB[.
M_?Q3BQTYK;7CUQ09.=KX0:M'#&,/>Q:S<G$HKRZ:9#_)59O:MLHN1_QA!K5[
MBYTF&&=J$%PAVS/-%_V.'>^@=4L+8:[FG9?S[2Y.WS"^Q]ESM,9R&^N.R/IM
MODJ+(&[_?I'FQ4U:_(2+.[Q.'Q.:+KLIB2OU.[>BMCWB<=E[O%=[NT-Z P.F
MC_NN@?ZP\27)ZB*^_J&"NYED:5G^$Y5316VX!O%5# K:"G8R$D@1?/W=7V>V
M,D)#S/H<;-.LB'[EG@-WRD__X<,Z$S#SV9MW-J9>9JB_<Q(;)*9JFF0=JOH(
MF!YZ+,NL_?6 %N:_LS7/2U&@YV\LQ[;EJV6BAJ<GQU30%>^%]<7AD-*(4:!7
MJ4'W*I@.>GA#3 M,P%29M9VANS8$2RED/>3?E\.59-7O"H*AD@Y=GT2<+S6#
M0$5&W9)B<):1A0^WY)_[*&0#*/\!)\HK&5::+IDUP)0VSRS4P+#.'FN?@[4F
MRJGJ&8H;9;2KM8'Q\8>4AA1J'Q_1*?ACGPRXFG1M::!<DT T4 P],Q64,1U@
MQ&H_HTO6?&OB?9(5G%5-J%3]D4UOC)IV<CV@!-2"M:3BKM;S3D=^EO89D^5-
MN&#[%'0%M'Q)<)8_13LC)P?H.]T1&VI69S/+5AD,18<B%L+F*TE(U+S$#\4%
MW3O+<K9+1O_$H@NJ<U^^-%_D^1Z'JFW?H86X).DX ]M,'58"&+J.@MWG+"T$
MK>M2SLH_TXW0J"[HK#K9CUA9WCG=6%VNV;BE=14H7[DUZSE=/-N:T5E(FY3
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MQ:GL6 S>H[@ MR71ND2YW+ QH(SA_@N.P_,WXAZ3]5M&G:TH([YS*@Z=@TN
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M39R>MJ];.D0GR_"J)D-O)!^$X.OC^1CSQP_HZ9[X[4]$K*)YR$9L-G;';S1
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M-@8+Y/JAG@/8N>0L[\1>D[HE4PJQGW96_M:Y0.*A!<!BX$CTPB9(/8WQX]V
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MLW?<G8QB@ZU+,WLD=.B3^.$2YGML+IFN=SADEZQ7Q"-KI\8-0HU&L2U?Q^A
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M.&&+Q[6H'G;(SE$C7 X(^E!GF6.?+6]%AG[0]^.[:!V[F54_G),5H?T7WEA
MZV-[@=3F40T@=#ZY<MZ&A/9\[*P%9((J8P?TU&92 1IT&D>;1\L)6.>FZ['O
MW2<O+F8/M_I7+*CED<[X]G3-)U.A"6S_G]J4*L.$3NR-%7PA$9LR]NX,MUY
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M(I&A=T-LW4!L+$=%0?Y2./SIL/R%\3]02P,$%     @ \99X5BC5G-B8'@
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MM8J%3HM,2".RL7BO1GDI\VNQ\ZHG  OVQ.@:G^UV1JJX4BH5[W1VIDR1Y9)
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M4SL8]!^W4/J\>KI%W(.^CC!Q"D[8O\?QQ!OY F7UZ#22,QFU64X5R_NDHK)
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M\I*-R41C?A='>TT$0 9.^L $+VQ)I%I<:>4WF!B;L?6NOC^EKYNJNE38*#^
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M=[;!)09$K78>NQ1]ZI!G^V1NB[D\/;3O+$MT333):%;842L/\H4Q"X<KQ.S
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M1E@%S#LIL +:E&9&GQ$7,V[M@5@R5^/20RY/&:U $ E+$<#=/)/VF["%(T8
M.<V+J@\=?!8Y90R\W^ @@7AJPS/,5LVUH\]VA;+;"8MOVD9!.E#KUPUNW3%S
MAQO'#( MH.\R%2?$--_9%,$*5VL5;&T'6.5*(EO#(!<^C5@ B#JAL'(^E0GG
M^2*&8A.$6H/ ,7<9\!E,D4RBTO8:IN@P:2.4@8W\.+<*SI5*QC)76/)G,[1Q
M#J-A4V1NN:#RMLD&P>X6P3CII20/*^"$:75_6=W#7RM.*>/5.SU68 $E&IW
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MQ=[/YT='O\(#N_OGL-!_G1P>G8OA+T?\<?_X]/P(WCK?PP'P^_.]L^.CBX&
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MAZ_+QLB67-_9Q#MD#[6Q)X>'<5@3X=Q.LDRHRK2<F&W;L.%V575C4J0SFS/
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M8'79 C#@:*6C4TO YG7A3*?]TC6(=24 BBYVP+0&!4"L5'1B'C<5G?>%U7$
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MZN2&:<+'("QV"+MHZBN-2V\HS&G]L765%8OWMDA"?UX'F,L4VBX705WWI/$
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M])C7OL;,A\7,;>[[,@*V@)&&5)P2TSRP^8PUKC;*XKK0H$[L1+:&P3)\&K$
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M#>'74=T'B.J^N;^H[@I4M'53U8N#TZ,_D">\^&7\Z_MW_P]02P,$%     @
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M"P )IQ3V+F8RX5("Q% 5-_KO]7L3;@7@\ZPBF425[?!+T6M21[#* Y':)@(
MSU;)1!8D?6P5"#5+T; ILK!L4'FC9(U@RT4PSLFI*!X".&$ZO=56]W"7DW-5
M2OW.@!580(E6ZSKK="3%5U]3& ,[.E !LWNXS*YM%PP2[H&\Q20[9\ 9;,6G
M*:#'EF\ L^!H+^H+Z,PQPN6N!+7G:-;5*O!$1H1_ROU@TS3&=Z#4XYW919;J
M"):ML7:)[N4AK=I=O2DX&TUL;.7Q9--=-U0K_^$8= =1F$M-%4+%#3M?_;Z
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M3&!-6S:P.MC?F-:OE)^"N((J2Y[&3U [^LV=PU,[/MZ8@M*3(%"QQWC\QJ?
M! ODINC (*\U>S73NTA[FI2ODWEJI%$*L-EE3LS)\ J@>/9U2\&(02%:@QDP
MNA?@,]VKC..E$AI^8\QFW\]:XQ.K%A(W\/E+^[NFX:>G8:$M:==I]!< 5LD
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MBY#4%C9-]'QWZWK>.89B3=\/\Z/9BYAN>+*YYXG72ZO>!R,M8UH8=664-#_
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MBFBF  N&>]W,H/7>MH>_'G\B?KN[B=^N-WZ[NXG?;@38K;8L2"WKI+II>ZE
M*S' ZK9P!R*N !RI-,X*-+(P<EL"CC?3!8?7P*)I\5[J0OPBBX^J%+_)I'))
M=C;\!2-X8AJU."T5BQY %\2@!-UL^HPB*E.;8K=@G;,U[L(3 RNO,=N?YB5!
MPYK2>N&O;5%2&U)JW 44[X;&\92:7$7P=>3&(B1()07+)RS<?(.1&U/N][YD
MSJS\(P6$8#1H8=J-18SU%+:&!(#K)]*Y5J6=O_==< ^2YK5^,>+&%.PCGLK
MY<C^$%PR_M?P$SPVO52AX_%!.1L>R_F/R)=59-4EGDV[80AG$C2>/2+-B^RR
MD'.[513[FR3:S%3LCO6DR#Z"NMKLX;=QJDS0IQ)7[!;62TYU6/Q$@HO," J<
M^IV&J\F"#0K\.F580ZS(R\N" B$+(FN)B;/ADV_ )XKY!/5ZE,TG05":*FD
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M<&2A>)#7N^SE9AV1]6!XS:X[MYMM8[/>3H3\+MYE>[;7O=?=&Y0SD%U!,TA
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M$1^PZ>,F=+/6T,WK=81N'D(F:LN__/S=Z?&_\/0\_WG\RX>W_P]02P,$%
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MIL(B4A5[* 5"% &I!\E<@2ED4/Z1.YN/44XB8A;YO8J W%C6@BC.9]$#?&^
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M\+[_T@OW%O[2G'T9?.BX=T[[XQ=P5"VG-@%>]7%WHH!UP>PI88(]2=@8.D8
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MP[;"A!&&D\1"W-H.CMS8<(8),[)J(:4WV*D4H!G/<28-?#]%[W'%HC%71><
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MY4G#T^1^\*IN6WE8C:W(V]N,HE@++&N)?=KAR3? $\5X@G(]2.83+Z. RMM
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M-!9NGM,Y8.+I%B&<YM8:-FS(24&!#338@ML# @6V/Y%1JE(Z#(F.M#@=X;B
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M.JAG>5!S.M8BO-_J6OO,#[.@WZQD[Z?UIV>Y#?0_F0*9R#L@7?I1,-V.?Q=
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M*'_FW1;C/74CME\TGWR)I:0?QBH>JZ3+LZPHF)43-'!23<%U*-7WA(V&_B;
MRVTOM'IXJ2G0NA>Z>M@>/%8=I6==ERLO/OC#%0!__C_7@X[6@N%50#YC#'I\
M3CQ'6WMA/.X,;)QA3UC+;;?./ QZ[JX'0OS02OL)>3,MP&SJI%;:^6O5U9VF
M-(W[)&:].V3G(_(-O&>G7"=5GM8#\K1>5H;2FZ/SDZ]( 6\^=[^<?OQ_4$L#
M!!0    ( /&6>%8Z7Z.J'64  .FN @ *    97@Q,"TW+FAT;>V]:W/;1K8N
M_)U5_ ]XI\Z>$JM@Q?(E-^>D2K:5B<Y);&])F3G[(T@V)4Q @,%%,O/KWW7K
M[M6X4'+&,2T%NW9-+)( &GU9UV<]Z[L?+W[^Z?OIY+L?3XY?PW\C_+_O+DXO
M?CKY_KLO^+_P[1?R]7<OW[[^G^C\XG]^.OG??UL5>?UM=/1X4T<7Z=I4T1MS
M$YT5ZR2/^8,X.C=ENOH;7 B7OOO0ZUY$ZZ2\3/-O(_CIBZ@V[^M'299>P@=E
M>GE5_^W[[WYX^^9"W_;1*EFGV?;;VVY,OZW2WPV/ ^[T\ON_Y_-J\^*[+U["
MB^-]X3_O[L?(3]Y?I?.TGDZ.'A]^=1]?X/Y._7$UG1RO3;XTR_LX_#?%M5G/
M33F=/(VC)X^?//FS7V)A\MJ4]W+[_"E#?WGZ]NSD_.+MV?'%Z3]/II.+'T_.
MCM^=GIS'T>F;5X?W\IU@'QU-)_!2K_XOOL3)&WRUZ-U/QV_^[-?Y=U/5Z6K[
M,=_'[JV=@YX7V?(/CKPND[Q:%>7ZVZC9;$RY2"K3MT;R60J2!I_X.,T_YEL>
MGUV<OOH)]M_1=R_/2,_C_[[[Y>S=V_.3A[AB'V/0[24Y?/YQ%^7BRDPGFZ;<
M%)6)BE547YGH95J<F:HNRJ1.KTT$/RF338IW.<T7ARC"CZ+SNEC\BG_#L/!'
M[[(DCP[PZK]GR]^:XL5WOWR/GWWWQ2_?_[VD3V916D5U$6W*8EW4AAY5-8N%
MJ:HHR9?3B<FO$K@A?7&=9 T-:/=@XBB)7ILLN4E*$RT*> W\7=$9RJMBO4GR
MK1Y-C ^-TKJ*SIMYE2[3I(3;3B<'214MS2K-S3*:FZRXF47S;92E^:]I?DEC
M@\5(K]-EDV3P3S@V,+P*AWJRWF3%UN#87A5YU61UDM?T;M&:-&#E9KA(RB7.
M17VEYET&^?>RP@'"4"J<Y"LX]W@IW@8& K,'S\:AP-Q=J;%4T4U:7\'/X#.[
M*G#FHZ*I*Q@(70)G'\4 SW(179H<9K/&98!O4OAQ:>JFS"L>VBTC.L3%X(6'
MA5TU)5Q1THR@I2(K#6.#863F/1B/65IO6W?N70.X!_XF+:/$7P1;)KV&L<*R
MU2#/%G4\G>#%,.*$?Q]5IKQ.83OQ?.+$ZMEI-K M;NCC?S?+2["GZMBM'V^&
M:F,6*:RJ6<$LU7J#KIH,ME>^;!;UX&H5&R.;#Z8C@W-MLBWLI(VALWOX$"7<
MP]%)3[1.>GWRP^F;TXO3MV_.H^,WKZ-7\(^+LU]>X2</<1GO@Z+Z%P@7<XU>
M!!Z^59&!9":!;,HU"$<0_TT%4D=$ 4DE^,<VJJZ2+(NNDFO6*VN3Y'!9Q6=]
ME5HA'T=-GJ$FPA_!2<>7B1:924HXQ"A&%B![0+*@C+M)*W,(9C2*![A7 V<=
M15U>-+D\#B1PUBSYB9NL*4&FW.#X@[M7A;_Q@Y0.]V%;/3D$-\+;"<?+=9JG
M%0@GL#B4M2#KBKN'UA#U*^JEJZ2V>H&W#JO4+$K\C5 CB,Z@;0GVA2A&VJ['
M99W"1L/ 2H1[I%@=1O]"35Z:%?PIJAJO7C9U:IP-$0P5=B^H9/^,FZL4C /:
M]7-C<E!#F;F$C49JN<C!Y"A!H\*&!,E;@:T2@0E8-6"NP/$J8+(6-.JCQX=?
MRIABO(+OZ@V8*WB5I*J:M5G&]#$>1FMU!>,+IY'>#$=")@P/X:":J2,XG8!Z
M7:=U;6BHX2-!#A2_PJO0U?)F-,GM'^)PTIQ?&[Z@H6[L>O#5-*7CZ=O;Z7L2
MG+[-)@-Y.,]@=R\6($YKE/#G:+W"DE8#Y_$??.1 3L-%9H.KK:Y^5X(P3C>9
M,RNC7_(4?P.WK=F-@&V2TPY*LNGD!]@P.5F!9P:\B7 $N,5HWY >B!+_F(U_
M#/[&70"[<)V F0MOUK9]K>48K=PC*QP36J9@3O*)#@8;K<R2I$ME%DV9DC1
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MX!I<QCCV3P)?[X-G^L#Z/06%(OX\[=&<R/M(E"%1P48Q&$7)'#ZZ0K8J^DE
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M>$H'T"=%@Y1T <!XC>Q@&R8=(&!OBKP,C&N>HP_*/P-_DWP3^[,0-*#8#6S
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M\>VK__L0E^X^B,BO)!/FTO]G0HYN.7)&O.#^\8)W8HAM+]P0%ZR&*H1=5?I
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M)RGVGG=E\6Q^S=+*UQPZ (=(I_9O!G/:TTDKC:WJ>W&GN<UIR@KSO&&17G2
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MN( @8FK/E$(C3*P@3TAE8FYHI@LG#.R57B;'%A L+S+"ZI(>,!<*"4$07&C
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M4>$5]:FD>J!UVXI=J'B,\JBRV;:[YV([;7?=WP!02P,$%     @ \99X5L]
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M'@US']U3CX;F42']W7KM8!P<ZHGXA<=1S]809E@A_^/CS:?D\3#_^>31MV'
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M)Y/T2](R5]*RX.@SL8OO%>+/8M&A.=?I+<G(HD@H<W7DE)1A\2C#@BO!3\9
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M_.3;)/(.X<]3.U5,Q-<3>#SR%$K2-UV(8HGZ)>J_BB#($N%+A%\5>>5G[O&
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M&.S6:P?OX!DSF/DI.P6.-F)\%7@S<@J]"?30L^< ^*Y'S$-T+V=O\=U+P)>
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MZVNX'Y;?LH)X'RPF+=GC-L9>.): (PNE97=8 ! 4;) KY>@%D*-WC_[] K+
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MBHGJD^>M%B?SA$<I0_ MOBK0;.$!7B$)#'S7\H&EI= MD0LHG2)&JMWJ;BK
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M$ Z7=B":ZJ6!J=;74G-I>,SH,%L6WB[K4]=DWX;)MJV?N8=SNWVJXRYY&NR
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M Q)O-89Q1JXOOW,0J%&V%:[R'S%$6-#57.=!.!C69KQZJDA O5K;QRU QTY
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MNE)Q?A2)/^ E-F'0*4Y?*B(+A,PC@O(3,FF2RS2II$+J+K9U"WS@0"90GY+
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M%L)BG@HO4YT:U4EE\P.L=*<ZZU:7O:E8GSZ=4/AQ^N>*J?=B Q5+0MM1!&^
MZ.2B#;JN@Y9Y=F"-)NMK#3/[</GS"E:&1-NQZ9O@M:DN3US>Q]JD@#J*1&V
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M>4T^08YU;,-8M1*+V-0 *PQ[Z;,(G<) +Q;*H_V#HZ+ G/&64I4K!=X#.;:
M$&.+:INT2K^I"SPJYW8[\"5J?(^""F"EDA2'%<B\0E= V35/"@$JX%["N)Z3
M7CL(25*RBMDT91/T2-,L6ZGHYG7-/;2JAJ4DB6WI(&Q5!TU7X/+:.@I<><Y5
MD84X3-^40@4^OZV@P)XB3360*OF0RDAN!4PI=K1+>*NHU86*4$QEU>O(F3<*
M2M/[&YD<A7T%L-E8L$S-'3!'H.&F!RJ#)5"7E H2U?(1;6 ^1?([>NFH=*:V
MAMJ@Q*=#E=JIR:<ASW3"ZG@3!WD?C2U81H!22J4QHRFC#YIXB)1K0%2QD9R4
M[.TTMI/A?$%(U(*2GP4%:PX4O$26%P9KJ9D3QEO82OBB^!)/E3]70=^C0FP5
M%U.:A<KO(NV"-#?1'>!%0G=X\K" 2NRNH,@=8DVZ3Y&E"WW++A%).XDF&F)Z
M9"6-B['U&+".  VD.@X$390<=#YD6T#''W1U?='M1IX/*J0)!-+%SD=06NVF
M7%)]8@4UHUC]G9]N5*I!<U&#%I2+O+RRMD2<)D6T-9! NC'/E'QU$CMMRE!7
M,$TW83S]Y<+:)$F_P['&2ESUX UI!4;)H$A+$M*-=2MCTBK%H"4&JY29%_%4
M2DHV)273$>]=;1M0- W-)V2'>9*8H11#K=-U)Z=[6*%#UJ%X$ 6.A*GY]I"4
MG$ X&B::/RG1KMIUL3 0CW'E!H2:NAFE\_73<+-0@3&>!A<E39<R\@@4/8GM
M?7?HBGHAWVEY'&4UY?'5E"E(PY14QFW!ZHHC2RK/LH*RE2F@K!RFXRHHC\H
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M2-E@1PF;$)5>Q1+K>^*4#8:0C_6EQ2QN^WO<9-!F[TW8,W/-K4.N8^&!_'=
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MA!W>=2"J0KCK5C;]Y?69R^S9534NC1SQ=:TRQ RGYV^2G_PI4MI-N!L'U?R
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M]\>1>-/5PQI1JO\:H<9>9#1(EN?"U_2Y*<.A[0#W*T$3;'X1:2A.7DO,X$S
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M?;;=,H/$3O(R<ST?DF--5=H:,ZV-9"O>E]75P:*Z M;.*B8GEBS9)/7TH!D
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M\C.]-P5_<]DUT^+^9F _ OK]<03]WBSH]\<1]#N"?N^(W3CQ/@,8E)5+ H:
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M[VFOH6]'Q9UP9;1TVQV\9LN:9=J/:FJ( A[2M<1),[7,J/"P)+**J3(8@.@
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M6SH?+GJO]12ZR)2TOU.Q=<A+U3)'6OAW7I-0ZH20QS&IDAP>E22>/[WVEG=
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M'&KKFR"O[H T^/]_N VO].4?B].3P-JC8=#J'&2#G/8+\'Q0A%P#XVZ4IJ6
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M%<N%>2LH!P\G4.@XFJD0UW$YVGZFB7:]009C?<T!94^9=S^FB1.BCR'2R>
MTRZYXFRQ]K5Q@19BJ)P4:+F [/N]G4<'_B]/]RI9'R6U8C82T2X\Z33@ZK4D
M4ZQK677*U >TV&,79/BM Y<$TUK(?PE+^<MK&8["N@O?2MZ_-L)>"U&SOV Z
MVW\Z*B3-.8$:*YC9*E ',5'2(0V>UURA'?(\0?[>2[32M@2/&GX,$FL_$XJ
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MLA]6154KQ6E@8[=SUERC(9@'W :M_P1[\RR?6DXAX3.M:)FXOKV4=:OIA*Y
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MS,.?M2T(:Q5P)%K0#];B$:/H*=QM+6X:Z:80^ES9EXI5T6YSP0@\9':K^B\
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MCD/#3&2('G;%7P1S%28FH/B%ZU ),F7EZ#2,GIQ5D4U-G(KL&_3='0A-4?*
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MVZGE(/86VHFY*5$67[@DTJ0\-KIGXN@NM5 "B\L+UB<RGG7+S?^C(BMC+'3
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M('<L]1['7_Q0BA8RH285>H4&Y)4=C;%/E-43Y/X# +&>(/<5<G^E+*XQH!F
M;[DV'/+ Z%-I:!XX05G4 /VI_<D,5Z8I;(0BAO _T6T]CF5-$/T/\:W\:=59
M9#EU52^*$3G%L^?FQ,R;_T \KM3\Q(U',-\?2C</NS\4DD8(*1Z7@/#(G  /
M:O3(_0S:9Q@&4;6JUA#DAF2Y:W3(\,57>WJ@(JQGW:$ES0L4I<#05[N:8N8
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M4J)F '*&SP/L0\.@=SR:T2/9"]-:II6,']8WW&?3OOWWC0\#+L4Q#;9 .D?
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MJ^+KT&]KF8+AX*"!?H[5[GB<UN3I<::LU/N?5!!J)@4FV=G1?U(3E,Y[\*I
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MQ&&,6I*%FPM>.<?F3'O[RF5<(S>O 1XP-:6B-DN5Q<AX3QIPX/ZP\[&!&69
M+_KU==L=4A\J+QZ=:Q+QX= GU8")_^LNZ/%+5);T98[W2+&%];9I#P&V>G%3
M]VA!)FVPP'\,\4<&)<!_<I]^.I5R5L]*CFFV\%1,4\2C16I/LWD;.;;6><*]
M/@O+A;,;(C],/^,'./7.I97F+1XF+2WY;EI/C%2]J#]D93*U$XJ*DJ+>26L\
MJ"?Y5H:?T+*HKFZ&DBKNZ#:VVF;C4G9.,KG*V^4&<*@NMBJ'/^.:S7'FQ$KB
M9.K8!5[K9#_)%\/E]$5$JSU]V9%\C!]G'URY\5DK,9:"C8>[>%26!)(GB( P
MZ17* W%Z(W-__\6!KP%;_#3Q=?^QP%OW"XU[Q+7KP.;,$=/+F >9)?*FYJ+[
M%D_?H2=Z2F*:ZC:^N&-6KKI/':VL 5(#OFN\9Z='R"RX),OEQNM6.!$BYRS_
M9R^H)3P!03<5JBC4OY,$+5IMH7$=3"EEFT*.8T%47:M4&WVUCFA153]X)KXY
MZ+Q2YD>[E$D=KK=2&=UN!5=2NIQD=FN9LFK(\8]-XQ8 NY"R*3<RQ+2;#Y&N
MBA]&/R?]J&;&]]S(!@BY5Z]L4-EM#UE(M!F)@R0<[;CTVTH?5LH/*G)F*B%H
MJQ9(>X[/<?'=[KAF ?R9P%F\!$4SR-3["/&H(N'K$#Y[R19U4'0P6-_L ?#D
MJ';K8^1ZR7=['SW/3X+"^X;\?,DP7_^R$35G?018]\1;>WAV]"RUZ[LWF2\$
M60=^9ZY?], VH*4YO.5[ODNK3;;SOFWG3TS$^?=0K0Y/7JTY0'^^#HR66'R'
M0E]BOWS.#.5:*1YGOGSVT=.GY0 /T5":3LE15+K<QJ-&D\MPJ!4;U:5PON[$
MNO(@'U=ZA Q<BB.\6:0D-8\>NBV%%ZD^*L39G#;DX.+;P+SD3?&B[N9[^OD+
M?,Y:Z/EV&ZJF%!7$/WRUWW(8+U\1\RZB;:E$QG>UX6P!!=U9/([P6WZSK+N>
M'_)7+GH+\%2MVITVM>AOZQUC*!]K\-B=9NB>K(4K(Z27RP*!EM^4$=+K=P&X
M/OPF%ZCS[W%3U6UJ_LV^J5\A:PG;+(]^(CU<;0P]EFFLI*5KO#E7DD,*QQD[
M==7D53J*])NQ-$27AX5"7PV[\;=5MPB+K.;%WD6H%C(W%8LZ91P[IZBS!>I;
M>@\E7D U:Y50]51]4(Q;HE[MF8$3\_'#(B. 2K8-DY:=+#8JT,R<&;-RK"](
MOI*)+9%#)H':[7="%W?JBLRL+?25:.M9V(S[1B6#*3"JM;@.C.E:=4T=,NS/
MR+(;@?3Q[1MO_:MX$;GF0'+2?N3-"C*,=[?P2*.?7):;0 KK 0G>H\L6K-D[
MU]J^Q$1=U2.)OW3KN;J\ #XPO.*3I]#SZH+-57HXQ[U<3?RAFWB[1?ZV.:3$
M;M[\P4=I(30YEQ=WG4@N\JQ-Q7!G8O%R="&X;Y"AMXK%I></5ZT,/OB2LO35
MB(Z XQYRGUS=X*PO!&E:QE)D#W9-YF+5*\=/ZFSUG:R"/%!MG(LYYZ"B26S.
M\;L5RSL\XJR\ T\#]H71>3# NV?&X*A:X6B %IYVTL\A:MLG-WE8E?88VR7#
M>E1MH5E@X\&#3))VR33:L<_.YRY-3@ZKZ:-B$VUF#6Q410?VSZ#%' L48@<4
MAB#C[>R%2MW<\=B<WO8D!X\W"?6&'M>G4X_KN^UQ?3KUN$X]KF>B,(9  0.'
M'G,$8G :B3\V!;=;)+B V%<6!]T!LJ-.68QC(*AF!]:<-.GR,7K.P;F65A3?
M^/JW4C[L@@>H<]>,'IAU&]WFLT7*!^B^)K:F GHZ%R"!B$R>#2U7('RS54J2
M1Z\<#;-;>:1R&C"WMMMZ@_MIA"7[&4.H!/4T"+;P%BXO<G\#7LNM.%*\*W@'
M#*5 +MI&,4/4E=JU5K1*]:]\<H?[Y7I!5D"_2*L>2PH2(LN"ZQ4[J,N<YOKR
M=Z*;&3%TQKR'S*-U&(P)G:":HRO'IUKQ G,@'7F&938MBI=DG@" L]@)2"^D
M@2NRQ'RBM)78VYSR*N\K:\;:QLH)&70/I'35-@N>7!UI>A0!!<=(TS/$9QS8
M*WQC?E._9G?/ZI0.F /]U8'N)PB$EQ<I_^;8MQ7KII<<L+1#<H9]2L'=MYWZ
MGMX2RMFQZA3KWX,B$KTZ 7HJ-20:"@W_!A4HU*K,'.31H(H@"@]-XV70! _Q
M6-8_/.C&6[< N[=E"8P6&OEDO",B**6ZDI5_/!HAZ7<@()*Q&*(W"0$1A>[?
M'<'ME\<![@!IGO%FVXWV%##KX3*2\60*.6Q^;3%I(6W4:YG"=;W"EMEN#EPC
M(;/+R4@-UO9A$&.1%1QY&^A27(8G?77C6'=1?D0'%;IU)''I$(NTEP]$-$B;
MH>4W[@ =\5HK/](#+]"'Y*%>U[T%@-V AR.-/-+K?"4:X$CG^-$([2"S[N=C
MJ!R;'.*-52@U_J(UAYO*033<[?:;>C<0[^'4YIBZBA.DZI)$AL<)E? \,77^
MFH[ZCQ$@;L+3N:<7^0T=L\N+>IFP+$89K]#%>'SD,GS0"/#%R3:?&',7;#$&
M=KW:36['?;L= ,D8 2]+@'%WBX0%..Y%MQMKCXE?/R*CR4AN2N:!#-S^47*Q
M:_X:7+4E-[$+^3I*RKNZQZ<\1- :_RZS1#YAFDDICB ^509E<"J"4\<UUR [
MJ_AM;DI!A@H]S4T"AK=0SJ#G3Z/&980W&3GRC]]\_\KF+R,-4#MKM(^Q5^S
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M3ML]W5% D(4]I ^.P^(Z;)B3(A$TFJW='61ZOIT+,XS0IW!M35DL.^T*9=C
M?M[5,P9WF''Y3D#15_5,D9(25+&P-QJ_:SB),K%Y Y-K.4:=48Y3;=C4L/!Y
MW,L$Y;F.C/]Q-%5IW+M44*_F($?!_E4"-OQH[G\52.16<Y[,6';5?B&R,F/2
M6(8$8&ZXI@\&GPF,.-">X6<>$(4Q8>H;!L7 Q87<]*#40I[@VE#49.P,@\L
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M$KX@F9%G&YG;Q9")=Z/ Y1[SSNCAU*BVFR"#VAVN%1,22&RTQU%.SJB1XUT
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MADD_KH-6)H!UE-&12&,V$B(8P*E#G-@2^$XLCOT=EI=>*;P*L7M7Q7.!J4\
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M-]EO+1GA%L;+?O;1?Q3,J]MIVR]]7'/ 4C$ "#D58Y2X?%8,S%;PI= #30]
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M54!1&0HMVZ*Y1H'4334I:#Y0B(($#V!1T"50U?*Z0<54#;K!R?HIEC+T.U+
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M&0Q\N\^_NN==4Z"*.8L],B<$'8G]:OV:^,3HD0XC.X),I8;RI8/EA,"8?A3
MD &0,59)-? <<$G>$'/&OO=O.<#=2;UHP8K;8]JL?1C]&C<7MH%%G&O:RZI
M),:V?MJ8H$ 0:= <_!/9@<UJ@+B,,^PG1S*0#QQ"C4>/I6$WDX%]9'6$[X8=
M[<*W*;)-2A>/*5::!P90ZJA&PB+NP"V*MP'0,2.9MN-D/Y,_<.CLIPJ5,?MQ
M0F_V&S4__7&UHC\'YF:?M=T0]-4,(:#Z1^F1<:>H[U"J;&#.U'? &1MY,?:
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MV0AF;I!<+&R<528<Z_IL*EQIG@LXE7M6+-GA"@DFU<$'X4Y,Q_0)**;ON5%
M>'CF!)MSB-#\@?\,$+N"H0,8(P_!\Q '12%03EEWT!N(4.%-)"(<;%%_#-6C
M8L*> 9BFN8[!XYP"#3DX8^>WC12&..)_::RMF!7<.R7 _A,JXW/L>]?<90Y!
M+:2D9ANWU,*1G86X.2BV.X1U&TQB)T(/>Z]MKU82XWXS-]4T(1'V9LJ\(R*.
MF#+OAX^T[MP,1(]*Z!.)(%BL\LWX>PW#T]8OQ3/8W%6WN /+0UY-+KU@J^80
MO!$[<X.4S&/P)79+? G\<GGX$KLEOL1LQ511\25*I?*LP\HBYC%]@$_*X^D0
M$Q]<^#A+7<#842#OP-#G']77[MHW8?@(VXA)U<.;<'I3(%?L^,"K@FA,2%5H
MO&Y\[PX#D>RVZ+[&I=4JV%06/O7H7,8XFE.>=0HYE:D;B/D!M!B]4ZUFRJ%^
MUZ@=3#G3C7KC9SHS/,JAYD;=L<>,B+O*C^;F@PJO5#?ZCD)$TJ/#4!J^%$$_
M%:9I"GKU?F#5J?N0:B7N1Y&%-83GIG /R[N1=5!$F-%0K2R<J5LJJ0).91$E
MQ9>C&&WW+>X>\H@,;3Z@[]6:\0$]TV2*=4R@F[G.J)P$%#F-+1]KK:1I*\=_
MD8*AYU"WM3G=<#+:AP,.1]P605BV5:U@HQU%"*K=9)X4'B*R%@PEE)IL'309
MIJ^3)L/\=6<F?[W47 6<RC%MP$4\K*Q7$R]RWW2X.1=U=N %1Z5Q'3F.H=I7
MX'>)ZL,&9#=8ZZ! ;0=3T(0Q&MHT&!HI&&K%!'^X'@V0&A1]JCRYF\)0F^O<
M;<1:;I!8+JYST$7&C@%<BU'JF ).A3JNW:1J9MB;X;J61?9G4U]F!6D8[ACU
MG8'$L>O.+J68B3-317).79A@&(6,\/]9F@YVJNV-3,<1&EU<7"4=TZ^P'1JV
M/]<0Y+VKJTL-/ZXPV!N"II+6;"8<U:S9CK&E7BG<5!;6*U2M4<:&BCV5!6-#
M7'G#JL=0[:GT52@?HRC:RPX%M9 (9!@Z"2+K !M4(3Z^:A63Y'^YJ'U\T"M
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M?.!QK&34AAV]#AV"2<Z,B8N2/D8H'SWO1/# 28 A ,FNLX]$*-X?/7!CR!D
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MO @!1,:^?6LJJ' %V:#JG]T;^#K>)2(P$:N!X#HE2 H0G&RT .&[5$?(])+
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M+V+W(IG27+^Q6M&N*3:]_%-\M-&_0+/SY<N1H:F96J5C\T_L]XV/!H0/BG)
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MYT<W&?"@! "$G!9*>4W0_+NWIA.9.IM;[3$%4U&:]K4UE^M$ZYL2*[PEQ$1
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MWP%;+GO?@IJX N8H7LUQ77;K/^,GOD1&N?2E98;$#EHE<%V:M=V?\;M8"OC
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M_H< /L4=,?"%W3 ?B95>PK$7.E'H=D*;<X4)YZ[$5E#D^^!&8#.+J%GWO*B
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MGLVFHPD#4C-A@/K0(OK ZQ?-R=3O<;G^+57H?JKO_:;;5F' :K$[8L<V8#3
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MT$"1L/HB#L$;8T $J\1IHNJ$U9N:$(1;:/[)7^+?3H'10PYY 664^"'VE(H
M6H@TU48D,H/4X3EWRY-6*T3XT*+,$2^J+-#<'>"M856=%-C.+C6<S@Y+MFA$
MXBQT,H8Y=) .GS7:M1CWSGGCB->%=!>T'L?R[$,GH'3+%@RUA\XXE(IT4:5%
MYV8O$$'4"$02J^?SGD6$571JN@'5/&9=<J!IB4V1-?(V\5>4B;W=C<-S1P\
M@.;@ /JD^EHE]9H13NR!JRMB&ZG'<O;@*:LKXY>XG[LWM"M#H& XPYIZ08Z:
MEVJ]&T7NWV#.+>0)H2PWNNT*\6>&:\^SCQ?=[*SU)I>.$&H_W9ZWJE=2:G ?
MKW]@ ]S: E+Z#VL_(XOGZ.J_+?&#RQ!';!_Z6*.IAMD+/BB)')1A%YL5+%";
M#"V?$'L 0.?D/G746]T827[AF=([&VOF[^W-VPUA@D<&YZ%H(Q3@XE!+8T!_
M0J!B *H9Q7055<Q0(9[2);^ X(>.K-Q\5Y=( O0/$H'- 5(G&6PH^!F@9(=X
MWQO&#RP4TB/5T-;<G0[\#NV6RYO)69#?W.4UHNS)I%/KF&!Z0%#'UFF<B1R3
M-3NS--FGJ$O"S!UU+>B<J[@'\0XN&-*3+=-O<TBHB)VQSBH/-(?9"&$1+$&Q
M]()68STLXW4X-'#^TJV@PG&!9CQ7V\/'3)-CS[FR^6_W]AIA(MM.6KM($&<A
MB,.3N@K:=C,"1BBB,3:&<R#S.@/0M8OY,BL8"5@4STV18W,9F:GX8*98HUEF
MQ-KXOYOKMY0"HB(!";6>*TCC+HFO5^7&2SDS2K_T3,/#&INB-[BV?C%<4]A\
M8@LUY,/KXEU'&!6BM_$U)K8T*A)X:I^JW-]%'&>S&2^O@=];OHO%?IGF3IBR
M,O:XU5]"F5RCUCWQ7>&^E0KW6'0_)>X+&Q\-4=F[IWYG7T#4=P';+#<'S9VH
MW&:!N;41^[*U3*V1\LHR42D)\_3, K.G1Z]\MSU/E6Z2KYG6\&ZV80:8]=\#
M!33CT7H<==^'DYR$[2ESY:<G.[:@]KCP7=A2*Z:_9ZN*@CI11.X%:XG&63S!
M.:VN9$U((.-AE**MK,,$8\R;;9W_YA*I* 'RM(@%J\QGW*6B",11!+HM2: D
M()Y8^:7F'.=KSGEZ$Z$3PZ*#NX=83):@_'G$92-@WS&T-*=!Q?+-9L;;K,B:
M?,^RD6S&E.4O@WF2:5I]*(@11&.YV^_)</"[L7O^#+892<Z^Q5;ZF#I"@W27
MM//IP&.TYS?-^SRJWG3>&^ECYM?%]ORYJ9?TV.PFUT185<([<'I"]H"S;<(W
MUPXGUP;4%^+=LHK9LW',3!F3)?Z*Q<,D#/7"[-BC10PT]I[#OT'A+,R>YE/2
MB8:ZH1#AO #HB@A_9MDHM%1=I*AD!F@C;_8 FK&B9&(E2#-'D;P!38'W]@T/
M1 K>(=]8ULV"FZ&U!-I"Z"_T(>ITBG^3"(TEP6B_>:09X^'G>9C=0E<?K^_1
ME8(?4*35^P:'-Q=IKLCN9K2-C?>CHXQ9IPP+!5=[ WD*SAC:U@)^*\JCL6Y"
M6<+F,]<3Z@YD\7U,$VTU\\$N+[/>0P(F&4[I *H&V" 18RU0YZUT%")'(L3W
M9*4(C67KA7.#7D NXE^(V@"0=.U4,!#Q>VIW,&--0P"Y4M3)QMKF/M8H,; #
M<KC,(&YFCG)ZTB>9'CKY91]_SAR3=!P9RQ1)!0_W/E9TBI5)O:;0%PF_R]9(
M,[BI  ;@(L-_I]K[37%_26B")"YFIYR_66\^B"XJT\4)6-MCK(Z-DG", @O#
M5\2V57;J[*E8-$T5]8W@4,!4\.9AZP@K$0 YRE.5!EH)$J-2/SVQO?W51/\W
M]-(!H)=N@&;I9&,6@E>H$3#NR(UGT"7TVA-%?L*+$KN/GV$"O+8 CT*D!^9^
MSL%H/V*%<%HZ"Z;$V]MX&NA-BY* 4[K=,8'=T,:]'C1D)HR >HUHQ'VB2%CA
M)?@OM!#%%"ZB3)VH)$Y/9:3<5TPD%U;*<L/8&7X+3QJX/VO"1);H[+AD-'MB
MH20 H"<AJ3,=*M($BL+/PP9HAN @FZRAKE'_"E/&0L$\%-(74$0^,$UPTT-P
MRSR)U&!,.Z!_V]!L*\*[#3MA+_$C82]U>M7H!)EHARMO=$+ GUFE<["FP435
M9G<QPI@$L>5%EG/#H'6 .<G63Y9B8>!5.?@2W$G"ENC(<>-K&F-*WM?;!(PB
M2HB17SY4!"1I5AJ0I552GX8B*7VXR'0:5+UD[\!8%G_!\\<GH<[.-.;-,1YC
M@$*T1,WLG&G3@.V*,=M7S.*F, 3;7UK/-P30#])WE($?038364P$^"6O4^9J
M5,41O 5(R9)-U9W\B@%^T&X.YO D@8H T,PHES4WCN0$3XGQHIFUAEC1,]'_
M$!Y2&8I=0Z\C_>X[L T,B(N7C%99-/ALFA6$J.Q:)#5>R&1'$D_,*549]P=@
M()!0_!C:EB!U:!"$-4^V*4SGIYU36-Z5[1.F<0. ZN,1HZ:.@^:($DOT4 ^I
M1CU1F/.S3"S7A!F=5&QT)[(^<)#*T(<&?):)8;36EA7Y;(G4,26300,S3IMB
ME2U"6VJ#9@X6C/%+Q3"L8";TR+&&I_[1F($.;3O4S'=QKG_44=G$9>*(Q:5Q
ML^UHI8;[PI!#%A\@6"DV#L2XUBN%L^<T9:QVD>;R;D"V4P=1CP*)*!!F(--J
M<9B* %NIC/"?':*,3H"FG0)S\BC7[@!+L==LV]P4J[#D=NBNIE$QYIX3:G(#
M%'!(T\K+0E615>/' M@ +9B0CR<[Y^G)WF#X]IRO9#+#V]3;Y7C#OG_K.2$@
M:UGB,='B/4>,-C?D/$ZW=R'1GG=JPW'E+9KIOF1^_&H6KTH7]S>ETY-:F2OG
M*PWN(7]S7^(:I>)]HU&I7G*%?+/2W E4W>'VYE]')-US:6NE?P1??K!$D07G
MC9OMTX0#&^=WF&-.KGHV11#:@Y<DX1^.+<?,62"9,#Z6(IX<[,K_^Q%+NE-=
MEJ33>'QT,5.%1EP678A$4W,Z+*AN_].]-L^%>'S=RU0-U>;&=[FWV]FUHUCT
MW5J><X>_G!FU?_]!NV6#?6=VH$<$@)GD?^J^>$9%Z)XDMK0G@?D1EAUX27UL
M0,L"R ]%_<FI_<Y?\6@R$D]D(_%4ZF\[SZ+ZC\DUE[H"%[,,O8_-_API&PCR
MH-> W[,YCMEL1)V/ U%''M8I4W22H.?<>CO@O>%HW'-G \7_N]S1;2A6__5*
MI_V/.:B9@9]UX#?1O$7#JK"2!P CR8;4E'Z2QQT^FVP]O%K02*R8QE)T!//U
M'^[915W38Z>V IK(;W:! 9.6-F]S-<9+1**9>"2;B'DDJ7N>C/>6>Q/BK@XS
MNOYAMA>MR<+,_.>5$=0G@L!5MFX^52'2@CP2,\K2DYW$<[+\&*O="Y^CD>3>
M:,0L8U^RH*]+1ZZ1+6(J')R8X@8Q16\J+WRC+O]^ZF^5X="UV_\W(!I-.I[X
M\>O,X5 *[T'&#WZ0">,@Y<;[X%)M*!T;(,F!#S*UA8/<F6*[CLH0^Z12M;%6
MP.KN'EIO6J]2']Q^Y-8[6R\N'_3T,OZGMV7=TVN;RNMOTZ[D[?M3X?DBK3]I
MO]>\69OL?FYON^_+W Y_!*:4ZKY47A_2747,Q/=V!%C#/?@19 Y^!*9\>>ZH
M#\/'P:0R6M,RV>0(EJ@" <6&&8/R***P!7_RJ?8\_QCE8T_UF?;</YJ2A /D
MY&^UHN)8)WY!VO30/&C2@M$'5\#9/=9LX06@$2IBR'P4XJ>WO!N\I:XT36WE
MWASC$@]QHVB:-YY ZOG]^O[V^?$I(9I7]][]?=D[BW&561AL7I\JWE_#%DPD
M(NETRJ_H'18GZII/FB:$R?$&D (Y"-$K0Q0Y/0$<#Y&^5E1DXOLEA6]-'?^?
M@790VQ7BTGZ+F@PFLE";M$;5?/(?O!MD*W["QYL4I=UJ&__=-WY+5?6Q/[=Q
M_)Y+_8ZY5F_9K=YG,6FM5S;R;FWICRO;O@1ZOSU_18]U-7OY5FJ*1Z.Q>3>
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MO>[96,J(@%F$:3G5 2I;%D@<K$""FT8<OIQO%HP@_.D)UE&I-."M-P%'33=
MMJT%<-[SMZFN+.YCEV#P?=NNP<YK1*]EOF]C5J5B3;-F15SP9 2FL:D(F?AM
M]H_3+[I@.'DS- @X:C1.*K"NV43M[./AR/K(=W1[Y(V^"S';TQ-MW*%Z,];#
M>(GLOS8 L4Y<)EP>3]#TR=C'L.N$O$9"%4R,0:P#?@1 4D,> EG9,AE(N-AJ
MG4L=.'A'=/H7KXD4%[?5'<'C26L(.& CVHM)5K=M)=T*_!96B?&7Y^PU^@//
M3)'3$P%U=&LH);"E8$0I[<'?,;[[JC1S'JG3B@! /PW!?^B')/PC:>L)$R(
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MX][[1[G^^I&S>4XLW=!TJ 57LC^U8['H9LZQ2"KJAUM,=XS4G2J0%H[ORHR
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M?"20K<H(A"SMO.L?\S;TDZUBF>K5O_] 4+M!70$<U&PQ<O^BAOC8##C#C9E
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MU*7'D#-3'9%35:$K0):.6MB:HL.X<-Y-QPMJ!W6AAM>2IP\-'*9T%=V#Y B
MFQT@&PUWS%4P]2$.+2L*[G9+$3M+H_)Z#P*&L',F1YQW)$4;+64$UX%#KMZ/
M& Y%M&ID4"SR#*>;:5X:/AEOR),7%(T=H0#-/12'B*E &WTN+&.;ZK/9[5!B
M/P3EM6<+^2?_:U['$C9=:@!#G-8D03"L%^W_]=F(/PS/*#S%@JRN[K:=GU-;
M7>]HS5Z!U+ZO%#H\USWJ. ?VIEF=KRE2B#14@(JY"$H:)HRE V& U0$999Q1
MJ@Z)W:0I<H4@$?R&*/E=UA8AXEHL:\NT9FRB]/( ].?F<]]765NUU*2P:YPJ
MU!I-*E\M4K7F5:E.-1[N[V]+=Z5J,W]K7 'Y5ZU^EV]6:M7/5>RVI@CJ$/5O
M:??ZM](%6Q<N'MNO?/ U7B_(6"RY5[D>15T<[5H7UYOJ<CLA#&MZ;J\P.Y(>
MP*Z(?FL)ABCVZ8G6:M9W#9I7-9'*T1IPMX5921);L_++A5ZM7K!T-AU@'I);
M4S2S2)%V+U+TI,#:O)U"](6?^%^H3.@B_JD+];8%0V4I;\^JE]N,V'W3[,HB
ML2WZYYC/2V]3A;=\Z,$/KEIP(*03,2;A9D1XUM+MV/KH^T #'1"UZ,#+QA*9
M\(_3G7\EW"PEU.>,N $'FLF_)/&CS]R5'R<W[0,FCQMY?M4YH^90R8%!S=1<
MB8XALA5/#Z5/!O/%1I_N<$R!3)/;CFU\3UO]DMJG&0EIS=H3NG;7[ __7.?V
M6.ZZJ$S&'6[P#J?VJ2YJGD3][ H3:%,MJ9)AS%380.J;T(N**A<PINX57'M7
ME+8AI+)=K#J_M5LCUC.M U['[VL)1#<*N_#4+P69T:@IM-*,)>Z?C' UZCK(
MA4Y-3"Y&I]97I$6&FK:'6G!$13,Q)K>^,4N(^L*V(J8J2_$.F2I@AF#C!-XH
M4U%'*32X<&[G8[4'**<]Y6T=O;?6?5 !KM;# 4\[X\WPZKY/::XDO32UK!7I
M]+N)'P&QZH5U!A#M7*&CLDDFEG%-==@30=HGE]_NY S?LMKEKI\>2C<OMURD
M3RXPZR*1RL2R]*ZL=']F1,$\"$=J1GPQ\\+YZUZ8@L7,C>6Y<@60OGN_3;UI
MZM0>GK[I;H+"L<4%A\L>F$0NEF"WZ>L2.'M(;'F&!G^HZCDFQ2>+U[?LD1QB
M<'Z(0)2NPRL0!V <WAE5UA'")796\(X*G9,N[^LE=M1UETL'PSU[X2'SD#0;
M2S![[RKC=IS)[8_38"- N+FJ_5%FO5[FN(XS.+T#FB/I9&#<Q&_5.]N:W=U^
M/#W?)9J7R>315,;N+^ENN:K80HT[3M,5^-\-$O(V?EIKUAYIKT]<?:!IS%$G
MZY5UN#]P>C(@50".;%_X1@5E;L4[J+>+B#.L#+L")1DO9A%;7>L5,.#@PU#F
M'U &JMD/W[K*R@LT.MPO-+@_/3%S?[Y3_B)$VHLI?[G6[*U;EBK<\WM?%'VE
M_)4?F@_U$G57J5;N'NZH^_P+RO)K4 _58JE.56O5>"%?+91N\Q>W)9+YUZ#*
MM3I5NR_5\\U*]9):J*7_%#F @:6$E04DQ"B4&19BUEO0J[:]RJ0WQ'$DKQDG
MGV5=,T0@\TIXIJP$U[/;W9FT4IJ9@9&B#JKP\<TQ$$?@#L*RKR(%T*')O_9>
MT[?/A?8#;]>>HU]_+*YTJU;AVRXR&-U]46//QF@?5K_OHPG=R[1R]!X$2#(:
MC>ML_"QM@9^(CS7'LJN9V:Y+\L/5'9.?SB%G8@/V%!K*&NL.V<KTK-G;LN_=
MH7P?Y.UD7&07JZ*4J8G.)W4&DP-AHR2[!4JZXF*/[TEBX4+H)>P@BH_];&\1
M^UUMN!B82#(Q.KNKK_2PK#(_0+5VT& QBI-P>2,N?5^?P[=O%GKA%U\?)+N"
MLS3IP$O)-EM"U<1>7G B<%&Z9*[II]=ZS?85KX+,;DQV34?2K;86,J;G8LED
M(M06H_O@LIZYJ_?DB'';8]S!#U7H^>+%ATN<]!-'M=#&E6V+A4Q"&_>NV*:-
M]9M#8C4M[)C"Z;&=D+'=I\-SMS1.OWY0NC4#CY4)QUUGK^KA5L7NK5->^-T:
M&WI;Q<-FM=((8:F'$Q0EF=G3/+WN:<VN>L_")=WO#(7<,9T Z='(T"X]&@NM
M6>WC\N-R]CQ44HD?OQL/%XW2GX=2M4F5'I%/ZC.T:_R$[2]JTNE)&;05TB,H
M@]W$B?GV%3V%P[TK5G7R:_0Y!5Q GLJCNX"DX@KSO(+Z"N$"](NI?8FA4>?'
MG,+7</\D]1*]0ZU(][@-W:4BJRH6+0F:9=*X!!1]RK1:7M2%YD:3IC->5\PU
MJ6DB\53K5J#Z,Q)X?;&[3:W;%3I 4<VF-4+CY:;Y)+S373MJA_=C-H""$#;
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MQ",8@5_Z[S]MF9_B#WUM(,(/_P]02P,$%     @ \99X5A_V+YW*3P  16
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MICN@0Y(A="YRRZ</X)M(L4R3W '1G]$>Y_\D+@KY/CE?3U:4;&Y1RLS@IZ!
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MH;IH8N9MTGH<2#[XVMU!E)NMNYLBZ(:(*>C=>4*\_<K>5)X\9A:=\WUS.%:
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M,9&^R):^(3UEA[C>)6LVOU*(263 N/K[B6G1P&0^@MUJ=O(+O2SY<&W 66'
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M%R?:%5UBDXWS+N&T8#B=^!M02P,$%     @ \99X5AZH9RX)W0  ?^   !
M  !F;W)M,3 M:U\P,#(N:G!GG+M55!Q!&RTZ>'!WMT!PUT$2/(3@3G -#L$U
MN,M@ 8*[Z^#N[CJX!0DVZ""!P_^?<^Y==ZWS<._]NONA5E7O_G;MKJ]V/_3K
MRNLV .>SK((L  X.#F#\=@!>UP!2  1X^/^<;X'X=B*]0T)"1$1"0T%!?H>!
MAH&!CH:.CHF%AX.)A8N%CHY#A(.+3T!(2(B!34Q"1$""1T!(\!\0.(2W>Q"1
M4)&04 DPT3$)_C_':P\ ]QT<"[PD AP= !X7#@$7[G4 0 T P"'!_3< _RO@
MX-]R1$9YAXJ&_C8 C . AT- @$=$^$_6;[U^;_T 1%PD/%KNC\CXJB8H=,X$
M/#\3\][1?ZKK)52;O63@-74)0D4C(B8A)6-\S\3\@86/7T!02%A$2EI&5DY>
MX;.ZAJ:6MHZNGIFYA:65M<UWUQ]N[AZ>7M[!(:%AX1&14:"DY)34M%_I&?D%
MA47%):5EY?4-C>"FYI;6MK[^@<&AX9'1L;GYA<6EY955R,[NWO[!G\.CXQ/H
MU?7-[=T][.'Q/[S@  AP_SO^C[QPWWC!(R(B(*+\AQ<<O,=_!N B(M%R(^-]
M5$4Q<<:GX_GYCN!38EY=+RH]K]HEH:G++!H1 ]\.(_0_U/[+[/\=L:#_7\S^
M+V+_-R\(  ,![DT\!%R !. ?U9+X!QL1RK/!HLFN(H9:"MZ/9@RY_]"B?KYP
M6'_"YI(J)[3O@2M1S$DVO[LGW& YV\;Z0$ZNK#I<!7#VR"%HK&);^Y>_IK;*
M@ZQ@5I>X&'F"A:*Z60YY-IL]!WLVWM8OT6>K"/!E^$;C(IKCK?3L5GF6:$"1
MNJH<L2+MYCE7)Y)8.<>S>C"HC52/-9&+]L:+6/C^*LK)]X&&73I"KK1SVE"4
MU26)&K>B(/ZEPZ-SMXZ</K2)9^\,2AG^>:N;PZI,J"?_I56*/!BZW];;(=T\
M+HBX'<8Z\!<3:^%*66!V9(H;$^FZ[[C&!0-?^#$[:V+ 8H(ZMJV%M:VI0JFS
MM"P8GF8M\2YB?D@ Z[7GK[4=84O2\[<R^J =03VNIY*\F_*E;N(?F>,5%0&G
M_TR%J_97QMFC2X1.G4=*'1R?/2A2:_6/+\7/_MBLQS"O?\+J^ U07LIK7>CP
MS2R,5HKS^D0RZ\$BUY+@P?7WYT@NNE8 <>/:T4$BWZ21G4M$W!/QESJA;:IN
MO32U-Q[%PY;SQVT]@NPA&G56]+_-]W(K7P'-OI)Q)"ELVZFFP9SOX<][UK]B
M UPD+[3.SCNLW"IE" ?SUU;Z)'SXI+'Y=FHUO/TVQ:P1JBY?P/:[Z' ^-G^\
M,"8"%4EED;YB?;PG+$HT5+=B&LA4)<YTM'=RET,('R()&A@?5NJW[CF.:BC9
M@%WX@"=S3=X_4P T:]U+21^T@0[[NX%B(E';C;9;Y*\ FV.HT:H>NJ#I,L]P
MK\'A <):G,^R)S.<=7X4@/F_5Q(?H/'W; 8S J_RTMG%K>(3<_>RKDAASB7C
MAIY^^.>]9]97 'U-=,#?1HE'CL9GHQT?(S)/5]59SL*VJ*E'>HQXJP]A*MCW
MYA1E>Z6YF+;C?^W%EVRCTT&;FP2<;/5<FC((#"!O $M3?-7QXVV,1X;%*5EH
M)@C/UHMP)G$!GA5ER!#]%1"2M--5LZ/O$T]C:%-C0CFP/5Y+<@>_M2G>!=[W
MUCZ=K]3_F^%?^L*@ Y>J<,%WQFXXMC;!7?C]LIP*:Z'?JOK*>P9EIH;GUYH8
MEX)H.U9QQ=KWU#1W&R_" >7O_:SB.[5!S@M/40]/,O\R;O_^  >K0XW6SA8@
MCM80ZPVSL$]#B+1=>['MT;X3VAD#F7=Z4 ZP5]7JB3A=C$V.N:(M$R>]7U[0
MD#,=,IR9UB<G<=.OKI+47U=.4MM"_"TJ1X$^40ZQ#==8!9=E#C5TX&:;8F<"
M>4&^&*=R%!?;P_17@&4WKE)YYYSGG#QMJO#R/9T,")L[*\9YI^F,=DCAD+F%
M?PN&O5-U&/C,&U!0]7AB^'V,W;S-AC11)ZLN:^! N^[O:"[6R? @V=<"9PR!
MMECP0)+4X5#B&.J/*4&X=:V0-+2"&E_W&OI+N=[Q"]3O&4CKS7<-Q8D6S@Z(
MW)3G%I8.);D&\9EE1[;9<_Y(L/QO',P7OE*$)>DN5FUA1"#EM,-]8;L+XQ6'
M%00"N N<$Y5UWH@L"];XMM41,<S/#BH*!^??8!O-3E-BSL>&C"@]&UH0/XKA
MFG\92T/\\:=-50S.' MPYE]=LX518O!5:GK(GX2JNZ:K*IOQ=?U212,AWZ 2
MY[]::+N./5=2CCQ44,!;WYLR/&/6IRFH;%:RS?SVCE"\:Y,X9IN1? CI48X-
ME7>50[Q+(CJ42K['5PVB0=;R'=">YF0,N&.LK+7V?\?<_&G])K5]'V,"E4F9
M\/ZUP$9V?<9!EU*UUV3'$K8&^@J?VK,33P!W0Y/D:I;A^!O[:[?1H2'S%OPM
MJ^[I9$W$OKY073)(07&PSRN6W&%_9&RMV0HNCNN[*/7/%YHP02]?1?K1.UI;
MO/!$/!IR1B?LJ4ID=/QVD#4"Q.Z6U>\3+GMCF3,J&W!DC37!R>N.'[%M,SL<
M[UM?X>A^J.604?T>M.9].XR\,AX-%O!U'B@/X5_Z!4*EVJ 89"7BD0ME$M6<
M%I[:2;!)VP(8J71%GKOQM_U,D/WC[BH^Z.:FTG,=U)%=P@=W2NR= HZ(61^K
M167049\ \L7.RG7JX5T*2?RJH8!Z]'XS&BCI?X#22_]8L][%%VG^55_\K$2%
MA8 #8_SYE-]:#*/=70&/ZQ!KIML-QB14YS:[8#=,[/2WY0$/#[:A0=[&*BBS
MXM9#/FY_Y;+FXSJ%"7==?%$6)1H.!#;I,^95K:7IE$44X&5Q@JF9SE-I#DE)
M2@Q]L9?(E11])' :\2>=$1L4^$"*=#)DI;A##WN(W,<C0F]))QCU_ABD36%D
M'5U9A4_]<T4NZI'MH;,KJ;MO"E]*J<"_I^?1TZFL#)X[,X;BKZZML:PI8?YR
MTV5?$$1@HAU/9CB$?169K^Y"/5GNQC:YW/N;K]@-YEO&-V@$R0@Q:R.:XWAM
M-!=;(RQ7\8M^^[3!P5ZL&.U!JDL8-G_^H1DRF)U:U[DQIE]8!<:(#1J>08.F
MPNBKUOHI5#W#A,UTI!V2V+(-3A@QZA*PQUI(&%Q<Q%@5AZF1W21(/$'CJO$&
MBD)GN=+R'<V689)QL0?7L25.P/U+9H3ET+X$;-6SN9S##\/T*"7\NSC/1%#X
M;SKCKP!4B=34*B>3)J2Q =UH5OS?([).:^T4&GB^J%#2>?I SXK[H*VQA J%
M2.6L/RQ8_M* E)']PQD5E':'(0^G#QC1*]>WQX8*NS7!RYLT#8%ZMDGZ!FLV
M"2N#;;K8+"<&=2@))^T*?R=56V"L%9/6E\.[1%S_ZD6KAFRD&X:('5/HK<[S
M#MZ=([M*4@UC[JOW__DDG;B_7?,V@U\+'-)4(8TGS7BTB71FUX2(\&\+E[O"
M%WO9C=$B>G 9'HM$7]BI?HSAH3E!;FPT= \6=K(PZT_XW=NPL_Q[G2W.)/]2
M#F-LXSSK)!T1:NS^;YXR]7NGKUZYV'HV@)AF<LEI0^Z_JG*E^@HHOQMH(UX!
MI'98+1>&BMM;08\U8;=*9(_7 VI&&RLXU;DC]-9W34=WJ4.HQA_%N'7;PGO0
MQSO%-7*,!%W%U[V>)AS*2U5UD%\>B49N<[%=KI.;9OH]\OB5E9?8;F7<P=G"
M>[%-J;'U"#^&ESI\U&%,E1L*Q>QID5I+Z#]^C75W<#JSQ7<&-YV>TH0.&R.S
ML#K^])[,CC>SL=DEK.5*0]J10R<#6NC0)8UNQ/!2Q/ED .Y\SM3FOX9:M&8+
MT5IJ8--CMD?V4$>6232R/Z?O7Z>9LVG)3KDG+FC'-_=N6*DL-D:>\V?:VHJ)
M"VFLZLO1T_/(4\9/?/6BP%_/4"9\IEZJX<<TTVE8*@:=*QC:BLHD)M.:C;E!
M/E)01 'NK,]Q"[#>0?IIN\ $(J&=$W&)7Y+X/)G,K$B/#06+GLF73FORVMN6
M)E\X4G=M?2(MN#M,E,><Y"9"G@N=?*+*J'LHC93GS]BJ.F13FRZ%URAL:59R
M6Z_5_[P"=*^Q6@T[WF0_8= T^OB 5H0%-A,O<C.CG%#[IE_>,5-A48 YT[S4
M,2N.=R+B&'+KQX+I+9?Z(F_)R3O2)ZOU7L;L=VA2H/M-Z9D_UG>R@&#^?P+3
M6D%BZEH"NXK'LVMH$>4:VX<QE"7"QQF VU$.^DB7\U+>F#J U5R%>(DMY:E6
M+)^M&TMC)+H :;*;G8]VU/0EJU&GOHZCK^K=FH]@G Z1\1\IG@?SAM][03':
M_T[,GE&6.L!64$1.5_)V+S74+U]C&RF'18>N!+E02*F2X2ZHK*J0-2F_HG3Z
M7F#W=A-]\PQ6T8]5JF9;$LH/NKLZ'C,H#_D62Y;@19OI=*2!]9&_^16 YCJ@
MLEX0T*?E4- $8FJ^%CRWKR:="!8R==+ ^OTG4"SDQ+WO@6UBI%E-[I!-M,LT
M=X\>4DVT5ZSDY1@E3GPB#ES@B]56Z8Q76K [@Q ITJV0%V&XM] +2VJCM%NV
M4@INY\1<O ?[20UPVM!!$MGW7>7GV3+W^W*G9HK0D!GPA]\V2FUBI]7^/XHT
MTHB8&]Z_T5)T''K.AE"^7YY);(MW.SI9.>(WLLQZ!9@V\Y 8VX])#;> =.R'
M)X=0+R:]E?NW,#8\E3]&?^WTK&:*DS5S?A>PF33]ZRE2-%X-A12H@J*K^NV;
ME)4CV_5(G119JA?)-O-;^60TA;7+) UD$R_^^+5_97@'D2=2$U(;C\F9REC'
M2('5;5\\DO[8' @HQ+K9@^KWH2\/M%F?O0*HX3NZEK=S(G?JP,V\,-]_6;0:
M("$#//H]IH.+S_[O/!/EA2XWM^N8)C%^>]FWPD-[IHWT3N\T GX='I8]EY0$
M]*U<!E!#U8X[0!++<1LV6Y=@(&T[]27HN.!E$\G+O!OA695>F2E]9^-J:#;%
MVB#_?'0LMH/*^TF;*J>>JBN"P%9/$6GO_?LWT<"*V$NF=RD!R8_X+T0E(1)'
M%O,!E[0!0TDO1#7!KX#_W>SR,UHE-^HQJ;)A, -*;^THO@(PXFMR'F*.C>Z/
MN_OB3<)> 3DA3Y^[Q_P07@'HVKVO@!N>XVX83O>>XG_:?=3_NVDDWGP:7U/-
M6WE,_[(J"%,+Z*?_>Q9CJZ?<?)[YS'Q'XO@ HYJKN<KY^ KH6[@,_X?1YOB"
MR F;?4-1_R]*SO]$B5\E-GH%Y$Z! LZ27@&AU)<CD%> T5D6$_7MZ-NM.;7]
M =-#_Q,IX/\,]+_2>07TT_T]+&XH? 5LE;S-B#+,W C'3&)-[ZO$W^@W9,[_
M<HL1*S(Z$'^;D="R'>PW3;>>WQE!"_X?4];E]PH(DUD>1M&=<WT%&.0\,[^U
MY9;K$BN/A5X!U4HO!#X8@L_/)F<LKX /-\3/[,KO F;&BU\!VY]> ;'4_]'P
M%2#%D?D*^(G^PG]]\<Q#'8%-KSOG_ 9F]%\P*2CV/^0?-4]7KX =N?\0[/FO
M<HC/6I>!0O\Q[%\9[H@!<]11F]BZP"8H1T9]@',U0"+%4S;SZ0,L4[&KN2-<
M>^[+TD6KU,"3_M^HDVIQ'%C]NR7MMLMZ+]6L:R7+B:^HI@KT\TM)!>'Z7XK4
M*IZ8WO+K6[YTTG2$*?S8J)3'/(RA<"N*WBT)X6"0WWU[Q/GP]QH(LH)8Q>$T
M(LR^XT=SAF.XK^*.F-%I4L><%&7ESWPK"0&QAF_VPSU&A$;ZT5[G'2*U.(2%
M89/!@>_VG9</J+.D2F2W<(M.9"#.=2?B!!)0/<_:^(<SU%? B&D[RQZ0KMW7
M9+?HY?3-)#!6S[6<)LUF_#+DB==(ZO<&'15I:UN3Z*71F'ZA</&<\O.L85SB
MHXYX? CJB23^O$'Q9]?GUY(;K39<%'87"??(=M2M8P3>=U5/5@,_6G-[5;L#
M@0J2<5*!K)9G9T,MR/# -.JQJKXRSB*P96_+DQWC*LSO#!R4LM&,%A)_<0@&
M"$Q_@57:V]T<M*:2:&H6+;S/(&5"3\'H%':@_#GLJRF!X^FX6UQ6M+6JY,,P
M,_IC&]TC$COY'7>M:U)CH <'W!2WUJUR9+9PPV+5J;[T%0=3R[\%Q>_7<G01
M>V8X3IXT#<BF7%S<&:UF>P$1@B=J]_)*'P[T06&B@IGCZ2H/3G4C "NFB2/G
M*$#G7@4U,2Q8]7*I;F?<)U;@V"2#*<X&5_K+H/O#4<^%<O*A(S!J;/ZF.PKT
MF2%3U1I/&+V0I_&+H=(8UE7%A-"ZIAS05<%^3R(B5<27HXLR23W;T]"(1T>/
MO3)Q:(K$_ Q+$<GHXD.5;0V!YX,O?9&AWK' LDAFT<"R<R$6RECN4* YH273
MUKG/#**6M\2 ;3P2NM<M*?OMX0*" @L;+6B+FDMJI-=8&;B]![8<+7K6#U,D
MMZY6^V'$7]0%LKY:C75"0Z*H.+2A,*NRE(,:#;7%1X2%V+-#CO0&/X1MHB@P
MNALK('6=+QS\I)9*TGL,B.ZB_TZ6U<&M*X?WS2[2T%XL!-<^,7@"Z_2,WAAP
M)<P'QWX7#N59MEH%VU07>"TB.$9^II&&G VSMD^LHS#%:$ZC0WS57U;:7Y:[
M:A49M;A$F9U.L0;5RC\BYC]D!W:):OD-#TB0VFYAFB\V;GPXXW2XL&A4YE@M
M!B%JN%T+("1UR9"( >CY]23(82]BGR0$Y;JBOS20FTN9_%%R\@U_<&TGN2:4
M-UGV)(!35[Q\!0S:DI=QA$XT7?CP*@FG[Z0_]Q(MHN1'-/\ 6"5F+-FC[,;E
M.&DK=S>G6\:@GE<#.W<U0BA7 %:^W4SUI?S\AW'^M#HP)JF%J@[VNW^&.T6*
M?SD_!.>IR?M: 7BJ 2]0*K!N%ZWG(WGD]4Y9"KT.%F8%"F,.7J$G R\2BXL?
M)N!]Y$YW1/,F\V7EX_ZU4HGN9X?W2+N2A96!D?#[[? :'%A<7OM:8B7]U)2,
M ^[+'AY2GYN[6KJE[$NI&R5R_K .IVZSP(>*6L07.?A*0N7B:1?!K$J<2BU!
M<XN[GM7LIQ/3!\]%A2,TXKNZ7VQ'T#,*-X&P),N0\7PE+['%!7;,>IWZ8<Q6
M W$C=P^K/_O.<X$?CL4QH4WIYE?3)EP+>W6X-A[N]\Q;IFOM3B"\M2\@<_,R
M>O935M<A/>I(M](#[?GJPN[,_KIR&5LWL&G[=<)(ETW/=+=3R5*% 6QM]VN.
MU:\.\0:I*VF,.E&@$#.9G,1POR @ //;Y7UDAZ/7;M770_5Y!]K:AKE]7 AD
MC2OV$)-42\L4H0%^ ,.)AQG^K8+_L/>1@S)%%+?,ER1]74@T>+C_<!>:7(9!
M;QRPZ,3]_#%SKJ'@3<8X]A<RV-<UI2>MG*KC><$<1\:Y6O-W.]*%($I! K/@
MC/B^31Y8N)])C:&1#2?E@K>OR_$2IKD&7T]]W91W8G #6![H"D57:&Y)4IO!
M@TIGXI\*U%M5EF,)NF"M3-=Z \+5+J=CW*81($60;^NV38\)K> X7=.A&>19
M%XU0\U&ST'T,MS(W;&Q8EQ+"T!)1DR"11T;*9<;2WEE43_7"-8:7!(U]-> L
M8RQG2!PX8W>K_[1F&VF_@^J&04PT\"ZY_2'=[:G' GFSD,PB)[:+ 7Q#;";'
MJ[])8HIOH->A4FF<U#U.S4-\Y'TF=)N+N=HH$<'CJ=V?FN$W=Y3F?CG&$4(N
M_J(]JM["=9S50V'5Z?K8W'\1(5*<1[@Q4.8R$UO7#9&V-. U;D$@I6%2]CX&
M;_@,"_BS+E6=LFV>3,*38]]H727=TS/^HMZ$>^])4GG480/EV=P=6_)#6PQ9
MIE%P7[J2(QMNB2V$'_Z-D+U6"D_R0R)JGFWI4$W@H]SC2(RH MH!,"\.)X==
MWX-A?ZD[FMV?#CPX,V>Q,FGR+F0 ^N#O?G$3V!OFL4>.O='#CQT%5("B*"^
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MT1DK_M_NNCG6XFG+70'5 MSVW:/CH#YCAJ>:PGGU;@Q0_9OLS, N7CJ@AMR
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M##$-)'\T LO'B3ZRQP[C-8E;71RQG-WWHF?)]64XI'%&4+%6\9SXM+.NG"V
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M">"]8NUOM5E@TT^Y#B\25>!78]-FD.H\[4.@[">X>K;LKJ?+]75QV!?>=J(
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ME^B,G(38^B'OZOZ:RM_"8!^'&9Z:]-GZDC/L67M7IGMF\^Y"IFFJH%3.M.:
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M%]*3+\<G[\7$+5;BA *NAT3FDW$ZKFP6X(9AVB]RRD2O@&7K@!N]92.#\-"
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MP%6,Q%1I W[X:%._$OVSX:3YK(JS(!3"%0ITTJ4BTM7^:^TB)#9_]"Q@JQ1
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M!(_8NP]L/C*\7&&V#"@QIFQ<MT$:\9",T2M<>ZY+@[![P8Y:[==(Z5,R=(N
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MN/MS0E<7(86[_Y0JYP>+:5./JABN!!, 5+X>9X:.A @32M"[OCN*_@RE=.V
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M^:#N?RE@<$Y18[$'79/=YAUWU%^"D\_V+2Z,NMM;%]O]&'5%;V=P=0>U"HZ
M\^B#Z:$Y@V>2 WJ#B44RENZ./B6ZHQZCW&JT2ZX-FU?-B"-R;V3]YO?A:UNR
M]7[?NQ(&ZWQT'D0C&",@+G)K9A4(A_(5'>\WNC,"\]W?)UM2YY? W:;R#73#
MQ&"R#VFC&UFUO>:V$X#M%N<WK^T0QLV/S=!IQCF9:(Z58_(PD;\-X8WEO'A3
MJ;W7E-O!HGZ2L>NDUB 2[5C3=]N#T!Y7"I\VW6^(QZBC\%G'9S%OM7.S4G>/
M*3!J]IVD10+]XPA F.Q-4REU[B*OIV2?X7M@H3=3THEB@CY^*)#1TOONC?$%
MN,::8>;'RE9<GE-2'<>?E.O) I]8-C#E4BQ0[B!8C6_0=U,%U:_"7Q.Z'E8J
M4VQ\#+3WH\6J&2IF)%KECD-G*.XB&NMYD(8' NGQ9;YAT=@*S*[Y?.ZC\+%_
M_\E\WX!K&"D4QVZBLNA18 Z$J=]V-[/;/OM%0*5^U7^:T&2ZV"CWD@4*U]_:
MY;)SKUZ2:>?8,WP!%.1PHEBBN4^.R'>/ XQA'P8J:?IX1@FS V975ON<W4S"
M?W^T(*,,B:"39T1*0.,G?W2!AB1.V5G;20RFG5XZ4.)F>G$W[2.)\[BJ##AO
M4LG>WY!6.U@)UC/*)!W^SO;\PH*!,_7@/:D&J$CG,PZ_E+:C=F0;;AQE-]L]
M96-  $4$6C(B(@P-3=H!5IK@\UNCDYR*?C^+PI\U-4/ZQ]]O(O[XL>J>=3!3
MT IOR3_*?C_7H/1IO"%C@GD7F"' (K%KS5J A8)1<#9A5P]_11D-H_9O08*Z
MLLIU:XD\*4BV:I599T8M1[HB$3G0E8%L^GGLN<;D8PR&V7,+^U1-3LW0DOL:
M T"?RZYU-1]"<0!LLL_K]K:)RX@B6K@H K7M\K<,ID*%N9K\WC# @7(O4F%I
M7H+)1D^BDC/MFP?,>(#D]R''KB79QTVG04%'Y+,)[RIM96A.GSTH8P+33[!>
MXTNY00[=R)[_P'UMAZ))DRJ87[]?3[DO^LP41*5PSZ][$QFI$+KL%(W+A1T-
MDGY8O00O!(M0T,11$W=V-C8J2;M[#'&\/GE$CFVZ$Q)2BF\..@SF.KF]E8%=
M+75M"Z:AQTLU&<2RJ\UFQ4UE.0<&>AO^;%-:CW+(7)A4'\6I=QS<\.M+\&G!
M,(3@E4A*RIF?G13>^3KQ:B*J+9T+M$G[^D4AW3IDGV5U<5Q^C%(CW$X2(LR,
MPTYZIN0HD^PB^#RT*2IWSW7>'-UURC)Z82C9V.40MXOF*XD):E?$8[F,,K"S
M#Y./!'DI(L3Y/HELEPYO2J(:>CMRQN"-%O?_=&D*M9I8^A4>L'&>Q+M*<**C
MW92-"#M=F PR905-K/2GWE!C]TH0JZ$C.>&B!/.#/L13DS;,<IX[,F6J9J_=
M<K1S-=NB'8_(/^2<>1!Q+(*=49<')SF+>J09]AH3ZU "3:3NTV@?^^+8WBOA
M;A65+-3@64T3Q;%91>R%"IGU?RX0I$T 4HG;_C,*AY[OJ'2&SI!:63;9#UOA
M=Z40ZB\KG$\0(N4DN# C:4G&2I!=/MX[?_&*.2*?W!- (K2F&Y3X\L;AH(B%
M(Y#7.TAGGL\/F]/V0^%<$;>3_+(6)4,SI_R.* ZJFC!1?%#>(]_#VX4B/]R:
MWB2#89XU&H[$^3!B@\?NT#6Y2IV9Z\E($?']G!+(&@2S7*I&7^'.NKR4.Q2]
MCZJBFV (.V8*Z4)" FZL'&7ILY]]^1ZRT BMS[K/=,'A^BK,,-.8#P=MI7/P
MZ^>5HFW.?J2(2&)2(UJQXXGQW\H,B;N9"#+WY^NP;U,52-+5 YXS1%S\,L&Y
M?5A&1:W>TW;PY]]$;Z@TFEA:7EU>_YB\9K79.73U>\CA,0J7@;1G.!>CZ05
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M: 9=R4XSO"P]SU1C;KX[A BU-&<(FT>.1<W1JCZ;H=*4U91R>XS!(C>[MY.
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MWPH7N(YA6KL9&G/W- : _"G-M7W*>SS0.K[D;G%$YK"WV&MHA[-Z6Q"902]
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M\]/U7GG5^^5K!J@&LG1[7%8Z<T[S7YOBUGKL2;OV72HROXU+L2AYZ!1-<)L
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M;F_2&G-[<)P#9- $MLCC_FOCK]1K$_.B_!HX4&B_?9%O@?3$!4;+A?8S$C5
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MB/*I^^A*_)^-N7R1<H17L:24WYIJT)!;#P0*/HH1%E7\RG6T6/=4HN<%J-]
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MY>*-8C9S<0 6-6BJ+3.Y$SZ0K:!(4@H'5=6WM/!)8X:[_;S- RF]'(;-KO
MN<"B-4,'=:Q#,$MC;25T=X"YS"")-PCU%%?+TJS>A_34(D=)@3EY-N?ZBWC/
MI-_'?3DU0#)$9Y#3@=/^/Q?=8"7^;S%(ZB9U3//"NW8\4> _WO_<Z5NH [KM
M[;S(.=&19%!&A6J^Q6J_==C[4.Q$EU7+WMPG=].XE?$O^IUIRKPL1Y. I+]_
M5_GWY^)-!QCF:I:6O'6-9QI=-BOZ%8=IZ Y!E$-NY!<:$B,D]V)+U^HS)R:S
M6"LIWSZ4" &OHP5ES[2D/:N)D8^ /H:XH.=S6[/<7ML4.6"P5^TIFZK1KI4:
MK9I[E!)F&;N#/LL_%3GC?<>;0?@N3+/>$%X>ZX71W+U-)8.WJU]87Y\@QV'2
MFVS]]6(>*^[C-K ZURL1\\$"I5OCT)HS4&FL=DNI9.^"'.' #ZA1C) "2KD\
M D O&I#G?1;//=6ADG/&G6UMM1&P"5:'ZFW?-S_YSK.D@B&5D>SB+B':> T:
M)<L:0!X[ER&@-C*L9S,A1T#U6MUPGLFHM[P2R/=5,B%._ @'TG 3$N!?@@[3
M[9@Y#ZUORSPZM12S&X]1?E5@M8I_NVT:AXPC@;J8'P:3&6C,S(Y>"P5Q5UFW
M"4EB&VG=I;.XG^%2WA?M3.,5B::6E'_[V^-85FGAV-TN5B6PF,>69<MR,<&:
M4Z?!=.) S<KV]@B#O>RZFJT)6=WO7:\*U[^LTF'B5X8,8S+P:MP^E?U[_792
M"T"KZW8H1_YWBJ[5?#AIN&U\0EA#^NF+R/15P*2JN3) &Z]&N71E2&HT?3HZ
M"WMDM^IZB&K*_#M54>J[6@=>EGMN\\!>WP\JS\#)DL[<N%J_JX46/<^C*2F"
MZ$2%AD >1/DFW:D5C"UT[[XDKG.:?B2.7RQ&X29N'_LS/(79-_UUGBBO<,RX
M\?C)_4!6V7P;R9Y\P('57H>\CK>SPRGR<_[Q&ORL,4&.5<5P"9N=.?_W547-
M"LQ$JY4&8N7:IIP!),2C-8@X#")&0TM?^UW[?7&=*%-EJ:.I^/(]+8W29187
MX+TJ\,",V[#]SW[ZR[8:LX\NS;1(&W4<F >C5FN_J2E+TS7;LN1T2.23V%\"
MW@=3:]6SR]0NP=H#/2VB\Y A[7BZ)-4-%]\M;GPOE,2BLL2/4["L9_,[ISLY
M'P$.K]CJVMY%[,FDO-V]O5"2MQHGQAN%?ZWRQ1/&.*5W#\<.N]79YUV]NCXW
MI_KG$A/[T^?#^V$3 ]V&+H1LBUNZ+%5?N,B9"0OM <][G!:;HNH? =$>1A#?
M>O]80S9UO;]S#9FN?9.*D@*T$2,CCP ;;;PJFB]TEVJ?M(6F=LUY&"*#.%1Q
M5MTA8;:SJR,L@L\BQ/3B;B%8*97+JT6$^EGVP<_8D)W13X].*7X^:4XY++&A
M^59PP<QBPT^2$(@#\&O*;AE@ASWW%IIT,W\"+GW0IYPV8?W]UU/?2CEWL[]Q
M=\1Y)@2#]X]HL[BYX*O?]*3H>/>:5?.CI5#G_09_?^'VM\'<4KZQ0N%]V2_6
MEL.[>_))G%*.Q(?Q)&3$CY5AA5>GJ>9/V,."V!QG#MT<,TZ],#>49699^]WX
M1H1=-.7'E$:K&Y3PV?%B9A8#Q%"D 6X_0>EOS)2!$*<MT%=#&)O+"_+$KPG%
M657B^20@,7QH6));'A1SBZ2I&FT0']S+A2)&6 K?G6=P]SG-*1Y^^^"WJ82)
M2L-^;B3+T(B.1+"B.C,JS([TEP:'3J[)WF!K<\<F?F<9VK#.55*2W$3)T]_N
M\T'9890NO@,0LZ6P(.9E^'IC?-D8F876O@:(M5>5FWD7:\PZA":NR3ILMHU(
M_2T*>UUTNKIR>K3FT,-HS9%,#=L<!!P]"Z'7U&NA$Y*GCW(A]<L.M =],=V7
M]B-<BH(9/NC,2\NK.YJ;)SL$LS;#J0M-E0K=Q_6Z0M(%DDAHA":<T)0*J)W,
MG-VIZ'.8%*OJXN(DU?QN]D-QEHMK1>^=-EXY=/Q=6UI?E:O:A="J=A-'GW1B
MV1_0_A^QK::$TTIGSP\>>X?ZM6\T[],PWPDVG]",D^R1#9UC-KC+$3[HUD2
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M-2'?=P^#\7_5-E4Y4V[!9AEL:DB,PQB^< 1RD-8:Y@8(EB50J+;205$9W[X
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M;6LL7IJY EBE;6MC*57  5^9Z\>:*<S^]OD"&#24_E>7_]7L?P%02P,$%
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MX;.\T(13?G3[34#%*KS.AO@'VK^0_=\!"_K_0O:?P/X[K@4 $3;6_<W#)@.
M '=:>9&<@/]_40$8<KU0^X3C\_0*Q8EE>5L'G&M29P"_AX?U^(LV(A0CA,<(
M0*TX%\/EW]X)/9$ ?8:2S7:LY:X^\,BH?H0P6CT+9HO)_/7T)E/W'#Y[8/^.
M%\IJ\7QFK\-/5S9=*W3GBZ9>*%+L<A#Y8G,D_*AV KC'Y<Y!Z.S/W !!@;%N
M8+4+$\2]KDMR/&X]S[98%8DJI!XK/M1U*]9,3GH&*^-[\?4BJLDN4JUG+C*H
M[W\+(E'8\OV#WVI+[?EG^7X8@$^@!V"?,^\SP?])N#A_X/S;/R#$.0;@I<@(
MJZ2E -1J?HJ>?/!;.5V,U/!^J&7&F\(W*M/2NA(@&6GKR:B4[W8SB5U2L$0J
MI_H2AT+COXCFI\^XN[99I:,*TV,*HXV G[2E]D8_#LQKE!E<6J1"Y!\FLQ)9
M=(A<[]P:0+KD_TY=$)X\ G,TQJJ6VQ)1MW-PLD8 FXVXUE/=4Z1)YJM:T 1R
MMRK&8!EX94?/!(F)2'L#5,%RAL_<0:8R;1-P*406]T.V[MJ7+MQ"YRUQ5(/S
M#\8V#""G,L!+/:G[ETXUO9>LN^"H3(+'[K$I@J2IU*=&.T<+YLG=9JV5%J7L
M6_)N:GA@*6=OH.Y3UF CS8.*/W]6]ALBB$,*KF#6WT-7A(X#Q"F/5TD# ;O>
M3+2PJE;;,F*@07U$-CVS+TW"_.MDTN>)"<J;C@%+VA^:S.E9-O>U[5=+2]>(
M'R>>/*L^IGD 8H#5HO#N*MJ?HB>:OSKG[R?890.)B&Y("KF5G0[ZO02'PC>+
MQ"^AM&GM#DY$4A\L0$<6*R$IA-%K =R2WVT_/MO4E5XQB2G5+94OQ@W<04^
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M6R4[/_X@>H/T'K5;?S5['EVR$=9*XH+U2&4N;)QPK2LWK(.I>GV_"4OW6[^
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M<-:T%YL^IS<"X>]5/;*I_:%KH'@GG+JU>D[9J[1B\:(EQ>OVL#<! ]#*V=$
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ME7)/ "Z _R( X?G_I5V5,IRX$/=<W7DX2@NMWBMACP& UMS-X#]K.ZYW2C"
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M)2N#U/: WJ9?FC&AGL7U&8:T5Q:;02SM!;?H]IZP*PWV<!-=/,VV+X)/!#F
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MS>^OCB"AF!>X7,JDCA:J+3/B>LF)$LD_=2GJAB2-X0=/ )D&0/Z^M,MX<[.
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M@,Y%G5,6/I.B7Y[NF<<'LEU#3H94.XV:4)B,7647/^&R8L?\1%>7\Z:=U;I
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M043@F,*8F6MS:9/A;&Y)J ]W'\$]"*>B^#HT@G/WSHMY4O&-G5GDUIO9[M^
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MAZ7'C!@JNK2^I;&Q)F]6Z>O'EW25&.8.-0@I>#^K^Z!XA^SO9*)FJ66E?;I
M7!R<65[H14R O4GYB8Y$5K3?_0"*.81-QF_9"!N[H:?,\L(V/]_='OO7B;3_
MG\3):??[3I[3"8J2302.(/JKWIZ6+SQ(S#1>_N56VXAP=1UO-;,\A=Z_5^MU
M)9:@OBG9,D ZP(8TB#:U/07^J-3V)=8S!5,$/ 69N^WHXP$.B(/GXA]9U5I2
M4C#VV4>K5C@4\X:Y;<>5AFS8&M:4.? G].UH=?T2;71MC/"]V=BS\6M7[L<>
ME-G+SB*->EGWNZU FY]ESMTN#1!3)B?LGP8Q:CREX7E3[@&U[%C?>@;&L%)_
M]A7N'77.:N.KK<3)]NG51,,<<5WU'D(999F0@#'A8L:<UC_OPE_;B!/$U,.&
MI9J@E/XZ+KZ]0TM-HJ>X$6HG_65S)DO/E]F?F_,S$HX89*^W<L>OF2,*"]]
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MI,O_VLAP4@(<OQ N:R.TQ\L;%#4$%,;V-+.BE<MI3+,);G1SJ7",9TE[2D<
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MUN189@(X7YW=W%Q[,U4W=I*O)2\00J&E]M\AG)P<MVBB\],,,C M*V?12W@
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MPV)_6GUD2*$C ZX?@$U/D_S55\6_"@YY\7Q39&I:0Q4VVY$!QWQOX(>#*F0
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M"V6=-24P)1A].^; E:OJ#B%LF]&%L;_M=-@%-).7Y_9OZUE/Y_= W_6^&\@
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M>"51?F0/)"E"A>(J;9N*\91Y)*:TU.V79\ 6[3\:4,KJ1PK#[*:?;C:"G_F
M.^''0J:KHV#BI>^]6TJ2=/Y_0[OUVM*[__+%#]YD2 ;<(+3&X9MI3'46"/1>
MJ/#].^4'P,VJ],UI.&C_//$&Y?4#14M, "^!4&<D^#SDOG&\#K(BAVP2LMMA
MO4X&/,\C>@GW<\36S>4# J56E.X1TR4M/(P#8'^E+?X@\5M_WV!COVRILB;B
M,RYP2 =F.S3,@R!+$;[9:(8:K$X'@E)#<AK>^ML'-TLR7B>!XD67K29_O5,)
M45IW@T 6F:.8(*#+!-4A4J!S%ZG?LD82ELPSQ*(H8.BRA1XL2H(+IO.L\?3
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M%36=?KZG71N9VVENUTQ98 ^N*.F,*_2!ZK)M0B1>'=5 G%W=;',!%1*<">O
M[4<7YN@.)6$:TZ?M:LE-Y=QQ.(/?+I(/G*\Y^$7)*Z;H$V-&)ZQ!B;P17].]
MC0#Y0L GR#5N/#O#L.1&7_]3K7'10U8IP?A%BQIZ7DKF1P\$J< ?^OW\W>*Y
M#PY9^[7,?Q6?IEJ>X0MP"&S;O&FF0\^K="M1MW[ 2VZG8R:/\N=0<;K0+2J6
MO46:<-A%IM\^B7/U^&3SD2H3K\ED^]);53&_9+-T12:NT$6,KR_5KBI^1^EF
M)E8F' %MKG8A)DCHPDC)&B1Q]&N^I;#4X?  W]V7]H/Z'4I_**R-6S85U\F
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MSBK6JTYO2=K@'@Z/(*''0M2.5ZKC7!OE(R[)N#:*BO[7VT1!'O\?4$L#!!0
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MB=E>\4>^%2M)R +28]&>T!T\;L6ZH<.OHW"(3"!+$Y#?[*\W3)PLE/O,6==
M-AR,X,4]CJ>HU/>?9[^\/D,&8Z(U>(UWC\IW6DJ"^ZV]]K++(R1F;= /F[R;
MK'0H<['0V<A>2X18_2357(4W[UY,1X8#IJP_+)^.;,BDH_YT5N6^O9$;>-.R
MO>;() 3W.=5X4/QACI"4@(20$[%MIL=?!W=M>UCM3G+TLT<^1O[3K9&QG?S5
MWO5INW9^[S*0;@LP.N OPEMO:0EZ:]4JZZPX,;H^20Q?T>CWT4=G6,X38TP0
MZ^\UODRZB<W/7T^0[LT)]O-WD" )X$[[1E)"AY,BF;)S+7,YM,TTOETDT.I7
M'S7E$8[*S&+$'ISUC,W)F_)>]K,O[Y Y!E%7"'GXBK//^^3+\ !M;.E;T?SJ
M(;J#A[=4:F/'.YXZT)%'.Z['M3FQO=5QT<D59.A.,S"![!S+]1BX<-][WX$S
M3S?7?2ZU_XQX3[RM'N%%_G$.-%@T,B5G=:G+!;!C8)E*&[=$^786(KW/@3F;
M@Y6R^$KO.E?+]DDVFH%0?K&+<IC&[-YJ;6[2R,*:4GH'^:M:1UZ)KBJU5,&V
MEN*&0SH_% OM/V"SD4GQWA=2K(D5[ZOA=:K6^VN,=R6DXU1ZR/0XZ3PTO4LB
MFB?8BL>=\DOA)2?\Z[-254W4\ER !G8Z+P"*=TY]CU>"AO'.;/(GA;#CLSQV
MKK76Z?6[8Y37.ZD04DQ<OTD>Y\"K5$PU]SDP=LHZH6JYS;0[@F'BA)NC^(LK
MX*M_Y&PT*ODQ\VR@DXCIDI;0=??BEY%U_B;SA"3#9J[4O[3"NT4:GH>^Z. ]
M7QPGQC556IZ)2J+-7<!PZY_ ?IOUDQ1]3'578ZS-%,/X(^U?AU22VC??:D!K
M%"LE<VYB(U\DNN(S2N1DE6X<V%OK,T0[*")^PNH5&ONKZ1?D:R@GI:YUE_H%
M@QR8PI^=E:M?=4/R!4(O;0Z/;'R-9_NY\P\=<.:?8%7;DI'2/FC6@C6U8KFN
M($$,?%'7>&,^TPP&[PIS[& Y>UL=[K_2SF./R^JYM23AIBDG^+7?(+7^:"/M
M'/#P?;E<%YQ:53="1<MI%',W&O,#(WJQD:)P,[M&9#D",@ MP?@X>S_/:X1R
MD?/62?43@A-1B*#3I70-'S:KX"Z(&D>=1BVGA M<9%IZC.7NC*_:</6&[>\%
M:?J.1SZ>,[ GD7.B/3#.^A$6&UN]<=7T7[C/K*<QO(@ZT >B#GGL2F,L K;9
MP3A&J1A$*ZO-'%X,C8NH1%]'3ZLS+ _:B1S)=^8\V)!JS"4](.S))*\2I@0]
M7EI:I*+:W@Z'XAQ*(FO$"=,[*PUEG$FQ(6_NHJ_J$IO04<I0@DA'W0#:]Z5-
M&#.7G8Y Z&/ \X 8H3W^=-E;W/!M/!"CA7A"[OW;DVNYQXQCO:M]777$#_?Q
MA,;?YARH7=[C1D<R(B:REB XA@JIDN;?!4]V=4\*F<87Q]SQAT^_"PSX.$6)
M=^)?&+O5S ^^S?A.>L'KTF%WUAGI)DK0QPXSEPQ2?X*CY>E"KJ8R/B$/.# K
M(&G"@39<68KH4^MBEMYUJ%,B0 2V7UOW4"WVR!:4A8$2O6[O91SMUK;$NVX=
M?JG^@;R,&%MFBW27>1F:@HS53%%!]#K_X!J^/@[?P3CL=G]^Y%$@?"0R83T3
M+!Q%.0K9Y94>ZHF5=*L6/BM *,V%/R.$>59LC4LLL)E?2^W!RYM $A&3HWD'
MT"W\,S\;#9C>7W/4:<+N,1-DJTC9- =C^_K6EH,<8B9YFJQ8UY+@WY32!4)D
M;%Z$M4-]*ZB I[Y^:G56U>.]9H08A<S<?-=<Q$Q<7]7'JTVQ4+EDE@!C+&-O
M[\CN&F)_\-OW7UQ( TL0[AQ UY ,<J&7M@3RA7ST4F_/5+NUL!*"\2&=$XM!
MO[[<=.I4+KP$QEL<51X;(C:4#P>SP5NVD=\7%2?Z'7A/>)*^C\O?Q-8\K\+@
M]4TCRG8N%["7P']#_6U%7PDT$V1PB C=:T_K<NW6HM!1Z@/DH<97CHWZ;H,.
MSU,ZI@XA>\P?MLCLA \?1CR)I2'LOT5Y]ZO]'>9N=B__OKLQQ!\TN'?PC^50
MRX>AC;ZT5],^+_<HG\4SIJ$8-7BS2&RM)F_-")JHV3MKHZXP4_MS@'C);9JC
MLW8XST\2P_G$:G]^1 ^+)(@;Y;88=U<S/1*YJTT==*85P4ED^LD^LWOV(:I$
M0@ "TP-(U6?O5;U#.^NUUHZT?>W[MC($?+,?*X9:CBJ> U@3)K99&ZD8N'?F
MM-"<TZ. F!O'5?3X.L*33^&L9R77<,EXPX#BQ860D8P%V4<DB9UJ,'D,2:G
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M:PZX;;"L>D1-[G:9^ 4+>N<>^;XH549[%&GW+&'8A('\E-N@IJAJF;$\/SI
M64*Z7>38QJK+]1/D.6Q=FJ,.MK8W264_.9GAE*$2OZ)M4W02R/T0S'65?''5
ME5&UV;#FH''T#$FY;) 11C=Y:)K1^;J7UTW)D_DFYUOO3I;O8N<_H\259XC[
M6'=E'<9W83$SHMU06M2[%2/_J]6A3SDVYW"[> -;N&WX\\:''2**$DD>SVN<
M!8V/7JIO>! U% 13JVNHJ<M2 _\I[  OM?I3_/\7A+B6;'W4D7[(JU"5R6Z*
MD3+H+$IN0JO8@=<B^=$:E^Y#5NF)K5FZ ]S,@1\[2?K95:=J@\QF?EH\\WH\
M/0Q&Z*]2[\*KB%]*]MG(I)KMS^RE3$TE&W5,UNI"+.A6R0^_<F023M\?';TP
M/_YHB5\7VY=*TV/W*V8- X1\S?S2EM^3K<CY.;EB]E&5%2?NUNFP_^?KSY?W
M?!4\I43O1W4P'!@_7(N9;6A/)T7FVL+VKOB-IR!:KN1-OSQFA3_4/B,;TGPY
M1$%#QV#F0[*%DKUR\2)]/NYN43W:J%IBPRAT8/\3F2(_RE8[QI/U.I3\T56;
MZB(7$7WN?L[$OK37N73$_$/)KK,26GC/@<[R$8FQ%U1UM*C*B7EW]B &412=
ML6(@X\T]0V:UOOP^?PB'\Y.Q#KP!L2A-48-4S_-R>CH%KFA4_4D]?NOJQ6?#
M[/I;Y;+,UJ 6'C'CY5L/HAX.O/@PQ.WA!Z$7O?]ER>V\A!CYX<K42Z)5FD.5
M=,[6^#[<.BQQ@K_X-(-B)\9=*I)/]&$&'AX;J%[%-@D#5/=TD(*#?:"=^,TM
M];^+S]A'9B5\1>P;[#LRY@<H%[5[NZ6Z6/J=OCWL.N.'0*\3)6]?R=BE,TQ
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MMN$'%;AG.Q0?>;G+E$&%U%&8L@XR$R_9C]=1DR!@%4/DG@4/_N*WS"Z&/"M
M-O/30-OX&M4]5Z 4-4%O'1KW1,O&'+/3J4B,/@C.]?:\"PM9%=_1.CP]"M)W
MZFZ9>8\"H=MC#!/A+94M*\QQ^MH55P_X$5&A.4='KJE3VW=:0MT&I-C="OR>
M3)(+F N0TB^K$W1,>.!$^IK580!2% @&#G!_6(*26B&G>]&<)''X]BUKN/:P
MR5<Y&ZW)>B=GM[3)W%#>T$!WRCF3GG?(9"F^5;BD0 Z3F+M:L ?=%P5UDPW.
M'%5#7QWAE8SRCJL[*$MEX<]>'E*O#6(4CJ--#=3YJ&7G!LA;Z%>;T^&J[1B
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MA:1R)G*L]5*Z9@4YRWOK&$#8_?[2XD9,\IPEHH=E6FHO)X_GX$=%5?CB(DT
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M,:7LD?UP/T8==MU6GXPX?/!];%VOKSK E"X5 'DEOJX8XQ3VE44.L)1Y6S/
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M0,;I7=NE\_$,E):+"0S.'X !3O]N _3/X@086[+?=^7?R%BU/"A?V@Q==L^
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M\(H\BL>)#/I;A?(* 6UO4BV>P  9;T_0!4IH?];6_U9_":F;SH#5_PPZW\<
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M0O_,"!^%KO)C47+^A1([(4B9.D#_>+M(B=3B<3>Y..W8K6S96I6\/0"]V,0
MYVV9_\R4^&']C%C)N"1^]A>Y&J"/S0P]J*!_&=8IXL R-OI#/&:FY^$:K[Q+
M.0;X#KT5AWK>'*T7]QG2<5+"!4,WY2!_P \J4_(.BZDD>Q0^O*Z1;M'?!I>Y
M4S2_2#TY+^CL''>WJZLRG_RN_#JW/VUH[I?)$>50C "T$?QD%5KF3GEQ#KW:
MC=DWDD'[+:$OBU^[5I_0776<9/Y5KS;CGS>RT5WCX"WL$#JJ!V;@GP)7_%X]
MQ+L@;]UL=@QMO203V60;<4!E/DC]'KG<5UJ\=E3U!=H:Y1NUF>9NZ<!S3D6_
M$NGH8=7;6@A&*@A5#,]F8BF"7D[,/,\,L.5.-WX<9*<HKM(3UP=;ZWAM:Y_3
M'$:JQ\U*] 6,?WO@.9$XO>IGWUM<(*36XBV#X PTU9RJ\.T!0VZ SD:%3@ST
M #=70LY^NF7E[B@&V-H%7VUA@**7DC+8WAZ>A\859Q2"U\6D<U714!8IS@Y^
MDMYLDV<UG]R*),3YF[Z&,/&FQLKC";#BYKZL^89D?0[K(!8JXF B]B@_BA1X
M>_-;9)FDJ::O^2AV(-SBY4?[?SH6@K;+_FE['!J7?1:*^G#V!'J"//93:O/1
M_DZ06]V^R-WT7$31D852D"WAS:^L]],6<CU7PO)*2*.5 _"KZ$D_2;M;3";E
M\_.&^0L>38IQFL$\JG+=<OB^HB@V?1/4->>Z+7CE_K]A4=VCO,#==<->V%DO
M0TG!UOV$#+QQ7D0U+HPZ:9%1BZQZWKSSGI,3+W*L2!)G98!4G-?A5,EK.5XT
MY,6]%(@CG4L96[RTUJXOY<NS#*1"9<O%I6HO]E!.3)N$G0^*%XS2I1@@%OH:
MNWV 5<AOFW$%SU+C Q3OG?'Y*+^C"AHP0%"$$G8"9:&B0+ X6^C):49<[ME7
MZ$.P!K8;P>KM#M*AQYFVI^ $3^@_[V?^BRP_*Y-^T/]NQ7/0NLT_W<!NKJQ*
M>X_1:I<)H(O+Z-NVITZ]OS674478A2#YL.5?S*W_M0[\T3X#79]@@,F<LELM
M[2#UG(D)34<4"-]-HE0./$JIOL_=7&S?>EY]/@LY-E H?_ EL-(\E63'_E?*
MYJ>WYS9=SY/#/4D>_/@VCXUZ@#_");(.*E)\Y8@!]#5F0E\?MZ!)^'L.[BX[
M@\L.6OX\/BOW4_:3P&Z?V&7X4SST"G<6 XB6I#<R9':L@NEM]&5_Q= T79]J
MERO2XT\8!<37'04NMECV6_<EC7VN5D"9"RMOTK"R;$JK%DF@\8WG<E%D(PZ-
MMH5>.FH.UMIP@IC<!3NZ:OW7<I$B]1_ORKV1$9=I2CD,>&JX6EZ)Y>B2MBAK
M:6]U3VU4R('"_N/9%=-45 D/[-L<UQO3R*R#9>?6*4-7DL=3=8,\Y#:'WB*J
M11S*/IQM1R$B2[>.JH3'^:U&]XM6E7R]ORMO*NU\*:KD\26X>R@5,%ZO&@JA
MH>QH:+(W*(<S3)Q>OY3B.EP<W<4+SK;T8)?A>,I$U+8E_+IK-')!:E8PFC8S
M1E1FL :D;^P'U3^WYP_R)YFLZAP[;>"G-1YJ9E"E8E(XO&M;+!K\T G4%]5:
M\WI';PQR:V0-+I>9TY-OXNUQ.127\V6=>,O@NE @D4'A C+=.]?#L*?7V![D
M9IOC<$9R8,0B&""!KK28JO6:6U9)6)DS4MDEF"@DKPYSSR^*VB_]I;52I_!9
MJ Q5>,? 8[BQB5)_$);1 24R,D":7]E6]>5.5DH4F;L'C=SO-'U\^.IQ1N--
M\]_)V3&9 X.WI'.U^1/294X\,C->7TR5V+600T1!'1B  AD_.MRIC?#9.@)7
M'5H&'PAU7CV+.&_3<8W-Y'0RG!*%V[?5.WT0CO #JY1/+#^_$W^NGLSPIB62
MF6URD'ZN-'+=(BZ5<39=)$W1Y;Z=J=UHC% T'>?XR*<]69K)=_B>4)SIC*@E
MR@L,\&6A!AU)T_Y_>EY66W+NDQZYTXX!6%CRKDM-IV:;V<>'4<I5.!A ]3%T
M6ZYY#GT&(8>3=M,VDX[?KVV<3JQ)'IZV2)=K?2_NV@@?7NA9,XFS=-GX/'-%
M^T0T7#BOF%L>6?7=;FGVT%'K7GGBTW@Y4M[.E]LI4]&*WL"L. .-.+)D)<'V
M15+231Y_N\+XV?K"8:8@MX]K6\Z=Y)GI]MM-692L<6D.-/TEG8,XF]&TZ:N+
MQXJ,^!7ILR\^]]/CTLY;0^]]W,_U?#411=B-8%R?](AEX.>W#.9(.'CC$7!S
MYL&=W@O%ME;)T:V89V*"/WZ4FL,GXZ2S>'XDKLP=F+4Y:L]$-<S?#KS5\KP#
MCZ6#YH,?W&RR1U=WK;QVW&U'MM*YSYK8MG''VLN "QK\TB-W*.C;$"*QKF X
MC)$@([LC3]&5?\8J8B@RBVRHG_U8 7"-WR=X<J+E),WK9: ROC7F> :J,)H+
MN945EY$P(2,$/OM- .(W?B<OZ9/0QQ=J).O:?!/NB6+78=RF/3&0S5TDM5#Z
MJ,]0:J8C;58CD[A:G:)99A!37G7]TS">KM=V[%??08UX[M#'#<MP[B\3_G=M
MZRF^N]I#V4)>))B%D"IY<WSY1)G:&DS?JZ9Z)U28HVB-VU<"3&ZB/T V:US@
M0E6<Q?[\J9FW9-M.^WGV4'THZ[:;FPXK95<,^<L5R_JZ"JNP8BK'(F,1KQ<.
MG%_JF/.UWOJD<S^?ZM%G1T1X%_3XM\Q4._<(G9-E<7%WLZFZO(QK7;^%SPRC
M4'07+9,;V3',A&C 3A6O+AR+V&]YFUC55WEMGHB$Z"*HXD>Y"9Y*(\C%FSF\
MH/N(\NSQ$Z:\1(4WX0NS.KP/PS3OKHM;FM:4]*O:&<(>RJ:I/#@K%O87\%+H
MLPC5\-JH-_M9WMH_$KLI^3(W82!?_;3(A-QK3@'^]A-'"L_^2/LG-'IA]>2^
MR_/>AN;C^$+!W8<G/=\E8_(/,RI"4=')2=?>T/W5YK@[^)"%*S%H[PYVF9]*
M0@]Q[^ ?G)8D_ (O,IS2@Y:_CZO+>O=X_?GX,GCM*67P&?AR=6)YX-Q^$6*+
M >X78R-Z0_UF8V3"&FD,@.0[-Z@8':KQQ(N5ITTOO[!R90M_3W!VT<*2L+N<
MELFZ52'LW75'EJ9-%V4YXE12/'++FZ>3ULEF<J2RADYCWOM]ZSWU-/B7%-9Q
MT,M4B TLQ6#^55*2AHR#1<V42J(+%=ZK WK*GOZKB21KPYB71UOR,?N;T;/A
MJV_1@D@-Q*JO1T-#F9=L:T))85:P^C>UL1>*H#T:!;_F(+-4Z<=>^L(@V_3C
M-E0;0PBB7R&'0E/2MC)R8WR#$.Y">'=D*+A/L/)'G13WJEP:])VE!:-!T<OM
M7D@*J2W;3;GR2M-L-DB@2T+?[K,>&KXB./?S$7>F!HE\Q[#*^ =\Q?>J/&M"
M;$F"PM:9"24^K^4-,J^N)[W._=%XTM5"7R0IX.=ECITZA6Y(1]EU#_7;SC4"
MJM2R=)(TUYN*1;X9X<;,E:,ME9P-R4SN]E4.B/T[^C,R*B27>:S1R,PTRIE?
M>P^*N=;61(/>NBO9DR[([O/EA%G.N9/*L9(%K^FYGC/$*0%0EA\Y,*=./'CN
MQZH&;@/;;Q5E-97)(O4U7IR?AK3??C8]=_X6>"0OW)&HY%KRXV=?H>WO!5)%
M=R8QQW+"F?5:V=BM'.K4]4F.(CAG1SU+GM#<U8F]'R*[<AI>>KWV?(Q?*LFL
M9G",E=I5U[!HWZU2)W47S,CCP&[C4'@H3% G2*K(6[0^0SN@6EDR*VIN\T9>
MY?W)X%NDZ*K<U]5! H,SVZ+-BO*0X\N'1>G\O&P1OQ:_U[G=%2':"Q?_[:*P
M9U/,-;8&"N$O>C%YD*<L**1('CZMB/C:6?:5*C.&P=)"8RX4E_EW!D,CMW#3
M.&QQ?GYVM@W_U_E-O=[> *NY6Z<K,[4SXS==Y9^ V(8F(W68,E'ZL,4Z5]ZJ
MBJ4L6,^[>R'VQ.8\;^ZJ,JZ[;"OT1WM3>]FO6B9%2BH[6&=3\:6Q!TU1LOT<
MD'S=(Q:6:2DED/[9U8Y/CW?XAS0%!NBE/<4 8\/H?N[?W!_^>O!B,'R)Q  S
MLIX3RY.3;Z_(^&'W__-1"ZO?F)*R4[TMSH71?P8EVZHFXEZ>!BD=QG?'W'W=
M%!UY^&YMBJU?%?:ZX"!Z:4Z=4-0VT&Y%:7$,$"95@@XZ.Z&33K@24?LTL"-G
M%-,MZ+$6DS?E.K+?+&9G1V_GHY)6+)180WM+R<U"D672FG*=3@[OYZ,+8G%@
M+=N5=XTN0AG.D6*9.Z=K>[DV5UDJIX?Z<#M1+;*',UYU,'FK[D<3_4J>C(7W
M:*=F^O&3(TJ4%IPS2%*D7CZTBECHD5/SDO#")^IDSUD:FKFKGX2X\V.2RO!;
MV.,^[>6ZX*R^ 5]%OGR!H5_:RU7WJ-B$4S+=,I:<_X.W]XYJJEO[18,BJ#1%
M>HM214!Z+U&1&@$ITHL*2@D0>H<H(DB-@'0!D5XCO8-TD=Y"+Z%W0@\0P@VZ
M][O/^;[OW''//W>,K#'62N9\RF_-^92L^<Q5K6ZUG#^FI9$X4>);KVYJM.JZ
MM2NM RTK:2%T,K82Q'@FB%^IV B3^NP$?-^##S";-T?E1I@G#?7K5R9X'VX_
M%!/PKBX4O[X8G5K7]&/1=8+".''_5#(WEB'@$**%Y"S0C9*]UR!AVCI@9("!
M*97VNTUGG+(&F\YL;/$R6$8F5&YSZ/AGV$T(&CACM8?91PO*Z7AY"PHW1<9=
MDOC$J,VOE==]6O]I$=43]W;*DWV4%MR7R1&8!@QDC>4LB"W89)P7FL* Y?MW
MZJ2S9N5";U>6#G-X!H32?_DM?_=EP0UV)^&0#VTI<K [5J=OX789^JM2<JF\
MH[?&QF@M]M],UN\MIJ+HKKXW1H@XK^GF#(:J\96?_(AE==*%^EX)D4Q/7.U?
MOKG=<!76:8^!70!>U4+/Z7@^+M<BWLWN&<L 0.OBD M .D\T+6X'I.B">K'1
M/#UP9GZ^CM%K8V!N*"_,[V7G?Y4GNGE%"(3D?EE;K]3M<82H<3X.\M%;R6[7
MKU.0K<M%(:O"DC4;IHYLGLW/\AT+/#Z;=(YP-/N\5"-Y"'K=P;G \E$6C.IF
M" IU@:"#CWCXU-7>+DW(+X.E'^0$W*?;V\O#'FL:&+HWF\@8MMDAUMW%Q>T<
MW66_\#B7\YDL4R;<I>M%BRU^?2<<\2 9$8AU=.@7[2W/\\TMFBO=U[9U**R=
M?&T09HP*B)=)^39LJ@3?*7-M2'Y8<*CRK39T,^=YJ--G7D>)"X"-$@67V3P]
MPCT1]-NS]\QX@Q'EER2Z5;\YFAC3FWVMR[3#EW>A^PS\4J3J*D$( 3!K1GJD
MY^I/-S_:1G#X@Z-3)(B;+7:R>YKTC$!_NHE^BD FS'N4)]?:CZ=XE*VR),FH
M2E TOKC*.J:008:BW!?!QGLR#;=+LTE&!/E8,ZX]5\F%!/*,E/FJNE=I",UH
MR+;^#@)R;5>L(%84!L_8)\\Z3,1;O&D,V#X\']Z<$T_7K*ST?S-IZ5I7'<6;
MR\:KKK/HTYY6B='.,!SO@)*U9]YI9QUW>D,FX)%M'5--QU>?)..<N, YZ,<Z
MAG%[]<H[U\3FSGA)UU$N]810W$O^+T2"]RH[-_IDUY"GXG":[JF*_'PUV0*:
M/8-VQ^M?DM+K.139&^YM?'7L,Y1,QWY+/U] !*$>1MJO][CGJE'N0DFC Y5I
M^VBO:2]= %+>W4GQ"LG.]Y%&^Z45V6AI>#/I>0V5[4"8=HFL,43ZP8PM5T(4
MR86R9PHPP"?#+B!BB)0'0\BZM;//*[LG4-%49\'@]-?.E83FS!L)_67B9TH?
M#OEN_M[=SOI15M8(";7JR3/*VI%(8#P.%G SWW-E?QL$L=6M[]UOD9)+1AT.
M9P7I16NG/J\3FC8QF2J LZ^G*2^\WRMR@Q=:PUZMW3'E_"XR+6?T_:G_@5&Z
MLKK0=1\+M-=R745'4\WQ!Q\UJ&OZA(IG5AO_^!QX+#*P;2*<-Y[MI=5Q.+;X
M1M],T0:JQM./K.RV?T6#R_*(/M,GF5'!PU6Q_0/6//)3$4L.5^_8++1;JB,B
M^15VWW.9WG'9)RF,Z$X[J$9C09."8 V$AJ].L!646I\JDUSYA?UQN\S#>?9!
M>PT#C^F+L2#.W@?0@!J^I;P6F'..35BXC7G*GL.@$A/I,P=_XJFFN\=L'PQI
M0.1ELJ#F&GC0:W_MS-DND:%T9??MR$KF0NP]948EN^\UAMQ['3^<P=7MTSX\
M@X><E+/K#)F'J\GV#=-\/^]XKEYIN7_WI8B-0-7"LOE,"0KCZ C-WJ!-NP4Y
M3FQ>_^&;@FZM^"ATB_VCQNM%_ZKNP'H&^#Q1YE HPU>X&+JOR9M/;*9]12NY
M2#2 DB3W%F^P@+7AHXR:V!-P:H*#AFRX&P,H8--%NFK;+L69W<O'R^8$GCK-
M1F-\FJ(!4AW_GABF-<:4<9I2^-_#NZ0+@"7%";,H\'0/[\G^/O;:JPXZ:Y'=
MI$ _7[__O6ZA[C+S;M[-QH;49)\[V)QTM>*CE%WUN/-D[V5/%A_:JUUVA0W<
M5[^=VE]I"+]L-O&GV8=YJ0TMC-:+_H]=)DF?Y/IYE6D51SWV6R47NKF_^DFL
M4*^_Q-T @A)@E$0NJ<1E][$*!1"D]CJ#;F&N:5-.4A+]SS/95M6N!@ZVJQZ1
M7>0!Q?,9)1BE-.L:M_17M),^]8HS$@]-LKJC;&,R]X7A#;W=*FL1@L;\1V:M
MC/F3)/KV6 5+U%H15\C\\KH';I8LP<>P ;:2QY1 8<9#OZAKTA@LHYV/,6UI
ME<K*SIFT<E9SA(".%(:?_YY'TD3PQ'?=CE]*,)DDCJPL=YG]M2]I@1M8-XQK
M]KUJ" FL ^<N5-75UD?Z#-)V5P>__G)UE5IQRD5FA*31OT;L^]/$K/0"F\I\
M7G<0I*::!9I\<W[FV<>K@J0QQV^Y)!$/^V$HR,:$:T0V2VX>:\]W!;YT=NF/
MO6?:M=VV6P9A&6+SPC\[J-?$I/3"7&!DF/G>]NV]L^=&'HO]#\M5:)2$9:N$
MWGF<//V&TJ"7R&Y\M 398O1R;Y%FIM4)TAQ"'/)(9^A&K'1]H:H/^SUD&T^]
M2.1^-XR)\@$B6(YA=31ULF1F/3$P.6OC3H>SIQUS<P?T*).G!*5B%OOH5_P*
MX?O/D#Z163*L8DW_DCA#WZ=;+:_<G2$L<GWW:\UX6ZB2.BU-FN4C IA<"KVW
M0/.\6_D3U37>WC3^WI+[]&?6*58IRK]D;MM_5UB;C;!I>+($W6)6PG(74A>X
MDGCNB()SH<C%'E>1N>X=F5SVB.MTI"RB;W[^[%!%@)ID*><AP9S#Y9ZHI*UG
M=C,HGR]12R\L(Q]I!OJ^6RCN!?2\LI$"A:8-V;'7UNPJ3(GK>07$Y6=,<4VD
M22=MWA-N;GF_;UZDN)X-2?=1"R?*]/3.!1?X%AC)9@BEE>V1O9]FS1*L,GZ_
M;QG8*Y%[0CZ(,Z\<:;B%@1GN<AP5NU.U>V^X5M953H3%W2R.C^FBGBJ@6GB@
MZ"&;K]3L=ZT"';Z<YI88FYLW8RH/A7*T9TI$!CCD\ZI6 0 $3;(;?647 %+,
MODI#90U<?Q3Z[,Y:#Y/X\76T1!31&41J(<; [:7ET@I] ?0&!CIOG\N93/M)
MM-"IEWX[>#AVS)."Y#I'EX(@U_$;;-TUNCFO1(BZ_Q)4B6W27H8_P\3FAJ]C
MNO6^F7\FE*-,*=+ D]B3?J%2M O3A^(/K(/F&4^O%SHR3V^%K'7\JKZ=',R5
M4$^PXK%J5(1D+9:C6O5C*]WE0&;/ZR!!9>5DE!T]49['AIZ[@0:/'S>K)!?^
M7.%"5ASF0$$HJ\EXYGLQ6%D1+YW1FZ9TVSZ'0E'2%3UU[H"0\AW[8,R;=.9Y
MBJ 49MW4Y[7#G .QX*RJ*%@YKV#XT?SX]Y.JL8%W@L.W(PUO>9@]*:ZN*:=]
M;R\:+L0G\ICC]TG48RK;D &$[EW)3OHB[W:V-C$_*F]?>?7B7=^I8Q5"/O.L
M!)I>H3"6=66#!C? W(.O5Y1L1SEGR8O,:TJ&"EQD5:W8X8HFPKKU"@8NJWS!
MM"0\EH*273[YQY41S6D[Q6"3\2D-]'[+1/A(1:9YH?'XNICUM>2*].R9+,RS
MVW6OB)_KIXNA?2.('O1&HRM;)DPC'2U?C@+-ZR J"0%G772,/M!:IEC)M[)[
MD'=#/B3S0$+,!,DT2SNXAUW=#A5Q1#?VX+[RA#6U QL%,)XPGB]@94<OS8=+
M'OBNX$I!OM7;:HAHDO3'XN1N62^R^)\'K(FC+I3J/(J/"WS8^LN[K-.J8L\)
MHTR[:KB/2LJ'>%3U(MH4"8Y[%=3F9C_6\+^W#^_].JHAJ3*2:&F2W?-9&?,<
M !0*,W]WHZ@AME#!N"71B*48'81[Y X[W(-]+CJJX@\ [5VMO0 @HK$?W<M1
MNICQ(SJ-.?G+Y\*M&_^4=8?CUG+O?Z,(:+3E'^>:YVJ'A?7,:Y :K96LV67+
MV]4LHY^>#1?+F&>+SL/0.\"PV?VE[Q> N5;8KNAI82E5K?.6F7Q0GV.\C6:Z
M6CX_VXHC/0W%'=T7;Y/'3S0O .2[F*X+@)PA/XY4Z4]ELW3' C_VQ*H1(PC$
MJOGE;QZG6]:[P KB<1O; A< 7;1LZHR?#JRESD_H M 7&WH!^'#[ M Z\-\H
MF>6=R:Z.[RB==L*W&U"P? ^6OAW0 Q!J!D0/6^E2N  T??I;<1WD@7US 4CE
MH[T $+%=UIN/^*8<V!ZGGUMT')LY_/_?\0(P4D=A>9P: [Q$L_$?-$7^F]*C
MZPU]7F+> [@2\S-$%>A_[B8ZA.4[#_#C]5":=_\H.OUD5,6(3%S;?WVNPX\^
MP.;G5U(GKUVS+$;9-3%OI*M$$+/60TJ;OE\U/K+^V1P2V:[+PA&^CF:4-K ]
MFF'0QK+9^?71R<)C-1]P'CZ'-;P X!HL+@#]X4Y+;LO)V(C-YO7;#\Z.TQW7
M*40L9\+.1@?U=P\H[&>^Q&.+P][&[:;O9D(%^B4W$C7,BJP]#]-3#5]]2VV)
M&&OC+Y)8D?$:P Q@!G]8<=FZTK7+*F7R9__X><3RY4MC.(_<')4F_L>A']>H
M_$3\1/2OA( 8-%HU7]+ #?$G[3'O#F'_^[)_?##2^/8(B$ZTD0#MX4/:TI!3
M!;DMGZS+4H#O3=8*EY4 /=+^EY4 0 :\*OEX?4:)$$2F&2N$YH1N",_=-" Z
M=!UVV);?=$PNN65:1*)<NB*LM--J.\#1RD^:4])V]\% U>\?LH^I%?=;:M33
MS*&6[IGCQN-&,0*&7?:%5 J*M#:1[]_C/5+_E*S5E&Q^_ZQS&X7&J_>;LL29
M?)RH#474AH(_*J(NU;3,RYLI1)S"$/\A!.(0^R>:IYI57@-57OU7+@ T2L1%
M"D!UN:]:]BQE^ ^ Q6OPL/V1Q%KDT)K*92MOS9?43O7D$AU$$=9_B1"1BCMX
MLB3G_NN2D"K_^.-?AN"\JM.4TG\9 ?2E$:C##Y,+ /;=#O&Y3.HYH=XWO0]&
MF+ S&?Y_+_7XO]FQD2QZ>S3"V$.CA=)$O2][C,::+DK?4E)RQ[2-ZX%2N8]2
MWJMRNZ<5L(5E]96S]GHF9GK=+U],(IA>Z ^"$XR/81AY+,^LVE ?]@:L'8Z_
MX+L /-H"X4[-=A&I%>'?/GNN=7Y[D*J)P<6L^RI"S:P\9PV#]E(?X1-^1I39
M*=':!>"X_P+  $)1H!'G5UTN &=KL/8&W^;%*PX: )J-@\R]IJ/31+GTAS%T
MN'**);EW%X  4'/C =E0XTXFOJ,91K[NDN?TOWBZG=W!#)3YPACDTD$GF([#
MG(/W![38>S-4%X!O]I<K0A 8O.&Y#OL(6F6\7.8!P8GN'XT<]R'#TV?WT]=%
M02MS#66-GT^)<;<N #=A_=(:%X"&H/^AS\#.R4"9-\[%]TDV%DN+C-L#7BH%
M1&G\56KB A .1 =AM''O:V#G1XT+9B [E@M ,J-2XXK2L VL[^?I($Y^%8B'
MC/NO^&=FN^G_8BI^R704"UG9NA3*ZAB[>AJN<8(!&IK]\KWZOTLB FMF_E]Y
M^IQ?"O6'%5 S]P( NKH!/J'X!L/CF_T7WRU8>V0=$&7LF+5V<@'P@(7[7  N
M^^2ERUX I.32M7%^%)=],LJ8V=3ZBU),6"9F)E#1D/KB:Q6''6:&4PQ9&5)J
M8J#I"\"&7K1?SX)[6#FY!M;3:P6#3Q_R9 FP/*UMVBX;HES.(RT].AD9D:WX
M/-\&M#\!.UN&;^'GNS=>/9]1:#FL!O1 #'&LM&2<K=(*^W]O\HB)>F1Z>J2L
M> K,_EE@8N/NSS9SF/D:;'\'BM?B<*-F]SL<H^ J/-MI/S*7G[C=HA6CW)EM
M_KMM-/R&@L34P=4,:WF<22$>$%P]<.Q4#WMFY <[]]I/2GXR.&I=55?Y3JB4
M1^5!SKU'O--> $4-F])C': M/J^&Y*_CH\4/&_@1D*KD>1Z=">LKKUP&M<>=
ML:GBOX) ^_#.V)BH9>M$Z^,!&TA>:203VWQZ %N9D-[9].7!^18V_F5I]F^6
M"^Q^#@$U)V?NG_;W[0X[LNME? 4O>[6<'H!6QF<N !9XM3;L+M5:Q75>/E)%
M3N[CP1Z]"L]>4J1@Q@\1,UU8+S]"">>;WHCKN&PQ,;D/7% ZDHO!NU/D+'Z<
MFU8Q9_I2H,"=[8*G X?6, %?+]#^Y@ZH1 1Q<E2![< ,G$?^6Y6ZHQDK!-^@
M!V>(!SN]"NO+WPL2O^X.AV36/O^QAWOY5Y<+P'^4X3I2_,LG'C\!YV*4B<->
M6J:E0YT$,=JG98WQ<O7 DR/WQG&I/R";8ZWP2C3^E=#4EWW@R6M*,),=SV:8
M9/M1NQLBMP-JX^SSR>!W%M%"[3MBQ-(E%$V'JWBOF=X/*C[X(^X% "^%^9K9
M_M;?N]VWX!IYM7V#5?S!JM/U0T*M3M8.QMJ:#H8KW9L.U(\ZV7&P&*!NW#Z9
M>9JO=<K27)(1Q$3N3;GR ,-KY;!%RRLUAG@\/S@53)!U![-V,?;5TZOKY&KZ
M4SCNF+XW?:%@+>(=[\D]&/994X&:^-%_WS[W_WQT2I_SS,NJN$-HSP%G.@E<
MV3,@7&-SPU1TVJE>J]>GZ0(S<LF:S\ZX70249\8R.MY'4.9&^06 WAIW#XG5
MM,LT"^6S80P%<\0$-)$R30)+#Y^@WDPIKSB=Z584+A1"=(;Y#OD8YE>M=8\'
MY:'V%:2Y7CT6[$^=?@KH)BWU$LE"ZFHP<-2D-%5CDH[^5H8*L\7$N".3OWA'
MPUXZ\VH#)@&U)70J;32MM^GNI%@B9,S&'TL/OA\-<ORD]21%G6?*]TN?<-*O
M_=9=O4^ND&FI^6O1K3QOUURI IL*!3WLLOAM'C/E50RDC&]H3?@\VF4:-%(Z
MSV1/%"FTK_3"#"2HA?4PTKZ3#_M!3NUNOC0E!!E([4A4PK)> -"1/=Z\7A(W
M%5I_U&R3/M+*4YR_P4;<H& .F1% I]1GMHJ"N]Y;')N]X=7U,)1\?%/+I(HG
M^>=+M/O-"-V&?FZSM%:KQCLR!@76I[:=K)VY4X75Y4-QZM*BUV<=8J'"&=Z"
MQ\[M,\Z)L1OS6?7.Z?1;%H*RA>'I,[1#TTQ3<9&6@7Q='[A^5Q$O'2_J&7SS
M4>NG59XFP+4-V*(B"<4U11ZFZ,RHWW8,U)IR[)281TQB3=#EK<C=C@+IA(J'
M**H A1IYAF!R019CZJ8=I?,&O5]3WOFY(AY%=GQR VZ[[*'7ND[(]N^SBS_/
M<(Y<YW:I#=T(?3T1_D7W3F!''-G/K[<WJ@A.="F"&KBL4CBC!DG<:@/WUI;U
MMQ[R)5NT.E%90I]."=#M&GG-5)NCNIY6-<2DJW#HFRLO6+-']CKDA0AU^'ML
M&>5ZQAM4%J<I.-_V447W-$]N(EFO>,:.DQ 1_M;,N.D\=+-PM'^H ,?FX?U\
M>*O@[C!]D;U/\2T!":W>% L;_3 BBY-W&R$^755.#1U@!:<&5DS,=XS3J&&4
M6;DI.#V/<<SVI36#F%.M'EMXAX/$0485)AME9%"$BGMQN[YF66'/3/*:_+6%
MV&M?;DD2#JZ <_!D]!2<)X"M?,2M-9$_AG8,P=W@LVJ^&=YX-/MS?:?.R)BM
MQ-)<3)?2P"&][0Y4)A<5NG6G,K:'N>XE)8/259LK!.U>0RL:.=5FYJ]#]J?-
M%JYE;\\^U2^7"'OV]@Y1\,)G,"7AFPY 06T]IJA#99<F>?X&/ZS4/F5;VF!F
M0J6"6M'U=0%UXR?_ZW+S43E)Y<V:CGI6 ]_#ED.RV+TJ-V<O &Q9Z7@C:'8F
M@<B@K1QL@)Y_!2VZ#,,V\/F&)?6!_]&I7N<R<(?TE(GV__ O5]"\Z'*Q]5RX
M'N[VI%+-Z$,V&C?';V=1JD\\"U<_W7CM_;HA>;<2&Y*(N&S<TF9ZOQAM%K0C
M6JC<=<3S0OON1Y+JSIMYQ+GLK@O(^F? )IY4V00?A^*YVUC0KEQX>@>*6T0Z
MV+8,8J?*)^?!*:Y97MZJ*>)X0_]*-Y,RN9(CLB;<7!<3>:T]\^%74=T1MJ@U
MB](HI&"V_%LJ$D^^J?.U&J8[G5/7F?1>P'9K-0;*(6=J8.416[ZMK<VEB'7E
M!1YGOO:=AU0$/X"+7$427*(46'Z-FQ!DKAUS1&&!H<F)V.8/?7HV(?4"K:G%
M!6^J-P>_%@^*\I6J5\0F1U@\W>?AP'5M&S$_>J1H?CC#J&[4Y)G&\U(R3Q+?
M1*Y@$S;CS8<]GY5,;U!7YDWYZ ^YG.S8<M4-EX-3MR1ZOB!7^>R0LH'3\P![
MTA:_J>C:NZ[4JQ/ 8*S@-ZQLD-D0WZ@J>KM/1)ZL6(G48DR[:]WBH9AYKFAT
MH8]#_P'X0[:I/"P+PD<0O5G9;P<Q,##^&4W6<>VW Y'C^OTR[]#$LZ<+? \;
M6%LR@R? 9X<",>+]8W;U@6-3WS[?C927R:=W(@#<CKB!>#ED",4HOA(3GC*9
M\@15)1EH,Y4 4<(  A8,_5$1;0N(06;#6["PB3UN=-^PQ9(HE<8@(VJ$T[>[
M \!M'H%ANFH:7F@C:%5C@LMT,D@K]0<'BQV^46!_O^UHJ,BI55=6K-2R-4]C
M< &H_#YH;B_S(;.3A]QK9Y]X*62A?,N]3==/H'[(SJZ<LSQ5IS1J<(_Q,4>=
M+B?-G:7ZI^_>:'"Q5=AL(=KJY9 0,/-;Y'H[IL,6^I#U?6+[H,J"4!LC>/TY
MBS=#KO?ND-I[6ZW1)Z/;*_4I4T:3H9IW>J#"MD894YYP&4L$6XA=6[ZQC5!#
MQU7'/!_-./E!OL+,D5>LZ\O2R:^]+=VKOQ#N&3\MWHFX&G="YZHE;DY4SX6*
M6?FTC,2J4'QB.=V3R-2M;*B"_ZIXZ40J^%2'^@&@Z\V'*P+.D>!=XGD=W,W=
MMT$6R$JRC"Z(9XZ-7G_3\HG#SV]?@ )-[&&1*6-,(\$-O%;H'BAS3VRA[4>[
MB65KV[ZX5RNP'%IBT#V_ZU<EIH0-)F2[W'':/5@>NP7$U=4)0L&*8O<LWT2>
MI#-!VPCD)'1,A>H!D=/+EZI?OY+"54MS37U4D'90?ELN9%ELR(Q*(9]?)YW0
MKXF(-@/J((D*Z8I%E\ZBHKZ%E< =%E+##;==U1]=*SVONQCD>;/H5KADN.)O
M6A9I/-/="<&QKZ60CZBG>D-S39[%6FHF%_ ]Z[2S+?&T8P^/_$@</<LT5++:
M>=SX91](:W,!H!0QNFV>H5!D(Z[KE=E9.IPB^LK=ME1AJ6 ]M]?<FMQ/\^-A
M46,3S\)U'P/+APC?').UX\Z<\K;Z[OO%AG0KP#=C.E?$%35FN!R8\S1N85T&
M77AJ)^E$>O1>#/--3)W'#E!YHKN$6CD4IX]?)'O8LBCPSC+526?4T9R6+P;N
M>2[IW9K\8N0Q:'[=6J?BT<S-W:^?-50IPP_?-%@R.HW--]SECRC"&I:L(6O*
MD;E9&W=ZLL9%:V!O^$HFE/F6]Z5*R\(_1(_Z"^K)4*7>.F1[*>IKI"4%B_&4
MR;/MUJ+5I^WRUUHGX?[<("#@22_1X^+LXX./9DO;VB)"BV9+Z0QY7MFP6:.B
M%GX)*U57O_A\RWN/IQB-^/10YK&YV^AG$J,-GO&"AZ]U.>3;/>ZF/'KPV\&+
MTOI^=BG1A)[5WF$U)AEJS1'SL0[.:RBUCAQ4N\EK"AMO)I-YWQ_LS,6<_[6J
M"@-W1S$FV1D>FU67U!37W1)+R$JM$!WX^,2H;_G^^0"G6?Q]IO>)I\)<R!B#
M2E>Y9)OZE"R_@8=!WW"]%8,&6,FAPF5X9Y7_S/4,.-U8UTW_JJT/;5[)#F;7
M07_K;[DNZV];\G=+-P0:?W["!VV1_RF__?]P"&G40.9EG\:,[/R28%U^YNO.
M MGJ).YJ\QGR1>MN0S9R%0OM":.E%W[;"[7.U]LVE-WOJ2[M:==*UOFBN5^"
M92N) $>S%.9<MPB9)_$VT.).*U?)I/Q%;>#W4A]&XR"E^0KMKC1X2.(]">E*
M%W%0(DVU4LZV3A3E8?J8K$)*L%I%#'C=\.$"\)'#\P+PV!MV=C"<BLZ @E;Y
MH1< O\1Z6.&KQ@06V,C&D9S7< .]:&-+TBR9M?A^IVS;A(EOGMMUS;IAM_O?
M[!Y=B:(BM9Q(*/"A'CSLRJJJ1[H:Y2>\M2XJHD_G7.M*#V2S'V;K>O'[G8.@
MV5-8<U0=/B,NKSP_L0&AE&<H3D(G\?ED5O9A ?_^O7/3QKU4D)D/<- 5;-0%
MZ>I:0\7_ZL^G EGP2Z0N+I %$SUZJ7B#N%P?CK)/8 X?J36>$C91NJ+&;LUD
M%";L^;M)YQIAI:F4'I[%7SYMC>>G>#XJIK#^U[.X<U'^@E>P!)+UPS,6,HH6
M1OU#9JFE<LAQD$9=U-[$N#_9QZEJ>/=56%PUO/,KT[Y1"BMZW<-?FLAH,EGJ
M6*.:UBVNHO;99W!9[EV!!X]U[_KSC,+^0QJ(QTX:0H-/A]=RSR&D%5%<ZR,[
MWD"I62PI^BB=)*-TG81M_#PR6^6=4[LV=VHV)0VO\#F2M8;;ARR[R_,H?$@I
M_ FSBGG8NWQV34_E;^8?)XB\E^O3<53A*^=$?!> G2$MO%:1_VB56HA"U/!<
MJG*[T$>X>+3<3OMYS3"_EM&&MG7)K 7X%H<1[.K#IL^WJ[XZ28_0^9&MW>KQ
M6CZ:UW07J':U2ILJ]0QEJW*H_='=Z"Y!+X%(@^'OQK]4X<)R,_:=DES>F.RT
M>8<=HV^G]=ZV'CUQ_IN;KAZB5(FHY<#UO:T7\=1\SG!AD%HZM9$IQMMRGK'P
M179C7427?H61B8;&)T2,1UZF9OQGU9(/(QH2"/RH^LAV.=1"+X<:[*\J]9>J
M-!:^VH)$H4>.B_>QL.L';:41-Z#VV6^TPH4ZJ!2:/":7KW^[<Y9)OQ&&7 G"
MLA$'':I9:H*KM^U=59Z6Y'^,D$"K,&H"Z%=BV]6)5!!O_CVB_\VF]E]LO,#4
M01$]9*B-+D6X>,=@-+*>[0^XUR[WO!O"&Z:;BOLX_Z/9X[7UAFKYDX^'AK._
M3?]+^'8!4-VE")0C2T+AJAUAHE/NWZUD(IF4=2(>]X%4#RZW++D39EC-TLVS
M(AC#IE7ZA;G/DD1=9XV#W45'#W0!N.$"V]_B6KY_ 0BH 9T<1>]3M[HF7Z/&
M9_+-)D#LF<I)" CU$([SS<"V 4#MJ7L/UA/6%D5]]@NL'3<2C8^$>F3K]$C*
M%RM\X6%'$J#?]7W&R#C]0?O-6,[P[+!OK[TLZSWGT,]:"J=@QTT(>1(M@5 M
M&6-7AAA+6D)/IEE"+!M'?1V)M3NA[A':Z"EK[:NR)YN[H+M+P[78CM+;@^6\
M..;56*&V!PH.^TJ.$#?V*">PFGWF:[=-#_/(_EW3RTU0GF7CS-@N  UD_-A[
MPK"^1=AQ9U$C%%R]XJMW9VR_'?TP9.8VE#1)SXXN\+PSYH._Q;XX,5,@Q?X5
MJ5L\TCAJT\")XN&E.*VJQJC;U]I:C]_,K %>-CBR+3^@>Z?(,WP!0-U(PL%8
M+QD T0$],WO\360L$W%.NA2W*I2^F/C<18\LP\^_[)H^3.PA4;&M?,H[H\7K
MF+_[ZV;H$+&DY')-CU8[LZ5Z?7'-M4+$76]K:G6!L$QUT%433;3Q=-'")=W[
M:./Z';:^L\#4RLN_/E+8BI>.&LE<.@:U)K7X<WM[K#FZ-]MTY\$6XR0E+F=?
M!79>H# @5!5?*_@\JUWPBI$&QUE=163SV7P$#<B1Z@) (;D-&?F7X*^OGK>
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M#-MHVP'5@D(_WF\W^O8]A$<XX]]E O]?#HN$"4<S'C.LT>CWX:)Y3:L7G"[
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MI)&W"C2@E":>\HTYPPK7MSDGB)XQ>C8B;=35;)-;5*$Z8OW%$#2S07>HL31
M(H3M#E/"\07@-GV?9!L'-\5XZV'53N%R776I2DS15@R+A_/^TZ(;3Y3.'KV
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M/].)JS$L,[6XU<2@O!?'!;E2P@F09!\%.\X!*4RL?ZSM6SO4?Q7LH52(;<Y
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M@;T\DR?:^17+E[TT9JYVVS;"VTA4;&.V06NK]=VT&X)E'N)XQ 1CVL08_4)
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MZ_C_=)"__1=02P$"% ,4    " #QEGA6;]V?P581  #GJP  $0
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M 0!E>#$P+3(Y+FAT;5!+ 0(4 Q0    ( /&6>%9-8II9&!X  (K8   +
M          "  4I+ 0!E>#$P+3,P+FAT;5!+ 0(4 Q0    ( /&6>%:71-]]
M%!X  /S6   +              "  8MI 0!E>#$P+3,Q+FAT;5!+ 0(4 Q0
M   ( /&6>%:X%KQE[!L  )3(   +              "  <B' 0!E>#$P+3,R
M+FAT;5!+ 0(4 Q0    ( /&6>%:R8;OTUQL  '+&   +              "
M =VC 0!E>#$P+3,S+FAT;5!+ 0(4 Q0    ( /&6>%8M7US8 AP  ,W/   +
M              "  =V_ 0!E>#$P+3,T+FAT;5!+ 0(4 Q0    ( /&6>%9,
M?0RSHA\  &?R   *              "  0C< 0!E>#$P+30N:'1M4$L! A0#
M%     @ \99X5CI?HZH=90  Z:X"  H              ( !TOL! &5X,3 M
M-RYH=&U02P$"% ,4    " #QEGA6.KW5_/,#  #\#P  "@
M@ $780( 97@R,RTQ+FAT;5!+ 0(4 Q0    ( /&6>%8>(P3!E ,  'P/   *
M              "  3)E @!E>#(S+3(N:'1M4$L! A0#%     @ \99X5L]
MT0HY"   "$4   H              ( ![F@" &5X,S$M,2YH=&U02P$"% ,4
M    " #QEGA649Z/M2,(   50P  "@              @ %/<0( 97@S,2TR
M+FAT;5!+ 0(4 Q0    ( /&6>%94RIVC\-$" $ZS&@ ,              "
M 9IY @!F;W)M,3 M:RYH=&U02P$"% ,4    " #QEGA6'_8OG<I/  !%8
M$               @ &T2P4 9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0    (
M /&6>%8>J&<N"=T  '_@   0              "  :R;!0!F;W)M,3 M:U\P
M,#(N:G!G4$L! A0#%     @ \99X5M0(5=\!I   !Z@  !
M ( !XW@& &9O<FTQ,"UK7S P,RYJ<&=02P$"% ,4    " #QEGA6RJBC55 ;
M  !2'   $               @ $2'0< 9F]R;3$P+6M?,# T+FIP9U!+ 0(4
M Q0    ( /&6>%959$1REY\  +2O   0              "  9 X!P!F;W)M
B,3 M:U\P,#4N:G!G4$L%!@     9 !D T04  %78!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
